nl_id,docebo_id,docebo_code,newTest_ID,newQues_ID,sequence,question_text,newQuesAns_ID,answer_sequence,answer_text,correct,course_name
6995,9812,Questions-0000-107,g3699,g14168,0,Which is not used as a Northside Hospital Patient Identifier??,g77064,0,a) Corporate ID,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14168,1,Which is not used as a Northside Hospital Patient Identifier??,g77065,1,b) Social Security no.,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14168,2,Which is not used as a Northside Hospital Patient Identifier??,g77068,2,c) Medical Record no.,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14169,0,"Use the ""Account Revision"" function in STAR Financials to revise accounts.",g37401,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14169,1,"Use the ""Account Revision"" function in STAR Financials to revise accounts.",g37402,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14170,0,Under which function in STAR would patient's demographics information be found?,g77069,0,a) Medical Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14170,1,Under which function in STAR would patient's demographics information be found?,g77070,1,b) Financial Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14170,2,Under which function in STAR would patient's demographics information be found?,g77071,2,c) Admission Information,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14171,0,Under which function in STAR will the patient's charges be found?,g77072,0,a) Medical Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14171,1,Under which function in STAR will the patient's charges be found?,g77073,1,b) Financial Information,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14171,2,Under which function in STAR will the patient's charges be found?,g77074,2,c) Admission Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14172,0,Under which function in STAR would DRG & diagnosis information be found?,g77075,0,a) Medical Information,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14172,1,Under which function in STAR would DRG & diagnosis information be found?,g77076,1,b) Financial Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14172,2,Under which function in STAR would DRG & diagnosis information be found?,g77077,2,c) Admission Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14173,0,"To manually type a note into STAR, which of the following is correct?",g77078,0,a) Manual notes are not allowed in STAR Notes,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14173,1,"To manually type a note into STAR, which of the following is correct?",g77079,1,"b) Go to Account Notes, Type ""S"", and enter a Standard Note Code",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14173,2,"To manually type a note into STAR, which of the following is correct?",g77080,2,"c) Go to Account Notes, Type ""F"", and enter a Free Form Note",1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14174,0,Transaction History in STAR contains the following:,g77081,0,a) All Payments and Adjustments,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14174,1,Transaction History in STAR contains the following:,g77082,1,b) All additions and removals of Insurances,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14174,2,Transaction History in STAR contains the following:,g77083,2,c) All of the above,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14175,0,"From the STAR Patient Account home Screen, to pull a list of ""shortcuts"" enter this punctuation?",g77084,0,"a) ""."" (Period)",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14175,1,"From the STAR Patient Account home Screen, to pull a list of ""shortcuts"" enter this punctuation?",g77085,1,"b) ""/P"" (Forward Slash + P)",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14175,2,"From the STAR Patient Account home Screen, to pull a list of ""shortcuts"" enter this punctuation?",g77086,2,"c) ""-"" (Hyphen)",1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14176,0,The equals sign (=) may be used on the STAR Account Search Screen to return to the last account number entered into STAR.,g77087,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14176,1,The equals sign (=) may be used on the STAR Account Search Screen to return to the last account number entered into STAR.,g77088,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14177,0,What key strokes are entered to display the previous screen in STAR?,g77089,0,a) F7 or Period (.) Enter,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14177,1,What key strokes are entered to display the previous screen in STAR?,g77090,1,"b) F6, Comma or Colon",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14177,2,What key strokes are entered to display the previous screen in STAR?,g77091,2,"c) F5, Asterisk or Dash",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14178,0,STAR notes are displayed with oldest notes at the top to most recent at the bottom.,g77092,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14178,1,STAR notes are displayed with oldest notes at the top to most recent at the bottom.,g77093,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14179,0,"After 3 failed attempts to sign in to STAR, it will prompt one to start over.",g37427,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14179,1,"After 3 failed attempts to sign in to STAR, it will prompt one to start over.",g37428,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14180,0,All employees' STAR Menu options are assigned by Job Class codes.,g77094,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14180,1,All employees' STAR Menu options are assigned by Job Class codes.,g77095,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14181,0,"In STAR, where is the blue transaction line located?",g77096,0,a) Top of the screen.,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14181,1,"In STAR, where is the blue transaction line located?",g77097,1,b) Middle of the screen.,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14181,2,"In STAR, where is the blue transaction line located?",g77098,2,a) Bottom of the screen,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14182,0,What altering selections can be made in Account Inquiry?,g77099,0,a) Alter Admission Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14182,1,What altering selections can be made in Account Inquiry?,g77100,1,b) Alter Medical information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14182,2,What altering selections can be made in Account Inquiry?,g77101,2,c) None of the above,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14183,0,Payments and charges in STAR can be found under the Admission Information function.,g37437,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14183,1,Payments and charges in STAR can be found under the Admission Information function.,g37438,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14184,0,Standard Note Codes are not really codes but manually typed notes in STAR.,g37439,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14184,1,Standard Note Codes are not really codes but manually typed notes in STAR.,g37440,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14185,0,Where can the ΓÇÿFinancial Class list be found?,g77102,0,a) Revenue Cycle Web Site,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14185,1,Where can the ΓÇÿFinancial Class list be found?,g77103,1,b) OneContent,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14185,2,Where can the ΓÇÿFinancial Class list be found?,g77104,2,"c)	The FET Tool",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14186,0,"The Tool consist of several different applications, Pre-Reg and Verifications Tool, the FET Tool and the _______.",g77105,0,a) MCCM Tool,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14186,1,"The Tool consist of several different applications, Pre-Reg and Verifications Tool, the FET Tool and the _______.",g77106,1,b) PFS Tool,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14186,2,"The Tool consist of several different applications, Pre-Reg and Verifications Tool, the FET Tool and the _______.",g77107,2,c) Revenue Cycle Website Tool,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14187,0,The FET Tool is used for?,g77108,0,a) Estimating Patient's financial liability,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14187,1,The FET Tool is used for?,g77109,1,b) Estimating NSH payouts,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14187,2,The FET Tool is used for?,g77110,2,c) Finding CPT codes,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14188,0,"A Patient's EOB, UB04 and Financial survey can be found here?",g77111,0,a) STAR,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14188,1,"A Patient's EOB, UB04 and Financial survey can be found here?",g77112,1,b) OneContent,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14188,2,"A Patient's EOB, UB04 and Financial survey can be found here?",g77113,2,c) The Tool,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14189,0,How can OneContent be accessed?,g77114,0,a) Northside Intranet,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14189,1,How can OneContent be accessed?,g77115,1,b) Revenue Cycle Website,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14189,2,How can OneContent be accessed?,g77116,2,c) All of the above,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14190,0,"In OneContent, which tab would be used to work queues/referrals?",g104353,0,"a)	Task Lists",1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14190,1,"In OneContent, which tab would be used to work queues/referrals?",g104354,1,"b)	Assignments",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14190,2,"In OneContent, which tab would be used to work queues/referrals?",g104355,2,"c)	Patient Referrals",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14191,0,"In OneContent, use the ""Reassign"" function to refer an account to another department.",g77120,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14191,1,"In OneContent, use the ""Reassign"" function to refer an account to another department.",g77121,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14192,0,"In OneContent, all Business Office queues begin with what three letters?",g77122,0,a) PFS,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14192,1,"In OneContent, all Business Office queues begin with what three letters?",g77123,1,b. HIS,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14192,2,"In OneContent, all Business Office queues begin with what three letters?",g77124,2,c) SIM,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14193,0,"The answer in question 23, abbreviation means?",g77125,0,a) Patient Financial Services,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14193,1,"The answer in question 23, abbreviation means?",g77126,1,b) Health Information Systems,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14193,2,"The answer in question 23, abbreviation means?",g77127,2,c) Simplified Identification Method,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14194,0,Can you identify one of the Six Service Standards?,g104301,0,"a)	Commitment to Co-workers",1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14194,1,Can you identify one of the Six Service Standards?,g104302,1,"b)	Performance Management",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14194,2,Can you identify one of the Six Service Standards?,g104303,2,"c)	Delegating",0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14195,0,When working in OneContent what icon will appear next to an account when that account is checked out and is currently being worked by someone else?,g77128,0,a) A check mark,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14195,1,When working in OneContent what icon will appear next to an account when that account is checked out and is currently being worked by someone else?,g77129,1,b) An eye,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14195,2,When working in OneContent what icon will appear next to an account when that account is checked out and is currently being worked by someone else?,g77130,2,c) A star,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14196,0,Which is not one of the Six Service Standards found in the NSH yearly Performance review?,g77131,0,a) Communication,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14196,1,Which is not one of the Six Service Standards found in the NSH yearly Performance review?,g77132,1,b) Professionalism,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14196,2,Which is not one of the Six Service Standards found in the NSH yearly Performance review?,g77133,2,c) Innovation,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14197,0,Email etiquette suggests one to put __________in the email subject line?,g77134,0,a) the purpose of the email,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14197,1,Email etiquette suggests one to put __________in the email subject line?,g77135,1,b) the introduction sentence,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g14197,2,Email etiquette suggests one to put __________in the email subject line?,g77136,2,c) who the email is to,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15874,0,What functions does STAR GUI and Character base STAR both have?*,g42968,0,a. Access Account Inquiry,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15874,1,What functions does STAR GUI and Character base STAR both have?*,g42969,1,b. Access Account Revision,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15874,2,What functions does STAR GUI and Character base STAR both have?*,g42970,2,c. Both Account Inquiry and Account Revision (Correct),1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15875,0,In STAR the DRG & diagnosis information is located under the Financial Information function.,g42974,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15875,1,In STAR the DRG & diagnosis information is located under the Financial Information function.,g42975,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15876,0,Patient demographic information in STAR is located under the Medical Information function.,g42976,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15876,1,Patient demographic information in STAR is located under the Medical Information function.,g42977,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15877,0,"GUI Based STAR and Character based STAR look the same, but have different functions.",g42978,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15877,1,"GUI Based STAR and Character based STAR look the same, but have different functions.",g42979,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15878,0,Charges in STAR can be found under the Admission Information function.,g42980,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15878,1,Charges in STAR can be found under the Admission Information function.,g42981,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15879,0,Standard Note Codes are manually typed notes in STAR.,g42982,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15879,1,Standard Note Codes are manually typed notes in STAR.,g42983,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15880,0,"Transaction history in STAR contains all payments, all adjustments and all additions and removals of insurances.*",g42984,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15880,1,"Transaction history in STAR contains all payments, all adjustments and all additions and removals of insurances.*",g42985,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15881,0,In OneContent a representative can search for patients using the patient tab.,g42986,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15881,1,In OneContent a representative can search for patients using the patient tab.,g42987,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15882,0,"In OneContent when there is an ""eye"" icon next to account indicates that the account is checked out.",g42988,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15882,1,"In OneContent when there is an ""eye"" icon next to account indicates that the account is checked out.",g42989,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15883,0,How would OneContent be accessed?,g42990,0,a. Northside Intranet,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15883,1,How would OneContent be accessed?,g42991,1,b. Business Office Website,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15883,2,How would OneContent be accessed?,g42992,2,c. All of the above,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15884,0,What two tab options are available in OneContent?,g42993,0,a. Assignment Worklist & Guarantor Search,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15884,1,What two tab options are available in OneContent?,g42994,1,b. Task List & Patient Search,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15884,2,What two tab options are available in OneContent?,g42995,2,c. Assignment & Patient Referrals,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15885,0,"In OneContent, which tab would be used to work queues/referrals?",g42996,0,a. Task Lists,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15885,1,"In OneContent, which tab would be used to work queues/referrals?",g42997,1,b. Assignments,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15885,2,"In OneContent, which tab would be used to work queues/referrals?",g42998,2,c. Patient Referrals,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15886,0,"In OneContent, which tab would be used to search for patient encounters?",g42999,0,a. Guarantor Search,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15886,1,"In OneContent, which tab would be used to search for patient encounters?",g43000,1,b. Patient Search,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15886,2,"In OneContent, which tab would be used to search for patient encounters?",g43001,2,c. None of the above,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15887,0,"In OneContent, always use ""Delete"" after completing a referral to remove the referral from the queue.",g43002,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15887,1,"In OneContent, always use ""Delete"" after completing a referral to remove the referral from the queue.",g43003,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15888,0,Which screen is the default screen when signing into OneContent?,g43004,0,a. Task List,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15888,1,Which screen is the default screen when signing into OneContent?,g43005,1,b. Patient Referrals,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15888,2,Which screen is the default screen when signing into OneContent?,g43006,2,c. Patient Search,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15889,0,"In OneContent, use ""Reassign"" function to refer the existing referral to another department.",g43007,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15889,1,"In OneContent, use ""Reassign"" function to refer the existing referral to another department.",g43008,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15890,0,"In OneContent, all Business Office and Patient Access queues begin with what three letters?",g43009,0,a. PFS,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15890,1,"In OneContent, all Business Office and Patient Access queues begin with what three letters?",g43010,1,b. HIS,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15890,2,"In OneContent, all Business Office and Patient Access queues begin with what three letters?",g43011,2,c. SIM,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15891,0,The encounter number in OneContent corresponds to the patient's Medical Record Number.,g43012,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15891,1,The encounter number in OneContent corresponds to the patient's Medical Record Number.,g43013,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15892,0,"After performing a Patient Search in OneContent, clicking on the patient name will pull documents for every visit the patient has had with Northside Hospital.",g43014,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15892,1,"After performing a Patient Search in OneContent, clicking on the patient name will pull documents for every visit the patient has had with Northside Hospital.",g43015,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15893,0,When printing from OneContent which option allows representative to print multiple documents from the document tree at one time?,g43016,0,a. My output jobs,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15893,1,When printing from OneContent which option allows representative to print multiple documents from the document tree at one time?,g43017,1,b. Current Page,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15893,2,When printing from OneContent which option allows representative to print multiple documents from the document tree at one time?,g43018,2,c. Output Queue,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15894,0,What icon will appear next to an account with the account is checked out and being worked?,g43019,0,a. A check mark,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15894,1,What icon will appear next to an account with the account is checked out and being worked?,g43020,1,b. An eye,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15894,2,What icon will appear next to an account with the account is checked out and being worked?,g43021,2,c. A star,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15895,0,What functions can be used in Account Revision?,g43022,0,a. Alter Admission Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15895,1,What functions can be used in Account Revision?,g43023,1,b. Alter Financial Information,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g15895,2,What functions can be used in Account Revision?,g43024,2,c. All of the above,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g25765,0,"Use the ""Account Revision"" function in STAR Financials to revise accounts.",g77066,0,TRUE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g25765,1,"Use the ""Account Revision"" function in STAR Financials to revise accounts.",g77067,1,FALSE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g33408,0,The encounter number in OneContent is the same as the patient's Medical Record Number.,g104356,0,TRUE,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g33408,1,The encounter number in OneContent is the same as the patient's Medical Record Number.,g104357,1,FALSE,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38761,0,What separates NSH from other hospitals in the industry?,g123934,0,Our upfront candor about the patient's estimate liability.,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38761,1,What separates NSH from other hospitals in the industry?,g123935,1,Helping patients to make clear financial decisions on their health care.,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38761,2,What separates NSH from other hospitals in the industry?,g123936,2,All of the above.,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38762,0,Schapptbook is primarily used for__________ _____________.,g123937,0,Scheduling appointments,1,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38762,1,Schapptbook is primarily used for__________ _____________.,g123938,1,Housing emails,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38762,2,Schapptbook is primarily used for__________ _____________.,g123939,2,Work Queues,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38763,0,The Business office will use PowerChart for patients medical charts and ________  _____________.,g123940,0,Task Lists,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38763,1,The Business office will use PowerChart for patients medical charts and ________  _____________.,g123941,1,Financial Assistance,0,RCT: BUSINESS OFFICE BASICS TEST
6995,9812,Questions-0000-107,g3699,g38763,2,The Business office will use PowerChart for patients medical charts and ________  _____________.,g123942,2,Running Reports,1,RCT: BUSINESS OFFICE BASICS TEST
6904,8327,Elearning-0000-1204,g3651,g13907,0,Patient is given bathing instructions from NSH Transplant Coordinator.,g36607,0,TRUE,1,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13907,1,Patient is given bathing instructions from NSH Transplant Coordinator.,g36608,1,FALSE,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13908,0,Which of the following steps are correct in regards to prepping the Bone Marrow Harvest patient in pre-op.,g36609,0,a. Clip mid-lumbar region to coccyx,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13908,1,Which of the following steps are correct in regards to prepping the Bone Marrow Harvest patient in pre-op.,g36610,1,b. Chloraprep mid-lumbar region to coccyx,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13908,2,Which of the following steps are correct in regards to prepping the Bone Marrow Harvest patient in pre-op.,g36611,2,c. Secure sterile towel with tape to mid-lumbar region to coccyx,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13908,3,Which of the following steps are correct in regards to prepping the Bone Marrow Harvest patient in pre-op.,g36612,3,d. Prep entire lumbar sacral area including gluteal fold to front of iliac crest,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13908,4,Which of the following steps are correct in regards to prepping the Bone Marrow Harvest patient in pre-op.,g36613,4,e. All of the above,1,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13909,0,Select the correct prep area:,g36623,0,A.,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13909,1,Select the correct prep area:,g36624,1,B.,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13909,2,Select the correct prep area:,g36625,2,C.,1,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13910,0,What documentation is required in the Pre-op chart regarding the Bone Marrow Harvest patient?,g36617,0,a. Surgical area clipped,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13910,1,What documentation is required in the Pre-op chart regarding the Bone Marrow Harvest patient?,g36618,1,b. Surgical area prepped,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13910,2,What documentation is required in the Pre-op chart regarding the Bone Marrow Harvest patient?,g36619,2,c. Name of prep solution used,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13910,3,What documentation is required in the Pre-op chart regarding the Bone Marrow Harvest patient?,g36620,3,d. Number of units of autologous blood available,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13910,4,What documentation is required in the Pre-op chart regarding the Bone Marrow Harvest patient?,g36621,4,e. Patient took shower per NSH Transplant Coordinators instructions.,0,BONE MARROW HARVEST RESOURCE BOOK
6904,8327,Elearning-0000-1204,g3651,g13910,5,What documentation is required in the Pre-op chart regarding the Bone Marrow Harvest patient?,g36622,5,f. All of the above,1,BONE MARROW HARVEST RESOURCE BOOK
6903,8329,Elearning-0000-1206,g3650,g13902,0,"Areas that are frequently touched by health care providers or patients called _______________, and it is important for perioperative team members to understand that frequent cleaning of these surfaces is essential to prevent the spread of potentially infectious organisms.",g36591,0,"a.  ""high-risk"" surfaces",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13902,1,"Areas that are frequently touched by health care providers or patients called _______________, and it is important for perioperative team members to understand that frequent cleaning of these surfaces is essential to prevent the spread of potentially infectious organisms.",g36592,1,"b. ""high-touch"" surfaces",1,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13902,2,"Areas that are frequently touched by health care providers or patients called _______________, and it is important for perioperative team members to understand that frequent cleaning of these surfaces is essential to prevent the spread of potentially infectious organisms.",g36593,2,"c. ""high-contamination"" surfaces",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13902,3,"Areas that are frequently touched by health care providers or patients called _______________, and it is important for perioperative team members to understand that frequent cleaning of these surfaces is essential to prevent the spread of potentially infectious organisms.",g36594,3,"d. ""high-infectivity"" surfaces",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13903,0,"Pathogens can live on environmental surfaces for days, weeks, and even months, causing risk of transmission to patients; however, if health care providers use gloves, this reduces the risk of HAI transmission.",g36595,0,TRUE,1,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13903,1,"Pathogens can live on environmental surfaces for days, weeks, and even months, causing risk of transmission to patients; however, if health care providers use gloves, this reduces the risk of HAI transmission.",g36596,1,FALSE,0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13904,0,"To reduce the risk for health care - associated infections, health care personnel can use strategies including: <ol> <li>1. using methods besides a broom to pick up debris and, at a minimum, mopping the OR floor between procedures if it is visibly soiled.</li> <li>2. mopping or wet vacuuming the entire floor during terminal OR cleaning.</li> <li>3. concentrating cleaning on high-touch objects</li> <li>4. waiting until after the surgical team has taken the patient from the room to start cleaning the OR.</li> <li>5. moving the OR bed during room turnover to check for debris under the bed and when mopping to help ensure a clean floor.</li> <li>6. performing a risk-benefit cost analysis if there is doubt about cleaning methods or a new process or product. </ol>",g36597,0,"a.  1, 3, and 5",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13904,1,"To reduce the risk for health care - associated infections, health care personnel can use strategies including: <ol> <li>1. using methods besides a broom to pick up debris and, at a minimum, mopping the OR floor between procedures if it is visibly soiled.</li> <li>2. mopping or wet vacuuming the entire floor during terminal OR cleaning.</li> <li>3. concentrating cleaning on high-touch objects</li> <li>4. waiting until after the surgical team has taken the patient from the room to start cleaning the OR.</li> <li>5. moving the OR bed during room turnover to check for debris under the bed and when mopping to help ensure a clean floor.</li> <li>6. performing a risk-benefit cost analysis if there is doubt about cleaning methods or a new process or product. </ol>",g36598,1,"b.  2, 4, and 6",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13904,2,"To reduce the risk for health care - associated infections, health care personnel can use strategies including: <ol> <li>1. using methods besides a broom to pick up debris and, at a minimum, mopping the OR floor between procedures if it is visibly soiled.</li> <li>2. mopping or wet vacuuming the entire floor during terminal OR cleaning.</li> <li>3. concentrating cleaning on high-touch objects</li> <li>4. waiting until after the surgical team has taken the patient from the room to start cleaning the OR.</li> <li>5. moving the OR bed during room turnover to check for debris under the bed and when mopping to help ensure a clean floor.</li> <li>6. performing a risk-benefit cost analysis if there is doubt about cleaning methods or a new process or product. </ol>",g36599,2,"c.  1, 2, 3, 5, and 6",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13904,3,"To reduce the risk for health care - associated infections, health care personnel can use strategies including: <ol> <li>1. using methods besides a broom to pick up debris and, at a minimum, mopping the OR floor between procedures if it is visibly soiled.</li> <li>2. mopping or wet vacuuming the entire floor during terminal OR cleaning.</li> <li>3. concentrating cleaning on high-touch objects</li> <li>4. waiting until after the surgical team has taken the patient from the room to start cleaning the OR.</li> <li>5. moving the OR bed during room turnover to check for debris under the bed and when mopping to help ensure a clean floor.</li> <li>6. performing a risk-benefit cost analysis if there is doubt about cleaning methods or a new process or product. </ol>",g36600,3,"d.  1, 2, 3 ,4 ,5 and 6",1,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13905,0,"Wxamples of noncritical surfaces that require low-level disinfection and require at least daily cleaning and disinfection include: <ol> <li>1. bedside rails</li> <li>2. blood pressure cuffs and monitors.</li> <li>3. sinks.</li> <li>4. over-bed tables</li> <li>5. ceilings, walls, and windowsills.</li> </ol>",g36601,0,a.  4 and 5,0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13905,1,"Wxamples of noncritical surfaces that require low-level disinfection and require at least daily cleaning and disinfection include: <ol> <li>1. bedside rails</li> <li>2. blood pressure cuffs and monitors.</li> <li>3. sinks.</li> <li>4. over-bed tables</li> <li>5. ceilings, walls, and windowsills.</li> </ol>",g36602,1,"b.  1, 2, and 3",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13905,2,"Wxamples of noncritical surfaces that require low-level disinfection and require at least daily cleaning and disinfection include: <ol> <li>1. bedside rails</li> <li>2. blood pressure cuffs and monitors.</li> <li>3. sinks.</li> <li>4. over-bed tables</li> <li>5. ceilings, walls, and windowsills.</li> </ol>",g36603,2,"c.  1, 2, 3, and 4",0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13905,3,"Wxamples of noncritical surfaces that require low-level disinfection and require at least daily cleaning and disinfection include: <ol> <li>1. bedside rails</li> <li>2. blood pressure cuffs and monitors.</li> <li>3. sinks.</li> <li>4. over-bed tables</li> <li>5. ceilings, walls, and windowsills.</li> </ol>",g36604,3,"d.  1, 2, 3, 4, and 5",1,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13906,0,Evidence shows that visual inspection is insufficient to ensure adequate pathogen removal.,g36605,0,TRUE,1,BACK TO BASICS: ENVIRONMENTAL CLEANING
6903,8329,Elearning-0000-1206,g3650,g13906,1,Evidence shows that visual inspection is insufficient to ensure adequate pathogen removal.,g36606,1,FALSE,0,BACK TO BASICS: ENVIRONMENTAL CLEANING
6902,8328,Elearning-0000-1205,g3649,g13897,0,"""Intimidating and disruptive behaviors"" in the health care setting that prevent nurses and others from speaking up can lead to medical errors and adverse effects for patients, as well as increase the cost of care and lead to low patient satisfaction.",g36575,0,TRUE,1,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13897,1,"""Intimidating and disruptive behaviors"" in the health care setting that prevent nurses and others from speaking up can lead to medical errors and adverse effects for patients, as well as increase the cost of care and lead to low patient satisfaction.",g36576,1,FALSE,0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13898,0,Leaders should demonstrate to employees and others that the needs of certain individual staff members are more important than others and should reinforce that all personnel should share this same vision and way of thinking.,g36577,0,TRUE,0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13898,1,Leaders should demonstrate to employees and others that the needs of certain individual staff members are more important than others and should reinforce that all personnel should share this same vision and way of thinking.,g36578,1,FALSE,1,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13899,0,"According to Leape et al, major steps that every leader should take to encourage a culture of respect include: <ol> <li>1.  creating awareness of the problem and motivating others to take action.</li> <li>2.  establishing preconditions for a culture of respect.</li> <li>3.  setting expectation for acceptable behavior.</li> <li>4.  eliminating the causes of disrespectful behavior by listening to and engaging with staff members.</li> <li>5.  working to eliminate hierarchical structures, fostering professionalism, and demonstrating respect.</li> <li>6.  enforcing a zero tolerance policy for disrepectful behavior. </ol>",g36579,0,"a. 1, 3, and 5",0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13899,1,"According to Leape et al, major steps that every leader should take to encourage a culture of respect include: <ol> <li>1.  creating awareness of the problem and motivating others to take action.</li> <li>2.  establishing preconditions for a culture of respect.</li> <li>3.  setting expectation for acceptable behavior.</li> <li>4.  eliminating the causes of disrespectful behavior by listening to and engaging with staff members.</li> <li>5.  working to eliminate hierarchical structures, fostering professionalism, and demonstrating respect.</li> <li>6.  enforcing a zero tolerance policy for disrepectful behavior. </ol>",g36580,1,"b. 2, 4, and 6",0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13899,2,"According to Leape et al, major steps that every leader should take to encourage a culture of respect include: <ol> <li>1.  creating awareness of the problem and motivating others to take action.</li> <li>2.  establishing preconditions for a culture of respect.</li> <li>3.  setting expectation for acceptable behavior.</li> <li>4.  eliminating the causes of disrespectful behavior by listening to and engaging with staff members.</li> <li>5.  working to eliminate hierarchical structures, fostering professionalism, and demonstrating respect.</li> <li>6.  enforcing a zero tolerance policy for disrepectful behavior. </ol>",g36581,2,"c. 2, 3, 5, and 6",0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13899,3,"According to Leape et al, major steps that every leader should take to encourage a culture of respect include: <ol> <li>1.  creating awareness of the problem and motivating others to take action.</li> <li>2.  establishing preconditions for a culture of respect.</li> <li>3.  setting expectation for acceptable behavior.</li> <li>4.  eliminating the causes of disrespectful behavior by listening to and engaging with staff members.</li> <li>5.  working to eliminate hierarchical structures, fostering professionalism, and demonstrating respect.</li> <li>6.  enforcing a zero tolerance policy for disrepectful behavior. </ol>",g36582,3,"d. 1, 2, 3, 4, 5, and 6",1,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13900,0,Ways that nurses can change their behavior and become empowered to speak up include: <ol> <li>1. sharing and listening to personal stories.</li> <li>2. practicing how to handle different scenarios through role playing and scripting.</li> <li>3. being socially confident and assertive at all times.</li> <li>4. focusing attention on the consistency and quality of safety behaviors.</li> </ol>,g36583,0,a.  1 and 3,0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13900,1,Ways that nurses can change their behavior and become empowered to speak up include: <ol> <li>1. sharing and listening to personal stories.</li> <li>2. practicing how to handle different scenarios through role playing and scripting.</li> <li>3. being socially confident and assertive at all times.</li> <li>4. focusing attention on the consistency and quality of safety behaviors.</li> </ol>,g36584,1,b. 2 and 4,0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13900,2,Ways that nurses can change their behavior and become empowered to speak up include: <ol> <li>1. sharing and listening to personal stories.</li> <li>2. practicing how to handle different scenarios through role playing and scripting.</li> <li>3. being socially confident and assertive at all times.</li> <li>4. focusing attention on the consistency and quality of safety behaviors.</li> </ol>,g36585,2,"c. 1, 2, and 4",1,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13900,3,Ways that nurses can change their behavior and become empowered to speak up include: <ol> <li>1. sharing and listening to personal stories.</li> <li>2. practicing how to handle different scenarios through role playing and scripting.</li> <li>3. being socially confident and assertive at all times.</li> <li>4. focusing attention on the consistency and quality of safety behaviors.</li> </ol>,g36586,3,"d. 1, 2, 3, and 4",0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13901,0,Actions that can help to change behavior include:,g36587,0,"a.  using the phrase ""it is a patient safety issue"" when speaking up.",1,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13901,1,Actions that can help to change behavior include:,g36588,1,b.  showing frustration or anger to demonstrate the seriousness of the behavior.,0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13901,2,Actions that can help to change behavior include:,g36589,2,c.  using clearly stated opinions during a confrontation.,0,BACK TO BASICS: SPEAK UP
6902,8328,Elearning-0000-1205,g3649,g13901,3,Actions that can help to change behavior include:,g36590,3,d.  using threats and influence to implement changes.,0,BACK TO BASICS: SPEAK UP
6899,8326,Elearning-0000-1203,g3646,g13881,0,I have read and understand the content and / or sought clarification from my leadership.,g36533,0,TRUE,1,BACK TO BASICS: EATING AT THE NURSES STATION
6899,8326,Elearning-0000-1203,g3646,g13881,1,I have read and understand the content and / or sought clarification from my leadership.,g36534,1,FALSE,0,BACK TO BASICS: EATING AT THE NURSES STATION
6677,8331,Elearning-0000-1208,g3589,g13659,0,I have read and understood the content of this module.,g35867,0,TRUE,1,TREATMENT OF CONTRAST EXTRAVASATION
6677,8331,Elearning-0000-1208,g3589,g13659,1,I have read and understood the content of this module.,g35868,1,FALSE,0,TREATMENT OF CONTRAST EXTRAVASATION
6665,8332,Elearning-0000-1209,g3582,g13652,0,I have read and understood the content of this module.,g35853,0,TRUE,1,IMPROVING SAFETY WITH VINCA ALKALOID & VELCADE
6665,8332,Elearning-0000-1209,g3582,g13652,1,I have read and understood the content of this module.,g35854,1,FALSE,0,IMPROVING SAFETY WITH VINCA ALKALOID & VELCADE
6578,8335,Elearning-0000-1211,g3565,g13528,0,I have read and understood the content of this module.,g35425,0,TRUE,1,MIDDLE EAST RESPIRATORY SYNDROME
6578,8335,Elearning-0000-1211,g3565,g13528,1,I have read and understood the content of this module.,g35426,1,FALSE,0,MIDDLE EAST RESPIRATORY SYNDROME
6532,8336,Elearning-0000-1212,g3544,g13457,0,Functional decline occurs by the second day of hospitalization.,g35197,0,TRUE,1,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13457,1,Functional decline occurs by the second day of hospitalization.,g35198,1,FALSE,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13458,0,It is better to do everything for our patients so they can recover faster.,g35199,0,TRUE,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13458,1,It is better to do everything for our patients so they can recover faster.,g35200,1,FALSE,1,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13459,0,Everyday of bedrest requires 2 days to regain strength.,g35201,0,TRUE,1,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13459,1,Everyday of bedrest requires 2 days to regain strength.,g35202,1,FALSE,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13460,0,To maximize function during hospitalization you would do which of the following:,g35203,0,"Focus on what patients can do, not the disability",0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13460,1,To maximize function during hospitalization you would do which of the following:,g35204,1,Eliminate or reduce immobilization,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13460,2,To maximize function during hospitalization you would do which of the following:,g35205,2,Incorporate mobility on whatever care is given to the patient,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13460,3,To maximize function during hospitalization you would do which of the following:,g35206,3,Encourage patient to be up and out of bed,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13460,4,To maximize function during hospitalization you would do which of the following:,g35207,4,Encourage self-care activities,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13460,5,To maximize function during hospitalization you would do which of the following:,g35208,5,All of the above,1,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13461,0,Immobility results in which of the following: <ol> <ol>a. Changes in blood pressure</ol> <ol>b. Blood clots in the legs and lungs</ol> <ol>c. Incontinence</ol> <ol>d. Pressure Ulcers</ol> <ol>e. Better resistance to infections</ol> <ol>f.   Pain</ol> </ol>,g35209,0,All of the above,0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13461,1,Immobility results in which of the following: <ol> <ol>a. Changes in blood pressure</ol> <ol>b. Blood clots in the legs and lungs</ol> <ol>c. Incontinence</ol> <ol>d. Pressure Ulcers</ol> <ol>e. Better resistance to infections</ol> <ol>f.   Pain</ol> </ol>,g35210,1,"a, b, c, d and f are correct",1,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6532,8336,Elearning-0000-1212,g3544,g13461,2,Immobility results in which of the following: <ol> <ol>a. Changes in blood pressure</ol> <ol>b. Blood clots in the legs and lungs</ol> <ol>c. Incontinence</ol> <ol>d. Pressure Ulcers</ol> <ol>e. Better resistance to infections</ol> <ol>f.   Pain</ol> </ol>,g35211,2,"a, b, d, and f are correct",0,PREVENTION OF FUNCTIONAL DECLINE FOR PCTS
6406,9432,Elearning-0000-67,g3496,g13320,0,I have received and printed the required initial competency documentation.,g34700,0,TRUE,1,INITIAL COMPETENCY FOR PHYSICIAN PRACTICES
6406,9432,Elearning-0000-67,g3496,g13320,1,I have received and printed the required initial competency documentation.,g34701,1,FALSE,0,INITIAL COMPETENCY FOR PHYSICIAN PRACTICES
6005,8340,Elearning-0000-1216,g3127,g13178,0,I have read and understood the content of this module.,g34306,0,TRUE,1,CARE PARTNER OVERVIEW
6005,8340,Elearning-0000-1216,g3127,g13178,1,I have read and understood the content of this module.,g34307,1,FALSE,0,CARE PARTNER OVERVIEW
5994,8341,Elearning-0000-1217,g3125,g13157,0,I have read and understood the content of this module.,g34230,0,TRUE,1,ECHO PRIORITY PROTOCOL: SURGICAL IMPLICATIONS
5994,8341,Elearning-0000-1217,g3125,g13157,1,I have read and understood the content of this module.,g34231,1,FALSE,0,ECHO PRIORITY PROTOCOL: SURGICAL IMPLICATIONS
5963,9589,Elearning-0000-812,g3123,g13151,0,Which of the following is most likely to be a symptom of Acute Coronary Syndrome (ACS)?,g34210,0,Bilateral arm tingling,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13151,1,Which of the following is most likely to be a symptom of Acute Coronary Syndrome (ACS)?,g34211,1,Right arm swelling,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13151,2,Which of the following is most likely to be a symptom of Acute Coronary Syndrome (ACS)?,g34212,2,Left jaw pain,1,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13151,3,Which of the following is most likely to be a symptom of Acute Coronary Syndrome (ACS)?,g34213,3,Frequent urination,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13152,0,Which of the following types of patients are most likely to experience atypical symptoms of ACS?,g34214,0,Females,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13152,1,Which of the following types of patients are most likely to experience atypical symptoms of ACS?,g34215,1,Diabetics,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13152,2,Which of the following types of patients are most likely to experience atypical symptoms of ACS?,g34216,2,Elderly,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13152,3,Which of the following types of patients are most likely to experience atypical symptoms of ACS?,g34217,3,All of the above,1,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13153,0,What should you do immediately after obtaining a 3-5 minute ECG?,g34218,0,Stamp it and show it to the physician,1,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13153,1,What should you do immediately after obtaining a 3-5 minute ECG?,g34219,1,Leave it on the physician's desk,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13153,2,What should you do immediately after obtaining a 3-5 minute ECG?,g34220,2,Put it on the patient's chart,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13153,3,What should you do immediately after obtaining a 3-5 minute ECG?,g34221,3,Give it to the triage nurse,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13154,0,You are working at the triage desk when a 50-year-old patient comes in and complains of heartburn.  What should you do FIRST?,g34222,0,Register them,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13154,1,You are working at the triage desk when a 50-year-old patient comes in and complains of heartburn.  What should you do FIRST?,g34223,1,Obtain a 12-lead ECG,1,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13154,2,You are working at the triage desk when a 50-year-old patient comes in and complains of heartburn.  What should you do FIRST?,g34224,2,Ask the triage nurse to see them,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13154,3,You are working at the triage desk when a 50-year-old patient comes in and complains of heartburn.  What should you do FIRST?,g34225,3,Ask to see their insurance card,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13155,0,"True or False?  If you are unsure whether a patient needs an ECG or not, you should be on the safe side & do the ECG.",g34226,0,TRUE,1,ACS SIGNS & SYMPTOMS FOR ED TECHS
5963,9589,Elearning-0000-812,g3123,g13155,1,"True or False?  If you are unsure whether a patient needs an ECG or not, you should be on the safe side & do the ECG.",g34227,1,FALSE,0,ACS SIGNS & SYMPTOMS FOR ED TECHS
5941,8343,Elearning-0000-1219,g3115,g13069,0,The Neptune 2 Waste Management System has been contraindicated for:,g34047,0,Connection to closed wound drainage systems,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13069,1,The Neptune 2 Waste Management System has been contraindicated for:,g34048,1,Connection directly to chest tubes,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13069,2,The Neptune 2 Waste Management System has been contraindicated for:,g34049,2,Both A and B,1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13069,3,The Neptune 2 Waste Management System has been contraindicated for:,g34050,3,None of the above,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13070,0,"The new color-coded labels that surround the two knobs indicate low (green), medium (yellow), and high (orange) levels of suction. What are the ranges in mm-Hg associated with each level?",g34051,0,"Low: 0-50, Medium: 50-120, High: 120-480",0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13070,1,"The new color-coded labels that surround the two knobs indicate low (green), medium (yellow), and high (orange) levels of suction. What are the ranges in mm-Hg associated with each level?",g34052,1,"Low: 50-75, Medium: 80-115, High: 120-480",1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13070,2,"The new color-coded labels that surround the two knobs indicate low (green), medium (yellow), and high (orange) levels of suction. What are the ranges in mm-Hg associated with each level?",g34053,2,"Low: 50-120, Medium: 120-200, High: 200-480",0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13070,3,"The new color-coded labels that surround the two knobs indicate low (green), medium (yellow), and high (orange) levels of suction. What are the ranges in mm-Hg associated with each level?",g34054,3,"Low: 0-80, Medium: 80-150, High: 150-480",0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13071,0,"The Neptune 2 rover can be used with organ/patient stabilizers, commonly referred to as ""bean bags.""",g34055,0,TRUE,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13071,1,"The Neptune 2 rover can be used with organ/patient stabilizers, commonly referred to as ""bean bags.""",g34056,1,FALSE,1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13072,0,Closed wound drains like Jackson-Pratt and Hemovac cannot be attached directly to Neptune 2.,g34057,0,TRUE,1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13072,1,Closed wound drains like Jackson-Pratt and Hemovac cannot be attached directly to Neptune 2.,g34058,1,FALSE,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13073,0,"In order to activate suction after turning the Neptune 2 rover on, you must:",g34059,0,Ensure both knobs used for adjusting levels of suction are turned down to 0,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13073,1,"In order to activate suction after turning the Neptune 2 rover on, you must:",g34060,1,Read the IFU,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13073,2,"In order to activate suction after turning the Neptune 2 rover on, you must:",g34061,2,Press OK on the warning screen demonstrating awareness that Neptune 2 is a high suction device,1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13073,3,"In order to activate suction after turning the Neptune 2 rover on, you must:",g34062,3,Empty both the 4- and 20-liter canisters,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13074,0,"When adjusting the level of suction, you might hear a beep. This indicates:",g34063,0,Suction has been activated,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13074,1,"When adjusting the level of suction, you might hear a beep. This indicates:",g34064,1,"Suction level in mm-Hg has moved into the ""Medium"" range",0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13074,2,"When adjusting the level of suction, you might hear a beep. This indicates:",g34065,2,The bottom canister is full,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13074,3,"When adjusting the level of suction, you might hear a beep. This indicates:",g34066,3,"Suction level in mm-Hg has moved into the ""High"" range",1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13075,0,"After adjusting levels of suction, you may notice the words ""Setting"" and/or ""Actual"" under the numeric suction level on the main display screen. What is the difference between the two?",g34067,0,"""Setting"" appears for 5 seconds after the level of suction has been adjusted; ""Actual"" appears after those 5 seconds to indicate the current level of suction in the canister.",1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13075,1,"After adjusting levels of suction, you may notice the words ""Setting"" and/or ""Actual"" under the numeric suction level on the main display screen. What is the difference between the two?",g34068,1,"""Setting"" is the default level of suction programmed into the rover and will always read ""0 mm-Hg""; ""Actual"" is the level of suction used the most often.",0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13075,2,"After adjusting levels of suction, you may notice the words ""Setting"" and/or ""Actual"" under the numeric suction level on the main display screen. What is the difference between the two?",g34069,2,"""Setting"" and ""Actual"" mean the same thing.",0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13075,3,"After adjusting levels of suction, you may notice the words ""Setting"" and/or ""Actual"" under the numeric suction level on the main display screen. What is the difference between the two?",g34070,3,"""Setting"" will always be lower than ""Actual.""",0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13076,0,"When suction has been adjusted into the ""High"" range, the main display screen will invert coloring; and the word ""High"" will appear next to the current suction level.",g34071,0,TRUE,1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13076,1,"When suction has been adjusted into the ""High"" range, the main display screen will invert coloring; and the word ""High"" will appear next to the current suction level.",g34072,1,FALSE,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13077,0,Specific labels were added to the Neptune 2 rover to show that it can be used both in the OR and post operatively.,g34073,0,TRUE,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13077,1,Specific labels were added to the Neptune 2 rover to show that it can be used both in the OR and post operatively.,g34074,1,FALSE,1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13078,0,What suction levels should you use for a procedure?,g34075,0,480 mm-Hg always,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13078,1,What suction levels should you use for a procedure?,g34076,1,Maximum required to achieve desired clinical outcome,0,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13078,2,What suction levels should you use for a procedure?,g34077,2,Minimum required to achieve desired clinical outcome,1,2014_NEPTUNE 2 UPGRADE TRAINING
5941,8343,Elearning-0000-1219,g3115,g13078,3,What suction levels should you use for a procedure?,g34078,3,"Any level considered ""Medium"" (80-115 mm-Hg)",0,2014_NEPTUNE 2 UPGRADE TRAINING
5929,8345,Elearning-0000-1220,g3113,g13065,0,It is not necessary for a doctor to be present during the apnea testing.,g34039,0,TRUE,0,BRAIN DEATH/APNEA TESTING
5929,8345,Elearning-0000-1220,g3113,g13065,1,It is not necessary for a doctor to be present during the apnea testing.,g34040,1,FALSE,1,BRAIN DEATH/APNEA TESTING
5929,8345,Elearning-0000-1220,g3113,g13066,0,Patient is to be placed on t-tube 100% FiO2 at 12 l/m or on vent in CPAP mode on 100% FiO2 to perform test.,g34041,0,TRUE,1,BRAIN DEATH/APNEA TESTING
5929,8345,Elearning-0000-1220,g3113,g13066,1,Patient is to be placed on t-tube 100% FiO2 at 12 l/m or on vent in CPAP mode on 100% FiO2 to perform test.,g34042,1,FALSE,0,BRAIN DEATH/APNEA TESTING
5929,8345,Elearning-0000-1220,g3113,g13067,0,If respiratory movements are absent and arterial PaCO2 is greater than or equal to 60 mmHg (consider optional 20 mmHg increase in PaCO2 over a normal baseline) as a positive test (supports diagnosis of brain death).,g34043,0,TRUE,1,BRAIN DEATH/APNEA TESTING
5929,8345,Elearning-0000-1220,g3113,g13067,1,If respiratory movements are absent and arterial PaCO2 is greater than or equal to 60 mmHg (consider optional 20 mmHg increase in PaCO2 over a normal baseline) as a positive test (supports diagnosis of brain death).,g34044,1,FALSE,0,BRAIN DEATH/APNEA TESTING
5926,8346,Elearning-0000-1221,g3112,g13055,0,An incident report must be completed for ALL IV infiltrations?,g34016,0,TRUE,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13055,1,An incident report must be completed for ALL IV infiltrations?,g34017,1,FALSE,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13056,0,The Charge Nurse is responsible for completing and IV infiltration related incident report.,g34018,0,TRUE,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13056,1,The Charge Nurse is responsible for completing and IV infiltration related incident report.,g34019,1,FALSE,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13057,0,Where do you find an online incident report?,g34020,0,"Lucidoc, Patient Care",0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13057,1,Where do you find an online incident report?,g34021,1,NetLearning,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13057,2,Where do you find an online incident report?,g34022,2,"NSH Intranet, Applications",1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13058,0,What Incident Category do IV infiltrations always fall under?,g34023,0,Patient General,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13058,1,What Incident Category do IV infiltrations always fall under?,g34024,1,Patient Operative and Other Procedures,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13058,2,What Incident Category do IV infiltrations always fall under?,g34025,2,Safety and Security,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13059,0,There is an IV RELATED option that should be chosen when specifying the type of incident.,g34026,0,TRUE,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13059,1,There is an IV RELATED option that should be chosen when specifying the type of incident.,g34027,1,FALSE,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13060,0,Which type of details should be included in your description of the event?,g34028,0,Subjective,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13060,1,Which type of details should be included in your description of the event?,g34029,1,Objective,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13061,0,An objective statement is a statement of opinion rather than a statement of fact.,g34030,0,TRUE,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13061,1,An objective statement is a statement of opinion rather than a statement of fact.,g34031,1,FALSE,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13062,0,The NP or MD should ALWAYS be notified of a suspected IV infiltration.,g34032,0,TRUE,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13062,1,The NP or MD should ALWAYS be notified of a suspected IV infiltration.,g34033,1,FALSE,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13063,0,"If an IV infiltration requires medical intervention, what is the correct Outcome to choose?",g34034,0,Treat IV infiltration with Hyaluronidaze per protocol,1,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13063,1,"If an IV infiltration requires medical intervention, what is the correct Outcome to choose?",g34035,1,Discontinue IV and elevate extremity,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13063,2,"If an IV infiltration requires medical intervention, what is the correct Outcome to choose?",g34036,2,Treat IV infiltration with saline soaks,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13064,0,It is appropriate to make a note in the Nurse's Notes section of a flow sheet that an incident report was completed?,g34037,0,TRUE,0,INFILTRATION INCIDENT REPORTING
5926,8346,Elearning-0000-1221,g3112,g13064,1,It is appropriate to make a note in the Nurse's Notes section of a flow sheet that an incident report was completed?,g34038,1,FALSE,1,INFILTRATION INCIDENT REPORTING
5907,8298,Elearning-0000-1179,g3103,g13035,0,Which of the following is a LONG acting insulin?,g33954,0,Regular,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13035,1,Which of the following is a LONG acting insulin?,g33955,1,Humalog,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13035,2,Which of the following is a LONG acting insulin?,g33956,2,Lantus,1,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13035,3,Which of the following is a LONG acting insulin?,g33957,3,All of the above,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13036,0,True or False?  Diabetic Ketoacidosis (DKA) is most common in Type 1 Diabetes.,g33958,0,TRUE,1,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13036,1,True or False?  Diabetic Ketoacidosis (DKA) is most common in Type 1 Diabetes.,g33959,1,FALSE,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13037,0,You have just given 1 amp of D50 (dextrose 50%) to a patient suffering from acute hypoglycemia.  When will you need to re-check the patient's blood glucose?,g33960,0,In 5 minutes,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13037,1,You have just given 1 amp of D50 (dextrose 50%) to a patient suffering from acute hypoglycemia.  When will you need to re-check the patient's blood glucose?,g33961,1,In 15 minutes,1,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13037,2,You have just given 1 amp of D50 (dextrose 50%) to a patient suffering from acute hypoglycemia.  When will you need to re-check the patient's blood glucose?,g33962,2,In 30 minutes,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13037,3,You have just given 1 amp of D50 (dextrose 50%) to a patient suffering from acute hypoglycemia.  When will you need to re-check the patient's blood glucose?,g33963,3,In 1 hour,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13038,0,You have just given a dose of regular insulin IV.  When will you need to re-check the patient's blood glucose?,g33964,0,In 15 minutes,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13038,1,You have just given a dose of regular insulin IV.  When will you need to re-check the patient's blood glucose?,g33965,1,In 30 minutes,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13038,2,You have just given a dose of regular insulin IV.  When will you need to re-check the patient's blood glucose?,g33966,2,In 1 hour,1,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13038,3,You have just given a dose of regular insulin IV.  When will you need to re-check the patient's blood glucose?,g33967,3,In 2 hours,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13039,0,"You have just taken report from another nurse, and the physician adds a new order for 5 units of regular insulin IV.  What should you do before administering this medication?",g33968,0,Check the patient's last blood glucose test result.,0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13039,1,"You have just taken report from another nurse, and the physician adds a new order for 5 units of regular insulin IV.  What should you do before administering this medication?",g33969,1,"After you draw up the insulin, have another RN verify that the medication, dose, route, and amount of insulin in the syringe are correct.",0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13039,2,"You have just taken report from another nurse, and the physician adds a new order for 5 units of regular insulin IV.  What should you do before administering this medication?",g33970,2,"Using the patient's arm band, verify two patient identifiers.",0,DIABETES MANAGEMENT FOR ED NURSES
5907,8298,Elearning-0000-1179,g3103,g13039,3,"You have just taken report from another nurse, and the physician adds a new order for 5 units of regular insulin IV.  What should you do before administering this medication?",g33971,3,All of the above.,1,DIABETES MANAGEMENT FOR ED NURSES
5901,9506,Elearning-0000-737,g3102,g13024,0,Identify this ectopic beat:,g33910,0,Delta Wave,0,CARDIAC RHYTHMS FOR ED NURSES
5901,9506,Elearning-0000-737,g3102,g13024,1,Identify this ectopic beat:,g33911,1,Premature Ventricular Contraction (PVC),0,CARDIAC RHYTHMS FOR ED NURSES
5901,9506,Elearning-0000-737,g3102,g13024,2,Identify this ectopic beat:,g33912,2,Premature Atrial Contraction (PAC),1,CARDIAC RHYTHMS FOR ED NURSES
5901,9506,Elearning-0000-737,g3102,g13024,3,Identify this ectopic beat:,g33913,3,Premature Junctional Contraction (PJC),0,CARDIAC RHYTHMS FOR ED NURSES
5865,8349,Elearning-0000-1224,g3093,g12984,0,Which is a risk factor for heart failure?,g33780,0,Diabetes,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12984,1,Which is a risk factor for heart failure?,g33781,1,Hypertension,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12984,2,Which is a risk factor for heart failure?,g33782,2,Cocaine use,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12984,3,Which is a risk factor for heart failure?,g33783,3,All of the above,1,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12985,0,Which of the following is NOT a symptom of heart failure?,g33784,0,Edema,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12985,1,Which of the following is NOT a symptom of heart failure?,g33785,1,Activity intolerance,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12985,2,Which of the following is NOT a symptom of heart failure?,g33786,2,Seizures,1,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12985,3,Which of the following is NOT a symptom of heart failure?,g33787,3,"""Wet"" cough",0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12986,0,Which elevated lab value may be an indicator of heart failure?,g33788,0,BNP,1,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12986,1,Which elevated lab value may be an indicator of heart failure?,g33789,1,WBC,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12986,2,Which elevated lab value may be an indicator of heart failure?,g33790,2,Troponin,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12986,3,Which elevated lab value may be an indicator of heart failure?,g33791,3,Lactate,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12987,0,Your heart failure patient tells you that they weigh 220 lbs.  What should you document for their weight?,g33792,0,220 lbs. (the patient said that's what they weigh!),0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12987,1,Your heart failure patient tells you that they weigh 220 lbs.  What should you document for their weight?,g33793,1,Get an exact weight and document that,1,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12987,2,Your heart failure patient tells you that they weigh 220 lbs.  What should you document for their weight?,g33794,2,230 lbs (the patient looks a little heavier than 220),0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12987,3,Your heart failure patient tells you that they weigh 220 lbs.  What should you document for their weight?,g33795,3,Nothing.  The inpatient nurse will get an actual weight when the patient gets admitted.,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12988,0,You are caring for a patient being admitted for heart failure.  The patient tells you they are thirsty.  What should you do?,g33796,0,Get them a glass of water,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12988,1,You are caring for a patient being admitted for heart failure.  The patient tells you they are thirsty.  What should you do?,g33797,1,Get them a diet soda,0,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12988,2,You are caring for a patient being admitted for heart failure.  The patient tells you they are thirsty.  What should you do?,g33798,2,Check with the physician,1,CHF FOR ED STAFF
5865,8349,Elearning-0000-1224,g3093,g12988,3,You are caring for a patient being admitted for heart failure.  The patient tells you they are thirsty.  What should you do?,g33799,3,Increase their IV fluid rate,0,CHF FOR ED STAFF
5862,9443,Elearning-0000-68,g3092,g12982,0,I have viewed and understood the content of this module.,g33778,0,Yes,1,TYPES OF HSCT & THEIR PREPARATIVE REGIMENS
5862,9443,Elearning-0000-68,g3092,g12982,1,I have viewed and understood the content of this module.,g33779,1,No,0,TYPES OF HSCT & THEIR PREPARATIVE REGIMENS
5854,8347,Elearning-0000-1222,g3085,g12924,0,I have read and fully understand the Xray Line and Tube Position CBL,g33579,0,Yes,1,XRAY LINE & TUBE POSITION
5854,8347,Elearning-0000-1222,g3085,g12924,1,I have read and fully understand the Xray Line and Tube Position CBL,g33580,1,No,0,XRAY LINE & TUBE POSITION
5851,2857,ILT-0000-13708,g3082,g12900,0,What is NAS?,g33528,0,Neonatal Abstinence Scoring,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12900,1,What is NAS?,g33529,1,Neonatal Abstinence Symptoms,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12900,2,What is NAS?,g33530,2,Neonatal Abstinence Syndrome,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12900,3,What is NAS?,g33531,3,Need Another System,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12901,0,When does NAS occur?,g33532,0,NAS can occur as a result of repeated use of drugs by the mother,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12901,1,When does NAS occur?,g33533,1,NAS can occur after short-term high dose drug administration to the infant,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12901,2,When does NAS occur?,g33534,2,NAS can occur as a result of repeated use of alcohol by the mother,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12901,3,When does NAS occur?,g33535,3,A & B,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12901,4,When does NAS occur?,g33536,4,All of the above,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12902,0,The symptoms of NAS depend on:,g33537,0,The type of drug that was used,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12902,1,The symptoms of NAS depend on:,g33538,1,How the mother's/infant's body breakdown the drug,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12902,2,The symptoms of NAS depend on:,g33539,2,How much and how long the drug was used,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12902,3,The symptoms of NAS depend on:,g33540,3,Whether the baby was born full-term or premature,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12902,4,The symptoms of NAS depend on:,g33541,4,All of the above,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12903,0,What is the benefit of maternal methadone to the infant?,g33542,0,Permits a more stable intrauterine environment for the fetus,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12903,1,What is the benefit of maternal methadone to the infant?,g33543,1,Decreasing chances of hypoxia,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12903,2,What is the benefit of maternal methadone to the infant?,g33544,2,Decreases birth weight,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12903,3,What is the benefit of maternal methadone to the infant?,g33545,3,All of the above,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12903,4,What is the benefit of maternal methadone to the infant?,g33546,4,A & B,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12904,0,Signs and symptoms of NAS may not be exhibited for up how many hours after birth?,g33547,0,Up to 24 hours,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12904,1,Signs and symptoms of NAS may not be exhibited for up how many hours after birth?,g33548,1,Up to 48 hours,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12904,2,Signs and symptoms of NAS may not be exhibited for up how many hours after birth?,g33549,2,Up to 72 hours,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12904,3,Signs and symptoms of NAS may not be exhibited for up how many hours after birth?,g33550,3,Up to 120 hours,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12905,0,Sub acute signs and symptoms that may persist for 4-6 months include:,g33551,0,Irritability and sleep pattern disturbance,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12905,1,Sub acute signs and symptoms that may persist for 4-6 months include:,g33552,1,Fever and nasal stuffiness,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12905,2,Sub acute signs and symptoms that may persist for 4-6 months include:,g33553,2,Feeding problems and hypertonia,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12905,3,Sub acute signs and symptoms that may persist for 4-6 months include:,g33554,3,A & C,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12905,4,Sub acute signs and symptoms that may persist for 4-6 months include:,g33555,4,All of the above,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12906,0,Therapeutic handling of the NAS infant includes all of the following except:,g33556,0,Swaddling,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12906,1,Therapeutic handling of the NAS infant includes all of the following except:,g33557,1,Swaying side to side,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12906,2,Therapeutic handling of the NAS infant includes all of the following except:,g33558,2,C- position,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12906,3,Therapeutic handling of the NAS infant includes all of the following except:,g33559,3,Rocking back and forth,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12906,4,Therapeutic handling of the NAS infant includes all of the following except:,g33560,4,Quiet environment,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12907,0,The mother and baby will be referred to case management/Social service for assessment and possible DFACS referral in the following circumstances,g33561,0,History of maternal drug use during this pregnancy,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12907,1,The mother and baby will be referred to case management/Social service for assessment and possible DFACS referral in the following circumstances,g33562,1,Positive maternal toxicology screen,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12907,2,The mother and baby will be referred to case management/Social service for assessment and possible DFACS referral in the following circumstances,g33563,2,"Positive newborn urine or meconium 	test",0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12907,3,The mother and baby will be referred to case management/Social service for assessment and possible DFACS referral in the following circumstances,g33564,3,Referral order from MD/NP,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12907,4,The mother and baby will be referred to case management/Social service for assessment and possible DFACS referral in the following circumstances,g33565,4,All of the above,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12908,0,Non Pharmacologic comfort measures for NAS include but are not limited to:,g33566,0,Pacifier Use for non nutritive sucking,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12908,1,Non Pharmacologic comfort measures for NAS include but are not limited to:,g33567,1,PRN nasal suctioning,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12908,2,Non Pharmacologic comfort measures for NAS include but are not limited to:,g33568,2,Skin care,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12908,3,Non Pharmacologic comfort measures for NAS include but are not limited to:,g33569,3,Demand feedings,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12908,4,Non Pharmacologic comfort measures for NAS include but are not limited to:,g33570,4,All of the above,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12909,0,It is not important for the primary care giver of a NAS baby to spend as much time as possible with the infant to begin building the skills they will need prior to discharge,g33571,0,TRUE,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12909,1,It is not important for the primary care giver of a NAS baby to spend as much time as possible with the infant to begin building the skills they will need prior to discharge,g33572,1,FALSE,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12910,0,"After titrating the prescribed withdrawal medication, how long will it take before the infant exhibits withdrawal symptoms related to the decreased dose?",g33573,0,6 hours,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12910,1,"After titrating the prescribed withdrawal medication, how long will it take before the infant exhibits withdrawal symptoms related to the decreased dose?",g33574,1,12 hours,1,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12910,2,"After titrating the prescribed withdrawal medication, how long will it take before the infant exhibits withdrawal symptoms related to the decreased dose?",g33575,2,24 Hours,0,NEONATAL ABSTINENCE SYNDROME
5851,2857,ILT-0000-13708,g3082,g12910,3,"After titrating the prescribed withdrawal medication, how long will it take before the infant exhibits withdrawal symptoms related to the decreased dose?",g33576,3,72 Hours,0,NEONATAL ABSTINENCE SYNDROME
5849,8350,Elearning-0000-1225,g3081,g12887,0,"Until resolution of the infiltrate is complete, site assessment/appearance of the infiltrate and all interventions should be documented in the shift assessment and nursing note at a minimum of once a shift.",g33494,0,TRUE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12887,1,"Until resolution of the infiltrate is complete, site assessment/appearance of the infiltrate and all interventions should be documented in the shift assessment and nursing note at a minimum of once a shift.",g33495,1,FALSE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12888,0,A warm compress may be applied to an infiltrate as a comfort measure and to reduce swelling.,g33496,0,TRUE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12888,1,A warm compress may be applied to an infiltrate as a comfort measure and to reduce swelling.,g33497,1,FALSE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12889,0,During infusions the nurse must evaluate and palpate IV sites and surrounding tissue hourly and document site appearance,g33498,0,TRUE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12889,1,During infusions the nurse must evaluate and palpate IV sites and surrounding tissue hourly and document site appearance,g33499,1,FALSE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12890,0,"Baby B has an infiltration. Nurse C's intervention will be to discontinue the catheter, apply pressure at the insertion site to prevent blood and fluid loss, and notify MD of infiltration.",g33500,0,TRUE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12890,1,"Baby B has an infiltration. Nurse C's intervention will be to discontinue the catheter, apply pressure at the insertion site to prevent blood and fluid loss, and notify MD of infiltration.",g33501,1,FALSE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12891,0,"Hyaluronidase, Phentolomine, and Nitroglycerin Ointment, are agents used in the SCN to treat infiltrations and require an MD order prior to use.",g33502,0,TRUE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12891,1,"Hyaluronidase, Phentolomine, and Nitroglycerin Ointment, are agents used in the SCN to treat infiltrations and require an MD order prior to use.",g33503,1,FALSE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12893,0,"When a pump occlusion is indicated, assess the IV site immediately. Observe for mechanical obstructions such as flexed limbs, clamped or kinked tubing, and armboards or tapes which may be obstructing infusion. If mechanical obstructions are  absent, disconnect the IVF and assess vein patency.",g33508,0,TRUE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12893,1,"When a pump occlusion is indicated, assess the IV site immediately. Observe for mechanical obstructions such as flexed limbs, clamped or kinked tubing, and armboards or tapes which may be obstructing infusion. If mechanical obstructions are  absent, disconnect the IVF and assess vein patency.",g33509,1,FALSE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12896,0,Hourly assessment of an infusion may be deferred for one hour but only for a sedated infant or an infant undergoing a procedure.,g33518,0,TRUE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12896,1,Hourly assessment of an infusion may be deferred for one hour but only for a sedated infant or an infant undergoing a procedure.,g33519,1,FALSE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12898,0,All infiltrations regardless of the severity should be reported to the MD/NP and Charge RN and documented that the above persons have been notified.,g33524,0,TRUE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12898,1,All infiltrations regardless of the severity should be reported to the MD/NP and Charge RN and documented that the above persons have been notified.,g33525,1,FALSE,0,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12899,0,All infiltrations regardless of the severity should be reported to the MD/NP and Charge RN and documented that the above persons have been notified.,g33526,0,TRUE,1,IV INFILTRATION
5849,8350,Elearning-0000-1225,g3081,g12899,1,All infiltrations regardless of the severity should be reported to the MD/NP and Charge RN and documented that the above persons have been notified.,g33527,1,FALSE,0,IV INFILTRATION
5810,9454,Elearning-0000-69,g3057,g12808,0,I have read and understood the content of this module.,g33228,0,Yes,1,INVESTIGATOR TRAINING & COMPLIANCE (11-2013)
5810,9454,Elearning-0000-69,g3057,g12808,1,I have read and understood the content of this module.,g33229,1,No,0,INVESTIGATOR TRAINING & COMPLIANCE (11-2013)
5747,9487,Elearning-0000-72,g3017,g12521,0,Which of the following statements regarding payment to subjects for study participation is true?,g32174,0,Payment for participation should be listed in the consent as a benefit,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12521,1,Which of the following statements regarding payment to subjects for study participation is true?,g32175,1,The amount and schedule of payment paid should not be stated in the consent,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12521,2,Which of the following statements regarding payment to subjects for study participation is true?,g32176,2,Payment should accrue as the study progresses and not be contingent upon the subject completing the entire study.,1,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12521,3,Which of the following statements regarding payment to subjects for study participation is true?,g32177,3,"Even if payments are given as part of the study, anything regarding payments should never be referenced in the consent",0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12522,0,"Under the statement of voluntary consent, the subject should be asked to certify completeness of disclosure (e.g., ""This study has been fully explained to me"", or ""I fully understand the study"").",g32178,0,TRUE,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12522,1,"Under the statement of voluntary consent, the subject should be asked to certify completeness of disclosure (e.g., ""This study has been fully explained to me"", or ""I fully understand the study"").",g32179,1,FALSE,1,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12524,0,"As a general requirement, the consent form should be consistent with which of the following?",g32184,0,Protocol,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12524,1,"As a general requirement, the consent form should be consistent with which of the following?",g32185,1,Northside Hospital Research Feasibility Assessment Form (FAF),0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12524,2,"As a general requirement, the consent form should be consistent with which of the following?",g32186,2,IRB Submission Application,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12524,3,"As a general requirement, the consent form should be consistent with which of the following?",g32187,3,Only b and c,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12524,4,"As a general requirement, the consent form should be consistent with which of the following?",g32188,4,All of the above,1,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12525,0,The consent form should contain language that:,g32189,0,Requires waiver of a subject's rights or releases any party from liability.,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12525,1,The consent form should contain language that:,g32190,1,Suggests coercion or undue influence,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12525,2,The consent form should contain language that:,g32191,2,Gives an explanation of the purpose(s) of the research and why the potential research subject is eligible to enroll.,1,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12525,3,The consent form should contain language that:,g32192,3,Suggests a guarantee or assumption of success,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12527,0,"The names, address and contact numbers for the following should be included in the consent:",g32197,0,Principal Investigator,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12527,1,"The names, address and contact numbers for the following should be included in the consent:",g32198,1,Regulatory Coordinator,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12527,2,"The names, address and contact numbers for the following should be included in the consent:",g32199,2,Study Sponsor,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12527,3,"The names, address and contact numbers for the following should be included in the consent:",g32200,3,All of the above,0,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5747,9487,Elearning-0000-72,g3017,g12527,4,"The names, address and contact numbers for the following should be included in the consent:",g32201,4,Only a and c,1,RESEARCH SUBJECT CONSENT FORMS (10-2013)
5680,9784,Elearning-0000-99,g2972,g12215,0,I have read and completely understand the VISIBILITY TRAINING: TRANSPORT PROCESSES CBL?,g31202,0,Yes,1,VISIBILITY TRAINING: TRANSPORT PROCESSES (09-2013)
5680,9784,Elearning-0000-99,g2972,g12215,1,I have read and completely understand the VISIBILITY TRAINING: TRANSPORT PROCESSES CBL?,g31203,1,No,0,VISIBILITY TRAINING: TRANSPORT PROCESSES (09-2013)
5659,8100,Elearning-0000-100,g2962,g12127,0,I have read and fully understand the VISIBILITY TRAINING EVS CBL.,g30922,0,Yes,1,VISIBILITY TRAINING EVS (09-2013)
5659,8100,Elearning-0000-100,g2962,g12127,1,I have read and fully understand the VISIBILITY TRAINING EVS CBL.,g30923,1,No,0,VISIBILITY TRAINING EVS (09-2013)
5643,9663,Elearning-0000-88,g2953,g12085,0,Who is responsible for working with a physician practice to set up a Vendor Contract?,g30781,0,Proposal and Contracts Coordinator (PCC),1,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12085,1,Who is responsible for working with a physician practice to set up a Vendor Contract?,g30782,1,Research Financial Analyst (RFA),0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12085,2,Who is responsible for working with a physician practice to set up a Vendor Contract?,g30783,2,Any research employee,0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12086,0,How often are vendors invoiced?,g30784,0,Daily,0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12086,1,How often are vendors invoiced?,g30785,1,Monthly,1,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12086,2,How often are vendors invoiced?,g30786,2,Quarterly,0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12087,0,Where should completed RER forms be sent prior to the patient's research visit?,g30787,0,Research Registration (ResReg@northside.com),1,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12087,1,Where should completed RER forms be sent prior to the patient's research visit?,g30788,1,The sponsor of the study,0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12087,2,Where should completed RER forms be sent prior to the patient's research visit?,g30789,2,The main business office for Northside Hospital's laboratory.,0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12088,0,How often does the Research Financial Analyst check the HPF web queue for new research accounts?,g30790,0,Every week,0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12088,1,How often does the Research Financial Analyst check the HPF web queue for new research accounts?,g30791,1,Every month,0,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5643,9663,Elearning-0000-88,g2953,g12088,2,How often does the Research Financial Analyst check the HPF web queue for new research accounts?,g30792,2,Daily,1,WP - ADM - 003 RESEARCH BILLING PROCEDURE(08-2013)
5637,8974,Elearning-0000-253,g2947,g12066,0,Any person is able to sign an informed consent for a relative participating in a clinical trial.,g30724,0,TRUE,0,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12066,1,Any person is able to sign an informed consent for a relative participating in a clinical trial.,g30725,1,FALSE,1,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12067,0,"In the case of a minor consent, who must sign?",g30726,0,Minor,0,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12067,1,"In the case of a minor consent, who must sign?",g30727,1,Legal guardian,0,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12067,2,"In the case of a minor consent, who must sign?",g30728,2,Legally authorized representative,0,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12067,3,"In the case of a minor consent, who must sign?",g30729,3,Either a and b OR a and c,1,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12068,0,When can study procedures or tests be done for a clinical trial?,g30730,0,Before the consent is signed,0,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12068,1,When can study procedures or tests be done for a clinical trial?,g30731,1,After the consent is signed,1,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12068,2,When can study procedures or tests be done for a clinical trial?,g30732,2,After the subject reports for his first study visit.,0,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12069,0,Informed Consent is a one-time event?,g30733,0,TRUE,0,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5637,8974,Elearning-0000-253,g2947,g12069,1,Informed Consent is a one-time event?,g30734,1,FALSE,1,PP - CLI - 002 INFORMED CONSENT PROCESS(08-2013)
5555,9696,Elearning-0000-91,g2890,g11825,0,I have read and understood the content of this CBL.,g29934,0,Yes,1,WOMEN'S SVCS WEB PAGES (06-2013)
5555,9696,Elearning-0000-91,g2890,g11825,1,I have read and understood the content of this CBL.,g29935,1,No,0,WOMEN'S SVCS WEB PAGES (06-2013)
5553,8352,Elearning-0000-1227,g2888,g11808,0,I have read and understood the contents of this CBL.,g29877,0,Yes,1,VISIBILITY TRAINING - TRANSFER PATIENTS BETWEEN UNITS (06-2013)
5553,8352,Elearning-0000-1227,g2888,g11808,1,I have read and understood the contents of this CBL.,g29878,1,No,0,VISIBILITY TRAINING - TRANSFER PATIENTS BETWEEN UNITS (06-2013)
5551,8111,Elearning-0000-101,g2886,g11806,0,I have read and understood the contents of this CBL.,g29873,0,Yes,1,VISIBILITY TRAINING - TRANSFER PATIENTS FROM ICU TO ANY UNIT (06-2013)
5551,8111,Elearning-0000-101,g2886,g11806,1,I have read and understood the contents of this CBL.,g29874,1,No,0,VISIBILITY TRAINING - TRANSFER PATIENTS FROM ICU TO ANY UNIT (06-2013)
5550,8122,Elearning-0000-102,g2885,g11805,0,I have read and understood the contents of this CBL.,g29871,0,Yes,1,VISIBILITY TRAINING - HIGH LEVEL PRODUCT OVERVIEW (06-2013)
5550,8122,Elearning-0000-102,g2885,g11805,1,I have read and understood the contents of this CBL.,g29872,1,No,0,VISIBILITY TRAINING - HIGH LEVEL PRODUCT OVERVIEW (06-2013)
5549,8133,Elearning-0000-103,g2884,g11804,0,I have read and understood the contents of this CBL.,g29869,0,Yes,1,VISIBILITY TRAINING - ENVIRONMENTAL SERVICES (06-2013)
5549,8133,Elearning-0000-103,g2884,g11804,1,I have read and understood the contents of this CBL.,g29870,1,No,0,VISIBILITY TRAINING - ENVIRONMENTAL SERVICES (06-2013)
5547,8353,Elearning-0000-1228,g2882,g11802,0,I have read and understood the content of this CBL,g29865,0,Yes,1,VISIBILITY TRAINING - CUSTOM VIEW (06-2013)
5547,8353,Elearning-0000-1228,g2882,g11802,1,I have read and understood the content of this CBL,g29866,1,No,0,VISIBILITY TRAINING - CUSTOM VIEW (06-2013)
5514,9195,Elearning-0000-454,g2853,g11630,0,"True or False: If another member of the healthcare team forgets to date or time their entry in the medical record, it is perfectly acceptable to time and date the entry for them.",g29391,0,TRUE,0,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11630,1,"True or False: If another member of the healthcare team forgets to date or time their entry in the medical record, it is perfectly acceptable to time and date the entry for them.",g29392,1,FALSE,1,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11631,0,Which of the following is an appropriate method of correcting handwritten entries in the medical record?,g29393,0,Drawing multiple dark lines through the incorrect entry,0,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11631,1,Which of the following is an appropriate method of correcting handwritten entries in the medical record?,g29394,1,Using white out liquid,0,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11631,2,Which of the following is an appropriate method of correcting handwritten entries in the medical record?,g29395,2,"Drawing a single line through the incorrect entry and writing ""error"" with initials, date and time",1,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11631,3,Which of the following is an appropriate method of correcting handwritten entries in the medical record?,g29396,3,Scratching out the incorrect entry so that it cannot be read,0,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11632,0,Which of the following statements is true?,g29397,0,"When team members are busy, it is acceptable to stamp their signature on medical record forms to help them out",0,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11632,1,Which of the following statements is true?,g29398,1,"If a team member forgets to date and time an entry in the medical record, it is acceptable to write in the date and time for them",0,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11632,2,Which of the following statements is true?,g29399,2,Staff members are to only sign for actions that they did themselves,1,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5514,9195,Elearning-0000-454,g2853,g11632,3,Which of the following statements is true?,g29400,3,"When staff are busy, it is acceptable to sign off of tasks or actions that you are going to do later in the day",0,MEDICAL RECORD ENTRY REQ'S - PHYS OFFICES (05-2013)
5487,9762,Elearning-0000-97,g2833,g11521,0,I acknowledge that I have read and understood the content of WELLS FARGO TRAINING MODULE,g29049,0,Yes,1,WELLS FARGO TRAINING MODULE
5487,9762,Elearning-0000-97,g2833,g11521,1,I acknowledge that I have read and understood the content of WELLS FARGO TRAINING MODULE,g29050,1,No,0,WELLS FARGO TRAINING MODULE
5433,8188,Elearning-0000-108,g2792,g11398,0,I acknowledge I have read and understand the Varicella: Care of Mother and Baby CBL.,g28669,0,YES,1,VARICELLA: CARE OF MOTHER AND BABY
5433,8188,Elearning-0000-108,g2792,g11398,1,I acknowledge I have read and understand the Varicella: Care of Mother and Baby CBL.,g28670,1,NO,0,VARICELLA: CARE OF MOTHER AND BABY
5386,8986,Elearning-0000-264,g2758,g11301,0,"If a piece of equipment has a Biomedical Engineering PM sticker in which the date is past the expiration date, it is acceptable to use the equipment on the patient until Biomed can come out and check out the piece of equipment.",g28356,0,TRUE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11301,1,"If a piece of equipment has a Biomedical Engineering PM sticker in which the date is past the expiration date, it is acceptable to use the equipment on the patient until Biomed can come out and check out the piece of equipment.",g28357,1,FALSE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11302,0,"A patient arrives in your office that speaks some English.  In conversations with the patient, you identify that they prefer to communicate health care information in a language other than English.  Which of the following is the appropriate  step to take?",g28358,0,Tell the patient to find another doctor because we don't provide interpretation services,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11302,1,"A patient arrives in your office that speaks some English.  In conversations with the patient, you identify that they prefer to communicate health care information in a language other than English.  Which of the following is the appropriate  step to take?",g28359,1,Use the family member as an interpreter for the patient,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11302,2,"A patient arrives in your office that speaks some English.  In conversations with the patient, you identify that they prefer to communicate health care information in a language other than English.  Which of the following is the appropriate  step to take?",g28360,2,Talk louder and slower in English so that the patient can understand as much as possible,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11302,3,"A patient arrives in your office that speaks some English.  In conversations with the patient, you identify that they prefer to communicate health care information in a language other than English.  Which of the following is the appropriate  step to take?",g28361,3,Contact the Pacific Interpreter language line and obtain a qualified interpreter,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11302,4,"A patient arrives in your office that speaks some English.  In conversations with the patient, you identify that they prefer to communicate health care information in a language other than English.  Which of the following is the appropriate  step to take?",g28362,4,Have the staff member in the department who speaks that language act as the interpreter,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11303,0,Cleaning of equipment based on low level disinfection principles only has to be done between patients if the patient has a draining wound or coughs in the exam room.,g28363,0,TRUE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11303,1,Cleaning of equipment based on low level disinfection principles only has to be done between patients if the patient has a draining wound or coughs in the exam room.,g28364,1,FALSE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11304,0,HIPAA Compliance measures refer to all of the following EXCEPT which one,g28365,0,Dictations are to be completed in a areas where the patient specific information cannot be heard,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11304,1,HIPAA Compliance measures refer to all of the following EXCEPT which one,g28366,1,C-bins are inaccessible to the public,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11304,2,HIPAA Compliance measures refer to all of the following EXCEPT which one,g28367,2,Charts are locked up in cabinets when not being used so that cleaning service employees and others who do not need to know patient specific information do not have access to that information,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11304,3,HIPAA Compliance measures refer to all of the following EXCEPT which one,g28368,3,A single line is drawn through the patient's name on the sign-in sheet after the patient has checked in,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11304,4,HIPAA Compliance measures refer to all of the following EXCEPT which one,g28369,4,Staff discuss personal health information about a patient in private areas only,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5386,8986,Elearning-0000-264,g2758,g11304,5,HIPAA Compliance measures refer to all of the following EXCEPT which one,g28370,5,Staff do not share passwords and use ID's for computer access,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 5: TOPICS FOR ALL STAFF
5385,8987,Elearning-0000-265,g2757,g11298,0,"Temperatures of refrigerators for patient food, supplies and medication do not need to be monitored over the weekend, holidays or other times the offices are closed.",g28346,0,TRUE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11298,1,"Temperatures of refrigerators for patient food, supplies and medication do not need to be monitored over the weekend, holidays or other times the offices are closed.",g28347,1,FALSE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11299,0,Employees who are concerned or worried about the care being provided to patients should do which of the following:,g28348,0,Ignore their concerns.  The physician knows what is best for the patient,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11299,1,Employees who are concerned or worried about the care being provided to patients should do which of the following:,g28349,1,Go home and sleep on it,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11299,2,Employees who are concerned or worried about the care being provided to patients should do which of the following:,g28350,2,Implement the Chain of Command,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11299,3,Employees who are concerned or worried about the care being provided to patients should do which of the following:,g28351,3,Refuse to provide care to the patients,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11300,0,Employees who do not recertify their CPR within the required 2 year timeframe will :,g28352,0,Be allowed to work until they can get into a CPR class,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11300,1,Employees who do not recertify their CPR within the required 2 year timeframe will :,g28353,1,Taken off of the work schedule until their CPR has been renewed,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11300,2,Employees who do not recertify their CPR within the required 2 year timeframe will :,g28354,2,Be reassigned to a job that does not require patient contact or interaction,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5385,8987,Elearning-0000-265,g2757,g11300,3,Employees who do not recertify their CPR within the required 2 year timeframe will :,g28355,3,Given a second warning,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 4: CLINICAL TOPICS
5384,8988,Elearning-0000-266,g2756,g11295,0,The employees can choose whether or not to follow the requirements for any of the NPSG without any consequence expected.,g28340,0,TRUE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 3: NPSG EDUCATION
5384,8988,Elearning-0000-266,g2756,g11295,1,The employees can choose whether or not to follow the requirements for any of the NPSG without any consequence expected.,g28341,1,FALSE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 3: NPSG EDUCATION
5384,8988,Elearning-0000-266,g2756,g11296,0,Employees should complete an incident report whenever they have a safety concern or issue with a process impacting patient or staff safety.,g28342,0,TRUE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 3: NPSG EDUCATION
5384,8988,Elearning-0000-266,g2756,g11296,1,Employees should complete an incident report whenever they have a safety concern or issue with a process impacting patient or staff safety.,g28343,1,FALSE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 3: NPSG EDUCATION
5384,8988,Elearning-0000-266,g2756,g11297,0,"After completing an incident report and following the chain-of-command for follow-up on your concerns, staff have the right to notify The Joint Commission of their complaint or concern without fear of retaliation or disciplinary action.",g28344,0,TRUE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 3: NPSG EDUCATION
5384,8988,Elearning-0000-266,g2756,g11297,1,"After completing an incident report and following the chain-of-command for follow-up on your concerns, staff have the right to notify The Joint Commission of their complaint or concern without fear of retaliation or disciplinary action.",g28345,1,FALSE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 3: NPSG EDUCATION
5383,8989,Elearning-0000-267,g2755,g11292,0,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28323,0,Assessment and Planning,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11292,1,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28324,1,The Patient,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11292,2,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28325,2,Reporting / Communications,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11292,3,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28326,3,Workman's Comp,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11292,4,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28327,4,Human Factors,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11292,5,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28328,5,Culture,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11292,6,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28329,6,Clinical Care Systems,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11292,7,Which of the following is NOT an element of the Patient Safety Strategy for NSH?,g28330,7,Data Analysis,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11293,0,The culture of patient safety at NSH is one that promotes both professional accountability and reporting of medical errors so that systems and processes for improving patient safety through organized analysis can occur.,g28331,0,TRUE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11293,1,The culture of patient safety at NSH is one that promotes both professional accountability and reporting of medical errors so that systems and processes for improving patient safety through organized analysis can occur.,g28332,1,FALSE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11294,0,"In order to minimize the risk of inappropriate behavior or contact with a patient, which of the following guidelines should be applied?",g28333,0,Conversations with patients with sexual connotations or innuendo or related to sexual activity are strictly prohibited except as part of a required assessment,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11294,1,"In order to minimize the risk of inappropriate behavior or contact with a patient, which of the following guidelines should be applied?",g28334,1,Staff will watch for potentially hazardous situations which may pose a threat to patient safety and intervene or notify the appropriate persons to intervene to minimize risk,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11294,2,"In order to minimize the risk of inappropriate behavior or contact with a patient, which of the following guidelines should be applied?",g28335,2,Staff are encouraged to apply situational awareness principles in their performance of work activities,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11294,3,"In order to minimize the risk of inappropriate behavior or contact with a patient, which of the following guidelines should be applied?",g28336,3,Staff will protect patient privacy to the extent reasonably possible to avoid visual or auditory exposure of patients,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11294,4,"In order to minimize the risk of inappropriate behavior or contact with a patient, which of the following guidelines should be applied?",g28337,4,Staff will ensure only those involved in care or service to the patient will be present,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11294,5,"In order to minimize the risk of inappropriate behavior or contact with a patient, which of the following guidelines should be applied?",g28338,5,"Staff will explain procedures or assessment prior to their performance and request permission prior to touching breast, perineal, or rectal areas",0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5383,8989,Elearning-0000-267,g2755,g11294,6,"In order to minimize the risk of inappropriate behavior or contact with a patient, which of the following guidelines should be applied?",g28339,6,All of the above,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 2: PATIENT SAFETY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11289,0,The document that guides the activities related to quality across the system is which one of the following:,g28313,0,Department Guide to Continuous Readiness,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11289,1,The document that guides the activities related to quality across the system is which one of the following:,g28314,1,Annual Quality and Patient Safety Appraisal,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11289,2,The document that guides the activities related to quality across the system is which one of the following:,g28315,2,Organizational-Wide Goals,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11289,3,The document that guides the activities related to quality across the system is which one of the following:,g28316,3,Plan for Performance Improvement and Patient Safety,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11290,0,The model for Performance Improvement at NSH is which one of the following:,g28317,0,LEAN,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11290,1,The model for Performance Improvement at NSH is which one of the following:,g28318,1,Rapid Cycle Change,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11290,2,The model for Performance Improvement at NSH is which one of the following:,g28319,2,FOCUS-PDCA,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11290,3,The model for Performance Improvement at NSH is which one of the following:,g28320,3,Six Sigma,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11291,0,"Since Northside Hospital receives it accreditation from The Joint Commission, staff must work to be knowledgeable of processes required to comply with these standards.",g28321,0,TRUE,1,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5382,8990,Elearning-0000-268,g2754,g11291,1,"Since Northside Hospital receives it accreditation from The Joint Commission, staff must work to be knowledgeable of processes required to comply with these standards.",g28322,1,FALSE,0,PHYSICIAN OFFICE STAFF ORIENTATION-MODULE 1: QUALITY OVERVIEW
5367,8449,Elearning-0000-132,g2743,g11247,0,The teach back educational method is:,g28162,0,One more thing I have to document throughout the day.,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11247,1,The teach back educational method is:,g28163,1,An educational method that ensures the patient has understood the information taught.,1,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11247,2,The teach back educational method is:,g28164,2,An educational method that asks the patient if they understood the information taught expecting a yes or no answer.,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11247,3,The teach back educational method is:,g28165,3,"An education method that is used once, because once the patient teaches back correctly, they know the information taught.",0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11248,0,Research shows that patients forget what percentage of information taught them immediately after hearing it?,g28166,0,40-80%,1,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11248,1,Research shows that patients forget what percentage of information taught them immediately after hearing it?,g28167,1,10-30%,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11248,2,Research shows that patients forget what percentage of information taught them immediately after hearing it?,g28168,2,90%,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11248,3,Research shows that patients forget what percentage of information taught them immediately after hearing it?,g28169,3,10%,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11249,0,What aspects of the patient's self-care should be addressed in the three-day teach-back method?,g28170,0,"Knowledge, Compliance, and Mood",0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11249,1,What aspects of the patient's self-care should be addressed in the three-day teach-back method?,g28171,1,"Knowledge, Attitude, and Behavior",1,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11249,2,What aspects of the patient's self-care should be addressed in the three-day teach-back method?,g28172,2,"Knowledge, Experience, and Marital Status",0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11249,3,What aspects of the patient's self-care should be addressed in the three-day teach-back method?,g28173,3,"Knowledge, Patient's gender, How long the patient has had their diagnosis",0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11250,0,"If the patient cannot correctly teach-back the information you provided, you should:",g28174,0,"Provide further education, ask the patient again to teach-back the information provided, and document concerns and barriers.",1,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11250,1,"If the patient cannot correctly teach-back the information you provided, you should:",g28175,1,Assume the patient has low intelligence because you explained the concepts well.,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11250,2,"If the patient cannot correctly teach-back the information you provided, you should:",g28176,2,"Document n/a on the education record, because this patient won't ever be able to understand the information.",0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11250,3,"If the patient cannot correctly teach-back the information you provided, you should:",g28177,3,None of the above.,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11251,0,If a patient has been in the hospital for six days but has not had any education documented on the three day teach-back record I will:,g28178,0,Assume the patient cannot understand the information and not attempt to provide any education.,0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11251,1,If a patient has been in the hospital for six days but has not had any education documented on the three day teach-back record I will:,g28179,1,"Not attempt to provide education because days one, two, and three of the patient's stay have already passed.",0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11251,2,If a patient has been in the hospital for six days but has not had any education documented on the three day teach-back record I will:,g28180,2,Start the day one education and pass on the information to the next nurse caring for the patient so that they can continue the following days' education.,1,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5367,8449,Elearning-0000-132,g2743,g11251,3,If a patient has been in the hospital for six days but has not had any education documented on the three day teach-back record I will:,g28181,3,"Go ahead and chart that education has been done, since the educational booklet about the patient's diagnosis on their bedside table.",0,TEACH-BACK METHOD: A TEACHING TOOL TO ENSURE PATIENT UNDERSTANDING
5363,9398,Elearning-0000-639,g2740,g11232,0,I acknowledge I have read and understand the EVS Visibility Training CBL.,g28114,0,YES,1,ENVIRONMENTAL SERVICES (EVS)-VISIBILITY TRAINING
5363,9398,Elearning-0000-639,g2740,g11232,1,I acknowledge I have read and understand the EVS Visibility Training CBL.,g28115,1,NO,0,ENVIRONMENTAL SERVICES (EVS)-VISIBILITY TRAINING
5324,9538,Elearning-0000-766,g2708,g11088,0,I acknowledge I have read and understand the BMT Town Hall Summary CBL.,g27644,0,YES,1,BMT TOWN HALL SUMMARY
5324,9538,Elearning-0000-766,g2708,g11088,1,I acknowledge I have read and understand the BMT Town Hall Summary CBL.,g27645,1,NO,0,BMT TOWN HALL SUMMARY
5229,9588,Elearning-0000-811,g2635,g10914,0,A 64-year-old woman with a history of hypertension and cardiovascular disease is brought to the emergency department by her husband because he noticed that the right side of her face is drooping. She is also having difficulty speaking. This  patient may be a candidate for alteplase administration if:,g27067,0,The patient experienced any seizure activity before or after the onset of her symptoms,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10914,1,A 64-year-old woman with a history of hypertension and cardiovascular disease is brought to the emergency department by her husband because he noticed that the right side of her face is drooping. She is also having difficulty speaking. This  patient may be a candidate for alteplase administration if:,g27068,1,The onset of her symptoms was less than 4.5 hours before the medication can be administered,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10914,2,A 64-year-old woman with a history of hypertension and cardiovascular disease is brought to the emergency department by her husband because he noticed that the right side of her face is drooping. She is also having difficulty speaking. This  patient may be a candidate for alteplase administration if:,g27069,2,She has a history of any medical problems that can cause decreased platelets or bleeding,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10914,3,A 64-year-old woman with a history of hypertension and cardiovascular disease is brought to the emergency department by her husband because he noticed that the right side of her face is drooping. She is also having difficulty speaking. This  patient may be a candidate for alteplase administration if:,g27070,3,There is any indication that the cause of the patient's symptoms is a subarachnoid hemorrhage,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10915,0,The results of a CT scan performed on a patient who weighs 75 kg indicate an ischemic stroke. The patient consents to receiving alteplase. The total dose of alteplase should be:,g27071,0,100 mg,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10915,1,The results of a CT scan performed on a patient who weighs 75 kg indicate an ischemic stroke. The patient consents to receiving alteplase. The total dose of alteplase should be:,g27072,1,67.5 mg,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10915,2,The results of a CT scan performed on a patient who weighs 75 kg indicate an ischemic stroke. The patient consents to receiving alteplase. The total dose of alteplase should be:,g27073,2,70 mg,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10915,3,The results of a CT scan performed on a patient who weighs 75 kg indicate an ischemic stroke. The patient consents to receiving alteplase. The total dose of alteplase should be:,g27074,3,80 mg,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10916,0,The alteplase has been infusing for 30 minutes. The patient begins to complain of a severe headache and starts vomiting. The emergency nurse should:,g27075,0,"Stop the alteplase infusion, notify the practitioner, and prepare the patient for an emergency CT scan",1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10916,1,The alteplase has been infusing for 30 minutes. The patient begins to complain of a severe headache and starts vomiting. The emergency nurse should:,g27076,1,Continue the infusion and prepare the patient for an emergency CT scan,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10916,2,The alteplase has been infusing for 30 minutes. The patient begins to complain of a severe headache and starts vomiting. The emergency nurse should:,g27077,2,Stop the alteplase infusion and prepare to administer protamine sulfate,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10916,3,The alteplase has been infusing for 30 minutes. The patient begins to complain of a severe headache and starts vomiting. The emergency nurse should:,g27078,3,"Stop the alteplase, initiate a heparin drip, and prepare for an emergency CT scan",0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10917,0,A 48-year-old man has received alteplase for an ischemic stroke. His wife expresses concern about bleeding from his gums. The nurse's most appropriate response is:,g27079,0,"""Your husband is going to need a blood transfusion because of the alteplase administration.""",0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10917,1,A 48-year-old man has received alteplase for an ischemic stroke. His wife expresses concern about bleeding from his gums. The nurse's most appropriate response is:,g27080,1,"""There is always some bleeding after alteplase administration, but he will be monitored closely.""",1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10917,2,A 48-year-old man has received alteplase for an ischemic stroke. His wife expresses concern about bleeding from his gums. The nurse's most appropriate response is:,g27081,2,"""Bleeding from the gums is an indication of internal bleeding after alteplase administration.""",0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10917,3,A 48-year-old man has received alteplase for an ischemic stroke. His wife expresses concern about bleeding from his gums. The nurse's most appropriate response is:,g27082,3,"""Bleeding is an indication that your husband's embolus is gone.""",0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10918,0,The emergency nurse is preparing to administer alteplase to a patient having a stroke. Which of the following actions should be taken?,g27083,0,Prepare to add the alteplase infusion to the same IV line that is used for other medications.,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10918,1,The emergency nurse is preparing to administer alteplase to a patient having a stroke. Which of the following actions should be taken?,g27084,1,Shake the vial vigorously to assure that the alteplase is thoroughly mixed.,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10918,2,The emergency nurse is preparing to administer alteplase to a patient having a stroke. Which of the following actions should be taken?,g27085,2,Place an inline filter on the IV tubing that is to be used for medication administration.,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10918,3,The emergency nurse is preparing to administer alteplase to a patient having a stroke. Which of the following actions should be taken?,g27086,3,Gently swirl the vial to mix the alteplase with the diluent.,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10919,0,"During an infusion of alteplase for Acute Ischemic Stroke (AIS), a patient vomits 150 ml of bright red blood. The nurse should anticipate notifying the practitioner and:",g27087,0,Administering Vitamin K,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10919,1,"During an infusion of alteplase for Acute Ischemic Stroke (AIS), a patient vomits 150 ml of bright red blood. The nurse should anticipate notifying the practitioner and:",g27088,1,Decreasing the infusion rate by one half,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10919,2,"During an infusion of alteplase for Acute Ischemic Stroke (AIS), a patient vomits 150 ml of bright red blood. The nurse should anticipate notifying the practitioner and:",g27089,2,Administering fresh frozen plasma,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10919,3,"During an infusion of alteplase for Acute Ischemic Stroke (AIS), a patient vomits 150 ml of bright red blood. The nurse should anticipate notifying the practitioner and:",g27090,3,Discontinuing the alteplase infusion,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10920,0,"A client is admitted with signs and symptoms of an acute stroke, and the nurse anticipates the possibility of an order for fibrinolytic therapy. Which of the following vascular access options is most appropriate for this patient?",g27091,0,A dual-lumen catheter,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10920,1,"A client is admitted with signs and symptoms of an acute stroke, and the nurse anticipates the possibility of an order for fibrinolytic therapy. Which of the following vascular access options is most appropriate for this patient?",g27092,1,A subclavian catheter,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10920,2,"A client is admitted with signs and symptoms of an acute stroke, and the nurse anticipates the possibility of an order for fibrinolytic therapy. Which of the following vascular access options is most appropriate for this patient?",g27093,2,An internal jugular line,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10920,3,"A client is admitted with signs and symptoms of an acute stroke, and the nurse anticipates the possibility of an order for fibrinolytic therapy. Which of the following vascular access options is most appropriate for this patient?",g27094,3,A femoral line,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10921,0,"How soon after r-tPA infusion can you start Heparin, Warfarin, Aspirin, anticoagulants or antiplatelet medications.",g27095,0,12 hours,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10921,1,"How soon after r-tPA infusion can you start Heparin, Warfarin, Aspirin, anticoagulants or antiplatelet medications.",g27096,1,24 hours,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10921,2,"How soon after r-tPA infusion can you start Heparin, Warfarin, Aspirin, anticoagulants or antiplatelet medications.",g27097,2,2 hours,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10921,3,"How soon after r-tPA infusion can you start Heparin, Warfarin, Aspirin, anticoagulants or antiplatelet medications.",g27098,3,2 days,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10922,0,"_____percent of the dose is administered as an intravenous bolus, followed by the remaining 90 percent given as a continuous infusion over 60 minutes",g27099,0,20,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10922,1,"_____percent of the dose is administered as an intravenous bolus, followed by the remaining 90 percent given as a continuous infusion over 60 minutes",g27100,1,10,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10922,2,"_____percent of the dose is administered as an intravenous bolus, followed by the remaining 90 percent given as a continuous infusion over 60 minutes",g27101,2,15,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10922,3,"_____percent of the dose is administered as an intravenous bolus, followed by the remaining 90 percent given as a continuous infusion over 60 minutes",g27102,3,5,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10923,0,The ED forms for patient who will be receiving t-PA include 1. NIH Stroke Scale Assessment and swallowing screen 2. R/O Acute Stroke TIA Guidelines 3. Stroke Flowsheet for TPA administration 4. IV r-tPA FOR ACUTE ISCHEMIC STROKE PHYSCIA N ORDER,g27103,0,Informed Consent for intravenous thrombolytic treatment (clot busting drugs)For NON-BLEEDING STROKE,1,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10923,1,The ED forms for patient who will be receiving t-PA include 1. NIH Stroke Scale Assessment and swallowing screen 2. R/O Acute Stroke TIA Guidelines 3. Stroke Flowsheet for TPA administration 4. IV r-tPA FOR ACUTE ISCHEMIC STROKE PHYSCIA N ORDER,g27104,1,Informed Consent for intravenous thrombolytic treatment (clot busting drugs)For symptoms greater than 3 hours,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10923,2,The ED forms for patient who will be receiving t-PA include 1. NIH Stroke Scale Assessment and swallowing screen 2. R/O Acute Stroke TIA Guidelines 3. Stroke Flowsheet for TPA administration 4. IV r-tPA FOR ACUTE ISCHEMIC STROKE PHYSCIA N ORDER,g27105,2,Informed Consent for intravenous thrombolytic treatment (clot busting drugs)For symptoms greater than 6 hours,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5229,9588,Elearning-0000-811,g2635,g10923,3,The ED forms for patient who will be receiving t-PA include 1. NIH Stroke Scale Assessment and swallowing screen 2. R/O Acute Stroke TIA Guidelines 3. Stroke Flowsheet for TPA administration 4. IV r-tPA FOR ACUTE ISCHEMIC STROKE PHYSCIA N ORDER,g27106,3,Informed Consent for intravenous thrombolytic treatment (clot busting drugs)For symptoms less than 3 hours,0,ACTION TPA COMPETENCY EDUCATION (NSC)
5211,8288,Elearning-0000-117,g2618,g10818,0,I acknowledge I have read and understand the Universal Protocol (Breast Care Imaging) CBL.,g26735,0,YES,1,UNIVERSAL PROTOCOL (BREAST CARE IMAGING)
5211,8288,Elearning-0000-117,g2618,g10818,1,I acknowledge I have read and understand the Universal Protocol (Breast Care Imaging) CBL.,g26736,1,NO,0,UNIVERSAL PROTOCOL (BREAST CARE IMAGING)
-1,8342,Elearning-0000-1218,g2612,g10802,0,I certify that I completed the color blindness test and the results of my testing demonstrated one of the following:,g26687,0,"I had at least 10 correct responses for all of  the color plates.  Therefore, I have normal color vision.",1,COLOR BLINDNESS TEST FOR AMNIOTEST
-1,8342,Elearning-0000-1218,g2612,g10802,1,I certify that I completed the color blindness test and the results of my testing demonstrated one of the following:,g26688,1,"I had 5 or more plates with incorrect responses.  Therefore, I may have a color vision defect.  I certify that I will bring this to the attention of my supervisor before I proceed in interpreting any tests that require interpretation of color changes.",0,COLOR BLINDNESS TEST FOR AMNIOTEST
5196,8090,Elearning-0000-01,g2604,g10793,0,I have read and understand the Web Punch For Physician Practice CBL.,g26661,0,Yes,1,WEB PUNCH FOR PHYSICIAN PRACTICE
5196,8090,Elearning-0000-01,g2604,g10793,1,I have read and understand the Web Punch For Physician Practice CBL.,g26662,1,No,0,WEB PUNCH FOR PHYSICIAN PRACTICE
5182,9419,Elearning-0000-658,g2592,g10739,0,I acknowledge I have read and understand the Documentation of Late Entries CBL.,g26512,0,YES,1,DOCUMENTATION OF LATE ENTRIES
5182,9419,Elearning-0000-658,g2592,g10739,1,I acknowledge I have read and understand the Documentation of Late Entries CBL.,g26513,1,NO,0,DOCUMENTATION OF LATE ENTRIES
5180,8211,Elearning-0000-110,g2590,g10738,0,I acknowledge I have read and understand the VAP Bundle Observation Tool CBL.,g26510,0,YES,1,VAP BUNDLE OBSERVATION TOOL (RESP CARE)
5180,8211,Elearning-0000-110,g2590,g10738,1,I acknowledge I have read and understand the VAP Bundle Observation Tool CBL.,g26511,1,NO,0,VAP BUNDLE OBSERVATION TOOL (RESP CARE)
5168,8946,Elearning-0000-228,g2580,g10722,0,I acknowledge I have read and understand the Patient Care Dosing Sheet.,g26469,0,YES,1,PATIENT CARE DOSING SHEET (RADIOLOGY)
5168,8946,Elearning-0000-228,g2580,g10722,1,I acknowledge I have read and understand the Patient Care Dosing Sheet.,g26470,1,NO,0,PATIENT CARE DOSING SHEET (RADIOLOGY)
5162,9019,Elearning-0000-294,g2578,g10711,0,Sponsors can use a variety of approaches to fulfill their responsibilities related to monitoring studies.,g26434,0,TRUE,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10711,1,Sponsors can use a variety of approaches to fulfill their responsibilities related to monitoring studies.,g26435,1,FALSE,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10712,0,The primary focus of monitoring should be on which of the following:,g26436,0,A. Processes critical to protecting human subjects,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10712,1,The primary focus of monitoring should be on which of the following:,g26437,1,B. Maintaining the integrity of study data,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10712,2,The primary focus of monitoring should be on which of the following:,g26438,2,C. Compliance with regulations,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10712,3,The primary focus of monitoring should be on which of the following:,g26439,3,D. A & C,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10712,4,The primary focus of monitoring should be on which of the following:,g26440,4,"E. A, B, & C",1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10713,0,The FDA will conduct on-site assessments of every clinical investigator conducting studies involving FDA-regulated products.,g26441,0,TRUE,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10713,1,The FDA will conduct on-site assessments of every clinical investigator conducting studies involving FDA-regulated products.,g26442,1,FALSE,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10714,0,Risk-based monitoring requires routine visits to all clinical sites.,g26443,0,TRUE,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10714,1,Risk-based monitoring requires routine visits to all clinical sites.,g26444,1,FALSE,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10715,0,Centralized monitoring processes can be used to achieve which of the following:,g26445,0,A. Replacement of on-site monitoring for activities that can be done remotely,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10715,1,Centralized monitoring processes can be used to achieve which of the following:,g26446,1,B. Monitoring of submitted data in real-time,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10715,2,Centralized monitoring processes can be used to achieve which of the following:,g26447,2,C. Complete administrative & regulatory tasks,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10715,3,Centralized monitoring processes can be used to achieve which of the following:,g26448,3,D. A & B,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10715,4,Centralized monitoring processes can be used to achieve which of the following:,g26449,4,E. A & C,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10715,5,Centralized monitoring processes can be used to achieve which of the following:,g26450,5,"F. A, B, & C",1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10716,0,FDA encourages greater reliance on centralized monitoring in place of on-site monitoring.,g26451,0,TRUE,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10716,1,FDA encourages greater reliance on centralized monitoring in place of on-site monitoring.,g26452,1,FALSE,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10717,0,Which of the following should not be included in a sponsor's risk assessment of a clinical trial?,g26453,0,A. Types of data to be collected during the trial,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10717,1,Which of the following should not be included in a sponsor's risk assessment of a clinical trial?,g26454,1,B. Specific activities required to collect the data,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10717,2,Which of the following should not be included in a sponsor's risk assessment of a clinical trial?,g26455,2,C. Target enrollment,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10717,3,Which of the following should not be included in a sponsor's risk assessment of a clinical trial?,g26456,3,D. Potential safety concerns,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10718,0,A sponsor should consider risk assessment findings when developing a monitoring plan.,g26457,0,TRUE,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10718,1,A sponsor should consider risk assessment findings when developing a monitoring plan.,g26458,1,FALSE,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10719,0,Which of the following types of data and processes should have more intensive monitoring?,g26459,0,A. Adherence to protocol eligibility criteria intended to include only subjects from the targeted study population for whom the test article is most appropriate,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10719,1,Which of the following types of data and processes should have more intensive monitoring?,g26460,1,B. Conduct and documentation of procedures for ensuring that the study blind is maintained,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10719,2,Which of the following types of data and processes should have more intensive monitoring?,g26461,2,"C. Verification that initial informed consent was obtained appropriately, prior to any study-specific procedures",0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10719,3,Which of the following types of data and processes should have more intensive monitoring?,g26462,3,D. Procedures for documenting appropriate accountability and administration of the investigational product,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10719,4,Which of the following types of data and processes should have more intensive monitoring?,g26463,4,E. All of the above,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10719,5,Which of the following types of data and processes should have more intensive monitoring?,g26464,5,F. C & D,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10720,0,"If a sponsor transfers monitoring responsibilities to a CRO, it is not responsible for oversight of the work done by the CRO.",g26465,0,TRUE,0,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5162,9019,Elearning-0000-294,g2578,g10720,1,"If a sponsor transfers monitoring responsibilities to a CRO, it is not responsible for oversight of the work done by the CRO.",g26466,1,FALSE,1,OVERSIGHT OF CLINICAL INVESTIGATIONS-A RISK-BASED APPROACH TO MONITORING
5081,8922,Elearning-0000-206,g2515,g10417,0,When do you need 3 transporters to push a bed?,g25514,0,A. patient weighs 410 lbs,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10417,1,When do you need 3 transporters to push a bed?,g25515,1,B. patient is on a brown bed with a trapeze,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10417,2,When do you need 3 transporters to push a bed?,g25516,2,C. patient is on a Stryker bed,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10417,3,When do you need 3 transporters to push a bed?,g25517,3,D. A and B,1,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10418,0,Slider sheets may need handle extensions added to keep the back straight when moving a patient.,g25518,0,TRUE,1,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10418,1,Slider sheets may need handle extensions added to keep the back straight when moving a patient.,g25519,1,FALSE,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10419,0,Only 1 slider sheet is need to move a patient.,g25520,0,TRUE,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10419,1,Only 1 slider sheet is need to move a patient.,g25521,1,FALSE,1,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10420,0,"When using the lift, wheels must be locked at all times",g25522,0,TRUE,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10420,1,"When using the lift, wheels must be locked at all times",g25523,1,FALSE,1,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10421,0,"The OR brought a 500 lb., 5'3'' tall patient in on a BariKare bed. Is this bed appropriate for this patient?",g25524,0,Yes,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10421,1,"The OR brought a 500 lb., 5'3'' tall patient in on a BariKare bed. Is this bed appropriate for this patient?",g25525,1,No,1,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10421,2,"The OR brought a 500 lb., 5'3'' tall patient in on a BariKare bed. Is this bed appropriate for this patient?",g25526,2,"Maybe, if the patient requests the bed",0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10422,0,Only 2 transports are needed for a BariKare bed if one of the transports is male.,g25527,0,TRUE,0,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5081,8922,Elearning-0000-206,g2515,g10422,1,Only 2 transports are needed for a BariKare bed if one of the transports is male.,g25528,1,FALSE,1,SAFE TRANSPORT & TRANSFER OF PATIENTS (SS)
5050,8540,Elearning-0000-141,g2490,g10318,0,I acknowledge that I have read and understand the contents of this reminder regarding proper dating of the sure step test strip container.,g25236,0,YES,1,SURESTEP TEST STRIP REMINDER (ORTHOPEDICS)
5050,8540,Elearning-0000-141,g2490,g10318,1,I acknowledge that I have read and understand the contents of this reminder regarding proper dating of the sure step test strip container.,g25237,1,NO,0,SURESTEP TEST STRIP REMINDER (ORTHOPEDICS)
5022,9544,Elearning-0000-771,g2471,g10295,0,I acknowledge I have read and understand the BHS Documentation Requirements CBL.,g25175,0,YES,1,BHS DOCUMENTATION REQUIREMENTS FOR MEDICAL RECORDS
5022,9544,Elearning-0000-771,g2471,g10295,1,I acknowledge I have read and understand the BHS Documentation Requirements CBL.,g25176,1,NO,0,BHS DOCUMENTATION REQUIREMENTS FOR MEDICAL RECORDS
9536,9842,Questions-0000-134,g2438,g10000,0,"Occurrence code 11, Onset of illness, means the beginning date of the patient's symptoms relative to the services being rendered.",g24261,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10000,1,"Occurrence code 11, Onset of illness, means the beginning date of the patient's symptoms relative to the services being rendered.",g24262,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10001,0,"14. When admitting a patient from OP to IP, which two fields need to be updated on the Medical Information Form?",g86123,0,"A.	Admission type, Admission source",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10001,1,"14. When admitting a patient from OP to IP, which two fields need to be updated on the Medical Information Form?",g86124,1,"B.	Arrival Date, Time",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10001,2,"14. When admitting a patient from OP to IP, which two fields need to be updated on the Medical Information Form?",g86125,2,"C.	Location, Service",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10002,0,3. The patient's name should be entered on the Patient Information Form in which following formats?,g24267,0,"A. First Name followed by comma (,) no space(s) followed by Last Name.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10002,1,3. The patient's name should be entered on the Patient Information Form in which following formats?,g24268,1,"B. First Name followed by Middle Name comma (,) then Last Name.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10002,2,3. The patient's name should be entered on the Patient Information Form in which following formats?,g24269,2,"C. Last Name followed by comma (,) no space(s) then First Name followed by one space then Middle Name",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10003,0,15. The Unit number is the same as the Medical Record Number.,g86126,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10003,1,15. The Unit number is the same as the Medical Record Number.,g86127,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10004,0,4. Patients with dual last names should have a space instead of a hyphen to separate the two last names.,g24276,0,TRUE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10004,1,4. Patients with dual last names should have a space instead of a hyphen to separate the two last names.,g24277,1,FALSE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10005,0,"5. Entering the patient's zip code in the City Field on the Patient Information Form will automatically populate the City, State and Zip code fields if entering a Georgia zip code.",g24278,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10005,1,"5. Entering the patient's zip code in the City Field on the Patient Information Form will automatically populate the City, State and Zip code fields if entering a Georgia zip code.",g24279,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10006,0,6. The Registration Representative is to ask the patient for their home address instead of their mailing address.,g24280,0,TRUE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10006,1,6. The Registration Representative is to ask the patient for their home address instead of their mailing address.,g24281,1,FALSE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10007,0,"7. The preferred method for entering an address as approved by the US Postal service is to enter an address using the street suffix abbreviations (i.e. St, Ave, Hwy, etc.)",g86128,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10007,1,"7. The preferred method for entering an address as approved by the US Postal service is to enter an address using the street suffix abbreviations (i.e. St, Ave, Hwy, etc.)",g86129,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10008,0,8. Who of the following should be entered as the guarantor when registering an account for an adult patient whose spouse is the policy holder/subscriber of the insurance plan?,g86130,0,"A.	Patient",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10008,1,8. Who of the following should be entered as the guarantor when registering an account for an adult patient whose spouse is the policy holder/subscriber of the insurance plan?,g86131,1,"B.	Spouse",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10008,2,8. Who of the following should be entered as the guarantor when registering an account for an adult patient whose spouse is the policy holder/subscriber of the insurance plan?,g86132,2,"C.	Legal Guardian",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10009,0,The policy holder/subscriber of the insurance plan will be named as the Guarantor on a Patient's registration.,g24290,0,TRUE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10009,1,The policy holder/subscriber of the insurance plan will be named as the Guarantor on a Patient's registration.,g24291,1,FALSE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10010,0,"10.	  When registering a minor patient in the ER who is accompanied by the mother and the father is the policy holder/subscriber of the insurance, who would be the guarantor on the patient's account?",g24292,0,A. Patient,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10010,1,"10.	  When registering a minor patient in the ER who is accompanied by the mother and the father is the policy holder/subscriber of the insurance, who would be the guarantor on the patient's account?",g24293,1,B. Mother,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10010,2,"10.	  When registering a minor patient in the ER who is accompanied by the mother and the father is the policy holder/subscriber of the insurance, who would be the guarantor on the patient's account?",g24294,2,C. Father,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10011,0,16. What two items are required to be requested from every patient at the time of Registration? .,g86133,0,"A.	Insurance Card and physician order",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10011,1,16. What two items are required to be requested from every patient at the time of Registration? .,g86134,1,"B.	ID and pre-certification letter",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10011,2,16. What two items are required to be requested from every patient at the time of Registration? .,g86135,2,"C.	Photo ID and insurance card",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10012,0,"When changing the guarantor to another responsible party guarantor, the following process should be followed",g35121,0,Change the relation to patient code as appropriate and conduct an MPI search for the appropriate entry,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10012,1,"When changing the guarantor to another responsible party guarantor, the following process should be followed",g35122,1,"If the relation to patient has not changed but the guarantor has changed, click on the Guarantor MPI search button",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10012,2,"When changing the guarantor to another responsible party guarantor, the following process should be followed",g35123,2,All of the above,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10013,0,"On the <b>Insurance Form</b>, the selection of ""<b>Notes</b>"" gives the registrar access to STAR Notes.",g24302,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10013,1,"On the <b>Insurance Form</b>, the selection of ""<b>Notes</b>"" gives the registrar access to STAR Notes.",g24303,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10014,0,The established number assigned to statements that assist with describing circumstances surrounding the registration process and used in STAR Notes are called ________________.,g24304,0,Patient Access Notes,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10014,1,The established number assigned to statements that assist with describing circumstances surrounding the registration process and used in STAR Notes are called ________________.,g24305,1,Standard Notes Codes,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10014,2,The established number assigned to statements that assist with describing circumstances surrounding the registration process and used in STAR Notes are called ________________.,g24306,2,Registration Statement Codes,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10015,0,"The ""<b>Freeform</b>"" button in <b>STAR Notes</b> stands for___________.",g24308,0,Free Services,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10015,1,"The ""<b>Freeform</b>"" button in <b>STAR Notes</b> stands for___________.",g24309,1,Freeform,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10015,2,"The ""<b>Freeform</b>"" button in <b>STAR Notes</b> stands for___________.",g24310,2,Format,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10016,0,"The ""<b>Use Standard</b>"" button in <b>STAR Notes</b> stands for____________.",g24312,0,Simple,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10016,1,"The ""<b>Use Standard</b>"" button in <b>STAR Notes</b> stands for____________.",g24313,1,Short,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10016,2,"The ""<b>Use Standard</b>"" button in <b>STAR Notes</b> stands for____________.",g24314,2,Standard,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10017,0,"20.	 Patient Types PRO/PCO/PFO/PDO/PLO on an account signal the Registration Representative to review STAR Notes for direction on handling the account as a Sign & Go  or Info To Validate account.",g35124,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10017,1,"20.	 Patient Types PRO/PCO/PFO/PDO/PLO on an account signal the Registration Representative to review STAR Notes for direction on handling the account as a Sign & Go  or Info To Validate account.",g35125,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10018,0,"17. When a patient requests to be a ""No Info Patient"" registrar must select ""Yes"" in the ΓÇÿOpt Out' field under ""Patient Preferences"" and select ""NO INFO"" in the ΓÇÿPublicity' field. What form in STAR must be completed with this information?",g86136,0,"A.	NSH RELATIVE ONE/EMERGENCY CONTACT INFORMATION",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10018,1,"17. When a patient requests to be a ""No Info Patient"" registrar must select ""Yes"" in the ΓÇÿOpt Out' field under ""Patient Preferences"" and select ""NO INFO"" in the ΓÇÿPublicity' field. What form in STAR must be completed with this information?",g86137,1,"B.	NSH GUARANTOR INFORMATION",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10018,2,"17. When a patient requests to be a ""No Info Patient"" registrar must select ""Yes"" in the ΓÇÿOpt Out' field under ""Patient Preferences"" and select ""NO INFO"" in the ΓÇÿPublicity' field. What form in STAR must be completed with this information?",g86138,2,"C.	NSH MISCELLANEOUS INFORMATION",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10019,0,"The Unknown Patient Naming Convention must be used for patients who cannot immediately be identified when presenting to the Emergency department. When these patients present, ED registrars must do which of the following:",g87364,0,"A.	Pull the UNKNOWN Patient Log from the Unknown Patient Accordion file, use the next available Unknown Patient account and convert the existing account number from a PTA/PTC/PTF patient type to a QER/QEC/QEF.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10019,1,"The Unknown Patient Naming Convention must be used for patients who cannot immediately be identified when presenting to the Emergency department. When these patients present, ED registrars must do which of the following:",g87365,1,"B.	Pull the corresponding Unknown pre-printed patient packet and leave the patient name in STAR as the Unknown patient name with the military alphabet as the last name, the word ΓÇÿUNKNOWN' for the first name, and NSA, NSC, or NSF for the middle name based on the facility and update the Admitting diagnosis and ED physician name to reflect actual information.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10019,2,"The Unknown Patient Naming Convention must be used for patients who cannot immediately be identified when presenting to the Emergency department. When these patients present, ED registrars must do which of the following:",g87366,2,"C.	Both A&B",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10020,0,"When a registrar registers a patient who has been involved with a Motor Vehicle Accident, the accident information should be completed on the Medical  Information form?",g24324,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10020,1,"When a registrar registers a patient who has been involved with a Motor Vehicle Accident, the accident information should be completed on the Medical  Information form?",g24325,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10021,0,Rule Out (R/O) diagnosis can be used as a diagnosis and not the patient's chief complaint or illness.,g24326,0,TRUE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10021,1,Rule Out (R/O) diagnosis can be used as a diagnosis and not the patient's chief complaint or illness.,g24327,1,FALSE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10022,0,It is necessary to look up the ICD-9 Diagnosis Code for all patients before free-forming the admitting Diagnosis using the pointer table.,g24328,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10022,1,It is necessary to look up the ICD-9 Diagnosis Code for all patients before free-forming the admitting Diagnosis using the pointer table.,g24329,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10023,0,"18. When asking a patient for their name to enter into STAR, if the patient states that their name is different from the name on the patient's form of identification, registrars must enter the name as indicated by the Guarantor.  PAS Registrars are to use SNC-8079 NAME DIFFERENT FROM ID and make a sufficient free form notation to explain.",g86190,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10023,1,"18. When asking a patient for their name to enter into STAR, if the patient states that their name is different from the name on the patient's form of identification, registrars must enter the name as indicated by the Guarantor.  PAS Registrars are to use SNC-8079 NAME DIFFERENT FROM ID and make a sufficient free form notation to explain.",g86191,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10024,0,The accident information is required for all accidents that involve third party liability.,g24334,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10024,1,The accident information is required for all accidents that involve third party liability.,g24335,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10025,0,A NOI Patient means?,g24336,0,No Other Info,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10025,1,A NOI Patient means?,g24337,1,Not on Injection,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10025,2,A NOI Patient means?,g24338,2,No Info,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10026,0,Which two fields on the Number Assignment Form require manual entry when back-loading a downtime registration when it's the patient's first visit to Northside?,g35129,0,Unit number and corporate number,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10026,1,Which two fields on the Number Assignment Form require manual entry when back-loading a downtime registration when it's the patient's first visit to Northside?,g35130,1,Account number and unit number,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10026,2,Which two fields on the Number Assignment Form require manual entry when back-loading a downtime registration when it's the patient's first visit to Northside?,g35131,2,Account number and corporate number,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10027,0,"If the patient's initial visit to Northside Hospital is during Downtime, the downtime number will become the patient's permanent Unit Number.",g24345,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10027,1,"If the patient's initial visit to Northside Hospital is during Downtime, the downtime number will become the patient's permanent Unit Number.",g24346,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10028,0,19. What is the correct process for completing the Financial Ack/Notice of Privacy Practice Form for existing and new patients?,g139433,0,"A.	Patient must sign and date the form. In addition, if the patient opts out of being contacted by Northside Hospital, they must initial next to the opt-out contact preference section. Scan the form into ILE PFS ANNUAL ACK-FIN AND HIPAA folder.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10028,1,19. What is the correct process for completing the Financial Ack/Notice of Privacy Practice Form for existing and new patients?,g86193,1,"B.	Check and update, if necessary, the Guarantor Form in STAR to include phone message preference and the ΓÇÿFinancial Ack/Notice of privacy practice' field on the Number Assignment Form in STAR.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10028,2,19. What is the correct process for completing the Financial Ack/Notice of Privacy Practice Form for existing and new patients?,g86194,2,"C.	Both A & B",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10029,0,The following scenarios are examples of when to cancel an account: if a patient went to a service location and was unable to go through with the procedure; if the patient was registered under the wrong medical record number; if a (T) account was not used by the rep during the registration process.,g35193,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10029,1,The following scenarios are examples of when to cancel an account: if a patient went to a service location and was unable to go through with the procedure; if the patient was registered under the wrong medical record number; if a (T) account was not used by the rep during the registration process.,g35194,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10030,0,The result of this key sequence: T+1 enter is,g35132,0,The system displays yesterday's date,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10030,1,The result of this key sequence: T+1 enter is,g35133,1,The system displays today's date,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10030,2,The result of this key sequence: T+1 enter is,g35134,2,The system displays tomorrow's date,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10031,0,"The Transaction Line located at the bottom of each separate form and is used for prompts, selecting field options, and indicating error messages.",g24357,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10031,1,"The Transaction Line located at the bottom of each separate form and is used for prompts, selecting field options, and indicating error messages.",g24358,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10032,0,"Charges or orders already placed on the account would prevent canceling an ER, ERF, and ERC Account?",g35135,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10032,1,"Charges or orders already placed on the account would prevent canceling an ER, ERF, and ERC Account?",g35136,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10033,0,What two items are required to be requested from every patient at the time of registration?,g35137,0,Insurance Card and physician order,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10033,1,What two items are required to be requested from every patient at the time of registration?,g35138,1,ID and  pre-certification letter,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10033,2,What two items are required to be requested from every patient at the time of registration?,g35139,2,Photo ID and insurance card,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10034,0,"The patient types of (IP, IPF, and IPC) are identified as____________.",g24368,0,Inpatient,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10034,1,"The patient types of (IP, IPF, and IPC) are identified as____________.",g24369,1,Observation,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10034,2,"The patient types of (IP, IPF, and IPC) are identified as____________.",g24370,2,Series,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10035,0,"The patient types of (QRA, QRF, and QRC) are identified as____________.",g24372,0,Quick Registration,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10035,1,"The patient types of (QRA, QRF, and QRC) are identified as____________.",g24373,1,Inpatient,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10035,2,"The patient types of (QRA, QRF, and QRC) are identified as____________.",g24374,2,Series,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10036,0,"The patient types of (OBV, OBF, and OBC) are identified as__________.",g24376,0,Inpatient,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10036,1,"The patient types of (OBV, OBF, and OBC) are identified as__________.",g24377,1,Observation,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10036,2,"The patient types of (OBV, OBF, and OBC) are identified as__________.",g24378,2,Series,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10037,0,"The patient types of (ER, ERF, and ERC) are identified as__________.",g35140,0,Inpatient,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10037,1,"The patient types of (ER, ERF, and ERC) are identified as__________.",g35141,1,Emergency,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10037,2,"The patient types of (ER, ERF, and ERC) are identified as__________.",g35142,2,Series,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10038,0,"What does a PRO, PFO, or PCO patient type mean?",g24384,0,The patient was pre-registered live by a registrar,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10038,1,"What does a PRO, PFO, or PCO patient type mean?",g24385,1,The patient was pre-registered via the scheduling department,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10038,2,"What does a PRO, PFO, or PCO patient type mean?",g24387,2,The patient was pre-registered over the phone or via internet,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10039,0,"12. Occurrence code 11, Onset of illness, means the beginning date of the patient's symptoms relative to the services being rendered.",g35143,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10039,1,"12. Occurrence code 11, Onset of illness, means the beginning date of the patient's symptoms relative to the services being rendered.",g35144,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10040,0,"Married minors, emancipated minors, and pregnant minors presenting for pregnancy related services should be entered as the guarantor of their own account.",g24393,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10040,1,"Married minors, emancipated minors, and pregnant minors presenting for pregnancy related services should be entered as the guarantor of their own account.",g24394,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10041,0,"The registrar should use ""Agreed Upon Responses"" to answer a patient's questions concerning the registration process.",g24395,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10041,1,"The registrar should use ""Agreed Upon Responses"" to answer a patient's questions concerning the registration process.",g24396,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10042,0,"All forms requiring patient's name, account number & service date should be printed from",g35145,0,STAR,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10042,1,"All forms requiring patient's name, account number & service date should be printed from",g35146,1,FOD,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10042,2,"All forms requiring patient's name, account number & service date should be printed from",g35147,2,PAW,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10049,0,24. This section of the Annual Acknowledgement Form explains a bill may be received from the hospital and the physicians practice for Hospital Based Physician Practices.,g35148,0,A. Assignment of Benefits,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10049,1,24. This section of the Annual Acknowledgement Form explains a bill may be received from the hospital and the physicians practice for Hospital Based Physician Practices.,g35149,1,B. Precertification,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10049,2,24. This section of the Annual Acknowledgement Form explains a bill may be received from the hospital and the physicians practice for Hospital Based Physician Practices.,g35150,2,C. About Your Billing,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10050,0,The Annual Acknowledgement Pre-Certification section indicates the patient is encouraged to review his/her obligation with  _______________ to protect himself/herself from financial loss.,g35151,0,"Utilization Review Program, Personal Physician, Insurance Company",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10050,1,The Annual Acknowledgement Pre-Certification section indicates the patient is encouraged to review his/her obligation with  _______________ to protect himself/herself from financial loss.,g35152,1,Northside Business Office,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10050,2,The Annual Acknowledgement Pre-Certification section indicates the patient is encouraged to review his/her obligation with  _______________ to protect himself/herself from financial loss.,g35153,2,Family and Friends,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10051,0,"Per AHIQA, Guarantor Address corrections must be made on the",g35154,0,STAR Guarantor Information Form,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10051,1,"Per AHIQA, Guarantor Address corrections must be made on the",g35155,1,STAR Patient Information Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10051,2,"Per AHIQA, Guarantor Address corrections must be made on the",g35156,2,STAR Relative One Information Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10055,0,"If the patient has question(s) pertaining to Northside's billing policies, the patient should contact:",g24414,0,The Business Office,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10055,1,"If the patient has question(s) pertaining to Northside's billing policies, the patient should contact:",g24415,1,Your Supervisor,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10055,2,"If the patient has question(s) pertaining to Northside's billing policies, the patient should contact:",g24417,2,The patient's Insurance Company and Physician,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10056,0,"This document is given to the patient and lists contact information for the Business Office and how patients can pre-register online, as well as information on who to contact about bills received for the professional component of their serv ices:",g24418,0,Notice of Privacy Practices,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10056,1,"This document is given to the patient and lists contact information for the Business Office and how patients can pre-register online, as well as information on who to contact about bills received for the professional component of their serv ices:",g24419,1,About Your Billing,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10056,2,"This document is given to the patient and lists contact information for the Business Office and how patients can pre-register online, as well as information on who to contact about bills received for the professional component of their serv ices:",g24420,2,Financial Responsibility Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10057,0,"When multiple medical records are found for the same patient, this form is completed and sent to the Medical Records department:",g24422,0,About Your Billing,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10057,1,"When multiple medical records are found for the same patient, this form is completed and sent to the Medical Records department:",g24423,1,Re-label Chart Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10057,2,"When multiple medical records are found for the same patient, this form is completed and sent to the Medical Records department:",g24424,2,Duplicate Medical Record Form,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10058,0,"26. When multiple medical records are found for the same patient, this form is completed and sent to the Medical Records department:",g24425,0,A. About Your Billing,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10058,1,"26. When multiple medical records are found for the same patient, this form is completed and sent to the Medical Records department:",g24426,1,B. Re-label Chart Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10058,2,"26. When multiple medical records are found for the same patient, this form is completed and sent to the Medical Records department:",g24427,2,C. Duplicate Medical Record Form,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10059,0,"27.	 Standard Note Codes (SNC), Memos, FO Systems, and the Global Downtime Workbook can be found on:",g35157,0,A. Rev Cycle Website,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10059,1,"27.	 Standard Note Codes (SNC), Memos, FO Systems, and the Global Downtime Workbook can be found on:",g35158,1,B. RevRunner,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g10059,2,"27.	 Standard Note Codes (SNC), Memos, FO Systems, and the Global Downtime Workbook can be found on:",g35159,2,C. Forms on Demand/EasyWEB,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11096,0,"According to the Annual Acknowledgment Form, the patient is not relieved from any charges incurred unless otherwise stated in the contract agreement between the insurance company and Northside Hospital.",g27671,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11096,1,"According to the Annual Acknowledgment Form, the patient is not relieved from any charges incurred unless otherwise stated in the contract agreement between the insurance company and Northside Hospital.",g27672,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11097,0,"By refusing to sign the Annual Acknowledgement Form, the patient is releasing themselves from charges that have incurred for that visit.",g27673,0,TRUE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11097,1,"By refusing to sign the Annual Acknowledgement Form, the patient is releasing themselves from charges that have incurred for that visit.",g27674,1,FALSE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11098,0,Northside Hospital would <u>NOT</u> refuse services to a patient if he/she refuses to sign the Annual Acknowledgement form.,g27675,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11098,1,Northside Hospital would <u>NOT</u> refuse services to a patient if he/she refuses to sign the Annual Acknowledgement form.,g27676,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11099,0,21. Which of the following statements is NOT found in the Assignment of Benefits section of the Annual  Acknowledgement Form?,g35160,0,A. The patient authorizes the hospital to bill their insurance company.,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11099,1,21. Which of the following statements is NOT found in the Assignment of Benefits section of the Annual  Acknowledgement Form?,g35161,1,B. The patient is still responsible for any charges for this visit that are not paid by the insurance company.,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11099,2,21. Which of the following statements is NOT found in the Assignment of Benefits section of the Annual  Acknowledgement Form?,g35162,2,C. The patient will receive payments from the insurance company to submit to the hospital.,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11100,0,22. Which of the following statements is NOT found in the About Your Billing section of the Annual Acknowledgement form?,g35163,0,A. The patient will receive a bill from Northside Hospital.,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11100,1,22. Which of the following statements is NOT found in the About Your Billing section of the Annual Acknowledgement form?,g35164,1,B. Professional services' phone numbers,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11100,2,22. Which of the following statements is NOT found in the About Your Billing section of the Annual Acknowledgement form?,g35165,2,C. The patient may receive separate bills for the professional component of their treatment.,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11101,0,23. Which of the following statements is NOT found in the Precertification section of the Annual Acknowledgement Form?,g35166,0,A. The patient's insurance policy may require compliance with an utilization program to review the appropriateness of his/her treatment plan.,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11101,1,23. Which of the following statements is NOT found in the Precertification section of the Annual Acknowledgement Form?,g35167,1,"B. If the utilization review program denies authorization for a patient's procedure, Northside will cover the costs of the procedure.",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11101,2,23. Which of the following statements is NOT found in the Precertification section of the Annual Acknowledgement Form?,g35168,2,"C. It is the patient's responsibility to review his/her obligations with his/her physician, insurance company and utilization review program to prevent unnecessary financial loss.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11102,0,After correcting STAR data field as directed from the AHIQA error pop-ups staff should:,g35169,0,call the Trainer,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11102,1,After correcting STAR data field as directed from the AHIQA error pop-ups staff should:,g35170,1,call the Supervisor,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11102,2,After correcting STAR data field as directed from the AHIQA error pop-ups staff should:,g35171,2,"Select ""Next"" from the pop up window",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11103,0,28. All AHIQA Error pop-ups should be corrected by what point in time?,g35172,0,A. Next Day,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11103,1,28. All AHIQA Error pop-ups should be corrected by what point in time?,g35173,1,B. End of shift,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11103,2,28. All AHIQA Error pop-ups should be corrected by what point in time?,g35174,2,C. End of week,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11104,0,"According to the Financial Responsibility statement of the Annual Patient Acknowledgement form, payment cannot be reequested from the patient prior to emergency screening and stabilizing treatment.",g27695,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g11104,1,"According to the Financial Responsibility statement of the Annual Patient Acknowledgement form, payment cannot be reequested from the patient prior to emergency screening and stabilizing treatment.",g27696,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g13869,0,The Request for Diagnostic or Rehabilitation Services By Order of Out-of-state Physician form is scanned to the following ILE folder:,g36500,0,Miscellaneous Correspondence,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g13869,1,The Request for Diagnostic or Rehabilitation Services By Order of Out-of-state Physician form is scanned to the following ILE folder:,g36501,1,Physician Orders,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g13869,2,The Request for Diagnostic or Rehabilitation Services By Order of Out-of-state Physician form is scanned to the following ILE folder:,g36502,2,The form is forwarded to Medical Records and is not scanned in ILE (Correct),1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g14239,0,"25. The form used to alert staff of duplicate accounts and is scanned to the ""Duplicate Account Notification"" folder in ILE is called the:",g37590,0,A. Re-label Chart Form,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g14239,1,"25. The form used to alert staff of duplicate accounts and is scanned to the ""Duplicate Account Notification"" folder in ILE is called the:",g37591,1,B. Cancel account form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g14239,2,"25. The form used to alert staff of duplicate accounts and is scanned to the ""Duplicate Account Notification"" folder in ILE is called the:",g37592,2,C. Worker's Compensation form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g14240,0,"The patient types of (OP, OPF, and OPC) are identified as____________.",g37593,0,Inpatient,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g14240,1,"The patient types of (OP, OPF, and OPC) are identified as____________.",g37594,1,Outpatient,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g14240,2,"The patient types of (OP, OPF, and OPC) are identified as____________.",g37595,2,Series,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g16299,0,"If the physician order does not provide an ICD-10 diagnosis code, then registration should search for the diagnosis code by using the description look-up in STAR. Free-forming the Admitting Diagnosis and Secondary Diagnosis fields with the description provided by the physician is not acceptable.",g44186,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g16299,1,"If the physician order does not provide an ICD-10 diagnosis code, then registration should search for the diagnosis code by using the description look-up in STAR. Free-forming the Admitting Diagnosis and Secondary Diagnosis fields with the description provided by the physician is not acceptable.",g44187,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g26819,0,"If the patient states that their name is different from the name stated on the patient's driver's license, registrars must enter the name as indicated by the Guarantor, use SNC 8005 - Name Correct, and add a Free Form note.",g80900,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g26819,1,"If the patient states that their name is different from the name stated on the patient's driver's license, registrars must enter the name as indicated by the Guarantor, use SNC 8005 - Name Correct, and add a Free Form note.",g80901,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g26820,0,What is the correct process for completing the Financial Ack/Notice of Privacy Practice Form for existing and new patients?,g80902,0,"A.	Patient must sign and date the form in addition to initializing next to the contact preference section and scan the form into ILE PFS ANNUAL ACK-FIN AND HIPAA folder",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g26820,1,What is the correct process for completing the Financial Ack/Notice of Privacy Practice Form for existing and new patients?,g80903,1,"B.	Check and update, if necessary, the Guarantor Form in STAR to include phone message preference and the ΓÇÿFinancial Ack/Notice of privacy practice' field on the Number Assignment Form in STAR.",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g26820,2,What is the correct process for completing the Financial Ack/Notice of Privacy Practice Form for existing and new patients?,g80904,2,"C.	Both A.& B.",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g28374,0,9. What is the definition of a Guarantor?,g86195,0,"A.	The policy holder/subscriber of an insurance plan",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g28374,1,9. What is the definition of a Guarantor?,g86196,1,"B.	The financially responsible party",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g28374,2,9. What is the definition of a Guarantor?,g86197,2,"C.	The court appointed Legal Guardian",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g38206,0,29. Which Form in STAR has a section to enable registration to inform the patient and initiate access to the MyOneChart Patient Portal?,g122217,0,Medical Information Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g38206,1,29. Which Form in STAR has a section to enable registration to inform the patient and initiate access to the MyOneChart Patient Portal?,g122218,1,Miscellaneous Information Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g38206,2,29. Which Form in STAR has a section to enable registration to inform the patient and initiate access to the MyOneChart Patient Portal?,g122219,2,Patient Information Form,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g38207,0,"30. In Cerner PowerChart, which of the following will open after clicking ΓÇÿPatient' and ΓÇÿView Images' to view/scan Physician Orders and Authorization Letters?",g122220,0,Document Image,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g38207,1,"30. In Cerner PowerChart, which of the following will open after clicking ΓÇÿPatient' and ΓÇÿView Images' to view/scan Physician Orders and Authorization Letters?",g122221,1,Encounter Search,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g38207,2,"30. In Cerner PowerChart, which of the following will open after clicking ΓÇÿPatient' and ΓÇÿView Images' to view/scan Physician Orders and Authorization Letters?",g122222,2,Patient Information Form,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9996,0,1. Name the Patient Identifiers required for the Smart ID MPI search.,g35115,0,"A.	Last Name, First Name, Gender, DOB",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9996,1,1. Name the Patient Identifiers required for the Smart ID MPI search.,g35116,1,B. Address and Insurance Card,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9996,2,1. Name the Patient Identifiers required for the Smart ID MPI search.,g35117,2,C. Photo ID and Insurance Card,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9997,0,"11. Married minors, emancipated minors, and pregnant minors presenting for pregnancy related services should be entered as the guarantor of their own account.",g86118,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9997,1,"11. Married minors, emancipated minors, and pregnant minors presenting for pregnancy related services should be entered as the guarantor of their own account.",g86119,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9998,0,13.  What is the format to be used when populating the Medical Comment Field found on the Medical Information Form when a Non-Northside Physician has been selected? .,g86120,0,"A.	Physician first name, Physician last name, Physician home address, Physician home phone number using no spaces, or punctuation marks",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9998,1,13.  What is the format to be used when populating the Medical Comment Field found on the Medical Information Form when a Non-Northside Physician has been selected? .,g86121,1,"B.	Physician office phone number, Physician office fax number using no spaces or punctuation marks",0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9998,2,13.  What is the format to be used when populating the Medical Comment Field found on the Medical Information Form when a Non-Northside Physician has been selected? .,g86122,2,"C.	Physician last name, Physician first name, NPI#, Physician office phone number, Physician office address, Physician office fax number using no spaces and separated by commas.",1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9999,0,"2.	 A patient may have one medical record number per facility for Atlanta, Cherokee, and Forsyth, and one for Duluth/Lawrenceville, but only one corporate ID number.",g24259,0,TRUE,1,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
9536,9842,Questions-0000-134,g2438,g9999,1,"2.	 A patient may have one medical record number per facility for Atlanta, Cherokee, and Forsyth, and one for Duluth/Lawrenceville, but only one corporate ID number.",g24260,1,FALSE,0,RCT: PROCESS & SYSTEMS UNIVERSITY TEST
4947,9505,Elearning-0000-736,g2416,g9797,0,"I acknowledge I have read and understand the ""Cardiac Rehabilitation Individual Treatment Plan"" CBL.",g23638,0,YES,1,CARDIAC REHABILITATION INDIVIDUAL TREATMENT PLAN
4947,9505,Elearning-0000-736,g2416,g9797,1,"I acknowledge I have read and understand the ""Cardiac Rehabilitation Individual Treatment Plan"" CBL.",g23639,1,NO,0,CARDIAC REHABILITATION INDIVIDUAL TREATMENT PLAN
4928,8099,Elearning-0000-10,g2403,g9688,0,I acknowledge I have completed the Security Risk Assessment Survey 2011.,g23263,0,YES,1,SECURITY RISK ASSESSMENT SURVEY
4928,8099,Elearning-0000-10,g2403,g9688,1,I acknowledge I have completed the Security Risk Assessment Survey 2011.,g23264,1,NO,0,SECURITY RISK ASSESSMENT SURVEY
4913,9404,Elearning-0000-644,g2390,g9551,0,I have read and understand my responsibilities with respect to ELC ORIENTATION: ROLES & RESPONSIBILITIES UPDATE 2011 as required for membership in the Employee Leadership Committee of Northside Hospital.  I feel comfortable that I can perfo rm my duties as a member or officer of the Employee Leadership Committee.   I understand that if I have any questions or concerns about the Employee Leadership Committee or my duties as a member or officer of the committee that I must speak with my supervisor or manager and a member of the Executive Committee immediately.,g22772,0,YES,1,ELC ORIENTATION: ROLES & RESPONSIBILITIES UPDATE 2011
4913,9404,Elearning-0000-644,g2390,g9551,1,I have read and understand my responsibilities with respect to ELC ORIENTATION: ROLES & RESPONSIBILITIES UPDATE 2011 as required for membership in the Employee Leadership Committee of Northside Hospital.  I feel comfortable that I can perfo rm my duties as a member or officer of the Employee Leadership Committee.   I understand that if I have any questions or concerns about the Employee Leadership Committee or my duties as a member or officer of the committee that I must speak with my supervisor or manager and a member of the Executive Committee immediately.,g22773,1,NO,0,ELC ORIENTATION: ROLES & RESPONSIBILITIES UPDATE 2011
4894,9254,Elearning-0000-508,g2371,g9439,0,I have read the IV Contrast 2011 CBL and will review the appropriate Lucidoc policy and procedures listed in the CBL.,g22433,0,YES,1,IV CONTRAST 2011 (RADIOLOGY)
4894,9254,Elearning-0000-508,g2371,g9439,1,I have read the IV Contrast 2011 CBL and will review the appropriate Lucidoc policy and procedures listed in the CBL.,g22434,1,NO,0,IV CONTRAST 2011 (RADIOLOGY)
4825,8894,Elearning-0000-180,g2318,g9276,0,Cigarette smoking is the primary cause of chronic obstructive pulmonary disease:,g21983,0,TRUE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9276,1,Cigarette smoking is the primary cause of chronic obstructive pulmonary disease:,g21984,1,FALSE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9277,0,World wide 80% of smokers reside in the middle and high income countries,g21985,0,TRUE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9277,1,World wide 80% of smokers reside in the middle and high income countries,g21986,1,FALSE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9278,0,Nicotine is not addictive:,g21987,0,TRUE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9278,1,Nicotine is not addictive:,g21988,1,FALSE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9279,0,In 1998 direct medical cost of smoking was estimated to be $75.5 billion:,g21989,0,TRUE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9279,1,In 1998 direct medical cost of smoking was estimated to be $75.5 billion:,g21990,1,FALSE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9280,0,"After 5-15 years of abstinence from smoking, the risk of both stroke and heart disease drops to the level of never-smokers:",g21991,0,TRUE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9280,1,"After 5-15 years of abstinence from smoking, the risk of both stroke and heart disease drops to the level of never-smokers:",g21992,1,FALSE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9281,0,Addiction to nicotine is believed to result from increased release of dopamine in the nucleus acumbens:,g21993,0,TRUE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9281,1,Addiction to nicotine is believed to result from increased release of dopamine in the nucleus acumbens:,g21994,1,FALSE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9282,0,Nicotine withdrawal symptoms are not time limited:,g21995,0,TRUE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9282,1,Nicotine withdrawal symptoms are not time limited:,g21996,1,FALSE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9283,0,Nicotine withdrawal symptoms include:,g21997,0,anxiety,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9283,1,Nicotine withdrawal symptoms include:,g21998,1,irritability,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9283,2,Nicotine withdrawal symptoms include:,g21999,2,depression,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9283,3,Nicotine withdrawal symptoms include:,g22000,3,Weight gain,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9283,4,Nicotine withdrawal symptoms include:,g22001,4,restlessness,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9283,5,Nicotine withdrawal symptoms include:,g22002,5,impatience,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9283,6,Nicotine withdrawal symptoms include:,g22003,6,All of the above,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9284,0,Review of available studies show that physician advice did not have an impact on a higher rate of smoking cessation:,g22004,0,TRUE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9284,1,Review of available studies show that physician advice did not have an impact on a higher rate of smoking cessation:,g22005,1,FALSE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9285,0,"According to the article, respiratory therapists can and should play key roles in smoking cessation strategies:",g22006,0,TRUE,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9285,1,"According to the article, respiratory therapists can and should play key roles in smoking cessation strategies:",g22007,1,FALSE,0,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9286,0,"I have reviewed and understood the article ""Treating Tobacco Use and Dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline Executive Summary""",g22008,0,YES,1,SMOKING CESSATION (RESP CARE)
4825,8894,Elearning-0000-180,g2318,g9286,1,"I have reviewed and understood the article ""Treating Tobacco Use and Dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline Executive Summary""",g22009,1,NO,0,SMOKING CESSATION (RESP CARE)
4808,9591,Elearning-0000-814,g2302,g9183,0,Denying someone shelter and clothing would fall under what abuse category?,g21698,0,Physical Abuse,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9183,1,Denying someone shelter and clothing would fall under what abuse category?,g21699,1,Sexual Abuse,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9183,2,Denying someone shelter and clothing would fall under what abuse category?,g21700,2,Neglect,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9183,3,Denying someone shelter and clothing would fall under what abuse category?,g21701,3,Emotional Abuse,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9184,0,Emotional Abuse is as damaging as physical abuse?,g21702,0,TRUE,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9184,1,Emotional Abuse is as damaging as physical abuse?,g21703,1,FALSE,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9185,0,In family violence the abuser may use which of the following tactics to control the victim? <ol> <li>Limit the victim's ability to maintain financial independence or employment.</li> <li>Threaten physical harm to the victim.</li> <li>Is olate the victim from family or friends.</li> <li>Blame the victim for causing the abuse.</li> </ol>,g21704,0,"A. 1, 2 & 3",0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9185,1,In family violence the abuser may use which of the following tactics to control the victim? <ol> <li>Limit the victim's ability to maintain financial independence or employment.</li> <li>Threaten physical harm to the victim.</li> <li>Is olate the victim from family or friends.</li> <li>Blame the victim for causing the abuse.</li> </ol>,g21705,1,B. 2 & 3,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9185,2,In family violence the abuser may use which of the following tactics to control the victim? <ol> <li>Limit the victim's ability to maintain financial independence or employment.</li> <li>Threaten physical harm to the victim.</li> <li>Is olate the victim from family or friends.</li> <li>Blame the victim for causing the abuse.</li> </ol>,g21706,2,"C. 2, 3, & 4",0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9185,3,In family violence the abuser may use which of the following tactics to control the victim? <ol> <li>Limit the victim's ability to maintain financial independence or employment.</li> <li>Threaten physical harm to the victim.</li> <li>Is olate the victim from family or friends.</li> <li>Blame the victim for causing the abuse.</li> </ol>,g21707,3,D. All of the above,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9186,0,Child sexual abuse usually occurs as an acute event?,g21708,0,TRUE,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9186,1,Child sexual abuse usually occurs as an acute event?,g21709,1,FALSE,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9187,0,A 12 year old patient presents to the hospital and she is noticeably pregnant. It is NSH policy to report pregnancy in a minor under the age of 16 to the appropriate social services agency and/or Law Enforcement?,g21710,0,TRUE,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9187,1,A 12 year old patient presents to the hospital and she is noticeably pregnant. It is NSH policy to report pregnancy in a minor under the age of 16 to the appropriate social services agency and/or Law Enforcement?,g21711,1,FALSE,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9188,0,"In caring for an elderly patient, which of the following may be a red flag of abuse? <ol> <li>Malnutrition and dehydration</li> <li>Bruises to the face, neck, back of thighs , or abdomen</li> <li>Patient reports inability to pay for med ications</li> <li>Delay in patient receiving care after an injury</li> </ol>",g21712,0,"A. 1, 2, & 3",0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9188,1,"In caring for an elderly patient, which of the following may be a red flag of abuse? <ol> <li>Malnutrition and dehydration</li> <li>Bruises to the face, neck, back of thighs , or abdomen</li> <li>Patient reports inability to pay for med ications</li> <li>Delay in patient receiving care after an injury</li> </ol>",g21713,1,B. 2 & 3 only,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9188,2,"In caring for an elderly patient, which of the following may be a red flag of abuse? <ol> <li>Malnutrition and dehydration</li> <li>Bruises to the face, neck, back of thighs , or abdomen</li> <li>Patient reports inability to pay for med ications</li> <li>Delay in patient receiving care after an injury</li> </ol>",g21714,2,C. None of the above,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9188,3,"In caring for an elderly patient, which of the following may be a red flag of abuse? <ol> <li>Malnutrition and dehydration</li> <li>Bruises to the face, neck, back of thighs , or abdomen</li> <li>Patient reports inability to pay for med ications</li> <li>Delay in patient receiving care after an injury</li> </ol>",g21715,3,D. All of the above,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9189,0,"When assessing a patient for potential abuse or neglect, you should always?",g21716,0,Question the patient in front of family members,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9189,1,"When assessing a patient for potential abuse or neglect, you should always?",g21717,1,Assume the patient is lying,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9189,2,"When assessing a patient for potential abuse or neglect, you should always?",g21718,2,Speak with the patient alone without family present,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9189,3,"When assessing a patient for potential abuse or neglect, you should always?",g21719,3,Tell the patient you don't feel comfortable discussing these types of concerns and refer them to a supervisor,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9190,0,When should a patient receive abuse/neglect screening and assessment?,g21720,0,Initial arrival only,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9190,1,When should a patient receive abuse/neglect screening and assessment?,g21721,1,On admission and discharge,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9190,2,When should a patient receive abuse/neglect screening and assessment?,g21722,2,Initial arrival and ongoing assessment throughout their stay,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9190,3,When should a patient receive abuse/neglect screening and assessment?,g21723,3,Only when the patient reports an abuse/neglect concern,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9191,0,"You are walking to the cafeteria to get lunch, you witness a mother slap her six year old child in the face, and hear her make the statement: ""That's what you get because you are so worthless!"" What is your obligation as a NSH employee?",g21724,0,Ignore it you only have 30 minutes for lunch.,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9191,1,"You are walking to the cafeteria to get lunch, you witness a mother slap her six year old child in the face, and hear her make the statement: ""That's what you get because you are so worthless!"" What is your obligation as a NSH employee?",g21725,1,Stop the mother and lecture her on better parenting,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9191,2,"You are walking to the cafeteria to get lunch, you witness a mother slap her six year old child in the face, and hear her make the statement: ""That's what you get because you are so worthless!"" What is your obligation as a NSH employee?",g21726,2,"Obtain a description of the mother and child, report the abuse to a supervisor and file a report with the appropriate agency",1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9191,3,"You are walking to the cafeteria to get lunch, you witness a mother slap her six year old child in the face, and hear her make the statement: ""That's what you get because you are so worthless!"" What is your obligation as a NSH employee?",g21727,3,"Nothing, the kid deserved it",0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9192,0,When you suspect abuse or neglect what form should you obtain to utilize for documentation?,g21728,0,Online Incident Reporting System,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9192,1,When you suspect abuse or neglect what form should you obtain to utilize for documentation?,g21729,1,Nursing Notes,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9192,2,When you suspect abuse or neglect what form should you obtain to utilize for documentation?,g21730,2,Suspected abuse or neglect screening and documentation form,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9192,3,When you suspect abuse or neglect what form should you obtain to utilize for documentation?,g21731,3,Employee health form,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9193,0,"When clothing is collected for evidence to be given to Law Enforcement, it should be?",g21732,0,Packed together in a plastic bag with a patient label,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9193,1,"When clothing is collected for evidence to be given to Law Enforcement, it should be?",g21733,1,Packed separately in paper bags and labeled,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9193,2,"When clothing is collected for evidence to be given to Law Enforcement, it should be?",g21734,2,"Discarded, law enforcement does not keep clothing",0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9193,3,"When clothing is collected for evidence to be given to Law Enforcement, it should be?",g21735,3,Given to security,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9194,0,Family Violence Brochures contain resource phone numbers they may be located in your unit's patient and staff bathroom.,g21736,0,TRUE,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9194,1,Family Violence Brochures contain resource phone numbers they may be located in your unit's patient and staff bathroom.,g21737,1,FALSE,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9195,0,"NSH tracks quality improvement information related to screening, documenting, and reporting of abuse/neglect  information viaΓÇª",g21738,0,Number of staff who have completed the CBL,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9195,1,"NSH tracks quality improvement information related to screening, documenting, and reporting of abuse/neglect  information viaΓÇª",g21739,1,NSH does not track this data,0,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9195,2,"NSH tracks quality improvement information related to screening, documenting, and reporting of abuse/neglect  information viaΓÇª",g21740,2,Ongoing medical record review audits,1,ABUSE/NEGLECT
4808,9591,Elearning-0000-814,g2302,g9195,3,"NSH tracks quality improvement information related to screening, documenting, and reporting of abuse/neglect  information viaΓÇª",g21741,3,Random chart review,0,ABUSE/NEGLECT
4790,9508,Elearning-0000-739,g2300,g9181,0,"I acknowledge I have read and understand the ""Calling in Codes"" CBL.",g21694,0,YES,1,CALLING IN CODES
4790,9508,Elearning-0000-739,g2300,g9181,1,"I acknowledge I have read and understand the ""Calling in Codes"" CBL.",g21695,1,NO,0,CALLING IN CODES
4787,8092,Elearning-0000-03,g2284,g9100,0,Objectives are statements made by an individual engaged in treatment that clearly state their hopes for their care.,g21428,0,TRUE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9100,1,Objectives are statements made by an individual engaged in treatment that clearly state their hopes for their care.,g21429,1,FALSE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9101,0,Objectives are meant to be used to evaluate whether someone should be in treatment.,g21430,0,TRUE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9101,1,Objectives are meant to be used to evaluate whether someone should be in treatment.,g21431,1,FALSE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9102,0,Objectives need to be vague to allow for a consumer to change their treatment as they work with a doctor or clinician.,g21432,0,TRUE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9102,1,Objectives need to be vague to allow for a consumer to change their treatment as they work with a doctor or clinician.,g21433,1,FALSE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9103,0,Objectives should be measureable.,g21434,0,TRUE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9103,1,Objectives should be measureable.,g21435,1,FALSE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9104,0,Goals are the actions an individual in treatment are willing to do to help in their recovery process.,g21436,0,TRUE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9104,1,Goals are the actions an individual in treatment are willing to do to help in their recovery process.,g21437,1,FALSE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9105,0,The recovery model states that individuals with mental illness require a professional to help them determine the decisions they need to make to become healthy.,g21438,0,TRUE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9105,1,The recovery model states that individuals with mental illness require a professional to help them determine the decisions they need to make to become healthy.,g21439,1,FALSE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9106,0,The medical model is based on the traditional concept that patients need assistance from trained caregivers.,g21440,0,TRUE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9106,1,The medical model is based on the traditional concept that patients need assistance from trained caregivers.,g21441,1,FALSE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9107,0,Northside Hospital Behavioral Health Services blends the recovery model and the medical model in an effort to provide all individuals in treatment the experience of a balanced treatment modality based on medications and self determined acti ons.,g21442,0,TRUE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9107,1,Northside Hospital Behavioral Health Services blends the recovery model and the medical model in an effort to provide all individuals in treatment the experience of a balanced treatment modality based on medications and self determined acti ons.,g21443,1,FALSE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9108,0,Interventions are actions the consumers family does to support the consumer of mental health services.,g21444,0,TRUE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9108,1,Interventions are actions the consumers family does to support the consumer of mental health services.,g21445,1,FALSE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9109,0,Progress notes are meant to tell the story of what transpired between the person requesting treatment and the provider of that treatment.,g21446,0,TRUE,1,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4787,8092,Elearning-0000-03,g2284,g9109,1,Progress notes are meant to tell the story of what transpired between the person requesting treatment and the provider of that treatment.,g21447,1,FALSE,0,TREATMENT PLAN DEVELOPMENT AND PROGRESS NOTES
4784,9458,Elearning-0000-693,g2283,g9096,0,"I acknowledge I have read and understand the ""Code One Emergency Button"" CBL.",g21414,0,YES,1,CODE ONE EMERGENCY BUTTON
4784,9458,Elearning-0000-693,g2283,g9096,1,"I acknowledge I have read and understand the ""Code One Emergency Button"" CBL.",g21415,1,NO,0,CODE ONE EMERGENCY BUTTON
4755,8299,Elearning-0000-118,g2258,g9002,0,Leukemia is a malignant disorder of the blood forming cells.,g21130,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9002,1,Leukemia is a malignant disorder of the blood forming cells.,g21131,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9003,0,The Leukemias are classified as :,g21132,0,A. High grade and well differentiate,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9003,1,The Leukemias are classified as :,g21133,1,B. Myeloid or lymphoid,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9003,2,The Leukemias are classified as :,g21134,2,C. Acute or Chronic,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9003,3,The Leukemias are classified as :,g21135,3,D. Diffuse and small cell,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9003,4,The Leukemias are classified as :,g21136,4,E. B & C,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9004,0,The proliferation of malignant blood forming cells in the marrow:,g21137,0,A. Fills up the marrow with immature non-functioning white cells,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9004,1,The proliferation of malignant blood forming cells in the marrow:,g21138,1,B. Causes a decrease in normal white cells,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9004,2,The proliferation of malignant blood forming cells in the marrow:,g21139,2,C. Causes a decrease in the number of normal red-cells,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9004,3,The proliferation of malignant blood forming cells in the marrow:,g21140,3,D. Causes a decrease in the number of platelets,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9004,4,The proliferation of malignant blood forming cells in the marrow:,g21141,4,E. All of the above,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9005,0,Blood cell development begins with a single stem cell which  gives rise to the pluripotent myeloid and lymphoid stem cell.,g21142,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9005,1,Blood cell development begins with a single stem cell which  gives rise to the pluripotent myeloid and lymphoid stem cell.,g21143,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9006,0,Clinical manifestations of  leukemia may include:,g21144,0,A. Increased hematocrit,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9006,1,Clinical manifestations of  leukemia may include:,g21145,1,B. Presence of petechia,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9006,2,Clinical manifestations of  leukemia may include:,g21146,2,C. Fever and delayed wound healing,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9006,3,Clinical manifestations of  leukemia may include:,g21147,3,D. Abnormally high WBC count,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9006,4,Clinical manifestations of  leukemia may include:,g21148,4,"E. B, C & D",1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9007,0,An abnormal finding in the leukemia patient is the presence of excess blast cells (> 5%) in the bone marrow.,g21149,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9007,1,An abnormal finding in the leukemia patient is the presence of excess blast cells (> 5%) in the bone marrow.,g21150,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9008,0,Blast cells circulating in the peripheral blood stream is a normal finding.,g21151,0,TRUE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9008,1,Blast cells circulating in the peripheral blood stream is a normal finding.,g21152,1,FALSE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9009,0,The myeloid stem cell gives rise to which of the following mature white cell?,g21153,0,T Lymphocyte,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9009,1,The myeloid stem cell gives rise to which of the following mature white cell?,g21154,1,B Lymphocyte,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9009,2,The myeloid stem cell gives rise to which of the following mature white cell?,g21155,2,Neutrophil,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9009,3,The myeloid stem cell gives rise to which of the following mature white cell?,g21156,3,Natural Killer Cell,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9010,0,The goal of treatment for AML and ALL is to obtain a complete remission.,g21157,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9010,1,The goal of treatment for AML and ALL is to obtain a complete remission.,g21158,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9011,0,Complete remission is defined as:,g21159,0,<10% blasts in the bone marrow and normal hematologic counts,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9011,1,Complete remission is defined as:,g21160,1,<5% blasts in the bone marrow,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9011,2,Complete remission is defined as:,g21161,2,"<, 5% blasts in the marrow and normal hematologic counts",1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9011,3,Complete remission is defined as:,g21162,3,normal hematologic counts,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9012,0,Initial therapy for the acute leukemia patient is called:,g21163,0,Maintenance,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9012,1,Initial therapy for the acute leukemia patient is called:,g21164,1,Induction,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9012,2,Initial therapy for the acute leukemia patient is called:,g21165,2,Consolidation,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9012,3,Initial therapy for the acute leukemia patient is called:,g21166,3,Intensification,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9013,0,Treatment of the acute leukemia patient results in a predictable but temporary suppression of hematological cell development.,g21167,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9013,1,Treatment of the acute leukemia patient results in a predictable but temporary suppression of hematological cell development.,g21168,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9014,0,A commonly used chemotherapy for AML is:,g21169,0,Busulfan and Hydroxyurea,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9014,1,A commonly used chemotherapy for AML is:,g21170,1,Cytosine Arabinaside ( ARA-C ) and Idarubicin,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9014,2,A commonly used chemotherapy for AML is:,g21171,2,VP-16 and Mitoxantrone,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9014,3,A commonly used chemotherapy for AML is:,g21172,3,"Vincristine, Prednisone, and Daunarubicin",0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9015,0,Leukemic infiltration into the CNS occurs most frequently in:,g21173,0,CML,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9015,1,Leukemic infiltration into the CNS occurs most frequently in:,g21174,1,AML,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9015,2,Leukemic infiltration into the CNS occurs most frequently in:,g21175,2,ALL,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9016,0,Maintenance therapy for the ALL patient is used in patients that:,g21176,0,Have a good prognosis for either cure or long term disease free survival,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9016,1,Maintenance therapy for the ALL patient is used in patients that:,g21177,1,Are good candidates for bone marrow or peripheral blood stem cell transplant.,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9016,2,Maintenance therapy for the ALL patient is used in patients that:,g21178,2,Did not get a complete remission with initial induction therapy.,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9017,0,"Chronic Leukemias develop more slowly than the acute leukemias and as a result, cell development appears more mature in the initial stages.",g21179,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9017,1,"Chronic Leukemias develop more slowly than the acute leukemias and as a result, cell development appears more mature in the initial stages.",g21180,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9018,0,The presence of the the Philadelphia chromosome is present in 90% of:,g21181,0,AML patients,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9018,1,The presence of the the Philadelphia chromosome is present in 90% of:,g21182,1,ALL patients,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9018,2,The presence of the the Philadelphia chromosome is present in 90% of:,g21183,2,CML patients,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9018,3,The presence of the the Philadelphia chromosome is present in 90% of:,g21184,3,CLL patients,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9019,0,The blastic phase of the CML results in :,g21185,0,A. Rapid increase in blast cells in the bone marrow and peripheral blood.,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9019,1,The blastic phase of the CML results in :,g21186,1,B. Clinical manifestations similar to those in acute leukemia,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9019,2,The blastic phase of the CML results in :,g21187,2,C. A general feeling of wellness in the patient.,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9019,3,The blastic phase of the CML results in :,g21188,3,D. A & B,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9020,0,Treatment of CML is dependent on:,g21189,0,The phase of the disease,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9020,1,Treatment of CML is dependent on:,g21190,1,The availability of tyrosine kinase inhibitors,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9020,2,Treatment of CML is dependent on:,g21191,2,The presence of the Philladelphia chromosome,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9021,0,Abnormal coags and the presence of DIC are common in the early stages of:,g21192,0,Acute leukemia,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9021,1,Abnormal coags and the presence of DIC are common in the early stages of:,g21193,1,Chronic leukemia,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9022,0,Nursing care of the leukemia patient requires:,g21194,0,"Constant awareness of the patient's hematological, coag, and chemistry lab values.",0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9022,1,Nursing care of the leukemia patient requires:,g21195,1,Prompt replacement of electrolytes and management of fluid balance.,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9022,2,Nursing care of the leukemia patient requires:,g21196,2,Prompt blood product support.,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9022,3,Nursing care of the leukemia patient requires:,g21197,3,Initiation of antibiotic therapy with the onset of fever within one hour.,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9022,4,Nursing care of the leukemia patient requires:,g21198,4,All of the above.,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9023,0,Physical assessment of the leukemia patient should occur at a minimum of every eight hours in order to minimize or prevent further complications.,g21199,0,TRUE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9023,1,Physical assessment of the leukemia patient should occur at a minimum of every eight hours in order to minimize or prevent further complications.,g21200,1,FALSE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9024,0,CLL ( Chronic Lymphocytic LLeukemia ) is staged according to risk level.,g21201,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9024,1,CLL ( Chronic Lymphocytic LLeukemia ) is staged according to risk level.,g21202,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9025,0,CLL occurs as a result of a single mutation in:,g21203,0,A myelocyte,0,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9025,1,CLL occurs as a result of a single mutation in:,g21204,1,A single lymphocyte,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9026,0,Overall cure rate for AML is approximately 25%.,g21205,0,TRUE,1,UNDERSTANDING THE LEUKEMIA PATIENT
4755,8299,Elearning-0000-118,g2258,g9026,1,Overall cure rate for AML is approximately 25%.,g21206,1,FALSE,0,UNDERSTANDING THE LEUKEMIA PATIENT
4751,9333,Elearning-0000-58,g2254,g8998,0,I acknowledge I have read and understood the Blueprint for Surgical Safety (NSC) CBL.,g21122,0,YES,1,BLUEPRINT FOR SURGICAL SAFETY (NSC)
4751,9333,Elearning-0000-58,g2254,g8998,1,I acknowledge I have read and understood the Blueprint for Surgical Safety (NSC) CBL.,g21123,1,NO,0,BLUEPRINT FOR SURGICAL SAFETY (NSC)
4727,8095,Elearning-0000-06,g2235,g8906,0,Under which circumstance/s should telavancin not be prescribed:,g20908,0,A. In patients requiring continuous infusions of anticoagulants,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8906,1,Under which circumstance/s should telavancin not be prescribed:,g20909,1,B. Surgery prophylaxis,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8906,2,Under which circumstance/s should telavancin not be prescribed:,g20910,2,C. In patients with renal impairment,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8906,3,Under which circumstance/s should telavancin not be prescribed:,g20911,3,D. A and B only,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8906,4,Under which circumstance/s should telavancin not be prescribed:,g20912,4,E. All of above,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8907,0,Telavancin is indicated for treatment of adult patients with complicated skin and skin structure infections caused by:,g20913,0,Vancomycin-resistant Enterococcus faecalis,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8907,1,Telavancin is indicated for treatment of adult patients with complicated skin and skin structure infections caused by:,g20914,1,Pseudomonas aeruginosa,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8907,2,Telavancin is indicated for treatment of adult patients with complicated skin and skin structure infections caused by:,g20915,2,Methicillin-resistant Staphylococcus aureus,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8907,3,Telavancin is indicated for treatment of adult patients with complicated skin and skin structure infections caused by:,g20916,3,Klebsiella pneumoniae,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8908,0,Which physicians are able to prescribe telavancin:,g20917,0,Internal Medicine Physicians,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8908,1,Which physicians are able to prescribe telavancin:,g20918,1,Infectious Diseases Physicians,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8908,2,Which physicians are able to prescribe telavancin:,g20919,2,Cardiology Physicians,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8908,3,Which physicians are able to prescribe telavancin:,g20920,3,Pulmonary Physicians,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8909,0,"At Northside Hospital, telavancin may be used as first line therapy in patients who are tolerant to vancomycin, Linezolid (Zyvox), and/or Daptomycin (Cubicin).",g20921,0,TRUE,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8909,1,"At Northside Hospital, telavancin may be used as first line therapy in patients who are tolerant to vancomycin, Linezolid (Zyvox), and/or Daptomycin (Cubicin).",g20922,1,FALSE,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8910,0,A patient's INR is drawn daily at 0600.  What is/are appropriate time/s for dosing telavancin 10mg/kg IV Q24H:,g20923,0,A. 0700,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8910,1,A patient's INR is drawn daily at 0600.  What is/are appropriate time/s for dosing telavancin 10mg/kg IV Q24H:,g20924,1,B. 0130,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8910,2,A patient's INR is drawn daily at 0600.  What is/are appropriate time/s for dosing telavancin 10mg/kg IV Q24H:,g20925,2,C. 1000,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8910,3,A patient's INR is drawn daily at 0600.  What is/are appropriate time/s for dosing telavancin 10mg/kg IV Q24H:,g20926,3,D. A and C only,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8910,4,A patient's INR is drawn daily at 0600.  What is/are appropriate time/s for dosing telavancin 10mg/kg IV Q24H:,g20927,4,E. All of above,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8911,0,"Prior to initiating telavancin, which laboratory test/s should be ordered and reviewed:",g20928,0,A. Pregnancy test,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8911,1,"Prior to initiating telavancin, which laboratory test/s should be ordered and reviewed:",g20929,1,B. PT / INR,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8911,2,"Prior to initiating telavancin, which laboratory test/s should be ordered and reviewed:",g20930,2,C. Renal function,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8911,3,"Prior to initiating telavancin, which laboratory test/s should be ordered and reviewed:",g20931,3,D. Liver function tests,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8911,4,"Prior to initiating telavancin, which laboratory test/s should be ordered and reviewed:",g20932,4,E. All of above,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8911,5,"Prior to initiating telavancin, which laboratory test/s should be ordered and reviewed:",g20933,5,F. A and C only,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8912,0,Telavancin can be initiated in a patient presenting on a continuous heparin infusion:,g20934,0,TRUE,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8912,1,Telavancin can be initiated in a patient presenting on a continuous heparin infusion:,g20935,1,FALSE,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8913,0,A patient is receiving telavancin 7.5mg/kg IV Q24H at 0400.  Which is earliest time coagulation test can be drawn:,g20936,0,2100,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8913,1,A patient is receiving telavancin 7.5mg/kg IV Q24H at 0400.  Which is earliest time coagulation test can be drawn:,g20937,1,1500,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8913,2,A patient is receiving telavancin 7.5mg/kg IV Q24H at 0400.  Which is earliest time coagulation test can be drawn:,g20938,2,2230,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8913,3,A patient is receiving telavancin 7.5mg/kg IV Q24H at 0400.  Which is earliest time coagulation test can be drawn:,g20939,3,800,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8914,0,Common adverse effects of telavancin include:,g20940,0,A. Foamy urine,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8914,1,Common adverse effects of telavancin include:,g20941,1,B. Metallic / soapy taste,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8914,2,Common adverse effects of telavancin include:,g20942,2,C. Nausea / vomiting,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8914,3,Common adverse effects of telavancin include:,g20943,3,D. Headache,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8914,4,Common adverse effects of telavancin include:,g20944,4,E. All of above,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8915,0,Dose adjustment of telavancin should occur if CrCL is &lt; 50mL/min.,g20945,0,TRUE,1,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4727,8095,Elearning-0000-06,g2235,g8915,1,Dose adjustment of telavancin should occur if CrCL is &lt; 50mL/min.,g20946,1,FALSE,0,TELAVANCIN (VIBATIV) PHARMACIST C.E.
4724,9256,Elearning-0000-51,g2232,g8895,0,"CJD is a rapidly progressing, fatal neurodegenerative disorder caused by a _____?",g20863,0,Neutron,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8895,1,"CJD is a rapidly progressing, fatal neurodegenerative disorder caused by a _____?",g20864,1,Bacteria,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8895,2,"CJD is a rapidly progressing, fatal neurodegenerative disorder caused by a _____?",g20865,2,Prion,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8895,3,"CJD is a rapidly progressing, fatal neurodegenerative disorder caused by a _____?",g20866,3,Virus,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8896,0,"CJD can be transmitted by contaminated dura mater, corneas or surgical instruments.",g20867,0,TRUE,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8896,1,"CJD can be transmitted by contaminated dura mater, corneas or surgical instruments.",g20868,1,FALSE,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8897,0,CJD cases will be scheduled at the _________of the day.,g20869,0,Beginning,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8897,1,CJD cases will be scheduled at the _________of the day.,g20870,1,Middle,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8897,2,CJD cases will be scheduled at the _________of the day.,g20871,2,End,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8898,0,"If equipment cannot be removed from the OR room during a CJD case, it should be covered with a/an _______________ coverings.",g20872,0,Clear,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8898,1,"If equipment cannot be removed from the OR room during a CJD case, it should be covered with a/an _______________ coverings.",g20873,1,Contaminated,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8898,2,"If equipment cannot be removed from the OR room during a CJD case, it should be covered with a/an _______________ coverings.",g20874,2,Impervious,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8898,3,"If equipment cannot be removed from the OR room during a CJD case, it should be covered with a/an _______________ coverings.",g20875,3,Regular,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8899,0,What sign should be placed on the outside of the OR door?,g20876,0,Airway precautions,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8899,1,What sign should be placed on the outside of the OR door?,g20877,1,Isolation,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8899,2,What sign should be placed on the outside of the OR door?,g20878,2,Contact precautions,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8899,3,What sign should be placed on the outside of the OR door?,g20879,3,Limited traffic,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,0,Scrubbed personnel's PPE will consist of :,g20880,0,A. Double gloves,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,1,Scrubbed personnel's PPE will consist of :,g20881,1,B. Eye protection,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,2,Scrubbed personnel's PPE will consist of :,g20882,2,C. Impervious gown,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,3,Scrubbed personnel's PPE will consist of :,g20883,3,D. Mask,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,4,Scrubbed personnel's PPE will consist of :,g20884,4,E. Shoe covers,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,5,Scrubbed personnel's PPE will consist of :,g20885,5,F. None of the above,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,6,Scrubbed personnel's PPE will consist of :,g20886,6,G. All of the above,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8900,7,Scrubbed personnel's PPE will consist of :,g20887,7,"H. B, C, D, E",0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,0,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20888,0,A. Shoe covers,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,1,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20889,1,B. Impervious gown,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,2,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20890,2,C. Single gloves,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,3,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20891,3,D. Eye protection,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,4,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20892,4,E. Mask,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,5,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20893,5,F. Double gloves,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,6,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20894,6,G. None of the above,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,7,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20895,7,H. All of the above,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8901,8,A circulator RN handling items contaminated with high-infectivity tissue will use the following PPE:,g20896,8,"I. A, B, D, E , F",1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8902,0,Scrub personnel will use a strict safe-zone technique-no hand to hand passing of sharps.,g20897,0,TRUE,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8902,1,Scrub personnel will use a strict safe-zone technique-no hand to hand passing of sharps.,g20898,1,FALSE,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8903,0,All specimens are to be _________ bagged prior to sending to the laboratory.,g20899,0,Single,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8903,1,All specimens are to be _________ bagged prior to sending to the laboratory.,g20900,1,Double,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8903,2,All specimens are to be _________ bagged prior to sending to the laboratory.,g20901,2,Triple,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8904,0,"After the case, the surgical instruments are to be autoclaved a ______┬░ F for ______ minutes and _____minutes of dry time.",g20902,0,273/18/22,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8904,1,"After the case, the surgical instruments are to be autoclaved a ______┬░ F for ______ minutes and _____minutes of dry time.",g20903,1,275/45/10,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8904,2,"After the case, the surgical instruments are to be autoclaved a ______┬░ F for ______ minutes and _____minutes of dry time.",g20904,2,270/60/8,1,CREUTZFELDT-JAKOB DISEASE (CJD)
4724,9256,Elearning-0000-51,g2232,g8904,3,"After the case, the surgical instruments are to be autoclaved a ______┬░ F for ______ minutes and _____minutes of dry time.",g20905,3,265/10/25,0,CREUTZFELDT-JAKOB DISEASE (CJD)
4700,8094,Elearning-0000-05,g2214,g8813,0,Time and Effort entries should be entered:,g20630,0,Daily,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8813,1,Time and Effort entries should be entered:,g20631,1,Weekly,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8813,2,Time and Effort entries should be entered:,g20632,2,Bi-Weekly,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8813,3,Time and Effort entries should be entered:,g20633,3,Monthly,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8814,0,Staff members that work directly on a research study must record their time and effort.,g20634,0,TRUE,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8814,1,Staff members that work directly on a research study must record their time and effort.,g20635,1,FALSE,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8815,0,What is the minimum number of hours required per week day to be recorded in the time and effort database?,g20636,0,6,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8815,1,What is the minimum number of hours required per week day to be recorded in the time and effort database?,g20637,1,8,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8815,2,What is the minimum number of hours required per week day to be recorded in the time and effort database?,g20638,2,10,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8815,3,What is the minimum number of hours required per week day to be recorded in the time and effort database?,g20639,3,12,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8816,0,An example of research related time is (time tracked to a specific study number):,g20640,0,Time spent in research meetings,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8816,1,An example of research related time is (time tracked to a specific study number):,g20641,1,Attending a training class for Microsoft Excel,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8816,2,An example of research related time is (time tracked to a specific study number):,g20642,2,Time spent with Mr. Jones reviewing a consent,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8816,3,An example of research related time is (time tracked to a specific study number):,g20643,3,Reading a protocol synopsis to determine feasibility of research project,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8817,0,It is not necessary to record every hour of your work day.,g20644,0,TRUE,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8817,1,It is not necessary to record every hour of your work day.,g20645,1,FALSE,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8818,0,"If a study number is not in the research pull-down menu and you believe it should be, you should:",g20646,0,Submit a time entry question to the Research Analyst,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8818,1,"If a study number is not in the research pull-down menu and you believe it should be, you should:",g20647,1,Type in the study number in the study number spot and enter your hours,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8818,2,"If a study number is not in the research pull-down menu and you believe it should be, you should:",g20648,2,Record the time as other/unspecified,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8818,3,"If a study number is not in the research pull-down menu and you believe it should be, you should:",g20649,3,Not work on the project,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8819,0,The time period for effort certification is:,g20650,0,One week excluding weekends,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8819,1,The time period for effort certification is:,g20651,1,One pay period / two weeks,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8819,2,The time period for effort certification is:,g20652,2,Two weeks excluding weekends,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8819,3,The time period for effort certification is:,g20653,3,One Month,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8820,0,Red numbers in the Total Time column mean:,g20654,0,The minimum 8 hours have not been entered for the day,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8820,1,Red numbers in the Total Time column mean:,g20655,1,Nothing.  The database creator liked the color red,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8820,2,Red numbers in the Total Time column mean:,g20656,2,You should stop recording your time,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8820,3,Red numbers in the Total Time column mean:,g20657,3,No Administrative / Other time has been recorded,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8821,0,Effort reporting is a process mandated by the Federal Government,g20658,0,TRUE,1,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8821,1,Effort reporting is a process mandated by the Federal Government,g20659,1,FALSE,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8822,0,Time should be captured in what time increments:,g20660,0,Whole hours only,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8822,1,Time should be captured in what time increments:,g20661,1,0.15 / 0.30 / 0.45 / 1.0,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8822,2,Time should be captured in what time increments:,g20662,2,Whole and half hours only,0,TIME AND EFFORT REPORTING
4700,8094,Elearning-0000-05,g2214,g8822,3,Time should be captured in what time increments:,g20663,3,0.25 / 0.50 / 0.75 / 1.0,1,TIME AND EFFORT REPORTING
4643,8093,Elearning-0000-04,g2162,g8594,0,I acknowledge I have read & understand the Timekeeper Policy Update.,g19995,0,YES,1,TIMEKEEPER POLICY
4643,8093,Elearning-0000-04,g2162,g8594,1,I acknowledge I have read & understand the Timekeeper Policy Update.,g19996,1,NO,0,TIMEKEEPER POLICY
4642,8991,Elearning-0000-269,g2161,g10728,0,I acknowledge I have read & understand this 2012 PHS Search Criteria Competency CBL.,g26479,0,YES,1,PHS DATABASE SEARCH
4642,8991,Elearning-0000-269,g2161,g10728,1,I acknowledge I have read & understand this 2012 PHS Search Criteria Competency CBL.,g26480,1,NO,0,PHS DATABASE SEARCH
4639,8984,Elearning-0000-262,g2158,g8580,0,It is appropriate to use the STAR Clinical Physicians Table to properly identify a physician.,g19948,0,TRUE,1,PHYSICIAN SELECTION CRITERIA
4639,8984,Elearning-0000-262,g2158,g8580,1,It is appropriate to use the STAR Clinical Physicians Table to properly identify a physician.,g19949,1,FALSE,0,PHYSICIAN SELECTION CRITERIA
4639,8984,Elearning-0000-262,g2158,g8581,0,"Before choosing a Non-Northside physician, you must search for the physician under the following:",g19950,0,STAR Clinicals Physician Table,1,PHYSICIAN SELECTION CRITERIA
4639,8984,Elearning-0000-262,g2158,g8581,1,"Before choosing a Non-Northside physician, you must search for the physician under the following:",g19951,1,MPI Search,0,PHYSICIAN SELECTION CRITERIA
4639,8984,Elearning-0000-262,g2158,g8581,2,"Before choosing a Non-Northside physician, you must search for the physician under the following:",g19952,2,STAR Insurance Codes and Plan Table,0,PHYSICIAN SELECTION CRITERIA
4639,8984,Elearning-0000-262,g2158,g8581,3,"Before choosing a Non-Northside physician, you must search for the physician under the following:",g19953,3,STAR Patient Denomination Table,0,PHYSICIAN SELECTION CRITERIA
4639,8984,Elearning-0000-262,g2158,g8582,0,"If a physician is already listed in the physician screen from a previous visit, it is not necessary to update the physician field.",g19954,0,TRUE,0,PHYSICIAN SELECTION CRITERIA
4639,8984,Elearning-0000-262,g2158,g8582,1,"If a physician is already listed in the physician screen from a previous visit, it is not necessary to update the physician field.",g19955,1,FALSE,1,PHYSICIAN SELECTION CRITERIA
4635,9399,Elearning-0000-64,g2154,g8557,0,I have read and understand my role and responsibility in ensuring the accuracy of Radiology Orders.,g19862,0,YES,1,ACCURACY OF RADIOLOGY ORDERS
4635,9399,Elearning-0000-64,g2154,g8557,1,I have read and understand my role and responsibility in ensuring the accuracy of Radiology Orders.,g19863,1,NO,0,ACCURACY OF RADIOLOGY ORDERS
4632,9267,Elearning-0000-52,g2152,g8552,0,What are strict I&Os?,g19844,0,"Measured, Numerical, Every 1 hour",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8552,1,What are strict I&Os?,g19845,1,"Measured, Numerical, Every 8 hours",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8552,2,What are strict I&Os?,g19846,2,"Measured, Numerical, Every 4 hours",1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8552,3,What are strict I&Os?,g19847,3,"Measured, Numerical, Every 2 hours",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8553,0,What kind of activities should you have the patient do on your shift?,g19848,0,a. Ambulate every 4 hours,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8553,1,What kind of activities should you have the patient do on your shift?,g19849,1,b. Lift their overnight bag from the chair to the bed,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8553,2,What kind of activities should you have the patient do on your shift?,g19850,2,"c. Turn Cough, Deep breath, reposition every 2 hours, ICS",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8553,3,What kind of activities should you have the patient do on your shift?,g19851,3,d. A & C only,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8553,4,What kind of activities should you have the patient do on your shift?,g19852,4,e. All of the above,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8554,0,Should a patient who just under went a cystectomy (removal of bladder) be wearing SCDs.,g19853,0,Yes,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8554,1,Should a patient who just under went a cystectomy (removal of bladder) be wearing SCDs.,g19854,1,No,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8554,2,Should a patient who just under went a cystectomy (removal of bladder) be wearing SCDs.,g19855,2,It depends on what the nurse says,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8555,0,What are 5 things you as the PCT for a Urology patient should be monitoring for and alerting the nurse?,g19856,0,"Abnormal Vital Signs, Low or No Urine Output, Unrelieved Pain, Change in color of Urine Output, Confusion",1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8555,1,What are 5 things you as the PCT for a Urology patient should be monitoring for and alerting the nurse?,g19857,1,"Normal Vital Signs, Low or No Urine Output, Unrelieved Pain, Change in color of Urine Output, Confusion",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8555,2,What are 5 things you as the PCT for a Urology patient should be monitoring for and alerting the nurse?,g19858,2,"Abnormal Vital Signs, Good Urine Output, Unrelieved Pain, Change in color of Urine Output, Confusion",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4632,9267,Elearning-0000-52,g2152,g8555,3,What are 5 things you as the PCT for a Urology patient should be monitoring for and alerting the nurse?,g19859,3,"Abnormal Vital Signs, Low or No Urine Output, Unrelieved Pain, Change in color of Urine Output, Patient not getting up out of bed",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC PCT)
4631,9278,Elearning-0000-53,g2151,g8544,0,What are some complications after a Nephrectomy?,g19806,0,Temporary shoulder tip pain & Abdominal bloating,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8544,1,What are some complications after a Nephrectomy?,g19807,1,Respiratory system compromise,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8544,2,What are some complications after a Nephrectomy?,g19808,2,Infection,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8544,3,What are some complications after a Nephrectomy?,g19809,3,Hernia in one or more of the incisions,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8544,4,What are some complications after a Nephrectomy?,g19810,4,All of the above,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8545,0,Why might a patient undergo a Nephrectomy?,g19811,0,Cancer,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8545,1,Why might a patient undergo a Nephrectomy?,g19812,1,Infection,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8545,2,Why might a patient undergo a Nephrectomy?,g19813,2,Kidneys partially functioning or not functioning at all,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8545,3,Why might a patient undergo a Nephrectomy?,g19814,3,All of the above,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8546,0,Why is post-op and discharge teaching so important for Nephrectomy patients?,g19815,0,Because these patients only have one kidney left and need to preserve its function to prevent from losing it as well,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8546,1,Why is post-op and discharge teaching so important for Nephrectomy patients?,g19816,1,They need to know about dialysis,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8546,2,Why is post-op and discharge teaching so important for Nephrectomy patients?,g19817,2,They need to know how to change their foley bags,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8546,3,Why is post-op and discharge teaching so important for Nephrectomy patients?,g19818,3,They need to know what medications may be nephrotoxic,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8547,0,What should your discharge teaching include for a patient with a Nephrectomy?,g19819,0,"Monitor for presence of UTI, calculi, and surgical site infection",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8547,1,What should your discharge teaching include for a patient with a Nephrectomy?,g19820,1,Encourage adequate fluid intake,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8547,2,What should your discharge teaching include for a patient with a Nephrectomy?,g19821,2,"Gradually increase exercise, and avoid heavy lifting",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8547,3,What should your discharge teaching include for a patient with a Nephrectomy?,g19822,3,"Incision care, drainage tube care, and foley care if applicable",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8547,4,What should your discharge teaching include for a patient with a Nephrectomy?,g19823,4,All of the above,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8548,0,Why might a patient undergo a TURP procedure?,g19824,0,a. To remove an enlarged prostate (BPH),0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8548,1,Why might a patient undergo a TURP procedure?,g19825,1,b. Treat symptoms associated with Prostate Cancer,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8548,2,Why might a patient undergo a TURP procedure?,g19826,2,c. To prevent from going to dialysis,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8548,3,Why might a patient undergo a TURP procedure?,g19827,3,d. Because its fun for the nurses to have patients with Murphy Drips,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8548,4,Why might a patient undergo a TURP procedure?,g19828,4,e. A & B,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8549,0,What is a Pyeloplasty?,g19829,0,Treatment for an obstruction of a ureter from the kidney,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8549,1,What is a Pyeloplasty?,g19830,1,A good nose job,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8549,2,What is a Pyeloplasty?,g19831,2,Removal of kidney stones from a ureter,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8549,3,What is a Pyeloplasty?,g19832,3,Treatment for an obstruction of bladder to the urethra,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8550,0,What should post op care for a patient with an Ileal Conduit include?,g19833,0,"Maintain strict I&Os, repositioning, TCDB, ICS, antibiotics",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8550,1,What should post op care for a patient with an Ileal Conduit include?,g19834,1,"Pain assessments, skin care, and stoma care",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8550,2,What should post op care for a patient with an Ileal Conduit include?,g19835,2,WOCN consults for stoma care,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8550,3,What should post op care for a patient with an Ileal Conduit include?,g19836,3,Monitor lab results for electrolyte imbalances,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8550,4,What should post op care for a patient with an Ileal Conduit include?,g19837,4,All of the above,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8551,0,What are some complications you might see with any patient undergoing a Urology procedure?,g19838,0,Infection,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8551,1,What are some complications you might see with any patient undergoing a Urology procedure?,g19839,1,Respiratory compromise,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8551,2,What are some complications you might see with any patient undergoing a Urology procedure?,g19840,2,"GI compromise, Fluid deficiency",0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8551,3,What are some complications you might see with any patient undergoing a Urology procedure?,g19841,3,Bladder Spasms,0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8551,4,What are some complications you might see with any patient undergoing a Urology procedure?,g19842,4,UTIs (recurring also),0,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4631,9278,Elearning-0000-53,g2151,g8551,5,What are some complications you might see with any patient undergoing a Urology procedure?,g19843,5,All of the above,1,CARE OF THE UROLOGY PATIENT (ORTHOPEDIC RN)
4617,9201,Elearning-0000-46,g2137,g8450,0,Who is required to participate in handoff communication,g19462,0,Technologists,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8450,1,Who is required to participate in handoff communication,g19463,1,Secretaries,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8450,2,Who is required to participate in handoff communication,g19464,2,Doctors,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8450,3,Who is required to participate in handoff communication,g19465,3,Anyone who provides care or support for patients,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8451,0,"When picking up a patient, you should inform the nurse what exam the patient is having",g19466,0,TRUE,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8451,1,"When picking up a patient, you should inform the nurse what exam the patient is having",g19467,1,FALSE,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8452,0,"When transporting a patient, you must ask if they are on oxygen, and how many liters",g19468,0,TRUE,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8452,1,"When transporting a patient, you must ask if they are on oxygen, and how many liters",g19469,1,FALSE,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8453,0,"When a patient is dropped off to Radiology, the tech assistant must perform hand off communication with the person responsible for performing the exam",g19470,0,TRUE,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8453,1,"When a patient is dropped off to Radiology, the tech assistant must perform hand off communication with the person responsible for performing the exam",g19471,1,FALSE,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8454,0,"Whenever providing patient care or transporting a patient, what information should you always know about your patient",g19472,0,Isolation,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8454,1,"Whenever providing patient care or transporting a patient, what information should you always know about your patient",g19473,1,Risk to Fall,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8454,2,"Whenever providing patient care or transporting a patient, what information should you always know about your patient",g19474,2,"Mental, Hearing, or Visual impairments",0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8454,3,"Whenever providing patient care or transporting a patient, what information should you always know about your patient",g19475,3,All of the above,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8455,0,"When a patient is returned to the floor, whom should you notify if the nurse is unavailable?",g19476,0,a. Charge Nurse,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8455,1,"When a patient is returned to the floor, whom should you notify if the nurse is unavailable?",g19477,1,b. Secretary,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8455,2,"When a patient is returned to the floor, whom should you notify if the nurse is unavailable?",g19478,2,c. Both A & B,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8455,3,"When a patient is returned to the floor, whom should you notify if the nurse is unavailable?",g19479,3,d. None of the above,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8456,0,"When handing off a patient to another technologist, it is not important that you perform handoff communication",g19480,0,TRUE,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8456,1,"When handing off a patient to another technologist, it is not important that you perform handoff communication",g19481,1,FALSE,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8457,0,"The primary objective of a ""hand off"" is to provide accurate information about",g19482,0,"Patient's care, treatment, and services",0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8457,1,"The primary objective of a ""hand off"" is to provide accurate information about",g19483,1,Current condition,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8457,2,"The primary objective of a ""hand off"" is to provide accurate information about",g19484,2,Any recent or anticipated changes,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8457,3,"The primary objective of a ""hand off"" is to provide accurate information about",g19485,3,All of the above,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8458,0,Handoff communication does not necessarily need to include a chance to ask questions:,g19486,0,TRUE,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8458,1,Handoff communication does not necessarily need to include a chance to ask questions:,g19487,1,FALSE,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8459,0,When should handoff communication be performed,g19488,0,Shift Change,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8459,1,When should handoff communication be performed,g19489,1,Change in person performing exam,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8459,2,When should handoff communication be performed,g19490,2,Patient going between modalities,0,HAND-OFF COMMUNICATION (RADIOLOGY)
4617,9201,Elearning-0000-46,g2137,g8459,3,When should handoff communication be performed,g19491,3,All of the above,1,HAND-OFF COMMUNICATION (RADIOLOGY)
4609,9058,Elearning-0000-33,g2130,g8357,0,The primary goal of the Institutional Review Board (IRB) is to protect the rights and welfare of human research subjects:,g19199,0,TRUE,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8357,1,The primary goal of the Institutional Review Board (IRB) is to protect the rights and welfare of human research subjects:,g19200,1,FALSE,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8358,0,The primary goal of the Research Oversight Committee (ROC) is to assess the feasibility of conducting a research study at Northside Hospital:,g19201,0,TRUE,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8358,1,The primary goal of the Research Oversight Committee (ROC) is to assess the feasibility of conducting a research study at Northside Hospital:,g19202,1,FALSE,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8359,0,The National Research Act was passed by Congress in 1974; the Act required regulations for the protection of human subjects including the requirement for review of research by an Institutional Review Board (IRB):,g19203,0,TRUE,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8359,1,The National Research Act was passed by Congress in 1974; the Act required regulations for the protection of human subjects including the requirement for review of research by an Institutional Review Board (IRB):,g19204,1,FALSE,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8360,0,The Belmont Report was published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.  Which of the following was not one of the three basic principles described in the Belmont Repor t?,g19205,0,Respect for persons,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8360,1,The Belmont Report was published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.  Which of the following was not one of the three basic principles described in the Belmont Repor t?,g19206,1,Beneficence,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8360,2,The Belmont Report was published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.  Which of the following was not one of the three basic principles described in the Belmont Repor t?,g19207,2,Justice,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8360,3,The Belmont Report was published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.  Which of the following was not one of the three basic principles described in the Belmont Repor t?,g19208,3,Freedom,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8361,0,"Prior to review by the Research Oversight Committee (ROC), a research proposal must first be submitted to the Institutional Review Board (IRB) for approval:",g19209,0,TRUE,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8361,1,"Prior to review by the Research Oversight Committee (ROC), a research proposal must first be submitted to the Institutional Review Board (IRB) for approval:",g19210,1,FALSE,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8362,0,The investigator is required to attend the Institutional Review Board (IRB) meeting to present a new research proposal:,g19211,0,TRUE,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8362,1,The investigator is required to attend the Institutional Review Board (IRB) meeting to present a new research proposal:,g19212,1,FALSE,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8363,0,"To protect the rights and welfare of human research subjects, which of the following is not considered by the IRB when reviewing research?",g19213,0,Ensure that risks are minimized and benefits are maximized,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8363,1,"To protect the rights and welfare of human research subjects, which of the following is not considered by the IRB when reviewing research?",g19214,1,Ensure that procedures for obtaining informed consent are adequate,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8363,2,"To protect the rights and welfare of human research subjects, which of the following is not considered by the IRB when reviewing research?",g19215,2,Ensure that the hospital is reimbursed for all labs that are performed,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8363,3,"To protect the rights and welfare of human research subjects, which of the following is not considered by the IRB when reviewing research?",g19216,3,Ensure safeguards for vulnerable subjects,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8364,0,"There are three levels of IRB review: exempt, expedited and full board review.  Who makes the determination for the appropriate level of review?",g19217,0,The patient,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8364,1,"There are three levels of IRB review: exempt, expedited and full board review.  Who makes the determination for the appropriate level of review?",g19218,1,The IRB,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8364,2,"There are three levels of IRB review: exempt, expedited and full board review.  Who makes the determination for the appropriate level of review?",g19219,2,The investigator,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8364,3,"There are three levels of IRB review: exempt, expedited and full board review.  Who makes the determination for the appropriate level of review?",g19220,3,The nurse that submits the study,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8365,0,All adverse events must be reported to the IRB.,g19221,0,TRUE,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8365,1,All adverse events must be reported to the IRB.,g19222,1,FALSE,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8366,0,The maximum length of time for an IRB approval period and frequency of interim reports for a research proposal is:,g19223,0,3 months,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8366,1,The maximum length of time for an IRB approval period and frequency of interim reports for a research proposal is:,g19224,1,6 months,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8366,2,The maximum length of time for an IRB approval period and frequency of interim reports for a research proposal is:,g19225,2,1 year,1,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4609,9058,Elearning-0000-33,g2130,g8366,3,The maximum length of time for an IRB approval period and frequency of interim reports for a research proposal is:,g19226,3,No limit,0,INSTITUTIONAL REVIEW BOARD REQUIREMENTS AN OVERVIEW
4608,9410,Elearning-0000-65,g2129,g8347,0,"Electronic signatures are considered equivalent to hand-written signatures when records are created, modified, maintained, and transmitted according to FDA regulations.",g19179,0,TRUE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8347,1,"Electronic signatures are considered equivalent to hand-written signatures when records are created, modified, maintained, and transmitted according to FDA regulations.",g19180,1,FALSE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8348,0,A faxed report is covered by this regulation.,g19181,0,TRUE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8348,1,A faxed report is covered by this regulation.,g19182,1,FALSE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8349,0,The FDA has no right to scrutinize an institution's password system.,g19183,0,TRUE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8349,1,The FDA has no right to scrutinize an institution's password system.,g19184,1,FALSE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8350,0,There are some government agencies for which electronic signatures are not acceptable.,g19185,0,TRUE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8350,1,There are some government agencies for which electronic signatures are not acceptable.,g19186,1,FALSE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8351,0,"Controls are designed to ensure the authenticity, integrity, and the confidentiality of electronic records.",g19187,0,TRUE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8351,1,"Controls are designed to ensure the authenticity, integrity, and the confidentiality of electronic records.",g19188,1,FALSE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8352,0,Written policies for system use and accountability are required to deter unauthorized use.,g19189,0,TRUE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8352,1,Written policies for system use and accountability are required to deter unauthorized use.,g19190,1,FALSE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8353,0,"Signed electronic records must contain the signer's name, employee number, and date and time of signature.",g19191,0,TRUE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8353,1,"Signed electronic records must contain the signer's name, employee number, and date and time of signature.",g19192,1,FALSE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8354,0,Electronic signatures are linked to an electronic record to minimize falsification of the records and to monitor usage of the system.,g19193,0,TRUE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8354,1,Electronic signatures are linked to an electronic record to minimize falsification of the records and to monitor usage of the system.,g19194,1,FALSE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8355,0,Components of electronic signatures should identify one person.,g19195,0,TRUE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8355,1,Components of electronic signatures should identify one person.,g19196,1,FALSE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8356,0,Procedures must be in place to manage any breaches of electronic signature security and to issue replacement identification codes as needed.,g19197,0,TRUE,1,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4608,9410,Elearning-0000-65,g2129,g8356,1,Procedures must be in place to manage any breaches of electronic signature security and to issue replacement identification codes as needed.,g19198,1,FALSE,0,"21 CRF 11 ELECTRONIC RECORDS, ELECTRONIC SIGNATURES (RESEARCH)"
4599,1129,ILT-0000-4454,g2120,g8301,0,I acknowledge that I have read and understand the Code Silver CBL.,g19068,0,YES,1,CODE SILVER (ACTIVE SHOOTER)
4599,1129,ILT-0000-4454,g2120,g8301,1,I acknowledge that I have read and understand the Code Silver CBL.,g19069,1,NO,0,CODE SILVER (ACTIVE SHOOTER)
4571,8633,Elearning-0000-15,g2097,g8165,0,"In laparoscopic procedures, smoke evacuation is critical to: <ol> <li>prevent absorption through tissue into the patient's abdomen.</li> <li>proper surgical technique.</li> <li>prevent absorption via the respiratory tract of the staff.< /li> <li>the surgeon's visibility.</li> </ol>",g18664,0,2 & 3,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8165,1,"In laparoscopic procedures, smoke evacuation is critical to: <ol> <li>prevent absorption through tissue into the patient's abdomen.</li> <li>proper surgical technique.</li> <li>prevent absorption via the respiratory tract of the staff.< /li> <li>the surgeon's visibility.</li> </ol>",g18665,1,1 & 4,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8165,2,"In laparoscopic procedures, smoke evacuation is critical to: <ol> <li>prevent absorption through tissue into the patient's abdomen.</li> <li>proper surgical technique.</li> <li>prevent absorption via the respiratory tract of the staff.< /li> <li>the surgeon's visibility.</li> </ol>",g18666,2,1 & 2,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8165,3,"In laparoscopic procedures, smoke evacuation is critical to: <ol> <li>prevent absorption through tissue into the patient's abdomen.</li> <li>proper surgical technique.</li> <li>prevent absorption via the respiratory tract of the staff.< /li> <li>the surgeon's visibility.</li> </ol>",g18667,3,3 & 4,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8166,0,The composition of surgical smoke and aerosol generated by a laser or electrosurgical procedure is 5% water and 95% other matter.,g18668,0,TRUE,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8166,1,The composition of surgical smoke and aerosol generated by a laser or electrosurgical procedure is 5% water and 95% other matter.,g18669,1,FALSE,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8167,0,The potentially toxic chemicals in surgical smoke and aerosols include: <ol> <li>Allergens</li> <li>Carcinogens</li> <li>Mutagens</li> <li>Toxins</li> </ol>,g18670,0,"1, 2, 3",0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8167,1,The potentially toxic chemicals in surgical smoke and aerosols include: <ol> <li>Allergens</li> <li>Carcinogens</li> <li>Mutagens</li> <li>Toxins</li> </ol>,g18671,1,"1, 3, 4",0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8167,2,The potentially toxic chemicals in surgical smoke and aerosols include: <ol> <li>Allergens</li> <li>Carcinogens</li> <li>Mutagens</li> <li>Toxins</li> </ol>,g18672,2,"2, 3, 4",0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8167,3,The potentially toxic chemicals in surgical smoke and aerosols include: <ol> <li>Allergens</li> <li>Carcinogens</li> <li>Mutagens</li> <li>Toxins</li> </ol>,g18673,3,All of the above,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8168,0,"The median aerodynamic diameter of particles contained in surgical smoke and aerosol of 0.31 micrometers is the most dangerous, because it is the optimal size to be deposited in the :",g18674,0,Eyes,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8168,1,"The median aerodynamic diameter of particles contained in surgical smoke and aerosol of 0.31 micrometers is the most dangerous, because it is the optimal size to be deposited in the :",g18675,1,Lower respiratory tract,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8168,2,"The median aerodynamic diameter of particles contained in surgical smoke and aerosol of 0.31 micrometers is the most dangerous, because it is the optimal size to be deposited in the :",g18676,2,Upper respiratory tract,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8168,3,"The median aerodynamic diameter of particles contained in surgical smoke and aerosol of 0.31 micrometers is the most dangerous, because it is the optimal size to be deposited in the :",g18677,3,None of the above,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8169,0,"Surgical smoke and aerosol, or plume, are created when:",g18678,0,Electricity is delivered to a cell in any form.,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8169,1,"Surgical smoke and aerosol, or plume, are created when:",g18679,1,Energy is delivered to tissue cells during surgery.,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8169,2,"Surgical smoke and aerosol, or plume, are created when:",g18680,2,Heat vaporizes extracellular fluid,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8169,3,"Surgical smoke and aerosol, or plume, are created when:",g18681,3,All of the above,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8170,0,Electrosurgical smoke and laser smoke possess similar particle content therefore the same dangers.,g18682,0,TRUE,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8170,1,Electrosurgical smoke and laser smoke possess similar particle content therefore the same dangers.,g18683,1,FALSE,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8171,0,"The amount of plume, smoke or aerosol generated varies with the:",g18684,0,Duration of application of thermal or mechanical energy,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8171,1,"The amount of plume, smoke or aerosol generated varies with the:",g18685,1,Surgical technique,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8171,2,"The amount of plume, smoke or aerosol generated varies with the:",g18686,2,Target tissue,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8171,3,"The amount of plume, smoke or aerosol generated varies with the:",g18687,3,All of the above,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8172,0,"Any instrument that oscillates, vibrates or spins within surgical sites can generate tissue aerosols that contain potentially harmful components.",g18688,0,TRUE,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8172,1,"Any instrument that oscillates, vibrates or spins within surgical sites can generate tissue aerosols that contain potentially harmful components.",g18689,1,FALSE,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8173,0,"The viruses of greatest concern to users of lasers, electrosurgery, and powered surgical instruments are: <ol> <li>E.Coli</li> <li>HIV</li> <li>HPV</li> <li>Staph aureus</li> </ol>",g18690,0,1 & 2,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8173,1,"The viruses of greatest concern to users of lasers, electrosurgery, and powered surgical instruments are: <ol> <li>E.Coli</li> <li>HIV</li> <li>HPV</li> <li>Staph aureus</li> </ol>",g18691,1,2 & 3,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8173,2,"The viruses of greatest concern to users of lasers, electrosurgery, and powered surgical instruments are: <ol> <li>E.Coli</li> <li>HIV</li> <li>HPV</li> <li>Staph aureus</li> </ol>",g18692,2,3 & 4,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8173,3,"The viruses of greatest concern to users of lasers, electrosurgery, and powered surgical instruments are: <ol> <li>E.Coli</li> <li>HIV</li> <li>HPV</li> <li>Staph aureus</li> </ol>",g18693,3,All of the above,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8174,0,The offensive odor of surgical smoke can: <ol> <li>Cause nausea and vomiting</li> <li>Heighten patient anxiety</li> <li>Irritate the eyes</li> <li>Lengthen the surgical procedure</li> <li>Warn personnel that they are inhaling harmful gases</li> </ol>,g18694,0,"1 ,2 ,3, 4",0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8174,1,The offensive odor of surgical smoke can: <ol> <li>Cause nausea and vomiting</li> <li>Heighten patient anxiety</li> <li>Irritate the eyes</li> <li>Lengthen the surgical procedure</li> <li>Warn personnel that they are inhaling harmful gases</li> </ol>,g18695,1,"1, 2, 3, 5",1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8174,2,The offensive odor of surgical smoke can: <ol> <li>Cause nausea and vomiting</li> <li>Heighten patient anxiety</li> <li>Irritate the eyes</li> <li>Lengthen the surgical procedure</li> <li>Warn personnel that they are inhaling harmful gases</li> </ol>,g18696,2,"1, 2, 4, 5",0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8174,3,The offensive odor of surgical smoke can: <ol> <li>Cause nausea and vomiting</li> <li>Heighten patient anxiety</li> <li>Irritate the eyes</li> <li>Lengthen the surgical procedure</li> <li>Warn personnel that they are inhaling harmful gases</li> </ol>,g18697,3,"2, 3, 4, 5",0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8175,0,The in-line filter in a wall suction unit is designed to protect:,g18698,0,Perioperative personnel,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8175,1,The in-line filter in a wall suction unit is designed to protect:,g18699,1,Surgical patients,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8175,2,The in-line filter in a wall suction unit is designed to protect:,g18700,2,The wall lines,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8175,3,The in-line filter in a wall suction unit is designed to protect:,g18701,3,All of the above,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8176,0,Standard surgical masks are very effective as a precaution against inhaling the particulate matter as small as that contained in surgical smoke and aerosol.,g18702,0,TRUE,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8176,1,Standard surgical masks are very effective as a precaution against inhaling the particulate matter as small as that contained in surgical smoke and aerosol.,g18703,1,FALSE,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8177,0,One drawback of using a high-efficiency mask to prevent the inhalation of dangerous particles from laser plume is that it:,g18704,0,Cannot stop small particles,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8177,1,One drawback of using a high-efficiency mask to prevent the inhalation of dangerous particles from laser plume is that it:,g18705,1,Is no more effective than a standard surgical mask,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8177,2,One drawback of using a high-efficiency mask to prevent the inhalation of dangerous particles from laser plume is that it:,g18706,2,Will not stop smoke if it gaps at the sides,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8177,3,One drawback of using a high-efficiency mask to prevent the inhalation of dangerous particles from laser plume is that it:,g18707,3,None of the above,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8178,0,The most effective way of protecting personnel and patients from inhaling the harmful components of surgical smoke / plume is to use a mechanical smoke evacuator system with a high-efficiency  filter during all smoke generating procedures.,g18708,0,TRUE,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8178,1,The most effective way of protecting personnel and patients from inhaling the harmful components of surgical smoke / plume is to use a mechanical smoke evacuator system with a high-efficiency  filter during all smoke generating procedures.,g18709,1,FALSE,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8179,0,A filter than captures 99.7% of particles 0.3 micrometers is called a(n):,g18710,0,HEPA filter,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8179,1,A filter than captures 99.7% of particles 0.3 micrometers is called a(n):,g18711,1,ULPA filter,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8179,2,A filter than captures 99.7% of particles 0.3 micrometers is called a(n):,g18712,2,VLSI filter,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8179,3,A filter than captures 99.7% of particles 0.3 micrometers is called a(n):,g18713,3,Prefilter,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8180,0,"Because they can absorb harmful chemicals, personnel involved in smoke-generating procedures should NOT wear:",g18714,0,Corrective eyeglasses,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8180,1,"Because they can absorb harmful chemicals, personnel involved in smoke-generating procedures should NOT wear:",g18715,1,Hard contact lenses,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8180,2,"Because they can absorb harmful chemicals, personnel involved in smoke-generating procedures should NOT wear:",g18716,2,Soft contact lenses,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8180,3,"Because they can absorb harmful chemicals, personnel involved in smoke-generating procedures should NOT wear:",g18717,3,Protective goggles,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8181,0,The regulations that have the force of law behind them are those of:,g18718,0,AORN,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8181,1,The regulations that have the force of law behind them are those of:,g18719,1,NIOSH,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8181,2,The regulations that have the force of law behind them are those of:,g18720,2,OSHA,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8181,3,The regulations that have the force of law behind them are those of:,g18721,3,None of the above,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8182,0,"The smoke evacuation nozzle should be moved in unison with the surgeon, keeping it about:",g18722,0,1 cm from the target tissue,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8182,1,"The smoke evacuation nozzle should be moved in unison with the surgeon, keeping it about:",g18723,1,1 inch form the target tissue,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8182,2,"The smoke evacuation nozzle should be moved in unison with the surgeon, keeping it about:",g18724,2,2 inches from the target tissue,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8182,3,"The smoke evacuation nozzle should be moved in unison with the surgeon, keeping it about:",g18725,3,6 inches from the target tissue,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8183,0,Patients undergoing smoke-generating procedures under local anesthesia:,g18726,0,Are protected by the anesthesia mask,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8183,1,Patients undergoing smoke-generating procedures under local anesthesia:,g18727,1,"Do not require protection, as they do not experience daily exposure",0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8183,2,Patients undergoing smoke-generating procedures under local anesthesia:,g18728,2,Should always wear a high-efficiency mask,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8183,3,Patients undergoing smoke-generating procedures under local anesthesia:,g18729,3,Should be protected using the same measures used by personnel,1,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8184,0,Some of the important criteria to consider when choosing a smoke evacuation system include:,g18730,0,Air flow capacity,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8184,1,Some of the important criteria to consider when choosing a smoke evacuation system include:,g18731,1,Filtration efficiency,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8184,2,Some of the important criteria to consider when choosing a smoke evacuation system include:,g18732,2,Noise level,0,REDUCING THE RISK OF SURGICAL SMOKE
4571,8633,Elearning-0000-15,g2097,g8184,3,Some of the important criteria to consider when choosing a smoke evacuation system include:,g18733,3,All of the above,1,REDUCING THE RISK OF SURGICAL SMOKE
4548,9406,Elearning-0000-646,g2085,g8145,0,I have read and understood the Inattentional Blindness CBL.,g18601,0,YES,1,INATTENTIONAL BLINDNESS (ED)
4548,9406,Elearning-0000-646,g2085,g8145,1,I have read and understood the Inattentional Blindness CBL.,g18602,1,NO,0,INATTENTIONAL BLINDNESS (ED)
4545,9478,Elearning-0000-711,g2082,g8102,0,The first draft of GMPs occurred in:,g18463,0,1906,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8102,1,The first draft of GMPs occurred in:,g18464,1,1938,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8102,2,The first draft of GMPs occurred in:,g18465,2,1958,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8102,3,The first draft of GMPs occurred in:,g18466,3,1963,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8103,0,GMPS are:,g18467,0,voluntary standards,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8103,1,GMPS are:,g18468,1,recommendations,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8103,2,GMPS are:,g18469,2,optional,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8103,3,GMPS are:,g18470,3,legal requirements,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8104,0,GMPs can be found in Title 21 CFRs under:,g18471,0,200 Series,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8104,1,GMPs can be found in Title 21 CFRs under:,g18472,1,800 Series,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8104,2,GMPs can be found in Title 21 CFRs under:,g18473,2,600 Series,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8104,3,GMPs can be found in Title 21 CFRs under:,g18474,3,All of the above,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8104,4,GMPs can be found in Title 21 CFRs under:,g18475,4,None of the above,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8105,0,A blood component is both a drug and a biologic product.,g18476,0,TRUE,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8105,1,A blood component is both a drug and a biologic product.,g18477,1,FALSE,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8106,0,A FDA 483 is a:,g18478,0,certificate of merit,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8106,1,A FDA 483 is a:,g18479,1,special license,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8106,2,A FDA 483 is a:,g18480,2,citation of deficiency,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8106,3,A FDA 483 is a:,g18481,3,new requirement,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8107,0,An example of a Record Keeping Error would be:,g18482,0,use of whiteout,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8107,1,An example of a Record Keeping Error would be:,g18483,1,use of a pencil,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8107,2,An example of a Record Keeping Error would be:,g18484,2,documentation after the fact,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8107,3,An example of a Record Keeping Error would be:,g18485,3,all of the above,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8107,4,An example of a Record Keeping Error would be:,g18486,4,none of the above,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8108,0,_______________________ establishes documented evidence which provides a high degree of assurance that a specific process will consistently produce a product that meets its pre-established quality and performance.,g18487,0,Calibration,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8108,1,_______________________ establishes documented evidence which provides a high degree of assurance that a specific process will consistently produce a product that meets its pre-established quality and performance.,g18488,1,Validation,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8108,2,_______________________ establishes documented evidence which provides a high degree of assurance that a specific process will consistently produce a product that meets its pre-established quality and performance.,g18489,2,Documentation,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8108,3,_______________________ establishes documented evidence which provides a high degree of assurance that a specific process will consistently produce a product that meets its pre-established quality and performance.,g18490,3,Record Keeping,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8109,0,Error management is:,g18491,0,a. punitive,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8109,1,Error management is:,g18492,1,b. non-punitive,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8109,2,Error management is:,g18493,2,c. optional,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8109,3,Error management is:,g18494,3,d. required,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8109,4,Error management is:,g18495,4,e. a & c,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8109,5,Error management is:,g18496,5,f.  b & d,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8110,0,Error management is a GMP legal requirement.,g18497,0,TRUE,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8110,1,Error management is a GMP legal requirement.,g18498,1,FALSE,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8111,0,"___________________ is the comparison of measurement standard or instrument of known accuracy with another standard or instrument of unknown accuracy in order to confirm, delete, correlate, report, or eliminate any variation in the accuracy  of the item being compared.",g18499,0,Calibration,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8111,1,"___________________ is the comparison of measurement standard or instrument of known accuracy with another standard or instrument of unknown accuracy in order to confirm, delete, correlate, report, or eliminate any variation in the accuracy  of the item being compared.",g18500,1,Validation,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8111,2,"___________________ is the comparison of measurement standard or instrument of known accuracy with another standard or instrument of unknown accuracy in order to confirm, delete, correlate, report, or eliminate any variation in the accuracy  of the item being compared.",g18501,2,Documentation,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8111,3,"___________________ is the comparison of measurement standard or instrument of known accuracy with another standard or instrument of unknown accuracy in order to confirm, delete, correlate, report, or eliminate any variation in the accuracy  of the item being compared.",g18502,3,Record Keeping,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8112,0,"Standard Operating Procedures must be reviewed, approved, and ______________.",g18503,0,followed,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8112,1,"Standard Operating Procedures must be reviewed, approved, and ______________.",g18504,1,deviated from,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8113,0,______________ labels shall be destroyed when no longer in use.,g18505,0,new,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8113,1,______________ labels shall be destroyed when no longer in use.,g18506,1,obsolete,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8113,2,______________ labels shall be destroyed when no longer in use.,g18507,2,current,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8113,3,______________ labels shall be destroyed when no longer in use.,g18508,3,pre-existing,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8114,0,Equipment should be maintained in a _____________ and _________________ manner.,g18509,0,"unclean, orderly",0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8114,1,Equipment should be maintained in a _____________ and _________________ manner.,g18510,1,"clean, disorderly",0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8114,2,Equipment should be maintained in a _____________ and _________________ manner.,g18511,2,"clean, orderly",1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8114,3,Equipment should be maintained in a _____________ and _________________ manner.,g18512,3,"unclean, disorderly",0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8115,0,Compliance with GMPs is _____________________ responsibility!,g18513,0,management's,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8115,1,Compliance with GMPs is _____________________ responsibility!,g18514,1,nursing's,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8115,2,Compliance with GMPs is _____________________ responsibility!,g18515,2,supervisor's,0,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4545,9478,Elearning-0000-711,g2082,g8115,3,Compliance with GMPs is _____________________ responsibility!,g18516,3,everyone's,1,CGMP: CURRENT GOOD MANUFACTURING PRACTICES (LAB)
4541,9212,Elearning-0000-47,g2081,g8096,0,"I hereby certify that I have completed the training for collection of specimens for fetal fibronectin testing.  I understand that it is my responsibility to read, understand and seek guidance, should I require clarification with regard to t his procedure.",g18445,0,Yes,1,FETAL FIBRONECTIN SAMPLING
4541,9212,Elearning-0000-47,g2081,g8096,1,"I hereby certify that I have completed the training for collection of specimens for fetal fibronectin testing.  I understand that it is my responsibility to read, understand and seek guidance, should I require clarification with regard to t his procedure.",g18446,1,No,0,FETAL FIBRONECTIN SAMPLING
4518,9311,Elearning-0000-56,g2064,g7950,0,Anyone can wear a respirator.,g18051,0,TRUE,0,BREATHE EASY TURBO PAPR ASSEMBLY
4518,9311,Elearning-0000-56,g2064,g7950,1,Anyone can wear a respirator.,g18052,1,FALSE,1,BREATHE EASY TURBO PAPR ASSEMBLY
4518,9311,Elearning-0000-56,g2064,g7951,0,Each person using the respirator does not have to read the entire User Instructions because there is so much to read.,g18053,0,TRUE,0,BREATHE EASY TURBO PAPR ASSEMBLY
4518,9311,Elearning-0000-56,g2064,g7951,1,Each person using the respirator does not have to read the entire User Instructions because there is so much to read.,g18054,1,FALSE,1,BREATHE EASY TURBO PAPR ASSEMBLY
4518,9311,Elearning-0000-56,g2064,g7952,0,Before each use of the respirator the user must inspect all parts of the unit to ensure all parts are in working order.,g18055,0,TRUE,1,BREATHE EASY TURBO PAPR ASSEMBLY
4518,9311,Elearning-0000-56,g2064,g7952,1,Before each use of the respirator the user must inspect all parts of the unit to ensure all parts are in working order.,g18056,1,FALSE,0,BREATHE EASY TURBO PAPR ASSEMBLY
4518,9311,Elearning-0000-56,g2064,g7953,0,"Use of the respirator system by untrained or unqualified persons, or use not in accordance with the instructions may adversely affect respirator performance and result in sickness or death.",g18057,0,TRUE,1,BREATHE EASY TURBO PAPR ASSEMBLY
4518,9311,Elearning-0000-56,g2064,g7953,1,"Use of the respirator system by untrained or unqualified persons, or use not in accordance with the instructions may adversely affect respirator performance and result in sickness or death.",g18058,1,FALSE,0,BREATHE EASY TURBO PAPR ASSEMBLY
4484,9428,Elearning-0000-666,g2035,g7781,0,I have reviewed and understand the Decon CBL contents.,g17525,0,Yes,1,DONNING AND DOFFING DECON SUITE SUPPORT
4484,9428,Elearning-0000-666,g2035,g7781,1,I have reviewed and understand the Decon CBL contents.,g17526,1,No,0,DONNING AND DOFFING DECON SUITE SUPPORT
4473,9137,Elearning-0000-401,g2025,g7722,0,According to the authors asthma is characterized by:,g17347,0,a.  Wheezing and shortness of breath,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7722,1,According to the authors asthma is characterized by:,g17348,1,b.  Airway inflammation and bronchial hyperresponsiveness,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7722,2,According to the authors asthma is characterized by:,g17349,2,c.  Wheezing and cyanosis,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7722,3,According to the authors asthma is characterized by:,g17350,3,d.  All of the above,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7723,0,Numerous mediators have been implicated in the pathogenesis of asthma including:,g17351,0,a.  Histamine,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7723,1,Numerous mediators have been implicated in the pathogenesis of asthma including:,g17352,1,b.  Chemokines and cysteinyl-leukotrienes,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7723,2,Numerous mediators have been implicated in the pathogenesis of asthma including:,g17353,2,c.  Nitric oxide,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7723,3,Numerous mediators have been implicated in the pathogenesis of asthma including:,g17354,3,d.  Immunoglobulin E (IgE),0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7723,4,Numerous mediators have been implicated in the pathogenesis of asthma including:,g17355,4,e.  All of the above,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7724,0,Inhaled corticosteroids (ICS) are the preferred anti-inflammatory medication for all patients with persistent asthma:,g17356,0,TRUE,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7724,1,Inhaled corticosteroids (ICS) are the preferred anti-inflammatory medication for all patients with persistent asthma:,g17357,1,FALSE,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7725,0,"The goal of asthma therapy is to reduce symptoms to the extent that patients can lead active, unlimited lives, and to minimize concern about exacerbations:",g17358,0,TRUE,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7725,1,"The goal of asthma therapy is to reduce symptoms to the extent that patients can lead active, unlimited lives, and to minimize concern about exacerbations:",g17359,1,FALSE,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7726,0,"The combination product budesonide plus formoterol in a metered dose inhaler (Symbicort, AstraZeneca, Wilmington, Delaware) is an ICS and a short-acting Beta 2 agonist:",g17360,0,TRUE,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7726,1,"The combination product budesonide plus formoterol in a metered dose inhaler (Symbicort, AstraZeneca, Wilmington, Delaware) is an ICS and a short-acting Beta 2 agonist:",g17361,1,FALSE,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7727,0,"Formoterol fumarate (Perforomist, Dey Napa, California) is formulated for nebulization and is indicated in chronic obstructive pulmonary disease including chronic bronchitis and emphysema:",g17362,0,TRUE,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7727,1,"Formoterol fumarate (Perforomist, Dey Napa, California) is formulated for nebulization and is indicated in chronic obstructive pulmonary disease including chronic bronchitis and emphysema:",g17363,1,FALSE,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7728,0,"Arformoterol tartate (Brovana, Sepracor, Marlborough, Massachusetts) is the (S) isomer of formoterol and is approved for the in patients with COPD:",g17364,0,TRUE,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7728,1,"Arformoterol tartate (Brovana, Sepracor, Marlborough, Massachusetts) is the (S) isomer of formoterol and is approved for the in patients with COPD:",g17365,1,FALSE,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7729,0,All of the following are inhaled corticosteroids except:,g17366,0,a.  Beclomethasone dipropionate,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7729,1,All of the following are inhaled corticosteroids except:,g17367,1,b.  Budesonide,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7729,2,All of the following are inhaled corticosteroids except:,g17368,2,c.  Pirbuterol,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7729,3,All of the following are inhaled corticosteroids except:,g17369,3,d.  Flunisolide,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7729,4,All of the following are inhaled corticosteroids except:,g17370,4,e.  Fluticasone propionate,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7730,0,All of the following are inhaled short-acting beta 2 agonists except:,g17371,0,a.  Albuterol,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7730,1,All of the following are inhaled short-acting beta 2 agonists except:,g17372,1,b.  Levalbuterol,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7730,2,All of the following are inhaled short-acting beta 2 agonists except:,g17373,2,c.  Salmeterol,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7730,3,All of the following are inhaled short-acting beta 2 agonists except:,g17374,3,d.  Metaproterenol,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7731,0,"Inhaled short-acting beta 2 agonists generally are not indicated for asthma, but rather for the relief of the symptoms of bronchospasms as part of reversible obstructive airway disease and for exercise-induced asthma:",g17375,0,TRUE,1,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4473,9137,Elearning-0000-401,g2025,g7731,1,"Inhaled short-acting beta 2 agonists generally are not indicated for asthma, but rather for the relief of the symptoms of bronchospasms as part of reversible obstructive airway disease and for exercise-induced asthma:",g17376,1,FALSE,0,NEW DRUGS FOR ASTHMA (RESPIRATORY CARE)
4469,9573,Elearning-0000-798,g2021,g7660,0,"The BMT ""TEAM"" consist of",g17152,0,A.  The BMT Department Coordinator,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7660,1,"The BMT ""TEAM"" consist of",g17153,1,B.  The Pharmacist and Physician,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7660,2,"The BMT ""TEAM"" consist of",g17154,2,C.  The ICU Manager or CNS,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7660,3,"The BMT ""TEAM"" consist of",g17155,3,"D.  The RN assigned to the BMT patient,  Pharmacist, Physician, Health Psychologist, Mid-level Practitioner",1,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7661,0,"Mr. X complains of feeling tired, more so than the day before. After reviewing the am labs you notice his Hgb/hct is 8/24 and Platelet count is 10K. After reviewing the lab values and standing orders, what is the next step?",g17156,0,A.  Call MD to notify him of abnormal lab results,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7661,1,"Mr. X complains of feeling tired, more so than the day before. After reviewing the am labs you notice his Hgb/hct is 8/24 and Platelet count is 10K. After reviewing the lab values and standing orders, what is the next step?",g17157,1,B.  Call MD to notify of patient complaints,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7661,2,"Mr. X complains of feeling tired, more so than the day before. After reviewing the am labs you notice his Hgb/hct is 8/24 and Platelet count is 10K. After reviewing the lab values and standing orders, what is the next step?",g17158,2,"C.  Verify consent for blood transfusion is on the chart,  order one unit of platelets and crossmatch for two units of PRBC's and prepare for transfusions",1,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7661,3,"Mr. X complains of feeling tired, more so than the day before. After reviewing the am labs you notice his Hgb/hct is 8/24 and Platelet count is 10K. After reviewing the lab values and standing orders, what is the next step?",g17159,3,D.  Wait for BMT TEAM to arrive and discuss findings and plan of care,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7662,0,The patient's Problem List is a useful tool for,g17160,0,A.  Providing an overall picture of the patient's treatment course,1,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7662,1,The patient's Problem List is a useful tool for,g17161,1,B.  Another sheet of paper,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7662,2,The patient's Problem List is a useful tool for,g17162,2,C.  Necessary for insurance and case management,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7662,3,The patient's Problem List is a useful tool for,g17163,3,D.  Is a method to determine what is the best way to care for a patient,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7663,0,The patients temperature max at 2000 the evening prior of 100.5 and the ANB is 300 what is the best response by the nurse,g17164,0,A.  Watt for the team to arrive to determine what is wrong,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7663,1,The patients temperature max at 2000 the evening prior of 100.5 and the ANB is 300 what is the best response by the nurse,g17165,1,B.  Review the vital signs over the past 24hours and determine when was the last  time blood cultures were done,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7663,2,The patients temperature max at 2000 the evening prior of 100.5 and the ANB is 300 what is the best response by the nurse,g17166,2,C.  Review the vital signs over the past 24hours and determine when was the last  time blood cultures were done and order  the appropriate antibiotic (per orders) if the patient is not already on an antibiotic.,1,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4469,9573,Elearning-0000-798,g2021,g7663,3,The patients temperature max at 2000 the evening prior of 100.5 and the ANB is 300 what is the best response by the nurse,g17167,3,D.  Review the vital signs over the past 24hours and determine when was the last  time blood cultures were done and determine if the patient is on antibiotics,0,AM ROUNDS FOR ICU (BMT CROSS TRAINING COMPETENCY)
4449,581,ILT-0000-1753,g2003,g7502,0,I have read and understand the Alcohol Withdrawal CBL course.,g16611,0,Yes,1,ALCOHOL WITHDRAWAL
4449,581,ILT-0000-1753,g2003,g7502,1,I have read and understand the Alcohol Withdrawal CBL course.,g16612,1,No,0,ALCOHOL WITHDRAWAL
4447,8992,Elearning-0000-27,g2001,g7412,0,"when implementing a teaching plan for the client with a low absolute neutrophil count (ANC), the nurse should plan to emphasize the following:",g16363,0,A.  Have fresh flowers in the room,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7412,1,"when implementing a teaching plan for the client with a low absolute neutrophil count (ANC), the nurse should plan to emphasize the following:",g16364,1,B.  Infection precautions,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7412,2,"when implementing a teaching plan for the client with a low absolute neutrophil count (ANC), the nurse should plan to emphasize the following:",g16365,2,C.  Avoid hand washing,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7412,3,"when implementing a teaching plan for the client with a low absolute neutrophil count (ANC), the nurse should plan to emphasize the following:",g16366,3,D.  Strenuous exercise,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7413,0,"The following bleeding precaution orders have been written for a client with a platelet count of 10,000/mm. Which of the following orders should the nurse question?",g16367,0,A.  Avoid using a blood pressure cuff or tourniquet,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7413,1,"The following bleeding precaution orders have been written for a client with a platelet count of 10,000/mm. Which of the following orders should the nurse question?",g16368,1,B.  Administer rectal acetaminophen for fever of 101┬░F,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7413,2,"The following bleeding precaution orders have been written for a client with a platelet count of 10,000/mm. Which of the following orders should the nurse question?",g16369,2,C.  Apply firm pressure to venipuncture sites for 5 minutes,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7413,3,"The following bleeding precaution orders have been written for a client with a platelet count of 10,000/mm. Which of the following orders should the nurse question?",g16370,3,D.  Administer stool softener twice a day,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7414,0,Clients are at severe risk of infection when the:,g16371,0,A.  Hemoglobin value is less than 10gm/dL,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7414,1,Clients are at severe risk of infection when the:,g16372,1,"B.  Platelet count is less than 20,000/mm",0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7414,2,Clients are at severe risk of infection when the:,g16373,2,C.  ANC is less than 1500/mm,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7414,3,Clients are at severe risk of infection when the:,g16374,3,D.  ANC is less than 500/mm,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7415,0,Nadir is a term used to describe:,g16375,0,A. The highest point the WBCs reach after cancer treatment,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7415,1,Nadir is a term used to describe:,g16376,1,B.   WBC lysis related to chemotherapy administration,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7415,2,Nadir is a term used to describe:,g16377,2,C.  DNA content on the WBC,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7415,3,Nadir is a term used to describe:,g16378,3,D.  The lowest point blood cells reach after a cancer treatment,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7416,0,Which measure would be important to follow for a client with an ANC less than 500/mm?,g16379,0,A.  Take rectal temperature regularly,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7416,1,Which measure would be important to follow for a client with an ANC less than 500/mm?,g16380,1,B.  Administer broad-spectrum antibiotics,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7416,2,Which measure would be important to follow for a client with an ANC less than 500/mm?,g16381,2,C.  Send fresh flowers to the room,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7416,3,Which measure would be important to follow for a client with an ANC less than 500/mm?,g16382,3,D.  Avoid bathing for 2 days,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7417,0,Myelosuppression is defined as the reduction in bone marrow function that results in a reduced release of which cells into the peripheral circulation?,g16383,0,"A.  RBCs, megakaryocytes, and tumor necrosis factor",0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7417,1,Myelosuppression is defined as the reduction in bone marrow function that results in a reduced release of which cells into the peripheral circulation?,g16384,1,"B.  RBCs, WBCs, and platelets",1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7417,2,Myelosuppression is defined as the reduction in bone marrow function that results in a reduced release of which cells into the peripheral circulation?,g16385,2,"C.  WBC, erythroblasts, and colony stimulating factors",0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7417,3,Myelosuppression is defined as the reduction in bone marrow function that results in a reduced release of which cells into the peripheral circulation?,g16386,3,"D.  Platelets, RBCs, and interleukin",0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7418,0,Neutropenia describes a decrease in the number of circulating:,g16387,0,A.  Basohils,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7418,1,Neutropenia describes a decrease in the number of circulating:,g16388,1,B.  WBCs,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7418,2,Neutropenia describes a decrease in the number of circulating:,g16389,2,C.  Neutrophils,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7418,3,Neutropenia describes a decrease in the number of circulating:,g16390,3,D.  RBCs,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7419,0,As the neutrophils decrease the only sign of infection may be:,g16391,0,A.  Purulent drainage from a vascular access device,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7419,1,As the neutrophils decrease the only sign of infection may be:,g16392,1,B.  Petechiae on the lower extremities,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7419,2,As the neutrophils decrease the only sign of infection may be:,g16393,2,C.  Fever,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7419,3,As the neutrophils decrease the only sign of infection may be:,g16394,3,"D.  Dry, hacking cough",0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7420,0,The best measure to institute to prevent infection in the client with low ANC is:,g16395,0,A.  Encourage visitors,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7420,1,The best measure to institute to prevent infection in the client with low ANC is:,g16396,1,B.  Encourage the client to bathe every 2 days,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7420,2,The best measure to institute to prevent infection in the client with low ANC is:,g16397,2,C.  Strict hand washing,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7420,3,The best measure to institute to prevent infection in the client with low ANC is:,g16398,3,D.  Use of a laminar flow room,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7421,0,"If a client is at risk risk for infection, measures that can be initiated to minimize the occurrence are:",g16399,0,A.  Inserting a urinary catheter to monitor the urine output,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7421,1,"If a client is at risk risk for infection, measures that can be initiated to minimize the occurrence are:",g16400,1,B.  Leaving all wounds to open air,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7421,2,"If a client is at risk risk for infection, measures that can be initiated to minimize the occurrence are:",g16401,2,"C.  Encouraging daily personal hygiene, oral hygiene, and perineal care",1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7421,3,"If a client is at risk risk for infection, measures that can be initiated to minimize the occurrence are:",g16402,3,D.  Flushing all lumens of a long-term catheter every 8 hours,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7422,0,Thrombocytopenia is defined as:,g16403,0,"A.  A decrease in the circulating platelets below 100,000/mm",1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7422,1,Thrombocytopenia is defined as:,g16404,1,B.  A decrease in the circulating WBCs below 1500/mm,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7422,2,Thrombocytopenia is defined as:,g16405,2,C.  A decrease in the circulating neutrophils below 1000/mm,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7422,3,Thrombocytopenia is defined as:,g16406,3,D.  A decrease in the circulating RBCs below 1000/mm,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7423,0,"Ms Z. arrives at the hospital emergency room with fever, chills, and malaise. Her signs and symptoms are indicative of:",g16407,0,A.  Anemia,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7423,1,"Ms Z. arrives at the hospital emergency room with fever, chills, and malaise. Her signs and symptoms are indicative of:",g16408,1,B.  Thrombocytopenia,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7423,2,"Ms Z. arrives at the hospital emergency room with fever, chills, and malaise. Her signs and symptoms are indicative of:",g16409,2,C.  Superior Vena Cava Syndrome,0,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4447,8992,Elearning-0000-27,g2001,g7423,3,"Ms Z. arrives at the hospital emergency room with fever, chills, and malaise. Her signs and symptoms are indicative of:",g16410,3,D.  Infection caused by Neutropenia,1,NEUTROPENIA/THROMBOCYTOPENIA QUIZ
4409,8896,Elearning-0000-182,g1970,g7206,0,I have reviewed and understand the Side Effects of the Chemotherapy CBL course.,g15830,0,Yes,1,SIDE EFFECTS OF CHEMOTHERAPY (GENERAL)
4409,8896,Elearning-0000-182,g1970,g7206,1,I have reviewed and understand the Side Effects of the Chemotherapy CBL course.,g15831,1,No,0,SIDE EFFECTS OF CHEMOTHERAPY (GENERAL)
4407,8915,Elearning-0000-20,g1968,g7204,0,I have read and understand the Radiology-ED Hand-Off Communication CBL course.,g15826,0,Yes,1,RADIOLOGY-ED HAND-OFF COMMUNICATION
4407,8915,Elearning-0000-20,g1968,g7204,1,I have read and understand the Radiology-ED Hand-Off Communication CBL course.,g15827,1,No,0,RADIOLOGY-ED HAND-OFF COMMUNICATION
4401,8338,Elearning-0000-1214,g1963,g7166,0,Mr. Moore is a post op day 1 Left THA.  He is complaining of pain on a scale of 7/10.  He was successfully weaned off his PCA and has received his second dose of Percocet 5/325mg two tablets at 1000.  At 1045 he rates his pain 4/10.  He cal ls you at 1115 stating his pain is back to a 7/10.  What can the nurse do to try to relieve his pain until he can receive another dose of the Percocet?,g15683,0,A.  Ice Therapy,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7166,1,Mr. Moore is a post op day 1 Left THA.  He is complaining of pain on a scale of 7/10.  He was successfully weaned off his PCA and has received his second dose of Percocet 5/325mg two tablets at 1000.  At 1045 he rates his pain 4/10.  He cal ls you at 1115 stating his pain is back to a 7/10.  What can the nurse do to try to relieve his pain until he can receive another dose of the Percocet?,g15684,1,B.  Reposition,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7166,2,Mr. Moore is a post op day 1 Left THA.  He is complaining of pain on a scale of 7/10.  He was successfully weaned off his PCA and has received his second dose of Percocet 5/325mg two tablets at 1000.  At 1045 he rates his pain 4/10.  He cal ls you at 1115 stating his pain is back to a 7/10.  What can the nurse do to try to relieve his pain until he can receive another dose of the Percocet?,g15685,2,C.  Guided Imagery,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7166,3,Mr. Moore is a post op day 1 Left THA.  He is complaining of pain on a scale of 7/10.  He was successfully weaned off his PCA and has received his second dose of Percocet 5/325mg two tablets at 1000.  At 1045 he rates his pain 4/10.  He cal ls you at 1115 stating his pain is back to a 7/10.  What can the nurse do to try to relieve his pain until he can receive another dose of the Percocet?,g15686,3,D.  Elevation of left leg,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7166,4,Mr. Moore is a post op day 1 Left THA.  He is complaining of pain on a scale of 7/10.  He was successfully weaned off his PCA and has received his second dose of Percocet 5/325mg two tablets at 1000.  At 1045 he rates his pain 4/10.  He cal ls you at 1115 stating his pain is back to a 7/10.  What can the nurse do to try to relieve his pain until he can receive another dose of the Percocet?,g15687,4,E.  All of the above,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7167,0,"When educating your TKA patient, you as the nurse would educate them on all of the following except?",g15688,0,A.  You can have a rolled towel under your heel for comfort,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7167,1,"When educating your TKA patient, you as the nurse would educate them on all of the following except?",g15689,1,B.  Stop the CPM anytime it becomes too painful,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7167,2,"When educating your TKA patient, you as the nurse would educate them on all of the following except?",g15690,2,C.  Do feet and ankle exercises while in the bed,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7167,3,"When educating your TKA patient, you as the nurse would educate them on all of the following except?",g15691,3,D.  You may place a pillow under your knee for comfort,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7167,4,"When educating your TKA patient, you as the nurse would educate them on all of the following except?",g15692,4,E.  B & D only,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7168,0,Your Right TKA patient arrives from the PACU. Which of the following should you check to prevent any complications?,g15693,0,A.  Knee control on the side rail is locked to prevent the patient from raising the foot of the bed,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7168,1,Your Right TKA patient arrives from the PACU. Which of the following should you check to prevent any complications?,g15694,1,B.  Their belongings to see if they have brought any medications with them.,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7168,2,Your Right TKA patient arrives from the PACU. Which of the following should you check to prevent any complications?,g15695,2,C.  That the abduction pillow is in place,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7168,3,Your Right TKA patient arrives from the PACU. Which of the following should you check to prevent any complications?,g15696,3,D.  Gag reflex to make sure the can have some water. Post op patients are always thirsty,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7169,0,All of the following are appropriate precautions to take when ambulating a THA patient except.,g15697,0,A.  No hip adduction,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7169,1,All of the following are appropriate precautions to take when ambulating a THA patient except.,g15698,1,B.  No Internal rotation,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7169,2,All of the following are appropriate precautions to take when ambulating a THA patient except.,g15699,2,C.  No pivoting when turning,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7169,3,All of the following are appropriate precautions to take when ambulating a THA patient except.,g15700,3,D.  Have patient bend forward to put on their socks.,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7170,0,All of the following are appropriate precautions to take when ambulating a TKA patient except,g15701,0,A.  Do not pivot with operative leg,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7170,1,All of the following are appropriate precautions to take when ambulating a TKA patient except,g15702,1,B.  Knee immobilizer in place,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7170,2,All of the following are appropriate precautions to take when ambulating a TKA patient except,g15703,2,C.  Have the patient use a walker,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7170,3,All of the following are appropriate precautions to take when ambulating a TKA patient except,g15704,3,D.  No adduction past neutral,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7171,0,"When performing a neurovascular check, the nurse would assess",g15705,0,A.  Capillary Refill,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7171,1,"When performing a neurovascular check, the nurse would assess",g15706,1,B.  Skin Color,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7171,2,"When performing a neurovascular check, the nurse would assess",g15707,2,C.  Presence and amount of edema,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7171,3,"When performing a neurovascular check, the nurse would assess",g15708,3,D.  Pain,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7171,4,"When performing a neurovascular check, the nurse would assess",g15709,4,E.  All of the above,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7172,0,One of the most important aspects of neurovascular checks is,g15710,0,A.  Changes in function the patient has experienced,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7172,1,One of the most important aspects of neurovascular checks is,g15711,1,B.  To determine if the nurse has sensation in her fingers,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7172,2,One of the most important aspects of neurovascular checks is,g15712,2,C.  To determine the 4W's of a Neurovascular check,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7172,3,One of the most important aspects of neurovascular checks is,g15713,3,D.  Changes in function the patient has experienced and the 5P's,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7173,0,"If a patient is in Buck's Traction, how often should skin and boney prominence be assessed?",g15714,0,A.  Daily,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7173,1,"If a patient is in Buck's Traction, how often should skin and boney prominence be assessed?",g15715,1,B.  On admission,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7173,2,"If a patient is in Buck's Traction, how often should skin and boney prominence be assessed?",g15716,2,C.  Before surgery,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7173,3,"If a patient is in Buck's Traction, how often should skin and boney prominence be assessed?",g15717,3,D.  Every shift,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7174,0,What are the expectations for Total Joint patients that are safe for mobilization regarding meals?,g15718,0,A.  Patient up for every breakfast,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7174,1,What are the expectations for Total Joint patients that are safe for mobilization regarding meals?,g15719,1,B.  Patient to sit at EOB for lunch,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7174,2,What are the expectations for Total Joint patients that are safe for mobilization regarding meals?,g15720,2,C.  Nurse and PCT to ambulate the patient to the kitchen to select their meal for the day,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7174,3,What are the expectations for Total Joint patients that are safe for mobilization regarding meals?,g15721,3,D.  Patient up for at least two meals,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7175,0,"For a Total Hip replacement, the surgeon replaces what part of the hip joint",g15722,0,A.  Neck of femur and acetabulum,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7175,1,"For a Total Hip replacement, the surgeon replaces what part of the hip joint",g15723,1,B.  Femur,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7175,2,"For a Total Hip replacement, the surgeon replaces what part of the hip joint",g15724,2,C.  Humerus and Ball and Socket,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7175,3,"For a Total Hip replacement, the surgeon replaces what part of the hip joint",g15725,3,D.  Tibia and Fibula,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7176,0,"For a Total Knee Replacement, the surgeon replaces what part of the knee joint",g15726,0,A.  Sacral and Coccyx,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7176,1,"For a Total Knee Replacement, the surgeon replaces what part of the knee joint",g15727,1,B.  Metatarsals and Tarsal,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7176,2,"For a Total Knee Replacement, the surgeon replaces what part of the knee joint",g15728,2,"C.  Patella, Distal Femur, Proximal Tibia",1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7176,3,"For a Total Knee Replacement, the surgeon replaces what part of the knee joint",g15729,3,D.  Tibia and Fibula,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7177,0,Post Operative complications for an amputation include,g15730,0,A.  Phantom sensation and pain,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7177,1,Post Operative complications for an amputation include,g15731,1,B.  Flexion contractures,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7177,2,Post Operative complications for an amputation include,g15732,2,C.  Hemorrhage,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7177,3,Post Operative complications for an amputation include,g15733,3,D.  Neurovascular compromise,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7177,4,Post Operative complications for an amputation include,g15734,4,E.  All of the above,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7178,0,What is the indication for Buck's Traction,g15735,0,A.  Keep confused patient in bed,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7178,1,What is the indication for Buck's Traction,g15736,1,B.  Provide comfort until surgery,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7178,2,What is the indication for Buck's Traction,g15737,2,C.  To give the Orthopedic Tech something to do,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7178,3,What is the indication for Buck's Traction,g15738,3,D.  To make the nurse more comfortable,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7179,0,What is the rationale behind usage of the abduction pillow,g15739,0,A.  To assist patient to remain in proper abduction,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7179,1,What is the rationale behind usage of the abduction pillow,g15740,1,B.  To assist patient to remain in proper adduction,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7179,2,What is the rationale behind usage of the abduction pillow,g15741,2,C.  To save on pillows,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7179,3,What is the rationale behind usage of the abduction pillow,g15742,3,D.  Because blue is a pretty color,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7180,0,Some surgeons require a Total Knee Replacement patient to have a CPM because,g15743,0,A.  To maintain a certain degree of flexion,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7180,1,Some surgeons require a Total Knee Replacement patient to have a CPM because,g15744,1,B.  Comfort measures for the patient,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7180,2,Some surgeons require a Total Knee Replacement patient to have a CPM because,g15745,2,C.  To assist with ROM,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7180,3,Some surgeons require a Total Knee Replacement patient to have a CPM because,g15746,3,D.  All of the above,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7181,0,When assessing a patient's pain for the first time it is important to ask which of the following,g15747,0,A.  Pain Score and Pain Goal on a 1-10 Scale,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7181,1,When assessing a patient's pain for the first time it is important to ask which of the following,g15748,1,B.  Type and Intensity of the Pain,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7181,2,When assessing a patient's pain for the first time it is important to ask which of the following,g15749,2,C.  What has the patient used in the past to help relieve the pain,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7181,3,When assessing a patient's pain for the first time it is important to ask which of the following,g15750,3,D.  What makes the pain worse,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7181,4,When assessing a patient's pain for the first time it is important to ask which of the following,g15751,4,E.  All of the above,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7182,0,Where can you find the algorithm for weaning a PCA or epidural?,g15752,0,A.  Under the PCA policy in Lucidoc,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7182,1,Where can you find the algorithm for weaning a PCA or epidural?,g15753,1,B.  On the back of the PCA or Epidural order sheet,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7182,2,Where can you find the algorithm for weaning a PCA or epidural?,g15754,2,C.  The Supervisors keep it in their office,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7182,3,Where can you find the algorithm for weaning a PCA or epidural?,g15755,3,D.  Pharmacy places the sheet on the chart when the patient comes back from surgery,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7183,0,When should a knee immobilizer be used on a TKA patient?,g15756,0,A.  While they are on the CPM,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7183,1,When should a knee immobilizer be used on a TKA patient?,g15757,1,B.  When they are up out of the bed or ambulating,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7183,2,When should a knee immobilizer be used on a TKA patient?,g15758,2,"C.  The knee immobilizer should remain in place at all times, and removed once a shift to check for skin breakdown",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7183,3,When should a knee immobilizer be used on a TKA patient?,g15759,3,D.  Only when they are working with PT and walking long distances,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7184,0,At 12:00 your TKA patient arrives to the floor with a Stryker Constavac drain in place.  It was initiated at 10:00 and currently has 400cc output note in the drain.  Which of the following would you do?,g15760,0,A.  Reinfuse the output per the physician's orders according to Northside Hospital policy.,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7184,1,At 12:00 your TKA patient arrives to the floor with a Stryker Constavac drain in place.  It was initiated at 10:00 and currently has 400cc output note in the drain.  Which of the following would you do?,g15761,1,B.  Reinfuse the output at 14:00 per the physician's orders according to Northside Hospital policy.,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7184,2,At 12:00 your TKA patient arrives to the floor with a Stryker Constavac drain in place.  It was initiated at 10:00 and currently has 400cc output note in the drain.  Which of the following would you do?,g15762,2,"C.  Continue to collect the blood until 14:00, there is not enough to reinfuse yet.",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7184,3,At 12:00 your TKA patient arrives to the floor with a Stryker Constavac drain in place.  It was initiated at 10:00 and currently has 400cc output note in the drain.  Which of the following would you do?,g15763,3,"D.  Refuse to accept the patient from PACU, 400cc is too much blood to lose in two hours on a fresh post op.",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7185,0,External Fixators are commonly used for which of the following,g15764,0,A.  Bone immobilization,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7185,1,External Fixators are commonly used for which of the following,g15765,1,B.  Traumatic injury to a bone with soft tissue damage-Open fractures,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7185,2,External Fixators are commonly used for which of the following,g15766,2,C.  Nonunions and limb-lengthening procedures,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7185,3,External Fixators are commonly used for which of the following,g15767,3,D.  Multiple fractures of one bone,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7185,4,External Fixators are commonly used for which of the following,g15768,4,E.  All of the above,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7186,0,Complications of Orthopedic surgery include which of the following:,g15769,0,A.  Delirium,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7186,1,Complications of Orthopedic surgery include which of the following:,g15770,1,B.  Skin Breakdown,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7186,2,Complications of Orthopedic surgery include which of the following:,g15771,2,C.  VTE,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7186,3,Complications of Orthopedic surgery include which of the following:,g15772,3,D.  Surgical Site Infection,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7186,4,Complications of Orthopedic surgery include which of the following:,g15773,4,E.  Hemorrhage,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7186,5,Complications of Orthopedic surgery include which of the following:,g15774,5,F.  All of the above,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7187,0,What action on the nurses part is the most important in preventing skin breakdown,g15775,0,A.  Identifying at risk patients and conducting skin assessments each shift,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7187,1,What action on the nurses part is the most important in preventing skin breakdown,g15776,1,B.  Having the PCT bath the patient first thing in the morning,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7187,2,What action on the nurses part is the most important in preventing skin breakdown,g15777,2,C.  Encourage mobility,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7187,3,What action on the nurses part is the most important in preventing skin breakdown,g15778,3,D.  Keep the skin dry at all times,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7188,0,"For prevention of VTE in the postoperative Orthopedic patient, the nurse should assess that the patient has all of the following",g15779,0,A.  SCDS,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7188,1,"For prevention of VTE in the postoperative Orthopedic patient, the nurse should assess that the patient has all of the following",g15780,1,"B.  Lovenox, Arixtra, or Coumadin",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7188,2,"For prevention of VTE in the postoperative Orthopedic patient, the nurse should assess that the patient has all of the following",g15781,2,C.  PT consult to make sure the patient gets out of bed and does feet/ankle exercises,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7188,3,"For prevention of VTE in the postoperative Orthopedic patient, the nurse should assess that the patient has all of the following",g15782,3,D.  Duplex scan and Doppler study 12 hours after the surgery,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7188,4,"For prevention of VTE in the postoperative Orthopedic patient, the nurse should assess that the patient has all of the following",g15783,4,E.  A & B only,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7189,0,The number one most important prevention technique in preventing Surgical Site Infections is,g15784,0,A.  Antibiotic within 8 hours of arrival to floor,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7189,1,The number one most important prevention technique in preventing Surgical Site Infections is,g15785,1,B.  Hand washing,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7189,2,The number one most important prevention technique in preventing Surgical Site Infections is,g15786,2,"C.  Assessing the incision every shift for pain, increased warmth, odor, and drainage",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7189,3,The number one most important prevention technique in preventing Surgical Site Infections is,g15787,3,"D.  None of the above, Surgical Site Infections cannot be prevented",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7190,0,A trauma patient with a Left tibia/fibula fracture is admitted to your floor with a cast. He complains of increasing pain and loss of sensation of the left lower leg.  When you assess his toes they are cool to the touch.  What should your f irst intervention be?,g15788,0,A.  Give him a bolus and call pain services,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7190,1,A trauma patient with a Left tibia/fibula fracture is admitted to your floor with a cast. He complains of increasing pain and loss of sensation of the left lower leg.  When you assess his toes they are cool to the touch.  What should your f irst intervention be?,g15789,1,B.  Cut the cast and call the physician,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7190,2,A trauma patient with a Left tibia/fibula fracture is admitted to your floor with a cast. He complains of increasing pain and loss of sensation of the left lower leg.  When you assess his toes they are cool to the touch.  What should your f irst intervention be?,g15790,2,C.  Elevate the leg and call the physician,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7190,3,A trauma patient with a Left tibia/fibula fracture is admitted to your floor with a cast. He complains of increasing pain and loss of sensation of the left lower leg.  When you assess his toes they are cool to the touch.  What should your f irst intervention be?,g15791,3,D.  All of the above,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7892,0,You have a patient arrive to the floor with a Total Knee Revision.  Do you place them on the Clinical Pathway?,g17879,0,Yes,1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7892,1,You have a patient arrive to the floor with a Total Knee Revision.  Do you place them on the Clinical Pathway?,g17880,1,No,0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7893,0,Orthopedic patients must have the following lab values monitored daily?,g17881,0,"a.	H&H",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7893,1,Orthopedic patients must have the following lab values monitored daily?,g17882,1,"b.	BMET",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7893,2,Orthopedic patients must have the following lab values monitored daily?,g17883,2,"c.	PT/INR",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7893,3,Orthopedic patients must have the following lab values monitored daily?,g17884,3,"d.	A & C",1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7894,0,Before a Total Joint Replacement patient gets up to ambulate there must be an order for?,g17885,0,"a.	Physical Therapy",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7894,1,Before a Total Joint Replacement patient gets up to ambulate there must be an order for?,g17886,1,"b.	Weight Bearing Status",1,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7894,2,Before a Total Joint Replacement patient gets up to ambulate there must be an order for?,g17887,2,"c.	VTE Prophylaxis",0,CARE OF THE ORTHOPEDIC PATIENT
4401,8338,Elearning-0000-1214,g1963,g7894,3,Before a Total Joint Replacement patient gets up to ambulate there must be an order for?,g17888,3,"d.	Knee Immobilizer",0,CARE OF THE ORTHOPEDIC PATIENT
4282,9157,Elearning-0000-42,g1875,g6577,0,I have reviewed and understood the HIPEC CBL course.,g13884,0,Yes,1,HIPEC
4282,9157,Elearning-0000-42,g1875,g6577,1,I have reviewed and understood the HIPEC CBL course.,g13885,1,No,0,HIPEC
4276,8097,Elearning-0000-08,g1869,g6538,0,I have reviewed and understood the Radiology Safe Patient Handling & Movement policy.,g13783,0,Yes,1,RADIOLOGY POLICY: SAFE PATIENT HANDLING & MOVEMENT
4276,8097,Elearning-0000-08,g1869,g6538,1,I have reviewed and understood the Radiology Safe Patient Handling & Movement policy.,g13784,1,No,0,RADIOLOGY POLICY: SAFE PATIENT HANDLING & MOVEMENT
4251,8743,Elearning-0000-16,g1852,g6295,0,I have reviewed and understood the Radiology Same Day Add-Ons Annual Competency document.,g13275,0,Yes,1,RADIOLOGY SAME DAY ADD-ON ANNUAL COMPETENCY
4251,8743,Elearning-0000-16,g1852,g6295,1,I have reviewed and understood the Radiology Same Day Add-Ons Annual Competency document.,g13276,1,No,0,RADIOLOGY SAME DAY ADD-ON ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9422,0,Correct data entry is part of all technologist Job Performance Standards?,g22375,0,TRUE,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9422,1,Correct data entry is part of all technologist Job Performance Standards?,g22376,1,FALSE,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9423,0,The Check-In time for an in-patient exam is:,g22377,0,What time you sent for the patient to be brought to radiology,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9423,1,The Check-In time for an in-patient exam is:,g22378,1,What time you complete the exam,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9423,2,The Check-In time for an in-patient exam is:,g22379,2,When the patient arrives to Radiology (before proceeding with the exam),1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9423,3,The Check-In time for an in-patient exam is:,g22380,3,None of the above,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9424,0,The Check-In time for an out-patient is:,g22381,0,A. What time they were scheduled for,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9424,1,The Check-In time for an out-patient is:,g22382,1,B. What time the patient arrived to Radiology,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9424,2,The Check-In time for an out-patient is:,g22383,2,C. Both A & B,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9424,3,The Check-In time for an out-patient is:,g22384,3,D. None of the above,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9425,0,Walk-in Out-patients should have their requested time entered as:,g22385,0,00:00 (Midnight),1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9425,1,Walk-in Out-patients should have their requested time entered as:,g22386,1,The time they arrive at the desk,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9425,2,Walk-in Out-patients should have their requested time entered as:,g22387,2,The time the technologist comes to the waiting room to get them.,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9425,3,Walk-in Out-patients should have their requested time entered as:,g22388,3,Any of the above,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9426,0,The technologist's Start and Stop time for and exam should be the following:,g22389,0,Start: when the patient was scheduled<br>Stop: when the patient got into their car and left,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9426,1,The technologist's Start and Stop time for and exam should be the following:,g22390,1,Start: when you pick up or receive your patient<br>Stop: when you release your patient form your area,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9426,2,The technologist's Start and Stop time for and exam should be the following:,g22391,2,Start / Stop: should always be the same time,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9426,3,The technologist's Start and Stop time for and exam should be the following:,g22392,3,Start / Stop: can be the same time as long as something is entered in the field,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9427,0,When should the technologist enter Non-procedural charges?,g22393,0,Before the exam begins,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9427,1,When should the technologist enter Non-procedural charges?,g22394,1,The radiologist will charge the exam under the EDE function,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9427,2,When should the technologist enter Non-procedural charges?,g22395,2,During the EDE (exam data entry) process,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9427,3,When should the technologist enter Non-procedural charges?,g22396,3,Any of the above,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9428,0,It is important that data entered into STAR is accurate because Quality Improvement (QI) reports are generated which measure; patients seen within 15 minutes of their scheduled time and time from exam requested to exam done.,g22397,0,TRUE,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9428,1,It is important that data entered into STAR is accurate because Quality Improvement (QI) reports are generated which measure; patients seen within 15 minutes of their scheduled time and time from exam requested to exam done.,g22398,1,FALSE,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9429,0,What two reports are generated from data entered into STAR?  The report data is based on accuracy of information entered into STAR from the Check-In process and EDE process.,g22399,0,A. Final report sent to the physician & Pending work report,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9429,1,What two reports are generated from data entered into STAR?  The report data is based on accuracy of information entered into STAR from the Check-In process and EDE process.,g22400,1,B. Outpatient wait time reports & Routine/STAT turnaround Time,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9429,2,What two reports are generated from data entered into STAR?  The report data is based on accuracy of information entered into STAR from the Check-In process and EDE process.,g22401,2,C. A & B,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9429,3,What two reports are generated from data entered into STAR?  The report data is based on accuracy of information entered into STAR from the Check-In process and EDE process.,g22402,3,D. None of the above,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9430,0,What are two Critical Tests that radiology is required to measure the time it takes to complete the exam?  This information is reported to QI & TJC.,g22403,0,A. MRI Brain & CT Brain,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9430,1,What are two Critical Tests that radiology is required to measure the time it takes to complete the exam?  This information is reported to QI & TJC.,g22404,1,B. Pelvic Ultrasound & CT Abdomen,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9430,2,What are two Critical Tests that radiology is required to measure the time it takes to complete the exam?  This information is reported to QI & TJC.,g22405,2,C. Both A & B,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9430,3,What are two Critical Tests that radiology is required to measure the time it takes to complete the exam?  This information is reported to QI & TJC.,g22406,3,D. Surgical Breast Specimens and Surgery Foreign Body films,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9431,0,The Data Entry Error report is sent to all Radiology supervisors daily (M-F).  The report lists any suspected Exam Data Entry errors such as: <ul> <li>Exam start time after stop time</li> <li>Exam start time equals stop time</li> <li>Ex am start to exam stop greater than 12 hours (except NM multiday studies)</li> <li>Exam start time is after transcription start time</li> </ul>,g22407,0,TRUE,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9431,1,The Data Entry Error report is sent to all Radiology supervisors daily (M-F).  The report lists any suspected Exam Data Entry errors such as: <ul> <li>Exam start time after stop time</li> <li>Exam start time equals stop time</li> <li>Ex am start to exam stop greater than 12 hours (except NM multiday studies)</li> <li>Exam start time is after transcription start time</li> </ul>,g22408,1,FALSE,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9432,0,Before turning in a requisition to the radiologist to be dictated the following must be done:,g22409,0,EDE to include charging of contrast or other supplies,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9432,1,Before turning in a requisition to the radiologist to be dictated the following must be done:,g22410,1,"Proper patient history along with all paperwork, including consent forms-filled out completely",0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9432,2,Before turning in a requisition to the radiologist to be dictated the following must be done:,g22411,2,Images Sent and Verified in PACs.,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9432,3,Before turning in a requisition to the radiologist to be dictated the following must be done:,g22412,3,All of the above,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9433,0,"If a report has been dictated and transcribed, will it release and print to the patient's physician if the technologist forgot to EDE (exam data entry) the exam in STAR?",g22413,0,"Yes--its ok if you forgot to EDE, the report will print anyway",0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9433,1,"If a report has been dictated and transcribed, will it release and print to the patient's physician if the technologist forgot to EDE (exam data entry) the exam in STAR?",g22414,1,No--the report will be held until the exam has been EDE'd in STAR,1,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9433,2,"If a report has been dictated and transcribed, will it release and print to the patient's physician if the technologist forgot to EDE (exam data entry) the exam in STAR?",g22415,2,Both of the above,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4206,8947,Elearning-0000-229,g1814,g9433,3,"If a report has been dictated and transcribed, will it release and print to the patient's physician if the technologist forgot to EDE (exam data entry) the exam in STAR?",g22416,3,None of the above--EDE has nothing to do with the report releasing to the physician,0,RADIOLOGY EXAM PROCESSING - ANNUAL COMPETENCY
4180,8838,Elearning-0000-17,g1796,g6072,0,I have read and understood the procedure for using the Radiology Patient Care Notes Form.,g12697,0,Yes,1,RADIOLOGY PATIENT CARE FORM
4180,8838,Elearning-0000-17,g1796,g6072,1,I have read and understood the procedure for using the Radiology Patient Care Notes Form.,g12698,1,No,0,RADIOLOGY PATIENT CARE FORM
4084,9069,Elearning-0000-34,g1735,g5584,0,I have read and understand the Complete Review of Inhaled Medication CBL course.,g11475,0,Yes,1,INHALED MEDICATION REVIEW
4084,9069,Elearning-0000-34,g1735,g5584,1,I have read and understand the Complete Review of Inhaled Medication CBL course.,g11476,1,No,0,INHALED MEDICATION REVIEW
3823,9036,Elearning-0000-31,g1621,g4867,0,I have reviewed the Lucidoc Training.  I now know how to find a policy using Lucidoc.,g9772,0,Yes,1,LUCIDOC DEFAULT USER TRAINING
3823,9036,Elearning-0000-31,g1621,g4867,1,I have reviewed the Lucidoc Training.  I now know how to find a policy using Lucidoc.,g9773,1,No,0,LUCIDOC DEFAULT USER TRAINING
3813,9300,Elearning-0000-55,g1615,g4841,0,I have read and understand the Care of Deceased Patient CBL course.,g9667,0,Yes,1,CARE OF DECEASED PATIENT (CHEROKEE)
3813,9300,Elearning-0000-55,g1615,g4841,1,I have read and understand the Care of Deceased Patient CBL course.,g9668,1,No,0,CARE OF DECEASED PATIENT (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4838,0,The initial role of nursing when a patient under legal or correctional limitations arrives for care is to:,g9653,0,a.   Try to find out what the patient did to get put in legal or correctional limitations,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4838,1,The initial role of nursing when a patient under legal or correctional limitations arrives for care is to:,g9654,1,b.   Acquire appropriate chairs and meals for the law enforcement officer,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4838,2,The initial role of nursing when a patient under legal or correctional limitations arrives for care is to:,g9655,2,c.    Notify security of their arrival and presence,1,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4838,3,The initial role of nursing when a patient under legal or correctional limitations arrives for care is to:,g9656,3,d.    Put a sign on their door informing staff not to enter the room unless they absolutely have to,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4839,0,"Upon identification that a patient has attempted or has ideations about committing suicide, staff members need to notify the following individual(s):",g9657,0,a.   Chaplain,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4839,1,"Upon identification that a patient has attempted or has ideations about committing suicide, staff members need to notify the following individual(s):",g9658,1,b.    Physician,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4839,2,"Upon identification that a patient has attempted or has ideations about committing suicide, staff members need to notify the following individual(s):",g9659,2,c.    Laboratory Staff,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4839,3,"Upon identification that a patient has attempted or has ideations about committing suicide, staff members need to notify the following individual(s):",g9660,3,d.   House Coordinator,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4839,4,"Upon identification that a patient has attempted or has ideations about committing suicide, staff members need to notify the following individual(s):",g9661,4,e.   A & C,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4839,5,"Upon identification that a patient has attempted or has ideations about committing suicide, staff members need to notify the following individual(s):",g9662,5,f.    B & D,1,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4840,0,Patients under suicide precautions or with an existing 1013/2013 need to have constant visualization,g9663,0,a.   During the night shift when there are fewer staff around,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4840,1,Patients under suicide precautions or with an existing 1013/2013 need to have constant visualization,g9664,1,b.    When security can come and stay with the patient,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4840,2,Patients under suicide precautions or with an existing 1013/2013 need to have constant visualization,g9665,2,c.    By a staff member who is providing care to another patient or group of patients,0,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3812,9289,Elearning-0000-54,g1614,g4840,3,Patients under suicide precautions or with an existing 1013/2013 need to have constant visualization,g9666,3,"d.   At all times by a security officer, staff member, or sitter",1,CARE OF SPECIAL POPULATIONS (CHEROKEE)
3774,9875,Questions-0000-164,g1584,g4528,0,I have received education on the Ultrasound exam description changes sent on 5/3/06.,g8799,0,Yes,1,ULTRASOUND TECHNOLOGIST EDUCATION
3774,9875,Questions-0000-164,g1584,g4528,1,I have received education on the Ultrasound exam description changes sent on 5/3/06.,g8800,1,No,0,ULTRASOUND TECHNOLOGIST EDUCATION
3736,9929,Questions-0000-63,g1556,g4407,0,I have reviewed 'Identifying Patients & Labeling Specimen_Poster Inservice'.,g8393,0,Yes,1,IDENTIFYING PATIENTS & LABELING SPECIMEN_POSTER INSERVICE
3736,9929,Questions-0000-63,g1556,g4407,1,I have reviewed 'Identifying Patients & Labeling Specimen_Poster Inservice'.,g8394,1,No,0,IDENTIFYING PATIENTS & LABELING SPECIMEN_POSTER INSERVICE
3646,9234,Elearning-0000-49,g1520,g4199,0,I have fully reviewed and understand the F-048 Critical Diagnostic Test Result Reporting policy.,g7781,0,Yes,1,CRITICAL DIAGNOSTIC TEST RESULT REPORTING
3646,9234,Elearning-0000-49,g1520,g4199,1,I have fully reviewed and understand the F-048 Critical Diagnostic Test Result Reporting policy.,g7782,1,No,0,CRITICAL DIAGNOSTIC TEST RESULT REPORTING
3581,9179,Elearning-0000-44,g1483,g4120,0,I have fully reviewed and understand the Helipad Safety CBL module.,g7571,0,Yes,1,HELIPAD SAFETY
3581,9179,Elearning-0000-44,g1483,g4120,1,I have fully reviewed and understand the Helipad Safety CBL module.,g7572,1,No,0,HELIPAD SAFETY
3577,9168,Elearning-0000-43,g1482,g4119,0,"""I have carefully reviewed and fully understood the HIPAA SECURITY RULE Training.""",g7569,0,Yes,1,HIPAA SECURITY RULES
3577,9168,Elearning-0000-43,g1482,g4119,1,"""I have carefully reviewed and fully understood the HIPAA SECURITY RULE Training.""",g7570,1,No,0,HIPAA SECURITY RULES
20292,4107,ILT-0000-18105,g14249,g65863,0,What is Cerner?,g220173,0,"a.	The billing application used by PBS",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65863,1,What is Cerner?,g220174,1,"b.	The Northside Hospital EMR and Practice Registration System.",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65863,2,What is Cerner?,g220175,2,"c.	The Payment Processing Systems used by physician practices",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65863,3,What is Cerner?,g220176,3,"d.	A physician practice billed through PBS",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65864,0,Finish the statement: Centricity Database N16 contains Provider Groups for practice on __________ _________ ________.,g220177,0,"a.	Cerner Practice Management",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65864,1,Finish the statement: Centricity Database N16 contains Provider Groups for practice on __________ _________ ________.,g220178,1,"b.	Revenue Cycle Website",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65864,2,Finish the statement: Centricity Database N16 contains Provider Groups for practice on __________ _________ ________.,g220179,2,"c.	Centricity Billing Software",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65864,3,Finish the statement: Centricity Database N16 contains Provider Groups for practice on __________ _________ ________.,g220180,3,"d.	Northside Hospital Campus",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65865,0,The PM Icon is used to:,g220181,0,"a.	Post Money",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65865,1,The PM Icon is used to:,g220182,1,"b.	Enter Charges",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65865,2,The PM Icon is used to:,g220183,2,"c.	Lookup Patients",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65865,3,The PM Icon is used to:,g220184,3,"d.	Enter Notes",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65866,0,Centricity is accessible through the Revenue Cycle Website.,g220185,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65866,1,Centricity is accessible through the Revenue Cycle Website.,g220186,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65867,0,Centricity is to be utilized ___________:,g220187,0,"A.	Weekly",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65867,1,Centricity is to be utilized ___________:,g220188,1,"B.	Monthly",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65867,2,Centricity is to be utilized ___________:,g220189,2,"C.	Hourly",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65867,3,Centricity is to be utilized ___________:,g220190,3,"D.	Daily",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65868,0,Which of the following web browser must be used when accessing Centricity?,g220191,0,"A.	Google Chrome",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65868,1,Which of the following web browser must be used when accessing Centricity?,g220192,1,"B.	Edge",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65868,2,Which of the following web browser must be used when accessing Centricity?,g220193,2,"C.	Internet Explorer",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65868,3,Which of the following web browser must be used when accessing Centricity?,g220194,3,"D.	Firefox",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65869,0,Centricity is the billing system used by Physician Billing Services.,g220195,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65869,1,Centricity is the billing system used by Physician Billing Services.,g220196,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65870,0,"Provider Group, is a primary assigned practice identifier in the billing system.",g220197,0,TRUE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65870,1,"Provider Group, is a primary assigned practice identifier in the billing system.",g220198,1,FALSE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65871,0,The system login (username) consist of how many characters?,g220199,0,"A.	6",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65871,1,The system login (username) consist of how many characters?,g220200,1,"B.	4",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65871,2,The system login (username) consist of how many characters?,g220201,2,"C.	5",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65871,3,The system login (username) consist of how many characters?,g220202,3,"D.	3",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65872,0,Who makes edits in Centricity?,g220203,0,"A.	Practice",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65872,1,Who makes edits in Centricity?,g220204,1,"B.	PBS",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65872,2,Who makes edits in Centricity?,g220205,2,"C.	Revenue Integrity",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65872,3,Who makes edits in Centricity?,g220206,3,"D.	Patient Registration",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65873,0,Search Criteria for patients include:,g220207,0,"A.	Account number, Last Name/First Name, Recent Patient drop box",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65873,1,Search Criteria for patients include:,g220208,1,"B.	Last Name/ First Name, Recent Patient drop box",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65873,2,Search Criteria for patients include:,g220209,2,"C.	Recent Patient drop box, Account Number",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65873,3,Search Criteria for patients include:,g220210,3,"D.	Last Name/First Name, Account Number",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65874,0,The Account Holder/Guarantor will always be the Subscriber.,g220211,0,TRUE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65874,1,The Account Holder/Guarantor will always be the Subscriber.,g220212,1,FALSE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65875,0,Which of the three items can be viewed within the Patient tab?,g220213,0,"A.	Patient charges, social security number, date of birth",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65875,1,Which of the three items can be viewed within the Patient tab?,g220214,1,"B.	Patient Address, Patient Sex, Patient Date of Birth",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65875,2,Which of the three items can be viewed within the Patient tab?,g220215,2,"C.	Date of birth, gender, primary care provider",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65875,3,Which of the three items can be viewed within the Patient tab?,g220216,3,"D.	First and last medical visits, comments, gender",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65876,0,Balances owed are found on the Account tab.,g220217,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65876,1,Balances owed are found on the Account tab.,g220218,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65877,0,"When the group number is not available for entry, what is entered into the Insurance Details?",g220219,0,"A.	Nothing is entered. The field is left blank.",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65877,1,"When the group number is not available for entry, what is entered into the Insurance Details?",g220220,1,"B.	The employer's name",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65877,2,"When the group number is not available for entry, what is entered into the Insurance Details?",g220221,2,"C.	999999",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65877,3,"When the group number is not available for entry, what is entered into the Insurance Details?",g220222,3,"D.	000000",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65878,0,"When adding a new insurance set, and the insurance is a health plan, Select:",g220223,0,"A.	Health Insurance",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65878,1,"When adding a new insurance set, and the insurance is a health plan, Select:",g220224,1,"B.	Set 4",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65878,2,"When adding a new insurance set, and the insurance is a health plan, Select:",g220225,2,"C.	Commercial",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65878,3,"When adding a new insurance set, and the insurance is a health plan, Select:",g220226,3,"D.	Medical",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65879,0,An effective date is not required when manually updating patient demographics.,g220227,0,TRUE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65879,1,An effective date is not required when manually updating patient demographics.,g220228,1,FALSE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65880,0,"When entering Insurance information, select the appropriate Relationship Code to reflect the:",g220229,0,"a.	Patient's Relationship to the Patient",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65880,1,"When entering Insurance information, select the appropriate Relationship Code to reflect the:",g220230,1,"b.	Patient's marital status",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65880,2,"When entering Insurance information, select the appropriate Relationship Code to reflect the:",g220231,2,"c.	Policy Holder's Relationship to the Insured",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65880,3,"When entering Insurance information, select the appropriate Relationship Code to reflect the:",g220232,3,"d.	Patient's employment status",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65881,0,"By clicking on the Comments hyperlink, staff are able to:",g220233,0,"a.	View existing Comments",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65881,1,"By clicking on the Comments hyperlink, staff are able to:",g220234,1,"b.	Create new Comments",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65881,2,"By clicking on the Comments hyperlink, staff are able to:",g220235,2,"c.	Append Comments",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65881,3,"By clicking on the Comments hyperlink, staff are able to:",g220236,3,"d.	All of the Above",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65882,0,Which of the following are ways to search for Transactions:,g220237,0,"a.	Date of Service, Display, Charge Status",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65882,1,Which of the following are ways to search for Transactions:,g220238,1,"b.	Charge Number, Display, Date of Service",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65882,2,Which of the following are ways to search for Transactions:,g220239,2,"c.	Charge Status, Charge Number, Display, Date of Service",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65882,3,Which of the following are ways to search for Transactions:,g220240,3,"d.	None of the Above",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65883,0,Appending means adding comments to an existing note.,g220241,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65883,1,Appending means adding comments to an existing note.,g220242,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65884,0,"To change a CPT on a charge, use the _____ button.",g220243,0,"a.	Edit",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65884,1,"To change a CPT on a charge, use the _____ button.",g220244,1,"b.	Correct",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65884,2,"To change a CPT on a charge, use the _____ button.",g220245,2,"c.	Repost",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65884,3,"To change a CPT on a charge, use the _____ button.",g220246,3,"d.	Close",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65885,0,Reposting a charge means to post again or post in place of.,g220247,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65885,1,Reposting a charge means to post again or post in place of.,g220248,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65886,0,"When searching for Transactions by Charge Status, ""All"" means:",g220249,0,"a.	Accounts with open balances, corrections, credits",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65886,1,"When searching for Transactions by Charge Status, ""All"" means:",g220250,1,"b.	Account paid in full, open balance, corrections",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65886,2,"When searching for Transactions by Charge Status, ""All"" means:",g220251,2,"c.	Accounts paid in full, corrections, credits, patient responsibility",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65886,3,"When searching for Transactions by Charge Status, ""All"" means:",g220252,3,"d.	Accounts with credits, corrections, paid in full, open balance",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65887,0,A Corrected charge is identified by:,g220253,0,"a.	Green Checkmark",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65887,1,A Corrected charge is identified by:,g220254,1,"b.	The word ""Corrected""",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65887,2,A Corrected charge is identified by:,g220255,2,"c.	Green Row",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65887,3,A Corrected charge is identified by:,g220256,3,"d.	All the Above",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65888,0,From the Group Management Screen click on F5 to change practice database.,g220257,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65888,1,From the Group Management Screen click on F5 to change practice database.,g220258,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65889,0,Selecting New Search will,g220259,0,"a.	Lookup a different charge within the same database",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65889,1,Selecting New Search will,g220260,1,"b.	Lookup a different payment within the same database",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65889,2,Selecting New Search will,g220261,2,"c.	Lookup a different patient within the same database",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65889,3,Selecting New Search will,g220262,3,"d.	Lookup insurances",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65890,0,Clicking on Login will refresh/sync the screen.,g220263,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65890,1,Clicking on Login will refresh/sync the screen.,g220264,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65891,0,WFE is another way of returning to the Group Management Menu Screen.,g220265,0,TRUE,1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65891,1,WFE is another way of returning to the Group Management Menu Screen.,g220266,1,FALSE,0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65892,0,To exit Centricity select __________,g220267,0,"a.	1 = Close Centricity",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65892,1,To exit Centricity select __________,g220268,1,"b.	4 = Exit Centricity",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65892,2,To exit Centricity select __________,g220269,2,"c.	7 = Close Patient Lookup",0,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20292,4107,ILT-0000-18105,g14249,g65892,3,To exit Centricity select __________,g220270,3,"d.	9 = Exit Group Management",1,RCTA PBS CENTRICITY BASICS UNIVERSITY TEST
20279,4840,ILT-0000-22456,g14236,g65813,0,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g220025,0,Hospital Name,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65813,1,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g220026,1,The department you are working/taking the payment,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65813,2,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g220027,2,Your location will automatically default after logging in according to your profile,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65814,0,The Internet Cashier tab is where payments are taken.,g220028,0,TRUE,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65814,1,The Internet Cashier tab is where payments are taken.,g220029,1,FALSE,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65815,0,Which tab can the Deposit Slips report be found?,g220030,0,Internet Cashier,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65815,1,Which tab can the Deposit Slips report be found?,g220031,1,Launchpad,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65815,2,Which tab can the Deposit Slips report be found?,g220032,2,Reports,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65816,0,Only users that collected a cash payment need to end their shift.,g220033,0,TRUE,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65816,1,Only users that collected a cash payment need to end their shift.,g220034,1,FALSE,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65817,0,Which report allows a user to view how many patient payments have been collected by a specific Location for a specific date range?,g220035,0,Shift Report,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65817,1,Which report allows a user to view how many patient payments have been collected by a specific Location for a specific date range?,g220036,1,Location Summary,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65817,2,Which report allows a user to view how many patient payments have been collected by a specific Location for a specific date range?,g220037,2,Transactions,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65818,0,Which reports allows a user to end shifts and create deposit slips to record cash and check transactions?,g220038,0,Shift Report,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65818,1,Which reports allows a user to end shifts and create deposit slips to record cash and check transactions?,g220039,1,Location Summary,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65818,2,Which reports allows a user to end shifts and create deposit slips to record cash and check transactions?,g220040,2,Transactions,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65819,0,A monthly report will be distributed regarding Cash Shifts missing deposit slips.,g220041,0,TRUE,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65819,1,A monthly report will be distributed regarding Cash Shifts missing deposit slips.,g220042,1,FALSE,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65820,0,"If payment information needs to be updated, a user will access the account, select View Details, then select which option?",g220043,0,Account Details,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65820,1,"If payment information needs to be updated, a user will access the account, select View Details, then select which option?",g220044,1,Internet Cashier,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65820,2,"If payment information needs to be updated, a user will access the account, select View Details, then select which option?",g220045,2,Account Activity,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65821,0,Which report allows a user to view patient payments collected by specific users over a specific date range?,g220046,0,User Summary,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65821,1,Which report allows a user to view patient payments collected by specific users over a specific date range?,g220047,1,Transactions,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65821,2,Which report allows a user to view patient payments collected by specific users over a specific date range?,g220048,2,Payment Matching,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65822,0,Which tab on the Revenue Cycle Website is Patientco found?,g220049,0,Tools & Forms,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65822,1,Which tab on the Revenue Cycle Website is Patientco found?,g220050,1,Quick Reference Tables,0,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20279,4840,ILT-0000-22456,g14236,g65822,2,Which tab on the Revenue Cycle Website is Patientco found?,g220051,2,Systems,1,RCT: PCO_PAS LEADERSHIP FUNCTIONS TEST
20255,4841,ILT-0000-22457,g14213,g65679,0,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g219550,0,Hospital Name,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65679,1,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g219551,1,The department you are working/taking the payment,1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65679,2,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g219552,2,Your location will automatically default after logging in according to your profile,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65680,0,It is important to choose your current location to ensure you are applying patient payments correctly.,g219553,0,TRUE,1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65680,1,It is important to choose your current location to ensure you are applying patient payments correctly.,g219554,1,FALSE,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65681,0,"It is the expectation that reps utilize the ""Search"" function not the ""Make Payment Now"" button when taking a payment in Internet Cashier.",g219555,0,TRUE,1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65681,1,"It is the expectation that reps utilize the ""Search"" function not the ""Make Payment Now"" button when taking a payment in Internet Cashier.",g219556,1,FALSE,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65682,0,Which of the following are the correct steps when taking a payment in Patientco for the Current Service?,g219557,0,"Use the ""Make Payment Now"" button and enter the patient account, select ""Prepayment"" as the ""Payment Type"".",0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65682,1,Which of the following are the correct steps when taking a payment in Patientco for the Current Service?,g219558,1,"Click Search button after entering the patient account number, click ""Accept"" then enter the payment method.",0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65682,2,Which of the following are the correct steps when taking a payment in Patientco for the Current Service?,g219559,2,"Use the Search function button, click ""Make Payment"" on the grey results bar, select ""Prepayment"" as the ""Payment Type.",1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65683,0,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g219560,0,AR,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65683,1,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g219561,1,Balance,1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65683,2,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g219562,2,Bad Debt,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65685,0,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g219566,0,"Select Payment Type ""Prepayment"" for the initial deposit, click the ""Add Payment"" button, select Payment Type ""Prepayment"" for remaining amount in the ""Amount to Pay"", click Scheduling Options hyperlink then select First Payment Date from the calendar, enter current visit account number, Service Location "".OTHER.",1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65685,1,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g219567,1,"Enter Payment Information for the initial deposit, process the payment method. Search for the patient account again and enter the Payment Information for the monthly payments, process the payment method.",0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65685,2,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g219568,2,Auto-draft monthly payments will not be processed in Patientco.,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65686,0,The payment method options accepted for Patientco are:,g219569,0,"Credit/Debit card (done via card swipe), eCheck (done via check scanner),  Paper Checks (deposit manual check) or cash (done via existing process).",0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65686,1,The payment method options accepted for Patientco are:,g219570,1,"Credit/Debit card (done via card swipe device), eCheck (used to scan information into Patientco via check scanner or manually enter in the event check scanner is down) or cash (done via existing process),  Paper Checks - do not use this button.",1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65686,2,The payment method options accepted for Patientco are:,g219571,2,Credit/Debit card (done via card swipe device) or eCheck (done via check scanner).,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65687,0,Which of the following should be selected as the Collection Method when the patient chooses to pay with their credit/debit card number via text.,g219572,0,CREDIT/DEBIT,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65687,1,Which of the following should be selected as the Collection Method when the patient chooses to pay with their credit/debit card number via text.,g219573,1,PATIENT MOBILE,1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65687,2,Which of the following should be selected as the Collection Method when the patient chooses to pay with their credit/debit card number via text.,g219574,2,CLICK/SWIPE,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65688,0,It is only necessary to end your shift if you took a cash payment.,g219575,0,TRUE,0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65688,1,It is only necessary to end your shift if you took a cash payment.,g219576,1,FALSE,1,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65690,0,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g219579,0,"Prepayment, Bad Debt",0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65690,1,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g219580,1,"Balance, Prepayment",0,RCT: PCO_PATIENT ACCESS TEST
20255,4841,ILT-0000-22457,g14213,g65690,2,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g219581,2,"Prepayment, Balance",1,RCT: PCO_PATIENT ACCESS TEST
20213,4842,ILT-0000-22458,g14176,g65312,0,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218214,0,Hospital name,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65312,1,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218215,1,The department you are working/taking the payment,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65312,2,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218216,2,Your location will automatically default after logging in according to your profile,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65313,0,It is important to choose your current location to ensure you are applying patient payments correctly,g218217,0,TRUE,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65313,1,It is important to choose your current location to ensure you are applying patient payments correctly,g218218,1,FALSE,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65314,0,"It is the expectation that reps utilize the ""Search"" function not the ""Make Payment Now"" button when taking a payment in Internet Cashier",g218219,0,TRUE,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65314,1,"It is the expectation that reps utilize the ""Search"" function not the ""Make Payment Now"" button when taking a payment in Internet Cashier",g218220,1,FALSE,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65315,0,How is the Dynapad/encrypted key pad activated to enter credit card information in Patientco?,g218221,0,It is automatically activated when Patientco is open on the screen,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65315,1,How is the Dynapad/encrypted key pad activated to enter credit card information in Patientco?,g218222,1,By clicking the Click & Swipe button on the Payment Method screen,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65315,2,How is the Dynapad/encrypted key pad activated to enter credit card information in Patientco?,g218223,2,It is not necessary to use the Dynapad/encrypted key pad,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65316,0,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g218224,0,AR,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65316,1,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g218225,1,Balance,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65316,2,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g218226,2,Bad Dept,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65317,0,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g218227,0,"Prepayment, Bad Dept",0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65317,1,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g218228,1,"Balance, Prepayment",0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65317,2,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g218229,2,"Prepayment, Balance",1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65318,0,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g218230,0,"Search for the patient account, select Payment Type ""Prepayment"", enter the Payment Information for the initial deposit, click the ""Add Payment"" button, select Payment Type ""Balance"", enter the total remaining amount in the ""Amount to Pay"", click Scheduling Options hyperlink and select the proper radio button, then select First Payment Date from the calendar, enter current visit account number, Service Location "".OTHER, click ""Continue"", click ""Confirm"", then process the payment method.",1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65318,1,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g218231,1,"Search for the patient account, enter the Payment Information for the initial deposit, process the payment method. Search for the patient account again and enter the Payment Information for the monthly payments, process the payment method.",0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65318,2,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g218232,2,Auto-draft monthly payments will not be processed in Patientco.,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65319,0,The payment method options accepted for Patientco are:,g218233,0,"Credit/Debit card (done via card swipe), eCheck (done via check scanner), Paper Checks (deposit manual check) or cash (done via existing process).",0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65319,1,The payment method options accepted for Patientco are:,g218234,1,"Credit/Debit card (done via card swipe device or encrypted keypad entry), eCheck (done via check scanner) or cash (done via existing process), Paper Checks should no longer be accepted for deposit (unless due to malfunction of check scanner).",1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65319,2,The payment method options accepted for Patientco are:,g218235,2,Credit/Debit card (done via card swipe device or encrypted keypad entry) or eCheck (done via check scanner).,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65320,0,Which of the following should be selected as the Collection Method when entering the credit/debit card information via encrypted keypad,g218236,0,WEB ENTRY,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65320,1,Which of the following should be selected as the Collection Method when entering the credit/debit card information via encrypted keypad,g218237,1,PATIENT MOBILE,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65320,2,Which of the following should be selected as the Collection Method when entering the credit/debit card information via encrypted keypad,g218238,2,CLICK/SWIPE,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65321,0,It is the expectation of your Leadership to complete the ________ _________ process prior to leaving for the day.,g218239,0,Make Payment,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65321,1,It is the expectation of your Leadership to complete the ________ _________ process prior to leaving for the day.,g218240,1,End Shift,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65321,2,It is the expectation of your Leadership to complete the ________ _________ process prior to leaving for the day.,g218241,2,CLICK/SWIPE,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65322,0,Messages pending work by a Northside representative will display in which of the following tabs?,g218242,0,Closed,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65322,1,Messages pending work by a Northside representative will display in which of the following tabs?,g218243,1,Waiting on Patient,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65322,2,Messages pending work by a Northside representative will display in which of the following tabs?,g218244,2,Needs Action,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65323,0,The Address Changes queue is located in which tab?,g218245,0,Internet Cashier,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65323,1,The Address Changes queue is located in which tab?,g218246,1,Messages,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65323,2,The Address Changes queue is located in which tab?,g218247,2,Reports,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65324,0,Patients will be able to create payment plans within the PatientWallet.,g218248,0,TRUE,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65324,1,Patients will be able to create payment plans within the PatientWallet.,g218249,1,FALSE,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65325,0,Each bill is assigned a unique:,g218250,0,9-digit SecureHealthCode,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65325,1,Each bill is assigned a unique:,g218251,1,Username,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65325,2,Each bill is assigned a unique:,g218252,2,Color,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65326,0,Professional fee payments will be posted in:,g218253,0,Wells Fargo,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65326,1,Professional fee payments will be posted in:,g218254,1,Patientco,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65326,2,Professional fee payments will be posted in:,g218255,2,Northside Intranet,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65327,0,Payments previously taken in Wells Fargo should be reviewed in:,g218256,0,Patientco,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65327,1,Payments previously taken in Wells Fargo should be reviewed in:,g218257,1,Wells Fargo,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65327,2,Payments previously taken in Wells Fargo should be reviewed in:,g218258,2,RevRunner,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65328,0,The __________ _________ queue houses statements that have been deemed undeliverable by the USPS and did not have a forwarding address.,g218259,0,Correspondence,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65328,1,The __________ _________ queue houses statements that have been deemed undeliverable by the USPS and did not have a forwarding address.,g218260,1,Address Changes,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65328,2,The __________ _________ queue houses statements that have been deemed undeliverable by the USPS and did not have a forwarding address.,g218261,2,Returned Mail,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65329,0,The __________ _________ queue houses bills that need to be reviewed and actioned.,g218262,0,Returned Mail,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65329,1,The __________ _________ queue houses bills that need to be reviewed and actioned.,g218263,1,Address Changes,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65329,2,The __________ _________ queue houses bills that need to be reviewed and actioned.,g218264,2,Held Bill,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65330,0,The __________ _________ queue houses documents received from patients that are more than a check and stub.,g218265,0,Held Bill,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65330,1,The __________ _________ queue houses documents received from patients that are more than a check and stub.,g218266,1,Correspondence,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65330,2,The __________ _________ queue houses documents received from patients that are more than a check and stub.,g218267,2,Returned Mail,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65331,0,Patient made payment plans can be found in the Self-Service tab on the Payment Plans page under the _____________ tab.,g218268,0,Reports,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65331,1,Patient made payment plans can be found in the Self-Service tab on the Payment Plans page under the _____________ tab.,g218269,1,Messages,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65331,2,Patient made payment plans can be found in the Self-Service tab on the Payment Plans page under the _____________ tab.,g218270,2,Payments,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65528,0,Credit card payment information should be entered utilizing the:,g218967,0,Computer keyboard,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65528,1,Credit card payment information should be entered utilizing the:,g218968,1,Encrypted Key Pad Device,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65528,2,Credit card payment information should be entered utilizing the:,g218969,2,None of the above,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65529,0,"When a new message has arrived from patients, a number will appear next to which tab in the navigation bar?",g218970,0,Messages,1,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65529,1,"When a new message has arrived from patients, a number will appear next to which tab in the navigation bar?",g218971,1,Internet Cashier,0,RCT: PCO_CUSTOMER SERVICE TEST
20213,4842,ILT-0000-22458,g14176,g65529,2,"When a new message has arrived from patients, a number will appear next to which tab in the navigation bar?",g218972,2,Payments,0,RCT: PCO_CUSTOMER SERVICE TEST
20191,4844,ILT-0000-22460,g14159,g65276,0,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218117,0,Hospital name,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65276,1,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218118,1,The department you are working/taking the payment,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65276,2,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218119,2,Your location will automatically default after logging in according to your profile,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65277,0,It is important to choose your current location to search for payments and request refunds?,g218120,0,TRUE,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65277,1,It is important to choose your current location to search for payments and request refunds?,g218121,1,FALSE,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65278,0,Click Account Activity to view patient payments.,g218122,0,TRUE,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65278,1,Click Account Activity to view patient payments.,g218123,1,FALSE,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65279,0,Patientco is:,g218124,0,A Payment Collection system,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65279,1,Patientco is:,g218125,1,Refund processing system,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65279,2,Patientco is:,g218126,2,Insurance verifications systems,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65280,0,Patientco can be accessed via:,g218127,0,Desktop icon,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65280,1,Patientco can be accessed via:,g218128,1,Northside Intranet,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65280,2,Patientco can be accessed via:,g218129,2,Revenue Cycle website,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65281,0,"To search payments, click on:",g218130,0,Internet Cashier,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65281,1,"To search payments, click on:",g218131,1,Refund Request,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65281,2,"To search payments, click on:",g218132,2,View Details,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65282,0,Clicking the Refund Payment button sends the account to the:,g218133,0,Account Activity,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65282,1,Clicking the Refund Payment button sends the account to the:,g218134,1,Refund Payment,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65282,2,Clicking the Refund Payment button sends the account to the:,g218135,2,Internet Cashier,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65283,0,Payments received in Wells Fargo can be refunded in Patientco.,g218136,0,TRUE,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65283,1,Payments received in Wells Fargo can be refunded in Patientco.,g218137,1,FALSE,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65284,0,When refunding a payment you will need to enter a _______ as to why you are doing so.,g218138,0,Reason,1,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65284,1,When refunding a payment you will need to enter a _______ as to why you are doing so.,g218139,1,Comment,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65284,2,When refunding a payment you will need to enter a _______ as to why you are doing so.,g218140,2,Request,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65285,0,The Pending Refunds queue is located in the:,g218141,0,Internet Cashier tab,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65285,1,The Pending Refunds queue is located in the:,g218142,1,Account activity,0,RCT: PCO_POST PAYMENT REVIEW TEST
20191,4844,ILT-0000-22460,g14159,g65285,2,The Pending Refunds queue is located in the:,g218143,2,Reports tab,1,RCT: PCO_POST PAYMENT REVIEW TEST
20189,4845,ILT-0000-22461,g14157,g65262,0,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218075,0,"A.	Hospital Name",0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65262,1,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218076,1,The department you are working/taking the payment,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65262,2,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g218077,2,"C.	Your location will automatically default after logging in according to your profile",0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65263,0,The Internet Cashier tab is where payments are taken.,g218078,0,TRUE,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65263,1,The Internet Cashier tab is where payments are taken.,g218079,1,FALSE,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65264,0,Which tab can the Deposit Slips report be found?,g218080,0,Internet Cashier,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65264,1,Which tab can the Deposit Slips report be found?,g218081,1,Launchpad,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65264,2,Which tab can the Deposit Slips report be found?,g218082,2,Reports,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65265,0,Which of the following statements about the Work Queue is NOT correct?,g218083,0,The On Track tasks will be listed individually at the top of the screen,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65265,1,Which of the following statements about the Work Queue is NOT correct?,g218084,1,The tasks needing attention will be listed in the area next to the red bar,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65265,2,Which of the following statements about the Work Queue is NOT correct?,g218085,2,"To view the On Track tasks click the ""View Tasks"" hyperlink in the area with the green bar",0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65266,0,Which report allows a user to view how many patient payments have been collected by a specific Location for a specific date range?,g218086,0,Shift Report,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65266,1,Which report allows a user to view how many patient payments have been collected by a specific Location for a specific date range?,g218087,1,Location Summary,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65266,2,Which report allows a user to view how many patient payments have been collected by a specific Location for a specific date range?,g218088,2,Transactions,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65267,0,Which reports allows a user to end shifts and create deposit slips to record cash and check transactions?,g218089,0,Shift Report,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65267,1,Which reports allows a user to end shifts and create deposit slips to record cash and check transactions?,g218090,1,Location Summary,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65267,2,Which reports allows a user to end shifts and create deposit slips to record cash and check transactions?,g218091,2,Transactions,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65268,0,A monthly report will be distributed by the QA Team regarding Open Cash Shifts.,g218092,0,TRUE,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65268,1,A monthly report will be distributed by the QA Team regarding Open Cash Shifts.,g218093,1,FALSE,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65269,0,"If payment information is entered incorrectly, a user should utilize which function in Payment Reports?",g218094,0,User Summary,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65269,1,"If payment information is entered incorrectly, a user should utilize which function in Payment Reports?",g218095,1,Shift Report,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65269,2,"If payment information is entered incorrectly, a user should utilize which function in Payment Reports?",g218096,2,Transaction Revisions,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65270,0,Which report allows a user to view patient payments collected by specific users over a specific date range?,g218097,0,User Summary,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65270,1,Which report allows a user to view patient payments collected by specific users over a specific date range?,g218098,1,Transactions,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65270,2,Which report allows a user to view patient payments collected by specific users over a specific date range?,g218099,2,Payment Matching,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65271,0,Which tab on the Revenue Cycle Website is Patientco found?,g218100,0,Tools & Forms,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65271,1,Which tab on the Revenue Cycle Website is Patientco found?,g218101,1,Quick Reference Tables,0,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20189,4845,ILT-0000-22461,g14157,g65271,2,Which tab on the Revenue Cycle Website is Patientco found?,g218102,2,Systems,1,RCT: PCO_LEADERSHIP FUNCTIONS TEST
20181,4846,ILT-0000-22462,g14149,g65229,0,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g217966,0,"A.	Hospital name",0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65229,1,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g217967,1,"B.	The department you are working/taking the payment",1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65229,2,"When choosing your location after logging into Patientco, select the location from the dropdown list as:",g217968,2,"C.	Your location will automatically default after logging in according to your profile",0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65230,0,It is important to choose the appropriate service location when taking a payment to ensure you are applying patient payments correctly.,g217969,0,A. True,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65230,1,It is important to choose the appropriate service location when taking a payment to ensure you are applying patient payments correctly.,g217970,1,B. False,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65231,0,"It is the expectation that reps utilize the ""Search"" function not the ""Make Payment Now"" button when taking a payment in Internet Cashier.",g217971,0,A. True,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65231,1,"It is the expectation that reps utilize the ""Search"" function not the ""Make Payment Now"" button when taking a payment in Internet Cashier.",g217972,1,B. False,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65233,0,How is the Dynapad/encrypted key pad activated to enter credit card information in Patientco.,g218070,0,It is automatically activated when Patientco is open on the screen.,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65233,1,How is the Dynapad/encrypted key pad activated to enter credit card information in Patientco.,g218071,1,By clicking the Click & Swipe button on the Payment Method screen.,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65233,2,How is the Dynapad/encrypted key pad activated to enter credit card information in Patientco.,g218072,2,It is not necessary to use the Dynapad/encrypted key pad.,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65234,0,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g217978,0,"A.	AR",0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65234,1,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g217979,1,"B.	Balance",1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65234,2,"When taking a payment for a Previous Balance Only, ensure that ____________is selected as the ""Payment Type"".",g217980,2,"C.	Bad Dept",0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65236,0,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g217983,0,"Prepayment, Bad Dept",0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65236,1,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g217984,1,"Balance, Prepayment",0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65236,2,"When taking a payment for Multiple Accounts, select Payment Type _____________ for the current visit account, then click the ""Add Payment"" button and select Payment Type __________________ for the OSB.",g217985,2,"Prepayment, Balance",1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65237,0,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g217986,0,"Search for the patient account, select Payment Type ""Prepayment"", enter the Payment Information for the initial deposit, click the ""Add Payment"" button, select Payment Type ""Balance"", enter the total remaining amount in the ""Amount to Pay"", click Scheduling Options hyperlink and select the proper radio button, then select First Payment Date from the calendar, enter current visit account number, Service Location "".OTHER, click ""Continue"", click ""Confirm"", then process the payment method.",1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65237,1,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g217987,1,"Search for the patient account, enter the Payment Information for the initial deposit, process the payment method. Search for the patient account again and enter the Payment Information for the monthly payments, process the payment method.",0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65237,2,When the insured patient agrees to payment option B payment plan and agrees to the auto-drafted monthly payments:,g217988,2,Auto-draft monthly payments will not be processed in Patientco.,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65238,0,Which of the following should be selected as the Collection Method when entering the credit/debit card information via encrypted keypad?,g217989,0,WEB ENTRY,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65238,1,Which of the following should be selected as the Collection Method when entering the credit/debit card information via encrypted keypad?,g217990,1,PATIENT MOBILE,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65238,2,Which of the following should be selected as the Collection Method when entering the credit/debit card information via encrypted keypad?,g217991,2,CLICK/SWIPE,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65239,0,"When canceling (voiding) a transaction, click the Cancel Payment button only. It is NOT necessary to enter a reason for the Cancel/Void.",g217992,0,TRUE,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65239,1,"When canceling (voiding) a transaction, click the Cancel Payment button only. It is NOT necessary to enter a reason for the Cancel/Void.",g217993,1,FALSE,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65240,0,It is the expectation of your Leadership to complete the ________ _________ process prior to leaving for the day.,g217994,0,Make Payment,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65240,1,It is the expectation of your Leadership to complete the ________ _________ process prior to leaving for the day.,g217995,1,End Shift,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65240,2,It is the expectation of your Leadership to complete the ________ _________ process prior to leaving for the day.,g217996,2,CLICK/SWIPE,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65468,0,Patient payment option when a patient is not comfortable providing credit card information over the phone.,g218764,0,Web Entry - Dynapad,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65468,1,Patient payment option when a patient is not comfortable providing credit card information over the phone.,g218765,1,Patient Mobile - Text to Pay,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65468,2,Patient payment option when a patient is not comfortable providing credit card information over the phone.,g218766,2,Patient must provide credit card information over the phone. There is no alternative option.,0,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65469,0,All payments are taken under Internet Cashier.,g218767,0,TRUE,1,RCT: PCO_PREREG TEST
20181,4846,ILT-0000-22462,g14149,g65469,1,All payments are taken under Internet Cashier.,g218768,1,FALSE,0,RCT: PCO_PREREG TEST
20152,9942,Questions-0000-76,g14122,g64959,0,Please list the location for this activity.,g217064,0,Atlanta,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64959,1,Please list the location for this activity.,g217065,1,Forsyth,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64959,2,Please list the location for this activity.,g217066,2,Cherokee,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64959,3,Please list the location for this activity.,g217067,3,Other,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64960,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify who is a candidate for a PICC.</ol>",g217068,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64960,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify who is a candidate for a PICC.</ol>",g217069,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64960,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify who is a candidate for a PICC.</ol>",g217070,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64960,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify who is a candidate for a PICC.</ol>",g217071,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64960,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify who is a candidate for a PICC.</ol>",g217072,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64961,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the advantages and disadvantages for PICC placement.</ol>",g217073,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64961,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the advantages and disadvantages for PICC placement.</ol>",g217074,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64961,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the advantages and disadvantages for PICC placement.</ol>",g217075,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64961,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the advantages and disadvantages for PICC placement.</ol>",g217076,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64961,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the advantages and disadvantages for PICC placement.</ol>",g217077,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64962,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe procedures for managing catheter mal-positioning.</ol>",g217078,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64962,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe procedures for managing catheter mal-positioning.</ol>",g217079,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64962,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe procedures for managing catheter mal-positioning.</ol>",g217080,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64962,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe procedures for managing catheter mal-positioning.</ol>",g217081,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64962,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe procedures for managing catheter mal-positioning.</ol>",g217082,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64963,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize potential complications associated with the use of PICCs.</ol>",g217083,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64963,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize potential complications associated with the use of PICCs.</ol>",g217084,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64963,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize potential complications associated with the use of PICCs.</ol>",g217085,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64963,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize potential complications associated with the use of PICCs.</ol>",g217086,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64963,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize potential complications associated with the use of PICCs.</ol>",g217087,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64964,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate appropriate documentation of ongoing PICC assessment.</ol>",g217088,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64964,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate appropriate documentation of ongoing PICC assessment.</ol>",g217089,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64964,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate appropriate documentation of ongoing PICC assessment.</ol>",g217090,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64964,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate appropriate documentation of ongoing PICC assessment.</ol>",g217091,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64964,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate appropriate documentation of ongoing PICC assessment.</ol>",g217092,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64965,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g217093,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64965,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g217094,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64965,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g217095,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64965,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g217096,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64965,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g217097,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64966,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g217098,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64966,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g217099,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64966,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g217100,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64966,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g217101,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64966,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g217102,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64967,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to PICC insertion, PICC care and PICC line maintenance.</OL>",g217103,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64967,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to PICC insertion, PICC care and PICC line maintenance.</OL>",g217104,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64967,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to PICC insertion, PICC care and PICC line maintenance.</OL>",g217105,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64967,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to PICC insertion, PICC care and PICC line maintenance.</OL>",g217106,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64967,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to PICC insertion, PICC care and PICC line maintenance.</OL>",g217107,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64968,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in clinical decision-making as it relates to troubleshooting PICC lines.</ol>,g217108,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64968,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in clinical decision-making as it relates to troubleshooting PICC lines.</ol>,g217109,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64968,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in clinical decision-making as it relates to troubleshooting PICC lines.</ol>,g217110,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64968,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in clinical decision-making as it relates to troubleshooting PICC lines.</ol>,g217111,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64968,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in clinical decision-making as it relates to troubleshooting PICC lines.</ol>,g217112,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64969,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g217113,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64969,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g217114,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64969,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g217115,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64969,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g217116,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64969,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g217117,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64970,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathryn Houlihan, BSN, RNC-NIC</ol>",g217118,0,Excellent,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64970,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathryn Houlihan, BSN, RNC-NIC</ol>",g217119,1,Very Good,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64970,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathryn Houlihan, BSN, RNC-NIC</ol>",g217120,2,Good,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64970,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathryn Houlihan, BSN, RNC-NIC</ol>",g217121,3,Fair,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64970,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathryn Houlihan, BSN, RNC-NIC</ol>",g217122,4,Poor,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64971,0,"Overall, this activity was:",g217123,0,Excellent,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64971,1,"Overall, this activity was:",g217124,1,Very Good,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64971,2,"Overall, this activity was:",g217125,2,Good,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64971,3,"Overall, this activity was:",g217126,3,Fair,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64971,4,"Overall, this activity was:",g217127,4,Poor,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64972,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g217128,0,Yes,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64972,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g217129,1,No,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64972,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g217130,2,N/A,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64975,0,How would you improve this class?,g217131,0,Reduce content covered in class,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64975,1,How would you improve this class?,g217132,1,Increase content covered in class,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64975,2,How would you improve this class?,g217133,2,Update content covered in class,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64975,3,How would you improve this class?,g217134,3,Improve the instructional methods,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64975,4,How would you improve this class?,g217135,4,Make course activities more stimulating,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64975,5,How would you improve this class?,g217136,5,Slow the pace of the class,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64975,6,How would you improve this class?,g217137,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64978,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g217138,0,Strongly Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64978,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g217139,1,Agree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64978,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g217140,2,No Opinion,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64978,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g217141,3,Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20152,9942,Questions-0000-76,g14122,g64978,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g217142,4,Strongly Disagree,0,NEONATAL PICC TRAINING WORKSHOP (EVALUATION SURVEY) 8.24.21
20151,9966,SCORM-0000-180,g14121,g64958,0,I have read and understood all of the material in the Fire Safety Orientation CBL.,g217062,0,TRUE,1,TEMP7
20151,9966,SCORM-0000-180,g14121,g64958,1,I have read and understood all of the material in the Fire Safety Orientation CBL.,g217063,1,FALSE,0,TEMP7
20140,8910,Elearning-0000-195,g14114,g64837,0,I acknowledge that I have read and understand the information provided in the SCN Totals CBL.,g216584,0,Yes,1,SCN TOTALS
20140,8910,Elearning-0000-195,g14114,g64837,1,I acknowledge that I have read and understand the information provided in the SCN Totals CBL.,g216585,1,No,0,SCN TOTALS
20138,9668,Elearning-0000-884,g14113,g64836,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Interpretation Services - Polices and Procedures Updated 2021"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g216582,0,TRUE,1,INTERPRETATION SERVICES - POLICIES AND PROCEDURES UPDATED 2021
20138,9668,Elearning-0000-884,g14113,g64836,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Interpretation Services - Polices and Procedures Updated 2021"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g216583,1,FALSE,0,INTERPRETATION SERVICES - POLICIES AND PROCEDURES UPDATED 2021
20134,9801,Questions-0000-07,g14110,g64813,0,Please list the location for this activity.,g216494,0,Atlanta,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64813,1,Please list the location for this activity.,g216495,1,Forsyth,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64813,2,Please list the location for this activity.,g216496,2,Cherokee,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64813,3,Please list the location for this activity.,g216497,3,Other,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64814,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the role of molecular biology in navigating the treatment of patients with early-stage breast cancer.</ol>",g216498,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64814,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the role of molecular biology in navigating the treatment of patients with early-stage breast cancer.</ol>",g216499,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64814,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the role of molecular biology in navigating the treatment of patients with early-stage breast cancer.</ol>",g216500,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64814,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the role of molecular biology in navigating the treatment of patients with early-stage breast cancer.</ol>",g216501,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64814,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the role of molecular biology in navigating the treatment of patients with early-stage breast cancer.</ol>",g216502,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64815,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify options for breast cancer based on receptor status.</ol>",g216503,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64815,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify options for breast cancer based on receptor status.</ol>",g216504,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64815,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify options for breast cancer based on receptor status.</ol>",g216505,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64815,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify options for breast cancer based on receptor status.</ol>",g216506,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64815,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify options for breast cancer based on receptor status.</ol>",g216507,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64816,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of the implications for BRCA mutational status on treatment planning.</ol>",g216508,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64816,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of the implications for BRCA mutational status on treatment planning.</ol>",g216509,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64816,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of the implications for BRCA mutational status on treatment planning.</ol>",g216510,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64816,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of the implications for BRCA mutational status on treatment planning.</ol>",g216511,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64816,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of the implications for BRCA mutational status on treatment planning.</ol>",g216512,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64817,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine the role of immunotherapy in treatment of patients with metastatic triple negative breast cancer.</ol>",g216513,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64817,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine the role of immunotherapy in treatment of patients with metastatic triple negative breast cancer.</ol>",g216514,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64817,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine the role of immunotherapy in treatment of patients with metastatic triple negative breast cancer.</ol>",g216515,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64817,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine the role of immunotherapy in treatment of patients with metastatic triple negative breast cancer.</ol>",g216516,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64817,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine the role of immunotherapy in treatment of patients with metastatic triple negative breast cancer.</ol>",g216517,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64818,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g216518,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64818,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g216519,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64818,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g216520,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64818,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g216521,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64818,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g216522,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64819,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to treatment planning for patients with early stage metastatic breast cancer.</OL>,g216523,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64819,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to treatment planning for patients with early stage metastatic breast cancer.</OL>,g216524,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64819,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to treatment planning for patients with early stage metastatic breast cancer.</OL>,g216525,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64819,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to treatment planning for patients with early stage metastatic breast cancer.</OL>,g216526,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64819,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to treatment planning for patients with early stage metastatic breast cancer.</OL>,g216527,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64820,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g216528,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64820,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g216529,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64820,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g216530,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64820,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g216531,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64820,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g216532,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64821,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g216533,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64821,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g216534,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64821,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g216535,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64821,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g216536,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64821,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g216537,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64822,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g216538,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64822,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g216539,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64822,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g216540,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64822,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g216541,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64822,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g216542,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64823,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Houda Aboujamous, PharmD, BCOP </ol>",g216543,0,Excellent,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64823,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Houda Aboujamous, PharmD, BCOP </ol>",g216544,1,Very Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64823,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Houda Aboujamous, PharmD, BCOP </ol>",g216545,2,Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64823,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Houda Aboujamous, PharmD, BCOP </ol>",g216546,3,Fair,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64823,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Houda Aboujamous, PharmD, BCOP </ol>",g216547,4,Poor,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64824,0,"Overall, this activity was:",g216548,0,Excellent,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64824,1,"Overall, this activity was:",g216549,1,Very Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64824,2,"Overall, this activity was:",g216550,2,Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64824,3,"Overall, this activity was:",g216551,3,Fair,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64824,4,"Overall, this activity was:",g216552,4,Poor,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64825,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g216553,0,Yes,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64825,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g216554,1,No,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64825,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g216555,2,N/A,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64828,0,How would you improve this class?,g216556,0,Reduce content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64828,1,How would you improve this class?,g216557,1,Increase content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64828,2,How would you improve this class?,g216558,2,Update content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64828,3,How would you improve this class?,g216559,3,Improve the instructional methods,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64828,4,How would you improve this class?,g216560,4,Make course activities more stimulating,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64828,5,How would you improve this class?,g216561,5,Slow the pace of the class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64828,6,How would you improve this class?,g216562,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64831,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents. </ol>",g216563,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64831,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents. </ol>",g216564,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64831,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents. </ol>",g216565,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64831,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents. </ol>",g216566,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64831,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents. </ol>",g216567,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64832,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g216568,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64832,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g216569,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64832,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g216570,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64832,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g216571,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64832,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g216572,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64834,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g216575,0,Excellent,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64834,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g216576,1,Very Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64834,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g216577,2,Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64834,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g216578,3,Fair,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20134,9801,Questions-0000-07,g14110,g64834,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g216579,4,Poor,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: BREAST CANCER (EVALUATION SURVEY) 8.24.21
20133,8913,Elearning-0000-198,g14109,g64787,0,ABHRs have greater bactericidal and residual properties than that of soap and water handwashing,g216420,0,TRUE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64787,1,ABHRs have greater bactericidal and residual properties than that of soap and water handwashing,g216421,1,FALSE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64788,0,Hand hygiene is effective against bacteria present on natural and artificial nails if soap and water or hand rubs are used as recommended by manufacturers.,g216422,0,TRUE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64788,1,Hand hygiene is effective against bacteria present on natural and artificial nails if soap and water or hand rubs are used as recommended by manufacturers.,g216423,1,FALSE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64789,0,Thumbs and fingertips are areas frequently missed during both handwashing and when using an ABHR.,g216424,0,TRUE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64789,1,Thumbs and fingertips are areas frequently missed during both handwashing and when using an ABHR.,g216425,1,FALSE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64790,0,"At a minimum, HH should be performed and gloves put on immediately before inserting, accessing, or manipulating any indwelling device.",g216426,0,TRUE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64790,1,"At a minimum, HH should be performed and gloves put on immediately before inserting, accessing, or manipulating any indwelling device.",g216427,1,FALSE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64791,0,"Part of the ""Commitment to Care"" is performing handwashing for 30 full seconds when initially entering the SCN.",g216428,0,TRUE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64791,1,"Part of the ""Commitment to Care"" is performing handwashing for 30 full seconds when initially entering the SCN.",g216429,1,FALSE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64792,0,LLD twice each shift is a component of the SCN's Cleaner Hands initiative.,g216430,0,TRUE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64792,1,LLD twice each shift is a component of the SCN's Cleaner Hands initiative.,g216431,1,FALSE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64793,0,"Illustrated in this CBL are the ""8 Moments for Hand Hygiene.""",g216432,0,TRUE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64793,1,"Illustrated in this CBL are the ""8 Moments for Hand Hygiene.""",g216433,1,FALSE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64794,0,It is ok for an MD to place a PAL without gloves as it is necessary to be able to palpate the artery effectively.,g216434,0,TRUE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64794,1,It is ok for an MD to place a PAL without gloves as it is necessary to be able to palpate the artery effectively.,g216435,1,FALSE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64795,0,ABHRs are effective sporacidals if 1-2 full pumps are used and hands are rubbed until completely dry.,g216436,0,TRUE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64795,1,ABHRs are effective sporacidals if 1-2 full pumps are used and hands are rubbed until completely dry.,g216437,1,FALSE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64796,0,Shakira is changing an infant's pulse oximeter probe when the resus phone rings.  She can waive performing hand hygiene to answer the phone as it may be an emergency.,g216438,0,TRUE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64796,1,Shakira is changing an infant's pulse oximeter probe when the resus phone rings.  She can waive performing hand hygiene to answer the phone as it may be an emergency.,g216439,1,FALSE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64797,0,"It is crucial to perform hand hygiene before and after touching any patient, the patient's equipment, or items within the patient's bedspace.",g216440,0,TRUE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64797,1,"It is crucial to perform hand hygiene before and after touching any patient, the patient's equipment, or items within the patient's bedspace.",g216441,1,FALSE,0,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64798,0,I have reviewed the contents of this CBL and am responsible for adhering to the infection prevention and hand hygiene guidelines herein.,g216442,0,TRUE,1,SCN HAND HYGIENE 2021
20133,8913,Elearning-0000-198,g14109,g64798,1,I have reviewed the contents of this CBL and am responsible for adhering to the infection prevention and hand hygiene guidelines herein.,g216443,1,FALSE,0,SCN HAND HYGIENE 2021
20125,9599,Elearning-0000-821,g14101,g64665,0,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215948,0,TRUE,1,PATIENT TRANSFER PROCESS
20125,9599,Elearning-0000-821,g14101,g64665,1,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215949,1,FALSE,0,PATIENT TRANSFER PROCESS
20124,9595,Elearning-0000-818,g14100,g64664,0,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215946,0,TRUE,1,RESEARCH REGULATORY SIGN OUT
20124,9595,Elearning-0000-818,g14100,g64664,1,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215947,1,FALSE,0,RESEARCH REGULATORY SIGN OUT
20123,9596,Elearning-0000-819,g14099,g64663,0,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215944,0,TRUE,1,REQUIRED NOTIFICATION OF RESEARCH PARTICIPANTS FOR PROTOCOL UPDATES
20123,9596,Elearning-0000-819,g14099,g64663,1,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215945,1,FALSE,0,REQUIRED NOTIFICATION OF RESEARCH PARTICIPANTS FOR PROTOCOL UPDATES
20122,9598,Elearning-0000-820,g14098,g64662,0,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215942,0,TRUE,1,INVESTIGATIONAL DRUG GUIDELINES
20122,9598,Elearning-0000-820,g14098,g64662,1,I acknowledge that I have read this policy/training document and that I understand the content in its entirety.,g215943,1,FALSE,0,INVESTIGATIONAL DRUG GUIDELINES
20114,8930,Elearning-0000-213,g14092,g64649,0,"When obtaining labs, one must connect a vented syringe to the stopcock and manually aspirate the amount of blood necessary.",g215910,0,TRUE,0,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64649,1,"When obtaining labs, one must connect a vented syringe to the stopcock and manually aspirate the amount of blood necessary.",g215911,1,FALSE,1,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64650,0,1 and 3mL vented syringes are heparinized to minimize clotting during blood sampling.,g215912,0,TRUE,0,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64650,1,1 and 3mL vented syringes are heparinized to minimize clotting during blood sampling.,g215913,1,FALSE,1,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64651,0,"When obtaining labs, before connecting the vented syringe to the stopcock, one must first aspirate into the vented syringe the amount of air equal to the amount of blood required for sampling.",g215914,0,TRUE,1,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64651,1,"When obtaining labs, before connecting the vented syringe to the stopcock, one must first aspirate into the vented syringe the amount of air equal to the amount of blood required for sampling.",g215915,1,FALSE,0,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64652,0,The radial artery is most often used as it is readily accessible and not immediately adjacent to other nerves and veins.,g215916,0,TRUE,1,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64652,1,The radial artery is most often used as it is readily accessible and not immediately adjacent to other nerves and veins.,g215917,1,FALSE,0,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64653,0,Rapid flushing after PAL blood sampling ensures that residual blood does not adhere to the side of the angio-cath or T-connector thereby minimizing clot formation.,g215918,0,TRUE,0,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64653,1,Rapid flushing after PAL blood sampling ensures that residual blood does not adhere to the side of the angio-cath or T-connector thereby minimizing clot formation.,g215919,1,FALSE,1,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64654,0,Blood collected in a waste syringe via a PAL should be infused slowly back into the patient so as to avoid unnecessary blood expenditures/losses.,g215920,0,TRUE,0,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64654,1,Blood collected in a waste syringe via a PAL should be infused slowly back into the patient so as to avoid unnecessary blood expenditures/losses.,g215921,1,FALSE,1,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64655,0,Most PAL complications can be minimized by utilizing standard precautions and aseptic technique during line insertion and assess in conjunction with continuous monitoring and observation of the PAL site post-insertion.,g215922,0,TRUE,1,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20114,8930,Elearning-0000-213,g14092,g64655,1,Most PAL complications can be minimized by utilizing standard precautions and aseptic technique during line insertion and assess in conjunction with continuous monitoring and observation of the PAL site post-insertion.,g215923,1,FALSE,0,FY2021 RESPIRATORY SCN PERIPHERAL ARTERIAL SAMPLING
20115,9635,Elearning-0000-854,g14091,g64648,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Process for Contaminated Autologous Tissue or Bone"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215908,0,TRUE,1,PROCESS FOR CONTAMINATED AUTOLOGOUS TISSUE OR BONE
20115,9635,Elearning-0000-854,g14091,g64648,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Process for Contaminated Autologous Tissue or Bone"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215909,1,FALSE,0,PROCESS FOR CONTAMINATED AUTOLOGOUS TISSUE OR BONE
20112,235,SCORM-0000-41,g14089,g64659,0,"When administering a controlled substance continuous infusion, a 2nd RN verification is required:",g215930,0,"a.	On initiation",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64659,1,"When administering a controlled substance continuous infusion, a 2nd RN verification is required:",g215931,1,"b.	When ending or starting a new cassette/bag",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64659,2,"When administering a controlled substance continuous infusion, a 2nd RN verification is required:",g215932,2,"c.	At shift change or caregiver handoff",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64659,3,"When administering a controlled substance continuous infusion, a 2nd RN verification is required:",g215933,3,"d.	All of the above",1,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64660,0,Which of the following is NOT part of the 2nd RN verification?,g215934,0,"a.	Correct medication",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64660,1,Which of the following is NOT part of the 2nd RN verification?,g215935,1,"b.	Correct concentration & infusion rate",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64660,2,Which of the following is NOT part of the 2nd RN verification?,g215936,2,"c.	Patient's pain/sedation level",1,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64660,3,Which of the following is NOT part of the 2nd RN verification?,g215937,3,"d.	Line reconciliation",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64661,0,"When ending a controlled substance continuous infusion, what should the nurse do with the medication?",g215938,0,"a.	Leave it hanging on the IV pole in case the infusion needs to be re-started later",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64661,1,"When ending a controlled substance continuous infusion, what should the nurse do with the medication?",g215939,1,"b.	Print the narcotics infusion report, attach it to the medication, and return to automated dispensing cabinet or to pharmacy",1,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64661,2,"When ending a controlled substance continuous infusion, what should the nurse do with the medication?",g215940,2,"c.	Waste the medication in the sink and have a 2nd RN witness the waste",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20112,235,SCORM-0000-41,g14089,g64661,3,"When ending a controlled substance continuous infusion, what should the nurse do with the medication?",g215941,3,"d.	Tube the medication to pharmacy along with the narcotics infusion report",0,FY2021 CONTINUOUS CONTROLLED SUBSTANCE INFUSION UPDATE: 2ND RN VERIFICATION REQUIREMENTS WITH AUDIO CONTENT
20111,9802,Questions-0000-08,g14088,g64629,0,Please list the location for this activity.,g215837,0,Atlanta,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64629,1,Please list the location for this activity.,g215838,1,Forsyth,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64629,2,Please list the location for this activity.,g215839,2,Cherokee,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64629,3,Please list the location for this activity.,g215840,3,Other,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64630,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of precision medicine and personalized cancer therapy.</ol>",g215841,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64630,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of precision medicine and personalized cancer therapy.</ol>",g215842,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64630,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of precision medicine and personalized cancer therapy.</ol>",g215843,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64630,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of precision medicine and personalized cancer therapy.</ol>",g215844,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64630,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize understanding of precision medicine and personalized cancer therapy.</ol>",g215845,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64631,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify clinical implications for pharmacogenomics and precision medicine in oncology.</ol>",g215846,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64631,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify clinical implications for pharmacogenomics and precision medicine in oncology.</ol>",g215847,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64631,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify clinical implications for pharmacogenomics and precision medicine in oncology.</ol>",g215848,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64631,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify clinical implications for pharmacogenomics and precision medicine in oncology.</ol>",g215849,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64631,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify clinical implications for pharmacogenomics and precision medicine in oncology.</ol>",g215850,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64632,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to appreciate current evidence for and the future direction of precision medicine in oncology.</ol>",g215851,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64632,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to appreciate current evidence for and the future direction of precision medicine in oncology.</ol>",g215852,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64632,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to appreciate current evidence for and the future direction of precision medicine in oncology.</ol>",g215853,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64632,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to appreciate current evidence for and the future direction of precision medicine in oncology.</ol>",g215854,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64632,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to appreciate current evidence for and the future direction of precision medicine in oncology.</ol>",g215855,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64633,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the role of pharmacy in the field of precision medicine.</ol>",g215856,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64633,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the role of pharmacy in the field of precision medicine.</ol>",g215857,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64633,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the role of pharmacy in the field of precision medicine.</ol>",g215858,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64633,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the role of pharmacy in the field of precision medicine.</ol>",g215859,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64633,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the role of pharmacy in the field of precision medicine.</ol>",g215860,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64634,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215861,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64634,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215862,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64634,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215863,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64634,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215864,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64634,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215865,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64635,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to scientific foundation of precision medicine and personalized cancer therapy.</OL>,g215866,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64635,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to scientific foundation of precision medicine and personalized cancer therapy.</OL>,g215867,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64635,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to scientific foundation of precision medicine and personalized cancer therapy.</OL>,g215868,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64635,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to scientific foundation of precision medicine and personalized cancer therapy.</OL>,g215869,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to scientific foundation of precision medicine and personalized cancer therapy.</OL>,g215870,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64636,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215871,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64636,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215872,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64636,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215873,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64636,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215874,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64636,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215875,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64637,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215876,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64637,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215877,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64637,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215878,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64637,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215879,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64637,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215880,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64638,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215881,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64638,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215882,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64638,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215883,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64638,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215884,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64638,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215885,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64639,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of B. Adam Hill, PharmD</ol>",g215886,0,Excellent,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64639,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of B. Adam Hill, PharmD</ol>",g215887,1,Very Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64639,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of B. Adam Hill, PharmD</ol>",g215888,2,Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64639,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of B. Adam Hill, PharmD</ol>",g215889,3,Fair,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64639,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of B. Adam Hill, PharmD</ol>",g215890,4,Poor,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64640,0,"Overall, this activity was:",g215891,0,Excellent,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64640,1,"Overall, this activity was:",g215892,1,Very Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64640,2,"Overall, this activity was:",g215893,2,Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64640,3,"Overall, this activity was:",g215894,3,Fair,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64640,4,"Overall, this activity was:",g215895,4,Poor,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64641,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215896,0,Yes,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64641,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215897,1,No,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64641,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215898,2,N/A,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64644,0,How would you improve this class?,g215899,0,Reduce content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64644,1,How would you improve this class?,g215900,1,Increase content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64644,2,How would you improve this class?,g215901,2,Update content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64644,3,How would you improve this class?,g215902,3,Improve the instructional methods,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64644,4,How would you improve this class?,g215903,4,Make course activities more stimulating,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64644,5,How would you improve this class?,g215904,5,Slow the pace of the class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20111,9802,Questions-0000-08,g14088,g64644,6,How would you improve this class?,g215905,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY: PRECISION MEDICINE (EVALUATION SURVEY) 8.19.21
20107,9954,Questions-0000-88,g14085,g64607,0,Please list the location for this activity.,g215751,0,Atlanta,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64607,1,Please list the location for this activity.,g215752,1,Forsyth,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64607,2,Please list the location for this activity.,g215753,2,Cherokee,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64607,3,Please list the location for this activity.,g215754,3,Other,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64608,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g215755,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64608,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g215756,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64608,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g215757,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64608,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g215758,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64608,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g215759,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64609,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g215760,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64609,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g215761,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64609,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g215762,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64609,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g215763,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64609,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g215764,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64610,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g215765,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64610,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g215766,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64610,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g215767,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64610,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g215768,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64610,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g215769,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64611,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g215770,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64611,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g215771,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64611,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g215772,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64611,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g215773,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64611,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g215774,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64612,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g215775,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64612,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g215776,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64612,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g215777,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64612,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g215778,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64612,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g215779,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64613,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g215780,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64613,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g215781,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64613,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g215782,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64613,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g215783,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64613,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g215784,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64614,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g215785,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64614,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g215786,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64614,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g215787,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64614,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g215788,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64614,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g215789,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64615,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215790,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64615,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215791,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64615,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215792,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64615,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215793,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64615,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215794,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64616,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g215795,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64616,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g215796,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64616,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g215797,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64616,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g215798,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64616,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g215799,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64617,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215800,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64617,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215801,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64617,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215802,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64617,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215803,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64617,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215804,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64618,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215805,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64618,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215806,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64618,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215807,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64618,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215808,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64618,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215809,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64619,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215810,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64619,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215811,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64619,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215812,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64619,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215813,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64619,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215814,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64620,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g215815,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64620,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g215816,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64620,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g215817,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64620,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g215818,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64620,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g215819,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64621,0,"Overall, this activity was:",g215820,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64621,1,"Overall, this activity was:",g215821,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64621,2,"Overall, this activity was:",g215822,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64621,3,"Overall, this activity was:",g215823,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64621,4,"Overall, this activity was:",g215824,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64622,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215825,0,Yes,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64622,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215826,1,No,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64622,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215827,2,N/A,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64625,0,How would you improve this class?,g215828,0,Reduce content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64625,1,How would you improve this class?,g215829,1,Increase content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64625,2,How would you improve this class?,g215830,2,Update content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64625,3,How would you improve this class?,g215831,3,Improve the instructional methods,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64625,4,How would you improve this class?,g215832,4,Make course activities more stimulating,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64625,5,How would you improve this class?,g215833,5,Slow the pace of the class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20107,9954,Questions-0000-88,g14085,g64625,6,How would you improve this class?,g215834,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-18-21
20106,9628,Elearning-0000-848,g14084,g64597,0,Timely recognition and treatment are key to preventing sepsis mortality.,g215713,0,a. True,1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64597,1,Timely recognition and treatment are key to preventing sepsis mortality.,g215714,1,b. False,0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64598,0,All of the following are sign and symptoms of sepsis <u>except</u>:,g215715,0,"a.	Extreme pain or discomfort",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64598,1,All of the following are sign and symptoms of sepsis <u>except</u>:,g215716,1,"b.	Mental changes",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64598,2,All of the following are sign and symptoms of sepsis <u>except</u>:,g215717,2,"c.	Tachypnea",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64598,3,All of the following are sign and symptoms of sepsis <u>except</u>:,g215718,3,"d.	Bradycardia",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64598,4,All of the following are sign and symptoms of sepsis <u>except</u>:,g215719,4,"e.	Shivering, fever, or very cold",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64599,0,"Systemic Inflammatory Response Syndrome (SIRS) criteria include all of the following, <u>except</u>:",g215720,0,"a.	Temperature >101.0┬░ F/38.3┬░ C, or <96.8┬░ F/36┬░ C",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64599,1,"Systemic Inflammatory Response Syndrome (SIRS) criteria include all of the following, <u>except</u>:",g215721,1,"b.	Lactate> 2",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64599,2,"Systemic Inflammatory Response Syndrome (SIRS) criteria include all of the following, <u>except</u>:",g215722,2,"c.	Tachycardia (HR >90)",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64599,3,"Systemic Inflammatory Response Syndrome (SIRS) criteria include all of the following, <u>except</u>:",g215723,3,"d.	Tachypnea (RR >20)",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64599,4,"Systemic Inflammatory Response Syndrome (SIRS) criteria include all of the following, <u>except</u>:",g215724,4,"e.	WBC >12,000 or <4,000",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64600,0,Severe sepsis is defined as:,g215725,0,"a.	Confirmed infection + 1 SIRS criteria + 2 organ dysfunction",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64600,1,Severe sepsis is defined as:,g215726,1,"b.	Confirmed infection + 2 SIRS criteria + 1 organ dysfunction",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64600,2,Severe sepsis is defined as:,g215727,2,"c.	Suspected infection + 2 SIRS criteria + 1 organ dysfunction",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64600,3,Severe sepsis is defined as:,g215728,3,"d.	Suspected infection + 1 SIRS criteria + 2 organ dysfunction",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64601,0,"True or False: The sepsis bundle time zero starts at the time the patient meets clinical criteria or when a provider documents ""severe sepsis"" in the patient's chart.",g215729,0,a. True,1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64601,1,"True or False: The sepsis bundle time zero starts at the time the patient meets clinical criteria or when a provider documents ""severe sepsis"" in the patient's chart.",g215730,1,b. False,0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64602,0,"A 55 y.o. female patient admitted with UTI presents with the following: <br> Admitting Vitals: HR 94, RR 20, T: 38, BP 104/65, P02: 98% RA<br> WBC -15.8<br> Creatinine 2.5<br> Based on these results the patient:<br>",g215731,0,"a.	Meets only SIRS criteria and should be monitored further",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64602,1,"A 55 y.o. female patient admitted with UTI presents with the following: <br> Admitting Vitals: HR 94, RR 20, T: 38, BP 104/65, P02: 98% RA<br> WBC -15.8<br> Creatinine 2.5<br> Based on these results the patient:<br>",g215732,1,"b.	Is stable and no further needs are necessary",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64602,2,"A 55 y.o. female patient admitted with UTI presents with the following: <br> Admitting Vitals: HR 94, RR 20, T: 38, BP 104/65, P02: 98% RA<br> WBC -15.8<br> Creatinine 2.5<br> Based on these results the patient:<br>",g215733,2,"c.	Should receive IV abx for UTI and continue to monitor",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64602,3,"A 55 y.o. female patient admitted with UTI presents with the following: <br> Admitting Vitals: HR 94, RR 20, T: 38, BP 104/65, P02: 98% RA<br> WBC -15.8<br> Creatinine 2.5<br> Based on these results the patient:<br>",g215734,3,"d.	Meets severe sepsis criteria and the provider should be notified for further orders.",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64603,0,"A patient presented to the ED with pneumonia and AMS at 0900. In the ED a UA, urine culture, blood cultures x 2 were done and the patient was started on oral antibiotics. The patient is found to meet severe sepsis criteria an hour after admission at 1100.  Which of the following best describes the bundle elements the nurse should expect to implement to meet the sepsis bundle requirement?",g215735,0,"a.	Repeat the blood cultures x 2, administer broad spectrum IV antibiotic within 3 hours, and draw a lactate.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64603,1,"A patient presented to the ED with pneumonia and AMS at 0900. In the ED a UA, urine culture, blood cultures x 2 were done and the patient was started on oral antibiotics. The patient is found to meet severe sepsis criteria an hour after admission at 1100.  Which of the following best describes the bundle elements the nurse should expect to implement to meet the sepsis bundle requirement?",g215736,1,"b.	Draw a lactate only since the patient has had blood cultures within the last 6 hours and is already on antibiotics.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64603,2,"A patient presented to the ED with pneumonia and AMS at 0900. In the ED a UA, urine culture, blood cultures x 2 were done and the patient was started on oral antibiotics. The patient is found to meet severe sepsis criteria an hour after admission at 1100.  Which of the following best describes the bundle elements the nurse should expect to implement to meet the sepsis bundle requirement?",g215737,2,"c.	Notify the provider and expect orders for an IV broad spectrum antibiotic and a lactate to meet the remaining bundle requirement.",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64603,3,"A patient presented to the ED with pneumonia and AMS at 0900. In the ED a UA, urine culture, blood cultures x 2 were done and the patient was started on oral antibiotics. The patient is found to meet severe sepsis criteria an hour after admission at 1100.  Which of the following best describes the bundle elements the nurse should expect to implement to meet the sepsis bundle requirement?",g215738,3,"d.	Notify the provider and expect orders for repeat blood cultures, IV broad spectrum antibiotic, and a lactate. And the nurse should wait to administer the antibiotic until the blood cultures are done.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64604,0,A patient met severe sepsis criteria and the initial sepsis bundle was completed. Upon review of the lactate the RN sees the initial lactate result was 3. The RN should:,g215739,0,"a.	Continue to monitor the patient.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64604,1,A patient met severe sepsis criteria and the initial sepsis bundle was completed. Upon review of the lactate the RN sees the initial lactate result was 3. The RN should:,g215740,1,"b.	Obtain an order for a repeat lactate since the value is greater than 2.",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64604,2,A patient met severe sepsis criteria and the initial sepsis bundle was completed. Upon review of the lactate the RN sees the initial lactate result was 3. The RN should:,g215741,2,"c.	Obtain an order for a 30ml/kg crystalloid fluid bolus.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64605,0,A 30ml/kg crystalloid fluid bolus should be ordered for which of the following?,g215742,0,"a.	Any 1 occurrence of SBP<90 , MAP <65, or SBP decrease >40",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64605,1,A 30ml/kg crystalloid fluid bolus should be ordered for which of the following?,g215743,1,"b.	Any two occurrences of SBP <90,  MAP <65, or SBP decrease > 40  in a 3 hour period.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64605,2,A 30ml/kg crystalloid fluid bolus should be ordered for which of the following?,g215744,2,"c.	Initial lactate =4 mmol/L",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64605,3,A 30ml/kg crystalloid fluid bolus should be ordered for which of the following?,g215745,3,"d.	A & B",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64605,4,A 30ml/kg crystalloid fluid bolus should be ordered for which of the following?,g215746,4,"e.	A & C",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64605,5,A 30ml/kg crystalloid fluid bolus should be ordered for which of the following?,g215747,5,"f.	B & C",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64606,0,"A patient who met severe sepsis criteria and received a 30ml/kg fluid bolus. While completing the required 2 blood pressure reassessment within the hour after, the RN notices that the patient's SPB remains < 90. What is the best next step?",g215748,0,"a.	Notify the provider for additional fluid bolus.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64606,1,"A patient who met severe sepsis criteria and received a 30ml/kg fluid bolus. While completing the required 2 blood pressure reassessment within the hour after, the RN notices that the patient's SPB remains < 90. What is the best next step?",g215749,1,"b.	Notify rapid response and the provider as the patient now meets septic shock criteria.",1,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20106,9628,Elearning-0000-848,g14084,g64606,2,"A patient who met severe sepsis criteria and received a 30ml/kg fluid bolus. While completing the required 2 blood pressure reassessment within the hour after, the RN notices that the patient's SPB remains < 90. What is the best next step?",g215750,2,"c.	Continue to monitor the blood pressures.",0,FY2021 SEPSIS RECOGNITION AND MANAGEMENT FOR MED-SURG NURSING
20098,9803,Questions-0000-09,g14083,g64580,0,Please list the location for this activity.,g215648,0,Atlanta,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64580,1,Please list the location for this activity.,g215649,1,Cherokee,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64580,2,Please list the location for this activity.,g215650,2,Forsyth,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64580,3,Please list the location for this activity.,g215651,3,Other,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64581,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components, characteristics, and function of blood and red blood cells.</ol>",g215652,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64581,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components, characteristics, and function of blood and red blood cells.</ol>",g215653,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64581,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components, characteristics, and function of blood and red blood cells.</ol>",g215654,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64581,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components, characteristics, and function of blood and red blood cells.</ol>",g215655,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64581,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components, characteristics, and function of blood and red blood cells.</ol>",g215656,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64582,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the pathophysiology of basic anemias.</ol>",g215657,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64582,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the pathophysiology of basic anemias.</ol>",g215658,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64582,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the pathophysiology of basic anemias.</ol>",g215659,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64582,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the pathophysiology of basic anemias.</ol>",g215660,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64582,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the pathophysiology of basic anemias.</ol>",g215661,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64583,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the pharmacist's role in the treatment of anemias.</ol>",g215662,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64583,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the pharmacist's role in the treatment of anemias.</ol>",g215663,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64583,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the pharmacist's role in the treatment of anemias.</ol>",g215664,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64583,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the pharmacist's role in the treatment of anemias.</ol>",g215665,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64583,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the pharmacist's role in the treatment of anemias.</ol>",g215666,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64584,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215667,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64584,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215668,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64584,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215669,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64584,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215670,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64584,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215671,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64585,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g215672,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64585,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g215673,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64585,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g215674,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64585,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g215675,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64585,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g215676,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64586,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215677,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64586,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215678,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64586,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215679,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64586,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215680,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64586,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g215681,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64587,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g215682,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64587,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g215683,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64587,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g215684,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64587,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g215685,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64587,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g215686,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64588,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g215687,0,Strongly Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64588,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g215688,1,Agree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64588,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g215689,2,No Opinion,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64588,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g215690,3,Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64588,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g215691,4,Strongly Disagree,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64589,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kellye Aschmeyer, PharmD, BCOP </ol>",g215692,4,Excellent,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64589,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kellye Aschmeyer, PharmD, BCOP </ol>",g215693,0,Very Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64589,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kellye Aschmeyer, PharmD, BCOP </ol>",g215694,1,Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64589,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kellye Aschmeyer, PharmD, BCOP </ol>",g215695,2,Fair,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64589,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kellye Aschmeyer, PharmD, BCOP </ol>",g215696,3,Poor,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64589,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kellye Aschmeyer, PharmD, BCOP </ol>",g215697,5,N/A,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64590,0,"Overall, this activity was:",g215698,0,Excellent,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64590,1,"Overall, this activity was:",g215699,1,Very Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64590,2,"Overall, this activity was:",g215700,2,Good,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64590,3,"Overall, this activity was:",g215701,3,Fair,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64590,4,"Overall, this activity was:",g215702,4,Poor,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64591,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215703,0,Yes,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64591,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215704,1,No,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64591,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215705,2,N/A,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64594,0,How would you improve this class (check all that apply)?,g215706,0,Reduce content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64594,1,How would you improve this class (check all that apply)?,g215707,1,Increase content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64594,2,How would you improve this class (check all that apply)?,g215708,2,Update content covered in class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64594,3,How would you improve this class (check all that apply)?,g215709,3,Improve the instructional methods,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64594,4,How would you improve this class (check all that apply)?,g215710,4,Make course activities more stimulating,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64594,5,How would you improve this class (check all that apply)?,g215711,5,Slow the pace of the class,0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20098,9803,Questions-0000-09,g14083,g64594,6,How would you improve this class (check all that apply)?,g215712,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,2021 PHARMACY DISEASE-SPECIFIC EDUCATION FOR ONCOLOGY_ANEMIA (EVALUATION SURVEY)  8.17.21
20105,9314,Elearning-0000-562,g14082,g64570,0,What is the best way for the nurse to verify they have the correct patient encounter open to document the operative procedure?,g215613,0,When you open the patient chart and select the Perioperative Document you are in the correct encounter,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64570,1,What is the best way for the nurse to verify they have the correct patient encounter open to document the operative procedure?,g215614,1,Look at the MRN# match it to the patient stickers,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64570,2,What is the best way for the nurse to verify they have the correct patient encounter open to document the operative procedure?,g215615,2,At the retrieval screen you verify the date of birth and the OR the case is in,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64570,3,What is the best way for the nurse to verify they have the correct patient encounter open to document the operative procedure?,g215616,3,None of the above,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64571,0,When documenting the Amniofix where is the Tissue ID number documented?,g215617,0,Lot/batch number,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64571,1,When documenting the Amniofix where is the Tissue ID number documented?,g215618,1,RFID,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64571,2,When documenting the Amniofix where is the Tissue ID number documented?,g215619,2,Catalog number,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64571,3,When documenting the Amniofix where is the Tissue ID number documented?,g215620,3,Serial number,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64572,0,"An unscheduled cesarean section turns into an emergency hysterectomy on the night shift. A new nurse off orientation for a month is circulating the case, and wants to document the calling of the GYN/Oncologist and Urologist. Where would the nurse be able to document additional pertinent information?",g215621,0,Nursing note,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64572,1,"An unscheduled cesarean section turns into an emergency hysterectomy on the night shift. A new nurse off orientation for a month is circulating the case, and wants to document the calling of the GYN/Oncologist and Urologist. Where would the nurse be able to document additional pertinent information?",g215622,1,Nowhere the providers will document all information that is not the RNs responsibility,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64572,2,"An unscheduled cesarean section turns into an emergency hysterectomy on the night shift. A new nurse off orientation for a month is circulating the case, and wants to document the calling of the GYN/Oncologist and Urologist. Where would the nurse be able to document additional pertinent information?",g215623,2,Text box at the bottom of the Perioperative document,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64572,3,"An unscheduled cesarean section turns into an emergency hysterectomy on the night shift. A new nurse off orientation for a month is circulating the case, and wants to document the calling of the GYN/Oncologist and Urologist. Where would the nurse be able to document additional pertinent information?",g215624,3,A & C,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64572,4,"An unscheduled cesarean section turns into an emergency hysterectomy on the night shift. A new nurse off orientation for a month is circulating the case, and wants to document the calling of the GYN/Oncologist and Urologist. Where would the nurse be able to document additional pertinent information?",g215625,4,None of the above,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64573,0,You need to add an additional team member to the case. Is it possible to add the new person without having to leave the line segment you are documenting in?,g215626,0,TRUE,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64573,1,You need to add an additional team member to the case. Is it possible to add the new person without having to leave the line segment you are documenting in?,g215627,1,FALSE,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64574,0,Where do you document the fundal assessment performed at the end of the case?,g215628,0,Final skin assessment,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64574,1,Where do you document the fundal assessment performed at the end of the case?,g215629,1,Patient care devices,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64574,2,Where do you document the fundal assessment performed at the end of the case?,g215630,2,Maternal/Fetal Assessment,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64574,3,Where do you document the fundal assessment performed at the end of the case?,g215631,3,None of the above,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64575,0,"Once a case is finalized, it cannot be re-opened and altered.",g215632,0,TRUE,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64575,1,"Once a case is finalized, it cannot be re-opened and altered.",g215633,1,FALSE,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64576,0,You are circulating the 1400 scheduled C/S with bilateral tubal ligation. The provider will use filshie clips to tie the patient's tubes. Where would you document filshie clips?,g215634,0,The implant log section,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64576,1,You are circulating the 1400 scheduled C/S with bilateral tubal ligation. The provider will use filshie clips to tie the patient's tubes. Where would you document filshie clips?,g215635,1,The tissue log section,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64576,2,You are circulating the 1400 scheduled C/S with bilateral tubal ligation. The provider will use filshie clips to tie the patient's tubes. Where would you document filshie clips?,g215636,2,The pick list,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64576,3,You are circulating the 1400 scheduled C/S with bilateral tubal ligation. The provider will use filshie clips to tie the patient's tubes. Where would you document filshie clips?,g215637,3,None of the above,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64577,0,You are the PACU nurse and just received report on a patient that had a 1500 QBL in the OR. How long are you expected to document vital signs and fundal assessments on this patient?,g215638,0,Q15 mins for 1 hour if the patient bleeding is stable,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64577,1,You are the PACU nurse and just received report on a patient that had a 1500 QBL in the OR. How long are you expected to document vital signs and fundal assessments on this patient?,g215639,1,"Q15 mins for 1 hour, then q 30 mins until the patient leaves the PACU",0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64577,2,You are the PACU nurse and just received report on a patient that had a 1500 QBL in the OR. How long are you expected to document vital signs and fundal assessments on this patient?,g215640,2,"Q15 mins for 2 hours, then q30 mins until the patient leaves the PACU",1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64577,3,You are the PACU nurse and just received report on a patient that had a 1500 QBL in the OR. How long are you expected to document vital signs and fundal assessments on this patient?,g215641,3,"Q15 mins for 1.5 hours, then hourly until the patient leaves the PACU",0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64578,0,It is the responsibility of the PACU nurse to make sure the PACU charges are completed before transferring the patient from PACU.,g215642,0,TRUE,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64578,1,It is the responsibility of the PACU nurse to make sure the PACU charges are completed before transferring the patient from PACU.,g215643,1,FALSE,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64579,0,Your provider used Arista in your case where would you chart the use of Arista?,g215644,0,Dressing and packing,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64579,1,Your provider used Arista in your case where would you chart the use of Arista?,g215645,1,Hemostatic/Adhesion Barrier,1,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64579,2,Your provider used Arista in your case where would you chart the use of Arista?,g215646,2,Nursing Note,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20105,9314,Elearning-0000-562,g14082,g64579,3,Your provider used Arista in your case where would you chart the use of Arista?,g215647,3,The Implant Log,0,FY2021 PERIOP PACU DOCUMENTATION TEST
20104,9649,Elearning-0000-867,g14081,g64564,0,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215587,0,"a.	Same userID and password as for AcuDose software cabinets.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64564,1,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215588,1,"b.	Network/Cerner userID and fingerprint for the first login of the day to a cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64564,2,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215589,2,"c.	Subsequent logins only require a fingerprint if you've already logged in to the same cabinet with a userID and fingerprint that day.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64564,3,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215590,3,"d.	Both B and C are true.",1,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64564,4,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215591,4,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64565,0,"True or False: If you cannot find your patient on the Local List, try the Global List, which shows all patients in the facility.",g215592,0,a. True,1,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64565,1,"True or False: If you cannot find your patient on the Local List, try the Global List, which shows all patients in the facility.",g215593,1,b. False,0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64566,0,Which of the following are TRUE about Omnicell software?,g215594,0,"a.	You can find tips about next steps in a gray area at the bottom of the screen.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64566,1,Which of the following are TRUE about Omnicell software?,g215595,1,"b.	To sign out of Omnicell, tap the Exit button at the bottom right of the screen.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64566,2,Which of the following are TRUE about Omnicell software?,g215596,2,"c.	To correct the count of items in a pocket, use the Change Bin Level button and enter the count that will remain AFTER you remove your dose.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64566,3,Which of the following are TRUE about Omnicell software?,g215597,3,"d.	All of the above are true.",1,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64566,4,Which of the following are TRUE about Omnicell software?,g215598,4,"e.	None of the above are true.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64567,0,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215599,0,"a.	Find the medication on the Active Med Orders or PRN Only tab.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64567,1,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215600,1,"b.	Override the medication using the Stocked Meds tab, even though there is an active order in Cerner.",1,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64567,2,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215601,2,"c.	Use the Active Med Orders or PRN Only tab and select Show All Orders to see if the order is not stocked in this Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64567,3,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215602,3,"d.	Check the patient's MAR in Cerner to verify the dispense location.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64568,0,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215603,0,"a.	Press All Meds to see all items dispensed for that patient by all users.",1,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64568,1,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215604,1,"b.	Press Stocked Meds and generate a Miscellaneous Return not connected to a previous dispense.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64568,2,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215605,2,"c.	Cancel and try a different Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64568,3,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215606,3,"c.	Cancel and try a different Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64568,4,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215607,4,"d.	Reboot the cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64568,5,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215608,5,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64569,0,Which of the following Omnicell buttons and functions are mismatched?,g215609,0,"a.	Remove Kits - Dispense a virtual kit for a patient.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64569,1,Which of the following Omnicell buttons and functions are mismatched?,g215610,1,"b.	Cycle Count - Inventory a pocket to verify or change the recorded quantity.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64569,2,Which of the following Omnicell buttons and functions are mismatched?,g215611,2,"c.	Return Meds - Return a medication to credit a patient.",0,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20104,9649,Elearning-0000-867,g14081,g64569,3,Which of the following Omnicell buttons and functions are mismatched?,g215612,3,"d.	None of the above are mismatched.",1,OMNICELL XT PROFILED CABINET CBL FOR RESPIRATORY
20102,9648,Elearning-0000-866,g14080,g64554,0,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215547,0,"a.	Same userID and password as for AcuDose software cabinets.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64554,1,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215548,1,"b.	Network/Cerner userID and fingerprint for the first login of the day to a cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64554,2,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215549,2,"c.	Subsequent logins only require a fingerprint if you've already logged in to the same cabinet with a userID and fingerprint that day.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64554,3,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215550,3,"d.	Both B and C are true.",1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64554,4,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215551,4,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64555,0,"True or False: If you cannot find your patient on the Local List, try the Global List, which shows all patients in the facility.",g215552,0,a. True,1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64555,1,"True or False: If you cannot find your patient on the Local List, try the Global List, which shows all patients in the facility.",g215553,1,b. False,0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64556,0,Which of the following are TRUE about Omnicell software?,g215554,0,"a.	You can find tips about next steps in a gray area at the bottom of the screen.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64556,1,Which of the following are TRUE about Omnicell software?,g215555,1,"b.	To sign out of Omnicell, tap the Exit button at the bottom right of the screen.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64556,2,Which of the following are TRUE about Omnicell software?,g215556,2,"c.	To correct the count of items in a pocket, use the Change Bin Level button and enter the count that will remain AFTER you remove your dose.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64556,3,Which of the following are TRUE about Omnicell software?,g215557,3,"d.	All of the above are true.",1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64556,4,Which of the following are TRUE about Omnicell software?,g215558,4,"e.	None of the above are true.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64557,0,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215559,0,"a.	Find the medication on the Active Med Orders or PRN Only tab.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64557,1,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215560,1,"b.	Override the medication using the Stocked Meds tab, even though there is an active order in Cerner.",1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64557,2,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215561,2,"c.	Use the Active Med Orders or PRN Only tab and select Show All Orders to see if the order is not stocked in this Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64557,3,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215562,3,"d.	Check the patient's MAR in Cerner to verify the dispense location.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64558,0,True or False: You must complete all returns for a patient before wasting medications.,g215563,0,a. True,1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64558,1,True or False: You must complete all returns for a patient before wasting medications.,g215564,1,b. False,0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64559,0,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215565,0,"a.	Press All Meds to see all items dispensed for that patient by all users.",1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64559,1,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215566,1,"b.	Press Stocked Meds and generate a Miscellaneous Return not connected to a previous dispense.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64559,2,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215567,2,"c.	Cancel and try a different Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64559,3,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215568,3,"d.	Reboot the cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64559,4,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215569,4,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64560,0,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215570,0,"a.	Press All Meds to see all items dispensed for that patient by all users.",1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64560,1,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215571,1,"b.	Press Stocked Meds and generate a Miscellaneous Waste not connected to a previous dispense.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64560,2,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215572,2,"c.	Cancel and try a different Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64560,3,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215573,3,"d.	Reboot the cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64560,4,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215574,4,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64561,0,"True or False: Wasting a whole dose is prohibited at Northside. Instead, you must return the dose to Omnicell using the return function and placing a written discrepancy form in the return bin with any remaining drug/packaging.",g215575,0,a. True,1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64561,1,"True or False: Wasting a whole dose is prohibited at Northside. Instead, you must return the dose to Omnicell using the return function and placing a written discrepancy form in the return bin with any remaining drug/packaging.",g215576,1,b. False,0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64562,0,Which of the following Omnicell buttons and functions are mismatched?,g215577,0,"a.	Remove Kits - Dispense a virtual kit for a patient.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64562,1,Which of the following Omnicell buttons and functions are mismatched?,g215578,1,"b.	Cycle Count - Inventory a pocket to verify or change the recorded quantity.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64562,2,Which of the following Omnicell buttons and functions are mismatched?,g215579,2,"c.	Return Meds - Return a medication to credit a patient.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64562,3,Which of the following Omnicell buttons and functions are mismatched?,g215580,3,"d.	Waste Meds - Waste a partial dose of a controlled medication.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64562,4,Which of the following Omnicell buttons and functions are mismatched?,g215581,4,"e.	None of the above are mismatched.",1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64563,0,Which of the following are TRUE regarding discrepancies?,g215582,0,"a.	You have unlimited chances to re-count the pocket as long as you select NO in response to ""Is this the correct count?"" and enter a different number.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64563,1,Which of the following are TRUE regarding discrepancies?,g215583,1,"b.	If you enter the same, incorrect number twice in a row, a discrepancy will be created.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64563,2,Which of the following are TRUE regarding discrepancies?,g215584,2,"c.	Only select YES in response to ""Is this the correct count?"" if you're completely sure the number you entered is the quantity actually in the pocket.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64563,3,Which of the following are TRUE regarding discrepancies?,g215585,3,"d.	A discrepancy receipt will print at the end of the transaction if a discrepancy was created.",0,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20102,9648,Elearning-0000-866,g14080,g64563,4,Which of the following are TRUE regarding discrepancies?,g215586,4,"e.	All of the above are true.",1,OMNICELL XT PROFILED CABINET CBL FOR PHARMACISTS
20100,271,SCORM-0000-81,g14079,g64553,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""NSH Service Standard: Responsiveness"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215545,0,TRUE,1,NSH SERVICE STANDARD: RESPONSIVENESS
20100,271,SCORM-0000-81,g14079,g64553,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""NSH Service Standard: Responsiveness"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215546,1,FALSE,0,NSH SERVICE STANDARD: RESPONSIVENESS
20099,270,SCORM-0000-80,g14078,g64552,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the NSH SERVICE STANDARD: OWNERSHIP AND ACCOUNTABILITY CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215543,0,TRUE,1,NSH SERVICE STANDARD: OWNERSHIP AND ACCOUNTABILITY
20099,270,SCORM-0000-80,g14078,g64552,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the NSH SERVICE STANDARD: OWNERSHIP AND ACCOUNTABILITY CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215544,1,FALSE,0,NSH SERVICE STANDARD: OWNERSHIP AND ACCOUNTABILITY
20097,9568,Elearning-0000-793,g14077,g64551,0,"I acknowledge that I have read and understand the ""FCC Preterm Labor DSC Overview"" CBL in it's entirely.",g215541,0,TRUE,1,FY 2021 FCC PRETERM LABOR DSC OVERVIEW
20097,9568,Elearning-0000-793,g14077,g64551,1,"I acknowledge that I have read and understand the ""FCC Preterm Labor DSC Overview"" CBL in it's entirely.",g215542,1,FALSE,0,FY 2021 FCC PRETERM LABOR DSC OVERVIEW
20096,9650,Elearning-0000-868,g14076,g64541,0,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215501,0,"a.	Same userID and password as for AcuDose software cabinets.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64541,1,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215502,1,"b.	Network/Cerner userID and fingerprint for the first login of the day to a cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64541,2,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215503,2,"c.	Subsequent logins only require a fingerprint if you've already logged in to the same cabinet with a userID and fingerprint that day.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64541,3,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215504,3,"d.	Both B and C are true.",1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64541,4,Which of the following are true regarding how to log in to an Omnicell software cabinet?,g215505,4,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64542,0,"True or False: If you cannot find your patient on the Local List, try the Global List, which shows all patients in the facility.",g215506,0,a. True,1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64542,1,"True or False: If you cannot find your patient on the Local List, try the Global List, which shows all patients in the facility.",g215507,1,b. False,0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64543,0,Which of the following are TRUE about Omnicell software?,g215508,0,"a.	You can find tips about next steps in a gray area at the bottom of the screen.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64543,1,Which of the following are TRUE about Omnicell software?,g215509,1,"b.	To sign out of Omnicell, tap the Exit button at the bottom right of the screen.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64543,2,Which of the following are TRUE about Omnicell software?,g215510,2,"c.	To correct the count of items in a pocket, use the Change Bin Level button and enter the count that will remain AFTER you remove your dose.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64543,3,Which of the following are TRUE about Omnicell software?,g215511,3,"d.	All of the above are true.",1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64543,4,Which of the following are TRUE about Omnicell software?,g215512,4,"e.	None of the above are true.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64544,0,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215513,0,"a.	Press All Meds to see all items dispensed for that patient by all users.",1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64544,1,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215514,1,"b.	Press Stocked Meds and generate a Miscellaneous Return not connected to a previous dispense.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64544,2,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215515,2,"c.	Cancel and try a different Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64544,3,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215516,3,"d.	Reboot the cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64544,4,"If you do not see the drug you're trying to RETURN on the Meds Eligible to Return tab, what should you do next?",g215517,4,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64545,0,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215518,0,"a.	Press All Meds to see all items dispensed for that patient by all users.",1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64545,1,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215519,1,"b.	Press Stocked Meds and generate a Miscellaneous Waste not connected to a previous dispense.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64545,2,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215520,2,"c.	Cancel and try a different Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64545,3,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215521,3,"d.	Reboot the cabinet.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64545,4,"If you do not see the drug you're trying to WASTE on the Meds Requiring Waste tab, what should you do next?",g215522,4,"e.	None of the above.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64546,0,True or False: You must complete all returns for a patient before wasting medications.,g215523,0,a. True,1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64546,1,True or False: You must complete all returns for a patient before wasting medications.,g215524,1,b. False,0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64547,0,"True or False: Wasting a whole dose is prohibited at Northside. Instead, you must return the dose to Omnicell using the return function.",g215525,0,a. True,1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64547,1,"True or False: Wasting a whole dose is prohibited at Northside. Instead, you must return the dose to Omnicell using the return function.",g215526,1,b. False,0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64548,0,Which of the following Omnicell buttons and functions are mismatched?,g215527,0,"a.	Remove Kits - Dispense a virtual kit for a patient.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64548,1,Which of the following Omnicell buttons and functions are mismatched?,g215528,1,"b.	Cycle Count - Inventory a pocket to verify or change the recorded quantity.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64548,2,Which of the following Omnicell buttons and functions are mismatched?,g215529,2,"c.	Return Meds - Return a medication to credit a patient.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64548,3,Which of the following Omnicell buttons and functions are mismatched?,g215530,3,"d.	Waste Meds - Waste a partial dose of a controlled medication.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64548,4,Which of the following Omnicell buttons and functions are mismatched?,g215531,4,"e.	None of the above are mismatched.",1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64549,0,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215532,0,"a.	Find the medication on the Active Med Orders or PRN Only tab.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64549,1,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215533,1,"b.	Override the medication using the Stocked Meds tab, even though there is an active order in Cerner.",1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64549,2,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215534,2,"c.	Use the Active Med Orders or PRN Only tab and select Show All Orders to see if the order is not stocked in this Omnicell.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64549,3,"If the patient's Scheduled Meds screen doesn't contain the medication you're looking for, which of the following is NOT the correct next step?",g215535,3,"d.	Check the patient's MAR in Cerner to verify the dispense location.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64550,0,Which of the following are TRUE regarding discrepancies?,g215536,0,"a.	You have unlimited chances to re-count the pocket as long as you select NO in response to ""Is this the correct count?""",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64550,1,Which of the following are TRUE regarding discrepancies?,g215537,1,"b.	If you enter the same, incorrect number twice in a row, a discrepancy will be created.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64550,2,Which of the following are TRUE regarding discrepancies?,g215538,2,"c.	Only select YES in response to ""Is this the correct count?"" if you're completely sure the number you entered is the quantity actually in the pocket.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64550,3,Which of the following are TRUE regarding discrepancies?,g215539,3,"d.	A discrepancy receipt will print at the end of the transaction if a discrepancy was created.",0,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20096,9650,Elearning-0000-868,g14076,g64550,4,Which of the following are TRUE regarding discrepancies?,g215540,4,"e.	All of the above are true.",1,OMNICELL XT PROFILED CABINET CBL FOR NURSING
20091,108,SCORM-0000-19,g14072,g64493,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""COVID-19 TRAINING PROGRAM Atlanta/Cherokee/Forsyth"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215323,0,TRUE,1,COVID-19 TRAINING PROGRAM (ATLANTA/CHEROKEE/FORSYTH)
20091,108,SCORM-0000-19,g14072,g64493,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""COVID-19 TRAINING PROGRAM Atlanta/Cherokee/Forsyth"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215324,1,FALSE,0,COVID-19 TRAINING PROGRAM (ATLANTA/CHEROKEE/FORSYTH)
20087,8560,Elearning-0000-143,g14070,g64523,0,Documentation for any assessment/intervention/procedure should be completed within how many hours after the actual action?,g215443,0,Within 2 hours,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64523,1,Documentation for any assessment/intervention/procedure should be completed within how many hours after the actual action?,g215444,1,Within 1 hour,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64523,2,Documentation for any assessment/intervention/procedure should be completed within how many hours after the actual action?,g215445,2,Always immediately,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64523,3,Documentation for any assessment/intervention/procedure should be completed within how many hours after the actual action?,g215446,3,Within 4 hours,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64524,0,What information must be included when documenting a critical lab value in the medical record?,g215447,0,The critical lab result,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64524,1,What information must be included when documenting a critical lab value in the medical record?,g215448,1,The date and time the provider is notified,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64524,2,What information must be included when documenting a critical lab value in the medical record?,g215449,2,All orders received,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64524,3,What information must be included when documenting a critical lab value in the medical record?,g215450,3,All of the above,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64525,0,A new Admission Team Nurse asks you what FCC's stance is on sucrose use with our newborns.  Where will you obtain this information?,g215451,0,Google,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64525,1,A new Admission Team Nurse asks you what FCC's stance is on sucrose use with our newborns.  Where will you obtain this information?,g215452,1,Your experience,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64525,2,A new Admission Team Nurse asks you what FCC's stance is on sucrose use with our newborns.  Where will you obtain this information?,g215453,2,Lucidoc,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64525,3,A new Admission Team Nurse asks you what FCC's stance is on sucrose use with our newborns.  Where will you obtain this information?,g215454,3,By asking other coworkers,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64526,0,What is the User Name and Password for Forms on Demand?,g215455,0,nsaforms/northside,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64526,1,What is the User Name and Password for Forms on Demand?,g215456,1,northside/welcome,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64526,2,What is the User Name and Password for Forms on Demand?,g215457,2,FCC forms/welcome,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64526,3,What is the User Name and Password for Forms on Demand?,g215458,3,Northsideforms/northside,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64527,0,A mother is taking a medication and you are unsure of its breastfeeding compatibility.  Where will you locate this information?,g215459,0,Place Lactation referral,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64527,1,A mother is taking a medication and you are unsure of its breastfeeding compatibility.  Where will you locate this information?,g215460,1,Call/Ask a lactation nurse,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64527,2,A mother is taking a medication and you are unsure of its breastfeeding compatibility.  Where will you locate this information?,g215461,2,Call Pharmacy,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64527,3,A mother is taking a medication and you are unsure of its breastfeeding compatibility.  Where will you locate this information?,g215462,3,Medications and Mother's Milk on the Intranet,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64528,0,A staff member comes up to you and states that only diaper count is populating on the newborn I&O band. How do you fix this for them?,g215463,0,Tell them to call the help desk,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64528,1,A staff member comes up to you and states that only diaper count is populating on the newborn I&O band. How do you fix this for them?,g215464,1,Tell them they do not have access to that screen,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64528,2,A staff member comes up to you and states that only diaper count is populating on the newborn I&O band. How do you fix this for them?,g215465,2,Pull band down from customized view,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64528,3,A staff member comes up to you and states that only diaper count is populating on the newborn I&O band. How do you fix this for them?,g215466,3,Instruct them to document in this field only,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64529,0,"During a Go Live of additional changes in the OneChart system, you are pulled out of staffing. What would your scheduled day look like?",g215467,0,Sit in the break room until a staff member asks for assistance,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64529,1,"During a Go Live of additional changes in the OneChart system, you are pulled out of staffing. What would your scheduled day look like?",g215468,1,Assist in patient care for the floor staff,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64529,2,"During a Go Live of additional changes in the OneChart system, you are pulled out of staffing. What would your scheduled day look like?",g215469,2,"Round with each Admission Team Nurse, asking staff if they need assistance",1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64529,3,"During a Go Live of additional changes in the OneChart system, you are pulled out of staffing. What would your scheduled day look like?",g215470,3,Go to your home floor to assist the staff there rather than your assigned floor,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64530,0,You have a staff member that comes to you quite often for the same charting issues. What is the best action to assist this staff member?,g215471,0,Tell them you have assisted with them in the past on this issue and they should review the information given to them previously,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64530,1,You have a staff member that comes to you quite often for the same charting issues. What is the best action to assist this staff member?,g215472,1,"Give them a quick, basic answer and move on to your patient care",0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64530,2,You have a staff member that comes to you quite often for the same charting issues. What is the best action to assist this staff member?,g215473,2,Assist them by walking them through the documentation while they document the needed                         information,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64530,3,You have a staff member that comes to you quite often for the same charting issues. What is the best action to assist this staff member?,g215474,3,Have them log in and complete the documentation for them. You will show them later,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64531,0,When should a Result Copy be performed during the Admission Process?,g215475,0,A. Beginning of Admission Process,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64531,1,When should a Result Copy be performed during the Admission Process?,g215476,1,B. After report is called to FCC Anchor Nurse,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64531,2,When should a Result Copy be performed during the Admission Process?,g215477,2,C. All information from maternal chart is automatically copied over to the newborn.,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64531,3,When should a Result Copy be performed during the Admission Process?,g215478,3,All the above,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64531,4,When should a Result Copy be performed during the Admission Process?,g215479,4,A & B,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64532,0,Birth Vitals should be documented within how many minutes of birth?,g215480,0,5 minutes,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64532,1,Birth Vitals should be documented within how many minutes of birth?,g215481,1,15 minutes,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64532,2,Birth Vitals should be documented within how many minutes of birth?,g215482,2,30 minutes,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64532,3,Birth Vitals should be documented within how many minutes of birth?,g215483,3,1 hour,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64533,0,"Once the Birth Vitals are taken, how often should vitals be taken on the newborn?",g215484,0,Q30 x4,1,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64533,1,"Once the Birth Vitals are taken, how often should vitals be taken on the newborn?",g215485,1,Q15 x8,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20087,8560,Elearning-0000-143,g14070,g64533,2,"Once the Birth Vitals are taken, how often should vitals be taken on the newborn?",g215486,2,Q1 x2,0,FCC ADMISSION TEAM SUPERUSER PRE-ASSESSMENT
20084,9854,Questions-0000-145,g14068,g64495,0,Please list the location for this activity.,g215327,0,Atlanta,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64495,1,Please list the location for this activity.,g215328,1,Cherokee,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64495,2,Please list the location for this activity.,g215329,2,Forsyth,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64495,3,Please list the location for this activity.,g215330,3,Other,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64496,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify neonates with serious heart disease.</ol>",g215331,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64496,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify neonates with serious heart disease.</ol>",g215332,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64496,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify neonates with serious heart disease.</ol>",g215333,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64496,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify neonates with serious heart disease.</ol>",g215334,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64496,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify neonates with serious heart disease.</ol>",g215335,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64497,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 4 predominate causes of cyanosis</ol>",g215336,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64497,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 4 predominate causes of cyanosis</ol>",g215337,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64497,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 4 predominate causes of cyanosis</ol>",g215338,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64497,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 4 predominate causes of cyanosis</ol>",g215339,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64497,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 4 predominate causes of cyanosis</ol>",g215340,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64498,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe treatment goals for infants with cyanotic heart lesions.</ol>",g215341,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64498,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe treatment goals for infants with cyanotic heart lesions.</ol>",g215342,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64498,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe treatment goals for infants with cyanotic heart lesions.</ol>",g215343,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64498,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe treatment goals for infants with cyanotic heart lesions.</ol>",g215344,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64498,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe treatment goals for infants with cyanotic heart lesions.</ol>",g215345,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64499,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 3 strategies to support parents through the NICU experience.</ol>",g215346,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64499,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 3 strategies to support parents through the NICU experience.</ol>",g215347,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64499,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 3 strategies to support parents through the NICU experience.</ol>",g215348,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64499,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 3 strategies to support parents through the NICU experience.</ol>",g215349,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64499,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 3 strategies to support parents through the NICU experience.</ol>",g215350,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64500,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for hypoglycemia.</ol>",g215351,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64500,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for hypoglycemia.</ol>",g215352,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64500,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for hypoglycemia.</ol>",g215353,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64500,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for hypoglycemia.</ol>",g215354,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64500,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for hypoglycemia.</ol>",g215355,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64501,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe surveillance, monitoring and treatment modalities for neonatal hypoglycemia.</ol>",g215356,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64501,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe surveillance, monitoring and treatment modalities for neonatal hypoglycemia.</ol>",g215357,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64501,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe surveillance, monitoring and treatment modalities for neonatal hypoglycemia.</ol>",g215358,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64501,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe surveillance, monitoring and treatment modalities for neonatal hypoglycemia.</ol>",g215359,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64501,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe surveillance, monitoring and treatment modalities for neonatal hypoglycemia.</ol>",g215360,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64502,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify situations that lead to moral distress and the impact on care provided.</ol>",g215361,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64502,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify situations that lead to moral distress and the impact on care provided.</ol>",g215362,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64502,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify situations that lead to moral distress and the impact on care provided.</ol>",g215363,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64502,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify situations that lead to moral distress and the impact on care provided.</ol>",g215364,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64502,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify situations that lead to moral distress and the impact on care provided.</ol>",g215365,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64503,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe sound principles of self-care.</ol>",g215366,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64503,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe sound principles of self-care.</ol>",g215367,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64503,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe sound principles of self-care.</ol>",g215368,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64503,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe sound principles of self-care.</ol>",g215369,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64503,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe sound principles of self-care.</ol>",g215370,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64504,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215371,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64504,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215372,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64504,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215373,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64504,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215374,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64504,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215375,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64505,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to early recognition and management of patients admitted to the Special Care Nursery and has improved my ability to optimize outcomes for these patients and their families.   <OL>,g215376,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64505,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to early recognition and management of patients admitted to the Special Care Nursery and has improved my ability to optimize outcomes for these patients and their families.   <OL>,g215377,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64505,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to early recognition and management of patients admitted to the Special Care Nursery and has improved my ability to optimize outcomes for these patients and their families.   <OL>,g215378,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64505,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to early recognition and management of patients admitted to the Special Care Nursery and has improved my ability to optimize outcomes for these patients and their families.   <OL>,g215379,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64505,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to early recognition and management of patients admitted to the Special Care Nursery and has improved my ability to optimize outcomes for these patients and their families.   <OL>,g215380,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64506,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and awareness as it relates to self-care and improved my ability to utilize self-care principles to minimize the negative effects of moral distress.</OL>,g215381,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64506,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and awareness as it relates to self-care and improved my ability to utilize self-care principles to minimize the negative effects of moral distress.</OL>,g215382,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64506,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and awareness as it relates to self-care and improved my ability to utilize self-care principles to minimize the negative effects of moral distress.</OL>,g215383,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64506,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and awareness as it relates to self-care and improved my ability to utilize self-care principles to minimize the negative effects of moral distress.</OL>,g215384,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64506,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge and awareness as it relates to self-care and improved my ability to utilize self-care principles to minimize the negative effects of moral distress.</OL>,g215385,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64507,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g215386,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64507,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g215387,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64507,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g215388,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64507,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g215389,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64507,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g215390,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64508,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215391,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64508,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215392,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64508,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215393,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64508,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215394,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64508,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215395,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64509,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.<OL>,g215396,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64509,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.<OL>,g215397,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64509,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.<OL>,g215398,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64509,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.<OL>,g215399,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64509,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.<OL>,g215400,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64510,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g215401,0,Strongly Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64510,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g215402,1,Agree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64510,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g215403,2,No Opinion,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64510,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g215404,3,Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64510,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g215405,4,Strongly Disagree,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64511,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Karen Dudley, MD</ol>",g215406,0,Excellent,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64511,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Karen Dudley, MD</ol>",g215407,1,Very Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64511,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Karen Dudley, MD</ol>",g215408,2,Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64511,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Karen Dudley, MD</ol>",g215409,3,Fair,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64511,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Karen Dudley, MD</ol>",g215410,4,Poor,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64512,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Glen Lanucci, MD</ol>",g215411,0,Excellent,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64512,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Glen Lanucci, MD</ol>",g215412,1,Very Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64512,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Glen Lanucci, MD</ol>",g215413,2,Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64512,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Glen Lanucci, MD</ol>",g215414,3,Fair,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64512,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Glen Lanucci, MD</ol>",g215415,4,Poor,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64513,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Melissa Smith, RN, CBC</ol>",g215416,0,Excellent,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64513,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Melissa Smith, RN, CBC</ol>",g215417,1,Very Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64513,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Melissa Smith, RN, CBC</ol>",g215418,2,Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64513,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Melissa Smith, RN, CBC</ol>",g215419,3,Fair,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64513,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Melissa Smith, RN, CBC</ol>",g215420,4,Poor,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64514,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pam Noonan, MS, BSN, NRD-BC</ol>",g215421,0,Excellent,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64514,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pam Noonan, MS, BSN, NRD-BC</ol>",g215422,1,Very Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64514,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pam Noonan, MS, BSN, NRD-BC</ol>",g215423,2,Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64514,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pam Noonan, MS, BSN, NRD-BC</ol>",g215424,3,Fair,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64514,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pam Noonan, MS, BSN, NRD-BC</ol>",g215425,4,Poor,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64515,0,"Overall, this activity was:",g215426,0,Excellent,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64515,1,"Overall, this activity was:",g215427,1,Very Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64515,2,"Overall, this activity was:",g215428,2,Good,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64515,3,"Overall, this activity was:",g215429,3,Fair,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64515,4,"Overall, this activity was:",g215430,4,Poor,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64516,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215431,0,Yes,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64516,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215432,1,No,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64516,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215433,2,N/A,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64519,0,How would you improve this class?,g215434,0,Reduce content covered in class,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64519,1,How would you improve this class?,g215435,1,Increase content covered in class,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64519,2,How would you improve this class?,g215436,2,Update content covered in class,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64519,3,How would you improve this class?,g215437,3,Improve the instructional methods,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64519,4,How would you improve this class?,g215438,4,Make course activities more stimulating,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64519,5,How would you improve this class?,g215439,5,Slow the pace of the class,0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20084,9854,Questions-0000-145,g14068,g64519,6,How would you improve this class?,g215440,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,SCN CLINICAL UPDATE 2021- SESSION II (EVALUATION SURVEY) NSA 8.11.21
20079,9894,Questions-0000-28,g14063,g64464,0,Please list the location for this activity.,g215209,0,Atlanta,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64464,1,Please list the location for this activity.,g215210,1,Forsyth,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64464,2,Please list the location for this activity.,g215211,2,Cherokee,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64464,3,Please list the location for this activity.,g215212,3,Other,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64465,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g215213,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64465,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g215214,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64465,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g215215,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64465,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g215216,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64465,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g215217,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64466,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g215218,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64466,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g215219,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64466,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g215220,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64466,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g215221,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64466,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g215222,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64467,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g215223,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64467,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g215224,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64467,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g215225,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64467,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g215226,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64467,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g215227,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64468,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g215228,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64468,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g215229,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64468,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g215230,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64468,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g215231,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64468,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g215232,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64469,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g215233,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64469,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g215234,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64469,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g215235,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64469,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g215236,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64469,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g215237,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64470,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g215238,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64470,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g215239,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64470,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g215240,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64470,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g215241,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64470,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g215242,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64471,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g215243,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64471,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g215244,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64471,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g215245,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64471,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g215246,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64471,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g215247,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64472,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g215248,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64472,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g215249,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64472,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g215250,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64472,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g215251,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64472,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g215252,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64473,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g215253,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64473,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g215254,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64473,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g215255,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64473,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g215256,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64473,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g215257,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64474,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g215258,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64474,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g215259,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64474,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g215260,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64474,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g215261,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64474,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g215262,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64475,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g215263,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64475,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g215264,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64475,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g215265,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64475,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g215266,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64475,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g215267,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64476,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215268,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64476,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215269,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64476,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215270,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64476,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215271,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64476,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g215272,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64477,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g215273,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64477,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g215274,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64477,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g215275,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64477,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g215276,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64477,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g215277,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64478,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215278,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64478,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215279,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64478,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215280,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64478,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215281,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64478,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g215282,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64479,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215283,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64479,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215284,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64479,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215285,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64479,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215286,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64479,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g215287,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64480,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g215288,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64480,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g215289,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64480,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g215290,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64480,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g215291,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64480,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g215292,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64481,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g215293,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64481,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g215294,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64481,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g215295,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64481,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g215296,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64481,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g215297,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64482,0,"Overall, this activity was:",g215298,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64482,1,"Overall, this activity was:",g215299,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64482,2,"Overall, this activity was:",g215300,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64482,3,"Overall, this activity was:",g215301,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64482,4,"Overall, this activity was:",g215302,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64483,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215303,0,Yes,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64483,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215304,1,No,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64483,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215305,2,N/A,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64486,0,How would you improve this class?,g215306,0,Reduce content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64486,1,How would you improve this class?,g215307,1,Increase content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64486,2,How would you improve this class?,g215308,2,Update content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64486,3,How would you improve this class?,g215309,3,Improve the instructional methods,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64486,4,How would you improve this class?,g215310,4,Make course activities more stimulating,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64486,5,How would you improve this class?,g215311,5,Slow the pace of the class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20079,9894,Questions-0000-28,g14063,g64486,6,How would you improve this class?,g215312,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21
20076,9699,Elearning-0000-912,g14059,g64414,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the Cleanliness in the MRI Room CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215041,0,TRUE,1,CLEANLINESS IN THE MRI ROOM
20076,9699,Elearning-0000-912,g14059,g64414,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the Cleanliness in the MRI Room CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215042,1,FALSE,0,CLEANLINESS IN THE MRI ROOM
20075,9692,Elearning-0000-906,g14058,g64413,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Emotional Support  For Staff CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215039,0,TRUE,1,2021 EMOTIONAL SUPPORT FOR STAFF CBL
20075,9692,Elearning-0000-906,g14058,g64413,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Emotional Support  For Staff CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g215040,1,FALSE,0,2021 EMOTIONAL SUPPORT FOR STAFF CBL
20070,9906,Questions-0000-40,g14055,g64395,0,Please list the location for this activity.,g214972,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64395,1,Please list the location for this activity.,g214973,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64395,2,Please list the location for this activity.,g214974,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64395,3,Please list the location for this activity.,g214975,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64396,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214976,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64396,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214977,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64396,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214978,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64396,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214979,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64396,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214980,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64397,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214981,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64397,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214982,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64397,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214983,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64397,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214984,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64397,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214985,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64398,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214986,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64398,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214987,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64398,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214988,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64398,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214989,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64398,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214990,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64399,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214991,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64399,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214992,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64399,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214993,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64399,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214994,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64399,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214995,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64400,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214996,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64400,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214997,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64400,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214998,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64400,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214999,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64400,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g215000,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64401,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g215001,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64401,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g215002,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64401,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g215003,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64401,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g215004,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64401,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g215005,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64402,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g215006,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64402,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g215007,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64402,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g215008,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64402,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g215009,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64402,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g215010,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64403,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215011,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64403,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215012,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64403,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215013,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64403,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215014,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64403,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g215015,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64404,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g215016,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64404,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g215017,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64404,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g215018,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64404,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g215019,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64404,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g215020,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64404,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g215021,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64405,0,"Overall, this activity was:",g215022,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64405,1,"Overall, this activity was:",g215023,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64405,2,"Overall, this activity was:",g215024,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64405,3,"Overall, this activity was:",g215025,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64405,4,"Overall, this activity was:",g215026,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64406,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215027,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64406,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215028,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64406,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g215029,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64409,0,How would you improve this class (check all that apply)?,g215030,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64409,1,How would you improve this class (check all that apply)?,g215031,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64409,2,How would you improve this class (check all that apply)?,g215032,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64409,3,How would you improve this class (check all that apply)?,g215033,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64409,4,How would you improve this class (check all that apply)?,g215034,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64409,5,How would you improve this class (check all that apply)?,g215035,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20070,9906,Questions-0000-40,g14055,g64409,6,How would you improve this class (check all that apply)?,g215036,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21
20071,9913,Questions-0000-47,g14054,g64372,0,Please list the location for this activity.,g214877,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64372,1,Please list the location for this activity.,g214878,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64372,2,Please list the location for this activity.,g214879,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64372,3,Please list the location for this activity.,g214880,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64373,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214881,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64373,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214882,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64373,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214883,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64373,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214884,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64373,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214885,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64374,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214886,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64374,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214887,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64374,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214888,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64374,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214889,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64374,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214890,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64375,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214891,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64375,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214892,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64375,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214893,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64375,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214894,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64375,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214895,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64376,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214896,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64376,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214897,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64376,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214898,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64376,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214899,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64376,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214900,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64377,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g214901,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64377,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g214902,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64377,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g214903,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64377,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g214904,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64377,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g214905,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64378,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g214906,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64378,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g214907,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64378,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g214908,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64378,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g214909,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64378,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g214910,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64379,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g214911,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64379,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g214912,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64379,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g214913,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64379,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g214914,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64379,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g214915,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64380,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g214916,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64380,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g214917,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64380,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g214918,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64380,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g214919,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64380,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g214920,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64381,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214921,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64381,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214922,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64381,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214923,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64381,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214924,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64381,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214925,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64382,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214926,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64382,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214927,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64382,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214928,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64382,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214929,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64382,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214930,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64383,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214931,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64383,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214932,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64383,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214933,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64383,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214934,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64383,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214935,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64384,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214936,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64384,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214937,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64384,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214938,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64384,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214939,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64384,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214940,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64385,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214941,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64385,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214942,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64385,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214943,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64385,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214944,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64385,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214945,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64386,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214946,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64386,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214947,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64386,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214948,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64386,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214949,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64386,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214950,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64387,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214951,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64387,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214952,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64387,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214953,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64387,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214954,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64387,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214955,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64387,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214956,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64388,0,"Overall, this activity was:",g214957,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64388,1,"Overall, this activity was:",g214958,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64388,2,"Overall, this activity was:",g214959,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64388,3,"Overall, this activity was:",g214960,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64388,4,"Overall, this activity was:",g214961,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64389,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214962,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64389,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214963,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64389,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214964,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64392,0,How would you improve this class (check all that apply)?,g214965,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64392,1,How would you improve this class (check all that apply)?,g214966,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64392,2,How would you improve this class (check all that apply)?,g214967,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64392,3,How would you improve this class (check all that apply)?,g214968,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64392,4,How would you improve this class (check all that apply)?,g214969,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64392,5,How would you improve this class (check all that apply)?,g214970,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20071,9913,Questions-0000-47,g14054,g64392,6,How would you improve this class (check all that apply)?,g214971,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21
20072,9919,Questions-0000-53,g14053,g64353,0,Please list the location for this activity.,g214802,0,Atlanta,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64353,1,Please list the location for this activity.,g214803,1,Cherokee,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64353,2,Please list the location for this activity.,g214804,2,Forsyth,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64353,3,Please list the location for this activity.,g214805,3,Other,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64354,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214806,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64354,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214807,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64354,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214808,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64354,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214809,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64354,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g214810,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64355,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214811,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64355,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214812,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64355,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214813,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64355,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214814,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64355,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g214815,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64356,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214816,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64356,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214817,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64356,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214818,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64356,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214819,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64356,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g214820,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64357,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214821,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64357,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214822,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64357,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214823,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64357,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214824,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64357,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g214825,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64358,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214826,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64358,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214827,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64358,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214828,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64358,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214829,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64358,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214830,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64359,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214831,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64359,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214832,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64359,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214833,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64359,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214834,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64359,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214835,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64360,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214836,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64360,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214837,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64360,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214838,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64360,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214839,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64360,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g214840,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64361,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214841,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64361,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214842,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64361,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214843,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64361,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214844,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64361,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g214845,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64362,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214846,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64362,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214847,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64362,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214848,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64362,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214849,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64362,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g214850,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64363,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g214851,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64363,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g214852,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64363,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g214853,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64363,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g214854,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64363,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g214855,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64364,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214856,4,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64364,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214857,0,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64364,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214858,1,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64364,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214859,2,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64364,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214860,3,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64364,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g214861,5,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64365,0,"Overall, this activity was:",g214862,0,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64365,1,"Overall, this activity was:",g214863,1,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64365,2,"Overall, this activity was:",g214864,2,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64365,3,"Overall, this activity was:",g214865,3,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64365,4,"Overall, this activity was:",g214866,4,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64366,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214867,0,Yes,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64366,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214868,1,No,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64366,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214869,2,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64369,0,How would you improve this class (check all that apply)?,g214870,0,Reduce content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64369,1,How would you improve this class (check all that apply)?,g214871,1,Increase content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64369,2,How would you improve this class (check all that apply)?,g214872,2,Update content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64369,3,How would you improve this class (check all that apply)?,g214873,3,Improve the instructional methods,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64369,4,How would you improve this class (check all that apply)?,g214874,4,Make course activities more stimulating,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64369,5,How would you improve this class (check all that apply)?,g214875,5,Slow the pace of the class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20072,9919,Questions-0000-53,g14053,g64369,6,How would you improve this class (check all that apply)?,g214876,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21"
20069,9678,Elearning-0000-893,g14052,g64348,0,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,g214780,0,a. Friction,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64348,1,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,g214781,1,b. Shear,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64348,2,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,g214782,2,c. Pressure,1,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64348,3,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,g214783,3,d. Moisture,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64349,0,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,g214784,0,a. Moisturize skin daily and right after bathing,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64349,1,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,g214785,1,b. Some protectants may be for prevention while others may be for treatment,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64349,2,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,g214786,2,c. Avoid rigorous scrubbing or rubbing of skin,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64349,3,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,g214787,3,d. Barriers can protect the skin from excessive moisture,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64349,4,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,g214788,4,e. Use cleansing products that are alkaline in nature,1,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64350,0,Skin protectants and liquid cyanoacrylates protect against?,g214789,0,a. Adhesive,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64350,1,Skin protectants and liquid cyanoacrylates protect against?,g214790,1,b. Friction,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64350,2,Skin protectants and liquid cyanoacrylates protect against?,g214791,2,c. Moisture and incontinence,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64350,3,Skin protectants and liquid cyanoacrylates protect against?,g214792,3,d. All of the above,1,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64350,4,Skin protectants and liquid cyanoacrylates protect against?,g214793,4,e. None of the above,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64351,0,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,g214794,0,a. Thorough skin inspection under and around a device is important to preventing these injuries,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64351,1,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,g214795,1,b. These pressure injuries cannot be staged,1,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64351,2,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,g214796,2,c. Devices should be assessed for proper fit,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64351,3,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,g214797,3,d. Respiratory devices are common sources of injury,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64352,0,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,g214798,0,a. The dressing can stay on for as long as it lasts without the skin being assessed,1,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64352,1,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,g214799,1,b. The cost associated with the dressing,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64352,2,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,g214800,2,c. The size and appropriateness of the dressing,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20069,9678,Elearning-0000-893,g14052,g64352,3,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,g214801,3,d. The ability of the dressing to manage microclimate and friction,0,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE
20067,9479,Elearning-0000-712,g14051,g64303,0,How does the newborn appear on the Circumcision Dashboard?,g214658,0,"A. The Admission Team documents ""Yes"" in the Birth Information Powerform to the parents having plans for their newborn to be circumcised.",0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64303,1,How does the newborn appear on the Circumcision Dashboard?,g214659,1,"B. The Anchor Nurse documents in Circumcision in iView ""Yes"" to the parents having plans for their newborn to be circumcised.",0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64303,2,How does the newborn appear on the Circumcision Dashboard?,g214660,2,C. All baby boys will automatically appear on the Circumcision Dashboard.,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64303,3,How does the newborn appear on the Circumcision Dashboard?,g214661,3,D. Answers A or B are both correct.,1,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64304,0,"True or False: A newborn has all 8 green check marks on the circumcision dashboard, so the Anchor Nurse can assume the newborn is eligible for circumcision.",g214662,0,TRUE,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64304,1,"True or False: A newborn has all 8 green check marks on the circumcision dashboard, so the Anchor Nurse can assume the newborn is eligible for circumcision.",g214663,1,FALSE,1,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64305,0,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,g214664,0,A. Before the Time-Out Procedure,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64305,1,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,g214665,1,B. Each Shift,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64305,2,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,g214666,2,C. As the different requirements are met,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64305,3,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,g214667,3,D. If newborn's medical status changes,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64305,4,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,g214668,4,E. All the above,1,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64306,0,"It was documented in the Pre-Circumcision Checklist that the newborn was feeding well. Two shifts have since passed, and the newborn is no longer feeding well. The Pediatrician is notified, and writes a ""Hold Circ"" order. The OB Provider then calls saying that they see the newborn has the 8 required green checks to be eligible for circumcision. What should the Anchor Nurse do?",g214669,0,A. Allow the OB Provider to come circumcise the newborn.,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64306,1,"It was documented in the Pre-Circumcision Checklist that the newborn was feeding well. Two shifts have since passed, and the newborn is no longer feeding well. The Pediatrician is notified, and writes a ""Hold Circ"" order. The OB Provider then calls saying that they see the newborn has the 8 required green checks to be eligible for circumcision. What should the Anchor Nurse do?",g214670,1,"B. Inform the Provider that the newborn has a ""Hold Circ"" order because they are no longer feeding well, and cannot be circumcised at this time.",1,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64306,2,"It was documented in the Pre-Circumcision Checklist that the newborn was feeding well. Two shifts have since passed, and the newborn is no longer feeding well. The Pediatrician is notified, and writes a ""Hold Circ"" order. The OB Provider then calls saying that they see the newborn has the 8 required green checks to be eligible for circumcision. What should the Anchor Nurse do?",g214671,2,C. None of the above,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64307,0,Which of the following is true?,g214672,0,A. It is the responsibility of the Mother Baby Nurse to fill out the Pre-Circumcision Checklist.,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64307,1,Which of the following is true?,g214673,1,B. It is the responsibility of the Anchor Nurse to fill out the Pre-Circumcision Checklist.,0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64307,2,Which of the following is true?,g214674,2,"C. The Mother Baby Nurse is responsible for obtaining signed consent for circumcision procedure and notifying the Anchor Nurse informed consent has been obtained, informing the Anchor Nurse when newborn has their first void and updating the Anchor Nurse with any changes in newborn status.",0,CERNER CIRCUMCISION DASHBOARD
20067,9479,Elearning-0000-712,g14051,g64307,3,Which of the following is true?,g214675,3,D. B&C,1,CERNER CIRCUMCISION DASHBOARD
20066,9863,Questions-0000-153,g14050,g64293,0,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,g214618,0,"a.	Occupational Safety and Health Administration",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64293,1,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,g214619,1,"b.	Environmental Protection Agency",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64293,2,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,g214620,2,"c.	U.S. Food and Drug Administration",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64293,3,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,g214621,3,"d.	Association of perioperative Registered Nurses",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64294,0,Regulations under the Clean Air Act are administered by the,g214622,0,"a.	Occupational Safety and Health Administration",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64294,1,Regulations under the Clean Air Act are administered by the,g214623,1,"b.	U.S. Food and Drug Administration",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64294,2,Regulations under the Clean Air Act are administered by the,g214624,2,"c.	Environmental Protection Agency",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64294,3,Regulations under the Clean Air Act are administered by the,g214625,3,"d.	Association of periOperative Registered Nurses",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64295,0,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,g214626,0,"a.	Occupational Safety and Health Administration",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64295,1,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,g214627,1,"b.	U.S. Food and Drug Administration",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64295,2,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,g214628,2,"c.	Environmental Protection Agency",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64295,3,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,g214629,3,"d.	Association for the Advancement of Medical Instrumentation",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64296,0,Healthcare regulations and standards establish,g214630,0,"a.	minimal levels of quality and safety",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64296,1,Healthcare regulations and standards establish,g214631,1,"b.	equal pay practices",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64296,2,Healthcare regulations and standards establish,g214632,2,"c.	productivity time lines",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64296,3,Healthcare regulations and standards establish,g214633,3,"d.	all of the above",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64297,0,Chemical indicators are classified as,g214634,0,"a.	FDA Class I medical devices",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64297,1,Chemical indicators are classified as,g214635,1,"b.	FDA Class II medical devices",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64297,2,Chemical indicators are classified as,g214636,2,"c.	FDA Class III medical devices",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64297,3,Chemical indicators are classified as,g214637,3,"d.	None, not regulatory by FDA",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64298,0,Heart valves and pacemakers are example of,g214638,0,"a.	FDA Class I medical devices",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64298,1,Heart valves and pacemakers are example of,g214639,1,"b.	FDA Class II medical devices",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64298,2,Heart valves and pacemakers are example of,g214640,2,"c.	FDA Class III medical devices",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64298,3,Heart valves and pacemakers are example of,g214641,3,"d.	None, not regulatory by FDA",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64299,0,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",g214642,0,"a.	Device manufacturer",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64299,1,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",g214643,1,"b.	Hospitals",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64299,2,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",g214644,2,"c.	All of the above",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64299,3,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",g214645,3,"d.	None of the above",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64300,0,Standards and regulations help set levels of ___________________________ in our departments.,g214646,0,"a.	quality",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64300,1,Standards and regulations help set levels of ___________________________ in our departments.,g214647,1,"b.	safety",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64300,2,Standards and regulations help set levels of ___________________________ in our departments.,g214648,2,"c.	efficiency",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64300,3,Standards and regulations help set levels of ___________________________ in our departments.,g214649,3,"d.	both quality and safety",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64301,0,Medical device reporting is regulated by the,g214650,0,"a.	National Fire Protection Associated",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64301,1,Medical device reporting is regulated by the,g214651,1,"b.	Environmental Protection Agency",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64301,2,Medical device reporting is regulated by the,g214652,2,"c.	World Health Organization",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64301,3,Medical device reporting is regulated by the,g214653,3,"d.	U.S. Food and Drug Administration",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64302,0,The Department of Transportation enforces statutes relating to the,g214654,0,"a.	transportation of clean and soiled instruments between facilities",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64302,1,The Department of Transportation enforces statutes relating to the,g214655,1,"b.	transportation of medical supplies for emergency use",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64302,2,The Department of Transportation enforces statutes relating to the,g214656,2,"c.	transportation of equipment for the decontamination area",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64302,3,The Department of Transportation enforces statutes relating to the,g214657,3,"d.	transportation of instrumentation across state lines",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64308,0,"Sometimes state or local regulations differ from Federal regulations and when that happens, the most stringent regulations apply.",g214676,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64308,1,"Sometimes state or local regulations differ from Federal regulations and when that happens, the most stringent regulations apply.",g214677,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64309,0,It is optional to allow the Occupational Safety and Health Administration's regulation for wearing personal protective equipment in the Central Service decontamination area.,g214678,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64309,1,It is optional to allow the Occupational Safety and Health Administration's regulation for wearing personal protective equipment in the Central Service decontamination area.,g214679,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64310,0,Third-party reprocessors are regulated by the U.S. Food and Drug Administration.,g214680,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64310,1,Third-party reprocessors are regulated by the U.S. Food and Drug Administration.,g214681,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64311,0,Recommendations regarding sterilization practices are provided by the Association for the Advancement of Medical Instrumentation.,g214682,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64311,1,Recommendations regarding sterilization practices are provided by the Association for the Advancement of Medical Instrumentation.,g214683,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64312,0,The Occupational Safety and Health Administration is a voluntary association dedicated to infection control and prevention.,g214684,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64312,1,The Occupational Safety and Health Administration is a voluntary association dedicated to infection control and prevention.,g214685,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64313,0,Failure to receive accreditation from The Joint Commission can result in the loss of Medicare and Medicaid payments.,g214686,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64313,1,Failure to receive accreditation from The Joint Commission can result in the loss of Medicare and Medicaid payments.,g214687,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64314,0,The Society of Gastroenterology Nurses and Associates is a source for information about the proper processing of flexible endoscopes.,g214688,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64314,1,The Society of Gastroenterology Nurses and Associates is a source for information about the proper processing of flexible endoscopes.,g214689,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64315,0,Class III medical devices are identified as high risk.,g214690,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64315,1,Class III medical devices are identified as high risk.,g214691,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64316,0,Reuse of single use medical devices is less regulated now than it was in the 1990's.,g214692,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64316,1,Reuse of single use medical devices is less regulated now than it was in the 1990's.,g214693,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64317,0,The U.S. Food and Drug Administration recalls may be either mandatory or voluntary.,g214694,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64317,1,The U.S. Food and Drug Administration recalls may be either mandatory or voluntary.,g214695,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64318,0,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",g214696,0,"a.	placed in an uptight position",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64318,1,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",g214697,1,"b.	loaded first",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64318,2,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",g214698,2,"c.	placed on edge",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64318,3,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",g214699,3,"d.	placed in a wire basket",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64319,0,The higher bioburden on an object,g214700,0,"a.	the more difficult it will be to sterilize",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64319,1,The higher bioburden on an object,g214701,1,"b.	the less time it will take to sterilize it",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64319,2,The higher bioburden on an object,g214702,2,"c.	the more biological tests will be needed in the load",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64319,3,The higher bioburden on an object,g214703,3,"d.	the longer it will take to cool after sterilization",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64320,0,"When combining loads, hard goods should be placed on the top shelves to allow for more efficient removal of the condensate.",g214704,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64320,1,"When combining loads, hard goods should be placed on the top shelves to allow for more efficient removal of the condensate.",g214705,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64321,0,The steam sterilization process can be affected by the design of the medical device being sterilized.,g214706,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64321,1,The steam sterilization process can be affected by the design of the medical device being sterilized.,g214707,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64322,0,Central Service technicians need to understand the anatomy of a steam sterilizer to,g214708,0,"a.	know how to properly clean the chamber",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64322,1,Central Service technicians need to understand the anatomy of a steam sterilizer to,g214709,1,"b.	understand how the sterilizer operates",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64322,2,Central Service technicians need to understand the anatomy of a steam sterilizer to,g214710,2,"c.	understand how to test the thermostatic trap",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64322,3,Central Service technicians need to understand the anatomy of a steam sterilizer to,g214711,3,"d.	know how to properly maintain the jacket",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64323,0,The weakest part of a steam sterilizer is the,g214712,0,"a.	jacket",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64323,1,The weakest part of a steam sterilizer is the,g214713,1,"b.	gasket",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64323,2,The weakest part of a steam sterilizer is the,g214714,2,"c.	door",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64323,3,The weakest part of a steam sterilizer is the,g214715,3,"d.	thermostatic valve",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64324,0,Three of the main phases of a terminal steam sterilizer cycle are,g214716,0,"a.	gravity, exposure and exhaust",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64324,1,Three of the main phases of a terminal steam sterilizer cycle are,g214717,1,"b.	pre-vacuum, exposure and exhaust",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64324,2,Three of the main phases of a terminal steam sterilizer cycle are,g214718,2,"c.	exposure, exhaust and dry",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64324,3,Three of the main phases of a terminal steam sterilizer cycle are,g214719,3,"d.	conditioning, exposure and exhaust",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64325,0,The most common reason for steam sterilization failure is,g214720,0,"a.	lack of steam contact with the instrument",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64325,1,The most common reason for steam sterilization failure is,g214721,1,"b.	insufficient temperature",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64325,2,The most common reason for steam sterilization failure is,g214722,2,"c.	inadequate exposure time",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64325,3,The most common reason for steam sterilization failure is,g214723,3,"d.	drying issues",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64326,0,The coolest place in a steam sterilizer is the,g214724,0,"a.	gasket",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64326,1,The coolest place in a steam sterilizer is the,g214725,1,"b.	thermostatic trap",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64326,2,The coolest place in a steam sterilizer is the,g214726,2,"c.	jacket",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64326,3,The coolest place in a steam sterilizer is the,g214727,3,"d.	chamber",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64327,0,Steam flush pressure pulse sterilizers are a type of gravity sterilizers,g214728,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64327,1,Steam flush pressure pulse sterilizers are a type of gravity sterilizers,g214729,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64328,0,Factors that can cause sterilant contact failure with the instrument are,g214730,0,"a.	cleaning, loosely packed load",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64328,1,Factors that can cause sterilant contact failure with the instrument are,g214731,1,"b.	conditioning, size and weight of the instrument",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64328,2,Factors that can cause sterilant contact failure with the instrument are,g214732,2,"c.	solid bottom containers, exposure time",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64328,3,Factors that can cause sterilant contact failure with the instrument are,g214733,3,"d.	crowded loads, clogged drain strainer",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64329,0,One of the most frequent causes of a clogged drain screen is,g214734,0,"a.	tape",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64329,1,One of the most frequent causes of a clogged drain screen is,g214735,1,"b.	wrapper particles",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64329,2,One of the most frequent causes of a clogged drain screen is,g214736,2,"c.	poor stream quality",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64329,3,One of the most frequent causes of a clogged drain screen is,g214737,3,"d.	malfunctioning baffle plate",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64330,0,After sterilization the load contents may take two hours or more to cool.,g214738,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64330,1,After sterilization the load contents may take two hours or more to cool.,g214739,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64331,0,Peel pouches should be placed ________________________________________ for sterilization.,g214740,0,"a.	on edge, paper to plastic",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64331,1,Peel pouches should be placed ________________________________________ for sterilization.,g214741,1,"b.	on edge, plastic to plastic",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64331,2,Peel pouches should be placed ________________________________________ for sterilization.,g214742,2,"c.	placed flat with the plastic side up",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64331,3,Peel pouches should be placed ________________________________________ for sterilization.,g214743,3,"d.	placed flat with the paper side up",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64332,0,Items with a standard steam sterilization cycle recommended by the manufacturer can be damaged if run in an extended cycle.,g214744,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64332,1,Items with a standard steam sterilization cycle recommended by the manufacturer can be damaged if run in an extended cycle.,g214745,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64333,0,How frequently should a sterilizer's strainer be removed and cleaned?,g214746,0,"a.	daily",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64333,1,How frequently should a sterilizer's strainer be removed and cleaned?,g214747,1,"b.	after each use",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64333,2,How frequently should a sterilizer's strainer be removed and cleaned?,g214748,2,"c.	once weekly",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64333,3,How frequently should a sterilizer's strainer be removed and cleaned?,g214749,3,"d.	only when the machine's operating control gauge indicates cleaning is necessary",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64334,0,Immediate use steam sterilization is the process to sterilize trays for future use.,g214750,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64334,1,Immediate use steam sterilization is the process to sterilize trays for future use.,g214751,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64335,0,Wood products should be sterilized in an extended steam cycle.,g214752,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64335,1,Wood products should be sterilized in an extended steam cycle.,g214753,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64336,0,When water is seen on the outside of a pack after sterilization the pack is considered safe to use if all other packs in the load are dry.,g214754,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64336,1,When water is seen on the outside of a pack after sterilization the pack is considered safe to use if all other packs in the load are dry.,g214755,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64337,0,Packs that are improperly packaged or loaded on the sterilizer cart frequently become wet packs.,g214756,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64337,1,Packs that are improperly packaged or loaded on the sterilizer cart frequently become wet packs.,g214757,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64338,0,Chapter 15:  Low-Temperature Sterilization<br> Woven reusable fabrics are the packaging of choice for ozone sterilization.,g214758,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64338,1,Chapter 15:  Low-Temperature Sterilization<br> Woven reusable fabrics are the packaging of choice for ozone sterilization.,g214759,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64339,0,Ethylene kills microorganisms by a process called oxidation.,g214760,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64339,1,Ethylene kills microorganisms by a process called oxidation.,g214761,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64340,0,"Ethylene oxide, hydrogen peroxide and ozone sterilization process must all be monitored using chemical, physical and biological monitors.",g214762,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64340,1,"Ethylene oxide, hydrogen peroxide and ozone sterilization process must all be monitored using chemical, physical and biological monitors.",g214763,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64341,0,"Ethylene oxide, hydrogen peroxide and ozone sterilization can all use the same packaging materials.",g214764,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64341,1,"Ethylene oxide, hydrogen peroxide and ozone sterilization can all use the same packaging materials.",g214765,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64342,0,Lumens should be moist when using hydrogen peroxide as a sterilizing agent.,g214766,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64342,1,Lumens should be moist when using hydrogen peroxide as a sterilizing agent.,g214767,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64343,0,Ethylene oxide is a toxic gas.,g214768,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64343,1,Ethylene oxide is a toxic gas.,g214769,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64344,0,Cellulose-containing packaging materials are not compatible with hydrogen peroxide sterilization.,g214770,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64344,1,Cellulose-containing packaging materials are not compatible with hydrogen peroxide sterilization.,g214771,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64345,0,Information about a device's compatibility with a specific sterilization process should be obtained from the device's manufacturer.,g214772,0,TRUE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64345,1,Information about a device's compatibility with a specific sterilization process should be obtained from the device's manufacturer.,g214773,1,FALSE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64346,0,An extended aeration cycle is required for items sterilized in ozone sterilization processes.,g214774,0,TRUE,0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64346,1,An extended aeration cycle is required for items sterilized in ozone sterilization processes.,g214775,1,FALSE,1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64347,0,Permissible exposure levels for low-temperature sterilization methods are established by the,g214776,0,"a.	U.S. Food and Drug Administration",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64347,1,Permissible exposure levels for low-temperature sterilization methods are established by the,g214777,1,"b.	Centers for Disease Control",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64347,2,Permissible exposure levels for low-temperature sterilization methods are established by the,g214778,2,"c.	Occupational Safety and Health Administration",1,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20066,9863,Questions-0000-153,g14050,g64347,3,Permissible exposure levels for low-temperature sterilization methods are established by the,g214779,3,"d.	Environmental Protection Agency",0,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15"
20065,9392,Elearning-0000-633,g14049,g64288,0,True or False?  When you come to work you are onstage?,g214604,0,TRUE,1,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64288,1,True or False?  When you come to work you are onstage?,g214605,1,FALSE,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64289,0,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,g214606,0,a. Legendary attention to detail,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64289,1,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,g214607,1,b. Exceeding people's expectations,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64289,2,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,g214608,2,c. Being customer/patient centered,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64289,3,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,g214609,3,d. All of the above,1,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64290,0,When looking for solutions focus on short term solution instead of long term solutions,g214610,0,TRUE,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64290,1,When looking for solutions focus on short term solution instead of long term solutions,g214611,1,FALSE,1,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64291,0,True or False? Never let backstage come onstage,g214612,0,TRUE,1,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64291,1,True or False? Never let backstage come onstage,g214613,1,FALSE,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64292,0,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,g214614,0,a. 90 seconds,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64292,1,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,g214615,1,b. 30 seconds,1,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64292,2,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,g214616,2,c. 60 seconds,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20065,9392,Elearning-0000-633,g14049,g64292,3,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,g214617,3,d. 15 seconds,0,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021
20063,228,SCORM-0000-34,g14047,g47181,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g154286,0,TRUE,1,FIRE SAFETY ORIENTATION UPDATED (2021)
20063,228,SCORM-0000-34,g14047,g47181,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g154287,1,FALSE,0,FIRE SAFETY ORIENTATION UPDATED (2021)
20063,228,SCORM-0000-34,g14047,g65073,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation Updated (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g217384,0,TRUE,1,FIRE SAFETY ORIENTATION UPDATED (2021)
20063,228,SCORM-0000-34,g14047,g65073,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation Updated (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g217385,1,FALSE,0,FIRE SAFETY ORIENTATION UPDATED (2021)
20061,9955,Questions-0000-89,g14046,g64266,0,Please list the location for this activity.,g214518,0,Atlanta,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64266,1,Please list the location for this activity.,g214519,1,Forsyth,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64266,2,Please list the location for this activity.,g214520,2,Cherokee,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64266,3,Please list the location for this activity.,g214521,3,Other,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64267,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g214522,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64267,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g214523,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64267,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g214524,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64267,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g214525,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64267,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g214526,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64268,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g214527,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64268,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g214528,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64268,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g214529,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64268,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g214530,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64268,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g214531,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64269,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g214532,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64269,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g214533,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64269,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g214534,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64269,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g214535,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64269,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g214536,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64270,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g214537,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64270,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g214538,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64270,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g214539,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64270,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g214540,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64270,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g214541,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64271,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g214542,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64271,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g214543,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64271,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g214544,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64271,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g214545,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64271,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g214546,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64272,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g214547,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64272,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g214548,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64272,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g214549,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64272,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g214550,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64272,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g214551,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64273,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g214552,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64273,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g214553,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64273,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g214554,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64273,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g214555,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64273,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g214556,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64274,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214557,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64274,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214558,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64274,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214559,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64274,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214560,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64274,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214561,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64275,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g214562,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64275,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g214563,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64275,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g214564,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64275,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g214565,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64275,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g214566,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64276,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214567,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64276,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214568,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64276,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214569,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64276,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214570,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64276,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214571,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64277,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214572,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64277,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214573,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64277,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214574,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64277,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214575,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64277,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214576,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64278,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214577,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64278,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214578,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64278,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214579,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64278,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214580,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64278,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214581,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64279,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g214582,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64279,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g214583,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64279,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g214584,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64279,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g214585,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64279,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g214586,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64280,0,"Overall, this activity was:",g214587,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64280,1,"Overall, this activity was:",g214588,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64280,2,"Overall, this activity was:",g214589,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64280,3,"Overall, this activity was:",g214590,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64280,4,"Overall, this activity was:",g214591,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64281,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214592,0,Yes,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64281,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214593,1,No,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64281,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214594,2,N/A,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64284,0,How would you improve this class?,g214595,0,Reduce content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64284,1,How would you improve this class?,g214596,1,Increase content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64284,2,How would you improve this class?,g214597,2,Update content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64284,3,How would you improve this class?,g214598,3,Improve the instructional methods,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64284,4,How would you improve this class?,g214599,4,Make course activities more stimulating,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64284,5,How would you improve this class?,g214600,5,Slow the pace of the class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20061,9955,Questions-0000-89,g14046,g64284,6,How would you improve this class?,g214601,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21
20058,9631,Elearning-0000-850,g14044,g64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,g214476,0,A. Ask her about her side effects and tell her to continue the way she is taking them.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64255,1,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,g214477,1,B. Tell her that she must stop immediately and make an appointment to see the MD.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64255,2,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,g214478,2,C. Document your call in EMR and notify the Physician/RN directly.  Instruct the patient to contact the office to discuss dose change with the Physician.,1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64255,3,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,g214479,3,D. Do nothing because some medication is better than her not taking it at all.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64256,0,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,g214480,0,"A. Patient name, patient's DOB, doctor's name, and medication",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,g214481,1,"B. Patient name, your name, your title, patient's medication, patient's medical record number, and doctor's name, and office location",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64256,2,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,g214482,2,"C. Patient name, your name, your title, and clinic's name",1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64256,3,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,g214483,3,"D. Doctor's name, office location, patient's name, patient's DOB, date of therapy, and name of medication",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64257,0,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,g214484,0,"A. Yes, you can double your dose any time you miss a dose as long as you don't take more than 2 days together.",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64257,1,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,g214485,1,"B. No, you should never double the dose of your medication. Skip the missed dose if it's too close to your next dose or take the missed dose as soon as you remember if it's not too close to your next dose.",1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,g214486,2,"C. Yes, you can take as many doses as needed to get back on schedule.",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64257,3,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,g214487,3,"D. No, don't double the dose. Skip a day as a wash out and start your therapy again from day 1.",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64258,0,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,g214488,0,A. Counsel her on the side effects of therapy and let her know to call the office with any questions and document your call in EMR.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64258,1,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,g214489,1,B. Remind the patient that the medication is most effective when it is taken as prescribed by the physician. Notify the physician and nursing staff she is having financial barriers to therapy and look into potential solutions or financial assistance and document your call in EMR.,1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64258,2,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,g214490,2,"C. Let her know that instead of taking her medication every other day, she can open the capsules and only take half so that it will last her the duration of therapy.",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,g214491,3,D. Document her change in therapy in the EMR but don't say anything to the physician or nursing staff.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64259,0,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,g214492,0,"A. Advise him that medications should never be shared and he should call the local drug take back center, take it to a local medication drop off unit in the community, or contact the pharmacy for instructions on proper disposal.",1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64259,1,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,g214493,1,B. Tell him it's all right as long as you can call the other patient to verify the dose of his therapy.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64259,2,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,g214494,2,C. Instruct him to bring the medication back to the office and you will dispose of it for him.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64259,3,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,g214495,3,"D. Tell him he can choose any of the above options, depending on what suits him the best.",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64260,0,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,g214496,0,A. Make an appointment with her to discuss her medication and counsel her.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64260,1,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,g214497,1,B. Refer her to the retail pharmacy because only certain pharmacists are authorized to counsel a patient on Revlimid due to the REMS program.,1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64260,2,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,g214498,2,C. Tell her that you cannot speak to her currently but you can set up a date/time to counsel her over the phone.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64260,3,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,g214499,3,D. Tell her you have a few minutes and can discuss her Revlimid now.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64261,0,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""<br> II. ""What did your provider tell you to expect while on therapy?""<br> III. ""What side effects will you be looking out for while on this medication?""<br> IV. ""Do you have any questions?""<br><br>",g214500,0,"A.	I, II, IV",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64261,1,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""<br> II. ""What did your provider tell you to expect while on therapy?""<br> III. ""What side effects will you be looking out for while on this medication?""<br> IV. ""Do you have any questions?""<br><br>",g214501,1,"B.	I, II, III, IV",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64261,2,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""<br> II. ""What did your provider tell you to expect while on therapy?""<br> III. ""What side effects will you be looking out for while on this medication?""<br> IV. ""Do you have any questions?""<br><br>",g214502,2,"C.	III, IV",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64261,3,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""<br> II. ""What did your provider tell you to expect while on therapy?""<br> III. ""What side effects will you be looking out for while on this medication?""<br> IV. ""Do you have any questions?""<br><br>",g214503,3,"D.	II, III",1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64262,0,What is the pharmacist's role in oral medication adherence?,g214504,0,A. Building a strong pharmacist-patient relationship.,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64262,1,What is the pharmacist's role in oral medication adherence?,g214505,1,"B. Recognizing barriers to therapy such as drug cost, inability to swallow pills, etc.",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64262,2,What is the pharmacist's role in oral medication adherence?,g214506,2,C. Increased potential for drug toxicity,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64262,3,What is the pharmacist's role in oral medication adherence?,g214507,3,D. A & B,1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64262,4,What is the pharmacist's role in oral medication adherence?,g214508,4,E. All of the above,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64263,0,"Prior to calling a patient, make sure to do the following:",g214509,0,"A.  Review patient's past and current course of therapy, identify correct treatment plan, appropriate dose, and need for dose adjustments",0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64263,1,"Prior to calling a patient, make sure to do the following:",g214510,1,B. Document the topics that you would like to discuss with the patient,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64263,2,"Prior to calling a patient, make sure to do the following:",g214511,2,C. Familiarize yourself with patient's medication,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64263,3,"Prior to calling a patient, make sure to do the following:",g214512,3,D. A &C,1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64263,4,"Prior to calling a patient, make sure to do the following:",g214513,4,E. None of the above,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64264,0,"True or False: All Adverse events, lack of compliance, or any other issue should be communicated to the physician and/or nursing staff and documented in the EMR.",g214514,0,TRUE,1,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20058,9631,Elearning-0000-850,g14044,g64264,1,"True or False: All Adverse events, lack of compliance, or any other issue should be communicated to the physician and/or nursing staff and documented in the EMR.",g214515,1,FALSE,0,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS
20057,9629,Elearning-0000-849,g14043,g64245,0,The magnitude of increase in red blood cell concentration is primarily controlled by the length of time erythropoietin concentrations are maintained.,g214443,0,TRUE,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64245,1,The magnitude of increase in red blood cell concentration is primarily controlled by the length of time erythropoietin concentrations are maintained.,g214444,1,FALSE,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64246,0,All are appropriate uses of ESAs except,g214445,0,a. Anemia of chronic kidney disease,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64246,1,All are appropriate uses of ESAs except,g214446,1,b. Myelodysplastic syndrome,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64246,2,All are appropriate uses of ESAs except,g214447,2,c. Zidovudine treated HIV+ patients,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64246,3,All are appropriate uses of ESAs except,g214448,3,d. Acute renal failure,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64247,0,"Typically, increases in hemoglobin, red blood cells and hematocrit are not seen for 2-6 weeks after beginning therapy.",g214449,0,TRUE,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64247,1,"Typically, increases in hemoglobin, red blood cells and hematocrit are not seen for 2-6 weeks after beginning therapy.",g214450,1,FALSE,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64248,0,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,g214451,0,a. CKD patients on hemodialysis,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64248,1,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,g214452,1,b. CKD patients not on hemodialysis,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64248,2,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,g214453,2,c. Chemotherapy induced anemia,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64248,3,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,g214454,3,d. B and C,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64248,4,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,g214455,4,"e. A, B and C",1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64249,0,Greater biological response to ESAs is not observed at doses exceeding,g214456,0,a. 120 units/kg three times weekly,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64249,1,Greater biological response to ESAs is not observed at doses exceeding,g214457,1,b. 200 units/kg three times weekly,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64249,2,Greater biological response to ESAs is not observed at doses exceeding,g214458,2,c. 300 units/kg three times weekly,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64249,3,Greater biological response to ESAs is not observed at doses exceeding,g214459,3,d. 500 units/kg three times weekly,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64250,0,"In almost all published studies, subcutaneous administration of ESAs in chronic kidney disease is associated with a 25-50% EPO dose reduction compared to IV administration.",g214460,0,TRUE,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64250,1,"In almost all published studies, subcutaneous administration of ESAs in chronic kidney disease is associated with a 25-50% EPO dose reduction compared to IV administration.",g214461,1,FALSE,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64251,0,ESAs have been shown to improve quality of life in patients with chemotherapy induced anemia.,g214462,0,TRUE,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64251,1,ESAs have been shown to improve quality of life in patients with chemotherapy induced anemia.,g214463,1,FALSE,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64252,0,Administration of iron helps to,g214464,0,a. Achieve and maintain goal hemoglobin levels,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64252,1,Administration of iron helps to,g214465,1,b. Prevent iron deficiencies,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64252,2,Administration of iron helps to,g214466,2,c. Minimize the dose of ESA needed,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64252,3,Administration of iron helps to,g214467,3,d. All of the above,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64253,0,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,g214468,0,a. Hemoglobin > 12 g/dL,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64253,1,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,g214469,1,b. Hemoglobin >11 g/dL,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64253,2,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,g214470,2,c. Hemoglobin >10 g/dL,0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64253,3,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,g214471,3,d. All of the above,1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64254,0,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,g214472,0,"a. fever, chills",0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64254,1,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,g214473,1,"b. backache, myalgia",0,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64254,2,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,g214474,2,"c. sweating, excessive lacrimation",1,RPH UPDATE ON RBCGFS 2021
20057,9629,Elearning-0000-849,g14043,g64254,3,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,g214475,3,"d. dizziness, syncope",0,RPH UPDATE ON RBCGFS 2021
20056,9657,Elearning-0000-874,g14042,g64235,0,Rituxan Hycela┬⌐ is available in:,g214410,0,a. 11..7 ml vial,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64235,1,Rituxan Hycela┬⌐ is available in:,g214411,1,b. 13.4 ml vial,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64235,2,Rituxan Hycela┬⌐ is available in:,g214412,2,c. 15.5 ml vial,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64235,3,Rituxan Hycela┬⌐ is available in:,g214413,3,d. a and b,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64236,0,A loading dose is required for Herceptin Hylecta┬⌐,g214414,0,a. True,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64236,1,A loading dose is required for Herceptin Hylecta┬⌐,g214415,1,b. False,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64237,0,Which of the following is correct about Darzalex Faspro┬⌐?,g214416,0,"a. Contains 1800 mg Darzalex/30,000units Hyaluronic acid in 15 ml.",1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64237,1,Which of the following is correct about Darzalex Faspro┬⌐?,g214417,1,b. Administration requires an infusion pump.,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64237,2,Which of the following is correct about Darzalex Faspro┬⌐?,g214418,2,c. Requires successful completion of a Darzalex┬⌐ IV dose prior to administration of Darzalex Faspro┬⌐.,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64237,3,Which of the following is correct about Darzalex Faspro┬⌐?,g214419,3,"d-	Requires premeds be given at least one hour before dose.",0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64238,0,Which technique is used to increase bioavailability of a subcutaneous combination of biological drug with enzyme rHuPH20 in oncology treatment?,g214420,0,"a. The two components are administered sequentially through the same needle, with rHuPH20 introduced first, followed by the immunoglobulin.",0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64238,1,Which technique is used to increase bioavailability of a subcutaneous combination of biological drug with enzyme rHuPH20 in oncology treatment?,g214421,1,b. rHuPH20 is co-formulated with the subcutaneous active biotherapeutic.,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64238,2,Which technique is used to increase bioavailability of a subcutaneous combination of biological drug with enzyme rHuPH20 in oncology treatment?,g214422,2,c. CADD pump administration allows for continuous SC administration,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64239,0,Fixed dosing for subcutaneous mABs is considered a drawback although it is more efficient and more convenient,g214423,0,a. True,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64239,1,Fixed dosing for subcutaneous mABs is considered a drawback although it is more efficient and more convenient,g214424,1,b. False,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64240,0,Herceptin Hylecta┬⌐ is injected SC over:,g214425,0,a. 2-5 min,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64240,1,Herceptin Hylecta┬⌐ is injected SC over:,g214426,1,b. 5 min,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64240,2,Herceptin Hylecta┬⌐ is injected SC over:,g214427,2,c. 10-15 min,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64240,3,Herceptin Hylecta┬⌐ is injected SC over:,g214428,3,d. 20-30 min,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64241,0,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",g214429,0,a. Cost savings opportunities,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64241,1,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",g214430,1,b. Shorter administration time,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64241,2,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",g214431,2,c. Decreased patient discomfort,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64241,3,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",g214432,3,d. All of the above,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64242,0,Rituxan Hycela using the new subcutaneous novel administration technique:,g214433,0,a. Requires administration of a BSA- adjusted intravenous Rituxan┬⌐ dose prior to Rituxan Hycela┬⌐.,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64242,1,Rituxan Hycela using the new subcutaneous novel administration technique:,g214434,1,b. Requires a 1400mg loading dose for follicular lymphoma.,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64242,2,Rituxan Hycela using the new subcutaneous novel administration technique:,g214435,2,c. Has flat 1600mg dose for all indications,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64242,3,Rituxan Hycela using the new subcutaneous novel administration technique:,g214436,3,d. Is interchangeable with Rituxan IV,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64243,0,Phesgo 600mg x 2 is interchangeable with Phesgo 1200mg. Either may be used for loading dose.,g214437,0,a. True,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64243,1,Phesgo 600mg x 2 is interchangeable with Phesgo 1200mg. Either may be used for loading dose.,g214438,1,b. False,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64244,0,Subcutaneous biologics are administered at home for all of the following diseases except:,g214439,0,a. Rheumatoid Arthritis,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64244,1,Subcutaneous biologics are administered at home for all of the following diseases except:,g214440,1,b. Multiple Sclerosis,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64244,2,Subcutaneous biologics are administered at home for all of the following diseases except:,g214441,2,c. Cancer,1,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20056,9657,Elearning-0000-874,g14042,g64244,3,Subcutaneous biologics are administered at home for all of the following diseases except:,g214442,3,d. Diabetes,0,2021 NOVEL SUBCUTANEOUS BIOLOGICS
20053,9601,Elearning-0000-823,g14039,g64233,0,I have reviewed the hospital Hand Hygiene Policy and this CBL. I attest that I will speak up if I witness any break in proper Hand Hygiene.,g214406,0,TRUE,1,HAND HYGIENE ATTESTATION 2021
20053,9601,Elearning-0000-823,g14039,g64233,1,I have reviewed the hospital Hand Hygiene Policy and this CBL. I attest that I will speak up if I witness any break in proper Hand Hygiene.,g214407,1,FALSE,0,HAND HYGIENE ATTESTATION 2021
20045,9651,Elearning-0000-869,g14032,g64216,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage.,g214364,0,TRUE,1,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64216,1,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage.,g214365,1,FALSE,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64217,0,Hemorrhage carts will be located,g214366,0,FCC,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64217,1,Hemorrhage carts will be located,g214367,1,L&D,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64217,2,Hemorrhage carts will be located,g214368,2,L&D only,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64217,3,Hemorrhage carts will be located,g214369,3,Both A&B,1,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64218,0,The OB Hemorrhage Cart is secured by:,g214370,0,A zip tie,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64218,1,The OB Hemorrhage Cart is secured by:,g214371,1,2 Digital locks,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64218,2,The OB Hemorrhage Cart is secured by:,g214372,2,Red security seal,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64218,3,The OB Hemorrhage Cart is secured by:,g214373,3,B and C,1,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64218,4,The OB Hemorrhage Cart is secured by:,g214374,4,All of the above,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64219,0,Medications are stored in the OB Hemorrhage Cart,g214375,0,TRUE,1,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64219,1,Medications are stored in the OB Hemorrhage Cart,g214376,1,FALSE,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64220,0,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,g214377,0,Red,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64220,1,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,g214378,1,Yellow,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64220,2,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,g214379,2,Green,1,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64221,0,How frequently should the cart thermometer be checked?,g214380,0,Once a day,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64221,1,How frequently should the cart thermometer be checked?,g214381,1,Every shift,1,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64221,2,How frequently should the cart thermometer be checked?,g214382,2,Once a week,0,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64222,0,"If a patient is transferred during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",g214383,0,TRUE,1,FY2021 OB HEMORRHAGE CART - NSF
20045,9651,Elearning-0000-869,g14032,g64222,1,"If a patient is transferred during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",g214384,1,FALSE,0,FY2021 OB HEMORRHAGE CART - NSF
20043,9586,Elearning-0000-81,g14030,g64213,0,"Please vote for one of the following staff members for the Clinical Excellence Award FY 21 Q 3,  Ni Aung or Jummy Kareem",g214358,0,Ni Aung,1,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3
20043,9586,Elearning-0000-81,g14030,g64213,1,"Please vote for one of the following staff members for the Clinical Excellence Award FY 21 Q 3,  Ni Aung or Jummy Kareem",g214359,1,Jummy Kareem,1,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3
20043,9586,Elearning-0000-81,g14030,g64214,0,"Please vote for one of the following staff members for the Unit star FY 21 Q 3,  Angie Dixon or Sabrena Sanders",g214360,0,Angie Dixon,1,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3
20043,9586,Elearning-0000-81,g14030,g64214,1,"Please vote for one of the following staff members for the Unit star FY 21 Q 3,  Angie Dixon or Sabrena Sanders",g214361,1,Sabrena Sanders,1,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3
20041,8993,Elearning-0000-270,g14029,g64212,0,"I acknowledge that I have read this CBL in its entirety, and I understand how to properly navigate functionality on the Philips Monitor IntellliVue MX400.",g214356,0,TRUE,1,PHILIPS MONITOR INTELLIVUE EDUCATION MX400
20041,8993,Elearning-0000-270,g14029,g64212,1,"I acknowledge that I have read this CBL in its entirety, and I understand how to properly navigate functionality on the Philips Monitor IntellliVue MX400.",g214357,1,FALSE,0,PHILIPS MONITOR INTELLIVUE EDUCATION MX400
20040,9944,Questions-0000-78,g14028,g64196,0,Please list the location for this activity.,g214297,0,Atlanta,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64196,1,Please list the location for this activity.,g214298,1,Cherokee,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64196,2,Please list the location for this activity.,g214299,2,Forsyth,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64196,3,Please list the location for this activity.,g214300,3,Other,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64197,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",g214301,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64197,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",g214302,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64197,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",g214303,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64197,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",g214304,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64197,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",g214305,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64198,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214306,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64198,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214307,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64198,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214308,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64198,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214309,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64198,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214310,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64199,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g214311,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64199,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g214312,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64199,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g214313,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64199,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g214314,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64199,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g214315,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64200,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g214316,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64200,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g214317,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64200,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g214318,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64200,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g214319,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64200,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g214320,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64201,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214321,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64201,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214322,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64201,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214323,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64201,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214324,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64201,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214325,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64202,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g214326,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64202,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g214327,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64202,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g214328,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64202,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g214329,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64202,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g214330,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64203,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g214331,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64203,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g214332,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64203,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g214333,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64203,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g214334,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64203,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g214335,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64204,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g214336,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64204,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g214337,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64204,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g214338,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64204,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g214339,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64204,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g214340,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64205,0,"Overall, this activity was:",g214341,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64205,1,"Overall, this activity was:",g214342,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64205,2,"Overall, this activity was:",g214343,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64205,3,"Overall, this activity was:",g214344,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64205,4,"Overall, this activity was:",g214345,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64206,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214346,0,Yes,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64206,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214347,1,No,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64206,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214348,2,N/A,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64209,0,How would you improve this class?,g214349,0,Reduce content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64209,1,How would you improve this class?,g214350,1,Increase content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64209,2,How would you improve this class?,g214351,2,Update content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64209,3,How would you improve this class?,g214352,3,Improve the instructional methods,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64209,4,How would you improve this class?,g214353,4,Make course activities more stimulating,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64209,5,How would you improve this class?,g214354,5,Slow the pace of the class,0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20040,9944,Questions-0000-78,g14028,g64209,6,How would you improve this class?,g214355,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)"
20039,9873,Questions-0000-162,g14027,g64177,0,Please list the location for this activity.,g214223,0,Atlanta,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64177,1,Please list the location for this activity.,g214224,1,Forsyth,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64177,2,Please list the location for this activity.,g214225,2,Cherokee,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64177,3,Please list the location for this activity.,g214226,3,Other,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64178,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",g214227,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64178,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",g214228,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64178,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",g214229,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64178,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",g214230,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64178,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",g214231,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64179,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",g214232,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64179,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",g214233,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64179,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",g214234,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64179,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",g214235,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64179,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",g214236,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64180,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",g214237,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64180,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",g214238,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64180,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",g214239,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64180,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",g214240,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64180,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",g214241,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64181,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g214242,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64181,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g214243,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64181,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g214244,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64181,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g214245,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64181,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g214246,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64182,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214247,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64182,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214248,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64182,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214249,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64182,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214250,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64182,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214251,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64183,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,g214252,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64183,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,g214253,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64183,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,g214254,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64183,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,g214255,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64183,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,g214256,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64184,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,g214257,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64184,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,g214258,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64184,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,g214259,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64184,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,g214260,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64184,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,g214261,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64185,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214262,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64185,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214263,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64185,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214264,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64185,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214265,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64185,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g214266,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64186,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214267,0,Strongly Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64186,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214268,1,Agree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64186,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214269,2,No Opinion,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64186,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214270,3,Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64186,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g214271,4,Strongly Disagree,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64187,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",g214272,0,Excellent,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64187,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",g214273,1,Very Good,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64187,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",g214274,2,Good,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64187,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",g214275,3,Fair,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64187,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",g214276,4,Poor,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64188,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",g214277,0,Excellent,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64188,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",g214278,1,Very Good,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64188,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",g214279,2,Good,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64188,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",g214280,3,Fair,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64188,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",g214281,4,Poor,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64189,0,"Overall, this activity was:",g214282,0,Excellent,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64189,1,"Overall, this activity was:",g214283,1,Very Good,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64189,2,"Overall, this activity was:",g214284,2,Good,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64189,3,"Overall, this activity was:",g214285,3,Fair,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64189,4,"Overall, this activity was:",g214286,4,Poor,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64190,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214287,0,Yes,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64190,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214288,1,No,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64190,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214289,2,N/A,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64193,0,How would you improve this class?,g214290,0,Reduce content covered in class,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64193,1,How would you improve this class?,g214291,1,Increase content covered in class,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64193,2,How would you improve this class?,g214292,2,Update content covered in class,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64193,3,How would you improve this class?,g214293,3,Improve the instructional methods,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64193,4,How would you improve this class?,g214294,4,Make course activities more stimulating,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64193,5,How would you improve this class?,g214295,5,Slow the pace of the class,0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20039,9873,Questions-0000-162,g14027,g64193,6,How would you improve this class?,g214296,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21
20037,9884,Questions-0000-18,g14025,g64131,0,Please list the location for this activity.,g214035,0,Atlanta,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64131,1,Please list the location for this activity.,g214036,1,Forsyth,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64131,2,Please list the location for this activity.,g214037,2,Cherokee,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64131,3,Please list the location for this activity.,g214038,3,Other,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64132,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",g214039,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64132,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",g214040,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64132,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",g214041,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64132,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",g214042,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64132,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",g214043,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64133,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",g214044,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64133,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",g214045,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64133,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",g214046,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64133,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",g214047,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64133,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",g214048,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64134,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",g214049,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64134,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",g214050,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64134,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",g214051,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64134,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",g214052,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64134,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",g214053,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64135,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",g214054,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64135,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",g214055,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64135,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",g214056,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64135,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",g214057,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64135,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",g214058,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64136,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",g214059,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64136,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",g214060,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64136,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",g214061,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64136,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",g214062,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64136,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",g214063,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64137,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",g214064,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64137,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",g214065,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64137,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",g214066,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64137,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",g214067,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64137,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",g214068,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64138,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214069,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64138,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214070,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64138,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214071,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64138,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214072,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64138,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g214073,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64139,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214074,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64139,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214075,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64139,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214076,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64139,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214077,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64139,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g214078,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64140,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g214079,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64140,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g214080,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64140,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g214081,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64140,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g214082,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64140,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g214083,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64141,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,g214084,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64141,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,g214085,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64141,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,g214086,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64141,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,g214087,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64141,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,g214088,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64142,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214089,0,Strongly Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64142,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214090,1,Agree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64142,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214091,2,No Opinion,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64142,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214092,3,Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64142,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g214093,4,Strongly Disagree,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64143,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",g214094,0,Excellent,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64143,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",g214095,1,Very Good,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64143,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",g214096,2,Good,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64143,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",g214097,3,Fair,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64143,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",g214098,4,Poor,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64144,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",g214099,0,Excellent,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64144,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",g214100,1,Very Good,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64144,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",g214101,2,Good,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64144,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",g214102,3,Fair,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64144,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",g214103,4,Poor,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64145,0,"Overall, this activity was:",g214104,0,Excellent,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64145,1,"Overall, this activity was:",g214105,1,Very Good,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64145,2,"Overall, this activity was:",g214106,2,Good,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64145,3,"Overall, this activity was:",g214107,3,Fair,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64145,4,"Overall, this activity was:",g214108,4,Poor,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64146,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214109,0,Yes,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64146,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214110,1,No,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64146,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g214111,2,N/A,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64149,0,How would you improve this class?,g214112,0,Reduce content covered in class,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64149,1,How would you improve this class?,g214113,1,Increase content covered in class,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64149,2,How would you improve this class?,g214114,2,Update content covered in class,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64149,3,How would you improve this class?,g214115,3,Improve the instructional methods,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64149,4,How would you improve this class?,g214116,4,Make course activities more stimulating,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64149,5,How would you improve this class?,g214117,5,Slow the pace of the class,0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20037,9884,Questions-0000-18,g14025,g64149,6,How would you improve this class?,g214118,6,"Nothing: (appropriate speakers, content, setting, etc.)",0,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21
20036,9253,Elearning-0000-507,g14024,g64130,0,"For questions about these statements, contact your manager or clinical specialist.<br><br>  I have reviewed the JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE for ACC & GCS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g214033,0,TRUE,1,JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE FOR ACC & GCS
20036,9253,Elearning-0000-507,g14024,g64130,1,"For questions about these statements, contact your manager or clinical specialist.<br><br>  I have reviewed the JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE for ACC & GCS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g214034,1,FALSE,0,JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE FOR ACC & GCS
20035,9552,Elearning-0000-779,g14023,g64115,0,"If a patient has a laryngectomy, the patient can be intubated through the mouth if mechanical ventilation is needed.",g213991,0,TRUE,0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64115,1,"If a patient has a laryngectomy, the patient can be intubated through the mouth if mechanical ventilation is needed.",g213992,1,FALSE,1,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64126,0,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",g214021,0,"a)	All of the above",0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64126,1,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",g214022,1,"b)	1, 3, 4",1,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64126,2,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",g214023,2,"c)	2, 3, 4",0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64126,3,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",g214024,3,"d)	1, 3",0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64127,0,"If the patient has a laryngectomy, what should be at the HOB?",g214025,0,"a)	Fresh Trach sign",0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64127,1,"If the patient has a laryngectomy, what should be at the HOB?",g214026,1,"b)	""I am a neck breather"" sign",1,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64127,2,"If the patient has a laryngectomy, what should be at the HOB?",g214027,2,"c)	Nothing needed at the HOB",0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64128,0,"If mechanical ventilation is necessary, an ETT should be placed through the stoma such that the balloon is nearly visible under the skin.",g214028,0,TRUE,1,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64128,1,"If mechanical ventilation is necessary, an ETT should be placed through the stoma such that the balloon is nearly visible under the skin.",g214029,1,FALSE,0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64129,0,What should be used to clean around the patient's laryngectomy stoma?,g214030,0,"a)	Hydrogen peroxide",0,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64129,1,What should be used to clean around the patient's laryngectomy stoma?,g214031,1,"b)	Sterile saline",1,LARYNGECTOMY
20035,9552,Elearning-0000-779,g14023,g64129,2,What should be used to clean around the patient's laryngectomy stoma?,g214032,2,"c)	Tap water",0,LARYNGECTOMY
20026,9893,Questions-0000-27,g14015,g64068,0,Please list the location for this activity.,g213830,0,Atlanta,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64068,1,Please list the location for this activity.,g213831,1,Forsyth,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64068,2,Please list the location for this activity.,g213832,2,Cherokee,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64068,3,Please list the location for this activity.,g213833,3,Other,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64069,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g213834,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64069,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g213835,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64069,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g213836,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64069,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g213837,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64069,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g213838,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64070,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g213839,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64070,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g213840,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64070,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g213841,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64070,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g213842,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64070,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g213843,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64071,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g213844,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64071,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g213845,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64071,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g213846,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64071,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g213847,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64071,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g213848,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64072,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g213849,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64072,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g213850,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64072,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g213851,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64072,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g213852,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64072,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g213853,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64073,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g213854,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64073,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g213855,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64073,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g213856,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64073,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g213857,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64073,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g213858,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64074,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g213859,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64074,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g213860,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64074,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g213861,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64074,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g213862,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64074,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g213863,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64075,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g213864,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64075,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g213865,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64075,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g213866,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64075,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g213867,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64075,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g213868,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64076,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g213869,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64076,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g213870,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64076,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g213871,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64076,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g213872,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64076,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g213873,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64077,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g213874,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64077,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g213875,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64077,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g213876,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64077,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g213877,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64077,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g213878,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64078,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g213879,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64078,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g213880,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64078,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g213881,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64078,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g213882,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64078,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g213883,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64079,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g213884,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64079,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g213885,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64079,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g213886,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64079,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g213887,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64079,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g213888,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64080,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213889,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64080,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213890,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64080,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213891,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64080,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213892,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64080,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213893,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64081,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g213894,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64081,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g213895,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64081,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g213896,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64081,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g213897,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64081,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g213898,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64082,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213899,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64082,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213900,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64082,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213901,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64082,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213902,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64082,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213903,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64083,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g213904,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64083,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g213905,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64083,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g213906,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64083,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g213907,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64083,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g213908,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64084,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g213909,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64084,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g213910,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64084,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g213911,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64084,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g213912,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64084,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g213913,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64085,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",g213914,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64085,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",g213915,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64085,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",g213916,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64085,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",g213917,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64085,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",g213918,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64086,0,"Overall, this activity was:",g213919,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64086,1,"Overall, this activity was:",g213920,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64086,2,"Overall, this activity was:",g213921,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64086,3,"Overall, this activity was:",g213922,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64086,4,"Overall, this activity was:",g213923,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64087,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g213924,0,Yes,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64087,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g213925,1,No,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64087,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g213926,2,N/A,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64090,0,How would you improve this class?,g213927,0,Reduce content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64090,1,How would you improve this class?,g213928,1,Increase content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64090,2,How would you improve this class?,g213929,2,Update content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64090,3,How would you improve this class?,g213930,3,Improve the instructional methods,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64090,4,How would you improve this class?,g213931,4,Make course activities more stimulating,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64090,5,How would you improve this class?,g213932,5,Slow the pace of the class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20026,9893,Questions-0000-27,g14015,g64090,6,How would you improve this class?,g213933,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21
20025,8634,Elearning-0000-150,g14014,g64067,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the CONTINUOUS READINESS SUPPLY STORAGE CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213828,0,TRUE,1,CONTINUOUS READINESS SUPPLY STORAGE
20025,8634,Elearning-0000-150,g14014,g64067,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the CONTINUOUS READINESS SUPPLY STORAGE CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213829,1,FALSE,0,CONTINUOUS READINESS SUPPLY STORAGE
20023,9189,Elearning-0000-449,g14012,g64065,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the MetaNeb-IPV FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213824,0,TRUE,1,METANEB-IPV FORSYTH
20023,9189,Elearning-0000-449,g14012,g64065,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the MetaNeb-IPV FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213825,1,FALSE,0,METANEB-IPV FORSYTH
20022,9560,Elearning-0000-786,g14011,g64064,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ASV-1.1 for RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213822,0,TRUE,1,ASV-1.1 FOR  RT FORSYTH
20022,9560,Elearning-0000-786,g14011,g64064,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ASV-1.1 for RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213823,1,FALSE,0,ASV-1.1 FOR  RT FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213477,0,"A.	Increase target Vt",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,1,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213478,1,"B.	Increase Pmax and Pmin",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,2,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213479,2,"C.	Increase EPAP",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,3,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213480,3,"D.	Decrease Rate",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,4,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213481,4,"E.	Decrease FiO2",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,5,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213482,5,"F.	Increase Rate",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,6,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213483,6,"G.	A, B, E, F",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,7,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213484,7,"H.	Only A & B",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63994,8,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",g213485,8,"I.	All of the above",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63995,0,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,g213486,0,"A.	Capnostream EtCO2 remote monitor",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63995,1,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,g213487,1,"B.	NellCor  remote monitored pulse oximeter",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63995,2,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,g213488,2,"C.	Nellcor N65 pulse oximeter",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63995,3,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,g213489,3,"D.	Floor Dynamap monitor",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63996,0,A patient with a trach transfers from ICU to your floor. What do you need to do?,g213490,0,"A.	Verify equipment such as oxygen, humidity therapy, & suction are set up",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63996,1,A patient with a trach transfers from ICU to your floor. What do you need to do?,g213491,1,"B.	Verify ambu-bag and extra trachs are at bedside including one of equal size, and one size smaller than the patient's trach size.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63996,2,A patient with a trach transfers from ICU to your floor. What do you need to do?,g213492,2,"C.	Set up remote pulse ox on patient and enter patient data and orders into all computer systems",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63996,3,A patient with a trach transfers from ICU to your floor. What do you need to do?,g213493,3,"D.	Assess patient and document assessment and recommendations in computer system",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63996,4,A patient with a trach transfers from ICU to your floor. What do you need to do?,g213494,4,"E.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63997,0,Which of the following are FALSE concerning Tracheostomy patients during transports?,g213495,0,"A.	Respiratory Therapist must accompany the patient during the entire transport (must stay with patient).",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63997,1,Which of the following are FALSE concerning Tracheostomy patients during transports?,g213496,1,"B.	A bag valve mask, obturator or spare tracheostomy must also accompany the patient during transport in the event the airway is displaced.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63997,2,Which of the following are FALSE concerning Tracheostomy patients during transports?,g213497,2,"C.	If a patient is having an MRI or CT performed, the Respiratory Therapist must stay in the MRI or CT room and be able to access the patient in the event of an emergency at all times.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63997,3,Which of the following are FALSE concerning Tracheostomy patients during transports?,g213498,3,"D.	Respiratory Therapist must accompany the patient during transport, and may leave patient (if stable) in area where procedure is to be performed",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63998,0,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",g213499,0,"A.	None. These are home meds and we don't recommend changing home meds.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63998,1,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",g213500,1,"B.	Keep meds as listed but add 0.5mg Atrovent Q4 and Spiriva 1 puff daily",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63998,2,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",g213501,2,"C.	Change Albuterol to Xopenex per interchange policy & add Spiriva 1 puff daily",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63998,3,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",g213502,3,"D.	Recommend discontinuing one of the duplications of inhaled corticosteroid and long-acting beta agonist medications, consider adding 0.5mg Atrovent Q4.",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63999,0,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,g213503,0,"A.	75%: Change SMI to PRN for nursing to follow, notify RN & Document in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63999,1,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,g213504,1,"B.	50% - 75%: Continue SMI for now, start IPPB in 3 days; Document in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63999,2,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,g213505,2,"C.	50%-75%: Start IBBP therapy and discontinue SMI; Document in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63999,3,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,g213506,3,"D.	<50%: Start IBBP and continue use of SMI BID or after each IPPB treatment to measure volume improvement until patient can achieve goal >50% for 2 consecutive visits;  Document both in EMR",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g63999,4,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,g213507,4,"E.	<50%: continue SMI, reassess in 72 hours for need for IPPB; Document in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64000,0,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",g213508,0,"A.	Write Goal and start date. Place sticker in chart",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64000,1,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",g213509,1,"B.	Write Goal and volume <50%. Place sticker on nebulizer",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64000,2,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",g213510,2,"C.	Write Goal and volume <50%. Place sticker just above goal line on SMI",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64000,3,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",g213511,3,"D.	What yellow sticker?",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,0,The proper steps for setting a patient up with Remote monitoring include:,g213512,0,"A.	Selecting the correct monitor and accessory equipment; putting in a remote monitoring order with start date and time",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,1,The proper steps for setting a patient up with Remote monitoring include:,g213513,1,"B.	Use the pink probe with the Pulse oximeter and the white probe with the Capnostream",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,2,The proper steps for setting a patient up with Remote monitoring include:,g213514,2,"C.	Placing the patient data in Bernoulli using 2 patient identifiers, start date & time and notify Telemetry at 43588",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,3,The proper steps for setting a patient up with Remote monitoring include:,g213515,3,"D.	Chart appropriately in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,4,The proper steps for setting a patient up with Remote monitoring include:,g213516,4,"E.	Completing Log Book in dept. to include patient name, account number, CB#, pager assigned, and device selected.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,5,The proper steps for setting a patient up with Remote monitoring include:,g213517,5,"F.	Patients on >5L O2 are placed on Capnostream EtCO2 monitoring",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,6,The proper steps for setting a patient up with Remote monitoring include:,g213518,6,"G.	A, C, D, E",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64001,7,The proper steps for setting a patient up with Remote monitoring include:,g213519,7,"H.	A, B, E, F",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64002,0,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",g213520,0,"A.	Start Albuterol nebs Q8 and AccuPAP for 24 hours then d/c therapy",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64002,1,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",g213521,1,"B.	Start SMI and 10cmH2O of IPPB therapy with 2.5mg Albuterol and 0.5mg Atrovent Q8 for 24 hours, then reassess.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64002,2,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",g213522,2,"C.	Enter start date and goal in SMI order's comment section",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64002,3,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",g213523,3,"D.	We don't do respiratory protocol on 5TC patients",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64002,4,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",g213524,4,"E.	Place correct orders in EMR and document assessment and therapy in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64002,5,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",g213525,5,"F.	B, C, E",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64002,6,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",g213526,6,"G.	A & E",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64003,0,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,g213527,0,"A.	Set flow at 60Lpm and 100% FiO2 and wean flow first by 5 liters until below 30Lpm before weaning oxygen",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64003,1,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,g213528,1,"B.	Set flow at 30Lpm and 50% FiO2; wean FiO2 before flow; follow MD recommendations for titration. Try to get patient in negative pressure room & place STOP sign AGP sign outside patient room.",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64003,2,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,g213529,2,"C.	Set flow at 40Lpm and 100% FiO2 and wean flow first by 5% until below 30L before weaning FiO2",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64003,3,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,g213530,3,"D.	All of the above",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64004,0,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,g213531,0,"A.	Proximal to the machine but after the 1st filter on the machine",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64004,1,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,g213532,1,"B.	Proximal to the patient but before the 2nd filter on the mask",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64004,2,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,g213533,2,"C.	Distal from the patient, proximal from the machine, but before the 1st filter",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64004,3,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,g213534,3,"D.	Proximal to the patient, between the 2nd filter and the mask or on the exhalation port.",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64005,0,Which statements are correct?,g213535,0,"A.	All vents in storage areas need to be clean, plugged in, & bagged with disposable supplies packaged with vent.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64005,1,Which statements are correct?,g213536,1,"B.	Any equipment that is SET-UP READY for USE, must be stickered with date of setup and RT initials. Set up is good for 2 weeks.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64005,2,Which statements are correct?,g213537,2,"C.	Equipment cleaning and set-up is everyone's responsibility",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64005,3,Which statements are correct?,g213538,3,"D.	All equipment must be set up and ready to go at all times",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64005,4,Which statements are correct?,g213539,4,"E.	A, B, C",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64005,5,Which statements are correct?,g213540,5,"F.	All of the above",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64006,0,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",g213541,0,"A.	Any patient who requires high flow oxygen > or = to 50%. The attending physician will be notified of the results immediately.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64006,1,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",g213542,1,"B.	Any patient with an exacerbation of their pulmonary condition in which their Acid/Base or PCO2 status is questionable.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64006,2,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",g213543,2,"C.	Any patient in which oximetry results are questionable",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64006,3,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",g213544,3,"D.	All of the Above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64007,0,"If an order reads, ""CPAP per RT Protocol"" you should set up:",g213545,0,"A.	Air-sense10 or ResMed S9 in auto mode",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64007,1,"If an order reads, ""CPAP per RT Protocol"" you should set up:",g213546,1,"B.	If O2 is needed, you can bleed in up to 15 L/min",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64007,2,"If an order reads, ""CPAP per RT Protocol"" you should set up:",g213547,2,"C.	If O2 is needed, you can bleed in up to 4 L/min",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64007,3,"If an order reads, ""CPAP per RT Protocol"" you should set up:",g213548,3,"D.	V-60 only if auto CPAP device not available; start with 5 cmH2O. This level may be increased in 2 cmH2O increments Q10minutes to a maximum of 18cmH2O.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64007,4,"If an order reads, ""CPAP per RT Protocol"" you should set up:",g213549,4,"E.	A, B, D",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64007,5,"If an order reads, ""CPAP per RT Protocol"" you should set up:",g213550,5,"F.	A, C, D",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64008,0,Home Oxygen Assessment documentation includes which of the following:,g213551,0,"A.	If room air SpO2 at rest is < 89, place patient on oxygen to get SpO2 >= 89%. If able to ambulate, monitor oxygen amount needed to keep SpO2 >88% on exertion",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64008,1,Home Oxygen Assessment documentation includes which of the following:,g213552,1,"B.	If room air SpO2 is >=89% at rest, do a room air SpO2 with exertion",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64008,2,Home Oxygen Assessment documentation includes which of the following:,g213553,2,"C.	If exertional SpO2 is <89%, document how much oxygen is needed to keep SpO2 > 89%.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64008,3,Home Oxygen Assessment documentation includes which of the following:,g213554,3,"D.	A & B",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64008,4,Home Oxygen Assessment documentation includes which of the following:,g213555,4,"E.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64009,0,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g213556,0,"A.	HR increases or decreases 20% from pre-therapy HR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64009,1,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g213557,1,"B.	Therapist is unable to achieve an adequate mask seal",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64009,2,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g213558,2,"C.	No improvement within 1 hour after post ABG",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64009,3,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g213559,3,"D.	A & C",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64009,4,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g213560,4,"E.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64010,0,Which are the components of the fresh trach protocol?,g213561,0,"A.	Signage on the door with the date and time the 48 hour observation ends",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64010,1,Which are the components of the fresh trach protocol?,g213562,1,"B.	EtCO2 documented Q4",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64010,2,Which are the components of the fresh trach protocol?,g213563,2,"C.	Ambu-bag & mask, same size trach, and one size smaller at bedside, Obturator at HOB",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64010,3,Which are the components of the fresh trach protocol?,g213564,3,"D.	Respiratory therapist to be at the bedside for all patient turns/movement",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64010,4,Which are the components of the fresh trach protocol?,g213565,4,"E.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64011,0,You have an order for an ABG. What is the process for analyzing this test?,g213566,0,"A.	Verify order in EMR FIRST! Use 2 patient identifiers (compare sticker to EMR chart)",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64011,1,You have an order for an ABG. What is the process for analyzing this test?,g213567,1,"B.	Run sample in analyzer, input data at analyzer including correct panel type",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64011,2,You have an order for an ABG. What is the process for analyzing this test?,g213568,2,"C.	Always pick Complete Panel regardless of order",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64011,3,You have an order for an ABG. What is the process for analyzing this test?,g213569,3,"D.	Address any critical comments with appropriate documentation, then approve sample,",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64011,4,You have an order for an ABG. What is the process for analyzing this test?,g213570,4,"E.	Verify results appear in EMR, complete ABG (Adhoc) collection form & chart Therapist time.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64011,5,You have an order for an ABG. What is the process for analyzing this test?,g213571,5,"F.	A, B, D, E",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64011,6,You have an order for an ABG. What is the process for analyzing this test?,g213572,6,"G.	A, B, C, D",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64012,0,You have an ABG with critical results. Which of the following statements is FALSE.,g213573,0,"A.	You have 30 minutes to contact a licensed provider or MD to report critical values",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64012,1,You have an ABG with critical results. Which of the following statements is FALSE.,g213574,1,"B.	You have 60 minutes to contact a licensed provider or MD to report critical values",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64012,2,You have an ABG with critical results. Which of the following statements is FALSE.,g213575,2,"C.	You must document in analyzer who you contacted and include first name or initial, full last name, AND credential.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64012,3,You have an ABG with critical results. Which of the following statements is FALSE.,g213576,3,"D.	Critical results can only be called to a licensed medical provider.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64013,0,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,g213577,0,"A.	ABG form",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64013,1,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,g213578,1,"B.	Non-ABG Lab Testing form",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64013,2,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,g213579,2,"C.	Blood Gas Sample Collection form",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64013,3,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,g213580,3,"D.	ABG-SCN (RT) form",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64014,0,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,g213581,0,"A.	Modify the Aerosol Treatment order under Respiratory Orders to change the frequency",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64014,1,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,g213582,1,"B.	Cancel & Reorder the Aerosol Treatment order under Respiratory Orders to change frequency",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64014,2,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,g213583,2,"C.	Modify the Albuterol order under Medications Orders to change the frequency",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64014,3,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,g213584,3,"D.	Cancel & Reorder the Albuterol order under Medication Orders to change the frequency",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64015,0,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,g213585,0,"A.	Skin integrity will be assessed with each device check",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64015,1,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,g213586,1,"B.	A skin barrier device, such as Protecta-Gel should be used, especially if irritation or redness present, and MD is notified.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64015,2,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,g213587,2,"C.	If skin breakdown occurs, a wound consult must be placed and an incident report must be filed",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64015,3,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,g213588,3,"D.	Use alternative interface such as ""under-the-nose"" mask",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64015,4,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,g213589,4,"E.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64016,0,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",g213590,0,"A.	Increase oxygen, notify RN, document Progress note in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64016,1,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",g213591,1,"B.	Change to High-Flow NC, titrate to increase SpO2 >= 92%",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64016,2,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",g213592,2,"C.	Order and Draw ABG per O2 protocol & notify MD of results",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64016,3,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",g213593,3,"D.	Leave oxygen at 6L, SpO2 of 91% is acceptable at rest",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64016,4,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",g213594,4,"E.	A, B, C",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64016,5,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",g213595,5,"F.	A & B only",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64016,6,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",g213596,6,"G.	D only",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64017,0,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",g213597,0,"A.	Assess patient in person",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64017,1,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",g213598,1,"B.	Decrease IPI Alarm to OFF",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64017,2,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",g213599,2,"C.	Verify Capnostream Nasal cannula is on patient and both prongs are in nares",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64017,3,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",g213600,3,"D.	Verify RR actual vs monitor reading",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64017,4,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",g213601,4,"E.	If patient is on oxygen too, verify flow is < 6L",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64017,5,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",g213602,5,"F.	A, C, D, E",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64017,6,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",g213603,6,"G.	All of the above",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64018,0,Which of the following statements is FALSE?,g213604,0,"A.	Notes or comments should be placed in a Progress Note in Cerner",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64018,1,Which of the following statements is FALSE?,g213605,1,"B.	Right-click any charting field and place a comment if necessary",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64018,2,Which of the following statements is FALSE?,g213606,2,"C.	Chart education on every patient on therapy at least once a shift",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64018,3,Which of the following statements is FALSE?,g213607,3,"D.	Smoking cessation education is charted in Social Habits Education section",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64019,0,Which Statements are FALSE about oxygen weaning/titration as NSH?,g213608,0,"A.	Once a shift, weaning or titration of oxygen should be attempted for any patient wearing low flow (<7L) oxygen, who does NOT wear oxygen at home, unless they meet certain criteria.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64019,1,Which Statements are FALSE about oxygen weaning/titration as NSH?,g213609,1,"B.	If a patient does not qualify for oxygen titration, the RT must select a reason for why patient was not weaned from the REASON NOT TITRATED field in EMR",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64019,2,Which Statements are FALSE about oxygen weaning/titration as NSH?,g213610,2,"C.	AMI, Comfort Care, Pt at home level, & SpO2 less than 90% are some of the choices for REASON NOT TITRATED. OTHER is another choice, that opens a free text window, where RT can chart why oxygen weaning not indicated.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64019,3,Which Statements are FALSE about oxygen weaning/titration as NSH?,g213611,3,"D.	 Oxygen titration must also be documented on ventilated patients Q shift",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64020,0,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,g213612,0,"A.	Skin integrity and airway status will be assessed with each device check, or therapy administered or minimum Qshift.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64020,1,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,g213613,1,"B.	A skin barrier device, such as Cavilon swabs, Drawtex drain pads,  Mepilex, or Duoderm,  will be used, especially if irritation or redness present, and MD is notified.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64020,2,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,g213614,2,"C.	If skin breakdown occurs, a wound consult must be placed and an incident report must be filed",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64020,3,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,g213615,3,"D.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64021,0,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",g213616,0,"A.	Place a Biomed work order for device inspection",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64021,1,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",g213617,1,"B.	Have patient sign release of liability form and place in Chart under Consents",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64021,2,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",g213618,2,"C.	Verify or place appropriate orders and protocols",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64021,3,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",g213619,3,"D.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64022,0,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",g213620,0,"A.	An EtCO2 measurement verifies airway placement in the lungs",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64022,1,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",g213621,1,"B.	An EtCO2 < 10mmHg indicates poor circulation and reduces the likelihood of ROSC",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64022,2,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",g213622,2,"C.	Adequacy of Chest compressions can be seen by a EtCO2 > 10-15 mmHg",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64022,3,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",g213623,3,"D.	A sudden rise in EtCO2 could indicated ROSC and a pulse check should be done",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64022,4,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",g213624,4,"E.	All of the above",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64023,0,Which of the following statements are true about remote monitoring?,g213625,0,"A.	All patients who need monitoring go on a pulse ox with a pink wrap probe and then get put Bernoulli.",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64023,1,Which of the following statements are true about remote monitoring?,g213626,1,"B.	If the patient is on the dynamap on the floor, they don't need to go on remote monitoring",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64023,2,Which of the following statements are true about remote monitoring?,g213627,2,"C.	Only PCA patients go on Remote Monitoring and only for 24 hours",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64023,3,Which of the following statements are true about remote monitoring?,g213628,3,"D.	The criteria for EtCO2 monitoring is located on the badge cards and includes high risk factors such as COPD, BMI >35, age >80, Sepsis, Respiratory distress (RR <10 or >30);",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64023,4,Which of the following statements are true about remote monitoring?,g213629,4,"E.	Patients with PaO2 on ABG <65 mmHg will go on remote pulse ox with RR, per Oxygen PDP",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64023,5,Which of the following statements are true about remote monitoring?,g213630,5,"F.	D & E",1,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20019,9804,Questions-0000-10,g14009,g64023,6,Which of the following statements are true about remote monitoring?,g213631,6,"G.	All of the above",0,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH
20020,8144,Elearning-0000-104,g14008,g63993,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 VENTILATOR MODES FOR RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213475,0,TRUE,1,2021 VENTILATOR MODES FOR RT FORSYTH
20020,8144,Elearning-0000-104,g14008,g63993,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 VENTILATOR MODES FOR RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213476,1,FALSE,0,2021 VENTILATOR MODES FOR RT FORSYTH
20018,8914,Elearning-0000-199,g14007,g63992,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213473,0,TRUE,1,SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH
20018,8914,Elearning-0000-199,g14007,g63992,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213474,1,FALSE,0,SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH
20015,9733,Elearning-0000-943,g14004,g63942,0,All intubated babies must have two healthcare providers at the bedside for repositioning to reduce unplanned extubations.,g213301,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63942,1,All intubated babies must have two healthcare providers at the bedside for repositioning to reduce unplanned extubations.,g213302,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63943,0,What is the primary role of the second person that is needed for repositioning an intubated baby?,g213303,0,A. To give the other person some company,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63943,1,What is the primary role of the second person that is needed for repositioning an intubated baby?,g213304,1,B. To offer encouragement to the primary caregiver,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63943,2,What is the primary role of the second person that is needed for repositioning an intubated baby?,g213305,2,"C. To maintain the airway before, during, and after patient repositioning",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63944,0,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,g213306,0,A. When damaged or visibly soiled,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63944,1,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,g213307,1,B. After it is used to deliver PPV,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63944,2,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,g213308,2,C. When admitting a new patient,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63944,3,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,g213309,3,D. All of the above,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63945,0,"When changing or setting-up the bedside bag and mask and/or t-piece resuscitator, the storage bag should be labeled with the date the equipment was set up.",g213310,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63945,1,"When changing or setting-up the bedside bag and mask and/or t-piece resuscitator, the storage bag should be labeled with the date the equipment was set up.",g213311,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63946,0,When should the closed suction setup for ET tubes be replaced?,g213312,0,A. Every night,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63946,1,When should the closed suction setup for ET tubes be replaced?,g213313,1,B. When visibly soiled or damaged,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63946,2,When should the closed suction setup for ET tubes be replaced?,g213314,2,C. Weekly on Sunday nights,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63946,3,When should the closed suction setup for ET tubes be replaced?,g213315,3,D. None of the above,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63946,4,When should the closed suction setup for ET tubes be replaced?,g213316,4,E. B & C,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63947,0,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,g213317,0,A. Entering the unit before shift report.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63947,1,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,g213318,1,B. Before and after patient contact.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63947,2,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,g213319,2,C. Before putting on gloves and after removal of gloves.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63947,3,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,g213320,3,D. Before touching anything in the infant's bed space.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63947,4,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,g213321,4,E. When moving from a contaminated body site to a clean site during care.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63947,5,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,g213322,5,F. All of the above.,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63948,0,Which of the following does maintaining NCPAP promote?,g213323,0,A.  FRC,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63948,1,Which of the following does maintaining NCPAP promote?,g213324,1,B.  Endogenous surfactant production,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63948,2,Which of the following does maintaining NCPAP promote?,g213325,2,C.  Oxygenation,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63948,3,Which of the following does maintaining NCPAP promote?,g213326,3,D.  All of the above,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63949,0,ALL babies < 30 weeks should have CPAP placed on them immediately in the delivery room.,g213327,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63949,1,ALL babies < 30 weeks should have CPAP placed on them immediately in the delivery room.,g213328,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63950,0,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,g213329,0,A.  Over distention,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63950,1,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,g213330,1,B.  Decreased oxygenation,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63950,2,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,g213331,2,C.  Atelectasis or loss of FRC,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63950,3,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,g213332,3,D.  B and C,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63951,0,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,g213333,0,A. Immediately upon admission to the unit,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63951,1,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,g213334,1,B. After lines are placed by the physician,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63951,2,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,g213335,2,"C. After 1 hour of continuous, uninterrupted time on CPAP",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63951,3,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,g213336,3,"D. After length, head, and chest are measured",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63952,0,"Any nasal redness, bruising, or skin breakdown due to nasal prong therapy requires the MD and RN to be notified and results charted.",g213337,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63952,1,"Any nasal redness, bruising, or skin breakdown due to nasal prong therapy requires the MD and RN to be notified and results charted.",g213338,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63953,0,How do you determine the correct size nasal prongs for CPAP or NIPPV?,g213339,0,A. Use the INCA Nasal Sizing Gauge,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63953,1,How do you determine the correct size nasal prongs for CPAP or NIPPV?,g213340,1,B. Use the prong size that fill the nares without dilating or causing blanching,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63953,2,How do you determine the correct size nasal prongs for CPAP or NIPPV?,g213341,2,C. Doesn't matter because the Cannulaide provides a seal,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63953,3,How do you determine the correct size nasal prongs for CPAP or NIPPV?,g213342,3,D. A & B,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63953,4,How do you determine the correct size nasal prongs for CPAP or NIPPV?,g213343,4,E. None of the above,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63954,0,"Normal saline should only be used to clear the in-line suction catheter and NOT instilled down the endotracheal tube as a lavage, UNLESS ordered by a physician.",g213344,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63954,1,"Normal saline should only be used to clear the in-line suction catheter and NOT instilled down the endotracheal tube as a lavage, UNLESS ordered by a physician.",g213345,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63955,0,"Prior to being placed on a patient, the device check and breathing circuit check must be performed on the Drager VN 500.",g213346,0,TRUE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63955,1,"Prior to being placed on a patient, the device check and breathing circuit check must be performed on the Drager VN 500.",g213347,1,FALSE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63956,0,Which statement best describes the Volume Guarantee mode?,g213348,0,"A.  Set volume, variable pressure",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63956,1,Which statement best describes the Volume Guarantee mode?,g213349,1,"B.  Set pressure, variable volume",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63956,2,Which statement best describes the Volume Guarantee mode?,g213350,2,"C.  Set volume, set pressure",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63957,0,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",g213351,0,A. Increase VG to blow-off CO2,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63957,1,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",g213352,1,B. Call MD for high PCO2,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63957,2,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",g213353,2,C. Call MD due to max VG,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63957,3,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",g213354,3,D. None of the above,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63958,0,"In the PC-SIMV/VG mode, only the set breaths are full ventilator breaths.",g213355,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63958,1,"In the PC-SIMV/VG mode, only the set breaths are full ventilator breaths.",g213356,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63959,0,"The vent settings are:<br> PC-AC/VG = 3.0mL 	PMAX= 25	 PEEP = 5.Rate = 30 	Set Ti = 0.5 seconds<br>  Your patient requires a PIP of 22 to deliver this volume. How will the delivered PIP change if your patient becomes more compliant?",g213357,0,A.  Delivered PIP will increase,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63959,1,"The vent settings are:<br> PC-AC/VG = 3.0mL 	PMAX= 25	 PEEP = 5.Rate = 30 	Set Ti = 0.5 seconds<br>  Your patient requires a PIP of 22 to deliver this volume. How will the delivered PIP change if your patient becomes more compliant?",g213358,1,B.  Delivered PIP will decrease.,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63959,2,"The vent settings are:<br> PC-AC/VG = 3.0mL 	PMAX= 25	 PEEP = 5.Rate = 30 	Set Ti = 0.5 seconds<br>  Your patient requires a PIP of 22 to deliver this volume. How will the delivered PIP change if your patient becomes more compliant?",g213359,2,C.  No change,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63960,0,Where should the initial flow trigger be set for patients on the Drager VN-500?,g213360,0,A.  0.2 for initial setting,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63960,1,Where should the initial flow trigger be set for patients on the Drager VN-500?,g213361,1,B.  High enough to stop the patient from being tachypneic,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63960,2,Where should the initial flow trigger be set for patients on the Drager VN-500?,g213362,2,"C.  Adjusted to prevent auto-cycling, but allow for easy patient triggering",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63960,3,Where should the initial flow trigger be set for patients on the Drager VN-500?,g213363,3,D.  A and C,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63961,0,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",g213364,0,A.  Increase the rate to 34,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63961,1,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",g213365,1,B.  Wean P Insp to maintain VT  5 to 7 cc per kg,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63961,2,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",g213366,2,C.  Extubate to Bubble CPAP,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63961,3,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",g213367,3,D.  Decrease rate to 25,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63962,0,The Ventilator Performance Check and Circuit Calibration on the 3100A  needs to be performed:,g213368,0,A. Every 500 hours of use,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63962,1,The Ventilator Performance Check and Circuit Calibration on the 3100A  needs to be performed:,g213369,1,B. After each patient use,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63962,2,The Ventilator Performance Check and Circuit Calibration on the 3100A  needs to be performed:,g213370,2,C. Before setting up for use on a new patient,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63963,0,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",g213371,0,A. Decreasing the Hz/Frequency,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63963,1,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",g213372,1,B. Increasing the Amps/Power,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63963,2,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",g213373,2,C. Increasing the Hz/Frequency,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63963,3,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",g213374,3,D. Increasing the MAP,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63963,4,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",g213375,4,E. A & B,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63963,5,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",g213376,5,F. All of the above,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63964,0,How do you assess adequate lung inflation for babies on HFOV?,g213377,0,A.  Auscultate for bilateral and equal breath sounds,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63964,1,How do you assess adequate lung inflation for babies on HFOV?,g213378,1,B.  Assess the amount of chest wiggle,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63964,2,How do you assess adequate lung inflation for babies on HFOV?,g213379,2,C.  Lung expansion on chest X-ray (diaphragm sits between 8 to 10 ribs),1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63965,0,How do you assess the baby for proper Power/Amplitude on 3100A?,g213380,0,A. Chest wiggle to mid-thigh,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63965,1,How do you assess the baby for proper Power/Amplitude on 3100A?,g213381,1,B. Chest wiggle to umbilicus,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63965,2,How do you assess the baby for proper Power/Amplitude on 3100A?,g213382,2,C. Auscultate for oscillations equally throughout all lobes,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63965,3,How do you assess the baby for proper Power/Amplitude on 3100A?,g213383,3,D. Chest X-ray,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63967,0,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,g213386,0,A.   When the lung expansion is = 10 ribs.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63967,1,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,g213387,1,B.   When the lung expansion is < 8 ribs.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63967,2,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,g213388,2,C.   When the MAP is > 30.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63967,3,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,g213389,3,D.   All of the above,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63967,4,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,g213390,4,E.   Just A & B,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63968,0,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",g213391,0,A. When PCO2 is > 65,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63968,1,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",g213392,1,B. When ordered by the MD,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63968,2,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",g213393,2,"C. When an ETCO2 or TcCO2 tracing, that has been correlated to a blood gas, trends higher than a stable level",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63968,3,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",g213394,3,D. All of the above,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63969,0,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",g213395,0,A. Decrease alveolar surface tension,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63969,1,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",g213396,1,B. Maintain bronchiolar patency,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63969,2,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",g213397,2,C. Preferentially improve the surface tension of collapsed alveoli,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63969,3,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",g213398,3,D. Increase the pressure needed to keep alveoli open,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63970,0,"The dose number of Curosurf (1st, 2nd, or 3rd dose) should be noted in the comments field of OneChart MAR and Respiratory Therapy iView.",g213399,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63970,1,"The dose number of Curosurf (1st, 2nd, or 3rd dose) should be noted in the comments field of OneChart MAR and Respiratory Therapy iView.",g213400,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63971,0,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,g213401,0,"A. Sterile gloves, clean chux or 4 x 4 gauze, unvented syringe for waste, vented syringe for blood sampling, 4 Site scrubs, heparin flush syringe and Curos green cap.",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63971,1,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,g213402,1,"B. Gloves, clean chux or 4 x 4 gauze, vented syringe for waste, vented syringe for blood sampling, 4 Site scrubs, heparin flush syringe and Curos green cap.",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63971,2,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,g213403,2,"C. Gloves, clean chux only, vented syringe for waste, vented syringe for blood sampling, 2 Site scrubs, heparin flush syringe and Curos green cap.",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63971,3,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,g213404,3,"D. Gloves, 4 x 4 gauze, unvented syringe for waste, unvented syringe for blood sampling, 4 Site scrubs, heparin flush syringe and Curos green cap.",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63972,0,How much heparin is required to flush an umbilical artery catheter in the SCN?,g213405,0,A. 1cc over 30 - 60 seconds,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63972,1,How much heparin is required to flush an umbilical artery catheter in the SCN?,g213406,1,B. 0.3 - 0.5cc over 30 - 60 seconds,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63972,2,How much heparin is required to flush an umbilical artery catheter in the SCN?,g213407,2,C. 0.5cc rapidly,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63972,3,How much heparin is required to flush an umbilical artery catheter in the SCN?,g213408,3,D. Until the line is clear,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63973,0,"There must be a new MD order to use the RAM prongs on a HFNC, BCPAP or NIPPV patient, even if the baby was already on RAM prongs during previous therapies.",g213409,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63973,1,"There must be a new MD order to use the RAM prongs on a HFNC, BCPAP or NIPPV patient, even if the baby was already on RAM prongs during previous therapies.",g213410,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63974,0,"When RAM prongs are ordered to be used with HFNC, the prongs used should not occlude the nares.",g213411,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63974,1,"When RAM prongs are ordered to be used with HFNC, the prongs used should not occlude the nares.",g213412,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63975,0,When does an Oxygen Index need to be calculated?,g213413,0,A. With every ABG for patients receiving inhaled nitric oxide therapy,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63975,1,When does an Oxygen Index need to be calculated?,g213414,1,B. With every patient on HFOV,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63975,2,When does an Oxygen Index need to be calculated?,g213415,2,C. Only when the patient is on 100% oxygen,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63975,3,When does an Oxygen Index need to be calculated?,g213416,3,D. If ordered by the physician,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63975,4,When does an Oxygen Index need to be calculated?,g213417,4,E. A & D,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63976,0,"Calculate the Oxygen Index for a 38 week newborn with confirmed pulmonary hypertension via echocardiogram on Inhaled Nitric Oxide based on the following parameters:,br> MAP = 25	FiO2 = 75%	PaO2 = 50",g213418,0,A. 60,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63976,1,"Calculate the Oxygen Index for a 38 week newborn with confirmed pulmonary hypertension via echocardiogram on Inhaled Nitric Oxide based on the following parameters:,br> MAP = 25	FiO2 = 75%	PaO2 = 50",g213419,1,B. 55,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63976,2,"Calculate the Oxygen Index for a 38 week newborn with confirmed pulmonary hypertension via echocardiogram on Inhaled Nitric Oxide based on the following parameters:,br> MAP = 25	FiO2 = 75%	PaO2 = 50",g213420,2,C. 37.5,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63977,0,What oxygen index requires a call to the MD?,g213421,0,A. OI > 20 for babies = 34 weeks,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63977,1,What oxygen index requires a call to the MD?,g213422,1,B.  OI > 10 for babies 26 - 33 6/7 weeks,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63977,2,What oxygen index requires a call to the MD?,g213423,2,C. None of the above,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63977,3,What oxygen index requires a call to the MD?,g213424,3,D. A & B,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63978,0,Which statement best describes the indication for use of inhaled nitric oxide?,g213425,0,A. Hypoxic Respiratory Failure associated with clinical or echocardiographic evidence of pulmonary hypertension,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63978,1,Which statement best describes the indication for use of inhaled nitric oxide?,g213426,1,B. Meconium Aspiration Syndrome requiring FiO2 > 50%,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63978,2,Which statement best describes the indication for use of inhaled nitric oxide?,g213427,2,C. Pulmonary Interstitial Ephysema requiring HFOV,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63979,0,Which of the following shows the correct placement and adaptors for the nitric injector module on a 3100 A/B HFOV?,g213428,0,A.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63979,1,Which of the following shows the correct placement and adaptors for the nitric injector module on a 3100 A/B HFOV?,g213429,1,B.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63979,2,Which of the following shows the correct placement and adaptors for the nitric injector module on a 3100 A/B HFOV?,g213430,2,C.,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63980,0,Which of the following shows the correct placement of the nitric sample line on HFOV? (sample line has a yellow tag),g213431,0,A.,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63980,1,Which of the following shows the correct placement of the nitric sample line on HFOV? (sample line has a yellow tag),g213432,1,B.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63980,2,Which of the following shows the correct placement of the nitric sample line on HFOV? (sample line has a yellow tag),g213433,2,C.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63981,0,Which of the following shows correct placement of the nitric injector module on the Drager VN-500?,g213434,0,A.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63981,1,Which of the following shows correct placement of the nitric injector module on the Drager VN-500?,g213435,1,B.,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63981,2,Which of the following shows correct placement of the nitric injector module on the Drager VN-500?,g213436,2,C.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63982,0,Which of the following shows correct placement of the nitric sampling line for the Drager?,g213437,0,A.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63982,1,Which of the following shows correct placement of the nitric sampling line for the Drager?,g213438,1,B.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63982,2,Which of the following shows correct placement of the nitric sampling line for the Drager?,g213439,2,C.,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63983,0,How often should the orange resus bags be checked for inventory?,g213440,0,"A)	Once per shift by the Resus RT",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63983,1,How often should the orange resus bags be checked for inventory?,g213441,1,"B)	Once per day by the charge therapist",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63983,2,How often should the orange resus bags be checked for inventory?,g213442,2,"C)	After each use, if an item is used",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63983,3,How often should the orange resus bags be checked for inventory?,g213443,3,"D)	A & C",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63984,0,All unplanned extubations need to be followed up with an incident report.,g213444,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63984,1,All unplanned extubations need to be followed up with an incident report.,g213445,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63985,0,What is the proper starting temperature for the TC probe when placing on a neonate?,g213446,0,"A)	41┬░C",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63985,1,What is the proper starting temperature for the TC probe when placing on a neonate?,g213447,1,"B)	37┬░C",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63985,2,What is the proper starting temperature for the TC probe when placing on a neonate?,g213448,2,"C)	39┬░C",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63985,3,What is the proper starting temperature for the TC probe when placing on a neonate?,g213449,3,"D)	42┬░C",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63986,0,What is the maximum temperature for the TC probe on a term neonate?,g213450,0,"A)	42┬░C",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63986,1,What is the maximum temperature for the TC probe on a term neonate?,g213451,1,"B)	41┬░C",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63986,2,What is the maximum temperature for the TC probe on a term neonate?,g213452,2,"C)	40┬░C",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63986,3,What is the maximum temperature for the TC probe on a term neonate?,g213453,3,"D)	39┬░C",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63987,0,"Unless the physician orders to NOT use a TC monitor, EVERY baby on HFOV must have a TC monitor.",g213454,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63987,1,"Unless the physician orders to NOT use a TC monitor, EVERY baby on HFOV must have a TC monitor.",g213455,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63988,0,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",g213456,0,"A.  If the baby is in an open crib or radiant warmer, remove the unheated portion of the inspiratory limb.",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63988,1,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",g213457,1,"B.  If the baby is in a Caleo isolette, remove the unheated portion of the inspiratory limb if the air temperature of the Caleo is < 34┬░C.",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63988,2,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",g213458,2,C.  Make sure temp probes are pushed all the way into the ports.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63988,3,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",g213459,3,"D.  If flow is < 5 Lpm, set heater to Non-Invasive.",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63988,4,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",g213460,4,E.  All of the above,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63989,0,"According to NRP, what is the single most effective way to reverse bradycardia?",g213461,0,"A.	Chest Compressions",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63989,1,"According to NRP, what is the single most effective way to reverse bradycardia?",g213462,1,"B.	Blow-by Therapy",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63989,2,"According to NRP, what is the single most effective way to reverse bradycardia?",g213463,2,"C.	Effective PPV confirmed by MRSOPA",1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63989,3,"According to NRP, what is the single most effective way to reverse bradycardia?",g213464,3,"D.	CPAP",0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63990,0,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,g213465,0,A. Once per day.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63990,1,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,g213466,1,B. Every 6 hours.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63990,2,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,g213467,2,C. Every 3 to 4 hours.,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63990,3,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,g213468,3,D. Once a shift.,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63991,0,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,g213469,0,A. P-CMV and orange,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63991,1,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,g213470,1,B. P-CPAP and green,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63991,2,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,g213471,2,C. P-SIMV and yellow,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g63991,3,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,g213472,3,D. P-AC and blue,0,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g64492,0,"Any unopened and unused vials of surfactant should be returned to pharmacy, whereas any used or unused portion of an opened vial or syringe should be discarded appropriately, per policy.",g215321,0,TRUE,1,2021 NICU COMPETENCY EXAM_ NSF
20015,9733,Elearning-0000-943,g14004,g64492,1,"Any unopened and unused vials of surfactant should be returned to pharmacy, whereas any used or unused portion of an opened vial or syringe should be discarded appropriately, per policy.",g215322,1,FALSE,0,2021 NICU COMPETENCY EXAM_ NSF
20014,9745,Elearning-0000-954,g14003,g63941,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 ABG CBL FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213299,0,TRUE,1,2021 ABG CBL FORSYTH
20014,9745,Elearning-0000-954,g14003,g63941,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 ABG CBL FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213300,1,FALSE,0,2021 ABG CBL FORSYTH
20011,8931,Elearning-0000-214,g14002,g63939,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213295,0,TRUE,1,RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH
20011,8931,Elearning-0000-214,g14002,g63939,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g213296,1,FALSE,0,RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH
20005,9917,Questions-0000-51,g13998,g63856,0,Please list the location for this activity.,g213006,0,Atlanta,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63856,1,Please list the location for this activity.,g213007,1,Cherokee,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63856,2,Please list the location for this activity.,g213008,2,Forsyth,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63856,3,Please list the location for this activity.,g213009,3,Other,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63857,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g213010,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63857,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g213011,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63857,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g213012,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63857,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g213013,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63857,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g213014,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63858,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g213015,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63858,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g213016,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63858,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g213017,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63858,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g213018,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63858,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g213019,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63859,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g213020,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63859,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g213021,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63859,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g213022,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63859,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g213023,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63859,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g213024,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63860,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g213025,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63860,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g213026,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63860,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g213027,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63860,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g213028,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63860,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g213029,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63861,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213030,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63861,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213031,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63861,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213032,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63861,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213033,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63861,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g213034,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63862,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213035,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63862,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213036,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63862,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213037,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63862,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213038,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63862,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g213039,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63863,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g213040,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63863,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g213041,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63863,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g213042,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63863,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g213043,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63863,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g213044,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63864,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g213045,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63864,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g213046,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63864,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g213047,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63864,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g213048,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63864,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g213049,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63865,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g213050,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63865,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g213051,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63865,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g213052,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63865,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g213053,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63865,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g213054,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63866,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g213055,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63866,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g213056,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63866,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g213057,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63866,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g213058,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63866,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g213059,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63867,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g213060,4,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63867,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g213061,0,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63867,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g213062,1,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63867,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g213063,2,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63867,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g213064,3,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63867,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g213065,5,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63868,0,"Overall, this activity was:",g213066,0,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63868,1,"Overall, this activity was:",g213067,1,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63868,2,"Overall, this activity was:",g213068,2,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63868,3,"Overall, this activity was:",g213069,3,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63868,4,"Overall, this activity was:",g213070,4,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63869,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g213071,0,Yes,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63869,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g213072,1,No,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63869,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g213073,2,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63872,0,How would you improve this class (check all that apply)?,g213074,0,Reduce content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63872,1,How would you improve this class (check all that apply)?,g213075,1,Increase content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63872,2,How would you improve this class (check all that apply)?,g213076,2,Update content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63872,3,How would you improve this class (check all that apply)?,g213077,3,Improve the instructional methods,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63872,4,How would you improve this class (check all that apply)?,g213078,4,Make course activities more stimulating,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63872,5,How would you improve this class (check all that apply)?,g213079,5,Slow the pace of the class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20005,9917,Questions-0000-51,g13998,g63872,6,How would you improve this class (check all that apply)?,g213080,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21"
20003,9728,Elearning-0000-939,g13997,g63844,0,"When a rapid response is called, you should ALWAYS inform your Charge RT/ 5335 and the nurse taking care of the patient.",g212968,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63844,1,"When a rapid response is called, you should ALWAYS inform your Charge RT/ 5335 and the nurse taking care of the patient.",g212969,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63845,0,On the code sheet you should ALWAYS make sure the Airway and ETC02 section is filled out correctly before signing the sheet.,g212970,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63845,1,On the code sheet you should ALWAYS make sure the Airway and ETC02 section is filled out correctly before signing the sheet.,g212971,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63846,0,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,g212972,0,1.  5 cm,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63846,1,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,g212973,1,2. 10 cm,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63846,2,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,g212974,2,3. 15 cm,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63846,3,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,g212975,3,4. Auto set mode with high pressure limit of 10cm.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63847,0,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",g212976,0,1. Do nothing.  The patient has the right to refuse treatment.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63847,1,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",g212977,1,2. Notify the Physician and place them on a Capnography Remote Monitor. Document in the EMR and write a Progress Note.,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63847,2,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",g212978,2,3.  Place them on 3 l/m nasal oxygen,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63847,3,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",g212979,3,4.  Place them on an Optiflow at 50 l/min & 50% Fio2,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63848,0,"Patients on CPAP, home unit or hospital unit that require more than 40% / >5 lpm bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",g212980,0,1. Remote Capnography,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63848,1,"Patients on CPAP, home unit or hospital unit that require more than 40% / >5 lpm bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",g212981,1,2. Remote Pulse Ox,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63849,0,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,g212982,0,1. A & B,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63849,1,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,g212983,1,2. B & C,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63849,2,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,g212984,2,3. B only,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63849,3,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,g212985,3,4. All of the above,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63850,0,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol"", you should set up:",g212986,0,"A. Air-sense or Lumis in autoset mode with a minimum pressure of 4cmH20, max of 18cmH20",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63850,1,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol"", you should set up:",g212987,1,B. Fixed CPAP of 15cmH20,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63850,2,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol"", you should set up:",g212988,2,C. Up to 15lpm of 02 bled inline,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63850,3,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol"", you should set up:",g212989,3,D. Up to 4lpm of 02 bled inline,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63850,4,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol"", you should set up:",g212990,4,E. A and D,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63851,0,"When using the Hamilton C-2/C-3 for BiPAP, it is important  to set the following :",g212991,0,"1. I- time lower than I- time Max and ETS to 50% to compensate for mask leaks, promoting synchrony and patient comfort",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63851,1,"When using the Hamilton C-2/C-3 for BiPAP, it is important  to set the following :",g212992,1,2.  I time needs to be higher than I time Max & ETS at 25%,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63852,0,"Per the Oxygen Administration Protocol, you can obtain ABGs when a patient is on 40% or greater FiO2 without a physician order:",g212993,0,TRUE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63852,1,"Per the Oxygen Administration Protocol, you can obtain ABGs when a patient is on 40% or greater FiO2 without a physician order:",g212994,1,FALSE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63853,0,All post-op thoracic patients for the first 24 hours will receive:,g212995,0,1. SMI/Accupap(+10cm)/albuterol and ipratropium bromide Q8,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63853,1,All post-op thoracic patients for the first 24 hours will receive:,g212996,1,2. Accupap only Q8,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63853,2,All post-op thoracic patients for the first 24 hours will receive:,g212997,2,3. SMI only Q8,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63853,3,All post-op thoracic patients for the first 24 hours will receive:,g212998,3,4. Aerosol treatments with Duoneb and Mucomyst Q8,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63854,0,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,g212999,0,"a.  If room air sat at rest is < 89, place patient on oxygen to get their sat  >or = 89.  If able to ambulate, see what o2 is needed to keep > 88 on exertion(pt at home might need higher o2 when ambulating)",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63854,1,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,g213000,1,"b.  If room air sat is > or = to  89% at rest, you need to do a room air sat with  exertion",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63854,2,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,g213001,2,c.  If exertional sat is lower than <89% you need to document how much o2 is needed to keep sat > 89%. Please relay to RN and Case Management,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63854,3,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,g213002,3,d.  All of the above,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63854,4,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,g213003,4,e.  None of the above,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63855,0,Any trach outside the ICU needs to be on a remote pulse oximeter:,g213004,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63855,1,Any trach outside the ICU needs to be on a remote pulse oximeter:,g213005,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63875,0,What is the Jackson size of this trach?,g213081,0,1) 8.5,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63875,1,What is the Jackson size of this trach?,g213082,1,2) 7.5,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63875,2,What is the Jackson size of this trach?,g213083,2,3) 8,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63875,3,What is the Jackson size of this trach?,g213084,3,4) 85,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63876,0,When a trach patient on the floor is de-cannulated you must :,g213085,0,1.   Stay in room with the patient for 24 hours,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63876,1,When a trach patient on the floor is de-cannulated you must :,g213086,1,2.   Keep the patient on a remote pulse ox for 24 hours per policy,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63876,2,When a trach patient on the floor is de-cannulated you must :,g213087,2,3.  Place on a remote capnography for 24 hours,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63877,0,The remote therapist will assess monitored patients and document results twice per shift.,g213088,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63877,1,The remote therapist will assess monitored patients and document results twice per shift.,g213089,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63898,0,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,g213160,0,1. Place the patient on a remote Capnography.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63898,1,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,g213161,1,2. Call the physician to have the remote monitor d/c'd.,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63898,2,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,g213162,2,3. Continue to use the remote pulse ox until the patient is discharged.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63898,3,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,g213163,3,4. Place the patient on a nasal cannula.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63899,0,Which of these statements is TRUE regarding the Remote monitors?,g213164,0,A.  The Capnography monitor attaches to the probe with blue end,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63899,1,Which of these statements is TRUE regarding the Remote monitors?,g213165,1,B.  The Remote Pulse-ox monitor attaches to the probe with the white end,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63899,2,Which of these statements is TRUE regarding the Remote monitors?,g213166,2,C.  The sensor with Sp02 and RR attaches to the Remote Pulse-ox monitor,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63899,3,Which of these statements is TRUE regarding the Remote monitors?,g213167,3,D.  All statements are true,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63900,0,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order.",g213168,0,TRUE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63900,1,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order.",g213169,1,FALSE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63901,0,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,g213170,0,"1.  If the frequency is increased or the patient calls more often for a treatment than ordered, the Physician or Mid-level must be contacted by phone to notify them of changes in the patient status.",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63901,1,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,g213171,1,2.  Budesonide (Pulmicort) ordered by the physician or mid-level cannot be discontinued or made PRN by the RT.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63901,2,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,g213172,2,"3.  If a physician or midlevel enters an order for concurrent therapy with Brovana , Pulmicort, Albuterol and Atrovent, they may be administered per RT discretion or patient preference.",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63901,3,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,g213173,3,"4.  If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat, the RT may order albuterol 2.5mg at the following frequencies:  Q4, Q6, BID, TID, QID, Q4 w/a or Q6 w/a.",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63902,0,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",g213174,0,1. Regular nebulizer,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63902,1,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",g213175,1,2. Pep Device,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63902,2,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",g213176,2,3. Aerogen,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63902,3,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",g213177,3,4. None of the above,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63903,0,Levalbuterol (Xopenex) 1.25mg may be substituted for albuterol if the physician indicates that or if the patient has an adverse reaction to albuterol.,g213178,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63903,1,Levalbuterol (Xopenex) 1.25mg may be substituted for albuterol if the physician indicates that or if the patient has an adverse reaction to albuterol.,g213179,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63904,0,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",g213180,0,1. B and C,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63904,1,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",g213181,1,"2. A, B, C",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63904,2,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",g213182,2,3. A and C,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63904,3,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",g213183,3,4. B only,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63905,0,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",g213184,0,1. Treatment of bronchospasms,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63905,1,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",g213185,1,2. Bacterial Pneumonia in cystic fibrosis patients,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63905,2,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",g213186,2,3. Prevention of PJP/pneumocystis,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63905,3,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",g213187,3,4. Treatment of RSV,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63906,0,Ribavirin is approved  for the treatment of:,g213188,0,1.  RSV,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63906,1,Ribavirin is approved  for the treatment of:,g213189,1,2.  Pneumocystis,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63906,2,Ribavirin is approved  for the treatment of:,g213190,2,3.  Pseudomonas,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63907,0,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,g213191,0,1. After each treatment,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63907,1,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,g213192,1,2. Q12,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63907,2,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,g213193,2,3. You don't need to clean,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63907,3,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,g213194,3,4. Between patients only,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63908,0,Where do the parts of the Ribavirin treatment go after each use?,g213195,0,1.  In the black chemo bucket in patient room,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63908,1,Where do the parts of the Ribavirin treatment go after each use?,g213196,1,2.  In the trash can,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63908,2,Where do the parts of the Ribavirin treatment go after each use?,g213197,2,3.  Its reused for 24 hours,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63908,3,Where do the parts of the Ribavirin treatment go after each use?,g213198,3,4.  Blue trash bin,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63909,0,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",g213199,0,1.   all of the above,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63909,1,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",g213200,1,"2.   A, C, & D",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63909,2,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",g213201,2,"3.   A, B, & D",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63909,3,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",g213202,3,"4.   B, C, & D",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63910,0,"When giving an aerosol treatment with Heliox, you should:<br>  A.   Use an 80:20 tank<br> B.   Use the 80:20 regulator(in wire cart in department)<br> C.   Use the heliox adaptable mask with the aerogen nebulizer<br> D.   If oxygen is needed , you can use a nasal cannula under the        mask or you can attach o2 tubing under the aerogen spacer        up to 6 l/min",g213203,0,1.    All of the above,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63910,1,"When giving an aerosol treatment with Heliox, you should:<br>  A.   Use an 80:20 tank<br> B.   Use the 80:20 regulator(in wire cart in department)<br> C.   Use the heliox adaptable mask with the aerogen nebulizer<br> D.   If oxygen is needed , you can use a nasal cannula under the        mask or you can attach o2 tubing under the aerogen spacer        up to 6 l/min",g213204,1,2.    Only A & B,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63910,2,"When giving an aerosol treatment with Heliox, you should:<br>  A.   Use an 80:20 tank<br> B.   Use the 80:20 regulator(in wire cart in department)<br> C.   Use the heliox adaptable mask with the aerogen nebulizer<br> D.   If oxygen is needed , you can use a nasal cannula under the        mask or you can attach o2 tubing under the aerogen spacer        up to 6 l/min",g213205,2,"3.    Only A, B, & C",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63911,0,Heliox:,g213206,0,"1. The mixture generates less resistance than atmospheric air when passing  through the airways of the lungs, and thus requires less effort by a patient",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63911,1,Heliox:,g213207,1,2.    Heliox is a breathing gas composed of a mixture of helium (He) and           oxygen (O2),0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63911,2,Heliox:,g213208,2,"3. Heliox is mainly used in conditions of large airway narrowing (upper airway  obstruction from tumors or foreign bodies and vocal cord dysfunction). There is also some use of heliox in conditions of the medium airways (croup, asthma and chronic obstructive pulmonary disease",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63911,3,Heliox:,g213209,3,4. All are true statements,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63911,4,Heliox:,g213210,4,5. Only 3 is a true statement,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63912,0,Empty inhalers and leftover Ribavirin medication will be disposed of in the black trash bin.<br>  Partial doses of Albuterol/Xopenex/Atrovent/Pulmicort/Mucomyst may be disposed of In the Blue trash bin,g213211,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63912,1,Empty inhalers and leftover Ribavirin medication will be disposed of in the black trash bin.<br>  Partial doses of Albuterol/Xopenex/Atrovent/Pulmicort/Mucomyst may be disposed of In the Blue trash bin,g213212,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63913,0,Which statement about CPAP documentation is FALSE?,g213213,0,A. A hospital owned CPAP device will be checked Q12 and with any change in settings or status of the patient,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63913,1,Which statement about CPAP documentation is FALSE?,g213214,1,B. Home CPAP units will be checked Qshift.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63913,2,Which statement about CPAP documentation is FALSE?,g213215,2,C. CPAP documentation includes skin integrity and the use of any skin barrier,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63914,0,"When using a BiPAP, Physician will be notified when:",g213216,0,A. Heart rate increases or decreases to > 20% from pre therapy heart rate.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63914,1,"When using a BiPAP, Physician will be notified when:",g213217,1,B. Therapist is unable to achieve an adequate mask seal.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63914,2,"When using a BiPAP, Physician will be notified when:",g213218,2,C. Tachydysrhythmias or Brachyarrhythmias occur.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63914,3,"When using a BiPAP, Physician will be notified when:",g213219,3,D. All of the above,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,0,Which are components of the fresh trach protocol?,g213220,0,A. Sign on the door with the date and time the 48 hour observation ends.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,1,Which are components of the fresh trach protocol?,g213221,1,B. ETC02 and breath sounds documentation with any patient repositioning.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,2,Which are components of the fresh trach protocol?,g213222,2,C. Same size trach and one size smaller.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,3,Which are components of the fresh trach protocol?,g213223,3,D. Obturator at the HOB.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,4,Which are components of the fresh trach protocol?,g213224,4,E. Airway box at bedside.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,5,Which are components of the fresh trach protocol?,g213225,5,F. Ambu bag/mask at bedside.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,6,Which are components of the fresh trach protocol?,g213226,6,G. Respiratory at the bedside for all repositioning.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63915,7,Which are components of the fresh trach protocol?,g213227,7,H. All of the above.,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63916,0,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,g213228,0,1. C and D,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63916,1,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,g213229,1,2. A and D,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63916,2,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,g213230,2,3. B only,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63916,3,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,g213231,3,4. C only,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63917,0,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",g213232,0,"1. A, B, C ,D",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63917,1,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",g213233,1,"2. A, B, D, E",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63917,2,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",g213234,2,"3. B, D, E",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63917,3,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",g213235,3,4. All of the above,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63918,0,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,g213236,0,1. B and C,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63918,1,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,g213237,1,"2. A, B, C",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63918,2,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,g213238,2,"3. A, D, E",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63918,3,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,g213239,3,"4. A, B, C, D, E",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63919,0,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",g213240,0,"1. A, C, E",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63919,1,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",g213241,1,"2. A, B, C, E",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63919,2,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",g213242,2,3. B and C,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63919,3,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",g213243,3,4. All of the above,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63920,0,"To place a Remote Pulse ox monitor in standby, you disconnect the pulse ox sensor from the cable then press DISMISS from the drop down menu and silence the alarm.",g213244,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63920,1,"To place a Remote Pulse ox monitor in standby, you disconnect the pulse ox sensor from the cable then press DISMISS from the drop down menu and silence the alarm.",g213245,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63921,0,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",g213246,0,"1. B, C, D, E",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63921,1,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",g213247,1,"2. A, B, C, D",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63921,2,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",g213248,2,3. All of the above,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63921,3,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",g213249,3,4. None of the above,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,0,All of the following are contraindications of using MetaNeb EXCEPT:,g213250,0,A.   Head or neck injury that has not been stabilized,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,1,All of the following are contraindications of using MetaNeb EXCEPT:,g213251,1,B.   Active pulmonary hemorrhaging,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,2,All of the following are contraindications of using MetaNeb EXCEPT:,g213252,2,"C.   Presence of ICP >20, recent facial/oral surgery or trauma",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,3,All of the following are contraindications of using MetaNeb EXCEPT:,g213253,3,D.   Esophageal surgery and/or gastric sleeve surgery,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,4,All of the following are contraindications of using MetaNeb EXCEPT:,g213254,4,E.    Neuromuscular disorders,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,5,All of the following are contraindications of using MetaNeb EXCEPT:,g213255,5,F.    COPD,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,6,All of the following are contraindications of using MetaNeb EXCEPT:,g213256,6,G.   Post-Op Management of Atelectasis,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,7,All of the following are contraindications of using MetaNeb EXCEPT:,g213257,7,H. All of the above,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63922,8,All of the following are contraindications of using MetaNeb EXCEPT:,g213258,8,"I.  E, F and G",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63923,0,Which statement regarding the delivery of IPV therapy is FALSE?,g213259,0,1.   The RT must remain with the patient while therapy is in progress.  Therapy must    be stopped before RT can leave the room.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63923,1,Which statement regarding the delivery of IPV therapy is FALSE?,g213260,1,2. Alternate between CPEP and CHFO modes every 2.5 minutes until the treatment is complete and the nebulizer is empty.,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63923,2,Which statement regarding the delivery of IPV therapy is FALSE?,g213261,2,"3. IPV facilitates the mobilization of secretions, lung expansion therapy,  and the treatment and prevention of pulmonary atelectasis",0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63923,3,Which statement regarding the delivery of IPV therapy is FALSE?,g213262,3,"4. If the physician does not order medications for nebulization, RT will order Duoneb Q6 and document in the EMR",1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63924,0,Respiratory Therapy is NOT responsible for bringing the code cart to any Code Blue in the 980/960 buildings.,g213263,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63924,1,Respiratory Therapy is NOT responsible for bringing the code cart to any Code Blue in the 980/960 buildings.,g213264,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63925,0,FYI'S: Please read. It's good information  Acknowledge slide review.,g213265,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63925,1,FYI'S: Please read. It's good information  Acknowledge slide review.,g213266,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63926,0,Home O2 Assessment<br>  Acknowledge slide review.,g213267,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63926,1,Home O2 Assessment<br>  Acknowledge slide review.,g213268,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63927,0,Smoking Cessation<br>  Acknowledge slide review.,g213269,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63927,1,Smoking Cessation<br>  Acknowledge slide review.,g213270,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63928,0,Learner Assessment<br>  Acknowledge slide review.,g213271,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63928,1,Learner Assessment<br>  Acknowledge slide review.,g213272,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63929,0,Provider Notification<br>  Acknowledge slide review.,g213273,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63929,1,Provider Notification<br>  Acknowledge slide review.,g213274,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63930,0,RT Handoff Notifications,g213275,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63930,1,RT Handoff Notifications,g213276,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63931,0,Code Blue and Rapid Response<br>  Acknowledge slide review.,g213277,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63931,1,Code Blue and Rapid Response<br>  Acknowledge slide review.,g213278,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63932,0,MetaNeb<br>  Acknowledge slide review.,g213279,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63932,1,MetaNeb<br>  Acknowledge slide review.,g213280,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63933,0,Cough Assist<br>  Acknowledge slide review.,g213281,0,TRUE,1,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20003,9728,Elearning-0000-939,g13997,g63933,1,Cough Assist<br>  Acknowledge slide review.,g213282,1,FALSE,0,2021 RESPIRATORY ADULT FLOOR COMPETENCY
20004,9904,Questions-0000-38,g13996,g63827,0,Please list the location for this activity.,g212903,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63827,1,Please list the location for this activity.,g212904,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63827,2,Please list the location for this activity.,g212905,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63827,3,Please list the location for this activity.,g212906,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63828,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212907,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63828,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212908,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63828,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212909,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63828,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212910,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63828,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212911,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63829,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212912,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63829,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212913,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63829,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212914,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63829,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212915,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63829,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212916,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63830,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212917,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63830,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212918,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63830,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212919,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63830,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212920,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63830,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212921,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63831,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212922,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63831,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212923,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63831,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212924,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63831,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212925,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63831,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212926,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63832,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212927,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63832,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212928,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63832,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212929,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63832,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212930,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63832,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212931,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63833,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212932,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63833,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212933,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63833,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212934,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63833,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212935,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63833,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212936,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63834,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212937,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63834,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212938,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63834,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212939,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63834,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212940,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63834,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212941,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63835,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212942,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63835,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212943,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63835,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212944,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63835,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212945,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63835,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212946,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63836,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g212947,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63836,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g212948,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63836,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g212949,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63836,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g212950,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63836,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g212951,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63836,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",g212952,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63837,0,"Overall, this activity was:",g212953,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63837,1,"Overall, this activity was:",g212954,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63837,2,"Overall, this activity was:",g212955,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63837,3,"Overall, this activity was:",g212956,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63837,4,"Overall, this activity was:",g212957,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63838,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212958,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63838,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212959,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63838,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212960,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63841,0,How would you improve this class (check all that apply)?,g212961,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63841,1,How would you improve this class (check all that apply)?,g212962,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63841,2,How would you improve this class (check all that apply)?,g212963,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63841,3,How would you improve this class (check all that apply)?,g212964,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63841,4,How would you improve this class (check all that apply)?,g212965,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63841,5,How would you improve this class (check all that apply)?,g212966,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20004,9904,Questions-0000-38,g13996,g63841,6,How would you improve this class (check all that apply)?,g212967,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21
20006,9911,Questions-0000-45,g13995,g63804,0,Please list the location for this activity.,g212808,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63804,1,Please list the location for this activity.,g212809,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63804,2,Please list the location for this activity.,g212810,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63804,3,Please list the location for this activity.,g212811,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63805,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212812,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63805,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212813,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63805,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212814,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63805,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212815,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63805,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g212816,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63806,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212817,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63806,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212818,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63806,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212819,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63806,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212820,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63806,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g212821,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63807,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g212822,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63807,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g212823,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63807,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g212824,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63807,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g212825,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63807,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g212826,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63808,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g212827,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63808,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g212828,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63808,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g212829,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63808,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g212830,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63808,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g212831,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63809,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g212832,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63809,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g212833,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63809,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g212834,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63809,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g212835,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63809,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g212836,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63810,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g212837,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63810,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g212838,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63810,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g212839,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63810,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g212840,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63810,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g212841,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63811,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g212842,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63811,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g212843,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63811,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g212844,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63811,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g212845,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63811,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g212846,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63812,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g212847,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63812,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g212848,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63812,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g212849,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63812,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g212850,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63812,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g212851,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63813,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212852,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63813,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212853,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63813,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212854,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63813,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212855,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63813,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212856,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63814,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212857,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63814,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212858,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63814,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212859,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63814,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212860,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63814,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212861,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63815,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212862,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63815,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212863,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63815,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212864,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63815,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212865,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63815,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g212866,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63816,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212867,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63816,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212868,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63816,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212869,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63816,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212870,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63816,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g212871,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63817,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212872,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63817,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212873,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63817,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212874,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63817,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212875,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63817,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212876,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63818,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212877,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63818,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212878,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63818,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212879,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63818,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212880,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63818,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212881,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63819,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",g212882,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63819,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",g212883,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63819,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",g212884,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63819,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",g212885,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63819,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",g212886,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63819,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",g212887,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63820,0,"Overall, this activity was:",g212888,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63820,1,"Overall, this activity was:",g212889,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63820,2,"Overall, this activity was:",g212890,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63820,3,"Overall, this activity was:",g212891,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63820,4,"Overall, this activity was:",g212892,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63821,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212893,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63821,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212894,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63821,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212895,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63824,0,How would you improve this class (check all that apply)?,g212896,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63824,1,How would you improve this class (check all that apply)?,g212897,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63824,2,How would you improve this class (check all that apply)?,g212898,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63824,3,How would you improve this class (check all that apply)?,g212899,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63824,4,How would you improve this class (check all that apply)?,g212900,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63824,5,How would you improve this class (check all that apply)?,g212901,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
20006,9911,Questions-0000-45,g13995,g63824,6,How would you improve this class (check all that apply)?,g212902,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21
19997,9807,Questions-0000-102,g13990,g63763,0,Please list the location for this activity.,g212663,0,Atlanta,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63763,1,Please list the location for this activity.,g212664,1,Cherokee,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63763,2,Please list the location for this activity.,g212665,2,Forsyth,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63763,3,Please list the location for this activity.,g212666,3,Other,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63764,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g212667,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63764,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g212668,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63764,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g212669,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63764,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g212670,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63764,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g212671,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63765,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g212672,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63765,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g212673,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63765,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g212674,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63765,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g212675,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63765,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g212676,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63766,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g212677,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63766,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g212678,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63766,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g212679,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63766,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g212680,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63766,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g212681,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63767,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g212682,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63767,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g212683,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63767,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g212684,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63767,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g212685,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63767,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g212686,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63768,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g212687,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63768,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g212688,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63768,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g212689,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63768,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g212690,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63768,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g212691,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63769,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g212692,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63769,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g212693,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63769,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g212694,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63769,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g212695,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63769,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g212696,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63770,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212697,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63770,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212698,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63770,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212699,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63770,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212700,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63770,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212701,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63771,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212702,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63771,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212703,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63771,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212704,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63771,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212705,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63771,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212706,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63772,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212707,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63772,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212708,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63772,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212709,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63772,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212710,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63772,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212711,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63773,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212712,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63773,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212713,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63773,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212714,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63773,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212715,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63773,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g212716,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63774,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g212717,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63774,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g212718,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63774,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g212719,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63774,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g212720,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63774,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g212721,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63775,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212722,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63775,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212723,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63775,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212724,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63775,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212725,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63775,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212726,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63776,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",g212727,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63776,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",g212728,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63776,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",g212729,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63776,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",g212730,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63776,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",g212731,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63777,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",g212732,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63777,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",g212733,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63777,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",g212734,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63777,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",g212735,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63777,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",g212736,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63778,0,"Overall, this activity was:",g212737,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63778,1,"Overall, this activity was:",g212738,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63778,2,"Overall, this activity was:",g212739,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63778,3,"Overall, this activity was:",g212740,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63778,4,"Overall, this activity was:",g212741,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63779,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212742,0,Yes,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63779,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212743,1,No,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63779,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212744,2,N/A,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63782,0,How would you improve this class?,g212745,0,Reduce content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63782,1,How would you improve this class?,g212746,1,Increase content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63782,2,How would you improve this class?,g212747,2,Update content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63782,3,How would you improve this class?,g212748,3,Improve the instructional methods,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63782,4,How would you improve this class?,g212749,4,Make course activities more stimulating,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63782,5,How would you improve this class?,g212750,5,Slow the pace of the class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19997,9807,Questions-0000-102,g13990,g63782,6,How would you improve this class?,g212751,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21
19996,9952,Questions-0000-86,g13989,g63742,0,Please list the location for this activity.,g212579,0,Atlanta,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63742,1,Please list the location for this activity.,g212580,1,Forsyth,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63742,2,Please list the location for this activity.,g212581,2,Cherokee,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63742,3,Please list the location for this activity.,g212582,3,Other,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63743,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g212583,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63743,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g212584,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63743,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g212585,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63743,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g212586,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63743,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g212587,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63744,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g212588,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63744,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g212589,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63744,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g212590,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63744,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g212591,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63744,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g212592,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63745,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g212593,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63745,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g212594,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63745,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g212595,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63745,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g212596,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63745,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g212597,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63746,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g212598,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63746,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g212599,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63746,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g212600,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63746,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g212601,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63746,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g212602,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63747,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g212603,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63747,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g212604,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63747,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g212605,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63747,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g212606,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63747,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g212607,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63748,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g212608,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63748,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g212609,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63748,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g212610,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63748,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g212611,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63748,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g212612,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63749,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g212613,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63749,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g212614,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63749,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g212615,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63749,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g212616,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63749,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g212617,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63750,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212618,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63750,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212619,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63750,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212620,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63750,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212621,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63750,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212622,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63751,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g212623,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63751,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g212624,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63751,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g212625,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63751,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g212626,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63751,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g212627,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63752,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212628,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63752,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212629,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63752,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212630,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63752,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212631,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63752,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212632,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63753,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212633,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63753,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212634,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63753,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212635,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63753,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212636,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63753,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212637,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63754,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212638,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63754,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212639,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63754,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212640,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63754,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212641,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63754,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g212642,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63755,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g212643,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63755,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g212644,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63755,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g212645,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63755,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g212646,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63755,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g212647,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63756,0,"Overall, this activity was:",g212648,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63756,1,"Overall, this activity was:",g212649,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63756,2,"Overall, this activity was:",g212650,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63756,3,"Overall, this activity was:",g212651,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63756,4,"Overall, this activity was:",g212652,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63757,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212653,0,Yes,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63757,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212654,1,No,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63757,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212655,2,N/A,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63760,0,How would you improve this class?,g212656,0,Reduce content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63760,1,How would you improve this class?,g212657,1,Increase content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63760,2,How would you improve this class?,g212658,2,Update content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63760,3,How would you improve this class?,g212659,3,Improve the instructional methods,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63760,4,How would you improve this class?,g212660,4,Make course activities more stimulating,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63760,5,How would you improve this class?,g212661,5,Slow the pace of the class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19996,9952,Questions-0000-86,g13989,g63760,6,How would you improve this class?,g212662,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21
19995,9886,Questions-0000-20,g13988,g63716,0,Please list the location for this activity.,g212470,0,Atlanta,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63716,1,Please list the location for this activity.,g212471,1,Cherokee,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63716,2,Please list the location for this activity.,g212472,2,Forsyth,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63716,3,Please list the location for this activity.,g212473,3,Other,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63717,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",g212474,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63717,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",g212475,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63717,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",g212476,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63717,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",g212477,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63717,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",g212478,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63718,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",g212479,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63718,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",g212480,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63718,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",g212481,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63718,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",g212482,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63718,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",g212483,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63719,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",g212484,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63719,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",g212485,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63719,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",g212486,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63719,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",g212487,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63719,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",g212488,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63720,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",g212489,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63720,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",g212490,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63720,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",g212491,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63720,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",g212492,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63720,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",g212493,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63721,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",g212494,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63721,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",g212495,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63721,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",g212496,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63721,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",g212497,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63721,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",g212498,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63722,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",g212499,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63722,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",g212500,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63722,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",g212501,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63722,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",g212502,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63722,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",g212503,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63723,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",g212504,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63723,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",g212505,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63723,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",g212506,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63723,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",g212507,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63723,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",g212508,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63724,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",g212509,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63724,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",g212510,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63724,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",g212511,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63724,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",g212512,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63724,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",g212513,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63725,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",g212514,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63725,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",g212515,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63725,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",g212516,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63725,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",g212517,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63725,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",g212518,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63726,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",g212519,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63726,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",g212520,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63726,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",g212521,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63726,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",g212522,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63726,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",g212523,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63727,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212524,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63727,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212525,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63727,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212526,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63727,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212527,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63727,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212528,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63728,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,g212529,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63728,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,g212530,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63728,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,g212531,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63728,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,g212532,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63728,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,g212533,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63729,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,g212534,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63729,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,g212535,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63729,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,g212536,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63729,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,g212537,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63729,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,g212538,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63730,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212539,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63730,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212540,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63730,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212541,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63730,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212542,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63730,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g212543,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63731,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212544,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63731,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212545,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63731,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212546,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63731,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212547,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63731,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212548,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63732,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212549,0,Strongly Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63732,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212550,1,Agree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63732,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212551,2,No Opinion,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63732,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212552,3,Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63732,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g212553,4,Strongly Disagree,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63733,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",g212554,0,Excellent,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63733,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",g212555,1,Very Good,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63733,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",g212556,2,Good,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63733,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",g212557,3,Fair,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63733,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",g212558,4,Poor,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63734,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g212559,0,Excellent,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63734,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g212560,1,Very Good,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63734,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g212561,2,Good,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63734,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g212562,3,Fair,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63734,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g212563,4,Poor,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63735,0,"Overall, this activity was:",g212564,0,Excellent,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63735,1,"Overall, this activity was:",g212565,1,Very Good,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63735,2,"Overall, this activity was:",g212566,2,Good,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63735,3,"Overall, this activity was:",g212567,3,Fair,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63735,4,"Overall, this activity was:",g212568,4,Poor,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63736,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212569,0,Yes,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63736,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212570,1,No,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63736,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212571,2,N/A,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63739,0,How would you improve this class?,g212572,0,Reduce content covered in class,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63739,1,How would you improve this class?,g212573,1,Increase content covered in class,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63739,2,How would you improve this class?,g212574,2,Update content covered in class,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63739,3,How would you improve this class?,g212575,3,Improve the instructional methods,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63739,4,How would you improve this class?,g212576,4,Make course activities more stimulating,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63739,5,How would you improve this class?,g212577,5,Slow the pace of the class,0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19995,9886,Questions-0000-20,g13988,g63739,6,How would you improve this class?,g212578,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21
19991,9727,Elearning-0000-938,g13985,g63655,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours.<br> B. IPPB PIP of 15cmH20.<br> C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness)<br> D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g212259,0,1. All of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63655,1,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours.<br> B. IPPB PIP of 15cmH20.<br> C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness)<br> D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g212260,1,2. A and C,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63655,2,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours.<br> B. IPPB PIP of 15cmH20.<br> C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness)<br> D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g212261,2,"3. A, C, D",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63656,0,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",g212262,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63656,1,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",g212263,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63657,0,Which statement about ASV mode is FALSE?,g212264,0,1. ASV maintains an operator-preset minimum minute ventilation independent of the patient's activity.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63657,1,Which statement about ASV mode is FALSE?,g212265,1,"2. On the G5, the maximum pressure set by ASV is always 10 cmH2O below the maximum pressure limit, thus the maximum pressure and the ASV limit co-vary.",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63657,2,Which statement about ASV mode is FALSE?,g212266,2,"3. The lowest Minute Volume % to be used in ASV mode is 100%.  Per protocol, the RT may set the MV% to 80% without a Physican's order for patients with a diagnosis of COPD.",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63657,3,Which statement about ASV mode is FALSE?,g212267,3,"4. When started, the device delivers 3 test breaths in synchronized intermittent mandatory pressure ventilation mode.",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63658,0,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",g212268,0,"1. A, B, C, D",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63658,1,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",g212269,1,2. A and C,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63658,2,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",g212270,2,"3. B, C, F",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63658,3,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",g212271,3,"4. A, B, C",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63658,4,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",g212272,4,5. All of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63659,0,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",g212273,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63659,1,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",g212274,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63660,0,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,g212275,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63660,1,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,g212276,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63661,0,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",g212277,0,1. A only,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63661,1,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",g212278,1,2. C and D,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63661,2,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",g212279,2,"3. B, C, D",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63661,3,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",g212280,3,4. C and E,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63662,0,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g212281,0,A. 255mL - 395mL,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63662,1,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g212282,1,B. 280mL - 420mL,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63662,2,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g212283,2,C. 300mL - 440mL,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63662,3,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g212284,3,D. 320mL - 460mL,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63663,0,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,g212285,0,1. A and B,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63663,1,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,g212286,1,"2. B, C, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63663,2,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,g212287,2,3. B and D,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63663,3,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,g212288,3,"4. A, B, D, E",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63663,4,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,g212289,4,"5. C, D, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63663,5,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,g212290,5,6. All of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63664,0,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",g212291,0,1. A and C,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63664,1,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",g212292,1,2. A and D,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63664,2,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",g212293,2,"3. A, B, C",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63664,3,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",g212294,3,4. All of the above,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63665,0,Which of these statements regarding Spontaneous mode is FALSE?,g212295,0,"a. When pressure support is set to zero, the mode functions like  a conventional CPAP system.",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63665,1,Which of these statements regarding Spontaneous mode is FALSE?,g212296,1,b. The patient determines the breath timing and may be either flow or  pressure triggered.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63665,2,Which of these statements regarding Spontaneous mode is FALSE?,g212297,2,"c. The settings in this mode include: Psupport, P-ramp, ETS, PEEP,  Fi02 and Trigger.",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63665,3,Which of these statements regarding Spontaneous mode is FALSE?,g212298,3,"d. If the back up mode is selected, the vent will transition from SPONT to APV-CMV mode when the apnea alarm is triggered.",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63666,0,"The vent weaning readiness criteria includes a PEEP = 8 cmH20, Fi02 = 50%, effective cough, manageable secretions, the patient is awake and alert.",g212299,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63666,1,"The vent weaning readiness criteria includes a PEEP = 8 cmH20, Fi02 = 50%, effective cough, manageable secretions, the patient is awake and alert.",g212300,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63667,0,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g212301,0,A. The SBT should not exceed 120 minutes unless ordered by MD or midlevel.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63667,1,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g212302,1,"B. If at any time the patient because unstable or has an increased RR > 35bpm, the mode should be changed to achieve the pre-trial minute volume.",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63667,2,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g212303,2,C. ASV at 100%MV or CPAP/PS mode may be used.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63667,3,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g212304,3,"D. ASV at 100%MV may be used and the Pinsp should be < 15cmH20 to be considered in a ""weaning"" mode.",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63667,4,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g212305,4,"E. If the patient is on pressors, the RT and RN must confirm that the physician is aware of the type and dose of pressors before a weaning trial is conducted.",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63668,0,The connection of the red alarm cable should be documented with every Q4h vent check as well as the audible and visual alarms.,g212306,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63668,1,The connection of the red alarm cable should be documented with every Q4h vent check as well as the audible and visual alarms.,g212307,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63669,0,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,g212308,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63669,1,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,g212309,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63670,0,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,g212310,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63670,1,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,g212311,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63671,0,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,g212312,0,1. All of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63671,1,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,g212313,1,"2. A, C, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63671,2,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,g212314,2,3. B and C,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63671,3,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,g212315,3,"4. A, B, C, E",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63672,0,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g212316,0,A. Hollister,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63672,1,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g212317,1,B. Silk tape then Stabiltube,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63672,2,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g212318,2,C. Hollister with Physician's order,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63672,3,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g212319,3,D.  B and C,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63673,0,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g212320,0,"A. Increased I-time, decreased E-time",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63673,1,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g212321,1,"B. Decreased I-time, increased E-time",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63673,2,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g212322,2,"C. Decreased I-time, decreased E-time",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63673,3,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g212323,3,D. None of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63674,0,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",g212324,0,A. Only the G5 can utilize Heliox.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63674,1,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",g212325,1,B. The G5 flow sensor must be recalibrated with Heliox prior to starting the therapy.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63674,2,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",g212326,2,C. The circuit must first be changed from a single limb with a  HME to a heated wire circuit prior to starting Heliox therapy.,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63675,0,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g212327,0,A.  68,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63675,1,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g212328,1,B.  70,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63675,2,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g212329,2,C.  66,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63675,3,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g212330,3,D.  49,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63676,0,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",g212331,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63676,1,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",g212332,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63677,0,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g212333,0,A. Peak airway pressure,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63677,1,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g212334,1,B. Optimal PEEP,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63677,2,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g212335,2,C. Dynamic lung compliance,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63677,3,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g212336,3,D. Plateau pressure,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63678,0,The Hamilton ventilator will display which of the following calculations and measurements?,g212337,0,A. Lung compliance,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63678,1,The Hamilton ventilator will display which of the following calculations and measurements?,g212338,1,B. AutoPEEP,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63678,2,The Hamilton ventilator will display which of the following calculations and measurements?,g212339,2,C. Rapid shallow breathing index,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63678,3,The Hamilton ventilator will display which of the following calculations and measurements?,g212340,3,D. Airway resistance,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63678,4,The Hamilton ventilator will display which of the following calculations and measurements?,g212341,4,"E. A, C, D",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63678,5,The Hamilton ventilator will display which of the following calculations and measurements?,g212342,5,F. All of the above,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63680,0,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,g212346,0,"1. A, D, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63680,1,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,g212347,1,"2. B, C, D",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63680,2,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,g212348,2,"3. A, B, D, E",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63680,3,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,g212349,3,4. A and E,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63680,4,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,g212350,4,5. All of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63681,0,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",g212351,0,"1. A, B, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63681,1,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",g212352,1,"2.   B, C and E",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63681,2,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",g212353,2,"3. C, D, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63681,3,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",g212354,3,4. All statements are true,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63682,0,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g212355,0,a.   NIV-ST,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63682,1,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g212356,1,b.   Spontaneous,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63682,2,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g212357,2,c.   NIV,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63682,3,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g212358,3,d.   NIPPV,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63683,0,"Per protocol, what are the initial HFO settings?",g212359,0,"a.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 50%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 35 lpm",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63683,1,"Per protocol, what are the initial HFO settings?",g212360,1,"b.  Hz 5, Power 5 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20 above mean pressure on conventional vent, Bias Flow 35 lpm",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63683,2,"Per protocol, what are the initial HFO settings?",g212361,2,"c.  Hz 3, Power 5 - adjusting for adequate chest wiggle, Ti 40%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 25 lpm",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63683,3,"Per protocol, what are the initial HFO settings?",g212362,3,"d.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20  below mean pressure on conventional vent, Bias Flow 45 lpm",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63684,0,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,g212363,0,1.  All of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63684,1,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,g212364,1,2.  A and B,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63684,2,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,g212365,2,"3.  A, B, C",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63684,3,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,g212366,3,4.  B and C,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63685,0,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g212367,0,a.   Frequency,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63685,1,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g212368,1,b.   Cuff Leak,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63685,2,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g212369,2,c.    I Time,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63685,3,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g212370,3,d. Amplitude,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63685,4,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g212371,4,e. A and B only,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63685,5,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g212372,5,"f. A, B, C, D",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63686,0,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g212373,0,a. MAP,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63686,1,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g212374,1,b.   FiO2,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63686,2,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g212375,2,c. Amplitude,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63686,3,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g212376,3,d. A and B only,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63686,4,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g212377,4,"e. A, B, C",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63687,0,"Per protocol, which changes could correct the following ABG using the HFO 3100B?<br>  pH 7.24<br> - PaC02 68 - Pa02 80<br> - HCO3 29<br> - BE 3.9<br>  A. Increase Hz, Decrease Power<br> B. Increase Power, Increase Hz<br> C. Decreased Hz, Increase Power<br> D. Cuff leak",g212378,0,"1.  A, D, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63687,1,"Per protocol, which changes could correct the following ABG using the HFO 3100B?<br>  pH 7.24<br> - PaC02 68 - Pa02 80<br> - HCO3 29<br> - BE 3.9<br>  A. Increase Hz, Decrease Power<br> B. Increase Power, Increase Hz<br> C. Decreased Hz, Increase Power<br> D. Cuff leak",g212379,1,2.  B and D,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63687,2,"Per protocol, which changes could correct the following ABG using the HFO 3100B?<br>  pH 7.24<br> - PaC02 68 - Pa02 80<br> - HCO3 29<br> - BE 3.9<br>  A. Increase Hz, Decrease Power<br> B. Increase Power, Increase Hz<br> C. Decreased Hz, Increase Power<br> D. Cuff leak",g212380,2,3.  C and D,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63688,0,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",g212381,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63688,1,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",g212382,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63689,0,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g212383,0,a.  5 PPM,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63689,1,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g212384,1,b.  10 PPM,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63689,2,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g212385,2,c.  Therapist discretion,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63689,3,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g212386,3,d.  20 PPM,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63690,0,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g212387,0,a. 20ppm,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63690,1,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g212388,1,b. 30ppm,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63690,2,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g212389,2,c. 40ppm,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63690,3,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g212390,3,d. 60ppm,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63691,0,"Hamilton C2-C3 in NIV-ST mode<br> Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",g212391,0,A.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63691,1,"Hamilton C2-C3 in NIV-ST mode<br> Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",g212392,1,B.,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63691,2,"Hamilton C2-C3 in NIV-ST mode<br> Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",g212393,2,C.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63692,0,When should you consider changing the Nitric oxide filter and sample line?,g212394,0,A. When you see fluid in the sample line,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63692,1,When should you consider changing the Nitric oxide filter and sample line?,g212395,1,B. When the measured Nitric oxide and Fi02 is inaccurate,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63692,2,When should you consider changing the Nitric oxide filter and sample line?,g212396,2,"C. After medications like Tobramycin, Mucomyst or Colistin are nebulized inline",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63692,3,When should you consider changing the Nitric oxide filter and sample line?,g212397,3,D. All of the above,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63693,0,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,g212398,0,1. All of the above,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63693,1,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,g212399,1,"2. A, B, D",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63693,2,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,g212400,2,3. A and B only,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63693,3,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,g212401,3,"4. A, C, D",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63694,0,Components of the Fresh Trach protocol include?,g212402,0,A. Signage on the door with the date and time the 48 hour observation ends,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63694,1,Components of the Fresh Trach protocol include?,g212403,1,B.  ETC02 Q4  and breath sounds documentation with any patient repositioning during the first 48 hours,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63694,2,Components of the Fresh Trach protocol include?,g212404,2,C.  Same size trach and one size smaller at bedside,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63694,3,Components of the Fresh Trach protocol include?,g212405,3,D.  Obturator at the HOB,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63694,4,Components of the Fresh Trach protocol include?,g212406,4,E.  Airway box at bedside,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63694,5,Components of the Fresh Trach protocol include?,g212407,5,F.  Ambu bag and mask at bedside,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63694,6,Components of the Fresh Trach protocol include?,g212408,6,G.  All of the above,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63695,0,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",g212409,0,"1. A, B, C, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63695,1,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",g212410,1,"2. B, C, D",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63695,2,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",g212411,2,3. A and E,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63695,3,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",g212412,3,4. All of the above,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63696,0,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",g212413,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63696,1,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",g212414,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63697,0,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,g212415,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63697,1,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,g212416,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63698,0,"49 F, 5'5"", with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",g212417,0,"A. APV-CMV Vt 500, RR 18, PEEP 12, Fi02 75%",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63698,1,"49 F, 5'5"", with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",g212418,1,"B. ASV 140%, PEEP 10, Fi02 100%.  Target 8lpm.",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63698,2,"49 F, 5'5"", with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",g212419,2,"C. P-CMV, PC 20cmH20, RR 16, PEEP 8, Fi02 85%, exh Vt 570mL",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63698,3,"49 F, 5'5"", with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",g212420,3,"D. APV-CMV Vt 400, RR 20, PEEP 10, Fi02 100%",1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63699,0,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,g212421,0,"1. B, C, D, E",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63699,1,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,g212422,1,"2. A, B, C, D",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63699,2,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,g212423,2,3. C and E,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63699,3,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,g212424,3,4. All of the above,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63700,0,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g212425,0,1. All statements are true,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63700,1,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g212426,1,2. A and D,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63700,2,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g212427,2,3. B and C,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63700,3,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g212428,3,4. B and D,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63701,0,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",g212429,0,"1. B, D, E, G",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63701,1,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",g212430,1,"2. A, D, G, H",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63701,2,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",g212431,2,"3. B, C, F, G,",0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63701,3,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",g212432,3,4. All of the above,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63702,0,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g212433,0,1. Cover the laryngectomy stoma with your hand or gauze and bag through the mouth with the AMBU bag.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63702,1,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g212434,1,2. Use an adult AMBU bag and a pediatric mask over the laryngectomy stoma to provide ventilation.,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63702,2,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g212435,2,3. Intubate through the mouth with an ETT and provide ventilation with the AMBU bag.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63702,3,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g212436,3,4. Do not use an AMBU bag for laryngectomy patients.,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63703,0,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Acknowledge this slide was reviewed.,g212437,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63703,1,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Acknowledge this slide was reviewed.,g212438,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63704,0,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater<br>  Acknowledge slide was reviewed.",g212439,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63704,1,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater<br>  Acknowledge slide was reviewed.",g212440,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63705,0,Heliox<br> The Heliox mask; attach the Aerogen spacer and nebulizer using elbow<br>  Acknowledge slide was reviewed.,g212441,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63705,1,Heliox<br> The Heliox mask; attach the Aerogen spacer and nebulizer using elbow<br>  Acknowledge slide was reviewed.,g212442,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63706,0,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Acknowledge slide was reviewed.",g212443,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63706,1,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Acknowledge slide was reviewed.",g212444,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63707,0,Heliox<br> G5 with Heliox: connection (we have 3 G5)<br>  Acknowledge slide was reviewed.,g212445,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63707,1,Heliox<br> G5 with Heliox: connection (we have 3 G5)<br>  Acknowledge slide was reviewed.,g212446,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63708,0,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox<br> You must calibrate the flowsensor with the Heliox***<br>  Acknowledge slide was reviewed.,g212447,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63708,1,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox<br> You must calibrate the flowsensor with the Heliox***<br>  Acknowledge slide was reviewed.,g212448,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63709,0,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.<br>  Acknowledge slide was reviewed.",g212449,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63709,1,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.<br>  Acknowledge slide was reviewed.",g212450,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63710,0,Skin Co-Signature for ETT's <br> (When The Tube holder is changed)<br>  Acknowledge slide was reviewed.,g212451,0,TRUE,1,2021 RESPIRATORY ADULT ICU COMPETENCY
19991,9727,Elearning-0000-938,g13985,g63710,1,Skin Co-Signature for ETT's <br> (When The Tube holder is changed)<br>  Acknowledge slide was reviewed.,g212452,1,FALSE,0,2021 RESPIRATORY ADULT ICU COMPETENCY
19975,9689,Elearning-0000-903,g13972,g63635,0,"If patient is complaining of pain and burning at the IV site, the nurse should consider extravasation and stop infusion and assess site immediately.",g212202,0,TRUE,1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63635,1,"If patient is complaining of pain and burning at the IV site, the nurse should consider extravasation and stop infusion and assess site immediately.",g212203,1,FALSE,0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63636,0,"If IV access has visible blood return, the nurse should consider IV is patent and there is no need to flush IV access.",g212204,0,TRUE,0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63636,1,"If IV access has visible blood return, the nurse should consider IV is patent and there is no need to flush IV access.",g212205,1,FALSE,1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63637,0,It is possible that Vesicant drugs could leak at the insertion site causing extravasation without the vein wall being punctured.,g212206,0,TRUE,1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63637,1,It is possible that Vesicant drugs could leak at the insertion site causing extravasation without the vein wall being punctured.,g212207,1,FALSE,0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63638,0,"A cold or warm compress should be applied on extravasation site for 20minutes, 4 times per day for the first 48hrs.",g212208,0,TRUE,1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63638,1,"A cold or warm compress should be applied on extravasation site for 20minutes, 4 times per day for the first 48hrs.",g212209,1,FALSE,0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63639,0,"When administering Amiodarone, an inline filter should always be used.",g212210,0,TRUE,1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63639,1,"When administering Amiodarone, an inline filter should always be used.",g212211,1,FALSE,0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63640,0,Which of the following are early signs/symptoms of extravasation?,g212212,0,"a.	Local blistering",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63640,1,Which of the following are early signs/symptoms of extravasation?,g212213,1,"b.	Loss of blood return",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63640,2,Which of the following are early signs/symptoms of extravasation?,g212214,2,"c.	Mild burning and discomfort  on IV site",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63640,3,Which of the following are early signs/symptoms of extravasation?,g212215,3,"d.	Increased pain",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63640,4,Which of the following are early signs/symptoms of extravasation?,g212216,4,"e.	Ulceration",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63640,5,Which of the following are early signs/symptoms of extravasation?,g212217,5,"f.	Increased swelling",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63640,6,Which of the following are early signs/symptoms of extravasation?,g212218,6,"g.	B,C",1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63641,0,What is the ideal time to administer extravasation antidotes to get the maximum effects?,g212219,0,"a.	Within 4hrs of extravasation",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63641,1,What is the ideal time to administer extravasation antidotes to get the maximum effects?,g212220,1,"b.	Within one hour",1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63641,2,What is the ideal time to administer extravasation antidotes to get the maximum effects?,g212221,2,"c.	It can be administered any time",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63641,3,What is the ideal time to administer extravasation antidotes to get the maximum effects?,g212222,3,"d.	Within 24hrs",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63642,0,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,g212223,0,"a.	2,3,1,4",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63642,1,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,g212224,1,"b.	2,1,3,4",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63642,2,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,g212225,2,"c.	2,4,3,1",1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63642,3,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,g212226,3,"d.	1,2,3,4",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63643,0,Which medication requires a warm compress?,g212227,0,"a.	Amiodarone",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63643,1,Which medication requires a warm compress?,g212228,1,"b.	Dobutamine",1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63643,2,Which medication requires a warm compress?,g212229,2,"c.	TPN",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63643,3,Which medication requires a warm compress?,g212230,3,"d.	Potassium Chloride",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63644,0,Hyalurondase should be administered,g212231,0,"a.	In a series of five 0.2ml injection in a clock wise manner around the circumference of the extravasation.",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63644,1,Hyalurondase should be administered,g212232,1,"b.	Using a new 25 gauge needle for each injection",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63644,2,Hyalurondase should be administered,g212233,2,"c.	A total dose of 1ml dose subcutaneously",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63644,3,Hyalurondase should be administered,g212234,3,"d.	All of the above",1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63645,0,Phentolamine should be administered,g212235,0,"a.	In a series of ten injections in a clock wise manner around the circumference of the extravasation",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63645,1,Phentolamine should be administered,g212236,1,"b.	Total dose should not exceed 0.2mg/kg or 5mg.",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63645,2,Phentolamine should be administered,g212237,2,"c.	Using a 25 gauge needle for each injection subcutaneously",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63645,3,Phentolamine should be administered,g212238,3,"d.	All of the above",1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63646,0,How often should the RN assess and document IV access while infusing Vesicant drugs,g212239,0,"a.	Once per shift and as needed",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63646,1,How often should the RN assess and document IV access while infusing Vesicant drugs,g212240,1,"b.	Twice a shift",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63646,2,How often should the RN assess and document IV access while infusing Vesicant drugs,g212241,2,"c.	A minimum of every 2hrs",1,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19975,9689,Elearning-0000-903,g13972,g63646,3,How often should the RN assess and document IV access while infusing Vesicant drugs,g212242,3,"d.	Once per shift",0,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION
19974,9938,Questions-0000-72,g13971,g63610,0,Please list the location for this activity.,g212098,0,Atlanta,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63610,1,Please list the location for this activity.,g212099,1,Forsyth,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63610,2,Please list the location for this activity.,g212100,2,Cherokee,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63610,3,Please list the location for this activity.,g212101,3,Other,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63611,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",g212102,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63611,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",g212103,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63611,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",g212104,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63611,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",g212105,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63611,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",g212106,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63612,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",g212107,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63612,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",g212108,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63612,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",g212109,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63612,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",g212110,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63612,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",g212111,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63613,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",g212112,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63613,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",g212113,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63613,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",g212114,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63613,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",g212115,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63613,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",g212116,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63614,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",g212117,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63614,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",g212118,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63614,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",g212119,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63614,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",g212120,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63614,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",g212121,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63615,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",g212122,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63615,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",g212123,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63615,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",g212124,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63615,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",g212125,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63615,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",g212126,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63616,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",g212127,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63616,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",g212128,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63616,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",g212129,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63616,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",g212130,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63616,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",g212131,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63617,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",g212132,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63617,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",g212133,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63617,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",g212134,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63617,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",g212135,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63617,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",g212136,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63618,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",g212137,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63618,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",g212138,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63618,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",g212139,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63618,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",g212140,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63618,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",g212141,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63619,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",g212142,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63619,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",g212143,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63619,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",g212144,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63619,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",g212145,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63619,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",g212146,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63620,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",g212147,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63620,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",g212148,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63620,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",g212149,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63620,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",g212150,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63620,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",g212151,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63621,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212152,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63621,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212153,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63621,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212154,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63621,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212155,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63621,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g212156,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63622,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212157,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63622,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212158,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63622,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212159,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63622,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212160,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63622,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g212161,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63623,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,g212162,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63623,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,g212163,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63623,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,g212164,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63623,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,g212165,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63623,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,g212166,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63624,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,g212167,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63624,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,g212168,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63624,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,g212169,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63624,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,g212170,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63624,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,g212171,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63625,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212172,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63625,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212173,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63625,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212174,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63625,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212175,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63625,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g212176,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63626,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g212177,0,Strongly Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63626,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g212178,1,Agree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63626,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g212179,2,No Opinion,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63626,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g212180,3,Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63626,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g212181,4,Strongly Disagree,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63627,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",g212182,0,Excellent,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63627,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",g212183,1,Very Good,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63627,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",g212184,2,Good,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63627,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",g212185,3,Fair,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63627,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",g212186,4,Poor,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63628,0,"Overall, this activity was:",g212187,0,Excellent,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63628,1,"Overall, this activity was:",g212188,1,Very Good,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63628,2,"Overall, this activity was:",g212189,2,Good,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63628,3,"Overall, this activity was:",g212190,3,Fair,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63628,4,"Overall, this activity was:",g212191,4,Poor,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63629,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212192,0,Yes,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63629,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212193,1,No,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63629,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g212194,2,N/A,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63632,0,How would you improve this class?,g212195,0,Reduce content covered in class,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63632,1,How would you improve this class?,g212196,1,Increase content covered in class,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63632,2,How would you improve this class?,g212197,2,Update content covered in class,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63632,3,How would you improve this class?,g212198,3,Improve the instructional methods,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63632,4,How would you improve this class?,g212199,4,Make course activities more stimulating,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63632,5,How would you improve this class?,g212200,5,Slow the pace of the class,0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19974,9938,Questions-0000-72,g13971,g63632,6,How would you improve this class?,g212201,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21
19972,9892,Questions-0000-26,g13969,g63563,0,Please list the location for this activity.,g211900,0,Atlanta,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63563,1,Please list the location for this activity.,g211901,1,Forsyth,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63563,2,Please list the location for this activity.,g211902,2,Cherokee,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63563,3,Please list the location for this activity.,g211903,3,Other,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63564,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g211904,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63564,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g211905,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63564,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g211906,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63564,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g211907,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63564,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g211908,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63565,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g211909,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63565,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g211910,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63565,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g211911,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63565,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g211912,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63565,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g211913,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63566,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g211914,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63566,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g211915,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63566,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g211916,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63566,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g211917,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63566,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g211918,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63567,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g211919,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63567,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g211920,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63567,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g211921,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63567,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g211922,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63567,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g211923,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63568,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g211924,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63568,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g211925,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63568,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g211926,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63568,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g211927,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63568,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g211928,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63569,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g211929,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63569,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g211930,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63569,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g211931,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63569,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g211932,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63569,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g211933,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63570,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g211934,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63570,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g211935,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63570,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g211936,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63570,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g211937,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63570,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g211938,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63571,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g211939,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63571,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g211940,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63571,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g211941,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63571,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g211942,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63571,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g211943,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63572,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g211944,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63572,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g211945,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63572,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g211946,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63572,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g211947,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63572,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g211948,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63573,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g211949,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63573,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g211950,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63573,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g211951,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63573,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g211952,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63573,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g211953,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63574,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g211954,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63574,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g211955,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63574,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g211956,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63574,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g211957,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63574,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g211958,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63575,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211959,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63575,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211960,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63575,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211961,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63575,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211962,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63575,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211963,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63576,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g211964,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63576,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g211965,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63576,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g211966,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63576,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g211967,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63576,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g211968,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63577,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211969,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63577,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211970,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63577,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211971,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63577,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211972,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63577,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211973,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63578,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g211974,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63578,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g211975,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63578,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g211976,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63578,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g211977,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63578,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g211978,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63579,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g211979,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63579,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g211980,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63579,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g211981,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63579,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g211982,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63579,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g211983,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63580,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g211984,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63580,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g211985,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63580,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g211986,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63580,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g211987,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63580,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g211988,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63581,0,"Overall, this activity was:",g211989,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63581,1,"Overall, this activity was:",g211990,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63581,2,"Overall, this activity was:",g211991,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63581,3,"Overall, this activity was:",g211992,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63581,4,"Overall, this activity was:",g211993,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63582,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211994,0,Yes,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63582,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211995,1,No,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63582,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211996,2,N/A,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63585,0,How would you improve this class?,g211997,0,Reduce content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63585,1,How would you improve this class?,g211998,1,Increase content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63585,2,How would you improve this class?,g211999,2,Update content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63585,3,How would you improve this class?,g212000,3,Improve the instructional methods,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63585,4,How would you improve this class?,g212001,4,Make course activities more stimulating,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63585,5,How would you improve this class?,g212002,5,Slow the pace of the class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19972,9892,Questions-0000-26,g13969,g63585,6,How would you improve this class?,g212003,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21
19970,9611,Elearning-0000-832,g13968,g63562,0,I acknowledge that I have read and understand the Timeless 116: Mothers Kiosk CBL in its entirety.,g211898,0,TRUE,1,TIMELESS 116: MOTHERS KIOSK
19970,9611,Elearning-0000-832,g13968,g63562,1,I acknowledge that I have read and understand the Timeless 116: Mothers Kiosk CBL in its entirety.,g211899,1,FALSE,0,TIMELESS 116: MOTHERS KIOSK
19964,9739,Elearning-0000-949,g13964,g63526,0,"Per protocol, you can obtain ABGs when a patient is on _____ or greater FiO2 and then contact the physician with the results.",g211793,0,"a.	30%",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63526,1,"Per protocol, you can obtain ABGs when a patient is on _____ or greater FiO2 and then contact the physician with the results.",g211794,1,"b.	40%",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63526,2,"Per protocol, you can obtain ABGs when a patient is on _____ or greater FiO2 and then contact the physician with the results.",g211795,2,"c.	50%",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63527,0,Which probe goes with the Capnography monitor?,g211796,0,"a.	Adult Respiratory Sensor with SpO2 and RR",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63527,1,Which probe goes with the Capnography monitor?,g211797,1,"b.	Neonatal-Adult SpO2 Sensor",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63528,0,Which statement about CPAP documentation is False?,g211798,0,a. the patient does not have to sign a release of liability to use their home CPAP,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63528,1,Which statement about CPAP documentation is False?,g211799,1,b. Home CPAP units will be checked Qshift,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63528,2,Which statement about CPAP documentation is False?,g211800,2,c. CPAP documentation includes the documentation of skin integrity,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63529,0,How often do you change an inner cannula?,g211801,0,A. BID and as needed,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63529,1,How often do you change an inner cannula?,g211802,1,B. Q24 on dayshift and as needed,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63529,2,How often do you change an inner cannula?,g211803,2,C. Q24 on nightshift and as needed,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63529,3,How often do you change an inner cannula?,g211804,3,D. Not during the 48 hour fresh trach protocol,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63530,0,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,g211805,0,"a.	If room air Sp02 at rest is < 89%, place patient on oxygen to get their Sp02 > or = 89%. If able to ambulate, see what 02 is needed to keep Sp02 > 88% on exertion)",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63530,1,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,g211806,1,"b.	If room air Sp02 is > or = to 89% at rest, you need to do a room air Sp02 with exertion",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63530,2,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,g211807,2,"c.	If exertional Sp02 is lower than < 89%, you need to document how much 02 is needed to keep Sp02 > 89%. Please relay to RN and Case Management",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63530,3,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,g211808,3,"d.	None of the above",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63530,4,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,g211809,4,"e.	All of the above",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63531,0,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",g211810,0,"A.	A, B, and E",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63531,1,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",g211811,1,"B.	D",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63531,2,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",g211812,2,"C.	A, B, C, D, E",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63531,3,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",g211813,3,"D.	A, B, D, E",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63532,0,Which of the following is not a component of the fresh trach protocol?,g211814,0,"a.	Signage on the door with the date and time the 48 hour observations ends",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63532,1,Which of the following is not a component of the fresh trach protocol?,g211815,1,"b.	Same size trach and one size smaller",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63532,2,Which of the following is not a component of the fresh trach protocol?,g211816,2,"c.	Speaking Valve in Room",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63532,3,Which of the following is not a component of the fresh trach protocol?,g211817,3,"d.	Obturator at the HOB",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63532,4,Which of the following is not a component of the fresh trach protocol?,g211818,4,"e.	Airway box at bedside",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63532,5,Which of the following is not a component of the fresh trach protocol?,g211819,5,"f.	Ambu bag at bedside",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63533,0,Any Trach patient outside the ICU needs to be placed on Remote monitoring.,g211820,0,TRUE,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63533,1,Any Trach patient outside the ICU needs to be placed on Remote monitoring.,g211821,1,FALSE,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63534,0,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",g211822,0,"i.	A and B",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63534,1,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",g211823,1,"ii.	C only",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63534,2,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",g211824,2,"iii.	A and C",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63534,3,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",g211825,3,"iv.	A, B, C and D",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63535,0,When should you consider weaning your patient off of optiflow?,g211826,0,"a.	At the earliest appropriate time",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63535,1,When should you consider weaning your patient off of optiflow?,g211827,1,"b.	When the fio2 is less than or equal to 50%",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63535,2,When should you consider weaning your patient off of optiflow?,g211828,2,"c.	Per physician order",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63535,3,When should you consider weaning your patient off of optiflow?,g211829,3,"d.	All of the above",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63536,0,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order",g211830,0,TRUE,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63536,1,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order",g211831,1,FALSE,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63537,0,"If an order reads, ""CPAP per RT protocol"", you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",g211832,0,"i.	A. only",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63537,1,"If an order reads, ""CPAP per RT protocol"", you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",g211833,1,"ii.	B. only",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63537,2,"If an order reads, ""CPAP per RT protocol"", you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",g211834,2,"iii.	A and C",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63537,3,"If an order reads, ""CPAP per RT protocol"", you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",g211835,3,"iv.	A and D",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63538,0,When a Trach patient on the floor is de-cannulated you must:,g211836,0,"a.	Stay in the room with the patient for 24 hours",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63538,1,When a Trach patient on the floor is de-cannulated you must:,g211837,1,"b.	Place on a remote pulse ox for 24 hours per policy",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63538,2,When a Trach patient on the floor is de-cannulated you must:,g211838,2,"c.	Place on a remote Capnography for 24 hours",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63538,3,When a Trach patient on the floor is de-cannulated you must:,g211839,3,"d.	B or C",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63538,4,When a Trach patient on the floor is de-cannulated you must:,g211840,4,"e.	A and B",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63539,0,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g211841,0,"a.	Heart rate increases or decreases to >20 from the pre therapy heart rate",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63539,1,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g211842,1,"b.	Therapist is unable to achieve an adequate mask seal",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63539,2,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g211843,2,"c.	Tach dysrhythmias or Brach arrhythmias Occur",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63539,3,"Per CPAP/BiPAP protocol, the physician will be contacted when:",g211844,3,"d.	All of the above",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63540,0,"When using the C1 or C3 in Non-invasive mode, it is important to set the following:",g211845,0,"a.	I-time lower than I time Max and ETS at least 50% to help compensate for leaks in the mask",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63540,1,"When using the C1 or C3 in Non-invasive mode, it is important to set the following:",g211846,1,"b.	I-time needs to be higher than I time Max and ETS at 25%",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63541,0,On the code sheet you should ALWAYS make sure the airway/Etco2 section is filled out correctly before signing the sheet,g211847,0,TRUE,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63541,1,On the code sheet you should ALWAYS make sure the airway/Etco2 section is filled out correctly before signing the sheet,g211848,1,FALSE,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63542,0,"What should you do when a patient is not compliant with CPAP, home or Hospital unit?",g211849,0,"a.	It's okay, they have the right to refuse treatment",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63542,1,"What should you do when a patient is not compliant with CPAP, home or Hospital unit?",g211850,1,"b.	Notify the physician, place them on a capnography remote monitor and educate on why it is needed.",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63542,2,"What should you do when a patient is not compliant with CPAP, home or Hospital unit?",g211851,2,"c.	Place them on 3L nc",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63543,0,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",g211852,0,"i.	A and C",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63543,1,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",g211853,1,"ii.	B and C",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63543,2,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",g211854,2,"iii.	A, B, C",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63543,3,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",g211855,3,"iv.	B only",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63544,0,"Remote monitors placed per protocol may be discontinued one hour after the PCA/Epidural has been discontinued, BIPAP/CPAP usage has been discontinued, or a repeat ABG results in a PaO2 > 65mmHg.",g211856,0,TRUE,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63544,1,"Remote monitors placed per protocol may be discontinued one hour after the PCA/Epidural has been discontinued, BIPAP/CPAP usage has been discontinued, or a repeat ABG results in a PaO2 > 65mmHg.",g211857,1,FALSE,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63545,0,"Patients on CPAP, home or Hospital Unit that require more than 40% / 5lpm FiO2 bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",g211858,0,"a.	Remote capnography",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63545,1,"Patients on CPAP, home or Hospital Unit that require more than 40% / 5lpm FiO2 bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",g211859,1,"b.	Remote Pulse Oximeter",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63546,0,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",g211860,0,"i.	A and C",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63546,1,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",g211861,1,"ii.	A, B, and C",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63546,2,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",g211862,2,"iii.	A,D,E",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63546,3,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",g211863,3,"iv.	All of the above",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63547,0,A patient may be on the floor with a cuffed Trach.,g211864,0,TRUE,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63547,1,A patient may be on the floor with a cuffed Trach.,g211865,1,FALSE,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63548,0,Which of the following patient type needs to be monitored by remote pulse oximetry,g211866,0,"a.	Patients with a PaO2 65 or less",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63548,1,Which of the following patient type needs to be monitored by remote pulse oximetry,g211867,1,"b.	Patients on comfort care",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63548,2,Which of the following patient type needs to be monitored by remote pulse oximetry,g211868,2,"c.	Any patient requiring more than 6l of oxygen to maintain their SpO2 greater than 92%",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63549,0,Patients on high flow device requiring an FiO2of 50% or greater to maintain a SpO2 of 92% or patients that have had a FiO2 increase of 10% or greater over 1-2 hours should have a pulmonary or critical care consult for management and to determine appropriate  hospital unit placement.,g211869,0,TRUE,1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63549,1,Patients on high flow device requiring an FiO2of 50% or greater to maintain a SpO2 of 92% or patients that have had a FiO2 increase of 10% or greater over 1-2 hours should have a pulmonary or critical care consult for management and to determine appropriate  hospital unit placement.,g211870,1,FALSE,0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63550,0,"If the therapist receives an order for a Bipap device from a provider other than Critical Care, they will stabilize the patient then:",g211871,0,"a.	Personally contact the critical care doc on call to notify them of the patient",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63550,1,"If the therapist receives an order for a Bipap device from a provider other than Critical Care, they will stabilize the patient then:",g211872,1,"b.	Communicate with the ordering physician that Critical Care must be consulted for further evaluation",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63551,0,When setting up a MetaNeb treatment on a patient which of the following is not set:,g211873,0,"a.	Oscillations",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63551,1,When setting up a MetaNeb treatment on a patient which of the following is not set:,g211874,1,"b.	Pressure",1,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19964,9739,Elearning-0000-949,g13964,g63551,2,When setting up a MetaNeb treatment on a patient which of the following is not set:,g211875,2,"c.	Resistance",0,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY
19966,274,SCORM-0000-84,g13963,g63525,0,I have read and understood the content within the Occupational Therapy and Heart Failure CBL.,g211791,0,TRUE,1,OCCUPATIONAL THERAPY AND HEART FAILURE
19966,274,SCORM-0000-84,g13963,g63525,1,I have read and understood the content within the Occupational Therapy and Heart Failure CBL.,g211792,1,FALSE,0,OCCUPATIONAL THERAPY AND HEART FAILURE
19962,9558,Elearning-0000-784,g13960,g63489,0,All fresh trachs performed by Atlanta Head and Neck Associates (AHNA) will use the fresh trach protocol without any changes.,g211675,0,TRUE,0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63489,1,All fresh trachs performed by Atlanta Head and Neck Associates (AHNA) will use the fresh trach protocol without any changes.,g211676,1,FALSE,1,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63490,0,What will dictate the care of the fresh trachs done by AHNA?,g211677,0,"a.	The surgeons will write specific orders that may change from patient-to-patient.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63490,1,What will dictate the care of the fresh trachs done by AHNA?,g211678,1,"b.	The nurse, the doctor and the RT must communicate to develop an appropriate plan of care.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63490,2,What will dictate the care of the fresh trachs done by AHNA?,g211679,2,"c.	Patients that do not have specific orders from the surgeon will follow the Fresh Trach Protocol with additional instructions.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63490,3,What will dictate the care of the fresh trachs done by AHNA?,g211680,3,"d.	All of the above",1,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63491,0,What considerations should be taken for patients with a reconstructive flap?,g211681,0,"a.	No trach ties or elastic bands can be used around the neck.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63491,1,What considerations should be taken for patients with a reconstructive flap?,g211682,1,"b.	Suctioning is done Q2 hours.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63491,2,What considerations should be taken for patients with a reconstructive flap?,g211683,2,"c.	The patients MUST have a humidification device as mucus plugging is common.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63491,3,What considerations should be taken for patients with a reconstructive flap?,g211684,3,"d.	A ""Head and Neck Flap"" sign should be present at the HOB until the patient leaves the ICU.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63491,4,What considerations should be taken for patients with a reconstructive flap?,g211685,4,"e.	A and B only.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63491,5,What considerations should be taken for patients with a reconstructive flap?,g211686,5,"f.	All of the above",1,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63492,0,How is humidification secured for patients with a reconstructive flap?,g211687,0,"a.	Safety pins attach the trach collar to tape on the patient's chest.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63492,1,How is humidification secured for patients with a reconstructive flap?,g211688,1,"b.	The green elastic strap goes behind the patient's neck to secure the trach collar.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63492,2,How is humidification secured for patients with a reconstructive flap?,g211689,2,"c.	If tape will not stick to the patient's chest, a towel may go behind the patient's neck and the safety pins should secure the trach collar to the towel",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63492,3,How is humidification secured for patients with a reconstructive flap?,g211690,3,"d.	No humidification is needed for patients with reconstructive neck flaps.",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63492,4,How is humidification secured for patients with a reconstructive flap?,g211691,4,"e.	A and C only",1,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63492,5,How is humidification secured for patients with a reconstructive flap?,g211692,5,"f.	All of the above",0,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63493,0,Can the RT remove sutures after 5 day for AHNA trach patients?,g211693,0,"a.	NO. The sutures can only be removed by the surgeon.",1,ATLANTA HEAD AND NECK ASSOCIATES
19962,9558,Elearning-0000-784,g13960,g63493,1,Can the RT remove sutures after 5 day for AHNA trach patients?,g211694,1,"b.	YES. The RT can remove the sutures after seeking physician approval.",0,ATLANTA HEAD AND NECK ASSOCIATES
19960,9675,Elearning-0000-890,g13959,g63469,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",g211603,0,a. True,1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63469,1,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",g211604,1,b. False,0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63470,0,Which one of the following hazardous medication list grouping is incorrect?,g211605,0,"a.	Group 2 - Hazardous agents (primarily reproductive risk)",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63470,1,Which one of the following hazardous medication list grouping is incorrect?,g211606,1,"b.	Group 1 - Hazardous agents (cytotoxic antineoplastic/reproductive risks)",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63470,2,Which one of the following hazardous medication list grouping is incorrect?,g211607,2,"c.	Group 2A - Non-hazardous antineoplastic agents",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63470,3,Which one of the following hazardous medication list grouping is incorrect?,g211608,3,"d.	Appendix D - Excluded drugs based on NSH risk assessment",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63471,0,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g211609,0,"a.	Decontamination",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63471,1,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g211610,1,"b.	Cleaning",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63471,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g211611,2,"c.	Disinfection",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63471,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g211612,3,"d.	Deactivate",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63471,4,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g211613,4,"e.	All of the above",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63472,0,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g211614,0,"a.	Protective Gown",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63472,1,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g211615,1,"b.	Eye/Face protection",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63472,2,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g211616,2,"c.	Respiratory protection",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63472,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g211617,3,"d.	Footwear",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63472,4,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g211618,4,"e.	Gloves",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63472,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g211619,5,"f.	All of the above",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63473,0,The spill response team is activated for any spills that is not contained by the following:,g211620,0,"a.	Two Spill Kits",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63473,1,The spill response team is activated for any spills that is not contained by the following:,g211621,1,"b.	Single Spill Kit",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63473,2,The spill response team is activated for any spills that is not contained by the following:,g211622,2,"c.	Three Spill Kits",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63473,3,The spill response team is activated for any spills that is not contained by the following:,g211623,3,"d.	Any spill in patient care area",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63473,4,The spill response team is activated for any spills that is not contained by the following:,g211624,4,"e.	Any spill in pharmacy area",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63474,0,Gloves used in the preparation of HDs must be:,g211625,0,"a.	Disposable",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63474,1,Gloves used in the preparation of HDs must be:,g211626,1,"b.	Powdered to facilitate removal",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63474,2,Gloves used in the preparation of HDs must be:,g211627,2,"c.	Specified as ASTM-tested chemotherapy gloves",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63474,3,Gloves used in the preparation of HDs must be:,g211628,3,"d.	A and C",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63475,0,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g211629,0,"a.	Filter needles",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63475,1,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g211630,1,"b.	Leur-Lock syringes",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63475,2,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g211631,2,"c.	Closed-system transfer devices (CSTDs)",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63475,3,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g211632,3,"d.	None of the above",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63476,0,When wearing double gloves:,g211633,0,"a.	The gown cuffs should be tucked over both gloves",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63476,1,When wearing double gloves:,g211634,1,"b.	The gown cuffs should be tucked under both gloves",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63476,2,When wearing double gloves:,g211635,2,"c.	The inner glove should be worn under the cuff and the outer glove should be worn over the gown cuff",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63476,3,When wearing double gloves:,g211636,3,"d.	It makes no difference if gown cuffs are worn over or under the gloves",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63477,0,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,g211637,0,"a.	True",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63477,1,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,g211638,1,"b.	False",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63478,0,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g211639,0,"a.	Biological safety cabinet (BSC)",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63478,1,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g211640,1,"b.	Horizontal laminar air flow workbench",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63478,2,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g211641,2,"c.	Compounding aseptic containment isolator (CACI)",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63478,3,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g211642,3,"d.	A and C",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63479,0,Spill kits:,g211643,0,"a.	May be obtained from Central Supply when needed",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63479,1,Spill kits:,g211644,1,"b.	Are kept wherever HDs and chemotherapy agents are handled",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63479,2,Spill kits:,g211645,2,"c.	Contain supplies needed to clean a HD spill",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63479,3,Spill kits:,g211646,3,"d.	All of the above",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63480,0,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",g211647,0,"a.	True",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63480,1,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",g211648,1,"b.	False",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63481,0,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",g211649,0,"a.	True",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63481,1,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",g211650,1,"b.	False",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63482,0,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",g211651,0,a. True,1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63482,1,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",g211652,1,b. False,0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63483,0,How often do you have to change the gown during hazardous drug compounding?,g211653,0,"a.	At least every 12 hours",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63483,1,How often do you have to change the gown during hazardous drug compounding?,g211654,1,"b.	At least every 24 hours",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63483,2,How often do you have to change the gown during hazardous drug compounding?,g211655,2,"c.	At least every 3 hours",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63483,3,How often do you have to change the gown during hazardous drug compounding?,g211656,3,"d.	At least every 8 hours",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63484,0,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g211657,0,"a.	At least every 8 hours",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63484,1,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g211658,1,"b.	At least every 3  hours",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63484,2,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g211659,2,"c.	At least every 30 minutes",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63484,3,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g211660,3,"d.	 At shift change",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63485,0,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,g211661,0,"a.	True",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63485,1,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,g211662,1,"b.	False",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63486,0,Which statement is true?,g211663,0,"a.	Cytotoxic chemotherapy doses maybe rounded down or up to the nearest vials size within < 5% of the calculated dose",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63486,1,Which statement is true?,g211664,1,"b.	Cytotoxic chemotherapy doses maybe rounded down to the nearest vials size within < 5% of the calculated dose",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63486,2,Which statement is true?,g211665,2,"c.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 10% of the calculated dose.",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63486,3,Which statement is true?,g211666,3,"d.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 5% of the calculated dose.",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63486,4,Which statement is true?,g211667,4,"e.	a & c",0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63486,5,Which statement is true?,g211668,5,"f.	b & c",1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63487,0,PA or NP may sign C1D1 chemotherapy orders.,g211669,0,a. True,0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63487,1,PA or NP may sign C1D1 chemotherapy orders.,g211670,1,b. False,1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63488,0,Which statement is false?,g211671,0,a. Verbal and telephone orders to initiate chemotherapy will not be accepted,0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63488,1,Which statement is false?,g211672,1,b. A physician must sign C1D1 chemotherapy orders,0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63488,2,Which statement is false?,g211673,2,c. Pregnancy screening is required at baseline and then at least once a week while the patient is on therapy,1,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19960,9675,Elearning-0000-890,g13959,g63488,3,Which statement is false?,g211674,3,d. Treating physicians are responsible for monitoring cumulative anthracycline doses,0,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION
19955,9681,Elearning-0000-896,g13956,g63452,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Hand Off Communication Perioperative Communication"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g211560,0,TRUE,1,HAND OFF COMMUNICATION PERIOPERATIVE COMMUNICATION
19955,9681,Elearning-0000-896,g13956,g63452,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Hand Off Communication Perioperative Communication"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g211561,1,FALSE,0,HAND OFF COMMUNICATION PERIOPERATIVE COMMUNICATION
19953,9730,Elearning-0000-940,g13954,g63409,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g211402,0,1. All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63409,1,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g211403,1,2. A and C,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63409,2,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g211404,2,"3. A, C, D",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63410,0,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",g211405,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63410,1,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",g211406,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63411,0,"Which statement about ASV mode is FALSE?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g211407,0,1. All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63411,1,"Which statement about ASV mode is FALSE?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g211408,1,2. A and C,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63411,2,"Which statement about ASV mode is FALSE?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",g211409,2,"3. A, C, D",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63412,0,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",g211410,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63412,1,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",g211411,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63413,0,Which statement about ASV mode is FALSE?,g211412,0,1. ASV maintains an operator-preset minimum minute ventilation independent of the patient's activity.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63413,1,Which statement about ASV mode is FALSE?,g211413,1,"2. On the G5, the maximum pressure set by ASV is always 10 cmH2O below the maximum pressure limit, thus the maximum pressure and the ASV limit co-vary.",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63413,2,Which statement about ASV mode is FALSE?,g211414,2,"3. The lowest Minute Volume % to be used in ASV mode is 100%.  Per protocol, the RT may set the MV% to 80% without a Physican's order for patients with a diagnosis of COPD.",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63413,3,Which statement about ASV mode is FALSE?,g211415,3,"4. When started, the device delivers 3 test breaths in synchronized intermittent mandatory pressure ventilation mode.",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63414,0,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",g211416,0,"1. A, B, C, D",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63414,1,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",g211417,1,2. A and C,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63414,2,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",g211418,2,"3. B, C, F",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63414,3,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",g211419,3,"4. A, B, C",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63414,4,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",g211420,4,5. All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63415,0,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",g211421,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63415,1,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",g211422,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63416,0,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,g211423,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63416,1,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,g211424,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63417,0,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",g211425,0,1. A only,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63417,1,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",g211426,1,2. C and D,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63417,2,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",g211427,2,"3. B, C, D",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63417,3,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",g211428,3,4. C and E,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63418,0,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g211429,0,A. 255mL - 395mL,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63418,1,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g211430,1,B. 280mL - 420mL,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63418,2,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g211431,2,C. 300mL - 440mL,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63418,3,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""",g211432,3,D. 320mL - 460mL,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63419,0,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,g211433,0,1. A and B,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63419,1,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,g211434,1,"2. B, C, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63419,2,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,g211435,2,3. B and D,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63419,3,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,g211436,3,"4. A, B, D, E",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63419,4,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,g211437,4,"5. C, D, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63419,5,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,g211438,5,6. All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63420,0,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",g211439,0,1. A and C,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63420,1,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",g211440,1,2. A and D,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63420,2,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",g211441,2,"3. A, B, C",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63420,3,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",g211442,3,4. All of the above,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63421,0,Which of these statements regarding Spontaneous mode is FALSE?,g211443,0,"a. When pressure support is set to zero, the mode functions like  a conventional CPAP system.",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63421,1,Which of these statements regarding Spontaneous mode is FALSE?,g211444,1,b. The patient determines the breath timing and may be either flow or  pressure triggered.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63421,2,Which of these statements regarding Spontaneous mode is FALSE?,g211445,2,"c. The settings in this mode include: Psupport, P-ramp, ETS, PEEP,  Fi02 and Trigger.",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63421,3,Which of these statements regarding Spontaneous mode is FALSE?,g211446,3,"d. If the back up mode is selected, the vent will transition from SPONT to APV-CMV mode when the apnea alarm is triggered.",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63422,0,"The vent weaning readiness criteria includes a PEEP =  8 cmH20, Fi02 = 50%, spontaneous respirations and a patient that follows commands.",g211447,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63422,1,"The vent weaning readiness criteria includes a PEEP =  8 cmH20, Fi02 = 50%, spontaneous respirations and a patient that follows commands.",g211448,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63423,0,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g211449,0,A. The SBT should not exceed 120 minutes unless ordered by MD or midlevel.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63423,1,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g211450,1,"B. If at any time the patient because unstable or has an increased RR > 35bpm, the mode should be changed to achieve the pre-trial minute volume.",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63423,2,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g211451,2,C. ASV at 100%MV or CPAP/PS mode may be used.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63423,3,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g211452,3,"D. ASV at 100%MV may be used and the Pinsp should be < 15cmH20 to be considered in a ""weaning"" mode.",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63423,4,Which statement regarding the Spontaneous Breathing Trial is FALSE?,g211453,4,"E. If the patient is on pressors, the RT and RN must confirm that the physician is aware of the type and dose of pressors before a weaning trial is conducted.",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63424,0,The red alarm cable connected should be documented with every Q4h vent check while confirmation of the audible and visual alarms should be documented with every vent check.,g211454,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63424,1,The red alarm cable connected should be documented with every Q4h vent check while confirmation of the audible and visual alarms should be documented with every vent check.,g211455,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63425,0,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,g211456,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63425,1,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,g211457,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63426,0,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,g211458,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63426,1,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,g211459,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63427,0,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,g211460,0,1. All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63427,1,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,g211461,1,"2. A, C, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63427,2,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,g211462,2,3. B and C,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63427,3,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,g211463,3,"4. A, B, C, E",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63428,0,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g211464,0,A. Hollister,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63428,1,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g211465,1,B. Silk tape then Stabiltube,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63428,2,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g211466,2,C. Hollister with Physician's order,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63428,3,"When patients are placed in the prone position, which of the following tube holders are acceptable?",g211467,3,D.  B and C,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63429,0,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g211468,0,"A. Increased I-time, decreased E-time",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63429,1,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g211469,1,"B. Decreased I-time, increased E-time",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63429,2,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g211470,2,"C. Decreased I-time, decreased E-time",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63429,3,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",g211471,3,D. None of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63430,0,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",g211472,0,A. Only the G5 can utilize Heliox.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63430,1,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",g211473,1,B. The G5 flow sensor must be recalibrated with Heliox prior to starting the therapy.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63430,2,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",g211474,2,C. The circuit must first be changed from a single limb with a HME to a heated wire circuit prior to starting Heliox therapy,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63431,0,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g211475,0,A. 68,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63431,1,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g211476,1,B.  70,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63431,2,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g211477,2,C.  66,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63431,3,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",g211478,3,D.  49,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63432,0,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",g211479,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63432,1,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",g211480,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63433,0,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g211481,0,A. Peak airway pressure,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63433,1,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g211482,1,B. Optimal PEEP,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63433,2,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g211483,2,C. Dynamic lung compliance,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63433,3,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,g211484,3,D. Plateau pressure,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63434,0,The Hamilton ventilator will display which of the following calculations and measurements?,g211485,0,A. Lung compliance,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63434,1,The Hamilton ventilator will display which of the following calculations and measurements?,g211486,1,B. AutoPEEP,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63434,2,The Hamilton ventilator will display which of the following calculations and measurements?,g211487,2,C. Rapid shallow breathing index,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63434,3,The Hamilton ventilator will display which of the following calculations and measurements?,g211488,3,D. Airway resistance,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63434,4,The Hamilton ventilator will display which of the following calculations and measurements?,g211489,4,"E. A, C, D",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63434,5,The Hamilton ventilator will display which of the following calculations and measurements?,g211490,5,F. All of the above,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63435,0,"Hamilton C2-C3 in NIV-ST mode<br>   Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",g211491,0,A.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63435,1,"Hamilton C2-C3 in NIV-ST mode<br>   Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",g211492,1,B.,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63435,2,"Hamilton C2-C3 in NIV-ST mode<br>   Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",g211493,2,C.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63436,0,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,g211494,0,"1. A, D, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63436,1,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,g211495,1,"2. B, C, D",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63436,2,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,g211496,2,"3. A, B, D, E",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63436,3,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,g211497,3,4. A and E,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63436,4,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,g211498,4,5. All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63437,0,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",g211499,0,"1. A, B, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63437,1,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",g211500,1,"2.   B, C and E",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63437,2,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",g211501,2,"3. C, D, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63437,3,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",g211502,3,4. All statements are true,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63438,0,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g211503,0,a.   NIV-ST,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63438,1,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g211504,1,b.   Spontaneous,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63438,2,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g211505,2,c.   NIV,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63438,3,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",g211506,3,d.   NIPPV,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63439,0,"Per protocol, what are the initial HFO settings?",g211507,0,"a.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 50%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 35 lpm",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63439,1,"Per protocol, what are the initial HFO settings?",g211508,1,"b.  Hz 5, Power 5 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20 above mean pressure on conventional vent, Bias Flow 35 lpm",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63439,2,"Per protocol, what are the initial HFO settings?",g211509,2,"c.  Hz 3, Power 5 - adjusting for adequate chest wiggle, Ti 40%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 25 lpm",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63439,3,"Per protocol, what are the initial HFO settings?",g211510,3,"d.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20  below mean pressure on conventional vent, Bias Flow 45 lpm",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63440,0,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,g211511,0,1.  All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63440,1,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,g211512,1,2.  A and B,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63440,2,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,g211513,2,"3.  A, B, C",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63440,3,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,g211514,3,4.  B and C,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63441,0,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g211515,0,a.   Frequency,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63441,1,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g211516,1,b.   Cuff Leak,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63441,2,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g211517,2,c.    I Time,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63441,3,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g211518,3,d. Amplitude,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63441,4,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g211519,4,e. A and B only,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63441,5,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",g211520,5,"f. A, B, C, D",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63442,0,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g211521,0,a.   MAP,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63442,1,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g211522,1,b.   FiO2,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63442,2,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g211523,2,c. Amplitude,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63442,3,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g211524,3,d. A and B only,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63442,4,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",g211525,4,"e. A, B, C",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63443,0,"Per protocol, which changes could correct the following ABG using the HFO 3100B? pH 7.24 - PaC02 68 - Pa02 80 - HCO3 29 - BE 3.9<br> A. Increase Hz, Decrease Power B. Increase Power, Increase Hz C. Decreased Hz, Increase Power D. Cuff leak",g211526,0,"1.  A, D, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63443,1,"Per protocol, which changes could correct the following ABG using the HFO 3100B? pH 7.24 - PaC02 68 - Pa02 80 - HCO3 29 - BE 3.9<br> A. Increase Hz, Decrease Power B. Increase Power, Increase Hz C. Decreased Hz, Increase Power D. Cuff leak",g211527,1,2.  B and D,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63443,2,"Per protocol, which changes could correct the following ABG using the HFO 3100B? pH 7.24 - PaC02 68 - Pa02 80 - HCO3 29 - BE 3.9<br> A. Increase Hz, Decrease Power B. Increase Power, Increase Hz C. Decreased Hz, Increase Power D. Cuff leak",g211528,2,3.  C and D,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63444,0,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",g211529,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63444,1,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",g211530,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63445,0,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g211531,0,a.  5 PPM,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63445,1,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g211532,1,b.  10 PPM,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63445,2,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g211533,2,c.  Therapist discretion,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63445,3,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,g211534,3,d.  20 PPM,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63446,0,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g211535,0,a. 20ppm,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63446,1,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g211536,1,b. 30ppm,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63446,2,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g211537,2,c. 40ppm,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63446,3,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,g211538,3,d. 60ppm,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63447,0,When should you consider changing the Nitric oxide filter and sample line?,g211539,0,A. When you see fluid in the sample line,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63447,1,When should you consider changing the Nitric oxide filter and sample line?,g211540,1,B. When the measured Nitric oxide and Fi02 is inaccurate,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63447,2,When should you consider changing the Nitric oxide filter and sample line?,g211541,2,"C. After medications like Tobramycin, Mucomyst or Colistin are nebulized inline",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63447,3,When should you consider changing the Nitric oxide filter and sample line?,g211542,3,D. All of the above,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63448,0,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,g211543,0,1. All of the above,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63448,1,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,g211544,1,"2. A, B, D",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63448,2,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,g211545,2,3. A and B only,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63448,3,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,g211546,3,"4. A, C, D",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63449,0,Components of the Fresh Trach protocol include?,g211547,0,A. Signage on the door with the date and time the 48 hour observation ends,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63449,1,Components of the Fresh Trach protocol include?,g211548,1,B.  ETC02 Q4  and breath sounds documentation with any patient repositioning during the first 48 hours,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63449,2,Components of the Fresh Trach protocol include?,g211549,2,C.  Same size trach and one size smaller at bedside,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63449,3,Components of the Fresh Trach protocol include?,g211550,3,D.  Obturator at the HOB,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63449,4,Components of the Fresh Trach protocol include?,g211551,4,E.  Airway box at bedside,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63449,5,Components of the Fresh Trach protocol include?,g211552,5,F.  Ambu bag and mask at bedside,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63449,6,Components of the Fresh Trach protocol include?,g211553,6,G.  All of the above,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63450,0,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",g211554,0,"1. A, B, C, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63450,1,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",g211555,1,"2. B, C, D",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63450,2,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",g211556,2,3. A and E,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63450,3,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",g211557,3,4. All of the above,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63453,0,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",g211562,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63453,1,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",g211563,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63454,0,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,g211564,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63454,1,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,g211565,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63455,0,"49 F, 5'5"", with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",g211566,0,"A. ASV 140%, PEEP 10, Fi02 100%.  Target 8lpm.",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63455,1,"49 F, 5'5"", with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",g211567,1,"B. P-CMV, PC 20cmH20, RR 16, PEEP 8, Fi02 85%, exh Vt 570mL",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63455,2,"49 F, 5'5"", with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",g211568,2,"C. APV-CMV Vt 400, RR 20, PEEP 10, Fi02 100%",1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63456,0,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,g211569,0,"1. B, C, D, E",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63456,1,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,g211570,1,"2. A, B, C, D",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63456,2,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,g211571,2,3. C and E,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63456,3,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,g211572,3,4. All of the above,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63457,0,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g211573,0,1. All statements are true,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63457,1,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g211574,1,2. A and D,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63457,2,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g211575,2,3. B and C,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63457,3,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",g211576,3,4. B and D,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63458,0,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",g211577,0,"1. B, D, E, G",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63458,1,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",g211578,1,"2. A, D, G, H",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63458,2,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",g211579,2,"3. B, C, F, G,",0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63458,3,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",g211580,3,4. All of the above,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63459,0,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g211581,0,1. Cover the laryngectomy stoma with your hand or gauze and bag through the mouth with the AMBU bag.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63459,1,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g211582,1,2. Use an adult AMBU bag and a pediatric mask over the laryngectomy stoma to provide ventilation.,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63459,2,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g211583,2,3. Intubate through the mouth with an ETT and provide ventilation with the AMBU bag.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63459,3,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,g211584,3,4. Do not use an AMBU bag for laryngectomy patients.,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63460,0,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Visual content only - Reviewed.,g211585,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63460,1,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Visual content only - Reviewed.,g211586,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63461,0,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater   Visual content only - Reviewed.",g211587,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63461,1,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater   Visual content only - Reviewed.",g211588,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63462,0,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Visual content only - Reviewed.",g211589,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63462,1,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Visual content only - Reviewed.",g211590,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63463,0,Heliox<br> G5 with Heliox: connection (we have 3 G5)  Visual content only - Reviewed.,g211591,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63463,1,Heliox<br> G5 with Heliox: connection (we have 3 G5)  Visual content only - Reviewed.,g211592,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63464,0,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox  Visual conten only - Reviewed.,g211593,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63464,1,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox  Visual conten only - Reviewed.,g211594,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63465,0,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.  Visual content only - Reviewed.",g211595,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63465,1,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.  Visual content only - Reviewed.",g211596,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63466,0,Skin Co-Signature for ETT's<br> (When The Tube holder is changed)  Visual content only - Reviewed.,g211597,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63466,1,Skin Co-Signature for ETT's<br> (When The Tube holder is changed)  Visual content only - Reviewed.,g211598,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63467,0,"Heliox<br> The Heliox mask, attach the Aerogen spacer and nebulizer using elbow  Visual content only - Reviewed.",g211599,0,TRUE,1,2021 RESPIRATORY ICU COMPETENCY
19953,9730,Elearning-0000-940,g13954,g63467,1,"Heliox<br> The Heliox mask, attach the Aerogen spacer and nebulizer using elbow  Visual content only - Reviewed.",g211600,1,FALSE,0,2021 RESPIRATORY ICU COMPETENCY
19952,9130,Elearning-0000-395,g13953,g63408,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ONS CONGRESS 2021 REFLECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g211400,0,TRUE,1,ONS CONGRESS 2021 REFLECTIONS
19952,9130,Elearning-0000-395,g13953,g63408,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ONS CONGRESS 2021 REFLECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g211401,1,FALSE,0,ONS CONGRESS 2021 REFLECTIONS
19949,9329,Elearning-0000-576,g13950,g63405,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD) CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g211394,0,TRUE,1,FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD)
19949,9329,Elearning-0000-576,g13950,g63405,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD) CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g211395,1,FALSE,0,FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD)
19948,125,SCORM-0000-205,g13949,g63404,0,I have read and understood the content within the WAVE Onboarding Report Tutorial CBL.,g211392,0,TRUE,1,WAVE ONBOARDING REPORT TUTORIAL
19948,125,SCORM-0000-205,g13949,g63404,1,I have read and understood the content within the WAVE Onboarding Report Tutorial CBL.,g211393,1,FALSE,0,WAVE ONBOARDING REPORT TUTORIAL
19947,9686,Elearning-0000-900,g13948,g63403,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""SCN Feeding Workflow Update"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g211390,0,TRUE,1,SCN FEEDING WORKFLOW UPDATE
19947,9686,Elearning-0000-900,g13948,g63403,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""SCN Feeding Workflow Update"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g211391,1,FALSE,0,SCN FEEDING WORKFLOW UPDATE
19945,241,SCORM-0000-47,g13945,g63395,0,Number 1 root cause for Sentinel Events is,g211360,0,A.  Poor Communication,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63395,1,Number 1 root cause for Sentinel Events is,g211361,1,B. Inexperience of Staff,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63395,2,Number 1 root cause for Sentinel Events is,g211362,2,C. Distractions,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63395,3,Number 1 root cause for Sentinel Events is,g211363,3,D. Fatigue,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63396,0,Successful HOC occurs when there is,g211364,0,A.  Active Listening and Interactive Communication between both parties,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63396,1,Successful HOC occurs when there is,g211365,1,B.  Time allotted for Questions and Verbal Verification of Received Information,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63396,2,Successful HOC occurs when there is,g211366,2,C. Limit to Interruptions during HOC,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63396,3,Successful HOC occurs when there is,g211367,3,D. All the above,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63397,0,True or False HOC should only be completed during permanent relief?,g211368,0,A. True,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63397,1,True or False HOC should only be completed during permanent relief?,g211369,1,B. False,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63398,0,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,g211370,0,A. Scrub Tech to Scrub Tech,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63398,1,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,g211371,1,B. Support Tech to Primary RN,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63398,2,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,g211372,2,C. Primary Nurse to Relief Nurse,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63398,3,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,g211373,3,D. All the above,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63399,0,When <b><u>MUST</u></b> a nurse document HOC?,g211374,0,A. Breaks,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63399,1,When <b><u>MUST</u></b> a nurse document HOC?,g211375,1,B. Meals Breaks,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63399,2,When <b><u>MUST</u></b> a nurse document HOC?,g211376,2,C. Permanent Relief,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63399,3,When <b><u>MUST</u></b> a nurse document HOC?,g211377,3,D. All the Above,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63400,0,Some of the elements that must be covered in HOC include?,g211378,0,"A. Time Out (patient name, date of birth, procedure, allergies)",0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63400,1,Some of the elements that must be covered in HOC include?,g211379,1,B. Medications on the field and amount administered to patient,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63400,2,Some of the elements that must be covered in HOC include?,g211380,2,C. Specimen Status,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63400,3,Some of the elements that must be covered in HOC include?,g211381,3,D. All the Above,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63401,0,Who is responsible for the patients care and well being after HOC?,g211382,0,A. Surgeon,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63401,1,Who is responsible for the patients care and well being after HOC?,g211383,1,B. Reporting RN and reporting Surgical Technologist,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63401,2,Who is responsible for the patients care and well being after HOC?,g211384,2,C. Receiving RN and receiving Surgical Technologist,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63401,3,Who is responsible for the patients care and well being after HOC?,g211385,3,D. First Assist,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63402,0,The use of a HOC checklist as a memory aid serves what purpose(s)?,g211386,0,A. Ensures that critical information necessary for patient care is not omitted,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63402,1,The use of a HOC checklist as a memory aid serves what purpose(s)?,g211387,1,B. Provides a consistent order in which information should be communicated from care provider to care provider,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63402,2,The use of a HOC checklist as a memory aid serves what purpose(s)?,g211388,2,C. Provides a visual guide for individuals to use during HOC,0,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19945,241,SCORM-0000-47,g13945,g63402,3,The use of a HOC checklist as a memory aid serves what purpose(s)?,g211389,3,D. All the Above,1,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION
19943,225,SCORM-0000-31,g13943,g63385,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the eTime Timekeeper Training CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g211331,0,TRUE,1,ETIME TIMEKEEPER TRAINING
19943,225,SCORM-0000-31,g13943,g63385,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the eTime Timekeeper Training CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g211332,1,FALSE,0,ETIME TIMEKEEPER TRAINING
19942,9316,Elearning-0000-564,g13942,g63384,0,I have read and understand the education surrounding post cath assessment and re assessment.  I attest to demonstrate assessment and documentation of assessment per provider orders,g211329,0,TRUE,1,FY2021 NSF ICU POST CATH DOCUMENTATION EDUCATION
19942,9316,Elearning-0000-564,g13942,g63384,1,I have read and understand the education surrounding post cath assessment and re assessment.  I attest to demonstrate assessment and documentation of assessment per provider orders,g211330,1,FALSE,0,FY2021 NSF ICU POST CATH DOCUMENTATION EDUCATION
19939,9912,Questions-0000-46,g13941,g63361,0,Please list the location for this activity.,g211234,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63361,1,Please list the location for this activity.,g211235,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63361,2,Please list the location for this activity.,g211236,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63361,3,Please list the location for this activity.,g211237,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63362,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211238,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63362,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211239,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63362,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211240,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63362,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211241,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63362,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211242,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63363,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211243,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63363,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211244,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63363,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211245,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63363,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211246,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63363,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211247,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63364,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211248,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63364,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211249,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63364,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211250,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63364,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211251,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63364,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211252,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63365,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211253,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63365,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211254,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63365,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211255,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63365,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211256,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63365,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211257,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63366,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g211258,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63366,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g211259,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63366,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g211260,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63366,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g211261,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63366,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g211262,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63367,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g211263,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63367,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g211264,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63367,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g211265,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63367,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g211266,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63367,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g211267,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63368,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g211268,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63368,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g211269,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63368,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g211270,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63368,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g211271,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63368,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g211272,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63369,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g211273,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63369,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g211274,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63369,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g211275,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63369,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g211276,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63369,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g211277,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63370,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211278,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63370,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211279,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63370,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211280,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63370,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211281,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63370,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211282,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63371,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211283,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63371,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211284,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63371,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211285,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63371,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211286,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63371,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211287,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63372,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211288,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63372,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211289,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63372,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211290,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63372,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211291,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63372,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211292,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63373,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211293,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63373,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211294,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63373,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211295,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63373,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211296,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63373,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211297,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63374,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211298,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63374,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211299,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63374,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211300,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63374,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211301,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63374,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211302,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63375,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211303,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63375,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211304,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63375,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211305,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63375,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211306,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63375,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211307,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63376,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211308,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63376,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211309,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63376,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211310,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63376,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211311,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63376,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211312,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63376,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211313,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63377,0,"Overall, this activity was:",g211314,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63377,1,"Overall, this activity was:",g211315,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63377,2,"Overall, this activity was:",g211316,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63377,3,"Overall, this activity was:",g211317,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63377,4,"Overall, this activity was:",g211318,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63378,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211319,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63378,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211320,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63378,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211321,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63381,0,How would you improve this class (check all that apply)?,g211322,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63381,1,How would you improve this class (check all that apply)?,g211323,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63381,2,How would you improve this class (check all that apply)?,g211324,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63381,3,How would you improve this class (check all that apply)?,g211325,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63381,4,How would you improve this class (check all that apply)?,g211326,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63381,5,How would you improve this class (check all that apply)?,g211327,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19939,9912,Questions-0000-46,g13941,g63381,6,How would you improve this class (check all that apply)?,g211328,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21
19940,9918,Questions-0000-52,g13940,g63342,0,Please list the location for this activity.,g211159,0,Atlanta,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63342,1,Please list the location for this activity.,g211160,1,Cherokee,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63342,2,Please list the location for this activity.,g211161,2,Forsyth,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63342,3,Please list the location for this activity.,g211162,3,Other,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63343,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211163,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63343,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211164,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63343,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211165,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63343,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211166,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63343,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211167,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63344,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211168,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63344,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211169,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63344,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211170,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63344,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211171,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63344,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211172,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63345,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211173,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63345,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211174,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63345,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211175,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63345,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211176,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63345,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g211177,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63346,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211178,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63346,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211179,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63346,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211180,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63346,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211181,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63346,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g211182,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63347,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211183,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63347,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211184,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63347,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211185,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63347,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211186,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63347,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211187,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63348,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211188,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63348,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211189,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63348,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211190,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63348,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211191,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63348,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211192,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63349,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211193,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63349,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211194,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63349,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211195,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63349,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211196,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63349,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211197,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63350,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211198,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63350,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211199,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63350,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211200,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63350,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211201,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63350,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211202,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63351,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211203,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63351,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211204,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63351,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211205,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63351,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211206,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63351,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211207,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63352,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g211208,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63352,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g211209,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63352,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g211210,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63352,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g211211,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63352,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g211212,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63353,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211213,4,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63353,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211214,0,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63353,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211215,1,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63353,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211216,2,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63353,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211217,3,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63353,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211218,5,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63354,0,"Overall, this activity was:",g211219,0,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63354,1,"Overall, this activity was:",g211220,1,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63354,2,"Overall, this activity was:",g211221,2,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63354,3,"Overall, this activity was:",g211222,3,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63354,4,"Overall, this activity was:",g211223,4,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63355,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211224,0,Yes,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63355,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211225,1,No,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63355,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211226,2,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63358,0,How would you improve this class (check all that apply)?,g211227,0,Reduce content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63358,1,How would you improve this class (check all that apply)?,g211228,1,Increase content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63358,2,How would you improve this class (check all that apply)?,g211229,2,Update content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63358,3,How would you improve this class (check all that apply)?,g211230,3,Improve the instructional methods,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63358,4,How would you improve this class (check all that apply)?,g211231,4,Make course activities more stimulating,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63358,5,How would you improve this class (check all that apply)?,g211232,5,Slow the pace of the class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19940,9918,Questions-0000-52,g13940,g63358,6,How would you improve this class (check all that apply)?,g211233,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21"
19941,9905,Questions-0000-39,g13939,g63325,0,Please list the location for this activity.,g211094,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63325,1,Please list the location for this activity.,g211095,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63325,2,Please list the location for this activity.,g211096,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63325,3,Please list the location for this activity.,g211097,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63326,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211098,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63326,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211099,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63326,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211100,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63326,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211101,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63326,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g211102,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63327,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211103,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63327,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211104,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63327,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211105,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63327,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211106,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63327,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g211107,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63328,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211108,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63328,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211109,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63328,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211110,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63328,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211111,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63328,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211112,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63329,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211113,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63329,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211114,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63329,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211115,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63329,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211116,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63329,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211117,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63330,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211118,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63330,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211119,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63330,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211120,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63330,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211121,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63330,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g211122,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63331,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211123,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63331,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211124,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63331,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211125,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63331,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211126,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63331,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g211127,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63332,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211128,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63332,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211129,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63332,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211130,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63332,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211131,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63332,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g211132,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63333,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g211133,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63333,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g211134,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63333,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g211135,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63333,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g211136,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63333,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g211137,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63334,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211138,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63334,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211139,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63334,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211140,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63334,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211141,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63334,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211142,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63334,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",g211143,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63335,0,"Overall, this activity was:",g211144,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63335,1,"Overall, this activity was:",g211145,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63335,2,"Overall, this activity was:",g211146,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63335,3,"Overall, this activity was:",g211147,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63335,4,"Overall, this activity was:",g211148,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63336,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211149,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63336,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211150,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63336,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211151,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63339,0,How would you improve this class (check all that apply)?,g211152,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63339,1,How would you improve this class (check all that apply)?,g211153,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63339,2,How would you improve this class (check all that apply)?,g211154,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63339,3,How would you improve this class (check all that apply)?,g211155,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63339,4,How would you improve this class (check all that apply)?,g211156,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63339,5,How would you improve this class (check all that apply)?,g211157,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19941,9905,Questions-0000-39,g13939,g63339,6,How would you improve this class (check all that apply)?,g211158,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21
19865,9808,Questions-0000-103,g13938,g63304,0,Please list the location for this activity.,g211010,0,Atlanta,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63304,1,Please list the location for this activity.,g211011,1,Cherokee,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63304,2,Please list the location for this activity.,g211012,2,Forsyth,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63304,3,Please list the location for this activity.,g211013,3,Other,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63305,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g211014,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63305,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g211015,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63305,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g211016,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63305,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g211017,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63305,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g211018,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63306,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g211019,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63306,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g211020,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63306,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g211021,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63306,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g211022,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63306,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g211023,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63307,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g211024,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63307,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g211025,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63307,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g211026,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63307,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g211027,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63307,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g211028,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63308,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g211029,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63308,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g211030,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63308,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g211031,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63308,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g211032,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63308,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g211033,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63309,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g211034,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63309,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g211035,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63309,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g211036,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63309,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g211037,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63309,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g211038,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63310,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g211039,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63310,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g211040,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63310,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g211041,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63310,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g211042,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63310,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g211043,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63311,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211044,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63311,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211045,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63311,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211046,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63311,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211047,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63311,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g211048,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63312,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211049,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63312,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211050,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63312,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211051,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63312,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211052,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63312,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211053,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63313,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211054,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63313,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211055,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63313,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211056,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63313,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211057,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63313,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g211058,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63314,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211059,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63314,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211060,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63314,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211061,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63314,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211062,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63314,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g211063,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63315,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g211064,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63315,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g211065,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63315,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g211066,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63315,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g211067,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63315,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g211068,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63316,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211069,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63316,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211070,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63316,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211071,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63316,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211072,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63316,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g211073,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63317,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g211074,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63317,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g211075,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63317,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g211076,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63317,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g211077,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63317,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g211078,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63318,0,"Overall, this activity was:",g211079,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63318,1,"Overall, this activity was:",g211080,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63318,2,"Overall, this activity was:",g211081,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63318,3,"Overall, this activity was:",g211082,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63318,4,"Overall, this activity was:",g211083,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63319,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211084,0,Yes,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63319,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211085,1,No,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63319,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211086,2,N/A,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63322,0,How would you improve this class?,g211087,0,Reduce content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63322,1,How would you improve this class?,g211088,1,Increase content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63322,2,How would you improve this class?,g211089,2,Update content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63322,3,How would you improve this class?,g211090,3,Improve the instructional methods,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63322,4,How would you improve this class?,g211091,4,Make course activities more stimulating,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63322,5,How would you improve this class?,g211092,5,Slow the pace of the class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19865,9808,Questions-0000-103,g13938,g63322,6,How would you improve this class?,g211093,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21
19938,9922,Questions-0000-56,g13937,g63282,0,Please list the location for this activity.,g210921,0,Atlanta,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63282,1,Please list the location for this activity.,g210922,1,Forsyth,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63282,2,Please list the location for this activity.,g210923,2,Cherokee,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63282,3,Please list the location for this activity.,g210924,3,Other,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63283,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",g210925,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63283,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",g210926,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63283,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",g210927,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63283,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",g210928,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63283,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",g210929,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63284,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",g210930,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63284,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",g210931,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63284,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",g210932,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63284,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",g210933,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63284,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",g210934,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63285,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",g210935,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63285,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",g210936,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63285,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",g210937,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63285,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",g210938,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63285,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",g210939,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63286,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",g210940,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63286,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",g210941,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63286,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",g210942,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63286,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",g210943,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63286,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",g210944,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63287,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",g210945,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63287,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",g210946,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63287,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",g210947,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63287,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",g210948,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63287,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",g210949,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63288,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",g210950,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63288,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",g210951,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63288,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",g210952,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63288,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",g210953,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63288,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",g210954,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63289,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",g210955,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63289,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",g210956,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63289,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",g210957,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63289,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",g210958,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63289,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",g210959,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63290,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210960,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63290,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210961,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63290,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210962,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63290,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210963,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63290,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210964,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63291,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,g210965,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63291,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,g210966,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63291,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,g210967,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63291,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,g210968,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63291,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,g210969,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63292,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,g210970,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63292,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,g210971,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63292,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,g210972,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63292,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,g210973,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63292,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,g210974,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63293,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210975,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63293,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210976,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63293,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210977,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63293,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210978,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63293,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210979,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63294,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210980,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63294,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210981,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63294,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210982,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63294,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210983,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63294,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210984,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63295,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210985,0,Strongly Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63295,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210986,1,Agree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63295,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210987,2,No Opinion,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63295,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210988,3,Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63295,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210989,4,Strongly Disagree,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63296,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",g210990,0,Excellent,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63296,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",g210991,1,Very Good,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63296,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",g210992,2,Good,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63296,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",g210993,3,Fair,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63296,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",g210994,4,Poor,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63297,0,"Overall, this activity was:",g210995,0,Excellent,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63297,1,"Overall, this activity was:",g210996,1,Very Good,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63297,2,"Overall, this activity was:",g210997,2,Good,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63297,3,"Overall, this activity was:",g210998,3,Fair,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63297,4,"Overall, this activity was:",g210999,4,Poor,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63298,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211000,0,Yes,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63298,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211001,1,No,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63298,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g211002,2,N/A,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63301,0,How would you improve this class?,g211003,0,Reduce content covered in class,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63301,1,How would you improve this class?,g211004,1,Increase content covered in class,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63301,2,How would you improve this class?,g211005,2,Update content covered in class,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63301,3,How would you improve this class?,g211006,3,Improve the instructional methods,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63301,4,How would you improve this class?,g211007,4,Make course activities more stimulating,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63301,5,How would you improve this class?,g211008,5,Slow the pace of the class,0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19938,9922,Questions-0000-56,g13937,g63301,6,How would you improve this class?,g211009,6,"No recommendation for improvement (appropriate content, speaker, etc.)",0,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21
19937,9953,Questions-0000-87,g13936,g63261,0,Please list the location for this activity.,g210837,0,Atlanta,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63261,1,Please list the location for this activity.,g210838,1,Forsyth,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63261,2,Please list the location for this activity.,g210839,2,Cherokee,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63261,3,Please list the location for this activity.,g210840,3,Other,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63262,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g210841,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63262,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g210842,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63262,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g210843,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63262,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g210844,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63262,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g210845,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63263,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g210846,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63263,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g210847,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63263,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g210848,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63263,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g210849,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63263,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g210850,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63264,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g210851,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63264,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g210852,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63264,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g210853,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63264,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g210854,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63264,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g210855,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63265,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g210856,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63265,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g210857,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63265,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g210858,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63265,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g210859,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63265,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g210860,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63266,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g210861,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63266,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g210862,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63266,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g210863,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63266,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g210864,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63266,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g210865,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63267,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g210866,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63267,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g210867,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63267,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g210868,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63267,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g210869,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63267,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g210870,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63268,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g210871,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63268,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g210872,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63268,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g210873,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63268,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g210874,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63268,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g210875,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63269,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210876,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63269,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210877,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63269,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210878,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63269,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210879,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63269,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210880,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63270,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g210881,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63270,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g210882,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63270,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g210883,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63270,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g210884,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63270,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g210885,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63271,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210886,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63271,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210887,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63271,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210888,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63271,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210889,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63271,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210890,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63272,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210891,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63272,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210892,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63272,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210893,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63272,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210894,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63272,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210895,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63273,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210896,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63273,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210897,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63273,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210898,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63273,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210899,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63273,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210900,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63274,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g210901,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63274,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g210902,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63274,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g210903,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63274,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g210904,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63274,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",g210905,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63275,0,"Overall, this activity was:",g210906,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63275,1,"Overall, this activity was:",g210907,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63275,2,"Overall, this activity was:",g210908,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63275,3,"Overall, this activity was:",g210909,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63275,4,"Overall, this activity was:",g210910,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63276,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210911,0,Yes,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63276,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210912,1,No,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63276,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210913,2,N/A,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63279,0,How would you improve this class?,g210914,0,Reduce content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63279,1,How would you improve this class?,g210915,1,Increase content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63279,2,How would you improve this class?,g210916,2,Update content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63279,3,How would you improve this class?,g210917,3,Improve the instructional methods,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63279,4,How would you improve this class?,g210918,4,Make course activities more stimulating,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63279,5,How would you improve this class?,g210919,5,Slow the pace of the class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19937,9953,Questions-0000-87,g13936,g63279,6,How would you improve this class?,g210920,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21
19930,9933,Questions-0000-67,g13933,g63235,0,Please list the location for this activity.,g210728,0,Atlanta,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63235,1,Please list the location for this activity.,g210729,1,Forsyth,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63235,2,Please list the location for this activity.,g210730,2,Cherokee,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63235,3,Please list the location for this activity.,g210731,3,Other,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63236,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210732,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63236,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210733,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63236,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210734,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63236,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210735,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63236,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210736,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63237,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210737,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63237,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210738,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63237,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210739,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63237,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210740,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63237,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210741,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63238,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210742,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63238,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210743,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63238,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210744,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63238,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210745,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63238,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210746,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63239,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210747,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63239,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210748,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63239,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210749,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63239,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210750,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63239,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210751,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63240,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210752,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63240,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210753,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63240,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210754,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63240,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210755,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63240,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210756,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63241,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210757,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63241,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210758,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63241,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210759,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63241,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210760,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63241,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210761,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63242,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210762,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63242,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210763,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63242,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210764,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63242,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210765,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63242,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210766,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63243,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210767,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63243,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210768,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63243,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210769,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63243,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210770,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63243,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210771,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63244,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210772,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63244,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210773,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63244,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210774,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63244,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210775,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63244,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210776,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63245,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210777,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63245,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210778,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63245,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210779,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63245,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210780,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63245,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210781,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63246,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210782,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63246,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210783,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63246,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210784,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63246,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210785,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63246,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210786,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63247,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210787,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63247,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210788,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63247,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210789,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63247,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210790,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63247,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210791,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63248,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210792,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63248,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210793,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63248,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210794,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63248,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210795,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63248,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210796,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63249,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210797,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63249,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210798,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63249,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210799,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63249,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210800,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63249,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210801,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63250,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210802,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63250,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210803,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63250,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210804,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63250,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210805,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63250,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210806,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63251,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210807,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63251,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210808,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63251,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210809,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63251,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210810,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63251,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210811,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63252,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,g210812,0,Excellent,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63252,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,g210813,1,Very Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63252,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,g210814,2,Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63252,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,g210815,3,Fair,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63252,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,g210816,4,Poor,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63253,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210817,0,Excellent,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63253,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210818,1,Very Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63253,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210819,2,Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63253,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210820,3,Fair,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63253,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210821,4,Poor,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63254,0,"Overall, this activity was:",g210822,0,Excellent,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63254,1,"Overall, this activity was:",g210823,1,Very Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63254,2,"Overall, this activity was:",g210824,2,Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63254,3,"Overall, this activity was:",g210825,3,Fair,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63254,4,"Overall, this activity was:",g210826,4,Poor,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63255,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210827,0,Yes,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63255,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210828,1,No,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63255,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210829,2,N/A,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63258,0,How would you improve this class?,g210830,0,Reduce content covered in class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63258,1,How would you improve this class?,g210831,1,Increase content covered in class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63258,2,How would you improve this class?,g210832,2,Update content covered in class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63258,3,How would you improve this class?,g210833,3,Improve the instructional methods,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63258,4,How would you improve this class?,g210834,4,Make course activities more stimulating,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63258,5,How would you improve this class?,g210835,5,Slow the pace of the class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19930,9933,Questions-0000-67,g13933,g63258,6,How would you improve this class?,g210836,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21
19929,9945,Questions-0000-79,g13932,g63219,0,Please list the location for this activity.,g210669,0,Atlanta,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63219,1,Please list the location for this activity.,g210670,1,Cherokee,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63219,2,Please list the location for this activity.,g210671,2,Forsyth,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63219,3,Please list the location for this activity.,g210672,3,Other,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63220,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g210673,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63220,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g210674,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63220,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g210675,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63220,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g210676,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63220,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g210677,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63221,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210678,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63221,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210679,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63221,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210680,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63221,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210681,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63221,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210682,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63222,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g210683,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63222,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g210684,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63222,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g210685,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63222,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g210686,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63222,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g210687,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63223,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g210688,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63223,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g210689,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63223,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g210690,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63223,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g210691,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63223,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g210692,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63224,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210693,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63224,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210694,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63224,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210695,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63224,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210696,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63224,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210697,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63225,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g210698,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63225,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g210699,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63225,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g210700,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63225,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g210701,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63225,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g210702,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63226,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g210703,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63226,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g210704,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63226,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g210705,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63226,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g210706,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63226,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g210707,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63227,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g210708,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63227,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g210709,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63227,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g210710,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63227,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g210711,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63227,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g210712,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63228,0,"Overall, this activity was:",g210713,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63228,1,"Overall, this activity was:",g210714,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63228,2,"Overall, this activity was:",g210715,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63228,3,"Overall, this activity was:",g210716,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63228,4,"Overall, this activity was:",g210717,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63229,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210718,0,Yes,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63229,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210719,1,No,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63229,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210720,2,N/A,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63232,0,How would you improve this class?,g210721,0,Reduce content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63232,1,How would you improve this class?,g210722,1,Increase content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63232,2,How would you improve this class?,g210723,2,Update content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63232,3,How would you improve this class?,g210724,3,Improve the instructional methods,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63232,4,How would you improve this class?,g210725,4,Make course activities more stimulating,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63232,5,How would you improve this class?,g210726,5,Slow the pace of the class,0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19929,9945,Questions-0000-79,g13932,g63232,6,How would you improve this class?,g210727,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)"
19925,9567,Elearning-0000-792,g13929,g63206,0,A device that is intended to be used on patient's mucous membranes is classified as:,g210633,0,A.  Non-critical,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63206,1,A device that is intended to be used on patient's mucous membranes is classified as:,g210634,1,B.  Semi-critical,1,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63206,2,A device that is intended to be used on patient's mucous membranes is classified as:,g210635,2,C.  Critical,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63207,0,What is the minimum reprocessing requirement for devices used in semi-critical applications?,g210636,0,A.  High level disinfection,1,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63207,1,What is the minimum reprocessing requirement for devices used in semi-critical applications?,g210637,1,B.  Low level disinfection,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63207,2,What is the minimum reprocessing requirement for devices used in semi-critical applications?,g210638,2,C.  Sterilization,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63208,0,Warnings/precautions regarding high level disinfectant chemicals common to all include:,g210639,0,"A.  Avoidance of contact with eyes, skin, clothing, food, fumes/vapors",0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63208,1,Warnings/precautions regarding high level disinfectant chemicals common to all include:,g210640,1,B.  Provision of adequate ventilation,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63208,2,Warnings/precautions regarding high level disinfectant chemicals common to all include:,g210641,2,C.  Attention to device rinsing per manufacturer's IFU,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63208,3,Warnings/precautions regarding high level disinfectant chemicals common to all include:,g210642,3,D.  Do not use on flexible endoscopes,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63208,4,Warnings/precautions regarding high level disinfectant chemicals common to all include:,g210643,4,"E.  A, B, C",1,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63208,5,Warnings/precautions regarding high level disinfectant chemicals common to all include:,g210644,5,F.  All of the above,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63209,0,"When considering the choice of the ideal high level disinfectant, one quality that does not make the list is:",g210645,0,A.  Act slowly,1,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63209,1,"When considering the choice of the ideal high level disinfectant, one quality that does not make the list is:",g210646,1,B.  Cost effective,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63209,2,"When considering the choice of the ideal high level disinfectant, one quality that does not make the list is:",g210647,2,C.  Be odorless and non-staining,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63210,0,What must be done prior to high level disinfection in order for it to be effective?,g210648,0,A.  Allow instruments to air dry,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63210,1,What must be done prior to high level disinfection in order for it to be effective?,g210649,1,B.  Clean instruments according to IFU to remove fluids or debris,1,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63210,2,What must be done prior to high level disinfection in order for it to be effective?,g210650,2,C.  Wipe instruments with a paper towel,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63211,0,How often must reusable high level disinfectant chemicals be tested using product specific indicators (test strips/discs)?,g210651,0,A.  Daily,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63211,1,How often must reusable high level disinfectant chemicals be tested using product specific indicators (test strips/discs)?,g210652,1,B.  Monthly,0,FY21 ANNUAL HLD UPDATE
19925,9567,Elearning-0000-792,g13929,g63211,2,How often must reusable high level disinfectant chemicals be tested using product specific indicators (test strips/discs)?,g210653,2,C.  Prior to each use,1,FY21 ANNUAL HLD UPDATE
19921,9117,Elearning-0000-383,g13927,g63191,0,Normal Axillary Temp in the newborn should be between 36.1 degrees Celcius and 36.4 Celcious?,g210579,0,TRUE,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63191,1,Normal Axillary Temp in the newborn should be between 36.1 degrees Celcius and 36.4 Celcious?,g210580,1,FALSE,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63192,0,Conduction is the method of heat loss when what occurs?,g210581,0,a. Airflow carrying heat to or away from an object occurs,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63192,1,Conduction is the method of heat loss when what occurs?,g210582,1,b.  Heat exchange between objects in direct contact with each other,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63192,2,Conduction is the method of heat loss when what occurs?,g210583,2,c.  Radiant energy exchange between tow objects not in contact with each other,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63192,3,Conduction is the method of heat loss when what occurs?,g210584,3,"d.  Thermal energy turns liquid into vapor, removing energy (heat) away from the object",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63193,0,Three characteristics that put newborns at a greater risk for heat loss is:,g210585,0,"a.  a smaller surface area to body mass ratio, decreased subcutaneous fat and greater body water content",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63193,1,Three characteristics that put newborns at a greater risk for heat loss is:,g210586,1,"b. having greater body water content, larger surface area to body mass ratio and ability to shiver",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63193,2,Three characteristics that put newborns at a greater risk for heat loss is:,g210587,2,"c.  having greater body water content, larger surface area to body mass ratio and not able to shiver",1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63193,3,Three characteristics that put newborns at a greater risk for heat loss is:,g210588,3,"d. decreased subcutaneous fat, peripheral cyanosis and skin that is mature leading to increased evaporative water and heat losses",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63194,0,Signs and symptoms of hypothermia include:,g210589,0,"a. acryocyanosis, cool mottled or pale skin",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63194,1,Signs and symptoms of hypothermia include:,g210590,1,"b. hypoglycemia, poor feeder, week or feeble cry",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63194,2,Signs and symptoms of hypothermia include:,g210591,2,"c. decreased activity, lethergy, hypotonia",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63194,3,Signs and symptoms of hypothermia include:,g210592,3,"d. bradycardia, tachypnea, respirtory distress, poor weight gain",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63194,4,Signs and symptoms of hypothermia include:,g210593,4,e. all of the above,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63195,0,True or False if left untreated hypothermia may lead to life theatening complications,g210594,0,TRUE,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63195,1,True or False if left untreated hypothermia may lead to life theatening complications,g210595,1,FALSE,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63196,0,Care activities to help prevent hypothermia include which of the following?,g210596,0,"a. Skin to skin, increase room temperature, and dress in clothes and place hat on infant",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63196,1,Care activities to help prevent hypothermia include which of the following?,g210597,1,b. place infant under radiant warmer with temp probe and set on manual,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63196,2,Care activities to help prevent hypothermia include which of the following?,g210598,2,"c. place infant under radiant warmer with temp probe and set on ""baby""",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63196,3,Care activities to help prevent hypothermia include which of the following?,g210599,3,d. a and c,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63196,4,Care activities to help prevent hypothermia include which of the following?,g210600,4,e. all of the above,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63197,0,Signs and symptoms of hyperthermia in the newborn include:,g210601,0,"a. tachycardia, tachypnea, apnea",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63197,1,Signs and symptoms of hyperthermia in the newborn include:,g210602,1,"b.lethargy, hypotonia,and irritibility",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63197,2,Signs and symptoms of hyperthermia in the newborn include:,g210603,2,"c. poor feeding, weak cry and warm extremities",0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63197,3,Signs and symptoms of hyperthermia in the newborn include:,g210604,3,"d. a, b and c",1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63197,4,Signs and symptoms of hyperthermia in the newborn include:,g210605,4,e. non of the above,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63198,0,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,g210606,0,a. take infant to nursery and place under radiant warmer with temp probe set to baby,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63198,1,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,g210607,1,"b. place skin to skin with mother, S. O. or other family member",1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63198,2,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,g210608,2,c. use heel warmers to warm infant 36.3 is too cold,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63198,3,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,g210609,3,d. do nothing this is an acceptable temperature.,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63199,0,When should you recheck Baby North's Temperature after initiating the first intervention?,g210610,0,a. in 1 hour,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63199,1,When should you recheck Baby North's Temperature after initiating the first intervention?,g210611,1,b. it does not need to be rechecked as it was within normal range,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63199,2,When should you recheck Baby North's Temperature after initiating the first intervention?,g210612,2,c. 30 minutes,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63199,3,When should you recheck Baby North's Temperature after initiating the first intervention?,g210613,3,d. with the next set of VS in 4 hours,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63200,0,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,g210614,0,"a. place infant on radiant warmer with skin probe set at 36.5 in ""baby"" mode",1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63200,1,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,g210615,1,b. do nothing temp is WNL,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63200,2,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,g210616,2,c. call SCN/TCN to transfer infant,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63200,3,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,g210617,3,d. call the provider,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63200,4,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,g210618,4,e. warm blankets in microwave and swaddle infant,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63201,0,Baby North needed to go to the nursery to be placed on a radiant warmer for rewarming protocol.  Baby North has now had two consecutive temperatures 30 mins apart and each was 36.8  and 36.9 so she may return to her mother.,g210619,0,TRUE,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63201,1,Baby North needed to go to the nursery to be placed on a radiant warmer for rewarming protocol.  Baby North has now had two consecutive temperatures 30 mins apart and each was 36.8  and 36.9 so she may return to her mother.,g210620,1,FALSE,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63202,0,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",g210621,0,a. Her temperature was normal and does not need rechecking,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63202,1,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",g210622,1,b. Every 30 mins times 4,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63202,2,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",g210623,2,c. Recheck temperature every hour times 2,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63202,3,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",g210624,3,d. Recheck temperature every 30 mins time 2 then every hour times 4 then may return to every 4 hours,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63203,0,"Policies frequently change and are updated.  If I am in doubt of what, how and or when procedures or processes should be done I should always look at the policy in Lucidoc and review and follow my policy.",g210625,0,TRUE,1,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19921,9117,Elearning-0000-383,g13927,g63203,1,"Policies frequently change and are updated.  If I am in doubt of what, how and or when procedures or processes should be done I should always look at the policy in Lucidoc and review and follow my policy.",g210626,1,FALSE,0,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021
19922,9871,Questions-0000-160,g13926,g63168,0,Please list the location for this activity.,g210488,0,Atlanta,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63168,1,Please list the location for this activity.,g210489,1,Cherokee,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63168,2,Please list the location for this activity.,g210490,2,Forsyth,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63168,3,Please list the location for this activity.,g210491,3,Other,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63169,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",g210492,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63169,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",g210493,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63169,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",g210494,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63169,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",g210495,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63169,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",g210496,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63170,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",g210497,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63170,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",g210498,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63170,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",g210499,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63170,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",g210500,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63170,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",g210501,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63171,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",g210502,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63171,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",g210503,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63171,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",g210504,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63171,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",g210505,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63171,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",g210506,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63172,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",g210507,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63172,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",g210508,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63172,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",g210509,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63172,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",g210510,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63172,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",g210511,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63173,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",g210512,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63173,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",g210513,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63173,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",g210514,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63173,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",g210515,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63173,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",g210516,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63174,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",g210517,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63174,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",g210518,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63174,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",g210519,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63174,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",g210520,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63174,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",g210521,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63175,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210522,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63175,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210523,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63175,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210524,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63175,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210525,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63175,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210526,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63176,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210527,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63176,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210528,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63176,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210529,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63176,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210530,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63176,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210531,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63177,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,g210532,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63177,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,g210533,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63177,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,g210534,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63177,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,g210535,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63177,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,g210536,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63178,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,g210537,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63178,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,g210538,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63178,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,g210539,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63178,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,g210540,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63178,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,g210541,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63179,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210542,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63179,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210543,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63179,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210544,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63179,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210545,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63179,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210546,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63180,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210547,0,Strongly Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63180,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210548,1,Agree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63180,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210549,2,No Opinion,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63180,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210550,3,Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63180,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210551,4,Strongly Disagree,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63181,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,g210552,0,Excellent,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63181,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,g210553,1,Very Good,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63181,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,g210554,2,Good,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63181,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,g210555,3,Fair,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63181,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,g210556,4,Poor,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63182,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",g210557,0,Excellent,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63182,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",g210558,1,Very Good,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63182,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",g210559,2,Good,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63182,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",g210560,3,Fair,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63182,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",g210561,4,Poor,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63183,0,"Overall, this activity was:",g210562,0,Excellent,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63183,1,"Overall, this activity was:",g210563,1,Very Good,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63183,2,"Overall, this activity was:",g210564,2,Good,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63183,3,"Overall, this activity was:",g210565,3,Fair,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63183,4,"Overall, this activity was:",g210566,4,Poor,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63184,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210567,0,Yes,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63184,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210568,1,No,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63184,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210569,2,N/A,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63187,0,How would you improve this class?,g210570,0,Reduce content covered in class,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63187,1,How would you improve this class?,g210571,1,Increase content covered in class,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63187,2,How would you improve this class?,g210572,2,Update content covered in class,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63187,3,How would you improve this class?,g210573,3,Improve the instructional methods,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63187,4,How would you improve this class?,g210574,4,Make course activities more stimulating,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63187,5,How would you improve this class?,g210575,5,Slow the pace of the class,0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19922,9871,Questions-0000-160,g13926,g63187,6,How would you improve this class?,g210576,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21
19920,9325,Elearning-0000-572,g13925,g63164,0,Which of the following are true statements,g210472,0,"a.	Veno-venous ECMO provides respiratory support for critically ill patients",0,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63164,1,Which of the following are true statements,g210473,1,"b.	Veno-arterial ECMO provides both cardiac and respiratory support for critically ill patients",0,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63164,2,Which of the following are true statements,g210474,2,"c.	ECMO is NOT a cure for respiratory or cardiac failure but can be used as short term therapy until organ function is recovered",0,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63164,3,Which of the following are true statements,g210475,3,"d.	All of the above",1,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63165,0,True or False: ECMO cannot be used in patients that have an absolute contraindication to anticoagulation,g210476,0,TRUE,1,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63165,1,True or False: ECMO cannot be used in patients that have an absolute contraindication to anticoagulation,g210477,1,FALSE,0,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63166,0,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,g210478,0,"a.	All ECMO heparin drips are monitoring with ACT",0,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63166,1,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,g210479,1,"b.	Heparin drips should be dosed using actual body weight with no weight cap",0,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63166,2,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,g210480,2,"c.	ECMO heparin drips should be titrated using the ECMO specific nomogram and all dose changes should be recorded on the ECMO heparin flowsheet",1,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63166,3,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,g210481,3,"d.	No double check is required for ECMO heparin drips due to the frequency of lab checks",0,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63167,0,"True or False: ECMO orders include concentrated options of sedation, analgesic, neuromuscular blocker, and vasopressor drips, when available, to limit fluid volumes",g210482,0,TRUE,1,FY2021 PHARMACY ECMO EDUCATION
19920,9325,Elearning-0000-572,g13925,g63167,1,"True or False: ECMO orders include concentrated options of sedation, analgesic, neuromuscular blocker, and vasopressor drips, when available, to limit fluid volumes",g210483,1,FALSE,0,FY2021 PHARMACY ECMO EDUCATION
19918,9932,Questions-0000-66,g13924,g63138,0,Please list the location for this activity.,g210363,0,Atlanta,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63138,1,Please list the location for this activity.,g210364,1,Forsyth,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63138,2,Please list the location for this activity.,g210365,2,Cherokee,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63138,3,Please list the location for this activity.,g210366,3,Other,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63139,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210367,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63139,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210368,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63139,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210369,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63139,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210370,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63139,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",g210371,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63140,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210372,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63140,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210373,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63140,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210374,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63140,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210375,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63140,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",g210376,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63141,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210377,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63141,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210378,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63141,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210379,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63141,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210380,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63141,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",g210381,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63142,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210382,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63142,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210383,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63142,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210384,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63142,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210385,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63142,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",g210386,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63143,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210387,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63143,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210388,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63143,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210389,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63143,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210390,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63143,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",g210391,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63144,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210392,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63144,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210393,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63144,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210394,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63144,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210395,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63144,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",g210396,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63145,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210397,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63145,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210398,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63145,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210399,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63145,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210400,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63145,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",g210401,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63146,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210402,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63146,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210403,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63146,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210404,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63146,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210405,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63146,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",g210406,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63147,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210407,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63147,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210408,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63147,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210409,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63147,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210410,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63147,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",g210411,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63148,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210412,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63148,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210413,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63148,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210414,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63148,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210415,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63148,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",g210416,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63149,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210417,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63149,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210418,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63149,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210419,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63149,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210420,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63149,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",g210421,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63150,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210422,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63150,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210423,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63150,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210424,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63150,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210425,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63150,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",g210426,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63151,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210427,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63151,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210428,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63151,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210429,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63151,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210430,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63151,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,g210431,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63152,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210432,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63152,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210433,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63152,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210434,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63152,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210435,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63152,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",g210436,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63153,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210437,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63153,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210438,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63153,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210439,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63153,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210440,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63153,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210441,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63154,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210442,0,Strongly Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63154,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210443,1,Agree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63154,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210444,2,No Opinion,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63154,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210445,3,Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63154,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g210446,4,Strongly Disagree,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63155,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,g210447,0,Excellent,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63155,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,g210448,1,Very Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63155,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,g210449,2,Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63155,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,g210450,3,Fair,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63155,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,g210451,4,Poor,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63156,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210452,0,Excellent,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63156,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210453,1,Very Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63156,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210454,2,Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63156,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210455,3,Fair,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63156,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,g210456,4,Poor,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63157,0,"Overall, this activity was:",g210457,0,Excellent,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63157,1,"Overall, this activity was:",g210458,1,Very Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63157,2,"Overall, this activity was:",g210459,2,Good,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63157,3,"Overall, this activity was:",g210460,3,Fair,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63157,4,"Overall, this activity was:",g210461,4,Poor,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63158,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210462,0,Yes,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63158,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210463,1,No,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63158,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210464,2,N/A,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63161,0,How would you improve this class?,g210465,0,Reduce content covered in class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63161,1,How would you improve this class?,g210466,1,Increase content covered in class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63161,2,How would you improve this class?,g210467,2,Update content covered in class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63161,3,How would you improve this class?,g210468,3,Improve the instructional methods,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63161,4,How would you improve this class?,g210469,4,Make course activities more stimulating,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63161,5,How would you improve this class?,g210470,5,Slow the pace of the class,0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19918,9932,Questions-0000-66,g13924,g63161,6,How would you improve this class?,g210471,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21
19919,9252,Elearning-0000-506,g13923,g63119,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",g210295,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63119,1,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",g210296,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63120,0,Which one of the following hazardous medication list grouping is incorrect?,g210297,0,"a.	Group 2 - Hazardous agents (primarily reproductive risk)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63120,1,Which one of the following hazardous medication list grouping is incorrect?,g210298,1,"b.	Group 1 - Hazardous agents (cytotoxic antineoplastic/reproductive risks)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63120,2,Which one of the following hazardous medication list grouping is incorrect?,g210299,2,"c.	Group 2A - Non-hazardous antineoplastic agents",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63120,3,Which one of the following hazardous medication list grouping is incorrect?,g210300,3,"d.	Appendix D - Excluded drugs based on NSH risk assessment",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63121,0,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",g210301,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63121,1,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",g210302,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63122,0,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g210303,0,"a.	Decontamination",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63122,1,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g210304,1,"b.	Cleaning",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63122,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g210305,2,"c.	Disinfection",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63122,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g210306,3,"d.	Deactivate",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63122,4,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g210307,4,"e.	All of the above",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63123,0,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",g210308,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63123,1,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",g210309,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63124,0,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g210310,0,"a.	Protective Gown",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63124,1,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g210311,1,"b.	Eye/Face protection",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63124,2,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g210312,2,"c.	Respiratory protection",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63124,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g210313,3,"d.	Footwear",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63124,4,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g210314,4,"e.	Gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63124,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g210315,5,"f.	All of the above",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63125,0,The spill response team is activated for any spills that is not contained by the following:,g210316,0,"a.	Two Spill Kits",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63125,1,The spill response team is activated for any spills that is not contained by the following:,g210317,1,"b.	Single Spill Kit",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63125,2,The spill response team is activated for any spills that is not contained by the following:,g210318,2,"c.	Three Spill Kits",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63125,3,The spill response team is activated for any spills that is not contained by the following:,g210319,3,"d.	Any spill in patient care area",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63125,4,The spill response team is activated for any spills that is not contained by the following:,g210320,4,"e.	Any spill in pharmacy area",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63126,0,Gloves used in the preparation of HDs must be:,g210321,0,"a.	Disposable",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63126,1,Gloves used in the preparation of HDs must be:,g210322,1,"b.	Powdered to facilitate removal",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63126,2,Gloves used in the preparation of HDs must be:,g210323,2,"c.	Specified as ASTM-tested chemotherapy gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63126,3,Gloves used in the preparation of HDs must be:,g210324,3,"d.	A and C",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63127,0,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g210325,0,"a.	Filter needles",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63127,1,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g210326,1,"b.	Leur-Lock syringes",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63127,2,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g210327,2,"c.	Closed-system transfer devices (CSTDs)",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63127,3,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g210328,3,"d.	None of the above",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63128,0,When wearing double gloves:,g210329,0,"a.	The gown cuffs should be tucked over both gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63128,1,When wearing double gloves:,g210330,1,"b.	The gown cuffs should be tucked under both gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63128,2,When wearing double gloves:,g210331,2,"c.	The inner glove should be worn under the cuff and the outer glove should be worn over the gown cuff",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63128,3,When wearing double gloves:,g210332,3,"d.	It makes no difference if gown cuffs are worn over or under the gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63129,0,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,g210333,0,TRUE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63129,1,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,g210334,1,FALSE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63130,0,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g210335,0,"a.	Biological safety cabinet (BSC)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63130,1,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g210336,1,"b.	Horizontal laminar air flow workbench",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63130,2,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g210337,2,"c.	Compounding aseptic containment isolator (CACI)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63130,3,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g210338,3,"d.	A and C",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63131,0,Spill kits:,g210339,0,"a.	May be obtained from Central Supply when needed",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63131,1,Spill kits:,g210340,1,"b.	Are kept wherever HDs and chemotherapy agents are handled",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63131,2,Spill kits:,g210341,2,"c.	Contain supplies needed to clean a HD spill",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63131,3,Spill kits:,g210342,3,"d.	All of the above",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63132,0,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",g210343,0,TRUE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63132,1,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",g210344,1,FALSE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63133,0,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",g210345,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63133,1,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",g210346,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63134,0,How often do you have to change the gown during hazardous drug compounding?,g210347,0,"a.	At least every 12 hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63134,1,How often do you have to change the gown during hazardous drug compounding?,g210348,1,"b.	At least every 24 hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63134,2,How often do you have to change the gown during hazardous drug compounding?,g210349,2,"c.	At least every 3 hours",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63134,3,How often do you have to change the gown during hazardous drug compounding?,g210350,3,"d.	At least every 8 hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63135,0,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g210351,0,"a.	At least every 8 hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63135,1,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g210352,1,"b.	At least every 3  hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63135,2,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g210353,2,"c.	At least every 30 minutes",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63135,3,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g210354,3,"d.	 At shift change",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63136,0,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,g210355,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63136,1,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,g210356,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63137,0,Which statement is true?,g210357,0,"a.	Cytotoxic chemotherapy doses maybe rounded down or up to the nearest vials size within < 5% of the calculated dose",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63137,1,Which statement is true?,g210358,1,"b.	Cytotoxic chemotherapy doses maybe rounded down to the nearest vials size within < 5% of the calculated dose",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63137,2,Which statement is true?,g210359,2,"c.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 10% of the calculated dose.",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63137,3,Which statement is true?,g210360,3,"d.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 5% of the calculated dose.",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63137,4,Which statement is true?,g210361,4,"e.	a & c",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19919,9252,Elearning-0000-506,g13923,g63137,5,Which statement is true?,g210362,5,"f.	b & c",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS
19914,9891,Questions-0000-25,g13920,g63093,0,Please list the location for this activity.,g210189,0,Atlanta,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63093,1,Please list the location for this activity.,g210190,1,Forsyth,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63093,2,Please list the location for this activity.,g210191,2,Cherokee,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63093,3,Please list the location for this activity.,g210192,3,Other,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63094,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g210193,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63094,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g210194,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63094,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g210195,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63094,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g210196,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63094,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g210197,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63095,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g210198,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63095,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g210199,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63095,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g210200,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63095,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g210201,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63095,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g210202,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63096,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g210203,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63096,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g210204,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63096,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g210205,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63096,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g210206,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63096,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g210207,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63097,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g210208,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63097,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g210209,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63097,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g210210,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63097,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g210211,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63097,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g210212,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63098,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g210213,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63098,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g210214,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63098,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g210215,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63098,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g210216,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63098,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g210217,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63099,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g210218,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63099,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g210219,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63099,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g210220,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63099,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g210221,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63099,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g210222,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63100,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g210223,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63100,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g210224,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63100,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g210225,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63100,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g210226,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63100,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g210227,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63101,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g210228,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63101,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g210229,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63101,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g210230,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63101,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g210231,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63101,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g210232,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63102,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g210233,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63102,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g210234,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63102,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g210235,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63102,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g210236,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63102,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g210237,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63103,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g210238,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63103,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g210239,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63103,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g210240,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63103,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g210241,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63103,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g210242,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63104,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g210243,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63104,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g210244,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63104,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g210245,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63104,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g210246,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63104,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g210247,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63105,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210248,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63105,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210249,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63105,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210250,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63105,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210251,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63105,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210252,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63106,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g210253,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63106,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g210254,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63106,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g210255,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63106,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g210256,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63106,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g210257,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63107,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210258,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63107,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210259,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63107,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210260,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63107,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210261,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63107,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210262,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63108,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210263,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63108,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210264,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63108,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210265,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63108,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210266,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63108,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g210267,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63109,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g210268,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63109,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g210269,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63109,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g210270,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63109,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g210271,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63109,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g210272,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63110,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g210273,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63110,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g210274,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63110,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g210275,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63110,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g210276,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63110,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",g210277,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63111,0,"Overall, this activity was:",g210278,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63111,1,"Overall, this activity was:",g210279,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63111,2,"Overall, this activity was:",g210280,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63111,3,"Overall, this activity was:",g210281,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63111,4,"Overall, this activity was:",g210282,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63112,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210283,0,Yes,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63112,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210284,1,No,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63112,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210285,2,N/A,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63115,0,How would you improve this class?,g210286,0,Reduce content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63115,1,How would you improve this class?,g210287,1,Increase content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63115,2,How would you improve this class?,g210288,2,Update content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63115,3,How would you improve this class?,g210289,3,Improve the instructional methods,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63115,4,How would you improve this class?,g210290,4,Make course activities more stimulating,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63115,5,How would you improve this class?,g210291,5,Slow the pace of the class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19914,9891,Questions-0000-25,g13920,g63115,6,How would you improve this class?,g210292,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21
19898,9302,Elearning-0000-551,g13918,g63074,0,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",g210115,0,"a.	Patient is not having a major, life-threatening bleed; Hold Rivaroxaban, provide supportive care and control bleeding site until the drug is out his system.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63074,1,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",g210116,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63074,2,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",g210117,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63074,3,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",g210118,3,"d.	Patient is having a major, life-threatening bleed; administer idarucizumab 5g IV as 2 consecutive doses of 2.5mg each",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63075,0,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",g210119,0,"a.	Bleeding at a critical site such as intracranial hemorrhage, CNS bleeds (intraocular, spinal), thoracic, intra-abdominal (not including intraluminal GI bleeding)",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63075,1,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",g210120,1,"b.	Bleeding that results in hemodynamic instability such as hypotension (SBP <90 mmHg or a drop in SBP >40 mmHg from baseline), tachycardia, or makers of poor organ perfusion (ex. UOP < 0.5mL/kg/hr)",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63075,2,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",g210121,2,"c.	Overt bleeding resulting in hemoglobin drop of 2 g/dL or more from baseline",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63075,3,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",g210122,3,"d.	All of the above",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63076,0,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210123,0,"a.	Patient is not having a major, life-threatening bleed; Hold Apixaban, provide supportive care and control bleeding site until the drug is out her system.",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63076,1,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210124,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63076,2,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210125,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63076,3,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210126,3,"d.	Patient is having a major, life-threatening bleed; administer idarucizumab 5g IV as 2 consecutive doses of 2.5mg each",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63077,0,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210127,0,"a.	Patient is not having a major, life-threatening bleed; Hold Apixaban, provide supportive care and control bleeding site until the drug is out her system.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63077,1,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210128,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63077,2,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210129,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63077,3,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",g210130,3,"d.	Patient is having a major, life-threatening bleed; administer idarucizumab 5g IV as 2 consecutive doses of 2.5mg each",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63078,0,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",g210131,0,"a.	Patient is not having a major, life-threatening bleed; Hold Edoxaban, provide supportive care and control bleeding site until the drug is out his system.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63078,1,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",g210132,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63078,2,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",g210133,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63078,3,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",g210134,3,"d.	Patient is having a major, life-threatening bleed; however, andexanet alfa is not indicated for reversal of Edoxaban. Administer 4PCC (Kcentra) 50units/kg.",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63079,0,What factors should be considered in the perioperative management of anticoagulant therapy?,g210135,0,"a.	Drug specific details including dose, elimination half-life, and method of drug elimination/excretion",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63079,1,What factors should be considered in the perioperative management of anticoagulant therapy?,g210136,1,"b.	Procedure specific risk for major bleeding",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63079,2,What factors should be considered in the perioperative management of anticoagulant therapy?,g210137,2,"c.	Patient risk factors for perioperative thrombotic events",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63079,3,What factors should be considered in the perioperative management of anticoagulant therapy?,g210138,3,"d.	All of the above",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63080,0,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",g210139,0,"a.	Hold Apixaban for 1 to 2 days prior to procedure",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63080,1,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",g210140,1,"b.	Hold Apixaban for 2 to 3 days prior to procedure",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63080,2,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",g210141,2,"c.	Consider using prophylactic doses of unfractionated heparin or enoxaparin while apixban is being held",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63080,3,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",g210142,3,"d.	Both A and C",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63080,4,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",g210143,4,"e.	Both B and C",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63081,0,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",g210144,0,"a.	This is a low bleed risk procedure; hold warfarin for 5 days or until INR <2 and it is not required to hold aspirin. The patient has a high risk for perioperative VTE, consider prophylactic heparin or enoxaparin while warfarin is being held.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63081,1,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",g210145,1,"b.	This is a minimal bleed risk procedure that may not require holding warfarin or aspirin. The patient has a high risk for perioperative VTE, and if the provider does wish to hold anticoagulation, consider prophylactic heparin or enoxaparin while warfarin is being held.",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63081,2,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",g210146,2,"c.	This is a low bleed risk procedure; hold warfarin for 5 days or until INR < 2 and it is not required to hold aspirin. There is no need to consider prophylactic anticoagulants while warfarin is being held.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63081,3,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",g210147,3,"d.	This is a minimal bleed risk procedure; hold warfarin for 2-3 days and it is not required to hold aspirin.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63082,0,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",g210148,0,"a.	This is a high bleed risk procedure, delay surgery for 5 days from the last dose of clopidogrel to allow for recovery of platelet function.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63082,1,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",g210149,1,"b.	The patient may be taken to surgery right away, it is not recommended to delay urgent or emergent surgery due to antiplatelet use alone.",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63082,2,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",g210150,2,"c.	This is a high bleed risk procedure, delay surgery for 7 days from the last dose of clopidogrel to allow for recovery of platelet function.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63082,3,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",g210151,3,"d.	This is a low bleed risk procedure and it is not required to hold antiplatelet agents.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63083,0,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",g210152,0,"a.	Hold Rivaroxaban for 3 days prior to surgery, consider using prophylactic heparin or enoxaparin while Rivaroxaban is being held.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63083,1,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",g210153,1,"b.	Hold Rivaroxaban for 2 days prior to surgery, patient has a low risk for perioperative VTE and prophylactic heparin or enoxaparin may not be needed while Rivaroxaban is being held.",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63083,2,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",g210154,2,"c.	Hold Rivaroxaban for 2 days prior to surgery and consider using prophylactic heparin or enoxaparin while Rivaroxaban is being held.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63083,3,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",g210155,3,"d.	Hold Rivaroxaban for 1 day prior to surgery, patient has a low risk for perioperative VTE and prophylactic heparin or enoxaparin may not be needed while Rivaroxaban is being held.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63084,0,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,g210156,0,"a.	Do not hold",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63084,1,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,g210157,1,"b.	Hold 12 hours/Resume in 6 hr",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63084,2,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,g210158,2,"c.	Hold 24 hours/Resume in 6 hr",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63084,3,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,g210159,3,"d.	Hold 24 hours/Resume in 48 hr",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63085,0,T/F Anesthesia should always be contacted when anticoagulant or antiplatelet agents and an epidural or intrathecal are ordered concurrently.,g210160,0,TRUE,1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63085,1,T/F Anesthesia should always be contacted when anticoagulant or antiplatelet agents and an epidural or intrathecal are ordered concurrently.,g210161,1,FALSE,0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63086,0,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",g210162,0,"a.	8 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63086,1,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",g210163,1,"b.	12 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63086,2,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",g210164,2,"c.	6 hours",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63086,3,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",g210165,3,"d.	24 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63087,0,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",g210166,0,"a.	6 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63087,1,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",g210167,1,"b.	12 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63087,2,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",g210168,2,"c.	1 hour",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63087,3,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",g210169,3,"d.	8 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63088,0,The first dose of enoxaparin 40mg daily may be given _________.,g210484,0,"a.	&#8805 12 hours after removal of epidural catheter.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63088,1,The first dose of enoxaparin 40mg daily may be given _________.,g210485,1,"b..	&#8805   4 hours after removal of epidural catheter.",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63088,2,The first dose of enoxaparin 40mg daily may be given _________.,g210486,2,"c.	&#8805   4 hours after removal of AND &#8805 12 hours after initial placement of epidural catheter; whichever is longer",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63088,3,The first dose of enoxaparin 40mg daily may be given _________.,g210487,3,"d.	&#8805 12 hours after removal of AND &#8805  24 hours after initial placement of epidural catheter; whichever is longer",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63089,0,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,g210174,0,"a.	12 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63089,1,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,g210175,1,"b.	24 hours",1,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63089,2,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,g210176,2,"c.	8 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19898,9302,Elearning-0000-551,g13918,g63089,3,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,g210177,3,"d.	6 hours",0,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT
19912,9581,Elearning-0000-805,g13917,g63073,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Heart Failure Disease Managament Clinic Cherokee CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g210113,0,TRUE,1,HEART FAILURE DISEASE MANAGAMENT CLINIC CHEROKEE
19912,9581,Elearning-0000-805,g13917,g63073,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Heart Failure Disease Managament Clinic Cherokee CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g210114,1,FALSE,0,HEART FAILURE DISEASE MANAGAMENT CLINIC CHEROKEE
19909,9713,Elearning-0000-925,g13916,g63061,0,When can you drawn an ABG per RT Protocol?,g210065,0,A. Any patient who is in distress or has had a change in status,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63061,1,When can you drawn an ABG per RT Protocol?,g210066,1,B. Any patient suddenly requiring greater than or equal to 50% FIO2,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63061,2,When can you drawn an ABG per RT Protocol?,g210067,2,C. Any patient with an exacerbation of their medical condition where their acid/base balance is questioned,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63061,3,When can you drawn an ABG per RT Protocol?,g210068,3,D. Any patient in which oximetry results are questionable,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63061,4,When can you drawn an ABG per RT Protocol?,g210069,4,E. ABGs may be obtained on a PRN basis based on the clinical presentation of the patient on the ventilator,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63061,5,When can you drawn an ABG per RT Protocol?,g210070,5,"F. A, B, and C Only",0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63061,6,When can you drawn an ABG per RT Protocol?,g210071,6,G. All of the above,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63062,0,Which statement is not true about AM ABGs in the ICU?,g210072,0,ABGs in the ICU are always a Complete Panel unless ordered otherwise,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63062,1,Which statement is not true about AM ABGs in the ICU?,g210073,1,Am ABGs in the ICU are only done if there is an active order in Cerner,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63062,2,Which statement is not true about AM ABGs in the ICU?,g210074,2,Am ABGs are done daily on all Vented patients,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63063,0,"You must take an ABG machine to the bedside, but in the event you cannot, what process is most appropriate?",g210075,0,"A. Pt sticker can be taken to the lab after verifying the Pt's name, FIN number, and DOB on the Patient's arm band",1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63063,1,"You must take an ABG machine to the bedside, but in the event you cannot, what process is most appropriate?",g210076,1,B. Pt sticker can be taken to the lab after verifying Pt's correct room number,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63063,2,"You must take an ABG machine to the bedside, but in the event you cannot, what process is most appropriate?",g210077,2,C. Pt sticker can be taken to the lab after verifying one patient identifier,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63064,0,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",g210078,0,A. Expired sample,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63064,1,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",g210079,1,B. Analyze time is before the draw time,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63064,2,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",g210080,2,C. Wrong patient sticker,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",g210081,3,D. No order entered in Cerner,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63064,4,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",g210082,4,"E. A, B, C",0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63064,5,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",g210083,5,F. A  and B,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63064,6,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",g210084,6,G. All of the above,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63065,0,"If the patients armband or sticker doesn't scan, you will have to manually enter ""AC"" followed by the patients FIN number. If entered correctly what should happen next?",g210085,0,A. Therapist will also manually enter Pt's full name and DOB,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63065,1,"If the patients armband or sticker doesn't scan, you will have to manually enter ""AC"" followed by the patients FIN number. If entered correctly what should happen next?",g210086,1,B. A gray demographics box will appear for the therapist to confirm correct Pt information was entered,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63065,2,"If the patients armband or sticker doesn't scan, you will have to manually enter ""AC"" followed by the patients FIN number. If entered correctly what should happen next?",g210087,2,C. None of the above,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63066,0,Which statement is true?,g210088,0,A. You do not have to have an ABG to wean,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63066,1,Which statement is true?,g210089,1,B. Use both SpO2 and EtCO2 to wean as long at they are correlating with previous gasses,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63066,2,Which statement is true?,g210090,2,C. None are true,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63066,3,Which statement is true?,g210091,3,D. A and B are true,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63067,0,Which statement is true regarding notification of critical ABG results?,g210092,0,A. Therapist must document under critical notification tab in Cerner,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63067,1,Which statement is true regarding notification of critical ABG results?,g210093,1,B. Therapist must document last name and credential. For example: Dr. Boyce,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63067,2,Which statement is true regarding notification of critical ABG results?,g210094,2,"C. Therapist must document first initial, last name, and credential. For example: P. Boyce MD",0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63067,3,Which statement is true regarding notification of critical ABG results?,g210095,3,D. Results can be given to a licensed health care professional,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63067,4,Which statement is true regarding notification of critical ABG results?,g210096,4,E. A and D are true,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63067,5,Which statement is true regarding notification of critical ABG results?,g210097,5,F. C and D are true,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63068,0,"If collateral circulation cannot be verified as a positive Allen's Test on either hand, you can do a brachial stick per protocol?",g210098,0,A. True,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63068,1,"If collateral circulation cannot be verified as a positive Allen's Test on either hand, you can do a brachial stick per protocol?",g210099,1,B. False,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63069,0,What is not considered a MANDATORY field when running an ABG?,g210100,0,"A. Correct Patient Name, Fin #, and DOB",0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63069,1,What is not considered a MANDATORY field when running an ABG?,g210101,1,B. Draw time,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63069,2,What is not considered a MANDATORY field when running an ABG?,g210102,2,C. Ordering MD,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63069,3,What is not considered a MANDATORY field when running an ABG?,g210103,3,D. Sample type,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63069,4,What is not considered a MANDATORY field when running an ABG?,g210104,4,E. Oxygen device,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63070,0,"Verification of orders, correct patient identification, proper technique in obtaining and prepping the blood sample, confirmation of demographic information, pertinent date entry, and reporting of critical values are all integral parts of the quality assurance process in ABG analysis.",g210105,0,A. True,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63070,1,"Verification of orders, correct patient identification, proper technique in obtaining and prepping the blood sample, confirmation of demographic information, pertinent date entry, and reporting of critical values are all integral parts of the quality assurance process in ABG analysis.",g210106,1,B. False,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63071,0,The image shows the correct charging of additional test when running a complete panel?,g210107,0,A. True,1,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63071,1,The image shows the correct charging of additional test when running a complete panel?,g210108,1,B. False,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63072,0,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,g210109,0,A. Red Rules are not reported if the Therapist self reports,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63072,1,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,g210110,1,B. Red Rules are not reported if the Nurse hands you the incorrect sticker during a CODE/Rapid Response,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63072,2,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,g210111,2,C. Red Rules are not reported if we catch the mistake immediately after the sample is approved,0,2021 RESPIRATORY ABG COMPETENCY CBL
19909,9713,Elearning-0000-925,g13916,g63072,3,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,g210112,3,D. All Red Rules are reported. It is your responsibility to report results on the correct patient,1,2021 RESPIRATORY ABG COMPETENCY CBL
19904,9683,Elearning-0000-898,g13915,g63060,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""GI LAB NSF: STERILE SUPPLY STORAGE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g210063,0,TRUE,1,GI LAB NSF: STERILE SUPPLY STORAGE
19904,9683,Elearning-0000-898,g13915,g63060,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""GI LAB NSF: STERILE SUPPLY STORAGE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g210064,1,FALSE,0,GI LAB NSF: STERILE SUPPLY STORAGE
19905,9903,Questions-0000-37,g13914,g63043,0,Please list the location for this activity.,g209998,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63043,1,Please list the location for this activity.,g209999,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63043,2,Please list the location for this activity.,g210000,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63043,3,Please list the location for this activity.,g210001,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63044,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g210002,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63044,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g210003,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63044,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g210004,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63044,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g210005,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63044,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g210006,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63045,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g210007,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63045,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g210008,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63045,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g210009,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63045,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g210010,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63045,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g210011,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63046,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210012,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63046,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210013,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63046,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210014,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63046,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210015,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63046,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g210016,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63047,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210017,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63047,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210018,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63047,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210019,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63047,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210020,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63047,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g210021,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63048,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g210022,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63048,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g210023,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63048,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g210024,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63048,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g210025,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63048,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g210026,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63049,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g210027,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63049,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g210028,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63049,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g210029,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63049,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g210030,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63049,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g210031,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63050,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g210032,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63050,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g210033,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63050,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g210034,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63050,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g210035,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63050,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g210036,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63051,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210037,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63051,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210038,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63051,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210039,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63051,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210040,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63051,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g210041,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63052,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g210042,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63052,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g210043,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63052,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g210044,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63052,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g210045,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63052,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g210046,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63052,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g210047,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63053,0,"Overall, this activity was:",g210048,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63053,1,"Overall, this activity was:",g210049,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63053,2,"Overall, this activity was:",g210050,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63053,3,"Overall, this activity was:",g210051,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63053,4,"Overall, this activity was:",g210052,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63054,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210053,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63054,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210054,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63054,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g210055,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63057,0,How would you improve this class (check all that apply)?,g210056,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63057,1,How would you improve this class (check all that apply)?,g210057,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63057,2,How would you improve this class (check all that apply)?,g210058,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63057,3,How would you improve this class (check all that apply)?,g210059,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63057,4,How would you improve this class (check all that apply)?,g210060,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63057,5,How would you improve this class (check all that apply)?,g210061,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19905,9903,Questions-0000-37,g13914,g63057,6,How would you improve this class (check all that apply)?,g210062,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21
19906,9916,Questions-0000-50,g13913,g63024,0,Please list the location for this activity.,g209923,0,Atlanta,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63024,1,Please list the location for this activity.,g209924,1,Cherokee,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63024,2,Please list the location for this activity.,g209925,2,Forsyth,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63024,3,Please list the location for this activity.,g209926,3,Other,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63025,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209927,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63025,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209928,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63025,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209929,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63025,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209930,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63025,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209931,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63026,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209932,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63026,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209933,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63026,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209934,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63026,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209935,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63026,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209936,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63027,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209937,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63027,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209938,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63027,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209939,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63027,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209940,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63027,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209941,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63028,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209942,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63028,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209943,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63028,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209944,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63028,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209945,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63028,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209946,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63029,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209947,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63029,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209948,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63029,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209949,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63029,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209950,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63029,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209951,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63030,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209952,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63030,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209953,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63030,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209954,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63030,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209955,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63030,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209956,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63031,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209957,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63031,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209958,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63031,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209959,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63031,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209960,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63031,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209961,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63032,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209962,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63032,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209963,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63032,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209964,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63032,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209965,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63032,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209966,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63033,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209967,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63033,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209968,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63033,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209969,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63033,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209970,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63033,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209971,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63034,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g209972,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63034,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g209973,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63034,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g209974,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63034,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g209975,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63034,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g209976,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63035,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209977,4,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63035,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209978,0,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63035,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209979,1,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63035,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209980,2,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63035,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209981,3,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63035,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209982,5,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63036,0,"Overall, this activity was:",g209983,0,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63036,1,"Overall, this activity was:",g209984,1,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63036,2,"Overall, this activity was:",g209985,2,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63036,3,"Overall, this activity was:",g209986,3,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63036,4,"Overall, this activity was:",g209987,4,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63037,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209988,0,Yes,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63037,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209989,1,No,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63037,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209990,2,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63040,0,How would you improve this class (check all that apply)?,g209991,0,Reduce content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63040,1,How would you improve this class (check all that apply)?,g209992,1,Increase content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63040,2,How would you improve this class (check all that apply)?,g209993,2,Update content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63040,3,How would you improve this class (check all that apply)?,g209994,3,Improve the instructional methods,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63040,4,How would you improve this class (check all that apply)?,g209995,4,Make course activities more stimulating,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63040,5,How would you improve this class (check all that apply)?,g209996,5,Slow the pace of the class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19906,9916,Questions-0000-50,g13913,g63040,6,How would you improve this class (check all that apply)?,g209997,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21"
19907,9910,Questions-0000-44,g13912,g63001,0,Please list the location for this activity.,g209828,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63001,1,Please list the location for this activity.,g209829,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63001,2,Please list the location for this activity.,g209830,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63001,3,Please list the location for this activity.,g209831,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63002,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209832,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63002,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209833,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63002,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209834,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63002,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209835,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63002,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g209836,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63003,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209837,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63003,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209838,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63003,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209839,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63003,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209840,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63003,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g209841,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63004,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209842,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63004,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209843,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63004,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209844,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63004,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209845,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63004,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g209846,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63005,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209847,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63005,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209848,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63005,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209849,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63005,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209850,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63005,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g209851,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63006,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g209852,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63006,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g209853,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63006,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g209854,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63006,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g209855,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63006,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g209856,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63007,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g209857,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63007,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g209858,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63007,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g209859,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63007,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g209860,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63007,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g209861,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63008,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g209862,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63008,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g209863,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63008,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g209864,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63008,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g209865,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63008,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g209866,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63009,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g209867,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63009,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g209868,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63009,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g209869,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63009,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g209870,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63009,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g209871,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63010,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209872,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63010,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209873,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63010,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209874,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63010,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209875,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63010,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209876,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63011,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209877,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63011,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209878,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63011,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209879,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63011,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209880,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63011,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209881,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63012,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209882,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63012,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209883,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63012,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209884,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63012,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209885,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63012,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g209886,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63013,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209887,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63013,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209888,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63013,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209889,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63013,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209890,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63013,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g209891,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63014,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209892,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63014,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209893,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63014,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209894,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63014,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209895,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63014,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g209896,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63015,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g209897,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63015,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g209898,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63015,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g209899,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63015,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g209900,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63015,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g209901,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63016,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209902,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63016,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209903,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63016,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209904,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63016,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209905,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63016,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209906,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63016,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g209907,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63017,0,"Overall, this activity was:",g209908,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63017,1,"Overall, this activity was:",g209909,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63017,2,"Overall, this activity was:",g209910,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63017,3,"Overall, this activity was:",g209911,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63017,4,"Overall, this activity was:",g209912,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63018,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209913,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63018,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209914,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63018,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209915,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63021,0,How would you improve this class (check all that apply)?,g209916,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63021,1,How would you improve this class (check all that apply)?,g209917,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63021,2,How would you improve this class (check all that apply)?,g209918,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63021,3,How would you improve this class (check all that apply)?,g209919,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63021,4,How would you improve this class (check all that apply)?,g209920,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63021,5,How would you improve this class (check all that apply)?,g209921,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19907,9910,Questions-0000-44,g13912,g63021,6,How would you improve this class (check all that apply)?,g209922,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21
19902,9644,Elearning-0000-862,g13910,g62993,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""PeopleFluent For Hiring Managers CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209803,0,TRUE,1,PEOPLEFLUENT FOR HIRING MANAGERS CBL
19902,9644,Elearning-0000-862,g13910,g62993,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""PeopleFluent For Hiring Managers CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209804,1,FALSE,0,PEOPLEFLUENT FOR HIRING MANAGERS CBL
19900,9593,Elearning-0000-816,g13909,g62992,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention - July 2021 - Pressure Injury Prevention Offloading"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209801,0,TRUE,1,HAPI PREVENTION EDUCATION - JULY 2021 - PRESSURE INJURY PREVENTION OFFLOADING
19900,9593,Elearning-0000-816,g13909,g62992,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention - July 2021 - Pressure Injury Prevention Offloading"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209802,1,FALSE,0,HAPI PREVENTION EDUCATION - JULY 2021 - PRESSURE INJURY PREVENTION OFFLOADING
19897,9645,Elearning-0000-863,g13907,g62980,0,"If a patient is not experiencing pain when you assess for it, you should still document at least once per shift that the patient is not experiencing pain.",g209766,0,TRUE,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62980,1,"If a patient is not experiencing pain when you assess for it, you should still document at least once per shift that the patient is not experiencing pain.",g209767,1,FALSE,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62981,0,Within what time frame do you need to reassess a patient's pain after treatment?,g209768,0,a.  3 hours,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62981,1,Within what time frame do you need to reassess a patient's pain after treatment?,g209769,1,b. 1 hour,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62981,2,Within what time frame do you need to reassess a patient's pain after treatment?,g209770,2,c. 2 hours,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62981,3,Within what time frame do you need to reassess a patient's pain after treatment?,g209771,3,d. 4 hours,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62982,0,"When assessing pain you always need to be sure to document Pain rating (0-10), Pain goal, Site, Characteristics, Duration, Sedation, and Interventions.",g209772,0,TRUE,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62982,1,"When assessing pain you always need to be sure to document Pain rating (0-10), Pain goal, Site, Characteristics, Duration, Sedation, and Interventions.",g209773,1,FALSE,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62983,0,"You need to document all non-pharmacological pain management interventions provided, and reassessment of those interventions as well.",g209774,0,TRUE,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62983,1,"You need to document all non-pharmacological pain management interventions provided, and reassessment of those interventions as well.",g209775,1,FALSE,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62984,0,What are non-pharmacological pain management interventions?,g209776,0,a. Ice,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62984,1,What are non-pharmacological pain management interventions?,g209777,1,b. Heat,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62984,2,What are non-pharmacological pain management interventions?,g209778,2,c. Massage,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62984,3,What are non-pharmacological pain management interventions?,g209779,3,d. Repositioning,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62984,4,What are non-pharmacological pain management interventions?,g209780,4,"e. a, b, c, d",1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62985,0,What pain score range is mild pain?,g209781,0,a. 1-4,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62985,1,What pain score range is mild pain?,g209782,1,b. 1-3,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62985,2,What pain score range is mild pain?,g209783,2,c. 1-2,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62985,3,What pain score range is mild pain?,g209784,3,d. 1-5,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62986,0,What pain score range is moderate pain?,g209785,0,a. 2-6,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62986,1,What pain score range is moderate pain?,g209786,1,b. 3-6,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62986,2,What pain score range is moderate pain?,g209787,2,c. 4-6,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62986,3,What pain score range is moderate pain?,g209788,3,d. 4-5,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62987,0,What pain score range is severe pain?,g209789,0,a. 7-10,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62987,1,What pain score range is severe pain?,g209790,1,b. 6-10,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62987,2,What pain score range is severe pain?,g209791,2,c. 5-10,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62987,3,What pain score range is severe pain?,g209792,3,d. 8-10,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62988,0,"Pain treatment should be based off of the patient's pain score dosing range, and you should always check orders to ensure that the treatment aligns with the patients pain score.",g209793,0,TRUE,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62988,1,"Pain treatment should be based off of the patient's pain score dosing range, and you should always check orders to ensure that the treatment aligns with the patients pain score.",g209794,1,FALSE,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62989,0,Pain should be included in the patients IPOC when they are experiencing pain.,g209795,0,TRUE,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62989,1,Pain should be included in the patients IPOC when they are experiencing pain.,g209796,1,FALSE,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62990,0,The Patient Preference Pain Management Standing order should be utilized when the patient requests pain medication which is in a lower category than what they score their pain as. The medication must be on the patient's medication list.,g209797,0,TRUE,1,PAIN MANAGEMENT - CARDIAC MED/SURG
19897,9645,Elearning-0000-863,g13907,g62990,1,The Patient Preference Pain Management Standing order should be utilized when the patient requests pain medication which is in a lower category than what they score their pain as. The medication must be on the patient's medication list.,g209798,1,FALSE,0,PAIN MANAGEMENT - CARDIAC MED/SURG
19896,9477,Elearning-0000-710,g13906,g62974,0,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",g209744,0,Repeat BP in 5 minutes,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62974,1,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",g209745,1,Repeat BP in 15 minutes,1,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62974,2,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",g209746,2,Administer an extra dose of labetalol 300 mg PO,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62974,3,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",g209747,3,Notify the provider,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62975,0,The patient's blood pressure 15 minutes later is 159/110 and she is now complaining of a headache.  What is your next nursing action?,g209748,0,Wait 30 minutes and recheck the blood pressure again to make sure it was a valid blood pressure reading,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62975,1,The patient's blood pressure 15 minutes later is 159/110 and she is now complaining of a headache.  What is your next nursing action?,g209749,1,Call the provider to determine what regimen to initiate,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62975,2,The patient's blood pressure 15 minutes later is 159/110 and she is now complaining of a headache.  What is your next nursing action?,g209750,2,Review the admission orders to determine which regimen was selected in the communication order,1,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62976,0,"The patient has a communication order to initiate the IV hydralazine regimen for severe, sustained hypertension.  What is your next nursing action?",g209751,0,Place an order for the hydralazine regimen via the OB Hypertension Acute NSH orders as a standing order,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62976,1,"The patient has a communication order to initiate the IV hydralazine regimen for severe, sustained hypertension.  What is your next nursing action?",g209752,1,Place an order for the hydralazine OB regimen via the Hypertension Acute NSH orders as a protocol order,1,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62976,2,"The patient has a communication order to initiate the IV hydralazine regimen for severe, sustained hypertension.  What is your next nursing action?",g209753,2,Place an order for the hydralazine regimen via the OB Hypertension Acute NSH orders as a telephone order,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62977,0,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",g209754,0,Repeat the BP in 15 minutes,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62977,1,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",g209755,1,Call the provider to obtain a new order for treatment,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62977,2,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",g209756,2,Administer the second dose of hydralazine 10 mg IV per the regimen,1,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62977,3,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",g209757,3,Administer labetalol 20 mg IV,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62978,0,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",g209758,0,Repeat BP in 15 minutes,1,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62978,1,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",g209759,1,"Administer Hydralazine 10 mg IV, and notify provider",0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62978,2,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",g209760,2,"Administer Labetalol 20 mg IV, and notify provider",0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62978,3,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",g209761,3,"Administer Labetalol 40 mg IV, and notify provider",0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62979,0,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,g209762,0,"Administer Hydralazine 10 mg IV, and notify provider",1,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62979,1,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,g209763,1,"Administer Labetalol 20 mg IV, and notify provider",0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62979,2,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,g209764,2,"Administer Labetalol 40 mg IV, and notify provider",0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19896,9477,Elearning-0000-710,g13906,g62979,3,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,g209765,3,Call the provider to obtain a new order for treatment,0,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS
19889,8388,Elearning-0000-126,g13901,g62968,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Telestroke Education Training For RRT and HC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g209728,0,TRUE,1,TELESTROKE EDUCATION TRAINING FOR RRT AND HC
19889,8388,Elearning-0000-126,g13901,g62968,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Telestroke Education Training For RRT and HC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g209729,1,FALSE,0,TELESTROKE EDUCATION TRAINING FOR RRT AND HC
19887,9251,Elearning-0000-505,g13899,g62947,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",g209658,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62947,1,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",g209659,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62948,0,Which one of the following hazardous medication list grouping is incorrect?,g209660,0,"a.	Group 2 - Hazardous agents (primarily reproductive risk)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62948,1,Which one of the following hazardous medication list grouping is incorrect?,g209661,1,"b.	Group 1 - Hazardous agents (cytotoxic antineoplastic/reproductive risks)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62948,2,Which one of the following hazardous medication list grouping is incorrect?,g209662,2,"c.	Group 2A - Non-hazardous antineoplastic agents",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62948,3,Which one of the following hazardous medication list grouping is incorrect?,g209663,3,"d.	Appendix D - Excluded drugs based on NSH risk assessment",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62949,0,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",g209664,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62949,1,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",g209665,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62950,0,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g209666,0,"a.	Decontamination",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62950,1,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g209667,1,"b.	Cleaning",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62950,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g209668,2,"c.	Disinfection",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62950,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g209669,3,"d.	Deactivate",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62950,4,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",g209670,4,"e.	All of the above",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62951,0,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",g209671,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62951,1,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",g209672,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62952,0,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g209673,0,"a.	Protective Gown",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62952,1,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g209674,1,"b.	Eye/Face protection",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62952,2,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g209675,2,"c.	Respiratory protection",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62952,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g209676,3,"d.	Footwear",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62952,4,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g209677,4,"e.	Gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62952,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,g209678,5,"f.	All of the above",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62953,0,The spill response team is activated for any spills that is not contained by the following:,g209679,0,"a.	Two Spill Kits",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62953,1,The spill response team is activated for any spills that is not contained by the following:,g209680,1,"b.	Single Spill Kit",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62953,2,The spill response team is activated for any spills that is not contained by the following:,g209681,2,"c.	Three Spill Kits",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62953,3,The spill response team is activated for any spills that is not contained by the following:,g209682,3,"d.	Any spill in patient care area",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62953,4,The spill response team is activated for any spills that is not contained by the following:,g209683,4,"e.	Any spill in pharmacy area",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62954,0,Gloves used in the preparation of HDs must be:,g209684,0,"a.	Disposable",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62954,1,Gloves used in the preparation of HDs must be:,g209685,1,"b.	Powdered to facilitate removal",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62954,2,Gloves used in the preparation of HDs must be:,g209686,2,"c.	Specified as ASTM-tested chemotherapy gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62954,3,Gloves used in the preparation of HDs must be:,g209687,3,"d.	A and C",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62955,0,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g209688,0,"a.	Filter needles",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62955,1,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g209689,1,"b.	Leur-Lock syringes",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62955,2,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g209690,2,"c.	Closed-system transfer devices (CSTDs)",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62955,3,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",g209691,3,"d.	None of the above",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62956,0,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,g209692,0,TRUE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62956,1,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,g209693,1,FALSE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62957,0,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g209694,0,"a.	Biological safety cabinet (BSC)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62957,1,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g209695,1,"b.	Horizontal laminar air flow workbench",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62957,2,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g209696,2,"c.	Compounding aseptic containment isolator (CACI)",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62957,3,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,g209697,3,"d.	A and C",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62958,0,Spill kits:,g209698,0,"a.	May be obtained from Central Supply when needed",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62958,1,Spill kits:,g209699,1,"b.	Are kept wherever HDs and chemotherapy agents are handled",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62958,2,Spill kits:,g209700,2,"c.	Contain supplies needed to clean a HD spill",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62958,3,Spill kits:,g209701,3,"d.	All of the above",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62959,0,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",g209702,0,TRUE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62959,1,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",g209703,1,FALSE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62960,0,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",g209704,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62960,1,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",g209705,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62961,0,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",g209706,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62961,1,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",g209707,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62962,0,How often do you have to change the gown during hazardous drug compounding?,g209708,0,"a.	At least every 12 hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62962,1,How often do you have to change the gown during hazardous drug compounding?,g209709,1,"b.	At least every 24 hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62962,2,How often do you have to change the gown during hazardous drug compounding?,g209710,2,"c.	At least every 3 hours",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62962,3,How often do you have to change the gown during hazardous drug compounding?,g209711,3,"d.	 At shift change",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62963,0,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,g209712,0,TRUE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62963,1,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,g209713,1,FALSE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62964,0,Which statement is true?,g209714,0,"a.	Cytotoxic chemotherapy doses maybe rounded down or up to the nearest vials size within < 5% of the calculated dose",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62964,1,Which statement is true?,g209715,1,"b.	Cytotoxic chemotherapy doses maybe rounded down to the nearest vials size within < 5% of the calculated dose",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62964,2,Which statement is true?,g209716,2,"c.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 10% of the calculated dose.",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62964,3,Which statement is true?,g209717,3,"d.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 5% of the calculated dose.",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62964,4,Which statement is true?,g209718,4,"e.	a & c",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62964,5,Which statement is true?,g209719,5,"f.	b & c",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62965,0,PA or NP may sign C1D1 chemotherapy orders.,g209720,0,TRUE,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62965,1,PA or NP may sign C1D1 chemotherapy orders.,g209721,1,FALSE,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62966,0,Which statement is false?,g209722,0,a. Verbal and telephone orders to initiate chemotherapy will not be accepted,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62966,1,Which statement is false?,g209723,1,b. A physician must sign C1D1 chemotherapy orders,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62966,2,Which statement is false?,g209724,2,c. Pregnancy screening is required at baseline and then at least once a week while the patient is on therapy,1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62966,3,Which statement is false?,g209725,3,d. Treating physicians are responsible for monitoring cumulative anthracycline doses,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62969,0,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g209730,0,"a.	At least every 8 hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62969,1,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g209731,1,"b.	At least every 3  hours",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62969,2,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g209732,2,"c.	At least every 30 minutes",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62969,3,How often do you have to change the outer gloves during hazardous drug sterile compounding?,g209733,3,At shift change,0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62970,0,When wearing double gloves:,g209734,0,"a.	The gown cuffs should be tucked over both gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62970,1,When wearing double gloves:,g209735,1,"b.	The gown cuffs should be tucked under both gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62970,2,When wearing double gloves:,g209736,2,"c.	The inner glove should be worn under the cuff and the outer glove should be worn over the gown cuff",1,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19887,9251,Elearning-0000-505,g13899,g62970,3,When wearing double gloves:,g209737,3,"d.	It makes no difference if gown cuffs are worn over or under the gloves",0,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION
19885,260,SCORM-0000-70,g13897,g49408,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Neurosurgery Spine Lecture - 6th Floor NSC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g161829,0,TRUE,1,NEUROSURGERY SPINE LECTURE - 6TH FLOOR NSC
19885,260,SCORM-0000-70,g13897,g49408,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Neurosurgery Spine Lecture - 6th Floor NSC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g161830,1,FALSE,0,NEUROSURGERY SPINE LECTURE - 6TH FLOOR NSC
19883,9647,Elearning-0000-865,g13896,g62946,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Policy & Procedure Updates for Oncology Nursing"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209656,0,TRUE,1,POLICY & PROCEDURE UPDATES FOR ONCOLOGY NURSING
19883,9647,Elearning-0000-865,g13896,g62946,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Policy & Procedure Updates for Oncology Nursing"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209657,1,FALSE,0,POLICY & PROCEDURE UPDATES FOR ONCOLOGY NURSING
19881,9472,Elearning-0000-706,g13894,g62944,0,What are the 4 indicators we are measuring for Pneumonia DSC?,g209650,0,"1. Nursing documentation of SMI, progressive mobility, antibiotic stewardship, pneumonia vaccination",0,CHEROKEE PNUEMONIA DSC FOR RT 2021
19881,9472,Elearning-0000-706,g13894,g62944,1,What are the 4 indicators we are measuring for Pneumonia DSC?,g209651,1,"2. Oral care, progressive mobility, diet reconciliation, oxygen weaning",0,CHEROKEE PNUEMONIA DSC FOR RT 2021
19881,9472,Elearning-0000-706,g13894,g62944,2,What are the 4 indicators we are measuring for Pneumonia DSC?,g209652,2,"3. Oxygen weaning, nursing documentation of SMI, progressive mobility, % of follow up appointment within 7days of discharge with PCP or Pulmonologist",1,CHEROKEE PNUEMONIA DSC FOR RT 2021
19881,9472,Elearning-0000-706,g13894,g62944,3,What are the 4 indicators we are measuring for Pneumonia DSC?,g209653,3,"4. Hand hygiene, oxygen weaning, oral care, progressive mobility",0,CHEROKEE PNUEMONIA DSC FOR RT 2021
19876,9569,Elearning-0000-794,g13892,g62929,0,A Bronch Wash is any volume less than 20ml,g209610,0,TRUE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62929,1,A Bronch Wash is any volume less than 20ml,g209611,1,FALSE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62930,0,A Bronchial Alveolar Lavage is any volume 20ml or greater,g209612,0,TRUE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62930,1,A Bronchial Alveolar Lavage is any volume 20ml or greater,g209613,1,FALSE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62931,0,What do you need to be aware of before giving Phenylephrine,g209614,0,1. It can decrease blood pressure,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62931,1,What do you need to be aware of before giving Phenylephrine,g209615,1,2. It can increase blood pressure,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62931,2,What do you need to be aware of before giving Phenylephrine,g209616,2,3. It can cause a fast/irregular heartbeat,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62931,3,What do you need to be aware of before giving Phenylephrine,g209617,3,4. It can increase the blood pressure and cause a fast/irregular heartbeat.,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62932,0,Correct mixture for Phenylephrine is,g209618,0,1. 10ml mixed with 1ml of 0.9% Sodium Chloride,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62932,1,Correct mixture for Phenylephrine is,g209619,1,2. 1ml mixed with 9ml of 0.9% Sodium Chloride,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62932,2,Correct mixture for Phenylephrine is,g209620,2,3. 1ml mixed with 9ml of 0.9% Sodium Bicarb,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62933,0,What is the best way to achieve hemostasis in the lung,g209621,0,1. CPAP,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62933,1,What is the best way to achieve hemostasis in the lung,g209622,1,2. Iced normal saline lavage,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62933,2,What is the best way to achieve hemostasis in the lung,g209623,2,3. Hold pressure with the bronchoscope,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62934,0,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",g209624,0,1. 10%,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62934,1,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",g209625,1,2. 1%,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62934,2,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",g209626,2,3. 5%,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62934,3,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",g209627,3,4. 2%,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62935,0,"When prepping a patient for a bronchoscopy, with platelets less than 50, you should prep the mouth instead of the nares",g209628,0,TRUE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62935,1,"When prepping a patient for a bronchoscopy, with platelets less than 50, you should prep the mouth instead of the nares",g209629,1,FALSE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62936,0,Cytology brushings are fixed on slides and sprayed with what fixative spray?,g209630,0,1. Formaldehyde,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62936,1,Cytology brushings are fixed on slides and sprayed with what fixative spray?,g209631,1,2. Alcohol,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62936,2,Cytology brushings are fixed on slides and sprayed with what fixative spray?,g209632,2,3. Peroxide,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62936,3,Cytology brushings are fixed on slides and sprayed with what fixative spray?,g209633,3,4. Hairspray,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62937,0,You should always wear gloves when touching a bronchoscope?,g209634,0,TRUE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62937,1,You should always wear gloves when touching a bronchoscope?,g209635,1,FALSE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62938,0,The Medication sheet should be:,g209636,0,1. Signed and dated only,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62938,1,The Medication sheet should be:,g209637,1,2. Noted and timed only,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62938,2,The Medication sheet should be:,g209638,2,"3. Signed, dated, timed, and noted",1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62938,3,The Medication sheet should be:,g209639,3,4. None of the above,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62939,0,The bedside pre-clean of the bronchoscope can be done after you take the samples to the lab,g209640,0,TRUE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62939,1,The bedside pre-clean of the bronchoscope can be done after you take the samples to the lab,g209641,1,FALSE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62940,0,The enzymatic sponge is utilized during the bedside pre-clean,g209642,0,TRUE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62940,1,The enzymatic sponge is utilized during the bedside pre-clean,g209643,1,FALSE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62941,0,You should transport a bronchoscope in a closed bin,g209644,0,TRUE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62941,1,You should transport a bronchoscope in a closed bin,g209645,1,FALSE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62942,0,It is ok if a clean bronchoscope touches another clean bronchoscope while stored in gi lab,g209646,0,TRUE,0,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62942,1,It is ok if a clean bronchoscope touches another clean bronchoscope while stored in gi lab,g209647,1,FALSE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62943,0,Physicians are responsible for placing bronch orders in to cerner,g209648,0,TRUE,1,2021 ANNUAL BRONCH TEST
19876,9569,Elearning-0000-794,g13892,g62943,1,Physicians are responsible for placing bronch orders in to cerner,g209649,1,FALSE,0,2021 ANNUAL BRONCH TEST
19875,9358,Elearning-0000-602,g13891,g62928,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Continuous Readiness: Fire Safety Education CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g209608,0,TRUE,1,CONTINUOUS READINESS: FIRE SAFETY EDUCATION
19875,9358,Elearning-0000-602,g13891,g62928,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Continuous Readiness: Fire Safety Education CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g209609,1,FALSE,0,CONTINUOUS READINESS: FIRE SAFETY EDUCATION
19872,9950,Questions-0000-84,g13888,g62905,0,Please list the location for this activity.,g209520,0,Atlanta,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62905,1,Please list the location for this activity.,g209521,1,Forsyth,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62905,2,Please list the location for this activity.,g209522,2,Cherokee,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62905,3,Please list the location for this activity.,g209523,3,Other,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62906,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g209524,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62906,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g209525,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62906,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g209526,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62906,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g209527,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62906,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g209528,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62907,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g209529,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62907,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g209530,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62907,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g209531,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62907,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g209532,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62907,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g209533,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62908,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g209534,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62908,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g209535,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62908,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g209536,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62908,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g209537,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62908,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g209538,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62909,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g209539,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62909,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g209540,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62909,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g209541,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62909,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g209542,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62909,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g209543,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62910,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g209544,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62910,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g209545,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62910,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g209546,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62910,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g209547,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62910,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g209548,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62911,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g209549,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62911,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g209550,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62911,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g209551,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62911,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g209552,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62911,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g209553,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62912,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g209554,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62912,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g209555,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62912,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g209556,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62912,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g209557,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62912,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g209558,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62913,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209559,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62913,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209560,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62913,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209561,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62913,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209562,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62913,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209563,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62914,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g209564,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62914,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g209565,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62914,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g209566,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62914,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g209567,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62914,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g209568,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62915,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209569,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62915,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209570,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62915,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209571,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62915,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209572,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62915,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209573,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62916,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g209574,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62916,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g209575,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62916,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g209576,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62916,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g209577,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62916,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g209578,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62917,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209579,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62917,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209580,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62917,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209581,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62917,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209582,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62917,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209583,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62918,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g209584,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62918,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g209585,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62918,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g209586,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62918,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g209587,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62918,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g209588,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62919,0,"Overall, this activity was:",g209589,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62919,1,"Overall, this activity was:",g209590,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62919,2,"Overall, this activity was:",g209591,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62919,3,"Overall, this activity was:",g209592,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62919,4,"Overall, this activity was:",g209593,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62920,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209594,0,Yes,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62920,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209595,1,No,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62920,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209596,2,N/A,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62923,0,How would you improve this class?,g209597,0,Reduce content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62923,1,How would you improve this class?,g209598,1,Increase content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62923,2,How would you improve this class?,g209599,2,Update content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62923,3,How would you improve this class?,g209600,3,Improve the instructional methods,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62923,4,How would you improve this class?,g209601,4,Make course activities more stimulating,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62923,5,How would you improve this class?,g209602,5,Slow the pace of the class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19872,9950,Questions-0000-84,g13888,g62923,6,How would you improve this class?,g209603,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21
19869,9809,Questions-0000-104,g13885,g62881,0,Please list the location for this activity.,g209427,0,Atlanta,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62881,1,Please list the location for this activity.,g209428,1,Cherokee,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62881,2,Please list the location for this activity.,g209429,2,Forsyth,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62881,3,Please list the location for this activity.,g209430,3,Other,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62882,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g209431,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62882,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g209432,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62882,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g209433,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62882,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g209434,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62882,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g209435,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62883,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g209436,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62883,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g209437,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62883,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g209438,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62883,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g209439,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62883,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g209440,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62884,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g209441,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62884,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g209442,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62884,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g209443,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62884,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g209444,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62884,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g209445,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62885,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g209446,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62885,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g209447,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62885,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g209448,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62885,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g209449,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62885,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g209450,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62886,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g209451,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62886,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g209452,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62886,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g209453,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62886,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g209454,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62886,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g209455,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62887,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g209456,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62887,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g209457,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62887,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g209458,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62887,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g209459,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62887,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g209460,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62888,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209461,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62888,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209462,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62888,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209463,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62888,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209464,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62888,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209465,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62889,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209466,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62889,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209467,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62889,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209468,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62889,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209469,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62889,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209470,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62890,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209471,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62890,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209472,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62890,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209473,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62890,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209474,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62890,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g209475,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62891,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209476,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62891,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209477,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62891,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209478,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62891,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209479,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62891,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g209480,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62892,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g209481,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62892,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g209482,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62892,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g209483,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62892,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g209484,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62892,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g209485,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62893,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209486,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62893,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209487,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62893,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209488,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62893,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209489,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62893,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g209490,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62894,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",g209491,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62894,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",g209492,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62894,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",g209493,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62894,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",g209494,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62894,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",g209495,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62895,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g209496,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62895,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g209497,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62895,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g209498,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62895,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g209499,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62895,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",g209500,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62896,0,"Overall, this activity was:",g209501,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62896,1,"Overall, this activity was:",g209502,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62896,2,"Overall, this activity was:",g209503,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62896,3,"Overall, this activity was:",g209504,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62896,4,"Overall, this activity was:",g209505,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62897,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209506,0,Yes,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62897,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209507,1,No,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62897,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209508,2,N/A,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62900,0,How would you improve this class?,g209509,0,Reduce content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62900,1,How would you improve this class?,g209510,1,Increase content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62900,2,How would you improve this class?,g209511,2,Update content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62900,3,How would you improve this class?,g209512,3,Improve the instructional methods,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62900,4,How would you improve this class?,g209513,4,Make course activities more stimulating,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62900,5,How would you improve this class?,g209514,5,Slow the pace of the class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19869,9809,Questions-0000-104,g13885,g62900,6,How would you improve this class?,g209515,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21
19868,9939,Questions-0000-73,g13884,g62864,0,Please list the location for this activity.,g209361,0,Atlanta,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62864,1,Please list the location for this activity.,g209362,1,Cherokee,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62864,2,Please list the location for this activity.,g209363,2,Forsyth,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62864,3,Please list the location for this activity.,g209364,3,Other,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62865,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g209365,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62865,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g209366,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62865,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g209367,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62865,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g209368,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62865,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g209369,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62866,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g209370,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62866,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g209371,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62866,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g209372,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62866,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g209373,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62866,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g209374,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62867,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g209375,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62867,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g209376,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62867,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g209377,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62867,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g209378,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62867,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g209379,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62868,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209380,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62868,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209381,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62868,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209382,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62868,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209383,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62868,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g209384,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62869,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g209385,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62869,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g209386,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62869,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g209387,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62869,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g209388,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62869,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g209389,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62870,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g209390,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62870,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g209391,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62870,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g209392,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62870,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g209393,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62870,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g209394,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62871,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g209395,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62871,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g209396,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62871,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g209397,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62871,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g209398,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62871,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g209399,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62872,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g209400,0,Excellent,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62872,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g209401,1,Very Good,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62872,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g209402,2,Good,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62872,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g209403,3,Fair,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62872,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g209404,4,Poor,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62872,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g209405,5,N/A,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62873,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g209406,0,Excellent,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62873,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g209407,1,Very Good,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62873,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g209408,2,Good,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62873,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g209409,3,Fair,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62873,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g209410,4,Poor,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62873,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g209411,5,N/A,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62874,0,"Overall, this activity was:",g209412,0,Excellent,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62874,1,"Overall, this activity was:",g209413,1,Very Good,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62874,2,"Overall, this activity was:",g209414,2,Good,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62874,3,"Overall, this activity was:",g209415,3,Fair,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62874,4,"Overall, this activity was:",g209416,4,Poor,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62875,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209417,0,Yes,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62875,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209418,1,No,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62875,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g209419,2,N/A,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62878,0,How would you improve this class (check all that apply)?,g209420,0,Reduce content covered in class,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62878,1,How would you improve this class (check all that apply)?,g209421,1,Increase content covered in class,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62878,2,How would you improve this class (check all that apply)?,g209422,2,Update content covered in class,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62878,3,How would you improve this class (check all that apply)?,g209423,3,Improve the instructional methods,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62878,4,How would you improve this class (check all that apply)?,g209424,4,Make course activities more stimulating,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62878,5,How would you improve this class (check all that apply)?,g209425,5,Slow the pace of the class,0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19868,9939,Questions-0000-73,g13884,g62878,6,How would you improve this class (check all that apply)?,g209426,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,MIND THE GAP (EVALUATION SURVEY) 6-17-21
19864,9691,Elearning-0000-905,g13880,g62810,0,State and federal law require hospitals to provide appropriate medical screening exams and stabilizing treatment to any patient who comes to the hospital requesting examination or treatment?,g209147,0,a. True,1,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62810,1,State and federal law require hospitals to provide appropriate medical screening exams and stabilizing treatment to any patient who comes to the hospital requesting examination or treatment?,g209148,1,b. False,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62811,0,Who may perform a screening examination?,g209149,0,a. Physician Assistant,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62811,1,Who may perform a screening examination?,g209150,1,b. Certified Nurse Midwife,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62811,2,Who may perform a screening examination?,g209151,2,c. Advanced Practice RN,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62811,3,Who may perform a screening examination?,g209152,3,d. MD,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62811,4,Who may perform a screening examination?,g209153,4,e. All of the above,1,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62812,0,"Northside hospital personnel should <u>not</u> advise parents to go to ""Children's Hospital"" before the screening exam is completed?",g209154,0,a. True,1,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62812,1,"Northside hospital personnel should <u>not</u> advise parents to go to ""Children's Hospital"" before the screening exam is completed?",g209155,1,b. False,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62813,0,Triage assessment by a RN is considered a medical screening exam?,g209156,0,a. True,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62813,1,Triage assessment by a RN is considered a medical screening exam?,g209157,1,b. False,1,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62814,0,Concerns regarding possible violations of the EMTALA policy should be referred to the,g209158,0,a. ED Supervisor,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62814,1,Concerns regarding possible violations of the EMTALA policy should be referred to the,g209159,1,b. House Coordinator/ PSC,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62814,2,Concerns regarding possible violations of the EMTALA policy should be referred to the,g209160,2,c. Risk Management,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62814,3,Concerns regarding possible violations of the EMTALA policy should be referred to the,g209161,3,d. either b or c,1,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62815,0,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",g209162,0,a. ED Supervisor,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62815,1,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",g209163,1,b. House Coordinator/ PSC/ Transfer Line for Gwinnett,1,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62815,2,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",g209164,2,c. ED Physician,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62815,3,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",g209165,3,d. Risk Management,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62816,0,"Patients  who leave from the ED or L&D prior to the medical screening being completed should be provided the form called ""Leaving Against Medical Advice"" to sign after review the content.",g209166,0,a. True,1,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19864,9691,Elearning-0000-905,g13880,g62816,1,"Patients  who leave from the ED or L&D prior to the medical screening being completed should be provided the form called ""Leaving Against Medical Advice"" to sign after review the content.",g209167,1,b. False,0,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF
19863,9655,Elearning-0000-872,g13879,g62807,0,Patients must have:,g209139,0,"a)	Relapsed/refractory Multiple Myeloma",1,NSH 1304 KARMMA-7
19863,9655,Elearning-0000-872,g13879,g62807,1,Patients must have:,g209140,1,"b)	Relapsed/refractory AML",0,NSH 1304 KARMMA-7
19863,9655,Elearning-0000-872,g13879,g62807,2,Patients must have:,g209141,2,"c)	Relapsed/refractory NHL",0,NSH 1304 KARMMA-7
19863,9655,Elearning-0000-872,g13879,g62807,3,Patients must have:,g209142,3,"d)	None of the above",0,NSH 1304 KARMMA-7
19863,9655,Elearning-0000-872,g13879,g62808,0,Patients will be randomized to receive either bb2121 CAR-T cells or a standard of care combination therapy.,g209143,0,"a)	True",0,NSH 1304 KARMMA-7
19863,9655,Elearning-0000-872,g13879,g62808,1,Patients will be randomized to receive either bb2121 CAR-T cells or a standard of care combination therapy.,g209144,1,"b)	False",1,NSH 1304 KARMMA-7
19863,9655,Elearning-0000-872,g13879,g62809,0,Patients must have achieved a minimal response or better to at least 1 prior regimen to be eligible.,g209145,0,a) True,1,NSH 1304 KARMMA-7
19863,9655,Elearning-0000-872,g13879,g62809,1,Patients must have achieved a minimal response or better to at least 1 prior regimen to be eligible.,g209146,1,b) False,0,NSH 1304 KARMMA-7
19862,9708,Elearning-0000-920,g13878,g62798,0,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,g209113,0,TRUE,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62798,1,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,g209114,1,FALSE,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62799,0,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209115,0,A) 10 minutes,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62799,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209116,1,B) 2 minutes,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62799,2,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209117,2,C) 1 minute,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62799,3,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209118,3,C) 1 hour,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62800,0,"True or False? <br> You receive a patient while Alteplase is infusing.  The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",g209119,0,TRUE,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62800,1,"True or False? <br> You receive a patient while Alteplase is infusing.  The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",g209120,1,FALSE,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62801,0,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br> <ul> <li>Every 15 minutes for 2 hours, thenΓÇª</li> <li>Every 30 minutes for 6 hours, thenΓÇª</li> <li>Every hour for __ hours.</li> </ul>",g209121,0,A. 10 hrs,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62801,1,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br> <ul> <li>Every 15 minutes for 2 hours, thenΓÇª</li> <li>Every 30 minutes for 6 hours, thenΓÇª</li> <li>Every hour for __ hours.</li> </ul>",g209122,1,B. 24 hrs,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62801,2,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br> <ul> <li>Every 15 minutes for 2 hours, thenΓÇª</li> <li>Every 30 minutes for 6 hours, thenΓÇª</li> <li>Every hour for __ hours.</li> </ul>",g209123,2,C. 16 hrs,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62802,0,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,g209124,0,A. Turn off Alteplase infusion,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62802,1,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,g209125,1,B. Give prn Labetalol as per the Alteplase order set,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62802,2,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,g209126,2,C. Do a stat EKG,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62803,0,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",g209127,0,A) 56.4 mg,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62803,1,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",g209128,1,B)  50 mg,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62803,2,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",g209129,2,C)  63 mg,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62804,0,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",g209130,0,A) 56.4 mg,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62804,1,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",g209131,1,B) 50 mg,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62804,2,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",g209132,2,C) 37 mg,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62805,0,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",g209133,0,A)  6.3 mg,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62805,1,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",g209134,1,B)  5 mg,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62805,2,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",g209135,2,C) 5.6 mg,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62806,0,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",g209136,0,A) 6.3 mg,0,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62806,1,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",g209137,1,B) 56.7 mg,1,ALTEPLASE EDUCATION FOR RRT
19862,9708,Elearning-0000-920,g13878,g62806,2,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",g209138,2,C) 53.8 mg,0,ALTEPLASE EDUCATION FOR RRT
19861,9709,Elearning-0000-921,g13877,g62789,0,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,g209087,0,TRUE,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62789,1,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,g209088,1,FALSE,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62790,0,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209089,0,A) 10 minutes,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62790,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209090,1,B) 2 minutes,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62790,2,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209091,2,C) 1 minute,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62790,3,Alteplase bolus should be 10% of total calculated dose and should be administered over:,g209092,3,D) 1 hour,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62791,0,"True or False? <br><br> You receive a patient while Alteplase is infusing.<br><br> The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",g209093,0,TRUE,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62791,1,"True or False? <br><br> You receive a patient while Alteplase is infusing.<br><br> The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",g209094,1,FALSE,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62792,0,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br><ul> <li>Every 15 minutes for 2 hours, thenΓÇª</li> <li>Every 30 minutes for 6 hours, thenΓÇª</li> <li>Every hour for __ hours.</li> </ul>",g209095,0,A. 10 hrs,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62792,1,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br><ul> <li>Every 15 minutes for 2 hours, thenΓÇª</li> <li>Every 30 minutes for 6 hours, thenΓÇª</li> <li>Every hour for __ hours.</li> </ul>",g209096,1,B. 24 hrs,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62792,2,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br><ul> <li>Every 15 minutes for 2 hours, thenΓÇª</li> <li>Every 30 minutes for 6 hours, thenΓÇª</li> <li>Every hour for __ hours.</li> </ul>",g209097,2,C. 16 hrs,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62793,0,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,g209098,0,A. Turn off Alteplase infusion,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62793,1,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,g209099,1,B. Give prn Labetalol as per the Alteplase order set,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62793,2,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,g209100,2,C. Do a stat EKG,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62794,0,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",g209101,0,A) 56.4 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62794,1,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",g209102,1,B)  50 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62794,2,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",g209103,2,C)  63 mg,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62795,0,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",g209104,0,A) 56.4 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62795,1,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",g209105,1,B) 50 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62795,2,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",g209106,2,C) 37 mg,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62796,0,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",g209107,0,A)  6.3 mg,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62796,1,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",g209108,1,B)  5 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62796,2,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",g209109,2,C) 5.6 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62797,0,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",g209110,0,A) 6.3 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62797,1,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",g209111,1,B) 56.7 mg,1,ALTEPLASE EDUCATION FOR CRITICAL CARE
19861,9709,Elearning-0000-921,g13877,g62797,2,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg &#247; 1 mg/mL &#247; 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",g209112,2,C) 53.8 mg,0,ALTEPLASE EDUCATION FOR CRITICAL CARE
19860,9627,Elearning-0000-847,g13876,g62788,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Culture of Safety, Accountability and Professionalism"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209085,0,TRUE,1,"FY2021 SURGICAL SERVICES: CULTURE OF SAFETY, ACCOUNTABILITY, AND PROFESSIONALISM"
19860,9627,Elearning-0000-847,g13876,g62788,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Culture of Safety, Accountability and Professionalism"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209086,1,FALSE,0,"FY2021 SURGICAL SERVICES: CULTURE OF SAFETY, ACCOUNTABILITY, AND PROFESSIONALISM"
19859,9693,Elearning-0000-907,g13875,g62783,0,True or False?  KINDER1 falls screening is used for both adult and pediatric patients.,g209069,0,TRUE,1,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62783,1,True or False?  KINDER1 falls screening is used for both adult and pediatric patients.,g209070,1,FALSE,0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62784,0,Which of the following patients are at risk to fall?,g209071,0,"a.	A 30-year-old who came to the ED because of a fall",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62784,1,Which of the following patients are at risk to fall?,g209072,1,"b.	An intoxicated patient",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62784,2,Which of the following patients are at risk to fall?,g209073,2,"c.	A 10-month old infant who cannot walk",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62784,3,Which of the following patients are at risk to fall?,g209074,3,"d.	All of the above",1,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62785,0,True or False?  Patients identified as at risk to fall do not need to have a safety plan documented.,g209075,0,TRUE,0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62785,1,True or False?  Patients identified as at risk to fall do not need to have a safety plan documented.,g209076,1,FALSE,1,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62786,0,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",g209077,0,"a.	Assist the patient to bed, notify the provider, and address immediate medical needs",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62786,1,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",g209078,1,"b.	Complete a new KINDER1 falls screening via Ad Hoc Forms and implement a safety plan",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62786,2,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",g209079,2,"c.	Complete an incident report",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62786,3,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",g209080,3,"d.	All of the above",1,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62787,0,Which falls scale will be used for Admission Holds in the ED?,g209081,0,"a.	KINDER1",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62787,1,Which falls scale will be used for Admission Holds in the ED?,g209082,1,"b.	Morse Fall Scale",1,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62787,2,Which falls scale will be used for Admission Holds in the ED?,g209083,2,"c.	Falls Risk Assessment Tool",0,ED KINDER1 FALLS SCREENING
19859,9693,Elearning-0000-907,g13875,g62787,3,Which falls scale will be used for Admission Holds in the ED?,g209084,3,"d.	None of the above",0,ED KINDER1 FALLS SCREENING
19857,8975,Elearning-0000-254,g13873,g62779,0,What are the benefits of positioning?,g209058,0,a. Promotes improved rest and neurobehavioral organization.,0,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62779,1,What are the benefits of positioning?,g209059,1,b. Guides normal fetal neuromotor and musculoskeletal development.,0,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62779,2,What are the benefits of positioning?,g209060,2,c. Protects skin integrity.,0,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62779,3,What are the benefits of positioning?,g209061,3,d. Assist in thermoregulation.,0,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62779,4,What are the benefits of positioning?,g209062,4,e. All of the above,1,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62780,0,All infants admitted to the NICU under 33 weeks are positioned in a Z-Flo.,g209063,0,TRUE,0,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62780,1,All infants admitted to the NICU under 33 weeks are positioned in a Z-Flo.,g209064,1,FALSE,1,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62781,0,"In all positions, the infant should be in a midline flexed position with containment.",g209065,0,TRUE,1,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62781,1,"In all positions, the infant should be in a midline flexed position with containment.",g209066,1,FALSE,0,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62782,0,"I acknowledge that I have read and understand the information provided in the ""Positioning and Zflo in the NICU"" CBL.",g209067,0,TRUE,1,POSITIONING AND ZFLO IN THE NICU
19857,8975,Elearning-0000-254,g13873,g62782,1,"I acknowledge that I have read and understand the information provided in the ""Positioning and Zflo in the NICU"" CBL.",g209068,1,FALSE,0,POSITIONING AND ZFLO IN THE NICU
19856,242,SCORM-0000-48,g13872,g62358,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the SURGICAL SERVICES: FY2021 END OF CASE SURGICAL DEBRIEF CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207512,0,TRUE,1,FY2021 SURGICAL SERVICES: END OF CASE SURGICAL DEBRIEF
19856,242,SCORM-0000-48,g13872,g62358,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the SURGICAL SERVICES: FY2021 END OF CASE SURGICAL DEBRIEF CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207513,1,FALSE,0,FY2021 SURGICAL SERVICES: END OF CASE SURGICAL DEBRIEF
19855,9602,Elearning-0000-824,g13871,g62775,0,The new ECD changes are only in the maternal chart. The newborn changes will happen at a later date.,g209033,0,TRUE,1,FORSYTH FCC ECD
19855,9602,Elearning-0000-824,g13871,g62775,1,The new ECD changes are only in the maternal chart. The newborn changes will happen at a later date.,g209034,1,FALSE,0,FORSYTH FCC ECD
19855,9602,Elearning-0000-824,g13871,g62776,0,The ECD changes will help streamline charting.,g209035,0,TRUE,1,FORSYTH FCC ECD
19855,9602,Elearning-0000-824,g13871,g62776,1,The ECD changes will help streamline charting.,g209036,1,FALSE,0,FORSYTH FCC ECD
19855,9602,Elearning-0000-824,g13871,g62777,0,I have read and understood the content of this module.,g209037,0,TRUE,1,FORSYTH FCC ECD
19855,9602,Elearning-0000-824,g13871,g62777,1,I have read and understood the content of this module.,g209038,1,FALSE,0,FORSYTH FCC ECD
19852,240,SCORM-0000-46,g13868,g62766,0,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",g209004,0,"a.	Urinary Dysfunction",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62766,1,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",g209005,1,"b.	No new IPOC needed as Knowledge Deficit addresses change in condition, admission diagnosis and discharge planning",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62766,2,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",g209006,2,"c.	Nausea Management and/or Pain Management Acute",1,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62766,3,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",g209007,3,"d.	Change in condition is not important",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62767,0,"A ""High-Risk Comorbidity"" is a condition that, if left untreated during the hospital stay, would be problematic for the patient.",g209008,0,TRUE,1,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62767,1,"A ""High-Risk Comorbidity"" is a condition that, if left untreated during the hospital stay, would be problematic for the patient.",g209009,1,FALSE,0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62768,0,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",g209010,0,"a.	All outcome target dates should be set for the anticipated date of discharge",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62768,1,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",g209011,1,"b.	When setting target dates, nursing should consider the patient condition and expected progress toward discharge so that (s)he can set a reasonable time-frame for each outcome",1,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62768,2,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",g209012,2,"c.	All target dates should be about 24-48 hours from the time they are initiated",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62768,3,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",g209013,3,"d.	The target dates are unimportant and thus all target dates should be set for the same date and time",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62769,0,How often should the IPOC be updated/evaluated?,g209014,0,"a.	Every 4 hours",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62769,1,How often should the IPOC be updated/evaluated?,g209015,1,"b.	At least once per shift",1,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62769,2,How often should the IPOC be updated/evaluated?,g209016,2,"c.	Only when something changes with the patient",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62769,3,How often should the IPOC be updated/evaluated?,g209017,3,"d.	Just before discharge",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62770,0,"What should you do with ""Suggested Plans"" before the end of your shift?",g209018,0,"a.	Nothing, they are just suggestions",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62770,1,"What should you do with ""Suggested Plans"" before the end of your shift?",g209019,1,"b.	""Accept"" plans that are appropriate and ""reject"" plans that are not",1,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62770,2,"What should you do with ""Suggested Plans"" before the end of your shift?",g209020,2,"c.	""Accept"" all suggested plans",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62770,3,"What should you do with ""Suggested Plans"" before the end of your shift?",g209021,3,"d.	Reject all plans as the system is suggesting them unnecessarily",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62771,0,"Each patient should have an <b>individualized</b> plan of care based upon patient history, reason for admission, provider orders, nursing assessment, and Peratrend or other early warning system.",g209022,0,TRUE,1,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62771,1,"Each patient should have an <b>individualized</b> plan of care based upon patient history, reason for admission, provider orders, nursing assessment, and Peratrend or other early warning system.",g209023,1,FALSE,0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62772,0,How can the IPOC be individualized for a particular patient?,g209024,0,"a.	No IPOC can be individualized because they are standardized bundles of care that cannot be altered.",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62772,1,How can the IPOC be individualized for a particular patient?,g209025,1,"b.	By applying target dates to outcomes/goals in consideration of patient needs and condition.",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62772,2,How can the IPOC be individualized for a particular patient?,g209026,2,"c.	By adding built-in components that are not default preselects but are appropriate to patient need and condition.",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62772,3,How can the IPOC be individualized for a particular patient?,g209027,3,"d.	By adding patient specific outcomes or patient specific interventions.",0,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19852,240,SCORM-0000-46,g13868,g62772,4,How can the IPOC be individualized for a particular patient?,g209028,4,"e.	b, c, and d are all ways that an IPOC can be individualized for a particular patient",1,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING
19851,8404,Elearning-0000-1274,g13867,g62765,0,I have reviewed the Revenue Integrity Intro to Pro Fee Cardiology Coding CBL and acknowledge that I am responsible for understanding the content therein.  I also understand that I should stop in the face of uncertainty and ask for clarification.  I know where and how to get my questions answered about this topic.,g209002,0,TRUE,1,REV INT - INTRO TO PRO FEE CARDIOLOGY CODING
19851,8404,Elearning-0000-1274,g13867,g62765,1,I have reviewed the Revenue Integrity Intro to Pro Fee Cardiology Coding CBL and acknowledge that I am responsible for understanding the content therein.  I also understand that I should stop in the face of uncertainty and ask for clarification.  I know where and how to get my questions answered about this topic.,g209003,1,FALSE,0,REV INT - INTRO TO PRO FEE CARDIOLOGY CODING
19848,9625,Elearning-0000-845,g13866,g62764,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""2021 STROKE FOR RT CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209000,0,TRUE,1,2021 STROKE FOR RT CBL
19848,9625,Elearning-0000-845,g13866,g62764,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""2021 STROKE FOR RT CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g209001,1,FALSE,0,2021 STROKE FOR RT CBL
19850,9695,Elearning-0000-909,g13865,g62763,0,What are the 4 indicators we are measuring for COPD DSC?,g208996,0,"1. Smoking cessation, mobility, incentive spirometry, COPD action plan documentation",0,2021 COPD FOR RT CBL
19850,9695,Elearning-0000-909,g13865,g62763,1,What are the 4 indicators we are measuring for COPD DSC?,g208997,1,"2. COPD action plan documentation, CUN7 (follow up visit with PCP/pulmonologist within 7 days), speech therapy consult, RT discharge topic education",1,2021 COPD FOR RT CBL
19850,9695,Elearning-0000-909,g13865,g62763,2,What are the 4 indicators we are measuring for COPD DSC?,g208998,2,"3. RT discharge topic education, pneumonia vaccine, mobility, smoking cessation",0,2021 COPD FOR RT CBL
19850,9695,Elearning-0000-909,g13865,g62763,3,What are the 4 indicators we are measuring for COPD DSC?,g208999,3,"4. Physical therapy consult, mobility, CUN7 (follow up visit with PCP/pulmonologist within 7 days), RT discharge topic education",0,2021 COPD FOR RT CBL
19843,9110,Elearning-0000-377,g13860,g62730,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage,g208871,0,TRUE,1,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62730,1,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage,g208872,1,FALSE,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62731,0,The OB Hemorrhage Cart is secured by:,g208873,0,A zip tie,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62731,1,The OB Hemorrhage Cart is secured by:,g208874,1,2 Digital locks,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62731,2,The OB Hemorrhage Cart is secured by:,g208875,2,Red security seal,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62731,3,The OB Hemorrhage Cart is secured by:,g208876,3,B and C,1,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62731,4,The OB Hemorrhage Cart is secured by:,g208877,4,All of the above,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62732,0,Medications are stored in the OB Hemorrhage Cart,g208878,0,TRUE,1,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62732,1,Medications are stored in the OB Hemorrhage Cart,g208879,1,FALSE,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62733,0,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,g208880,0,Red,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62733,1,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,g208881,1,Yellow,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62733,2,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,g208882,2,Green,1,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62734,0,How frequently should the cart thermometer be checked?,g208883,0,Once a day,0,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62734,1,How frequently should the cart thermometer be checked?,g208884,1,Every shift,1,NSC HEMORRHAGE CART
19843,9110,Elearning-0000-377,g13860,g62734,2,How frequently should the cart thermometer be checked?,g208885,2,Once a week,0,NSC HEMORRHAGE CART
19842,9662,Elearning-0000-879,g13859,g62729,0,What are 4 of the indicators we are measuring?,g208867,0,"1. Oral Care Provided; toothbrush BID, PT consult, Pain Goal met, Nodal Stations and Length of stay.",0,2021 LUNG CANCER DSC FOR RT CBL
19842,9662,Elearning-0000-879,g13859,g62729,1,What are 4 of the indicators we are measuring?,g208868,1,"2. Patient Education, SLP consult, Documentation of Nodal Stations and Length of stay.",0,2021 LUNG CANCER DSC FOR RT CBL
19842,9662,Elearning-0000-879,g13859,g62729,2,What are 4 of the indicators we are measuring?,g208869,2,"3. Ambulation initiation by nursing, Nursing documentation of Incentive Spirometry, Prehab Referrals, and Speech Therapy optimization of safe swallow function.",1,2021 LUNG CANCER DSC FOR RT CBL
19842,9662,Elearning-0000-879,g13859,g62729,3,What are 4 of the indicators we are measuring?,g208870,3,"4. Patients up out of bed on day of surgery, Oral Care Provided; toothbrush BID, OT consult, Length of stay.",0,2021 LUNG CANCER DSC FOR RT CBL
19841,9643,Elearning-0000-861,g13858,g62728,0,What are the 4 indicators we are measuring for Pneumonia DSC?,g208863,0,"1. Nursing documentation of SMI, progressive mobility, antibiotic stewardship, pneumonia vaccination",0,2021 PNEUMONIA DSC FOR RT CBL
19841,9643,Elearning-0000-861,g13858,g62728,1,What are the 4 indicators we are measuring for Pneumonia DSC?,g208864,1,"2. Oral care, progressive mobility, diet reconciliation, oxygen weaning",0,2021 PNEUMONIA DSC FOR RT CBL
19841,9643,Elearning-0000-861,g13858,g62728,2,What are the 4 indicators we are measuring for Pneumonia DSC?,g208865,2,"3. Oxygen weaning, nursing documentation of SMI, progressive mobility, diet reconciliation",1,2021 PNEUMONIA DSC FOR RT CBL
19841,9643,Elearning-0000-861,g13858,g62728,3,What are the 4 indicators we are measuring for Pneumonia DSC?,g208866,3,"4. Hand hygiene, oxygen weaning, oral care, progressive mobility",0,2021 PNEUMONIA DSC FOR RT CBL
19840,9634,Elearning-0000-853,g13857,g62727,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Pulmonary Hypertension for RT CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g208861,0,TRUE,1,2021 PULMONARY HYPERTENSION FOR RT CBL
19840,9634,Elearning-0000-853,g13857,g62727,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Pulmonary Hypertension for RT CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g208862,1,FALSE,0,2021 PULMONARY HYPERTENSION FOR RT CBL
19839,243,SCORM-0000-49,g13856,g62726,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 Surgical Services: Lumbar Drain Management for PACU CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g208859,0,TRUE,1,FY2021 SURGICAL SERVICES: LUMBAR DRAIN MANAGEMENT FOR PACU
19839,243,SCORM-0000-49,g13856,g62726,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 Surgical Services: Lumbar Drain Management for PACU CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g208860,1,FALSE,0,FY2021 SURGICAL SERVICES: LUMBAR DRAIN MANAGEMENT FOR PACU
19833,9909,Questions-0000-43,g13854,g62702,0,Please list the location for this activity.,g208762,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62702,1,Please list the location for this activity.,g208763,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62702,2,Please list the location for this activity.,g208764,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62702,3,Please list the location for this activity.,g208765,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62703,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208766,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62703,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208767,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62703,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208768,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62703,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208769,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62703,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208770,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62704,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208771,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62704,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208772,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62704,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208773,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62704,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208774,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62704,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208775,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62705,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208776,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62705,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208777,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62705,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208778,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62705,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208779,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62705,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208780,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62706,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208781,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62706,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208782,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62706,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208783,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62706,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208784,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62706,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208785,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62707,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g208786,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62707,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g208787,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62707,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g208788,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62707,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g208789,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62707,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g208790,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62708,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g208791,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62708,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g208792,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62708,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g208793,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62708,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g208794,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62708,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g208795,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62709,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g208796,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62709,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g208797,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62709,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g208798,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62709,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g208799,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62709,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g208800,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62710,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g208801,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62710,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g208802,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62710,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g208803,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62710,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g208804,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62710,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g208805,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62711,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208806,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62711,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208807,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62711,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208808,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62711,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208809,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62711,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208810,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62712,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208811,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62712,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208812,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62712,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208813,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62712,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208814,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62712,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208815,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62713,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208816,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62713,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208817,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62713,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208818,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62713,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208819,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62713,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208820,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62714,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208821,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62714,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208822,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62714,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208823,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62714,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208824,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62714,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208825,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62715,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208826,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62715,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208827,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62715,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208828,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62715,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208829,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62715,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208830,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62716,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208831,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62716,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208832,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62716,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208833,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62716,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208834,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62716,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208835,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62717,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208836,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62717,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208837,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62717,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208838,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62717,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208839,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62717,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208840,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62717,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208841,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62718,0,"Overall, this activity was:",g208842,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62718,1,"Overall, this activity was:",g208843,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62718,2,"Overall, this activity was:",g208844,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62718,3,"Overall, this activity was:",g208845,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62718,4,"Overall, this activity was:",g208846,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62719,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208847,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62719,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208848,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62719,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208849,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62722,0,How would you improve this class (check all that apply)?,g208850,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62722,1,How would you improve this class (check all that apply)?,g208851,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62722,2,How would you improve this class (check all that apply)?,g208852,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62722,3,How would you improve this class (check all that apply)?,g208853,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62722,4,How would you improve this class (check all that apply)?,g208854,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62722,5,How would you improve this class (check all that apply)?,g208855,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19833,9909,Questions-0000-43,g13854,g62722,6,How would you improve this class (check all that apply)?,g208856,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21
19834,9915,Questions-0000-49,g13853,g62683,0,Please list the location for this activity.,g208687,0,Atlanta,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62683,1,Please list the location for this activity.,g208688,1,Cherokee,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62683,2,Please list the location for this activity.,g208689,2,Forsyth,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62683,3,Please list the location for this activity.,g208690,3,Other,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62684,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208691,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62684,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208692,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62684,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208693,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62684,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208694,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62684,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208695,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62685,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208696,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62685,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208697,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62685,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208698,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62685,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208699,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62685,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208700,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62686,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208701,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62686,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208702,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62686,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208703,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62686,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208704,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62686,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g208705,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62687,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208706,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62687,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208707,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62687,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208708,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62687,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208709,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62687,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g208710,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62688,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208711,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62688,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208712,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62688,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208713,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62688,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208714,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62688,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208715,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62689,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208716,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62689,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208717,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62689,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208718,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62689,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208719,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62689,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208720,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62690,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208721,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62690,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208722,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62690,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208723,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62690,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208724,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62690,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208725,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62691,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208726,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62691,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208727,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62691,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208728,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62691,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208729,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62691,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208730,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62692,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208731,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62692,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208732,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62692,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208733,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62692,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208734,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62692,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208735,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62693,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g208736,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62693,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g208737,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62693,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g208738,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62693,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g208739,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62693,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g208740,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62694,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208741,4,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62694,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208742,0,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62694,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208743,1,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62694,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208744,2,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62694,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208745,3,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62694,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208746,5,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62695,0,"Overall, this activity was:",g208747,0,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62695,1,"Overall, this activity was:",g208748,1,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62695,2,"Overall, this activity was:",g208749,2,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62695,3,"Overall, this activity was:",g208750,3,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62695,4,"Overall, this activity was:",g208751,4,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62696,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208752,0,Yes,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62696,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208753,1,No,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62696,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208754,2,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62699,0,How would you improve this class (check all that apply)?,g208755,0,Reduce content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62699,1,How would you improve this class (check all that apply)?,g208756,1,Increase content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62699,2,How would you improve this class (check all that apply)?,g208757,2,Update content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62699,3,How would you improve this class (check all that apply)?,g208758,3,Improve the instructional methods,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62699,4,How would you improve this class (check all that apply)?,g208759,4,Make course activities more stimulating,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62699,5,How would you improve this class (check all that apply)?,g208760,5,Slow the pace of the class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19834,9915,Questions-0000-49,g13853,g62699,6,How would you improve this class (check all that apply)?,g208761,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21"
19835,9902,Questions-0000-36,g13852,g62666,0,Please list the location for this activity.,g208622,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62666,1,Please list the location for this activity.,g208623,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62666,2,Please list the location for this activity.,g208624,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62666,3,Please list the location for this activity.,g208625,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62667,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208626,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62667,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208627,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62667,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208628,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62667,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208629,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62667,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208630,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62668,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208631,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62668,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208632,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62668,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208633,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62668,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208634,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62668,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208635,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62669,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208636,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62669,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208637,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62669,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208638,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62669,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208639,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62669,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208640,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62670,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208641,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62670,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208642,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62670,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208643,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62670,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208644,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62670,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208645,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62671,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208646,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62671,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208647,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62671,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208648,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62671,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208649,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62671,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208650,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62672,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208651,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62672,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208652,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62672,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208653,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62672,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208654,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62672,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208655,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62673,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208656,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62673,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208657,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62673,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208658,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62673,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208659,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62673,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208660,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62674,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208661,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62674,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208662,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62674,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208663,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62674,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208664,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62674,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208665,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62675,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208666,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62675,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208667,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62675,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208668,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62675,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208669,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62675,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208670,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62675,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",g208671,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62676,0,"Overall, this activity was:",g208672,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62676,1,"Overall, this activity was:",g208673,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62676,2,"Overall, this activity was:",g208674,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62676,3,"Overall, this activity was:",g208675,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62676,4,"Overall, this activity was:",g208676,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62677,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208677,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62677,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208678,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62677,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208679,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62680,0,How would you improve this class (check all that apply)?,g208680,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62680,1,How would you improve this class (check all that apply)?,g208681,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62680,2,How would you improve this class (check all that apply)?,g208682,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62680,3,How would you improve this class (check all that apply)?,g208683,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62680,4,How would you improve this class (check all that apply)?,g208684,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62680,5,How would you improve this class (check all that apply)?,g208685,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19835,9902,Questions-0000-36,g13852,g62680,6,How would you improve this class (check all that apply)?,g208686,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21
19830,9575,Elearning-0000-80,g13850,g62653,0,"1.	If a code purple is announced you shouldΓÇª",g208579,0,"a.	Remain at nurses station",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62653,1,"1.	If a code purple is announced you shouldΓÇª",g208580,1,"b.	Answer call lights and phones",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62653,2,"1.	If a code purple is announced you shouldΓÇª",g208581,2,"c.	Direct traffic",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62653,3,"1.	If a code purple is announced you shouldΓÇª",g208582,3,"d.	All the above",1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62654,0,"2.	If you should happen to see a patient matching the description called over the intercom and/or wearing a purple armband is observed call security and keep patient in sight",g208583,0,TRUE,1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62654,1,"2.	If you should happen to see a patient matching the description called over the intercom and/or wearing a purple armband is observed call security and keep patient in sight",g208584,1,FALSE,0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62655,0,"3.	If a Bomb threat (code orange) is called in via the phone you shouldΓÇª",g208585,0,"a.	Attempt to keep caller talking and try to get as much as information as possible",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62655,1,"3.	If a Bomb threat (code orange) is called in via the phone you shouldΓÇª",g208586,1,"b.	Complete bomb threat checklist located in Lucidoc",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62655,2,"3.	If a Bomb threat (code orange) is called in via the phone you shouldΓÇª",g208587,2,"c.	Alert nearby employee and have them contact security",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62655,3,"3.	If a Bomb threat (code orange) is called in via the phone you shouldΓÇª",g208588,3,"d.	All the above",1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62656,0,"4.	If a Bomb threat (code orange) is a written message you should, handle the message as little as possible, notify security and place message in a clean plastic bag",g208589,0,TRUE,1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62656,1,"4.	If a Bomb threat (code orange) is a written message you should, handle the message as little as possible, notify security and place message in a clean plastic bag",g208590,1,FALSE,0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62657,0,"5.	If a code Brown is activated you can expect toΓÇª",g208591,0,"a.	Evacuate horizontally from one smoke compartment to another and place the patient's medical records in a pillow case to move with the patient",1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62657,1,"5.	If a code Brown is activated you can expect toΓÇª",g208592,1,"b.	To find a person wandering the halls",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62657,2,"5.	If a code Brown is activated you can expect toΓÇª",g208593,2,"c.	Get under the desk",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62657,3,"5.	If a code Brown is activated you can expect toΓÇª",g208594,3,"d.	Scream for help",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62658,0,"6.	For a code Grey, you would do all EXCEPTΓÇª",g208595,0,"a.	Remain at nurses station",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62658,1,"6.	For a code Grey, you would do all EXCEPTΓÇª",g208596,1,"b.	Answer call lights and phones",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62658,2,"6.	For a code Grey, you would do all EXCEPTΓÇª",g208597,2,"c.	Direct traffic",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62658,3,"6.	For a code Grey, you would do all EXCEPTΓÇª",g208598,3,"d.	Take shelter under desks",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62658,4,"6.	For a code Grey, you would do all EXCEPTΓÇª",g208599,4,"e.	Scream for help",1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62659,0,"7.	If you notice discolored water or low water pressure (code dry) you should notifyΓÇª",g208600,0,"a.	Biomed",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62659,1,"7.	If you notice discolored water or low water pressure (code dry) you should notifyΓÇª",g208601,1,"b.	Engineering",1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62659,2,"7.	If you notice discolored water or low water pressure (code dry) you should notifyΓÇª",g208602,2,"c.	MD",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62659,3,"7.	If you notice discolored water or low water pressure (code dry) you should notifyΓÇª",g208603,3,"d.	No one",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62660,0,"8.	It is important to obtain the name and number of a caller reporting a victim contaminated with hazardous material (code yellow) before transferring the caller to the ED in case of disconnection",g208604,0,TRUE,1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62660,1,"8.	It is important to obtain the name and number of a caller reporting a victim contaminated with hazardous material (code yellow) before transferring the caller to the ED in case of disconnection",g208605,1,FALSE,0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62661,0,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",g208606,0,"a.	Call 8911",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62661,1,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",g208607,1,"b.	Remain at nurses station",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62661,2,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",g208608,2,"c.	Answer call lights and phones",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62661,3,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",g208609,3,"d.	Make calls as directed by RN and/or charge nurse, call MD as directed",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62661,4,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",g208610,4,"e.	All the above",1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62662,0,"10.	During a code pink, stop any visitor or employee that passes through with any item large enough to fit an infant in. Say ""we have an infant alert and I notice you have an object that could conceal an infant, I apologize for the delay but would you mind opening the (item) so that we can clear you to leave the hospital?"" If no infant seen thank them, apologize for any delay and ask them to wait for security to avoid being stopped again. If they refuse to let you look in object notify security immediately. Alert other employees to help you. A staff member may follow them at a safe distance. Do not attempt to detain them",g208611,0,TRUE,1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62662,1,"10.	During a code pink, stop any visitor or employee that passes through with any item large enough to fit an infant in. Say ""we have an infant alert and I notice you have an object that could conceal an infant, I apologize for the delay but would you mind opening the (item) so that we can clear you to leave the hospital?"" If no infant seen thank them, apologize for any delay and ask them to wait for security to avoid being stopped again. If they refuse to let you look in object notify security immediately. Alert other employees to help you. A staff member may follow them at a safe distance. Do not attempt to detain them",g208612,1,FALSE,0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62663,0,"11.	If there is an active shooter (code silver) in the hospital you shouldΓÇª",g208613,0,"a.	Try to remain calm",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62663,1,"11.	If there is an active shooter (code silver) in the hospital you shouldΓÇª",g208614,1,"b.	Try not to provoke the threat",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62663,2,"11.	If there is an active shooter (code silver) in the hospital you shouldΓÇª",g208615,2,"c.	Shelter in place by barricading a room, turn off lights, close blinds, and silence cell phones",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62663,3,"11.	If there is an active shooter (code silver) in the hospital you shouldΓÇª",g208616,3,"d.	You should only make the personal choice to attempt to negotiate with or overpower the shooter if it is a last resort and there is no possibility of escape",0,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62663,4,"11.	If there is an active shooter (code silver) in the hospital you shouldΓÇª",g208617,4,"e.	All the above",1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62664,0,"12.	You should remain at the nurses station, answer call lights and phones, and direction traffic during a code red",g208618,0,TRUE,1,WSU EMERGENCY CODES _UCS
19830,9575,Elearning-0000-80,g13850,g62664,1,"12.	You should remain at the nurses station, answer call lights and phones, and direction traffic during a code red",g208619,1,FALSE,0,WSU EMERGENCY CODES _UCS
19828,8360,Elearning-0000-1234,g13848,g62645,0,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",g208556,0,"every 15 minutes x 4, every 30 minutes x 4, then every hour x 4",0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62645,1,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",g208557,1,"every 5 minutes x 4, every 15 minutes x 4, then every hour x 4",0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62645,2,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",g208558,2,"every 15 minutes x 4, every 30 minutes x 2, then every hour x 4",1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62645,3,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",g208559,3,Vital signs are done in Cath lab.,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62646,0,"After a cardiac catheter is completed the nurse should assess for pain, pallor, pulse, paresthesia, and paralysis.",g208560,0,TRUE,1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62646,1,"After a cardiac catheter is completed the nurse should assess for pain, pallor, pulse, paresthesia, and paralysis.",g208561,1,FALSE,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62647,0,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,g208562,0,Patient Assessment,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62647,1,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,g208563,1,Adult Systems Assessment,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62647,2,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,g208564,2,Cardiovascular Post-Procedure Monitoring,1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62647,3,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,g208565,3,Adult Education,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62648,0,Patients post-cardiac catheter should position head of bed at 40 degrees.,g208566,0,TRUE,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62648,1,Patients post-cardiac catheter should position head of bed at 40 degrees.,g208567,1,FALSE,1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62649,0,Complications associated with Femoral Access post catheter procedure include all except:,g208568,0,"Neural damage, Death",0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62649,1,Complications associated with Femoral Access post catheter procedure include all except:,g208569,1,"Thrombosis, Free bleeding",0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62649,2,Complications associated with Femoral Access post catheter procedure include all except:,g208570,2,"Hematoma, Venous thrombosis",0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62649,3,Complications associated with Femoral Access post catheter procedure include all except:,g208571,3,"itching to skin, hypothermia",1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62650,0,If complications occur after a cardiac catheter it is best to call rapid response team.,g208572,0,TRUE,1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62650,1,If complications occur after a cardiac catheter it is best to call rapid response team.,g208573,1,FALSE,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62651,0,Complications that can occur after a radial post catheter procedure can include:,g208574,0,itching,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62651,1,Complications that can occur after a radial post catheter procedure can include:,g208575,1,Bleeding and spasms,1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62651,2,Complications that can occur after a radial post catheter procedure can include:,g208576,2,Retroperitoneal hemorrage,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62652,0,"I understand my responsibilities as a nurse to monitor a cardiac catheter patient as instructed in this training, that charting will be in real time and completed with all details under the Cardiovascular Post-Procedure Monitoring tab in Cerner. I also understand the complications that can occur for both a",g208577,0,TRUE,1,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19828,8360,Elearning-0000-1234,g13848,g62652,1,"I understand my responsibilities as a nurse to monitor a cardiac catheter patient as instructed in this training, that charting will be in real time and completed with all details under the Cardiovascular Post-Procedure Monitoring tab in Cerner. I also understand the complications that can occur for both a",g208578,1,FALSE,0,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT
19770,9901,Questions-0000-35,g13847,g62628,0,Please list the location for this activity.,g208491,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62628,1,Please list the location for this activity.,g208492,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62628,2,Please list the location for this activity.,g208493,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62628,3,Please list the location for this activity.,g208494,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62629,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208495,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62629,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208496,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62629,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208497,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62629,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208498,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62629,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g208499,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62630,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208500,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62630,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208501,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62630,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208502,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62630,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208503,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62630,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g208504,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62631,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208505,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62631,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208506,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62631,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208507,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62631,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208508,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62631,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208509,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62632,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208510,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62632,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208511,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62632,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208512,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62632,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208513,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62632,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208514,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62633,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208515,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62633,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208516,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62633,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208517,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62633,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208518,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62633,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g208519,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62634,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208520,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62634,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208521,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62634,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208522,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62634,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208523,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62634,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g208524,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62635,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208525,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62635,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208526,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62635,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208527,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62635,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208528,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g208529,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62636,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208530,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62636,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208531,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62636,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208532,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62636,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208533,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62636,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208534,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62637,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g208535,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62637,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g208536,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62637,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g208537,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62637,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g208538,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62637,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g208539,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62637,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g208540,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62638,0,"Overall, this activity was:",g208541,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62638,1,"Overall, this activity was:",g208542,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62638,2,"Overall, this activity was:",g208543,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62638,3,"Overall, this activity was:",g208544,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62638,4,"Overall, this activity was:",g208545,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62639,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208546,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62639,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208547,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62639,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208548,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62642,0,How would you improve this class (check all that apply)?,g208549,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62642,1,How would you improve this class (check all that apply)?,g208550,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62642,2,How would you improve this class (check all that apply)?,g208551,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62642,3,How would you improve this class (check all that apply)?,g208552,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62642,4,How would you improve this class (check all that apply)?,g208553,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62642,5,How would you improve this class (check all that apply)?,g208554,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19770,9901,Questions-0000-35,g13847,g62642,6,How would you improve this class (check all that apply)?,g208555,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21
19827,9210,Elearning-0000-468,g13846,g62622,0,Multiple patient deaths and injuries have occurred due to lack of line reconciliation being done.,g208474,0,TRUE,1,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62622,1,Multiple patient deaths and injuries have occurred due to lack of line reconciliation being done.,g208475,1,FALSE,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62623,0,The following lines should be reconciled at the change of shift:,g208476,0,Tube feedings,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62623,1,The following lines should be reconciled at the change of shift:,g208477,1,Urinary Catheters,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62623,2,The following lines should be reconciled at the change of shift:,g208478,2,JP drains,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62623,3,The following lines should be reconciled at the change of shift:,g208479,3,All the above,1,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62624,0,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,g208480,0,Ask the last shift nurse to label it.,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62624,1,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,g208481,1,Discard the entire IV set-up.,1,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62624,2,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,g208482,2,Assume it was from the admission date.,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62624,3,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,g208483,3,Nothing,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62625,0,Line Reconciliation process should be done the following times:,g208484,0,"Hand-off communication, patient returns from procedure",1,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62625,1,Line Reconciliation process should be done the following times:,g208485,1,"Prior to initiating any new infusion, before patient returns from procedure",0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62625,2,Line Reconciliation process should be done the following times:,g208486,2,"When assuming care of a patient, within one hour of transferring to the unit.",0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62626,0,Line reconciliation should be documented in cerner only one time a shift.,g208487,0,TRUE,0,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62626,1,Line reconciliation should be documented in cerner only one time a shift.,g208488,1,FALSE,1,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62627,0,Patients with suction hook-up in room should have line reconciliation done.,g208489,0,TRUE,1,FY2021 LINE RECONCILIATION
19827,9210,Elearning-0000-468,g13846,g62627,1,Patients with suction hook-up in room should have line reconciliation done.,g208490,1,FALSE,0,FY2021 LINE RECONCILIATION
19795,9869,Questions-0000-159,g13844,g62590,0,Please list the location for this activity.,g208338,0,Atlanta,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62590,1,Please list the location for this activity.,g208339,1,Forsyth,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62590,2,Please list the location for this activity.,g208340,2,Cherokee,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62590,3,Please list the location for this activity.,g208341,3,Other,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62591,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",g208342,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62591,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",g208343,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62591,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",g208344,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62591,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",g208345,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62591,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",g208346,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62592,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",g208347,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62592,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",g208348,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62592,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",g208349,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62592,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",g208350,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62592,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",g208351,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62593,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",g208352,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62593,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",g208353,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62593,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",g208354,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62593,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",g208355,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62593,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",g208356,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62594,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",g208357,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62594,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",g208358,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62594,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",g208359,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62594,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",g208360,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62594,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",g208361,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62595,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",g208362,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62595,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",g208363,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62595,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",g208364,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62595,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",g208365,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62595,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",g208366,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62596,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",g208367,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62596,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",g208368,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62596,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",g208369,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62596,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",g208370,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62596,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",g208371,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62597,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",g208372,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62597,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",g208373,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62597,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",g208374,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62597,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",g208375,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62597,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",g208376,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62598,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",g208377,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62598,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",g208378,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62598,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",g208379,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62598,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",g208380,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62598,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",g208381,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62599,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",g208382,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62599,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",g208383,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62599,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",g208384,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62599,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",g208385,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62599,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",g208386,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62600,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",g208387,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62600,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",g208388,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62600,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",g208389,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62600,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",g208390,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62600,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",g208391,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62601,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",g208392,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62601,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",g208393,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62601,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",g208394,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62601,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",g208395,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62601,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",g208396,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62602,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",g208397,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62602,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",g208398,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62602,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",g208399,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62602,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",g208400,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62602,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",g208401,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62603,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",g208402,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62603,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",g208403,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62603,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",g208404,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62603,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",g208405,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62603,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",g208406,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62604,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",g208407,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62604,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",g208408,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62604,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",g208409,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62604,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",g208410,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62604,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",g208411,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62605,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208412,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62605,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208413,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62605,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208414,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62605,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208415,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62605,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208416,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62606,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,g208417,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62606,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,g208418,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62606,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,g208419,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62606,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,g208420,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62606,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,g208421,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62607,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208422,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62607,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208423,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62607,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208424,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62607,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208425,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62607,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208426,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62608,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g208427,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62608,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g208428,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62608,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g208429,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62608,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g208430,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62608,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g208431,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62609,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208432,0,Strongly Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62609,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208433,1,Agree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62609,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208434,2,No Opinion,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62609,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208435,3,Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62609,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g208436,4,Strongly Disagree,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62610,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,g208437,0,Excellent,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62610,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,g208438,1,Very Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62610,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,g208439,2,Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62610,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,g208440,3,Fair,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62610,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,g208441,4,Poor,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62611,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,g208442,0,Excellent,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62611,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,g208443,1,Very Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62611,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,g208444,2,Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62611,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,g208445,3,Fair,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62611,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,g208446,4,Poor,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62612,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,g208447,0,Excellent,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62612,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,g208448,1,Very Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62612,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,g208449,2,Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62612,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,g208450,3,Fair,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62612,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,g208451,4,Poor,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62613,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,g208452,0,Excellent,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62613,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,g208453,1,Very Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62613,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,g208454,2,Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62613,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,g208455,3,Fair,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62613,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,g208456,4,Poor,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62614,0,"Overall, this activity was:",g208457,0,Excellent,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62614,1,"Overall, this activity was:",g208458,1,Very Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62614,2,"Overall, this activity was:",g208459,2,Good,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62614,3,"Overall, this activity was:",g208460,3,Fair,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62614,4,"Overall, this activity was:",g208461,4,Poor,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62615,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208462,0,Yes,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62615,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208463,1,No,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62615,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208464,2,N/A,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62618,0,How would you improve this class?,g208465,0,Reduce content covered in class,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62618,1,How would you improve this class?,g208466,1,Increase content covered in class,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62618,2,How would you improve this class?,g208467,2,Update content covered in class,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62618,3,How would you improve this class?,g208468,3,Improve the instructional methods,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62618,4,How would you improve this class?,g208469,4,Make course activities more stimulating,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62618,5,How would you improve this class?,g208470,5,Slow the pace of the class,0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19795,9869,Questions-0000-159,g13844,g62618,6,How would you improve this class?,g208471,6,"No Suggestions for improvement ( right content, speakers, location, etc.)",0,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21
19794,9481,Elearning-0000-714,g13813,g62584,0,I acknowledge that I have read and understood the FY2021 Interdisciplinary Plan of Care for Dialysis Patients: Nursing CBL in its entirety.,g208320,0,TRUE,1,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62584,1,I acknowledge that I have read and understood the FY2021 Interdisciplinary Plan of Care for Dialysis Patients: Nursing CBL in its entirety.,g208321,1,FALSE,0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62585,0,What is the purpose of a persistent note (yellow highlighted text) in the IPOC?,g208322,0,"a.	Persistent notes have no real purpose. You can choose to use them if you want.",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62585,1,What is the purpose of a persistent note (yellow highlighted text) in the IPOC?,g208323,1,"b.	Persistent notes provide important information such as guidance in selecting appropriate goals/outcomes and interventions based on a patient's individual needs and condition",1,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62585,2,What is the purpose of a persistent note (yellow highlighted text) in the IPOC?,g208324,2,"c.	Persistent notes are reminders on issues to follow up with the MD",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62586,0,Where do you find the reference document with the list of applicable IPOCS,g208325,0,"a.	OneChart Central: Job Aids: Clinical Care tab and Women's Health tab",1,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62586,1,Where do you find the reference document with the list of applicable IPOCS,g208326,1,"b.	Pdrive: IPOCs",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62586,2,Where do you find the reference document with the list of applicable IPOCS,g208327,2,"c.	Under Orders in OneChart",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62587,0,You can add Patient Specific Goals and Patient Specific Interventions to any IPOC if the built in elements do not meet the patient's needs.,g208328,0,TRUE,1,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62587,1,You can add Patient Specific Goals and Patient Specific Interventions to any IPOC if the built in elements do not meet the patient's needs.,g208329,1,FALSE,0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62588,0,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,g208330,0,"a.	Fluid Volume Excess Prevention and Management",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62588,1,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,g208331,1,"b.	Nutritional Deficit",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62588,2,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,g208332,2,"c.	Fluid Volume Deficit",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62588,3,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,g208333,3,"d.	Infection Prevention and Management: CLABSI phase",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62588,4,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,g208334,4,"e.	Any of the above may be appropriate according to patient condition and need",1,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62589,0,"What should you do with ""Suggested Plans"" before the end of your shift?",g208335,0,"a.	Nothing, they are just suggestions",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62589,1,"What should you do with ""Suggested Plans"" before the end of your shift?",g208336,1,"b.	""Accept/Initiate"" plans that are appropriate and ""reject"" plans that are not appropriate, based on patient condition and need",1,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19794,9481,Elearning-0000-714,g13813,g62589,2,"What should you do with ""Suggested Plans"" before the end of your shift?",g208337,2,"c.	""Accept"" all plans",0,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING
19791,9493,Elearning-0000-725,g13810,g62534,0,Patients must be:,g208114,0,"a)	Eligible for high dose chemotherapy and autologous stem cell transplant.",0,C-459 BMT CTN 1903
19791,9493,Elearning-0000-725,g13810,g62534,1,Patients must be:,g208115,1,"b)	HIV+ but with the viral load below the limit of detection by standard commercial assay.",0,C-459 BMT CTN 1903
19791,9493,Elearning-0000-725,g13810,g62534,2,Patients must be:,g208116,2,"c)	Diagnosed with relapsed/refractory DLBCL having received 2-3 prior regimens.",0,C-459 BMT CTN 1903
19791,9493,Elearning-0000-725,g13810,g62534,3,Patients must be:,g208117,3,"d)	All of the above",1,C-459 BMT CTN 1903
19791,9493,Elearning-0000-725,g13810,g62535,0,Patients will receive the HST-NEETs on Day +1 (the day after autologous stem cell transplant).,g208118,0,TRUE,0,C-459 BMT CTN 1903
19791,9493,Elearning-0000-725,g13810,g62535,1,Patients will receive the HST-NEETs on Day +1 (the day after autologous stem cell transplant).,g208119,1,FALSE,1,C-459 BMT CTN 1903
19791,9493,Elearning-0000-725,g13810,g62536,0,A universal donor will be used for HST-NEET manufacturing that will occur 1 week prior to autologous stem cell transplant.,g208120,0,TRUE,0,C-459 BMT CTN 1903
19791,9493,Elearning-0000-725,g13810,g62536,1,A universal donor will be used for HST-NEET manufacturing that will occur 1 week prior to autologous stem cell transplant.,g208121,1,FALSE,1,C-459 BMT CTN 1903
19789,8983,Elearning-0000-261,g13808,g62522,0,"1.	Post-Intensive Care Syndrome is a constellation of new or worsening impairments in cognition, physical ability and/or psychological well-being for individuals who have survived critical illness requiring intensive care. a.	TRUE  b.	FALSE",g208074,0,TRUE,1,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62522,1,"1.	Post-Intensive Care Syndrome is a constellation of new or worsening impairments in cognition, physical ability and/or psychological well-being for individuals who have survived critical illness requiring intensive care. a.	TRUE  b.	FALSE",g208075,1,FALSE,0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62523,0,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",g208076,0,"a.	Cancer",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62523,1,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",g208077,1,"b.	Stroke",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62523,2,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",g208078,2,"c.	Sepsis",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62523,3,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",g208079,3,"d.	Respiratory Distress/ARDS",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62523,4,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",g208080,4,"e.	COVID-19",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62523,5,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",g208081,5,"f.	All of the above",1,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62524,0,"3.	Patients who develop PICS can have cognitive impairment, physical impairments, and psychiatric illness that can last for years after their hospitalization. a.	TRUE  b.	FALSE",g208082,0,TRUE,1,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62524,1,"3.	Patients who develop PICS can have cognitive impairment, physical impairments, and psychiatric illness that can last for years after their hospitalization. a.	TRUE  b.	FALSE",g208083,1,FALSE,0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62525,0,"4.	When a Speech Pathologist evaluates a PICS patient, they only need to address dysphagia, and not cognition and/or dysphonia. a.	TRUE b.	FALSE",g208084,0,TRUE,0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62525,1,"4.	When a Speech Pathologist evaluates a PICS patient, they only need to address dysphagia, and not cognition and/or dysphonia. a.	TRUE b.	FALSE",g208085,1,FALSE,1,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62526,0,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",g208086,0,"a.	Pain",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62526,1,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",g208087,1,"b.	Respiratory, Core, and Limb Muscle Strength",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62526,2,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",g208088,2,"c.	Activity Limitations",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62526,3,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",g208089,3,"d.	None of the above",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62526,4,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",g208090,4,"e.	A,B, and C",1,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62527,0,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",g208091,0,"a.	at all Out-Patient locations",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62527,1,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",g208092,1,"b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62527,2,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",g208093,2,"c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated",0,PICS FOR ACUTE CARE REHAB
19789,8983,Elearning-0000-261,g13808,g62527,3,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",g208094,3,"d.	all of the above",1,PICS FOR ACUTE CARE REHAB
19787,95,SCORM-0000-177,g13807,g62521,0,I have read and understood the content within the SuccessFactors System Training 2021 CBL.,g208069,0,TRUE,1,SUCCESSFACTORS SYSTEM TRAINING 2021
19787,95,SCORM-0000-177,g13807,g62521,1,I have read and understood the content within the SuccessFactors System Training 2021 CBL.,g208070,1,FALSE,0,SUCCESSFACTORS SYSTEM TRAINING 2021
19785,9806,Questions-0000-101,g13805,g62499,0,Please list the location for this activity.,g207983,0,Atlanta,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62499,1,Please list the location for this activity.,g207984,1,Cherokee,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62499,2,Please list the location for this activity.,g207985,2,Forsyth,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62499,3,Please list the location for this activity.,g207986,3,Other,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62500,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g207987,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62500,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g207988,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62500,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g207989,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62500,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g207990,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62500,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",g207991,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62501,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g207992,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62501,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g207993,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62501,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g207994,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62501,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g207995,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62501,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy"" and identify specific mechanisms of action for commonly prescribed drugs.</ol>",g207996,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62502,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g207997,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62502,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g207998,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62502,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g207999,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62502,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g208000,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62502,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",g208001,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62503,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g208002,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62503,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g208003,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62503,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g208004,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62503,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g208005,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62503,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",g208006,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62504,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g208007,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62504,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g208008,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62504,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g208009,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62504,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g208010,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62504,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",g208011,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62505,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g208012,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62505,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g208013,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62505,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g208014,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62505,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g208015,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62505,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",g208016,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62506,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208017,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62506,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208018,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62506,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208019,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62506,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208020,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62506,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g208021,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62507,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208022,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62507,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208023,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62507,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208024,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62507,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208025,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62507,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208026,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62508,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208027,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62508,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208028,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62508,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208029,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62508,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208030,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62508,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g208031,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62509,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208032,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62509,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208033,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62509,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208034,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62509,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208035,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62509,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,g208036,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62510,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g208037,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62510,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g208038,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62510,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g208039,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62510,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g208040,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62510,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g208041,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62511,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208042,0,Strongly Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62511,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208043,1,Agree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62511,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208044,2,No Opinion,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62511,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208045,3,Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62511,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g208046,4,Strongly Disagree,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62512,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g208047,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62512,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g208048,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62512,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g208049,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62512,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g208050,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62512,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",g208051,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62513,0,"Overall, this activity was:",g208052,0,Excellent,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62513,1,"Overall, this activity was:",g208053,1,Very Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62513,2,"Overall, this activity was:",g208054,2,Good,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62513,3,"Overall, this activity was:",g208055,3,Fair,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62513,4,"Overall, this activity was:",g208056,4,Poor,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62514,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208057,0,Yes,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62514,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208058,1,No,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62514,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g208059,2,N/A,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62517,0,How would you improve this class?,g208060,0,Reduce content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62517,1,How would you improve this class?,g208061,1,Increase content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62517,2,How would you improve this class?,g208062,2,Update content covered in class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62517,3,How would you improve this class?,g208063,3,Improve the instructional methods,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62517,4,How would you improve this class?,g208064,4,Make course activities more stimulating,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62517,5,How would you improve this class?,g208065,5,Slow the pace of the class,0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19785,9806,Questions-0000-101,g13805,g62517,6,How would you improve this class?,g208066,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21
19783,9940,Questions-0000-74,g13803,g62475,0,Please list the location for this activity.,g207895,0,Atlanta,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62475,1,Please list the location for this activity.,g207896,1,Cherokee,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62475,2,Please list the location for this activity.,g207897,2,Forsyth,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62475,3,Please list the location for this activity.,g207898,3,Other,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62476,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g207899,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62476,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g207900,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62476,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g207901,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62476,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g207902,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62476,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",g207903,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62477,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g207904,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62477,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g207905,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62477,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g207906,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62477,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g207907,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62477,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",g207908,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62478,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g207909,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62478,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g207910,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62478,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g207911,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62478,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g207912,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62478,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",g207913,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62479,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207914,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62479,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207915,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62479,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207916,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62479,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207917,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62479,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207918,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62480,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g207919,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62480,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g207920,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62480,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g207921,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62480,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g207922,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62480,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,g207923,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62481,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g207924,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62481,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g207925,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62481,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g207926,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62481,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g207927,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62481,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",g207928,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62482,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207929,0,Strongly Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62482,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207930,1,Agree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62482,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207931,2,No Opinion,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62482,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207932,3,Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62482,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207933,4,Strongly Disagree,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62483,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g207934,0,Excellent,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62483,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g207935,1,Very Good,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62483,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g207936,2,Good,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62483,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g207937,3,Fair,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62483,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g207938,4,Poor,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62483,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",g207939,5,N/A,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62484,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g207940,0,Excellent,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62484,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g207941,1,Very Good,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62484,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g207942,2,Good,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62484,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g207943,3,Fair,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62484,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g207944,4,Poor,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62484,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",g207945,5,N/A,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62485,0,"Overall, this activity was:",g207946,0,Excellent,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62485,1,"Overall, this activity was:",g207947,1,Very Good,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62485,2,"Overall, this activity was:",g207948,2,Good,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62485,3,"Overall, this activity was:",g207949,3,Fair,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62485,4,"Overall, this activity was:",g207950,4,Poor,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62486,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207951,0,Yes,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62486,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207952,1,No,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62486,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207953,2,N/A,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62489,0,How would you improve this class (check all that apply)?,g207954,0,Reduce content covered in class,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62489,1,How would you improve this class (check all that apply)?,g207955,1,Increase content covered in class,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62489,2,How would you improve this class (check all that apply)?,g207956,2,Update content covered in class,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62489,3,How would you improve this class (check all that apply)?,g207957,3,Improve the instructional methods,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62489,4,How would you improve this class (check all that apply)?,g207958,4,Make course activities more stimulating,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62489,5,How would you improve this class (check all that apply)?,g207959,5,Slow the pace of the class,0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19783,9940,Questions-0000-74,g13803,g62489,6,How would you improve this class (check all that apply)?,g207960,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,MIND THE GAP (EVALUATION SURVEY) 6-8-21
19777,8907,Elearning-0000-192,g13799,g62467,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g207877,0,TRUE,1,TIPS FOR HIGH QUALITY HAND-OFFS
19777,8907,Elearning-0000-192,g13799,g62467,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g207878,1,FALSE,0,TIPS FOR HIGH QUALITY HAND-OFFS
19775,9660,Elearning-0000-877,g13797,g62465,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207873,0,TRUE,1,FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS
19775,9660,Elearning-0000-877,g13797,g62465,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207874,1,FALSE,0,FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS
19772,9914,Questions-0000-48,g13795,g62445,0,Please list the location for this activity.,g207796,0,Atlanta,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62445,1,Please list the location for this activity.,g207797,1,Cherokee,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62445,2,Please list the location for this activity.,g207798,2,Forsyth,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62445,3,Please list the location for this activity.,g207799,3,Other,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62446,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207800,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62446,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207801,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62446,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207802,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62446,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207803,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62446,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207804,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62447,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207805,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62447,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207806,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62447,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207807,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62447,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207808,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62447,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207809,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62448,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207810,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62448,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207811,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62448,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207812,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62448,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207813,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62448,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207814,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62449,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207815,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62449,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207816,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62449,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207817,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62449,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207818,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62449,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207819,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62450,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207820,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62450,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207821,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62450,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207822,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62450,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207823,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62450,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207824,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62451,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207825,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62451,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207826,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62451,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207827,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62451,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207828,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62451,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207829,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62452,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207830,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62452,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207831,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62452,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207832,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62452,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207833,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62452,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207834,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62453,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207835,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62453,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207836,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62453,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207837,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62453,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207838,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62453,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207839,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62454,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207840,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62454,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207841,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62454,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207842,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62454,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207843,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62454,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207844,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62455,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g207845,0,Strongly Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62455,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g207846,1,Agree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62455,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g207847,2,No Opinion,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62455,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g207848,3,Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62455,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g207849,4,Strongly Disagree,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62456,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207850,4,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62456,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207851,0,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62456,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207852,1,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62456,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207853,2,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62456,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207854,3,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62456,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207855,5,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62457,0,"Overall, this activity was:",g207856,0,Excellent,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62457,1,"Overall, this activity was:",g207857,1,Very Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62457,2,"Overall, this activity was:",g207858,2,Good,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62457,3,"Overall, this activity was:",g207859,3,Fair,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62457,4,"Overall, this activity was:",g207860,4,Poor,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62458,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207861,0,Yes,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62458,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207862,1,No,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62458,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207863,2,N/A,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62461,0,How would you improve this class (check all that apply)?,g207864,0,Reduce content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62461,1,How would you improve this class (check all that apply)?,g207865,1,Increase content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62461,2,How would you improve this class (check all that apply)?,g207866,2,Update content covered in class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62461,3,How would you improve this class (check all that apply)?,g207867,3,Improve the instructional methods,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62461,4,How would you improve this class (check all that apply)?,g207868,4,Make course activities more stimulating,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62461,5,How would you improve this class (check all that apply)?,g207869,5,Slow the pace of the class,0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19772,9914,Questions-0000-48,g13795,g62461,6,How would you improve this class (check all that apply)?,g207870,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21"
19773,9908,Questions-0000-42,g13793,g62405,0,Please list the location for this activity.,g207636,0,Atlanta,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62405,1,Please list the location for this activity.,g207637,1,Cherokee,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62405,2,Please list the location for this activity.,g207638,2,Forsyth,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62405,3,Please list the location for this activity.,g207639,3,Other,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62406,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207640,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62406,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207641,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62406,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207642,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62406,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207643,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62406,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",g207644,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62407,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207645,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62407,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207646,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62407,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207647,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62407,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207648,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62407,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",g207649,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62408,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207650,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62408,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207651,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62408,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207652,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62408,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207653,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62408,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",g207654,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62409,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207655,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62409,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207656,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62409,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207657,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62409,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207658,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62409,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",g207659,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62410,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g207660,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62410,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g207661,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62410,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g207662,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62410,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g207663,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62410,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",g207664,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62411,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g207665,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62411,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g207666,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62411,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g207667,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62411,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g207668,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62411,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",g207669,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62412,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g207670,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62412,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g207671,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62412,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g207672,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62412,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g207673,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62412,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",g207674,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62413,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g207675,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62413,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g207676,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62413,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g207677,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62413,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g207678,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62413,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",g207679,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62414,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207680,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62414,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207681,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62414,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207682,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62414,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207683,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62414,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207684,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62415,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207685,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62415,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207686,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62415,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207687,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62415,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207688,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62415,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207689,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62416,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207690,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62416,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207691,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62416,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207692,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62416,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207693,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62416,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,g207694,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62417,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207695,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62417,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207696,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62417,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207697,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62417,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207698,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62417,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,g207699,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62418,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207700,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62418,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207701,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62418,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207702,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62418,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207703,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62418,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,g207704,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62419,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g207705,0,Strongly Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62419,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g207706,1,Agree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62419,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g207707,2,No Opinion,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62419,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g207708,3,Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62419,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g207709,4,Strongly Disagree,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62420,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207710,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62420,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207711,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62420,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207712,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62420,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207713,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62420,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207714,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62420,5,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",g207715,5,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62421,0,"Overall, this activity was:",g207716,0,Excellent,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62421,1,"Overall, this activity was:",g207717,1,Very Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62421,2,"Overall, this activity was:",g207718,2,Good,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62421,3,"Overall, this activity was:",g207719,3,Fair,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62421,4,"Overall, this activity was:",g207720,4,Poor,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62422,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207721,0,Yes,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62422,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207722,1,No,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62422,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207723,2,N/A,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62425,0,How would you improve this class (check all that apply)?,g207724,0,Reduce content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62425,1,How would you improve this class (check all that apply)?,g207725,1,Increase content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62425,2,How would you improve this class (check all that apply)?,g207726,2,Update content covered in class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62425,3,How would you improve this class (check all that apply)?,g207727,3,Improve the instructional methods,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62425,4,How would you improve this class (check all that apply)?,g207728,4,Make course activities more stimulating,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62425,5,How would you improve this class (check all that apply)?,g207729,5,Slow the pace of the class,0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19773,9908,Questions-0000-42,g13793,g62425,6,How would you improve this class (check all that apply)?,g207730,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21
19771,9513,Elearning-0000-743,g13792,g62404,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g207634,0,TRUE,1,C-401 VERSION 3.0
19771,9513,Elearning-0000-743,g13792,g62404,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g207635,1,FALSE,0,C-401 VERSION 3.0
19762,9413,Elearning-0000-652,g13789,g62379,0,ECMO is a new support system and has only been around for 10 years.,g207565,0,TRUE,0,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62379,1,ECMO is a new support system and has only been around for 10 years.,g207566,1,FALSE,1,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62380,0,Venovenous (VV) ECMO only supports the heart.,g207567,0,TRUE,0,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62380,1,Venovenous (VV) ECMO only supports the heart.,g207568,1,FALSE,1,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62381,0,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",g207569,0,TRUE,1,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62381,1,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",g207570,1,FALSE,0,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62382,0,The ICU nurse will be responsible for documenting the head to toe assessment as well as documenting on the ECMO flowsheet.,g207571,0,TRUE,0,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62382,1,The ICU nurse will be responsible for documenting the head to toe assessment as well as documenting on the ECMO flowsheet.,g207572,1,FALSE,1,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62383,0,There will always be an ECMO designee at the bedside and an ECMO physician in close proximity to the patient.,g207573,0,TRUE,1,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19762,9413,Elearning-0000-652,g13789,g62383,1,There will always be an ECMO designee at the bedside and an ECMO physician in close proximity to the patient.,g207574,1,FALSE,0,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19760,9412,Elearning-0000-651,g13788,g62363,0,"Two random controlled trials have been utilized to justify the efficacy of ECMO in the adult respiratory population, those are called the CESAR and EOLIA Trials.",g207522,0,TRUE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62363,1,"Two random controlled trials have been utilized to justify the efficacy of ECMO in the adult respiratory population, those are called the CESAR and EOLIA Trials.",g207523,1,FALSE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62364,0,"A patient with a PaO2 of 160, Murray score of 2, and peep of 5 would make a good candidate for ECMO.",g207524,0,TRUE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62364,1,"A patient with a PaO2 of 160, Murray score of 2, and peep of 5 would make a good candidate for ECMO.",g207525,1,FALSE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62365,0,There are no absolute contraindications to ECLS.,g207526,0,TRUE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62365,1,There are no absolute contraindications to ECLS.,g207527,1,FALSE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62366,0,The basic goal(s) of VV ECMO management include:,g207528,0,"Using High peep, High Oxygen, and the use of iNO",0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62366,1,The basic goal(s) of VV ECMO management include:,g207529,1,"Decrease further lung damage, Reduce oxygen toxicity, and provide lung rest",1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62366,2,The basic goal(s) of VV ECMO management include:,g207530,2,Use very high ECMO flows to support the work of the heart,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62367,0,Optimal ventilator while on VV ECMO are:,g207531,0,"Rate=15, PIP=30, PEEP=10, FiO2=40%",0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62367,1,Optimal ventilator while on VV ECMO are:,g207532,1,"Rate=25, PIP=25, Peep=20, FiO2=30%",0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62367,2,Optimal ventilator while on VV ECMO are:,g207533,2,"Rate=10, PIP=15, Peep=15, FiO2=21%",0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62367,3,Optimal ventilator while on VV ECMO are:,g207534,3,"Rate=10, PIP=10, Peep=10, Fio2=40%",1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62368,0,A SaO2 of 85% and a PaO2 of 50 is acceptable on VV ECMO.,g207535,0,TRUE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62368,1,A SaO2 of 85% and a PaO2 of 50 is acceptable on VV ECMO.,g207536,1,FALSE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62369,0,"Depending on the patient's condition, the patient will not always be on ""rest vent settings"" while on VA ECMO.",g207537,0,TRUE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62369,1,"Depending on the patient's condition, the patient will not always be on ""rest vent settings"" while on VA ECMO.",g207538,1,FALSE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62370,0,"While on ECMO, CO2 removal is controlled by the ECMO blood flow.",g207539,0,TRUE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62370,1,"While on ECMO, CO2 removal is controlled by the ECMO blood flow.",g207540,1,FALSE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62371,0,"While on ECMO, Oxygenation is controlled by the ECMO Sweep gas.",g207541,0,TRUE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62371,1,"While on ECMO, Oxygenation is controlled by the ECMO Sweep gas.",g207542,1,FALSE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62372,0,Routine ventilator changes are not made unless ECMO and Critical Care Physicians are notified.,g207543,0,TRUE,1,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19760,9412,Elearning-0000-651,g13788,g62372,1,Routine ventilator changes are not made unless ECMO and Critical Care Physicians are notified.,g207544,1,FALSE,0,FY2021 ECMO RESPIRATORY CARE SPECIFIC
19761,284,SCORM-0000-94,g13787,g62378,0,I have read and understood the content within the Philips Monitor IntelliVue Education CBL.,g207563,0,TRUE,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62378,1,I have read and understood the content within the Philips Monitor IntelliVue Education CBL.,g207564,1,FALSE,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62384,0,The X3 (small brain) on the back of the monitors can be undocked to utilize as a handheld monitor.,g207575,0,TRUE,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62384,1,The X3 (small brain) on the back of the monitors can be undocked to utilize as a handheld monitor.,g207576,1,FALSE,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62385,0,Sheila is performing a CSAT and gets a phone call from Admission team. She can barely hear what the nurse is saying on the phone. Sheila should turn the volume down on the Philips Monitor.,g207577,0,TRUE,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62385,1,Sheila is performing a CSAT and gets a phone call from Admission team. She can barely hear what the nurse is saying on the phone. Sheila should turn the volume down on the Philips Monitor.,g207578,1,FALSE,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62386,0,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",g207579,0,1,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62386,1,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",g207580,1,2,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62386,2,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",g207581,2,3,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62386,3,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",g207582,3,5,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62387,0,The Philips Monitor defaults as Profile ______ .,g207583,0,Neo,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62387,1,The Philips Monitor defaults as Profile ______ .,g207584,1,Car,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62387,2,The Philips Monitor defaults as Profile ______ .,g207585,2,Pedi,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62387,3,The Philips Monitor defaults as Profile ______ .,g207586,3,CCHD,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62388,0,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",g207587,0,"Click ""Stop Car"" and allow Monique to utilize the Philips Monitor.",0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62388,1,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",g207588,1,"Click ""End Case"", obtain vitals, and allow Monique to utilize the Philips Monitor.",0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62388,2,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",g207589,2,"Obtain vitals, click ""End Case"", and allow Monique to utilize the Philips Monitor.",1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62388,3,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",g207590,3,Allow Monique to utilize the Philips Monitor and obtain vitals afterwards.,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62389,0,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207591,0,Main Setup,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62389,1,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207592,1,Vitals Trend,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62389,2,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207593,2,Event Review,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62389,3,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207594,3,Profiles,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62390,0,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207595,0,Main Setup,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62390,1,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207596,1,Vitals Trend,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62390,2,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207597,2,Event Review,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62390,3,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,g207598,3,Profiles,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62391,0,"The Smart Key ""Start Car"" defaults as ______ minutes duration.",g207599,0,30,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62391,1,"The Smart Key ""Start Car"" defaults as ______ minutes duration.",g207600,1,60,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62391,2,"The Smart Key ""Start Car"" defaults as ______ minutes duration.",g207601,2,90,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62391,3,"The Smart Key ""Start Car"" defaults as ______ minutes duration.",g207602,3,120,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62392,0,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car"" Smart Key?",g207603,0,Ensure that the Profile is set to Profile Car.,1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62392,1,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car"" Smart Key?",g207604,1,Ensure that the alarm volume has been reduced to 3.,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62392,2,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car"" Smart Key?",g207605,2,Ensure that the Profile is set to Profile Neo.,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62392,3,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car"" Smart Key?",g207606,3,Ensure that the timer is set to 60 minutes.,0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62393,0,What is the indicator for each alarm?,g207607,0,Yellow (inoperable); red (life-threatening events); blue (non-life-threatening events),0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62393,1,What is the indicator for each alarm?,g207608,1,Yellow (non-life-threatening events); red (life-threatening events); blue (inoperable),1,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62393,2,What is the indicator for each alarm?,g207609,2,Yellow (life-threatening events); red (non-life-threatening events); blue (inoperable),0,PHILIPS MONITOR INTELLIVUE EDUCATION
19761,284,SCORM-0000-94,g13787,g62393,3,What is the indicator for each alarm?,g207610,3,Yellow (non-life-threatening events); red (inoperable); blue (life-threatening events),0,PHILIPS MONITOR INTELLIVUE EDUCATION
19758,9414,Elearning-0000-653,g13786,g62360,0,ECMO is a new support system and has only been around for 10 years.,g207516,0,TRUE,0,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19758,9414,Elearning-0000-653,g13786,g62360,1,ECMO is a new support system and has only been around for 10 years.,g207517,1,FALSE,1,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19758,9414,Elearning-0000-653,g13786,g62361,0,Venovenous (VV) ECMO only supports the heart.,g207518,0,TRUE,0,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19758,9414,Elearning-0000-653,g13786,g62361,1,Venovenous (VV) ECMO only supports the heart.,g207519,1,FALSE,1,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19758,9414,Elearning-0000-653,g13786,g62362,0,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",g207520,0,TRUE,1,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19758,9414,Elearning-0000-653,g13786,g62362,1,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",g207521,1,FALSE,0,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION
19751,9449,Elearning-0000-685,g13783,g62353,1,"True/False - Complex Regional Pain Syndrome (CRPS) is a form of chronic pain that usually affects an arm or a leg. It typically happens after an injury, surgery, stroke, or hear attack.",g207494,1,FALSE,0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62353,0,"True/False - Complex Regional Pain Syndrome (CRPS) is a form of chronic pain that usually affects an arm or a leg. It typically happens after an injury, surgery, stroke, or hear attack.",g207495,0,TRUE,1,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62354,0,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,g207496,0,"a.	CRPS I occurs after an illness or injury that directly damaged the nerves in the affected limb",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62354,2,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,g207497,2,"c.	CRPS I only occurs at birth",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62354,3,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,g207498,3,"d.	CRPS II only occurs later in life",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62354,1,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,g207499,1,"b.	CRPS II occurs after an illness or injury that directly damaged the nerves in the affected limb",1,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62355,0,True/False - Every patient with CRPS presents with the same symptoms and follows the same treatment plan.,g207500,0,TRUE,0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62355,1,True/False - Every patient with CRPS presents with the same symptoms and follows the same treatment plan.,g207501,1,FALSE,1,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62356,1,"True/False - Prior to surgery, the surgeon should discuss the pain management plan with the patient and document in the H&P.",g207502,1,FALSE,0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62356,0,"True/False - Prior to surgery, the surgeon should discuss the pain management plan with the patient and document in the H&P.",g207503,0,TRUE,1,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,0,Treatment options for CRPS include:,g207504,0,"a.	Medications (e.g. NSAIDS, oioids, corticosteroids, antidepressants, etc.)",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,1,Treatment options for CRPS include:,g207505,1,"b.	Heat therapy",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,2,Treatment options for CRPS include:,g207506,2,"c.	Cold therapy",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,3,Treatment options for CRPS include:,g207507,3,"d.	Physical therapy",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,4,Treatment options for CRPS include:,g207508,4,"e.	There are no treatment options for CRPS",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,5,Treatment options for CRPS include:,g207509,5,"f.	All of the above",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,7,Treatment options for CRPS include:,g207510,7,"h.	A, B, C, D only",0,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19751,9449,Elearning-0000-685,g13783,g62357,6,Treatment options for CRPS include:,g207511,6,"g.	A, B, D only",1,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING
19750,9951,Questions-0000-85,g13782,g62332,0,Please list the location for this activity.,g207410,0,Atlanta,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62332,1,Please list the location for this activity.,g207411,1,Forsyth,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62332,2,Please list the location for this activity.,g207412,2,Cherokee,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62332,3,Please list the location for this activity.,g207413,3,Other,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62333,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g207414,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62333,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g207415,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62333,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g207416,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62333,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g207417,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62333,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",g207418,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62334,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g207419,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62334,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g207420,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62334,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g207421,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62334,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g207422,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62334,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",g207423,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62335,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g207424,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62335,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g207425,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62335,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g207426,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62335,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g207427,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62335,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",g207428,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62336,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g207429,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62336,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g207430,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62336,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g207431,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62336,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g207432,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62336,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",g207433,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62337,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g207434,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62337,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g207435,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62337,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g207436,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62337,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g207437,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62337,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",g207438,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62338,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g207439,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62338,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g207440,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62338,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g207441,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62338,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g207442,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62338,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",g207443,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62339,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g207444,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62339,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g207445,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62339,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g207446,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62339,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g207447,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62339,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",g207448,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62340,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207449,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62340,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207450,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62340,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207451,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62340,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207452,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62340,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g207453,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62341,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g207454,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62341,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g207455,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62341,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g207456,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62341,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g207457,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62341,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,g207458,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62342,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207459,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62342,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207460,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62342,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207461,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62342,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207462,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62342,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207463,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62343,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207464,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62343,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207465,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62343,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207466,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62343,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207467,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62343,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207468,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62344,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g207469,0,Strongly Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62344,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g207470,1,Agree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62344,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g207471,2,No Opinion,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62344,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g207472,3,Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62344,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g207473,4,Strongly Disagree,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62345,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g207474,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62345,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g207475,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62345,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g207476,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62345,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g207477,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62345,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",g207478,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62346,0,"Overall, this activity was:",g207479,0,Excellent,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62346,1,"Overall, this activity was:",g207480,1,Very Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62346,2,"Overall, this activity was:",g207481,2,Good,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62346,3,"Overall, this activity was:",g207482,3,Fair,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62346,4,"Overall, this activity was:",g207483,4,Poor,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62347,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207484,0,Yes,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62347,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207485,1,No,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62347,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207486,2,N/A,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62350,0,How would you improve this class?,g207487,0,Reduce content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62350,1,How would you improve this class?,g207488,1,Increase content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62350,2,How would you improve this class?,g207489,2,Update content covered in class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62350,3,How would you improve this class?,g207490,3,Improve the instructional methods,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62350,4,How would you improve this class?,g207491,4,Make course activities more stimulating,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62350,5,How would you improve this class?,g207492,5,Slow the pace of the class,0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19750,9951,Questions-0000-85,g13782,g62350,6,How would you improve this class?,g207493,6,"Nothing: (appropriate content, speaker, setting, setting.)",0,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21
19748,9671,Elearning-0000-887,g13781,g62331,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207408,0,TRUE,1,FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE
19748,9671,Elearning-0000-887,g13781,g62331,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207409,1,FALSE,0,FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE
19747,9613,Elearning-0000-834,g13780,g62330,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207406,0,TRUE,1,FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS
19747,9613,Elearning-0000-834,g13780,g62330,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g207407,1,FALSE,0,FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS
19746,9946,Questions-0000-80,g13779,g62314,0,Please list the location for this activity.,g207347,0,Atlanta,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62314,1,Please list the location for this activity.,g207348,1,Cherokee,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62314,2,Please list the location for this activity.,g207349,2,Forsyth,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62314,3,Please list the location for this activity.,g207350,3,Other,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62315,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g207351,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62315,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g207352,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62315,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g207353,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62315,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g207354,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62315,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",g207355,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62316,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207356,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62316,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207357,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62316,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207358,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62316,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207359,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62316,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g207360,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62317,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g207361,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62317,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g207362,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62317,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g207363,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62317,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g207364,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62317,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g207365,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62318,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g207366,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62318,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g207367,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62318,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g207368,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62318,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g207369,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62318,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g207370,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62319,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207371,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62319,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207372,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62319,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207373,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62319,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207374,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62319,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g207375,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62320,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207376,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62320,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207377,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62320,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207378,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62320,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207379,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62320,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g207380,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62321,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g207381,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62321,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g207382,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62321,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g207383,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62321,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g207384,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62321,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g207385,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62322,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g207386,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62322,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g207387,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62322,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g207388,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62322,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g207389,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62322,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g207390,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62323,0,"Overall, this activity was:",g207391,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62323,1,"Overall, this activity was:",g207392,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62323,2,"Overall, this activity was:",g207393,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62323,3,"Overall, this activity was:",g207394,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62323,4,"Overall, this activity was:",g207395,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62324,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207396,0,Yes,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62324,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207397,1,No,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62324,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g207398,2,N/A,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62327,0,How would you improve this class?,g207399,0,Reduce content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62327,1,How would you improve this class?,g207400,1,Increase content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62327,2,How would you improve this class?,g207401,2,Update content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62327,3,How would you improve this class?,g207402,3,Improve the instructional methods,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62327,4,How would you improve this class?,g207403,4,Make course activities more stimulating,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62327,5,How would you improve this class?,g207404,5,Slow the pace of the class,0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19746,9946,Questions-0000-80,g13779,g62327,6,How would you improve this class?,g207405,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)"
19742,9700,Elearning-0000-913,g13775,g62246,0,Which two leads would reveal an anterior wall MI?,g207088,0,"a.	V1 and V2",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62246,1,Which two leads would reveal an anterior wall MI?,g207089,1,"b.	Leads I, II and AVF",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62246,2,Which two leads would reveal an anterior wall MI?,g207090,2,"c.	V3 and V4",1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62246,3,Which two leads would reveal an anterior wall MI?,g207091,3,"d.	V5 and V6",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62247,0,Any metformin containing medication must be held only for 3 days post procedure.,g207092,0,a. True,0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62247,1,Any metformin containing medication must be held only for 3 days post procedure.,g207093,1,b. False,1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62248,0,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",g207094,0,"a.	Vasovagal",1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62248,1,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",g207095,1,"b.	Retroperitoneal bleed",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62248,2,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",g207096,2,"c.	Dehydration",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62248,3,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",g207097,3,"d.	Ventricular arrhythmia",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62249,0,When should ACE inhibitors be prescribed for PCI patients:,g207098,0,"a.	Indefinitely with heart failure, LV dysfunction with LVEF <40%, hypertension, or diabetes",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62249,1,When should ACE inhibitors be prescribed for PCI patients:,g207099,1,"b.	Absence of LV dysfunction, hypertension or diabetes",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62249,2,When should ACE inhibitors be prescribed for PCI patients:,g207100,2,"c.	HF with LVEF of >40%",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62249,3,When should ACE inhibitors be prescribed for PCI patients:,g207101,3,"d.	All of the above",1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62250,0,Reversal for heparin,g207102,0,"a.	Platelet infusion",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62250,1,Reversal for heparin,g207103,1,"b.	Protamine",1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62250,2,Reversal for heparin,g207104,2,"c.	No available reversal agent",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62250,3,Reversal for heparin,g207105,3,"d.	Naloxone",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62251,0,Reopro (abciximab) can be administered up to 8 hours post PCI procedure.,g207106,0,a. True,0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62251,1,Reopro (abciximab) can be administered up to 8 hours post PCI procedure.,g207107,1,b. False,1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62252,0,Heparin is compatible with amiodarone and can be infused through the same IV line.,g207108,0,a. True,0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62252,1,Heparin is compatible with amiodarone and can be infused through the same IV line.,g207109,1,b. False,1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62253,0,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,g207110,0,"a.	Continue to monitor",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62253,1,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,g207111,1,"b.	Get a 12-lead ECG",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62253,2,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,g207112,2,"c.	Perform more frequent VS",0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62253,3,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,g207113,3,"d.	Notify the Medical Team",1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62254,0,A pseudoaneurysm is typically associated with Inadequate compression after sheath removal and hemostasis,g207114,0,a. True,1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62254,1,A pseudoaneurysm is typically associated with Inadequate compression after sheath removal and hemostasis,g207115,1,b. False,0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62255,0,"Upon Discharge, it is important that the patient receive the following information",g207116,0,a. Test result,0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62255,1,"Upon Discharge, it is important that the patient receive the following information",g207117,1,b. Follow up appointment(s),0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62255,2,"Upon Discharge, it is important that the patient receive the following information",g207118,2,c. Aware of smoking risk,0,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19742,9700,Elearning-0000-913,g13775,g62255,3,"Upon Discharge, it is important that the patient receive the following information",g207119,3,d. All of the above,1,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI
19736,9744,Elearning-0000-953,g13770,g62187,0,Acute Coronary Syndrome include all the following except:,g206857,0,"a.	STEMI",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62187,1,Acute Coronary Syndrome include all the following except:,g206858,1,"b.	Aortic Dissection",1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62187,2,Acute Coronary Syndrome include all the following except:,g206859,2,"c.	NSTEMI",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62187,3,Acute Coronary Syndrome include all the following except:,g206860,3,"d.	Unstable Angina",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62188,0,True/False: In hospital STEMI results in improved outcomes vs outpatient STEMI's.,g206861,0,TRUE,0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62188,1,True/False: In hospital STEMI results in improved outcomes vs outpatient STEMI's.,g206862,1,FALSE,1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62189,0,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,g206863,0,"a.	Coronary plaque erosion",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62189,1,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,g206864,1,"b.	Coronary plaque rupture (plaque rupture and plaque erosion can result in thrombosis. STEMI is most often from coronary thrombosis after plaque rupture and less often from fixed obstruction)",1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62189,2,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,g206865,2,"c.	Coronary plaque progression causing progressive stenosis",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62189,3,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,g206866,3,"d.	Coronary Vasospasm",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62190,0,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",g206867,0,"a.	Start an IV",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62190,1,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",g206868,1,"b.	Call the physician",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62190,2,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",g206869,2,"c. 	Obtain a 12 lead ECG",1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62190,3,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",g206870,3,"d.	Obtain Vital Signs",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62191,0,True/False: A New left bundle branch block (LBBB) may be considered a STEMI,g206871,0,TRUE,1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62191,1,True/False: A New left bundle branch block (LBBB) may be considered a STEMI,g206872,1,FALSE,0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62192,0,NSTEMI may present with ST depression including T wave inversion which means?,g206873,0,"a.	Partial occlusion of major coronary artery",1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62192,1,NSTEMI may present with ST depression including T wave inversion which means?,g206874,1,"b.	Complete occlusion of major coronary artery",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62192,2,NSTEMI may present with ST depression including T wave inversion which means?,g206875,2,"c.	Sustained Coronary Spasms",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62192,3,NSTEMI may present with ST depression including T wave inversion which means?,g206876,3,"d.	Normal coronary artery flow",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62193,0,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,g206877,0,"a.	Septal Wall",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62193,1,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,g206878,1,"b.	Inferior Wall",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62193,2,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,g206879,2,"c.	Anterior Wall",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62193,3,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,g206880,3,"d.	Anterior/Lateral Wall",1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62194,0,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,g206881,0,"a.	120 minutes",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62194,1,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,g206882,1,"b.	60 minutes",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62194,2,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,g206883,2,"c.	90 minutes",1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62194,3,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,g206884,3,"d.	75 minutes",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62195,0,True/False: A patient comes to the ED with chest pain but the 12 ECG does not show a STEMI.  This is conclusive that there is no further evaluation needed.,g206885,0,TRUE,0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62195,1,True/False: A patient comes to the ED with chest pain but the 12 ECG does not show a STEMI.  This is conclusive that there is no further evaluation needed.,g206886,1,FALSE,1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62196,0,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,g206887,0,"a.	Heart Failure Clinic Referral",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62196,1,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,g206888,1,"b.	Cardiac Rehab Referral",1,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62196,2,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,g206889,2,"c.	Coumadin Clinic Referral",0,FY2021 ACUTE CORONARY SYNDROME
19736,9744,Elearning-0000-953,g13770,g62196,3,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,g206890,3,"d.	Cardiology Referral",0,FY2021 ACUTE CORONARY SYNDROME
19734,9427,Elearning-0000-665,g13768,g62180,0,What is the maximum amount of time a Bronchoscope should soak?,g206831,0,"a.	2 hours",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62180,1,What is the maximum amount of time a Bronchoscope should soak?,g206832,1,"b.	1 hour",1,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62180,2,What is the maximum amount of time a Bronchoscope should soak?,g206833,2,"c.	24 hours",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62180,3,What is the maximum amount of time a Bronchoscope should soak?,g206834,3,"d.	30 minutes",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62181,0,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,g206835,0,"a.	To help document the time it took to finished the procedure",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62181,1,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,g206836,1,"b.	To document the time it took to do the pre-cleaning",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62181,2,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,g206837,2,"c.	There is no point to put the time on the bag.",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62181,3,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,g206838,3,"d.	To help ensure the scope is reprocessed with the 60 minute window per the FDA in order the minimize risk of infection for patients?",1,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62182,0,What is the minimum amount of time an ERCP scope should be soaked?,g206839,0,"a.	 2 hours",1,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62182,1,What is the minimum amount of time an ERCP scope should be soaked?,g206840,1,"b.	10 hours",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62182,2,What is the minimum amount of time an ERCP scope should be soaked?,g206841,2,"c.	1 hours",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62182,3,What is the minimum amount of time an ERCP scope should be soaked?,g206842,3,"d.	24 hours",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62183,0,What is the maximum of amount time any scope should be soaked?,g206843,0,"a.	2 hours",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62183,1,What is the maximum of amount time any scope should be soaked?,g206844,1,"b.	10 hours",1,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62183,2,What is the maximum of amount time any scope should be soaked?,g206845,2,"c.	1 hour",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62183,3,What is the maximum of amount time any scope should be soaked?,g206846,3,"d.	24 hours",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62184,0,What does intercept foam do?,g206847,0,"a.	Intercept foam cleans the scope",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62184,1,What does intercept foam do?,g206848,1,"b.	Intercept foam kill the bacteria?",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62184,2,What does intercept foam do?,g206849,2,"c.	Intercept foam replaces the pre-cleaning process?",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62184,3,What does intercept foam do?,g206850,3,"d.	Intercept foam used according to the IFU's protects the inside and outside of the scope from the formation of Biofilm up to 72 hours.",1,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62185,0,What is the correct product to soak the scope in for delayed reprocessing?,g206851,0,"a.	Water",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62185,1,What is the correct product to soak the scope in for delayed reprocessing?,g206852,1,"b.	Cidex",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62185,2,What is the correct product to soak the scope in for delayed reprocessing?,g206853,2,"c.	Cotton Candy",0,DELAYED REPROCESSING
19734,9427,Elearning-0000-665,g13768,g62185,3,What is the correct product to soak the scope in for delayed reprocessing?,g206854,3,"d.	Diluted Enzol",1,DELAYED REPROCESSING
19732,9250,Elearning-0000-504,g13766,g62164,0,"1.	The new standard maximum drip rate for Fentanyl is",g206780,0,"a.	450 mcg/hr.",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62164,1,"1.	The new standard maximum drip rate for Fentanyl is",g206781,1,"b.	250 mcg/hr.",1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62164,2,"1.	The new standard maximum drip rate for Fentanyl is",g206782,2,"c.	500 mcg/hr.",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62164,3,"1.	The new standard maximum drip rate for Fentanyl is",g206783,3,"d.	None of the above",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62165,0,"2.	Providers may modify drip max to allow for higher maximum to meet individual patient needs on either analgesic or sedative continuous infusions.",g206784,0,TRUE,1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62165,1,"2.	Providers may modify drip max to allow for higher maximum to meet individual patient needs on either analgesic or sedative continuous infusions.",g206785,1,FALSE,0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62166,0,"3.	You should contact the patient's provider if the patient is not at PAYEN or RASS goal and is at/approaching maximum rate to discuss changing maximum or adding other therapy.",g206786,0,TRUE,1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62166,1,"3.	You should contact the patient's provider if the patient is not at PAYEN or RASS goal and is at/approaching maximum rate to discuss changing maximum or adding other therapy.",g206787,1,FALSE,0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62167,0,"4.	The new standard maximum drip rate for Midazolam is",g206788,0,"a.	250mcg/hr.",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62167,1,"4.	The new standard maximum drip rate for Midazolam is",g206789,1,"b.	20mg/hr.",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62167,2,"4.	The new standard maximum drip rate for Midazolam is",g206790,2,"c.	10mg/hr.",1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62167,3,"4.	The new standard maximum drip rate for Midazolam is",g206791,3,"d.	None of the above",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62168,0,"5.	For patients that are on analgesic and sedative infusions, a Ketamine loading dose may not be required.",g206792,0,TRUE,1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62168,1,"5.	For patients that are on analgesic and sedative infusions, a Ketamine loading dose may not be required.",g206793,1,FALSE,0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62169,0,"6.	All Ketamine drips will be linked to an order for Midazolam for emergence reactions.",g206794,0,TRUE,1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62169,1,"6.	All Ketamine drips will be linked to an order for Midazolam for emergence reactions.",g206795,1,FALSE,0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62170,0,"7.	Per the new orders, a physician may not choose between",g206796,0,"a.	Fixed rate infusion of Ketamine",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62170,1,"7.	Per the new orders, a physician may not choose between",g206797,1,"b.	Titratable infusion of Ketamine",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62170,2,"7.	Per the new orders, a physician may not choose between",g206798,2,"c.	All of the above",1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62171,0,"8.	If titratable ketamine infusion is ordered, stop titrating all previously ordered infusions for that same indication.",g206799,0,TRUE,1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62171,1,"8.	If titratable ketamine infusion is ordered, stop titrating all previously ordered infusions for that same indication.",g206800,1,FALSE,0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62172,0,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",g206801,0,"a.	Hallucinations",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62172,1,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",g206802,1,"b.	Confusion, delirium",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62172,2,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",g206803,2,"c.	Combativeness, irrational behavior",0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62172,3,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",g206804,3,"d.	All of the above",1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62173,0,"10.	I have read the information on ICU Sedative and Analgesic Drip Updates in its entirety.  I understand that if I have questions, I can ask an ICU leadership team member.",g206805,0,TRUE,1,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19732,9250,Elearning-0000-504,g13766,g62173,1,"10.	I have read the information on ICU Sedative and Analgesic Drip Updates in its entirety.  I understand that if I have questions, I can ask an ICU leadership team member.",g206806,1,FALSE,0,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021
19731,8902,Elearning-0000-188,g13765,g62160,0,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusingΓÇª",g206766,0,"a.	The ICU nurse will see a task on Care Compass. b.	The task serves as a reminder to follow through with the new workflow c.	Do not complete the task until the infusion is complete and the end time is documented in the MAR.  d.	All of the above.",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62160,1,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusingΓÇª",g206767,1,"b.	The task serves as a reminder to follow through with the new workflow",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62160,2,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusingΓÇª",g206768,2,"c.	Do not complete the task until the infusion is complete and the end time is documented in the MAR.",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62160,3,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusingΓÇª",g206769,3,"d.	All of the above.",1,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62161,0,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusionΓÇª a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)"" box c.	Click Apply d.	Click on the blue ""Pending"" box e.	Ensure that the ""to"" time is updated for the end-time of the infusion bag",g206770,0,"i.	a, b, c, d, e",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62161,1,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusionΓÇª a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)"" box c.	Click Apply d.	Click on the blue ""Pending"" box e.	Ensure that the ""to"" time is updated for the end-time of the infusion bag",g206771,1,"ii.	a, d, b, e, c",1,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62161,2,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusionΓÇª a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)"" box c.	Click Apply d.	Click on the blue ""Pending"" box e.	Ensure that the ""to"" time is updated for the end-time of the infusion bag",g206772,2,"iii.	a, c, b, d, e",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62161,3,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusionΓÇª a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)"" box c.	Click Apply d.	Click on the blue ""Pending"" box e.	Ensure that the ""to"" time is updated for the end-time of the infusion bag",g206773,3,"iv.	a, e, d, b, c",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62162,0,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in eitherΓÇª",g206774,0,"a.	Pre-Arrival IV fluid amount",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62162,1,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in eitherΓÇª",g206775,1,"b.	Sepsis Bolus Continuous infusion",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62162,2,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in eitherΓÇª",g206776,2,"c.	A and b",1,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62162,3,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in eitherΓÇª",g206777,3,"d.	None of the above",0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62163,0,"4.	If a patient requires subsequent infusions to complete the total sepsis bolus dose, return to the normal process-start the bag in MAW and document the end time in Infusion Billing and the infused volume in I & O.",g206778,0,TRUE,1,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19731,8902,Elearning-0000-188,g13765,g62163,1,"4.	If a patient requires subsequent infusions to complete the total sepsis bolus dose, return to the normal process-start the bag in MAW and document the end time in Infusion Billing and the infused volume in I & O.",g206779,1,FALSE,0,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU
19729,9549,Elearning-0000-776,g13764,g62159,0,"I have read the CBL in it's entirety.  I understand that if I have questions, I can contact a leadership team member.",g206764,0,TRUE,1,NSC ICU BBRAUN 400 ES PUMP UPDATE
19729,9549,Elearning-0000-776,g13764,g62159,1,"I have read the CBL in it's entirety.  I understand that if I have questions, I can contact a leadership team member.",g206765,1,FALSE,0,NSC ICU BBRAUN 400 ES PUMP UPDATE
19728,9021,Elearning-0000-296,g13763,g62158,0,I have read and understand the FY21 On-Q Pump Education CBL.,g206762,0,TRUE,1,ON-Q PUMP EDUCATION WSU FY21
19728,9021,Elearning-0000-296,g13763,g62158,1,I have read and understand the FY21 On-Q Pump Education CBL.,g206763,1,FALSE,0,ON-Q PUMP EDUCATION WSU FY21
19722,9006,Elearning-0000-282,g13757,g62132,0,"According to current Northside policy, which age group requires all medication orders to be double checked?",g206668,0,"A.	< 1 year old",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62132,1,"According to current Northside policy, which age group requires all medication orders to be double checked?",g206669,1,"B.	11 years and younger",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62132,2,"According to current Northside policy, which age group requires all medication orders to be double checked?",g206670,2,"C.	12 years and younger",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62132,3,"According to current Northside policy, which age group requires all medication orders to be double checked?",g206671,3,"D.	18 years and younger",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62133,0,What is the most common source of pediatric patient harm during medical treatment?,g206672,0,"A.	Procedural technique errors",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62133,1,What is the most common source of pediatric patient harm during medical treatment?,g206673,1,"B.	Delays in therapeutic management",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62133,2,What is the most common source of pediatric patient harm during medical treatment?,g206674,2,"C.	Medication errors",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62133,3,What is the most common source of pediatric patient harm during medical treatment?,g206675,3,"D.	Lack of clinical guidelines",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62134,0,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,g206676,0,A. Surgery patients,1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62134,1,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,g206677,1,B. ED patients,0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62134,2,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,g206678,2,C. ICU patients,0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62134,3,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,g206679,3,D. < 2 years old,0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62135,0,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",g206680,0,"A.	2",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62135,1,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",g206681,1,"B.	3",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62135,2,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",g206682,2,"C.	4",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62135,3,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",g206683,3,"D.	5",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62136,0,Which of the following is true about independent double checks?,g206684,0,"A.	When done appropriately, double checks can decrease errors by 80%",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62136,1,Which of the following is true about independent double checks?,g206685,1,"B.	Every situation requires two pharmacists to perform a double check",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62136,2,Which of the following is true about independent double checks?,g206686,2,"C.	Only high risk medications require a double check",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62136,3,Which of the following is true about independent double checks?,g206687,3,"D.	The first practitioner should not communicate their findings to the 2nd practitioner",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62137,0,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,g206688,0,"A.	Some medications are not commercially available as a liquid",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62137,1,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,g206689,1,"B.	Some commercially available products have unfavorable excipients",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62137,2,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,g206690,2,"C.	Some commercially available products are too concentrated for smaller patients and infants",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62137,3,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,g206691,3,"D.	All of the above",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62138,0,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",g206692,0,"A.	Acetaminophen",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62138,1,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",g206693,1,"B.	Adrenals, corticosteroids",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62138,2,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",g206694,2,"C.	Insulin",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62138,3,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",g206695,3,"D.	Opioids",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62139,0,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,g206696,0,"A.	Adult and pediatric medications stored together",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62139,1,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,g206697,1,"B.	Crowded pharmacy",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62139,2,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,g206698,2,"C.	Staff distracted by their cell phone",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62139,3,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,g206699,3,"D.	New electronic medical record implementation",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62140,0,Which medication does Northside NICU further dilute to improve measurability?,g206700,0,"A.	Carvedilol",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62140,1,Which medication does Northside NICU further dilute to improve measurability?,g206701,1,"B.	Omeprazole",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62140,2,Which medication does Northside NICU further dilute to improve measurability?,g206702,2,"C.	Baclofen",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62140,3,Which medication does Northside NICU further dilute to improve measurability?,g206703,3,"D.	Propranolol",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62141,0,"What patient areas are excluded from the ""Pediatric Patient Alert""?",g206704,0,"A.	NICU and Well Baby Nursery",1,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62141,1,"What patient areas are excluded from the ""Pediatric Patient Alert""?",g206705,1,"B.	Main OR",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62141,2,"What patient areas are excluded from the ""Pediatric Patient Alert""?",g206706,2,"C.	Labor and Delivery",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19722,9006,Elearning-0000-282,g13757,g62141,3,"What patient areas are excluded from the ""Pediatric Patient Alert""?",g206707,3,"D.	Emergency Department",0,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY
19720,9324,Elearning-0000-571,g13756,g62121,0,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",g206626,0,"a.	High-alert medications",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62121,1,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",g206627,1,"b.	Low-alert medications",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62121,2,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",g206628,2,"c.	Highly addictive medications",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62121,3,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",g206629,3,"d.	None of the above",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62122,0,Potential adverse effects of heparin include:,g206630,0,"a.	Systemic bleeding",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62122,1,Potential adverse effects of heparin include:,g206631,1,"b.	Heparin-induced thrombocytopenia",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62122,2,Potential adverse effects of heparin include:,g206632,2,"c.	Heparin-induced osteopenia",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62122,3,Potential adverse effects of heparin include:,g206633,3,"d.	All of the above",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62123,0,Heparin is indicated for:,g206634,0,"a.	Prophylaxis for DVT/PE",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62123,1,Heparin is indicated for:,g206635,1,"b.	Treatment of DVT/PE",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62123,2,Heparin is indicated for:,g206636,2,"c.	Acute Coronary Syndrome",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62123,3,Heparin is indicated for:,g206637,3,"d.	All of the above",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62124,0,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",g206638,0,"a.	The patient has an increased risk of bleeding due to their anti-Xa and concurrent anti-platelet therapy.",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62124,1,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",g206639,1,"b.	The heparin drip should be held and the physician contacted for orders.",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62124,2,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",g206640,2,"c.	The headache and elevated BP could be an indication of an impending serious adverse drug event",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62124,3,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",g206641,3,"d.	All of the above are true.",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62125,0,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,g206642,0,"a.	6160 units",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62125,1,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,g206643,1,"b.	6000 units",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62125,2,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,g206644,2,"c.	5000 units",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62125,3,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,g206645,3,"d.	10,000 units",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62126,0,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",g206646,0,"a.	2 ml",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62126,1,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",g206647,1,"b.	4 ml",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62126,2,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",g206648,2,"c.	6 ml",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62126,3,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",g206649,3,"d.	8 ml",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62127,0,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",g206650,0,"a.	1400 units/hour",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62127,1,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",g206651,1,"b.	1402.2 units/hour",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62127,2,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",g206652,2,"c.	1387 units/hour",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62127,3,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",g206653,3,"d.	1500 units/hour",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62128,0,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",g206654,0,"a.	28 ml/hour",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62128,1,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",g206655,1,"b.	28.1 ml/hour",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62128,2,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",g206656,2,"c.	27 ml/hour",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62128,3,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",g206657,3,"d.	30 ml/hour",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62129,0,"Prior to administration of a heparin bolus dose, the nurse should",g206658,0,"a.	Verify the bolus dose calculations with a pharmacist or physician",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62129,1,"Prior to administration of a heparin bolus dose, the nurse should",g206659,1,"b.	Read the medication label three times (drug name, concentration, and vial size)",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62129,2,"Prior to administration of a heparin bolus dose, the nurse should",g206660,2,"c.	Confirm the amount in the syringe (both the dose in units, and volume in ml) with a second RN",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62129,3,"Prior to administration of a heparin bolus dose, the nurse should",g206661,3,"d.	All of the above",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62130,0,Argatroban can be used in patients with Heparin-Induced Thrombocytopenia (HIT),g206662,0,TRUE,1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62130,1,Argatroban can be used in patients with Heparin-Induced Thrombocytopenia (HIT),g206663,1,FALSE,0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62131,0,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",g206664,0,"a.	8000 mcg/hr",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62131,1,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",g206665,1,"b.	9000 mcg/hr",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62131,2,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",g206666,2,"c.	8220 mcg/hr",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62131,3,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",g206667,3,"d.	8550 mcg/hr",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62175,0,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",g206809,0,"a.	9 mL/hr",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62175,1,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",g206810,1,"b.	8.5 mL/hr",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62175,2,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",g206811,2,"c.	8.3 mL/hr",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62175,3,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",g206812,3,"d.	8.2 mL.hr",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62176,0,The initials of the nurse performing calculations and the pharmacist (or physician) performing the independent double check must be recorded on the heparin or argatroban flow sheet.,g206813,0,TRUE,1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62176,1,The initials of the nurse performing calculations and the pharmacist (or physician) performing the independent double check must be recorded on the heparin or argatroban flow sheet.,g206814,1,FALSE,0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62177,0,Pump settings must be verified and documented at all of the following exceptΓÇª,g206815,0,"a.	Infusion initiation",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62177,1,Pump settings must be verified and documented at all of the following exceptΓÇª,g206816,1,"b.	Bag changes",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62177,2,Pump settings must be verified and documented at all of the following exceptΓÇª,g206817,2,"c.	Tubing changes",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62177,3,Pump settings must be verified and documented at all of the following exceptΓÇª,g206818,3,"d.	Rate changes",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62177,4,Pump settings must be verified and documented at all of the following exceptΓÇª,g206819,4,"e.	Shift changes",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62177,5,Pump settings must be verified and documented at all of the following exceptΓÇª,g206820,5,"f.	Therapeutic Anti-Xa/PTT values",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62178,0,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",g206821,0,"a.	Contact the physician for additional instructions/orders",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62178,1,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",g206822,1,"b.	Stop the infusion and recheck level in 6 hours",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62178,2,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",g206823,2,"c.	Decrease the rate by ┬╜ and contact the physician",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62178,3,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",g206824,3,"d.	Continue the current rate and recheck level in 6 hours",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62179,0,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,g206825,0,"a.	Take no action, no change is required to the infusion rate",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62179,1,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,g206826,1,"b.	Document the correct dosing weight in the EMR and notify pharmacy",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62179,2,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,g206827,2,"c.	Print a new flowsheet, write the correct dosing weight and re-calculate the infusion rate",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62179,3,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,g206828,3,"d.	Cross out the incorrect weight on the current flowsheet and write the correct weight.",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62179,4,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,g206829,4,"e.	B and C",1,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19720,9324,Elearning-0000-571,g13756,g62179,5,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,g206830,5,"f.	B and D",0,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY
19719,9315,Elearning-0000-563,g13755,g62111,0,Vasopressors increase vasoconstriction which can increase perfusion to distal tissue like the skin,g206600,0,TRUE,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62111,1,Vasopressors increase vasoconstriction which can increase perfusion to distal tissue like the skin,g206601,1,FALSE,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62112,0,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,g206602,0,1. Titrating gtts every time a MAP is outside of ordered range,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62112,1,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,g206603,1,2.  2 consecutive MAPs> ordered upper parameter without decreasing the vasopressor gtt,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62112,2,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,g206604,2,"3,  Titrating gtt when MAP is within ordered range",0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62112,3,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,g206605,3,4.  All of the above,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62113,0,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",g206606,0,1.  Titrate the vasopressor up by the ordered dose,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62113,1,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",g206607,1,2.  Titrate vasopressor down by ordered dose,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62113,2,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",g206608,2,"3.  Continue to monitor VS every 15 minutes until 2 consecutive MAP's are out of range, then titrate according to order",1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62113,3,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",g206609,3,4.  None of the above,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62114,0,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",g206610,0,1.  MAP 65-70 for the majority of patients,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62114,1,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",g206611,1,"2.  MAP 70-80, higher is better",0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62114,2,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",g206612,2,3.  MAP 60-50,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62114,3,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",g206613,3,4. MAP 75-85,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62115,0,It is best to complete all titrations through the MAR,g206614,0,TRUE,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62115,1,It is best to complete all titrations through the MAR,g206615,1,FALSE,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62116,0,"At the beginning of every shift, the oncoming RN should enter gtt rates in iVIEW gtt section during handoff for verification of line reconciliation and to ensure baseline rate for all gtt titrations for the shift",g206616,0,TRUE,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62116,1,"At the beginning of every shift, the oncoming RN should enter gtt rates in iVIEW gtt section during handoff for verification of line reconciliation and to ensure baseline rate for all gtt titrations for the shift",g206617,1,FALSE,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62117,0,If a patient has 2 VS sources (Cuff pressure and Aline)- both sources must be documented in the EMR every 15 minutes for the duration of all vasoactive gtts.,g206618,0,TRUE,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62117,1,If a patient has 2 VS sources (Cuff pressure and Aline)- both sources must be documented in the EMR every 15 minutes for the duration of all vasoactive gtts.,g206619,1,FALSE,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62118,0,Communications orders should only be used for 1 time events,g206620,0,TRUE,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62118,1,Communications orders should only be used for 1 time events,g206621,1,FALSE,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62119,0,"It is ok to titrate vasoactive gtts when VS are within ordered range (example:  MAP is 75, order is to maintain MAP of 60-80)",g206622,0,TRUE,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62119,1,"It is ok to titrate vasoactive gtts when VS are within ordered range (example:  MAP is 75, order is to maintain MAP of 60-80)",g206623,1,FALSE,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62120,0,"I have read and understand the content of the CBL entitled FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION, understand that I am responsible for the content contained herein, and proper vasoactive gtt titrations following provider orders.  I will seek assistance or further education as needed.",g206624,0,TRUE,1,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19719,9315,Elearning-0000-563,g13755,g62120,1,"I have read and understand the content of the CBL entitled FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION, understand that I am responsible for the content contained herein, and proper vasoactive gtt titrations following provider orders.  I will seek assistance or further education as needed.",g206625,1,FALSE,0,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION
19718,8952,Elearning-0000-233,g13754,g62081,0,"1.	Radiation Oncology price estimates consist of what two types of estimates?",g206520,0,"a.	Profee and Technical",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62081,1,"1.	Radiation Oncology price estimates consist of what two types of estimates?",g206521,1,"b.	Technical only",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62081,2,"1.	Radiation Oncology price estimates consist of what two types of estimates?",g206522,2,"c.	Profee only",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62082,0,2. The Oncology Financial Resource Specialist should create a _____________ and ______________ estimate for employed physicians.,g206523,0,"a.	Professional and Contracted",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62082,1,2. The Oncology Financial Resource Specialist should create a _____________ and ______________ estimate for employed physicians.,g206524,1,"b.	Professional and Technical",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62082,2,2. The Oncology Financial Resource Specialist should create a _____________ and ______________ estimate for employed physicians.,g206525,2,"c.	Technical and Commercial",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62083,0,"3.	The Oncology Financial Resource Specialist should create a _____________ ________ only for contracted physicians.",g206526,0,"a.	Technical estimate",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62083,1,"3.	The Oncology Financial Resource Specialist should create a _____________ ________ only for contracted physicians.",g206527,1,"b.	Insurance estimate",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62083,2,"3.	The Oncology Financial Resource Specialist should create a _____________ ________ only for contracted physicians.",g206528,2,"c.	Contracted estimate",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62084,0,"4.	If the patient has a Profee and a technical estimate, which should be generated first?",g206529,0,"a.	Either one - it does not matter which order they are created in",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62084,1,"4.	If the patient has a Profee and a technical estimate, which should be generated first?",g206530,1,"b.	Technical",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62084,2,"4.	If the patient has a Profee and a technical estimate, which should be generated first?",g206531,2,"c.	Profee",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62085,0,"5.	The Oncology Financial Resource Specialist should review previous accounts for outstanding balances and bad debt. This should be included in the FET as it is the total patient financial responsibility.",g206532,0,TRUE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62085,1,"5.	The Oncology Financial Resource Specialist should review previous accounts for outstanding balances and bad debt. This should be included in the FET as it is the total patient financial responsibility.",g206533,1,FALSE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62086,0,"6.	When creating the technical estimate, it is not necessary to deduct the Profee estimate from the remaining insurance benefits.",g206534,0,TRUE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62086,1,"6.	When creating the technical estimate, it is not necessary to deduct the Profee estimate from the remaining insurance benefits.",g206535,1,FALSE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62087,0,"7.	What is the first step in preparation for creating a Radiation Oncology price estimate?",g206536,0,"a.	Access STAR ILE and locate Modality Treatment Plan",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62087,1,"7.	What is the first step in preparation for creating a Radiation Oncology price estimate?",g206537,1,"b.	Access STAR to obtain insurance benefits",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62087,2,"7.	What is the first step in preparation for creating a Radiation Oncology price estimate?",g206538,2,"c.	Log into the FET Tool",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62088,0,"8.	What is the name of the tool used by the Oncology Financial Resource Specialist to calculate the technical fees listed on the Modality Treatment Plan?",g206539,0,"a.	Estimation Workbook",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62088,1,"8.	What is the name of the tool used by the Oncology Financial Resource Specialist to calculate the technical fees listed on the Modality Treatment Plan?",g206540,1,"b.	FET",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62088,2,"8.	What is the name of the tool used by the Oncology Financial Resource Specialist to calculate the technical fees listed on the Modality Treatment Plan?",g206541,2,"c.	Technical Workbook",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62089,0,9. A standard note code must be added to each account to notate the financial outcome.,g206542,0,TRUE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62089,1,9. A standard note code must be added to each account to notate the financial outcome.,g206543,1,FALSE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62090,0,10. A financial clearance/ non-clearance email will be sent to the appropriate email distribution list after the Oncology Financial Resource Specialist works each account.,g206544,0,TRUE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62090,1,10. A financial clearance/ non-clearance email will be sent to the appropriate email distribution list after the Oncology Financial Resource Specialist works each account.,g206545,1,FALSE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62091,0,"11.	The Modality Treatment plan specifies the quantities of CPT codes and differentiates which codes are Profee versus technical.",g206546,0,TRUE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62091,1,"11.	The Modality Treatment plan specifies the quantities of CPT codes and differentiates which codes are Profee versus technical.",g206547,1,FALSE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62092,0,"12.	When creating the technical estimate, the Oncology Financial Resource Specialist will refer to the standard processes and procedures via the Financial Estimation Tool.",g206548,0,TRUE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62092,1,"12.	When creating the technical estimate, the Oncology Financial Resource Specialist will refer to the standard processes and procedures via the Financial Estimation Tool.",g206549,1,FALSE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62093,0,"13.	Each treatment plan has either 3 days or 5 days listed at the top. What does the Oncology Financial Resource Specialist use this for?",g206550,0,"a.	This does not indicate anything",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62093,1,"13.	Each treatment plan has either 3 days or 5 days listed at the top. What does the Oncology Financial Resource Specialist use this for?",g206551,1,"b.	The number of treatments",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62093,2,"13.	Each treatment plan has either 3 days or 5 days listed at the top. What does the Oncology Financial Resource Specialist use this for?",g206552,2,"c.	The number of business days to financially clear the patient",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62094,0,"14. If an ABN is located in STAR, the Oncology Financial Resource Specialist should create a self-pay estimate for the applicable non-covered CPT codes?",g206553,0,TRUE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62094,1,"14. If an ABN is located in STAR, the Oncology Financial Resource Specialist should create a self-pay estimate for the applicable non-covered CPT codes?",g206554,1,FALSE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62095,0,"15.	 Once the Oncology Financial Resource Specialist completes the ABN, the completed document should be scanned into what ILE folder?",g206555,0,"a.	PFS: Primary Insurance",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62095,1,"15.	 Once the Oncology Financial Resource Specialist completes the ABN, the completed document should be scanned into what ILE folder?",g206556,1,"b.	PFS: Insurance Information",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62095,2,"15.	 Once the Oncology Financial Resource Specialist completes the ABN, the completed document should be scanned into what ILE folder?",g206557,2,"c.	PFS: ABN",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62096,0,"16.	The Intake team will write ________________ across the top of the treatment plan when a patient's care must begin immediately.",g206558,0,"a.	Hurry Up",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62096,1,"16.	The Intake team will write ________________ across the top of the treatment plan when a patient's care must begin immediately.",g206559,1,"b.	Emergency",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62096,2,"16.	The Intake team will write ________________ across the top of the treatment plan when a patient's care must begin immediately.",g206560,2,"c.	ASAP",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62097,0,"17.	 If an emergency patient is unable to make a suitable payment arrangement or qualify for financial assistance, their appointment ______ _______ be postponed.",g206561,0,"a.	Will",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62097,1,"17.	 If an emergency patient is unable to make a suitable payment arrangement or qualify for financial assistance, their appointment ______ _______ be postponed.",g206562,1,"b.	Will not",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62097,2,"17.	 If an emergency patient is unable to make a suitable payment arrangement or qualify for financial assistance, their appointment ______ _______ be postponed.",g206563,2,"c.	May be",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62098,0,"18.	 The Oncology Financial Resource Specialist fills out the Patient Tracker on each patient worked.",g206564,0,TRUE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62098,1,"18.	 The Oncology Financial Resource Specialist fills out the Patient Tracker on each patient worked.",g206565,1,FALSE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62099,0,"19. If a non-emergency patient cannot make a suitable payment arrangement or qualify for financial assistance, the treatment is  ____________________",g206566,0,"a.	Postponed/rescheduled",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62099,1,"19. If a non-emergency patient cannot make a suitable payment arrangement or qualify for financial assistance, the treatment is  ____________________",g206567,1,"b.	Continued",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62099,2,"19. If a non-emergency patient cannot make a suitable payment arrangement or qualify for financial assistance, the treatment is  ____________________",g206599,2,"c.	Cancelled",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62100,0,"20.	Generic Treatment Plans will be created for patients that do not have an estimated amount due for radiation oncology treatment but may have _______________",g206568,0,"a.	Outstanding balances and/or bad debt",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62100,1,"20.	Generic Treatment Plans will be created for patients that do not have an estimated amount due for radiation oncology treatment but may have _______________",g206569,1,"b.	A regularly scheduled appointment",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62100,2,"20.	Generic Treatment Plans will be created for patients that do not have an estimated amount due for radiation oncology treatment but may have _______________",g206570,2,"c.	Paperwork that needs to be updated",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62101,0,21. The Radiation Oncology Estimation Workbook is located in what folder?,g206571,0,"a.	Patient Access All - Radiation Oncology Estimator Worksheet",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62101,1,21. The Radiation Oncology Estimation Workbook is located in what folder?,g206572,1,"b.	Patient Access All - Rad Onc Profee Worksheet",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62101,2,21. The Radiation Oncology Estimation Workbook is located in what folder?,g206573,2,"c.	Patient Access All - Profee Workbook",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62102,0,"22.	When saving an estimate letter in the Radiation Oncology Estimation Workbook, the following process is followed:",g206574,0,"a.	While on the letter tab, hit the save button",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62102,1,"22.	When saving an estimate letter in the Radiation Oncology Estimation Workbook, the following process is followed:",g206575,1,"b.	While on the letter tab, do ""file, save as"" and save letter to desktop",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62102,2,"22.	When saving an estimate letter in the Radiation Oncology Estimation Workbook, the following process is followed:",g206576,2,"c.	Return to the patient tab and hit the gray save button at the top",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62103,0,"23.	 By selecting the gray ""SAVE""    button on the Patient Form tab of the Radiation Oncology Estimation Workbook, the estimate letter is:",g206577,0,"a.	Automatically saved to the Galen folder",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62103,1,"23.	 By selecting the gray ""SAVE""    button on the Patient Form tab of the Radiation Oncology Estimation Workbook, the estimate letter is:",g206578,1,"b.	Automatically saved to the desktop",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62103,2,"23.	 By selecting the gray ""SAVE""    button on the Patient Form tab of the Radiation Oncology Estimation Workbook, the estimate letter is:",g206579,2,"c.	Automatically sent to the patient",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62104,0,"24.	 Once the Profee estimate letter is saved on the Galen drive, the Oncology Financial Resource Specialist should access the Galen drive and",g206580,0,"a.	Open the excel workbook, access the estimate letter and change to a PDF format",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62104,1,"24.	 Once the Profee estimate letter is saved on the Galen drive, the Oncology Financial Resource Specialist should access the Galen drive and",g206581,1,"b.	Open the excel workbook and delete the estimate letter",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62104,2,"24.	 Once the Profee estimate letter is saved on the Galen drive, the Oncology Financial Resource Specialist should access the Galen drive and",g206582,2,"c.	Do nothing.  Galen does not need the letter",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62105,0,"25.	 Profee and technical payments are applied to the same outlet in Wells Fargo.",g206583,0,TRUE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62105,1,"25.	 Profee and technical payments are applied to the same outlet in Wells Fargo.",g206584,1,FALSE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62106,0,"26.	 What two steps have to be done in order to create the Profee Financial Estimate letter once the Oncology Financial Resource Specialist accesses the Radiation Oncology Estimation Workbook?",g206585,0,"a.	Fill in the insurance benefits on the Patient Form and review the Detailed Bill Estimate tab",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62106,1,"26.	 What two steps have to be done in order to create the Profee Financial Estimate letter once the Oncology Financial Resource Specialist accesses the Radiation Oncology Estimation Workbook?",g206586,1,"b.	Fill in the insurance benefits on the Patient Form tab and save to the desktop",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62106,2,"26.	 What two steps have to be done in order to create the Profee Financial Estimate letter once the Oncology Financial Resource Specialist accesses the Radiation Oncology Estimation Workbook?",g206587,2,"c.	Fill in the insurance benefits on the Patient Form tab and compare the Treatment Plan CPT Codes and Quantities to the ones listed on the Template List tab and update as needed",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62107,0,"27.	 If an Oncology Financial Resource Specialist is unable to reach a patient to provide an estimate prior to treatment, the patient is considered financially cleared.",g206588,0,TRUE,0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62107,1,"27.	 If an Oncology Financial Resource Specialist is unable to reach a patient to provide an estimate prior to treatment, the patient is considered financially cleared.",g206589,1,FALSE,1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62108,0,"28.	 When should the Oncology Financial Resource Specialist run eligibility through RevRunner (if applicable) to see if the patient has met more of their deductible or out of pocket prior to creating the estimate letter?",g206590,0,"a.	Only if benefits were verified by the Intake Team within the past two weeks",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62108,1,"28.	 When should the Oncology Financial Resource Specialist run eligibility through RevRunner (if applicable) to see if the patient has met more of their deductible or out of pocket prior to creating the estimate letter?",g206591,1,"b.	Only if benefits were verified by the Intake Team within the past week",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62108,2,"28.	 When should the Oncology Financial Resource Specialist run eligibility through RevRunner (if applicable) to see if the patient has met more of their deductible or out of pocket prior to creating the estimate letter?",g206592,2,"c.	Prior to every estimate",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62109,0,"29.	 The Oncology Financial Resource Specialist should scan both the profee and technical estimate letters to what folder in ILE?",g206593,0,"a.	PFS:  POS COLLECTIONS DOCUMENTS",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62109,1,"29.	 The Oncology Financial Resource Specialist should scan both the profee and technical estimate letters to what folder in ILE?",g206594,1,"b.	PFS:  PRICE ESTIMATE LETTERS",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62109,2,"29.	 The Oncology Financial Resource Specialist should scan both the profee and technical estimate letters to what folder in ILE?",g206595,2,"c.	PFS:  COLLECTIONS LETTERS",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62110,0,"30.	  If a patient pays more than the required 1/3 down deposit the Oncology Financial Resource Specialist should use what form located on the Revenue Cycle Website?",g206596,0,"a.	Generic FET Letter",1,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62110,1,"30.	  If a patient pays more than the required 1/3 down deposit the Oncology Financial Resource Specialist should use what form located on the Revenue Cycle Website?",g206597,1,"b.	Copay FET Letter",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19718,8952,Elearning-0000-233,g13754,g62110,2,"30.	  If a patient pays more than the required 1/3 down deposit the Oncology Financial Resource Specialist should use what form located on the Revenue Cycle Website?",g206598,2,"c.	1/3 Down/Copay Only FET Letter",0,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021
19717,9608,Elearning-0000-83,g13753,g62080,0,"I have completed my updated Constant Observer Sheet using the Case Study provided in this CBL, filled out the top section of my Behavioral Health Annual Competency Form and signed the back, and placed these two forms in the Clinician's box.",g206518,0,TRUE,1,WSU BHS COMPETENCY 2021
19717,9608,Elearning-0000-83,g13753,g62080,1,"I have completed my updated Constant Observer Sheet using the Case Study provided in this CBL, filled out the top section of my Behavioral Health Annual Competency Form and signed the back, and placed these two forms in the Clinician's box.",g206519,1,FALSE,0,WSU BHS COMPETENCY 2021
19712,9446,Elearning-0000-682,g13749,g62076,0,I have read the contents of this CBL in its entirety and I have filled out a Constant Observer Flowsheet and submitted it in Tara's mailbox.,g206510,0,TRUE,1,CONSTANT OBSERVER CASE STUDY CBL
19712,9446,Elearning-0000-682,g13749,g62076,1,I have read the contents of this CBL in its entirety and I have filled out a Constant Observer Flowsheet and submitted it in Tara's mailbox.,g206511,1,FALSE,0,CONSTANT OBSERVER CASE STUDY CBL
19708,9159,Elearning-0000-421,g13745,g62042,0,Which of the definitions below is CORRECT?,g206383,0,"a.	Neonate refers to a person from birth to 28 days of age",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62042,1,Which of the definitions below is CORRECT?,g206384,1,"b.	Infant refers to a child who is >28 days to 1 year of age",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62042,2,Which of the definitions below is CORRECT?,g206385,2,"c.	Pediatric refers to children from 1 year to 11 years",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62042,3,Which of the definitions below is CORRECT?,g206386,3,"d.	Adolescent refers to a person who is 12-17 years",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62042,4,Which of the definitions below is CORRECT?,g206387,4,"e.	Adult refers to a person who is 18 years or greater",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62042,5,Which of the definitions below is CORRECT?,g206388,5,"f.	All of the above are correct",1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62043,0,Which of the following statements is INCORRECT?,g206389,0,"a.	Neonatal code carts are located in Special Care Nursery, L&D, and FCC, and are used to resuscitate neonates and infants after birth until discharge.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62043,1,Which of the following statements is INCORRECT?,g206390,1,"b.	Neonatal carts are located in ED and are used to Resuscitate Neonates and Infants up to 1 year of age.",1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62043,2,Which of the following statements is INCORRECT?,g206391,2,"c.	Broselow carts are located in ED and Surgery and are used for resuscitation of children in those areas (Infants and pediatrics).",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62043,3,Which of the following statements is INCORRECT?,g206392,3,"d.	Adult Code Carts contain a drawer (drawer 4) which contains medications and references for Infant and Pediatric Resuscitation.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62044,0,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,g206393,0,"a.	The ED will call the Neonatal evaluation team and use the Neonatal Code Cart and NRP algorithms for resuscitation",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62044,1,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,g206394,1,"b.	The ED will use the Broselow Code Cart and PALS algorithms for resuscitation",1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62044,2,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,g206395,2,"c.	The ED will use the Adult Code Cart and ACLS algorithms for resuscitation",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62044,3,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,g206396,3,"d.	None of the above is correct",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62045,0,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",g206397,0,"a.	Neonatal Code Carts have reference binders on each cart with dosing sheets to calculate exact doses of medications based on weight or gestational age as applicable.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62045,1,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",g206398,1,"b.	Broselow Carts have color coded weight based PALS Pediatric Dosing Sheets in the medication drawer that correspond to drawer color and medication concentrations, and should be used to determine exact doses of medications based on weight.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62045,2,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",g206399,2,"c.	At Northside Hospital, the Broselow Tape in the Pediatric Medication Drawer should only be used to obtain an estimated weight range of a pediatric patient by measuring height / length if actual weight is not known.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62045,3,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",g206400,3,"d.	Adult Code Carts have weight based Pediatric Dosing Sheets located in the Pediatric Drawer (Drawer 4), which is identical to the Broselow Code Cart medication drawer.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62045,4,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",g206401,4,"e.	All of the above are correct.",1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62046,0,"True or false? The PALS dosing reference indicates initial dosing and rate for epinephrine and dopamine drips, and a weight based titration chart has been added for drip titration.",g206402,0,TRUE,1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62046,1,"True or false? The PALS dosing reference indicates initial dosing and rate for epinephrine and dopamine drips, and a weight based titration chart has been added for drip titration.",g206403,1,FALSE,0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62047,0,Which of the below is INCORRECT regarding the preferred way to administer 0.01mg/ kg epinephrine dose for PEA to a 9 kg infant in the ED:,g206404,0,"a.	Use the PALS dosing sheet in the pediatric medication tray of the Broselow Code Cart to verify the correct exact dose in mg and mL based on the patient's weight",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62047,1,Which of the below is INCORRECT regarding the preferred way to administer 0.01mg/ kg epinephrine dose for PEA to a 9 kg infant in the ED:,g206405,1,"b.	Using the 1mg/ 10mL epinephrine Abboject in the pediatric medication drawer, withdraw 0.9ml (0.09mg) epinephrine into a syringe with appropriate markings of measurement using a transfer device (Rapidfill connector or stopcock)",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62047,2,Which of the below is INCORRECT regarding the preferred way to administer 0.01mg/ kg epinephrine dose for PEA to a 9 kg infant in the ED:,g206406,2,"c.	Using the 1mg/ 10mL epinephrine Abboject in the pediatric medication drawer, inject  0.9ml (0.09mg) epinephrine dose into the infant's IV or IO access directly from the 1mg/ 10ml epinephrine Abboject syringe.",1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62048,0,Which of the following is CORRECT regarding Neonatal Resuscitation?,g206407,0,"a.	Epinephrine is the primary pharmacologic treatment in NRP algorithm for neonatal resuscitation",1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62048,1,Which of the following is CORRECT regarding Neonatal Resuscitation?,g206408,1,"b.	Lidocaine and amiodarone are the primary treatment options for pulseless ventricular fibrillation and ventricular tachycardia in NRP the algorithm.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62048,2,Which of the following is CORRECT regarding Neonatal Resuscitation?,g206409,2,"c.	The NRP algorithm includes defibrillation for pulseless ventricular fibrillation and ventricular tachycardia.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62049,0,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,g206410,0,"a.	Epinephrine is the only pharmacologic treatment in the PALS algorithms for infant and pediatric resuscitation",1,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62049,1,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,g206411,1,"b.	Epinephrine and Atropine are both options for symptomatic bradycardia in the PALS bradycardia algorithm.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62049,2,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,g206412,2,"c.	Lidocaine and amiodarone are antiarrhythmic treatment options for pulseless ventricular fibrillation and ventricular tachycardia in the PALS Cardiac Arrest algorithm.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19708,9159,Elearning-0000-421,g13745,g62049,3,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,g206413,3,"d.	The PALS algorithm includes defibrillation for pulseless ventricular fibrillation and ventricular tachycardia.",0,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY
19707,9094,Elearning-0000-362,g13744,g62041,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g206381,0,TRUE,1,NSH1208 AMENDMENT 3
19707,9094,Elearning-0000-362,g13744,g62041,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g206382,1,FALSE,0,NSH1208 AMENDMENT 3
19705,9072,Elearning-0000-342,g13742,g62018,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g206290,0,TRUE,1,NSH1297 AMENDMENT 4
19705,9072,Elearning-0000-342,g13742,g62018,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g206291,1,FALSE,0,NSH1297 AMENDMENT 4
19700,9116,Elearning-0000-382,g13738,g62003,0,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",g206244,0,"a.	Patients are NPO immediately post-op",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62003,1,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",g206245,1,"b.	Once cleared by the Surgeon, all medications will be given via the J-tube",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62003,2,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",g206246,2,"c.	The provider will evaluate the patient for utilization of the J-tube about 48 hours post-operatively",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62003,3,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",g206247,3,"d.	All of the above",1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62004,0,"2.	Post-operatively, do not manipulate, move, or discontinue the patient's NG tube without permission from the Surgeon.",g206248,0,TRUE,1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62004,1,"2.	Post-operatively, do not manipulate, move, or discontinue the patient's NG tube without permission from the Surgeon.",g206249,1,FALSE,0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62005,0,"3.	Medications may be given via the NG Tube post-operatively.",g206250,0,TRUE,0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62005,1,"3.	Medications may be given via the NG Tube post-operatively.",g206251,1,FALSE,1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62006,0,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",g206252,0,"a.	In 4 hours",1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62006,1,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",g206253,1,"b.	In 8 hours",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62006,2,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",g206254,2,"c.	In 12 hours",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62006,3,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",g206255,3,"d.	All of the above",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62007,0,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",g206256,0,"a.	The surgery severs 2 of the 3 major arteries supplying the stomach.",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62007,1,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",g206257,1,"b.	Abdominal distention can cut off the existing blood supply and cause ischemia to occur.",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62007,2,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",g206258,2,"c.	The patient is high risk for aspiration.",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62007,3,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",g206259,3,"d.	All of the above",1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62008,0,"6.	You should report white milky-colored drainage from the JP chest drain to the Thoracic Surgeon immediately since this can be an indication of a Chyle leak related to lymphatic system injury.",g206260,0,TRUE,1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62008,1,"6.	You should report white milky-colored drainage from the JP chest drain to the Thoracic Surgeon immediately since this can be an indication of a Chyle leak related to lymphatic system injury.",g206261,1,FALSE,0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62009,0,"7.	I have read the CBL in its entirety and understand that I am responsible for this information.",g206262,0,TRUE,1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62009,1,"7.	I have read the CBL in its entirety and understand that I am responsible for this information.",g206263,1,FALSE,0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62010,0,"8.	I have listened to the video in its entirety and understand that I am responsible for this information.",g206264,0,TRUE,1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62010,1,"8.	I have listened to the video in its entirety and understand that I am responsible for this information.",g206265,1,FALSE,0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62011,0,"9.	Oral care is essential for these patients in order to prevent",g206266,0,"a.	HAP",1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62011,1,"9.	Oral care is essential for these patients in order to prevent",g206267,1,"b.	CAP",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62011,2,"9.	Oral care is essential for these patients in order to prevent",g206268,2,"c.	VAP",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62011,3,"9.	Oral care is essential for these patients in order to prevent",g206269,3,"d.	None of the above",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62012,0,"10.	A potential complication for this surgery that has a high mortality rate is",g206270,0,"a.	Pneumonia and ARDS",1,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62012,1,"10.	A potential complication for this surgery that has a high mortality rate is",g206271,1,"b.	Unresolved pain",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62012,2,"10.	A potential complication for this surgery that has a high mortality rate is",g206272,2,"c.	J tube complications",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19700,9116,Elearning-0000-382,g13738,g62012,3,"10.	A potential complication for this surgery that has a high mortality rate is",g206273,3,"d.	None of the above",0,NSC ICU ESOPHAGOGASTRECTOMY SURGERY
19699,9890,Questions-0000-24,g13737,g61978,0,Please list the location for this activity.,g206140,0,Atlanta,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61978,1,Please list the location for this activity.,g206141,1,Forsyth,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61978,2,Please list the location for this activity.,g206142,2,Cherokee,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61978,3,Please list the location for this activity.,g206143,3,Other,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61979,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g206144,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61979,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g206145,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61979,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g206146,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61979,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g206147,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61979,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g206148,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61980,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g206149,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61980,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g206150,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61980,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g206151,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61980,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g206152,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61980,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g206153,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61981,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g206154,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61981,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g206155,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61981,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g206156,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61981,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g206157,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61981,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g206158,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61982,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g206159,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61982,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g206160,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61982,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g206161,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61982,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g206162,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61982,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g206163,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61983,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g206164,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61983,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g206165,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61983,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g206166,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61983,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g206167,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61983,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g206168,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61984,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g206169,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61984,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g206170,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61984,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g206171,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61984,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g206172,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61984,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g206173,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61985,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g206174,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61985,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g206175,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61985,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g206176,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61985,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g206177,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61985,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g206178,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61986,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g206179,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61986,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g206180,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61986,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g206181,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61986,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g206182,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61986,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g206183,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61987,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g206184,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61987,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g206185,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61987,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g206186,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61987,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g206187,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61987,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g206188,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61988,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g206189,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61988,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g206190,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61988,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g206191,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61988,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g206192,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61988,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g206193,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61989,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g206194,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61989,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g206195,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61989,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g206196,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61989,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g206197,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61989,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g206198,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61990,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g206199,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61990,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g206200,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61990,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g206201,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61990,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g206202,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61990,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g206203,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61991,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g206204,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61991,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g206205,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61991,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g206206,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61991,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g206207,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61991,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g206208,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61992,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g206209,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61992,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g206210,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61992,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g206211,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61992,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g206212,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61992,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g206213,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61993,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g206214,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61993,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g206215,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61993,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g206216,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61993,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g206217,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61993,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g206218,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61994,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g206219,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61994,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g206220,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61994,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g206221,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61994,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g206222,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61994,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,g206223,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61995,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g206224,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61995,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g206225,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61995,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g206226,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61995,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g206227,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61995,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g206228,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61996,0,"Overall, this activity was:",g206229,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61996,1,"Overall, this activity was:",g206230,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61996,2,"Overall, this activity was:",g206231,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61996,3,"Overall, this activity was:",g206232,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61996,4,"Overall, this activity was:",g206233,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61997,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g206234,0,Yes,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61997,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g206235,1,No,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g61997,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g206236,2,N/A,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g62000,0,How would you improve this class?,g206237,0,Reduce content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g62000,1,How would you improve this class?,g206238,1,Increase content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g62000,2,How would you improve this class?,g206239,2,Update content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g62000,3,How would you improve this class?,g206240,3,Improve the instructional methods,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g62000,4,How would you improve this class?,g206241,4,Make course activities more stimulating,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g62000,5,How would you improve this class?,g206242,5,Slow the pace of the class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19699,9890,Questions-0000-24,g13737,g62000,6,How would you improve this class?,g206243,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21
19696,9603,Elearning-0000-825,g13731,g61866,0,I have read and understand the CBL Dialysis Communication Update May 2021(2) and the subsequent expectations for compliance.,g205700,0,TRUE,1,DIALYSIS COMMUNICATION UPDATE  MAY 2021(2)
19696,9603,Elearning-0000-825,g13731,g61866,1,I have read and understand the CBL Dialysis Communication Update May 2021(2) and the subsequent expectations for compliance.,g205701,1,FALSE,0,DIALYSIS COMMUNICATION UPDATE  MAY 2021(2)
19692,8529,Elearning-0000-140,g13727,g61831,0,True or false- (Malignant Hyperthermia) MH and Local Anesthetic Toxicity (LAST) should be treated as an emergency,g205592,0,TRUE,1,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61831,1,True or false- (Malignant Hyperthermia) MH and Local Anesthetic Toxicity (LAST) should be treated as an emergency,g205593,1,FALSE,0,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61832,0,True or false- MH only occurs immediately after a triggering agent is administered.,g205594,0,TRUE,0,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61832,1,True or false- MH only occurs immediately after a triggering agent is administered.,g205595,1,FALSE,1,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61833,0,What medications can cause LAST?,g205596,0,A)      Exparel,0,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61833,1,What medications can cause LAST?,g205597,1,B)      Bupivacaine,0,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61833,2,What medications can cause LAST?,g205598,2,C)      Ropivacaine,0,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61833,3,What medications can cause LAST?,g205599,3,D)      Lidocaine,0,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61833,4,What medications can cause LAST?,g205600,4,E)      A&B only,0,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19692,8529,Elearning-0000-140,g13727,g61833,5,What medications can cause LAST?,g205601,5,F)       All of the above,1,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY
19691,9204,Elearning-0000-462,g13726,g61823,0,How often should DTR's be assessed and documented per policy?,g205564,0,"a.	Every 30 minutes",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61823,1,How often should DTR's be assessed and documented per policy?,g205565,1,"b.	Every hour",1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61823,2,How often should DTR's be assessed and documented per policy?,g205566,2,"c.	Every 2 hours",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61823,3,How often should DTR's be assessed and documented per policy?,g205567,3,"d.	Every 15 minutes",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61824,0,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",g205568,0,"a.	6.4 mg/dl",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61824,1,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",g205569,1,"b.	7.4 mg/dl",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61824,2,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",g205570,2,"c.	8.4 mg/dl",1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61824,3,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",g205571,3,"d.	9.4 mg/dl",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61825,0,"3.	How long do you have to communicate a critical value with the physician?",g205572,0,"a.	5 minutes",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61825,1,"3.	How long do you have to communicate a critical value with the physician?",g205573,1,"b.	15 minutes",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61825,2,"3.	How long do you have to communicate a critical value with the physician?",g205574,2,"c.	1 hour",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61825,3,"3.	How long do you have to communicate a critical value with the physician?",g205575,3,"d.	30 minutes",1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61826,0,"4.	How often should urine output be assessed and documented per policy?",g205576,0,"a.	Every hour",1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61826,1,"4.	How often should urine output be assessed and documented per policy?",g205577,1,"b.	Every 2 hours",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61826,2,"4.	How often should urine output be assessed and documented per policy?",g205578,2,"c.	Every 4 hours",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61826,3,"4.	How often should urine output be assessed and documented per policy?",g205579,3,"d.	Every 8 hours",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61827,0,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",g205580,0,"a.	Every hour",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61827,1,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",g205581,1,"b.	Every 5 min",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61827,2,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",g205582,2,"c.	Every 15 min",1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61827,3,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",g205583,3,"d.	Every 30 min",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61828,0,". During magnesium maintenance infusion, VS should be assessed and documented every hour",g205584,0,TRUE,1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61828,1,". During magnesium maintenance infusion, VS should be assessed and documented every hour",g205585,1,FALSE,0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61829,0,Initiation and maintenance of magnesium sulfate does not require verification by 2 RN's.,g205586,0,TRUE,0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61829,1,Initiation and maintenance of magnesium sulfate does not require verification by 2 RN's.,g205587,1,FALSE,1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61830,0,"8.	Which of the following is the antagonist of magnesium sulfate?",g205588,0,"a.	Calcium Carbonate",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61830,1,"8.	Which of the following is the antagonist of magnesium sulfate?",g205589,1,"b.	Calcium Gluconate",1,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61830,2,"8.	Which of the following is the antagonist of magnesium sulfate?",g205590,2,"c.	Sodium Chloride",0,NSC ICU MAG SULFATE POLICY
19691,9204,Elearning-0000-462,g13726,g61830,3,"8.	Which of the following is the antagonist of magnesium sulfate?",g205591,3,"d.	Magnesium Sulfate does not have an antagonist",0,NSC ICU MAG SULFATE POLICY
19688,9956,Questions-0000-90,g13720,g61760,0,Please list the location for this activity.,g205334,0,Atlanta,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61760,1,Please list the location for this activity.,g205335,1,Cherokee,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61760,2,Please list the location for this activity.,g205336,2,Forsyth,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61760,3,Please list the location for this activity.,g205337,3,Other,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61761,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",g205338,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61761,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",g205339,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61761,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",g205340,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61761,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",g205341,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61761,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",g205342,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61762,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",g205343,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61762,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",g205344,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61762,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",g205345,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61762,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",g205346,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61762,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",g205347,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61763,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",g205348,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61763,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",g205349,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61763,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",g205350,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61763,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",g205351,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61763,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",g205352,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61764,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",g205353,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61764,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",g205354,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61764,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",g205355,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61764,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",g205356,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61764,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",g205357,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61765,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",g205358,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61765,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",g205359,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61765,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",g205360,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61765,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",g205361,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61765,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",g205362,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61766,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",g205363,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61766,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",g205364,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61766,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",g205365,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61766,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",g205366,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61766,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",g205367,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61767,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",g205368,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61767,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",g205369,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61767,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",g205370,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61767,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",g205371,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61767,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",g205372,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61768,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",g205373,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61768,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",g205374,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61768,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",g205375,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61768,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",g205376,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61768,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",g205377,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61769,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",g205378,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61769,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",g205379,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61769,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",g205380,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61769,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",g205381,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61769,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",g205382,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61770,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",g205383,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61770,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",g205384,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61770,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",g205385,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61770,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",g205386,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61770,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",g205387,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61771,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",g205388,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61771,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",g205389,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61771,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",g205390,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61771,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",g205391,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61771,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",g205392,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61772,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",g205393,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61772,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",g205394,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61772,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",g205395,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61772,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",g205396,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61772,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",g205397,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61773,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",g205398,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61773,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",g205399,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61773,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",g205400,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61773,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",g205401,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61773,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",g205402,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61774,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g205403,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61774,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g205404,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61774,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g205405,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61774,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g205406,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61774,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g205407,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61775,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g205408,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61775,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g205409,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61775,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g205410,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61775,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g205411,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61775,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g205412,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61776,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,g205413,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61776,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,g205414,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61776,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,g205415,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61776,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,g205416,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61776,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,g205417,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61777,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g205418,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61777,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g205419,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61777,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g205420,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61777,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g205421,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61777,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g205422,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61778,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g205423,0,Strongly Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61778,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g205424,1,Agree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61778,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g205425,2,No Opinion,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61778,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g205426,3,Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61778,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g205427,4,Strongly Disagree,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61779,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",g205428,0,Excellent,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61779,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",g205429,1,Very Good,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61779,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",g205430,2,Good,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61779,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",g205431,3,Fair,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61779,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",g205432,4,Poor,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61780,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g205433,0,Excellent,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61780,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g205434,1,Very Good,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61780,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g205435,2,Good,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61780,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g205436,3,Fair,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61780,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",g205437,4,Poor,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61781,0,"Overall, this activity was:",g205438,0,Excellent,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61781,1,"Overall, this activity was:",g205439,1,Very Good,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61781,2,"Overall, this activity was:",g205440,2,Good,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61781,3,"Overall, this activity was:",g205441,3,Fair,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61781,4,"Overall, this activity was:",g205442,4,Poor,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61782,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g205443,0,Yes,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61782,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g205444,1,No,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61782,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g205445,2,N/A,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61785,0,How would you improve this class?,g205446,0,Reduce content covered in class,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61785,1,How would you improve this class?,g205447,1,Increase content covered in class,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61785,2,How would you improve this class?,g205448,2,Update content covered in class,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61785,3,How would you improve this class?,g205449,3,Improve the instructional methods,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61785,4,How would you improve this class?,g205450,4,Make course activities more stimulating,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61785,5,How would you improve this class?,g205451,5,Slow the pace of the class,0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19688,9956,Questions-0000-90,g13720,g61785,6,How would you improve this class?,g205452,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21
19687,114,SCORM-0000-195,g13719,g61789,0,I have read and understood the content within the Timeless 112: Feed Consents CBL.,g205455,0,TRUE,1,TIMELESS 112: FEED CONSENTS
19687,114,SCORM-0000-195,g13719,g61789,1,I have read and understood the content within the Timeless 112: Feed Consents CBL.,g205456,1,FALSE,0,TIMELESS 112: FEED CONSENTS
19686,113,SCORM-0000-194,g13718,g61790,0,I have read and understood the content within the Timeless 111: Mother's Features CBL.,g205457,0,TRUE,1,TIMELESS 111: MOTHER FEATURES
19686,113,SCORM-0000-194,g13718,g61790,1,I have read and understood the content within the Timeless 111: Mother's Features CBL.,g205458,1,FALSE,0,TIMELESS 111: MOTHER FEATURES
19685,112,SCORM-0000-193,g13717,g61791,0,I have read and understood the content within the Timeless 110: Bags/Bins CBL.,g205459,0,TRUE,1,TIMELESS 110: BAGS/BINS
19685,112,SCORM-0000-193,g13717,g61791,1,I have read and understood the content within the Timeless 110: Bags/Bins CBL.,g205460,1,FALSE,0,TIMELESS 110: BAGS/BINS
19681,9328,Elearning-0000-575,g13716,g61755,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g205324,0,TRUE,1,FY2021 PHARMACY BIOSIMILAR EDUCATION
19681,9328,Elearning-0000-575,g13716,g61755,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g205325,1,FALSE,0,FY2021 PHARMACY BIOSIMILAR EDUCATION
19684,115,SCORM-0000-196,g13715,g61788,0,I have read and understood the content within the Timeless 113: Manage Community Order CBL.,g205453,0,TRUE,1,TIMELESS 113: MANAGE COMMUNITY ORDER
19684,115,SCORM-0000-196,g13715,g61788,1,I have read and understood the content within the Timeless 113: Manage Community Order CBL.,g205454,1,FALSE,0,TIMELESS 113: MANAGE COMMUNITY ORDER
19683,116,SCORM-0000-197,g13714,g61759,0,I have read and understood the content within the Timeless 114: Admin Management CBL.,g205332,0,TRUE,1,TIMELESS 114: ADMIN MANAGEMENT
19683,116,SCORM-0000-197,g13714,g61759,1,I have read and understood the content within the Timeless 114: Admin Management CBL.,g205333,1,FALSE,0,TIMELESS 114: ADMIN MANAGEMENT
19682,111,SCORM-0000-192,g13713,g61798,0,I have read and understood the content within the Timeless 109: Milk/Product Disposal and Discharge CBL.,g205473,0,TRUE,1,TIMELESS 109: MILK/PRODUCT DISPOSAL AND DISCHARGE
19682,111,SCORM-0000-192,g13713,g61798,1,I have read and understood the content within the Timeless 109: Milk/Product Disposal and Discharge CBL.,g205474,1,FALSE,0,TIMELESS 109: MILK/PRODUCT DISPOSAL AND DISCHARGE
19680,117,SCORM-0000-198,g13712,g61758,0,I have read and understood the content within the Timeless 115: Product Management CBL.,g205330,0,TRUE,1,TIMELESS 115: PRODUCT MANAGEMENT
19680,117,SCORM-0000-198,g13712,g61758,1,I have read and understood the content within the Timeless 115: Product Management CBL.,g205331,1,FALSE,0,TIMELESS 115: PRODUCT MANAGEMENT
19679,110,SCORM-0000-191,g13711,g61797,0,I have read and understood the content within the Timeless 108: Move Bottles/Products CBL.,g205471,0,TRUE,1,TIMELESS 108: MOVE BOTTLES/PRODUCT
19679,110,SCORM-0000-191,g13711,g61797,1,I have read and understood the content within the Timeless 108: Move Bottles/Products CBL.,g205472,1,FALSE,0,TIMELESS 108: MOVE BOTTLES/PRODUCT
19678,109,SCORM-0000-190,g13709,g61796,0,I have read and understood the content within the Timeless 107: Feeding CBL.,g205469,0,TRUE,1,TIMELESS 107: FEEDING
19678,109,SCORM-0000-190,g13709,g61796,1,I have read and understood the content within the Timeless 107: Feeding CBL.,g205470,1,FALSE,0,TIMELESS 107: FEEDING
19677,107,SCORM-0000-189,g13708,g61795,0,I have read and understood the content within the Timeless 106: Advanced Prepare CBL.,g205467,0,TRUE,1,TIMELESS 106: ADVANCED PREPARE
19677,107,SCORM-0000-189,g13708,g61795,1,I have read and understood the content within the Timeless 106: Advanced Prepare CBL.,g205468,1,FALSE,0,TIMELESS 106: ADVANCED PREPARE
19675,106,SCORM-0000-188,g13707,g61794,0,I have read and understood the content within the Timeless 105: Advanced Prepare Introduction CBL.,g205465,0,TRUE,1,TIMELESS 105: ADVANCED PREPARE INTRODUCTION
19675,106,SCORM-0000-188,g13707,g61794,1,I have read and understood the content within the Timeless 105: Advanced Prepare Introduction CBL.,g205466,1,FALSE,0,TIMELESS 105: ADVANCED PREPARE INTRODUCTION
19674,105,SCORM-0000-187,g13706,g61793,0,I have read and understood the content within the Timeless 104: Simple Prepare CBL.,g205463,0,TRUE,1,TIMELESS 104: SIMPLE PREPARE
19674,105,SCORM-0000-187,g13706,g61793,1,I have read and understood the content within the Timeless 104: Simple Prepare CBL.,g205464,1,FALSE,0,TIMELESS 104: SIMPLE PREPARE
19673,104,SCORM-0000-186,g13705,g61792,0,I have read and understood the content within the Timeless 103: Receive Milk/Products CBL.,g205461,0,TRUE,1,TIMELESS 103: RECEIVE MILK/PRODUCTS
19673,104,SCORM-0000-186,g13705,g61792,1,I have read and understood the content within the Timeless 103: Receive Milk/Products CBL.,g205462,1,FALSE,0,TIMELESS 103: RECEIVE MILK/PRODUCTS
19672,103,SCORM-0000-185,g13704,g61757,0,I have read and understood the content within the Timeless 102: Label Printing CBL.,g205328,0,TRUE,1,TIMELESS 102: LABEL PRINTING
19672,103,SCORM-0000-185,g13704,g61757,1,I have read and understood the content within the Timeless 102: Label Printing CBL.,g205329,1,FALSE,0,TIMELESS 102: LABEL PRINTING
19671,102,SCORM-0000-184,g13703,g61756,0,I have read and understood the content within the Timeless 101: Introduction CBL.,g205326,0,TRUE,1,TIMELESS 101: INTRODUCTION
19671,102,SCORM-0000-184,g13703,g61756,1,I have read and understood the content within the Timeless 101: Introduction CBL.,g205327,1,FALSE,0,TIMELESS 101: INTRODUCTION
19665,9492,Elearning-0000-724,g13700,g61742,0,Why is the Distress Screening completed?,g205275,0,"a)	We are told to do it",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61742,1,Why is the Distress Screening completed?,g205276,1,"b)	To remain accredited with COC, providing a high standard of care",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61742,2,Why is the Distress Screening completed?,g205277,2,"c)	To assess level of distress of patients, identify their needs and establish quality care and assistance",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61742,3,Why is the Distress Screening completed?,g205278,3,"d)	Both B and C",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61743,0,When would it be more appropriate to use a 2013 versus 1013?,g205279,0,"a)	The patient is incapacitated by alcohol, drugs or other substance on a re-occurring basis and present as a substantial risk of imminent harm to self and/or others if left untreated",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61743,1,When would it be more appropriate to use a 2013 versus 1013?,g205280,1,"b)	The patient has mental illness and presents as a substantial risk of harm to self or others",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61743,2,When would it be more appropriate to use a 2013 versus 1013?,g205281,2,"c)	The patient has only mental illness and presents substantial risk of imminent harm to self or others with no primary diagnosis of alcoholism or other substance abuse nor dependency, he/she presents as a substantial risk of imminent harm to self or others.",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61743,3,When would it be more appropriate to use a 2013 versus 1013?,g205282,3,"d)	Patient is unable to care for his/her own physical health or safety as to create an imminently life-threatening crisis",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61744,0,If a patient score 4-7,g205283,0,"a)	Review and sign form, assess patient for any immediate needs/concerns",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61744,1,If a patient score 4-7,g205284,1,"b)	RN signs form, which is scanned into EMR",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61744,2,If a patient score 4-7,g205285,2,"c)	Email distress screening tool to OCSW",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61744,3,If a patient score 4-7,g205286,3,"d)	Notify patient that they will receive call from Social Worker",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61744,4,If a patient score 4-7,g205287,4,"e)	All of the above",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61745,0,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",g205288,0,"a)	Keep the patient on the phone",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61745,1,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",g205289,1,"b)	Notify the supervisor or another staff member to locate the patient's address",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61745,2,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",g205290,2,"c)	Call 911 to go to the patient's location",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61745,3,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",g205291,3,"d)	Do not document in patient's medical chart since the patient is not in the office.",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61745,4,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",g205292,4,"e)	Submit an incident report",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61746,0,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,g205293,0,"a)	Follow the Chain of Command Communication for your area and notify OSW/Behavioral Health Services, notify MD if available",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61746,1,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,g205294,1,"b)	Do not leave patient alone",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61746,2,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,g205295,2,"c)	Call 911 first, then call security, if available, to make aware of the situation.",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61746,3,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,g205296,3,"d)	Document facts of the event in the patient ΓÇÿs medical chart and complete an incident report",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61747,0,"In handling type 1 patients, which of the following processes should be utilized?",g205297,0,"a)	Follow the chain of command for your area and notify the OSW/Behavioral Health Services",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61747,1,"In handling type 1 patients, which of the following processes should be utilized?",g205298,1,"b)	Call Security for your respective location; patient should not be left alone",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61747,2,"In handling type 1 patients, which of the following processes should be utilized?",g205299,2,"c)	If OSW does not respond within a reasonable timeframe, call the Psych-Oncology Coordinator, respective Supervisor/ Lead OSW, or BHS, notify MD, if available.",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61747,3,"In handling type 1 patients, which of the following processes should be utilized?",g205300,3,"d)	Initiate a 1013 and transfer process with appropriate documentation",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61747,4,"In handling type 1 patients, which of the following processes should be utilized?",g205301,4,"e)	All of the above",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61748,0,Why is the Distress Screening completed?,g205302,0,"a)	We are told to do it",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61748,1,Why is the Distress Screening completed?,g205303,1,"b)	To remain accredited with COC, providing a high standard of care",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61748,2,Why is the Distress Screening completed?,g205304,2,"c)	To assess level of distress of patients, identify their needs and establish quality care and assistance",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61748,3,Why is the Distress Screening completed?,g205305,3,"d)	Both B and C",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61749,0,If a patient scores 8-10,g205306,0,"a)	Review form with patient, assess for immediate needs/concerns, call/text OCSW/Behavioral Health for immediate assessment (in-person or telephone);",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61749,1,If a patient scores 8-10,g205307,1,"b)	Input data into EMR",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61749,2,If a patient scores 8-10,g205308,2,"c)	Email to OSW's email",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61749,3,If a patient scores 8-10,g205309,3,"d)	All of the above",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61750,0,Patient scores 0-3,g205310,0,"a)	Review form with patient, assess for immediate needs/concerns",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61750,1,Patient scores 0-3,g205311,1,"b)	Input form in EMR, making sure to input score and check box ""reviewed by RN""",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61750,2,Patient scores 0-3,g205312,2,"c)	Educate patient on availability of psychosocial services. Handout accompanies distress tool",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61750,3,Patient scores 0-3,g205313,3,"d)	All of the above",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61751,0,When should patient be screen in order to remain in compliance with the distress screening guidelines?,g205314,0,"a)	Give distress screen whenever you want",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61751,1,When should patient be screen in order to remain in compliance with the distress screening guidelines?,g205315,1,"b)	1st, 2nd or no later than 3rd visit",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61751,2,When should patient be screen in order to remain in compliance with the distress screening guidelines?,g205316,2,"c)	Whenever there is a regimen change",0,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19665,9492,Elearning-0000-724,g13700,g61751,3,When should patient be screen in order to remain in compliance with the distress screening guidelines?,g205317,3,"d)	B & C",1,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER
19664,9707,Elearning-0000-92,g13699,g61741,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g205273,0,TRUE,1,FY2021 AD HOC MEDICATION ADMINISTRATION FOR EMERGENT AND INTRAOPERATIVE USE
19664,9707,Elearning-0000-92,g13699,g61741,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g205274,1,FALSE,0,FY2021 AD HOC MEDICATION ADMINISTRATION FOR EMERGENT AND INTRAOPERATIVE USE
19662,92,SCORM-0000-174,g13697,g61735,0,All new Shiley Flex tubes come with a tapered percutaneous tip.,g205271,0,TRUE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61735,1,All new Shiley Flex tubes come with a tapered percutaneous tip.,g205272,1,FALSE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61856,0,The Shiley Flex tube flange is rigid and will not conform to the patient's anatomy.,g205676,0,TRUE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61856,1,The Shiley Flex tube flange is rigid and will not conform to the patient's anatomy.,g205677,1,FALSE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61857,0,"The new Shiley Flex tubes have a built in 15 mm connector, so the inner cannula is not required for manual ventilation.",g205678,0,TRUE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61857,1,"The new Shiley Flex tubes have a built in 15 mm connector, so the inner cannula is not required for manual ventilation.",g205679,1,FALSE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61858,0,The inner cannulas for the Legacy Shiley and the new Shiley Flex tubes are not compatible and cannot be interchanged.,g205680,0,TRUE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61858,1,The inner cannulas for the Legacy Shiley and the new Shiley Flex tubes are not compatible and cannot be interchanged.,g205681,1,FALSE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61859,0,The Shiley Flex inner cannula does not need to be changed unless it is visibly soiled.,g205682,0,TRUE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61859,1,The Shiley Flex inner cannula does not need to be changed unless it is visibly soiled.,g205683,1,FALSE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61860,0,The recommended cuff pressure for the Shiley Flex taperguard cuff is,g205684,0,(A) 15 cmH2O,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61860,1,The recommended cuff pressure for the Shiley Flex taperguard cuff is,g205685,1,(B) 20 cmH2O,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61860,2,The recommended cuff pressure for the Shiley Flex taperguard cuff is,g205686,2,(C) 25 cmH2O,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61860,3,The recommended cuff pressure for the Shiley Flex taperguard cuff is,g205687,3,(D) 35 cmH2O,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61861,0,You do not need to place a laminated sign at the head of the patient's bed if a legacy Shiley trach tube is in use.,g205688,0,TRUE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61861,1,You do not need to place a laminated sign at the head of the patient's bed if a legacy Shiley trach tube is in use.,g205689,1,FALSE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61862,0,"Whenever a trach tube is downsized, the new obturator must be placed at the head of the bed and the old one discarded.",g205690,0,TRUE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61862,1,"Whenever a trach tube is downsized, the new obturator must be placed at the head of the bed and the old one discarded.",g205691,1,FALSE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61863,0,The transparent and flexible design of the Shiley Flex flange results in 80% less pressure injuries compared to the Shiley Legacy.,g205692,0,TRUE,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61863,1,The transparent and flexible design of the Shiley Flex flange results in 80% less pressure injuries compared to the Shiley Legacy.,g205693,1,FALSE,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61864,0,"If your product reference code is 8CN85H, your trach size is",g205694,0,(A) non-disposable 8.5 cuffed tracheostomy tube,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61864,1,"If your product reference code is 8CN85H, your trach size is",g205695,1,(B) disposable 8.5 cuffless tracheostomy tube,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61864,2,"If your product reference code is 8CN85H, your trach size is",g205696,2,(C) non-disposable 8 cuffed tracheostomy tube,0,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19662,92,SCORM-0000-174,g13697,g61864,3,"If your product reference code is 8CN85H, your trach size is",g205697,3,(D) disposable 8 cuffed tracheostomy tube,1,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES
19659,9622,Elearning-0000-842,g13696,g61672,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 CPG Stroke Education"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g205015,0,TRUE,1,FY2021 CPG STROKE EDUCATION
19659,9622,Elearning-0000-842,g13696,g61672,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 CPG Stroke Education"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g205016,1,FALSE,0,FY2021 CPG STROKE EDUCATION
19494,9623,Elearning-0000-843,g13695,g61665,0,"BEFAST means: Balance, Eyes, Face, Arms, Speech, Time.",g205001,0,TRUE,1,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT
19494,9623,Elearning-0000-843,g13695,g61665,1,"BEFAST means: Balance, Eyes, Face, Arms, Speech, Time.",g205002,1,FALSE,0,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT
19494,9623,Elearning-0000-843,g13695,g61666,0,It is important to know the last known well (LKW) of the patient.,g205003,0,TRUE,1,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT
19494,9623,Elearning-0000-843,g13695,g61666,1,It is important to know the last known well (LKW) of the patient.,g205004,1,FALSE,0,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT
19494,9623,Elearning-0000-843,g13695,g61667,0,"You can help to decrease your personal risk factors with diet, exercise, tobacco free life, and taking your prescribed medications.",g205005,0,TRUE,1,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT
19494,9623,Elearning-0000-843,g13695,g61667,1,"You can help to decrease your personal risk factors with diet, exercise, tobacco free life, and taking your prescribed medications.",g205006,1,FALSE,0,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT
19638,9896,Questions-0000-30,g13679,g61632,0,Please list the location for this activity.,g204902,0,Atlanta,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61632,1,Please list the location for this activity.,g204903,1,Forsyth,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61632,2,Please list the location for this activity.,g204904,2,Cherokee,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61632,3,Please list the location for this activity.,g204905,3,Other,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61633,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",g204906,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61633,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",g204907,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61633,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",g204908,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61633,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",g204909,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61633,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",g204910,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61634,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",g204911,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61634,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",g204912,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61634,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",g204913,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61634,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",g204914,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61634,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",g204915,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61635,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204916,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61635,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204917,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61635,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204918,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61635,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204919,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204920,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61636,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204921,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61636,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204922,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61636,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204923,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61636,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204924,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61636,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204925,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61637,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,g204926,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61637,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,g204927,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61637,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,g204928,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61637,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,g204929,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61637,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,g204930,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61638,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204931,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61638,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204932,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61638,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204933,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61638,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204934,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61638,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204935,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61639,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,g204936,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61639,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,g204937,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61639,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,g204938,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61639,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,g204939,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61639,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,g204940,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61640,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204941,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61640,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204942,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61640,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204943,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61640,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204944,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61640,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204945,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61641,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",g204946,0,Excellent,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61641,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",g204947,1,Very Good,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61641,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",g204948,2,Good,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61641,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",g204949,3,Fair,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61641,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",g204950,4,Poor,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61642,0,"Overall, this activity was:",g204951,0,Excellent,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61642,1,"Overall, this activity was:",g204952,1,Very Good,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61642,2,"Overall, this activity was:",g204953,2,Good,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61642,3,"Overall, this activity was:",g204954,3,Fair,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61642,4,"Overall, this activity was:",g204955,4,Poor,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61643,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204956,0,Yes,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61643,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204957,1,No,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61643,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204958,2,N/A,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61646,0,How would you improve this class?,g204959,0,Reduce content covered in class,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61646,1,How would you improve this class?,g204960,1,Increase content covered in class,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61646,2,How would you improve this class?,g204961,2,Update content covered in class,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61646,3,How would you improve this class?,g204962,3,Improve the instructional methods,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61646,4,How would you improve this class?,g204963,4,Make course activities more stimulating,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61646,5,How would you improve this class?,g204964,5,Slow the pace of the class,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61646,6,How would you improve this class?,g204965,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61649,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",g204966,0,Strongly Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61649,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",g204967,1,Agree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61649,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",g204968,2,No Opinion,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61649,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",g204969,3,Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19638,9896,Questions-0000-30,g13679,g61649,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",g204970,4,Strongly Disagree,0,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21
19637,9889,Questions-0000-23,g13675,g61596,0,Please list the location for this activity.,g204778,0,Atlanta,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61596,1,Please list the location for this activity.,g204779,1,Forsyth,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61596,2,Please list the location for this activity.,g204780,2,Cherokee,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61596,3,Please list the location for this activity.,g204781,3,Other,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61597,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g204782,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61597,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g204783,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61597,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g204784,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61597,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g204785,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61597,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",g204786,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61598,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g204787,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61598,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g204788,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61598,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g204789,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61598,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g204790,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61598,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",g204791,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61599,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g204792,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61599,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g204793,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61599,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g204794,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61599,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g204795,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61599,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",g204796,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61600,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g204797,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61600,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g204798,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61600,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g204799,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61600,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g204800,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61600,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",g204801,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61601,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g204802,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61601,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g204803,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61601,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g204804,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61601,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g204805,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61601,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",g204806,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61602,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g204807,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61602,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g204808,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61602,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g204809,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61602,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g204810,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61602,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",g204811,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61603,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g204812,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61603,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g204813,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61603,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g204814,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61603,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g204815,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61603,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",g204816,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61604,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g204817,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61604,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g204818,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61604,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g204819,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61604,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g204820,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61604,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",g204821,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61605,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g204822,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61605,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g204823,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61605,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g204824,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61605,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g204825,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61605,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",g204826,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61606,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g204827,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61606,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g204828,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61606,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g204829,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61606,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g204830,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61606,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",g204831,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61607,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g204832,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61607,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g204833,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61607,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g204834,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61607,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g204835,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61607,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",g204836,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61608,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204837,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61608,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204838,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61608,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204839,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61608,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204840,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61608,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204841,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61609,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g204842,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61609,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g204843,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61609,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g204844,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61609,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g204845,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61609,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,g204846,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61610,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204847,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61610,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204848,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61610,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204849,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61610,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204850,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61610,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204851,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61611,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204852,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61611,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204853,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61611,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204854,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61611,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204855,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61611,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204856,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61612,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204857,0,Strongly Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61612,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204858,1,Agree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61612,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204859,2,No Opinion,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61612,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204860,3,Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61612,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204861,4,Strongly Disagree,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61613,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g204862,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61613,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g204863,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61613,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g204864,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61613,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g204865,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61613,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",g204866,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61614,0,"Overall, this activity was:",g204867,0,Excellent,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61614,1,"Overall, this activity was:",g204868,1,Very Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61614,2,"Overall, this activity was:",g204869,2,Good,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61614,3,"Overall, this activity was:",g204870,3,Fair,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61614,4,"Overall, this activity was:",g204871,4,Poor,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61615,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204872,0,Yes,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61615,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204873,1,No,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61615,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204874,2,N/A,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61618,0,How would you improve this class?,g204875,0,Reduce content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61618,1,How would you improve this class?,g204876,1,Increase content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61618,2,How would you improve this class?,g204877,2,Update content covered in class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61618,3,How would you improve this class?,g204878,3,Improve the instructional methods,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61618,4,How would you improve this class?,g204879,4,Make course activities more stimulating,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61618,5,How would you improve this class?,g204880,5,Slow the pace of the class,0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19637,9889,Questions-0000-23,g13675,g61618,6,How would you improve this class?,g204881,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21
19636,9653,Elearning-0000-870,g13674,g61595,0,I have read the attached preceptor flyer.  I understand that I need to take my Net learning transcript and class date to my manager/manager designee to enroll in the Preceptor Development Part B classes.,g205483,0,Yes,1,NURSE PRECEPTOR CLASS REGISTRATION PROCESS
19636,9653,Elearning-0000-870,g13674,g61595,1,I have read the attached preceptor flyer.  I understand that I need to take my Net learning transcript and class date to my manager/manager designee to enroll in the Preceptor Development Part B classes.,g205484,1,No,0,NURSE PRECEPTOR CLASS REGISTRATION PROCESS
19631,9947,Questions-0000-81,g13669,g61579,0,Please list the location for this activity.,g204717,0,Atlanta,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61579,1,Please list the location for this activity.,g204718,1,Cherokee,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61579,2,Please list the location for this activity.,g204719,2,Forsyth,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61579,3,Please list the location for this activity.,g204720,3,Other,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61580,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",g204721,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61580,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",g204722,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61580,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",g204723,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61580,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",g204724,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61580,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",g204725,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61581,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204726,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61581,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204727,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61581,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204728,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61581,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204729,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61581,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204730,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61582,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g204731,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61582,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g204732,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61582,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g204733,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61582,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g204734,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61582,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,g204735,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61583,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g204736,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61583,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g204737,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61583,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g204738,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61583,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g204739,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61583,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,g204740,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61584,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204741,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61584,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204742,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61584,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204743,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61584,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204744,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61584,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204745,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61585,0,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204746,0,Strongly Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61585,1,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204747,1,Agree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61585,2,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204748,2,No Opinion,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61585,3,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204749,3,Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61585,4,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,g204750,4,Strongly Disagree,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61586,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g204751,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61586,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g204752,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61586,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g204753,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61586,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g204754,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61586,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",g204755,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61587,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g204756,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61587,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g204757,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61587,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g204758,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61587,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g204759,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61587,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",g204760,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61588,0,"Overall, this activity was:",g204761,0,Excellent,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61588,1,"Overall, this activity was:",g204762,1,Very Good,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61588,2,"Overall, this activity was:",g204763,2,Good,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61588,3,"Overall, this activity was:",g204764,3,Fair,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61588,4,"Overall, this activity was:",g204765,4,Poor,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61589,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204766,0,Yes,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61589,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204767,1,No,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61589,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204768,2,N/A,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61592,0,How would you improve this class?,g204769,0,Reduce content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61592,1,How would you improve this class?,g204770,1,Increase content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61592,2,How would you improve this class?,g204771,2,Update content covered in class,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61592,3,How would you improve this class?,g204772,3,Improve the instructional methods,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61592,4,How would you improve this class?,g204773,4,Make course activities more stimulating,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61592,5,How would you improve this class?,g204774,5,Slow the pace of the class,0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19631,9947,Questions-0000-81,g13669,g61592,6,How would you improve this class?,g204775,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)"
19630,121,SCORM-0000-201,g13668,g61578,0,I'm able to view this CBL successfully.,g204715,0,a. True,1,TRALIANT_LMS_TEST_COURSE_072220_SCORM12
19630,121,SCORM-0000-201,g13668,g61578,1,I'm able to view this CBL successfully.,g204716,1,b. False,0,TRALIANT_LMS_TEST_COURSE_072220_SCORM12
19627,9616,Elearning-0000-837,g13666,g61541,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Esophagectomy Patient Care"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204562,0,TRUE,1,FY2021 SURGICAL SERVICES: ESOPHAGECTOMY PATIENT CARE
19627,9616,Elearning-0000-837,g13666,g61541,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Esophagectomy Patient Care"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204563,1,FALSE,0,FY2021 SURGICAL SERVICES: ESOPHAGECTOMY PATIENT CARE
-1,9604,Elearning-0000-826,g13664,g61539,0,I have read and understand the contents of the CBL Dialysis Communication Update 2021(2) and agree to follow the expectations outlined.,g204558,0,TRUE,1,DIALYSIS COMMUNICATION UPDATE 2021(2)
-1,9604,Elearning-0000-826,g13664,g61539,1,I have read and understand the contents of the CBL Dialysis Communication Update 2021(2) and agree to follow the expectations outlined.,g204559,1,FALSE,0,DIALYSIS COMMUNICATION UPDATE 2021(2)
19622,9679,Elearning-0000-894,g13662,g61537,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention Education - May 2021 - Braden Scale Risk Factors"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204554,0,TRUE,1,HAPI PREVENTION EDUCATION - MAY 2021 - BRADEN SCALE RISK FACTORS
19622,9679,Elearning-0000-894,g13662,g61537,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention Education - May 2021 - Braden Scale Risk Factors"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204555,1,FALSE,0,HAPI PREVENTION EDUCATION - MAY 2021 - BRADEN SCALE RISK FACTORS
19618,9583,Elearning-0000-807,g13659,g61512,0,Which of the following is true in regards to intraosseous administration of medications?,g204508,0,"a.	Most meds that can be given IV can also be given IO",1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61512,1,Which of the following is true in regards to intraosseous administration of medications?,g204509,1,"b.	The dose for most IO meds are twice (2x) the amount of IV doses",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61512,2,Which of the following is true in regards to intraosseous administration of medications?,g204510,2,"c.	Endotracheal route is preferred over IO route for med administration during codes",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61512,3,Which of the following is true in regards to intraosseous administration of medications?,g204511,3,"d.	IO can only be considered peripheral access",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61513,0,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,g204512,0,"a.	Epinephrine 1mg IVP q3-5mins",1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61513,1,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,g204513,1,"b.	Lidocaine 1-1.5mg/kg IVP",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61513,2,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,g204514,2,"c.	Defibrillation after first round of chest compressions",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61513,3,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,g204515,3,"d.	Amiodarone 300mg IVP",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61514,0,"Drawer 5 in the Adult Code Cart contains Respiratory Supplies, and Drawer 6 in the Adult Code Cart contains general miscellaneous supplies.",g204516,0,TRUE,1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61514,1,"Drawer 5 in the Adult Code Cart contains Respiratory Supplies, and Drawer 6 in the Adult Code Cart contains general miscellaneous supplies.",g204517,1,FALSE,0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61515,0,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm"" - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",g204518,0,"a.	Suggest epinephrine 1mg IVP if the patient remains hypotensive",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61515,1,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm"" - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",g204519,1,"b.	Check the patient's IV pole to see if a dobutamine drip is really hanging as it is not in the code cart",1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61515,2,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm"" - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",g204520,2,"c.	Breathe a sigh of relief that the code was not real and walk away",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61515,3,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm"" - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",g204521,3,"d.	Suggest an amiodarone drip at 1mg/min for 6 hrs, then 0.5mg/min for 18 hrs thereafter",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61516,0,Options for treating symptomatic bradycardia includes all of the following except:,g204522,0,"a.	Atropine 1 mg IVP",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61516,1,Options for treating symptomatic bradycardia includes all of the following except:,g204523,1,"b.	Dobutamine drip 5mcg/kg/min",1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61516,2,Options for treating symptomatic bradycardia includes all of the following except:,g204524,2,"c.	Dopamine drip 5-20mcg/kg/min",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61516,3,Options for treating symptomatic bradycardia includes all of the following except:,g204525,3,"d.	Epinephrine 2-10mcg/min",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61517,0,There are no controlled medications in the adult code cart.,g204526,0,TRUE,1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61517,1,There are no controlled medications in the adult code cart.,g204527,1,FALSE,0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61518,0,Which of the following drug-location pairs are matched incorrectly?,g204528,0,"a.	Flumazenil 0.5mg/5mLvial - adult code cart 2nd drawer",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61518,1,Which of the following drug-location pairs are matched incorrectly?,g204529,1,"b.	Normal saline 1000mL IV bags - adult code cart 3rd drawer",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61518,2,Which of the following drug-location pairs are matched incorrectly?,g204530,2,"c.	Sodium bicarbonate 50mEq/50mL abbojects - adult code cart 1st drawer",1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61518,3,Which of the following drug-location pairs are matched incorrectly?,g204531,3,"d.	Succinylcholine 100mg/ 5ml- pharmacy auxiliary box",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61519,0,Which of the following medications would you never give via IV push?,g204532,0,"a.	Epinephrine",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61519,1,Which of the following medications would you never give via IV push?,g204533,1,"b.	Sodium bicarbonate",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61519,2,Which of the following medications would you never give via IV push?,g204534,2,"c.	Dopamine",1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61519,3,Which of the following medications would you never give via IV push?,g204535,3,"d.	Lidocaine",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61520,0,There are no medications for Rapid Sequence Intubation in the pharmacy auxiliary box.,g204536,0,TRUE,0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61520,1,There are no medications for Rapid Sequence Intubation in the pharmacy auxiliary box.,g204537,1,FALSE,1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61521,0,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",g204538,0,"a.	The pharmacist should remove the amiodarone bolus bag 1 from tray 1 of the adult code cart and prepare a 300mg bolus syringe for IV push.",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61521,1,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",g204539,1,"b.	The pharmacist should remove the amiodarone bolus bag 2 from tray 1 of the adult code cart and prepare a 150mg bolus syringe for IV push.",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61521,2,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",g204540,2,"c.	The pharmacist should disregard the bolus order and hand the nurse the premixed drip from drawer 1 of the code cart, instructing the RN to bolus from the bag.",0,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19618,9583,Elearning-0000-807,g13659,g61521,3,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",g204541,3,"d.	The pharmacist should obtain a stat amiodarone 150mg/ 100ml IVPB which is not in the adult code cart to infuse over 10 minutes, (not IV push, as the patient now has a pulse), then proceed with the premixed drip at 1mg/ minute.",1,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY
19612,9457,Elearning-0000-692,g13657,g61507,0,Which of the following is not true?,g204490,0,a. person dies by suicide every 12 minutes.,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61507,1,Which of the following is not true?,g204491,1,"b. Over 40,000 people die by suicide each year.",0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61507,2,Which of the following is not true?,g204492,2,c. Highest risk age group is 30-45,1,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61507,3,Which of the following is not true?,g204493,3,d. 45% of people who died by suicide saw their primary care provider within a month of their death.,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61508,0,What are the key contributing factors to suicide?,g204494,0,a. Psychological pain,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61508,1,What are the key contributing factors to suicide?,g204495,1,b. Wish to Escape,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61508,2,What are the key contributing factors to suicide?,g204496,2,c. Seeking a Solution,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61508,3,What are the key contributing factors to suicide?,g204497,3,d. Ambivalence,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61508,4,What are the key contributing factors to suicide?,g204498,4,e. All of the Above,1,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61509,0,"True or False: The Columbia Protocol, also known as the Columbia Suicide-Severity Rating Scale, supports suicide risk assessment through a series of simple, plain-language questions that anyone can ask.",g204499,0,TRUE,1,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61509,1,"True or False: The Columbia Protocol, also known as the Columbia Suicide-Severity Rating Scale, supports suicide risk assessment through a series of simple, plain-language questions that anyone can ask.",g204500,1,FALSE,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61510,0,Which of the following is not a good example of how to ask someone if they are suicidal?,g204501,0,a. Have you wished you were dead or wished you could go to sleep and not wake up?,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61510,1,Which of the following is not a good example of how to ask someone if they are suicidal?,g204502,1,b. Have you been thinking about how you might kill yourself?,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61510,2,Which of the following is not a good example of how to ask someone if they are suicidal?,g204503,2,c. You aren't thinking of suicide are you?,1,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61511,0,Why should nurses ask about suicide risk?,g204504,0,a. Nurses spend more time with patients than other healthcare providers.,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61511,1,Why should nurses ask about suicide risk?,g204505,1,b. Nurses see every patient.,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61511,2,Why should nurses ask about suicide risk?,g204506,2,c. Nurses already screen for other safety/risk factors.,0,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19612,9457,Elearning-0000-692,g13657,g61511,3,Why should nurses ask about suicide risk?,g204507,3,d. All of the above.,1,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS)
19611,9219,Elearning-0000-476,g13656,g61506,0,I acknowledge that I have read and understand the information provided in the NSC L&D Team Leader Class 2021 CBL,g204488,0,TRUE,1,NSC L&D TEAM LEADER CLASS 2021
19611,9219,Elearning-0000-476,g13656,g61506,1,I acknowledge that I have read and understand the information provided in the NSC L&D Team Leader Class 2021 CBL,g204489,1,FALSE,0,NSC L&D TEAM LEADER CLASS 2021
19610,9482,Elearning-0000-715,g13655,g61505,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g204486,0,TRUE,1,NSH 1298 BB2121 EAP
19610,9482,Elearning-0000-715,g13655,g61505,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g204487,1,FALSE,0,NSH 1298 BB2121 EAP
19609,9483,Elearning-0000-716,g13654,g61504,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g204484,0,TRUE,1,NSH 1282 JCAR017 EAP
19609,9483,Elearning-0000-716,g13654,g61504,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g204485,1,FALSE,0,NSH 1282 JCAR017 EAP
19607,9307,Elearning-0000-556,g13652,g61493,0,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,g204455,0,TRUE,1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61493,1,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,g204456,1,FALSE,0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61494,0,Mitten(s) are NOT a type of physical restraint,g204457,0,TRUE,1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61494,1,Mitten(s) are NOT a type of physical restraint,g204458,1,FALSE,0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61495,0,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,g204459,0,TRUE,0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61495,1,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,g204460,1,FALSE,1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61496,0,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g204461,0,"a.	A patient with an emotional disorder poses a physical threat to other patients.",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61496,1,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g204462,1,"b.	A patient is pulling at his Foley catheter and demonstrates lack of understanding to comply with safety directions.",1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61496,2,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g204463,2,"c.	A patient with an emotional disorder is attempting to cause physical harm to himself.",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61496,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g204464,3,"d.	A patient with a behavioral disorder poses a threat to the staff.",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61497,0,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,g204465,0,TRUE,1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61497,1,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,g204466,1,FALSE,0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61498,0,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",g204467,0,TRUE,1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61498,1,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",g204468,1,FALSE,0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61499,0,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",g204469,0,TRUE,0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61499,1,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",g204470,1,FALSE,1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61500,0,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g204471,0,"a.	Patient is pulling at lines",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61500,1,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g204472,1,"b.	Patient is pulling at tubes",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61500,2,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g204473,2,"c.	Patient wants to get out of bed unattended",1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61500,3,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g204474,3,"d.	Patient demonstrates lack of understanding to comply with safety directions",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61501,0,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g204475,0,"a.	Used the right-sized restraint",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61501,1,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g204476,1,"b.	Applied the restraints according to manufacturer's directions",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61501,2,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g204477,2,"c.	Secured the restraints to the siderails",1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61501,3,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g204478,3,"d.	Tied knots so they can be quickly released",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61502,0,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",g204479,0,"a.	Patient is an imminent risk of intentional harm to self",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61502,1,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",g204480,1,"b.	Patient is verbally abusive to staff",1,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19607,9307,Elearning-0000-556,g13652,g61502,2,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",g204481,2,"c.	Patient is an imminent risk of intentional harm to others",0,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF
19605,9330,Elearning-0000-577,g13650,g61491,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g204451,0,TRUE,1,FY2021 5 C POST CARDIAC CATH DOCUMENTATION IN ONECHART
19605,9330,Elearning-0000-577,g13650,g61491,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g204452,1,FALSE,0,FY2021 5 C POST CARDIAC CATH DOCUMENTATION IN ONECHART
19590,9849,Questions-0000-140,g13640,g61433,0,Please list the location for this activity.,g204226,0,Atlanta,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61433,1,Please list the location for this activity.,g204227,1,Forsyth,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61433,2,Please list the location for this activity.,g204228,2,Cherokee,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61433,3,Please list the location for this activity.,g204229,3,Other,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61434,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",g204230,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61434,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",g204231,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61434,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",g204232,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61434,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",g204233,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61434,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",g204234,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61435,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",g204235,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61435,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",g204236,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61435,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",g204237,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61435,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",g204238,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61435,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",g204239,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61436,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",g204240,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61436,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",g204241,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61436,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",g204242,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61436,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",g204243,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61436,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",g204244,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61437,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",g204245,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61437,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",g204246,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61437,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",g204247,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61437,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",g204248,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61437,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",g204249,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61438,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",g204250,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61438,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",g204251,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61438,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",g204252,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61438,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",g204253,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61438,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",g204254,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61439,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",g204255,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61439,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",g204256,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61439,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",g204257,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61439,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",g204258,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61439,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",g204259,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61440,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",g204260,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61440,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",g204261,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61440,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",g204262,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61440,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",g204263,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61440,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",g204264,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61441,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",g204265,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61441,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",g204266,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61441,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",g204267,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61441,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",g204268,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61441,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",g204269,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61442,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",g204270,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61442,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",g204271,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61442,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",g204272,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61442,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",g204273,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61442,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",g204274,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61443,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",g204275,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61443,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",g204276,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61443,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",g204277,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61443,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",g204278,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61443,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",g204279,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61444,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",g204280,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61444,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",g204281,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61444,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",g204282,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61444,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",g204283,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61444,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",g204284,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61445,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204285,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61445,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204286,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61445,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204287,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61445,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204288,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61445,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204289,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61446,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,g204290,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61446,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,g204291,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61446,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,g204292,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61446,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,g204293,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61446,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,g204294,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61447,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,g204295,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61447,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,g204296,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61447,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,g204297,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61447,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,g204298,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61447,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,g204299,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61448,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,g204300,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61448,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,g204301,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61448,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,g204302,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61448,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,g204303,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61448,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,g204304,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61449,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g204305,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61449,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g204306,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61449,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g204307,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61449,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g204308,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61449,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,g204309,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61450,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204310,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61450,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204311,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61450,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204312,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61450,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204313,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61450,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g204314,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61451,0,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204315,0,Strongly Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61451,1,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204316,1,Agree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61451,2,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204317,2,No Opinion,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61451,3,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204318,3,Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61451,4,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,g204319,4,Strongly Disagree,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61452,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,g204320,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61452,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,g204321,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61452,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,g204322,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61452,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,g204323,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61452,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,g204324,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61453,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,g204325,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61453,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,g204326,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61453,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,g204327,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61453,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,g204328,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61453,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,g204329,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61454,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,g204330,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61454,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,g204331,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61454,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,g204332,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61454,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,g204333,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61454,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,g204334,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61455,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,g204335,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61455,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,g204336,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61455,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,g204337,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61455,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,g204338,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61455,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,g204339,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61456,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,g204340,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61456,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,g204341,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61456,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,g204342,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61456,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,g204343,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61456,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,g204344,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61457,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,g204345,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61457,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,g204346,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61457,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,g204347,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61457,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,g204348,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61457,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,g204349,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61458,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,g204350,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61458,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,g204351,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61458,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,g204352,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61458,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,g204353,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61458,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,g204354,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61459,0,"Overall, this activity was:",g204355,0,Excellent,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61459,1,"Overall, this activity was:",g204356,1,Very Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61459,2,"Overall, this activity was:",g204357,2,Good,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61459,3,"Overall, this activity was:",g204358,3,Fair,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61459,4,"Overall, this activity was:",g204359,4,Poor,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61460,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204360,0,Yes,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61460,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204361,1,No,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61460,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204362,2,N/A,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61463,0,How would you improve this class?,g204363,0,Reduce content covered in class,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61463,1,How would you improve this class?,g204364,1,Increase content covered in class,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61463,2,How would you improve this class?,g204365,2,Update content covered in class,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61463,3,How would you improve this class?,g204366,3,Improve the instructional methods,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61463,4,How would you improve this class?,g204367,4,Make course activities more stimulating,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61463,5,How would you improve this class?,g204368,5,Slow the pace of the class,0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19590,9849,Questions-0000-140,g13640,g61463,6,How would you improve this class?,g204369,6,"No improvement needed (appropriate content, handout, setting, etc.)",0,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021"
19580,9851,Questions-0000-142,g13629,g61379,0,Please list the location for this activity.,g204025,0,Atlanta,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61379,1,Please list the location for this activity.,g204026,1,Cherokee,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61379,2,Please list the location for this activity.,g204027,2,Forsyth,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61379,3,Please list the location for this activity.,g204028,3,Other,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61380,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",g204029,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61380,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",g204030,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61380,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",g204031,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61380,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",g204032,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61380,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",g204033,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61381,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",g204034,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61381,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",g204035,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61381,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",g204036,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61381,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",g204037,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61381,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",g204038,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61382,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",g204039,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61382,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",g204040,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61382,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",g204041,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61382,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",g204042,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61382,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",g204043,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61383,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",g204044,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61383,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",g204045,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61383,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",g204046,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61383,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",g204047,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61383,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",g204048,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61384,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204049,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61384,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204050,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61384,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204051,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61384,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204052,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61384,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g204053,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61385,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",g204054,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61385,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",g204055,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61385,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",g204056,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61385,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",g204057,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61385,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",g204058,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61386,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to"" person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",g204059,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61386,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to"" person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",g204060,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61386,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to"" person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",g204061,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61386,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to"" person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",g204062,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61386,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to"" person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",g204063,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61387,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g204064,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61387,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g204065,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61387,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g204066,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61387,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g204067,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61387,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",g204068,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61388,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204069,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61388,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204070,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61388,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204071,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61388,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204072,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61388,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g204073,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61389,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,g204074,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61389,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,g204075,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61389,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,g204076,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61389,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,g204077,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61389,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,g204078,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61390,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g204079,0,Strongly Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61390,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g204080,1,Agree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61390,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g204081,2,No Opinion,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61390,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g204082,3,Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61390,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,g204083,4,Strongly Disagree,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61391,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",g204084,0,Excellent,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61391,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",g204085,1,Very Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61391,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",g204086,2,Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61391,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",g204087,3,Fair,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61391,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",g204088,4,Poor,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61392,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",g204089,0,Excellent,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61392,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",g204090,1,Very Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61392,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",g204091,2,Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61392,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",g204092,3,Fair,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61392,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",g204093,4,Poor,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61393,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",g204094,0,Excellent,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61393,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",g204095,1,Very Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61393,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",g204096,2,Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61393,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",g204097,3,Fair,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61393,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",g204098,4,Poor,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61394,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",g204099,0,Excellent,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61394,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",g204100,1,Very Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61394,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",g204101,2,Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61394,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",g204102,3,Fair,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61394,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",g204103,4,Poor,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61395,0,"Overall, this activity was:",g204104,0,Excellent,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61395,1,"Overall, this activity was:",g204105,1,Very Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61395,2,"Overall, this activity was:",g204106,2,Good,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61395,3,"Overall, this activity was:",g204107,3,Fair,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61395,4,"Overall, this activity was:",g204108,4,Poor,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61396,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204109,0,Yes,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61396,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204110,1,No,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61396,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g204111,2,N/A,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61399,0,How would you improve this class?,g204112,0,Reduce content covered in class,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61399,1,How would you improve this class?,g204113,1,Increase content covered in class,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61399,2,How would you improve this class?,g204114,2,Update content covered in class,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61399,3,How would you improve this class?,g204115,3,Improve the instructional methods,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61399,4,How would you improve this class?,g204116,4,Make course activities more stimulating,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61399,5,How would you improve this class?,g204117,5,Slow the pace of the class,0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19580,9851,Questions-0000-142,g13629,g61399,6,How would you improve this class?,g204118,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21
19576,9620,Elearning-0000-840,g13627,g61373,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Temperature, Humidity and Airflow"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204010,0,TRUE,1,"FY2021 SURGICAL SERVICES: TEMPERATURE, HUMIDITY AND AIRFLOW"
19576,9620,Elearning-0000-840,g13627,g61373,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Temperature, Humidity and Airflow"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204011,1,FALSE,0,"FY2021 SURGICAL SERVICES: TEMPERATURE, HUMIDITY AND AIRFLOW"
19575,9309,Elearning-0000-558,g13626,g61372,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES ISOLATION - ANESTHESIA TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204008,0,TRUE,1,FY2021 SURGICAL SERVICES: ISOLATION - ANESTHESIA TECHS
19575,9309,Elearning-0000-558,g13626,g61372,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES ISOLATION - ANESTHESIA TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g204009,1,FALSE,0,FY2021 SURGICAL SERVICES: ISOLATION - ANESTHESIA TECHS
19570,9726,Elearning-0000-937,g13623,g61356,0,It is acceptable to return cold medication stock to the GCS annex on Fridays.,g203968,0,TRUE,0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61356,1,It is acceptable to return cold medication stock to the GCS annex on Fridays.,g203969,1,FALSE,1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61357,0,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,g203970,0,"a.	Day",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,g203971,1,"b.	Other month",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61357,2,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,g203972,2,"c.	Month",1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61357,3,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,g203973,3,"d.	Year",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61358,0,Which is not a benefit of managing inventory?,g203974,0,"a.	Decreased inventory cost",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61358,1,Which is not a benefit of managing inventory?,g203975,1,"b.	Minimizing drug waste",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61358,2,Which is not a benefit of managing inventory?,g203976,2,"c.	Increased inventory turnover",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61358,3,Which is not a benefit of managing inventory?,g203977,3,"d.	Increased quantity of expired drugs",1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61359,0,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",g203978,0,"a.	3",1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61359,1,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",g203979,1,"b.	2",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61359,2,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",g203980,2,"c.	6",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",g203981,3,"d.	4",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61360,0,Irinotecan 250mg dose is ordered.  Which is the optimal vial size combination to minimize waste?,g203982,0,"a.	2 x 100mg + 2 x 40mg",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61360,1,Irinotecan 250mg dose is ordered.  Which is the optimal vial size combination to minimize waste?,g203983,1,"b.	1 x 100mg + 4 x 40mg",1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61361,0,The product expiration report may be used to identify expiring items within 3 months.,g203984,0,TRUE,1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61361,1,The product expiration report may be used to identify expiring items within 3 months.,g203985,1,FALSE,0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61362,0,"Medication should be ordered 5 days prior to treatment for GCS and 2 days prior to treatment for ACC, NGDC, and SHOA.",g203986,0,TRUE,0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61362,1,"Medication should be ordered 5 days prior to treatment for GCS and 2 days prior to treatment for ACC, NGDC, and SHOA.",g203987,1,FALSE,1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61363,0,Pharmacy staff should plan 3-4 additional days out for holiday closures and inclement weather and other shipping delays.,g203988,0,TRUE,1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61363,1,Pharmacy staff should plan 3-4 additional days out for holiday closures and inclement weather and other shipping delays.,g203989,1,FALSE,0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61364,0,Auto reorder is a useful tool for managing fast moving items.,g203990,0,TRUE,1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61364,1,Auto reorder is a useful tool for managing fast moving items.,g203991,1,FALSE,0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61365,0,"When restocking and dispensing medication, pharmacy technician should verify:",g203992,0,"a.	NDC#",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61365,1,"When restocking and dispensing medication, pharmacy technician should verify:",g203993,1,"b.	Lot #",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61365,2,"When restocking and dispensing medication, pharmacy technician should verify:",g203994,2,"c.	Expiration date",0,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19570,9726,Elearning-0000-937,g13623,g61365,3,"When restocking and dispensing medication, pharmacy technician should verify:",g203995,3,"d.	All the above",1,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE
19569,9737,Elearning-0000-947,g13622,g61346,0,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,g203933,0,"A.	200m & 800mg",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61346,1,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,g203934,1,"B.	100mg & 900mg",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61346,2,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,g203935,2,"C.	600mg & 400mg",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61346,3,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,g203936,3,"D.	300mg & 700mg",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61347,0,YERVOY is available in MDV sizes of 50 mg and 200mg.,g203937,0,TRUE,0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61347,1,YERVOY is available in MDV sizes of 50 mg and 200mg.,g203938,1,FALSE,1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61348,0,All of the following medications are available as RTU (ready to use) except:,g203939,0,"A.	Empliciti",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61348,1,All of the following medications are available as RTU (ready to use) except:,g203940,1,"B.	Perjeta",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61348,2,All of the following medications are available as RTU (ready to use) except:,g203941,2,"C.	Bavencio",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61348,3,All of the following medications are available as RTU (ready to use) except:,g203942,3,"D.	Darzalex",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61349,0,A loading dose is required by Herceptin Hylecta?,g203943,0,TRUE,0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61349,1,A loading dose is required by Herceptin Hylecta?,g203944,1,FALSE,1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61350,0,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,g203945,0,"A.	None",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61350,1,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,g203946,1,"B.	70mLs",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61350,2,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,g203947,2,"C.	45mLs",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61350,3,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,g203948,3,"D.	15mls",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61351,0,Pharmacy received an order for Darzalex in D5W for IV infusion for a patient that is diabetic. Why does the Pharmacist need to call Physician to change order?,g203949,0,"A.	Diabetic patients can NOT receive D5W infusion due to risk of high blood sugar after Infusion.",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61351,1,Pharmacy received an order for Darzalex in D5W for IV infusion for a patient that is diabetic. Why does the Pharmacist need to call Physician to change order?,g203950,1,"B.	Darzalex can only be mixed with 0.9% NS.",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61351,2,Pharmacy received an order for Darzalex in D5W for IV infusion for a patient that is diabetic. Why does the Pharmacist need to call Physician to change order?,g203951,2,"C.	Pharmacist does not have to call Physician for any of the above reasons.",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61352,0,Which is the following statements is NOT correct about Imfinzi ?,g203952,0,"a.	It requires an in-line filter for Infusion",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61352,1,Which is the following statements is NOT correct about Imfinzi ?,g203953,1,"b.	It is stable for 24 hours at room temperature after dilution",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61352,2,Which is the following statements is NOT correct about Imfinzi ?,g203954,2,"c.	Imfinzi vials should be kept refrigerated and in original package until dilution",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61352,3,Which is the following statements is NOT correct about Imfinzi ?,g203955,3,"d.	It comes in 2 vials sizes of 120 and 500 mg",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61353,0,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,g203956,0,"a.	Keytruda",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61353,1,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,g203957,1,"b.	Imfinzi",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61353,2,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,g203958,2,"c.	Bavencio",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61353,3,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,g203959,3,"d.	Tecentriq",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61354,0,Which checkpoint inhibitor does not require a filter?,g203960,0,"a.	Keytruda",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61354,1,Which checkpoint inhibitor does not require a filter?,g203961,1,"b.	Opdivo",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61354,2,Which checkpoint inhibitor does not require a filter?,g203962,2,"c.	Tecentriq",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61354,3,Which checkpoint inhibitor does not require a filter?,g203963,3,"d.	Libtayo",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61355,0,Adcetris is,g203964,0,"a.	Available as SDV of 50mg lyophilized powder",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61355,1,Adcetris is,g203965,1,"b.	Indicated for Hodgkin's lymphoma",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61355,2,Adcetris is,g203966,2,"c.	Mixed in Normal Saline",0,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19569,9737,Elearning-0000-947,g13622,g61355,3,Adcetris is,g203967,3,"d.	All of the above",1,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE
19567,9850,Questions-0000-141,g13620,g61319,0,Please list the location for this activity.,g203819,0,Atlanta,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61319,1,Please list the location for this activity.,g203820,1,Cherokee,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61319,2,Please list the location for this activity.,g203821,2,Forsyth,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61319,3,Please list the location for this activity.,g203822,3,Other,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61320,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",g203823,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61320,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",g203824,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61320,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",g203825,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61320,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",g203826,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61320,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",g203827,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61321,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",g203828,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61321,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",g203829,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61321,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",g203830,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61321,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",g203831,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61321,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",g203832,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61322,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",g203833,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61322,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",g203834,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61322,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",g203835,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61322,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",g203836,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61322,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",g203837,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61323,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",g203838,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61323,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",g203839,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61323,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",g203840,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61323,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",g203841,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61323,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",g203842,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61324,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203843,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61324,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203844,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61324,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203845,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61324,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203846,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61324,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203847,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61325,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203848,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61325,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203849,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61325,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203850,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61325,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203851,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61325,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",g203852,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61326,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",g203853,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61326,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",g203854,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61326,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",g203855,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61326,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",g203856,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61326,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",g203857,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61327,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",g203858,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61327,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",g203859,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61327,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",g203860,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61327,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",g203861,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61327,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",g203862,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61328,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",g203863,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61328,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",g203864,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61328,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",g203865,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61328,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",g203866,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61328,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",g203867,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61329,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g203868,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61329,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g203869,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61329,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g203870,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61329,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g203871,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61329,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,g203872,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61330,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,g203873,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61330,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,g203874,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61330,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,g203875,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61330,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,g203876,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61330,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,g203877,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61331,0,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,g203878,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61331,1,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,g203879,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61331,2,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,g203880,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61331,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,g203881,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61331,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,g203882,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61332,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g203883,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61332,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g203884,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61332,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g203885,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61332,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g203886,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61332,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",g203887,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61333,0,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g203888,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61333,1,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g203889,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61333,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g203890,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61333,3,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g203891,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61333,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",g203892,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61334,0,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g203893,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61334,1,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g203894,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61334,2,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g203895,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61334,3,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g203896,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61334,4,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,g203897,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61335,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,g203898,0,Excellent,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61335,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,g203899,1,Very Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61335,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,g203900,2,Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61335,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,g203901,3,Fair,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61335,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,g203902,4,Poor,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61336,0,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",g203903,0,Excellent,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61336,1,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",g203904,1,Very Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61336,2,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",g203905,2,Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61336,3,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",g203906,3,Fair,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61336,4,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",g203907,4,Poor,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61337,0,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,g203908,0,Excellent,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61337,1,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,g203909,1,Very Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61337,2,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,g203910,2,Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61337,3,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,g203911,3,Fair,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61337,4,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,g203912,4,Poor,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61338,0,"Overall, this activity was:",g203913,0,Excellent,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61338,1,"Overall, this activity was:",g203914,1,Very Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61338,2,"Overall, this activity was:",g203915,2,Good,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61338,3,"Overall, this activity was:",g203916,3,Fair,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61338,4,"Overall, this activity was:",g203917,4,Poor,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61339,0,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g203918,0,Yes,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61339,1,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g203919,1,No,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61339,2,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",g203920,2,N/A,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61342,0,How would you improve this class?,g203921,0,Reduce content covered in class,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61342,1,How would you improve this class?,g203922,1,Increase content covered in class,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61342,2,How would you improve this class?,g203923,2,Update content covered in class,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61342,3,How would you improve this class?,g203924,3,Improve the instructional methods,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61342,4,How would you improve this class?,g203925,4,Make course activities more stimulating,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61342,5,How would you improve this class?,g203926,5,Slow the pace of the class,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61342,6,How would you improve this class?,g203927,6,"Nothing: (appropriate speakers, content, facility, etc.)",0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61345,0,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",g203928,0,Strongly Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61345,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",g203929,1,Agree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61345,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",g203930,2,No Opinion,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61345,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",g203931,3,Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19567,9850,Questions-0000-141,g13620,g61345,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",g203932,4,Strongly Disagree,0,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21
19566,9185,Elearning-0000-445,g13619,g61318,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 Surgical Services MH For Non RN Surgical Services  CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g203817,0,TRUE,1,FY2021 SURGICAL SERVICES MH FOR NON RN SURGICAL SERVICES
19566,9185,Elearning-0000-445,g13619,g61318,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 Surgical Services MH For Non RN Surgical Services  CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g203818,1,FALSE,0,FY2021 SURGICAL SERVICES MH FOR NON RN SURGICAL SERVICES
19562,9642,Elearning-0000-860,g13615,g61254,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g203552,0,TRUE,1,FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION
19562,9642,Elearning-0000-860,g13615,g61254,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g203553,1,FALSE,0,FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION
19561,9736,Elearning-0000-946,g13614,g61251,0,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,g203540,0,"a.	Hypotension",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61251,1,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,g203541,1,"b.	Excessive sweating",1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61251,2,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,g203542,2,"c.	Fatigue",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61251,3,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,g203543,3,"d.	Hair Loss",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61251,4,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,g203544,4,"e.	Abnormal thyroid test",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61252,0,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,g203545,0,"a.	Discontinue nivolumab and consult Gastroenterology",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61252,1,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,g203546,1,"b.	Initiate high dose steroids followed by infliximab",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61252,2,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,g203547,2,"c.	Initiate prednisone 1-2mg/kg/day follow by corticosteroid taper and consider mycophenolate for persistent severe hepatitis despite high dose corticosteroids.",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61252,3,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,g203548,3,"d.	A and C only",1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61252,4,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,g203549,4,"e.	All of the above",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61253,0,Diarrhea is a more common complaint with the use of CTLA-4 inhibitor versus an anti-PD1.,g203550,0,TRUE,1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61253,1,Diarrhea is a more common complaint with the use of CTLA-4 inhibitor versus an anti-PD1.,g203551,1,FALSE,0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61255,0,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,g203554,0,"a.	At baseline and then every 12 weeks during immunotherapy",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61255,1,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,g203555,1,"b.	Prior to initiating immunotherapy only",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61255,2,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,g203556,2,"c.	At baseline and every 4-6 weeks for all immunotherapy",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61255,3,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,g203557,3,"d.	At baseline and with each dose of ipilimumab",1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61256,0,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,g203558,0,"a.	Cough and SOB",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61256,1,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,g203559,1,"b.	Radiographic changes",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61256,2,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,g203560,2,"c.	Chest pain",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61256,3,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,g203561,3,"d.	Fever",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61256,4,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,g203562,4,"e.	All of the above",1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61257,0,Most immune-related adverse events associated with checkpoint inhibitor immunotherapy occur immediately after the first dose.,g203563,0,TRUE,0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61257,1,Most immune-related adverse events associated with checkpoint inhibitor immunotherapy occur immediately after the first dose.,g203564,1,FALSE,1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61258,0,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",g203565,0,"a.	Hold pembrolizumab and initiate IV methylprednisolone 1mg/kg/day",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61258,1,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",g203566,1,"b.	If there is no response after starting IV steroids in 2-3 days, may increase dose to 2mg/kg/day. Change to prednisone when appropriate",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61258,2,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",g203567,2,"c.	Treat with steroids until symptoms improve to Grade 1 or less. Permanently discontinue pembrolizumab.",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61258,3,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",g203568,3,"d.	Never treat gastrointestinal adverse events with infliximab.",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61258,4,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",g203569,4,"e.	A and B",1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61259,0,Ocular toxicity is the most common immune-related adverse event associated with checkpoint inhibitors.,g203570,0,TRUE,0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61259,1,Ocular toxicity is the most common immune-related adverse event associated with checkpoint inhibitors.,g203571,1,FALSE,1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61260,0,Successful management of immune checkpoint inhibitor toxicities require:,g203572,0,"a.	Excellent patient-provider communication, early diagnosis, and rapid use of corticosteroids.",1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61260,1,Successful management of immune checkpoint inhibitor toxicities require:,g203573,1,"b.	Premedication in the form of a corticosteroid prior to administration of any checkpoint inhibitor immunotherapy.",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61260,2,Successful management of immune checkpoint inhibitor toxicities require:,g203574,2,"c.	Patients to report symptoms of potential toxicities once the patient does not show any improvement after 5 days of those specific symptoms",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61260,3,Successful management of immune checkpoint inhibitor toxicities require:,g203575,3,"d.	None of the above.",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61261,0,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,g203576,0,"a.	Pharmacokinetics",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61261,1,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,g203577,1,"b.	Mechanism of Action",1,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61261,2,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,g203578,2,"c.	Dosing",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19561,9736,Elearning-0000-946,g13614,g61261,3,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,g203579,3,"d.	Administration",0,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES
19555,226,SCORM-0000-32,g13608,g61172,0,I have read and understood the content within the FCC Postpartum Hemorrhage Education CBL.,g203246,0,TRUE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61172,1,I have read and understood the content within the FCC Postpartum Hemorrhage Education CBL.,g203247,1,FALSE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61214,0,"1.	The location where all of the carts will be include:",g203410,0,"a)	1st floor",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61214,1,"1.	The location where all of the carts will be include:",g203411,1,"b)	4th floor",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61214,2,"1.	The location where all of the carts will be include:",g203412,2,"c)	5th floor",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61214,3,"1.	The location where all of the carts will be include:",g203413,3,"d)	6th floor",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61214,4,"1.	The location where all of the carts will be include:",g203414,4,"e)	FCC, HRP, and L&D",1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61215,0,"2.	The Jada system and BT Balloon will be used in all of Women's Services:",g203415,0,TRUE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61215,1,"2.	The Jada system and BT Balloon will be used in all of Women's Services:",g203416,1,FALSE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61216,0,"3.	Bleach and hydrogen peroxide wipe can be used to clean the hemorrhage cart:",g203417,0,TRUE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61216,1,"3.	Bleach and hydrogen peroxide wipe can be used to clean the hemorrhage cart:",g203418,1,FALSE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61217,0,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",g203419,0,"a)	Once a day",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61217,1,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",g203420,1,"b)	Every shift",1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61217,2,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",g203421,2,"c)	Once a month",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61217,3,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",g203422,3,"d)	Once a week",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61218,0,"5.	You can lock the QBL scale drawer open by:",g203423,0,"a)	Pulling the red latch up",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61218,1,"5.	You can lock the QBL scale drawer open by:",g203424,1,"b)	Pushing the red latch down",1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61218,2,"5.	You can lock the QBL scale drawer open by:",g203425,2,"c)	Leaving the red latch alone",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61219,0,"6.	Drawer 2 contains which medical items:",g203426,0,"a)	Refrigerated medications- Methergine and Hemabate",1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61219,1,"6.	Drawer 2 contains which medical items:",g203427,1,"b)	IV start kits and needles",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61219,2,"6.	Drawer 2 contains which medical items:",g203428,2,"c)	IV tubing",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61219,3,"6.	Drawer 2 contains which medical items:",g203429,3,"d)	Straight catheter, Foley catheter, and BT catheter",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61220,0,"7.	Drawer 7 contains which medical items:",g203430,0,"a)	IV tubing",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61220,1,"7.	Drawer 7 contains which medical items:",g203431,1,"b)	Straight catheter, Foley catheter, and BT catheter",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61220,2,"7.	Drawer 7 contains which medical items:",g203432,2,"c)	Blue Chux pads, Linens bags, biohazard bags, surgical gowns, and pads",1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61220,3,"7.	Drawer 7 contains which medical items:",g203433,3,"d)	JADA system",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61221,0,"8.	Every OB hemorrhage Cart will have cart number that goes along with a binder, that's at sits on the top of the cart:",g203434,0,TRUE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61221,1,"8.	Every OB hemorrhage Cart will have cart number that goes along with a binder, that's at sits on the top of the cart:",g203435,1,FALSE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61222,0,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",g203436,0,"a)	Pounds",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61222,1,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",g203437,1,"b)	Grams",1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61222,2,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",g203438,2,"c)	Kilograms",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61222,3,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",g203439,3,"d)	Liters",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61223,0,"10.	All bloody items will be placed in the Joey Pouch for measurement and then placed in a linen bag or a biohazard bag:",g203440,0,TRUE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61223,1,"10.	All bloody items will be placed in the Joey Pouch for measurement and then placed in a linen bag or a biohazard bag:",g203441,1,FALSE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61224,0,"11.	Green used tape will be placed over the lock bar when returning the cart to Central Distribution:",g203442,0,TRUE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61224,1,"11.	Green used tape will be placed over the lock bar when returning the cart to Central Distribution:",g203443,1,FALSE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61225,0,"12.	FCC will be responsible for contacting Central Distribution to obtain a new cart for the unit:",g203444,0,TRUE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61225,1,"12.	FCC will be responsible for contacting Central Distribution to obtain a new cart for the unit:",g203445,1,FALSE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61226,0,"13.	Hemorrhage carts should be plugged into a regular outlet when not in use on the units:",g203446,0,TRUE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61226,1,"13.	Hemorrhage carts should be plugged into a regular outlet when not in use on the units:",g203447,1,FALSE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61227,0,"14.	All carts will be secured with  red security seal tape, which indicates it's a new, unused cart:",g203448,0,TRUE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61227,1,"14.	All carts will be secured with  red security seal tape, which indicates it's a new, unused cart:",g203449,1,FALSE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61228,0,"15.	If the  patient is transferred to another unit(mainly L&D) the cart will be transferred to L&D with the patient:",g203450,0,TRUE,1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61228,1,"15.	If the  patient is transferred to another unit(mainly L&D) the cart will be transferred to L&D with the patient:",g203451,1,FALSE,0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61229,0,"16.	A medication charge sheet will be placed in which drawer:",g203452,0,"a)	Drawer 1",1,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61229,1,"16.	A medication charge sheet will be placed in which drawer:",g203453,1,"b)	Drawer 2",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61229,2,"16.	A medication charge sheet will be placed in which drawer:",g203454,2,"c)	Drawer 3",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19555,226,SCORM-0000-32,g13608,g61229,3,"16.	A medication charge sheet will be placed in which drawer:",g203455,3,"d)	Drawer 4",0,FCC POSTPARTUM HEMORRHAGE CART EDUCATION
19551,9365,Elearning-0000-609,g13604,g61164,0,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,g203220,0,Labor or Antepartum Order Sets,0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61164,1,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,g203221,1,Labor and Delivery Nurse Initiated Standing Orders,1,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61164,2,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,g203222,2,Hypertensive Regimen Orders,0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61164,3,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,g203223,3,HIV communication orders,0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61165,0,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",g203224,0,Verbal,0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61165,1,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",g203225,1,Telephone,1,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61165,2,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",g203226,2,Protocol,0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61165,3,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",g203227,3,Standing,0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61166,0,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",g203228,0,Telephone (because that's how the provider placed the initial communication order in the order set),0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61166,1,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",g203229,1,Protocol (because it's already been ordered by the provider and this order is completing the protocol),1,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61166,2,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",g203230,2,Standing (because the order is already standing and we are just activating it),0,LD FY 2021 ORDER TYPES CLARIFICATION
19551,9365,Elearning-0000-609,g13604,g61166,3,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",g203231,3,Verbal (because it's first on the list and any type is fine in this case),0,LD FY 2021 ORDER TYPES CLARIFICATION
19550,9927,Questions-0000-61,g13602,g61150,0,What is considered the normal range for the PR interval?,g203176,0,"a.	0.12- 0.20 minutes",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61150,1,What is considered the normal range for the PR interval?,g203177,1,"b.	0.06- 0.10 minutes",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61150,3,What is considered the normal range for the PR interval?,g203178,3,"d.	0.06- 0.10 seconds",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61150,2,What is considered the normal range for the PR interval?,g203179,2,"c.	0.12- 0.20 seconds",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61151,0,The most appropriate treatment for Torsades de pointes is,g203180,0,"a.	BLS, epinephrine",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61151,1,The most appropriate treatment for Torsades de pointes is,g203181,1,"b.	Transcutaneous pacing or atropine",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61151,2,The most appropriate treatment for Torsades de pointes is,g203182,2,"c.	BLS, defibrillation, epinephrine, amiodarone",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61151,3,The most appropriate treatment for Torsades de pointes is,g203183,3,"d.	Magnesium, overdrive pacing, isoproterenol",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61152,1,What is considered the normal range for the QT interval?,g203184,1,"b.	0.20- 0.50 seconds",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61152,2,What is considered the normal range for the QT interval?,g203185,2,"c.	0.50- 0.75 seconds",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61152,3,What is considered the normal range for the QT interval?,g203186,3,"d.	0.12- 0.20 seconds",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61152,0,What is considered the normal range for the QT interval?,g203187,0,"a.	0.36- 0.44 seconds",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61153,0,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",g203188,0,"a.	Lead II",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61153,1,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",g203189,1,"b.	Lead I",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61153,3,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",g203190,3,"d.	Lead aVF",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61153,2,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",g203191,2,"c.	Lead VI",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61154,0,A QRS complex represents,g203192,0,"a.	Atrial depolarization",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61154,1,A QRS complex represents,g203193,1,"b.	Atrial repolarization",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61154,3,A QRS complex represents,g203194,3,"d.	Ventricular repolarization",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61154,2,A QRS complex represents,g203195,2,"c.	Ventricular depolarization",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61155,0,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",g203196,0,"a.	Sinus bradycardia",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61155,2,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",g203197,2,"c.	Second degree heart block type II",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61155,3,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",g203198,3,"d.	Third degree heart block",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61155,1,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",g203199,1,"b.	Pulseless electrical activity",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61156,1,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",g203200,1,"b.	Stable supraventricular tachycardia",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61156,2,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",g203201,2,"c.	Ventricular tachycardia",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61156,3,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",g203202,3,"d.	Sinus tachycardia",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61156,0,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",g203203,0,"a.	Unstable supraventricular tachycardia",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61157,0,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,g203204,0,"a.	Failure to fire",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61157,2,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,g203205,2,"c.	Failure to sense",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61157,3,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,g203206,3,"d.	Oversensing",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61157,1,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,g203207,1,"b.	Failure to capture",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61158,1,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,g203208,1,"b.	Synchronized cardioversion",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61158,2,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,g203209,2,"c.	Administration of adenosine 12 mg IV push",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61158,3,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,g203210,3,"d.	Administration of atropine 0.5mg IV push",0,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19550,9927,Questions-0000-61,g13602,g61158,0,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,g203211,0,"a.	Defibrillation",1,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL
19549,9118,Elearning-0000-384,g13601,g61133,0,I acknowledge that I have read and understand the information provided in the NSC FCC Exclusive Breastfeeding Rounding CBL.,g203110,0,TRUE,1,NSC FCC EXCLUSIVE BREASTFEEDING ROUNDING
19549,9118,Elearning-0000-384,g13601,g61133,1,I acknowledge that I have read and understand the information provided in the NSC FCC Exclusive Breastfeeding Rounding CBL.,g203111,1,FALSE,0,NSC FCC EXCLUSIVE BREASTFEEDING ROUNDING
19535,9306,Elearning-0000-555,g13595,g61049,0,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,g202782,0,TRUE,1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61049,1,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,g202783,1,FALSE,0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61050,0,Mitten(s) are NOT a type of physical restraint,g202784,0,TRUE,1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61050,1,Mitten(s) are NOT a type of physical restraint,g202785,1,FALSE,0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61051,0,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,g202786,0,TRUE,0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61051,1,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,g202787,1,FALSE,1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61052,0,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g202788,0,"a.	A patient with an emotional disorder poses a physical threat to other patients.",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61052,1,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g202789,1,"b.	A patient is pulling at his Foley catheter and demonstrates lack of understanding to comply with safety directions.",1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61052,2,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g202790,2,"c.	A patient with an emotional disorder is attempting to cause physical harm to himself.",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61052,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",g202791,3,"d.	A patient with a behavioral disorder poses a threat to the staff.",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61053,0,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,g202792,0,TRUE,1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61053,1,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,g202793,1,FALSE,0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61054,0,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",g202794,0,TRUE,1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61054,1,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",g202795,1,FALSE,0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61055,0,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",g202796,0,TRUE,0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61055,1,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",g202797,1,FALSE,1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61056,0,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g202798,0,"a.	Patient is pulling at lines",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61056,1,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g202799,1,"b.	Patient is pulling at tubes",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61056,2,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g202800,2,"c.	Patient wants to get out of bed unattended",1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61056,3,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",g202801,3,"d.	Patient demonstrates lack of understanding to comply with safety directions",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61057,0,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g202802,0,"a.	Used the right-sized restraint",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61057,1,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g202803,1,"b.	Applied the restraints according to manufacturer's directions",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61057,2,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g202804,2,"c.	Secured the restraints to the siderails",1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61057,3,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,g202805,3,"d.	Tied knots so they can be quickly released",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61058,0,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",g202806,0,"a.	Patient is an imminent risk of intentional harm to self",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61058,1,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",g202807,1,"b.	Patient is verbally abusive to staff",1,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19535,9306,Elearning-0000-555,g13595,g61058,2,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",g202808,2,"c.	Patient is an imminent risk of intentional harm to others",0,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES
19534,9270,Elearning-0000-522,g13591,g61017,0,"VS, Aldrete Score, and End Tidal CO2 must be assessed q5 minutes during the procedure and 30 minutes post sedation",g202691,0,TRUE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61017,1,"VS, Aldrete Score, and End Tidal CO2 must be assessed q5 minutes during the procedure and 30 minutes post sedation",g202692,1,FALSE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61018,0,A large total dose is ordered initially to be given in smaller doses over the entire procedure,g202693,0,TRUE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61018,1,A large total dose is ordered initially to be given in smaller doses over the entire procedure,g202694,1,FALSE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61019,0,The RN may administer Propofol pushes when ordered in the procedural sedation power plan,g202695,0,TRUE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61019,1,The RN may administer Propofol pushes when ordered in the procedural sedation power plan,g202696,1,FALSE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61020,0,ICU Moderate Sedation Band is where procedural sedation is documented,g202697,0,TRUE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61020,1,ICU Moderate Sedation Band is where procedural sedation is documented,g202698,1,FALSE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61021,0,The recovery Aldrete score should be 9 or the patients baseline Aldrete score,g202699,0,TRUE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61021,1,The recovery Aldrete score should be 9 or the patients baseline Aldrete score,g202700,1,FALSE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61022,0,The RN must scan each individual dose of Fentanyl during the procedure,g202701,0,TRUE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61022,1,The RN must scan each individual dose of Fentanyl during the procedure,g202702,1,FALSE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61023,0,"When Propofol is documented in the MAR, ""performed by"" needs to remain the NAME OF the RN",g202703,0,TRUE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61023,1,"When Propofol is documented in the MAR, ""performed by"" needs to remain the NAME OF the RN",g202704,1,FALSE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61024,0,Only some procedures require universal protocol,g202705,0,TRUE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61024,1,Only some procedures require universal protocol,g202706,1,FALSE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61025,0,Procedural/Moderate sedation meds should be administered as soon as the powerplan is ordered,g202707,0,TRUE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61025,1,Procedural/Moderate sedation meds should be administered as soon as the powerplan is ordered,g202708,1,FALSE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61026,0,"when a patient is on a sedating IV continuous drip, the provider can give an order for the rate to be changed for the procedure",g202709,0,TRUE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61026,1,"when a patient is on a sedating IV continuous drip, the provider can give an order for the rate to be changed for the procedure",g202710,1,FALSE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61027,0,"The Aldrete scale is composed of Activity, Respiration, Circulation, Consciousness, and Oxygen Saturation",g202711,0,TRUE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61027,1,"The Aldrete scale is composed of Activity, Respiration, Circulation, Consciousness, and Oxygen Saturation",g202712,1,FALSE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61028,0,I have viewed the ICU Moderate Sedation Power Point and workflow video and understand the information presented to me.  I understand that I can go to a Clinician or Leadership team member with questions.,g202713,0,TRUE,1,NSC ICU PROCEDURAL MODERATE SEDATION
19534,9270,Elearning-0000-522,g13591,g61028,1,I have viewed the ICU Moderate Sedation Power Point and workflow video and understand the information presented to me.  I understand that I can go to a Clinician or Leadership team member with questions.,g202714,1,FALSE,0,NSC ICU PROCEDURAL MODERATE SEDATION
19532,9349,Elearning-0000-594,g13589,g61014,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g202685,0,TRUE,1,FY2020-2021 STERILIZER LOAD STICKER & PACKAGE LABELS
19532,9349,Elearning-0000-594,g13589,g61014,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g202686,1,FALSE,0,FY2020-2021 STERILIZER LOAD STICKER & PACKAGE LABELS
19528,9667,Elearning-0000-883,g13587,g61012,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""KRONOS Time and Attendance for New Timekeepers"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g202681,0,TRUE,1,KRONOS TIME AND ATTENDANCE FOR NEW TIMEKEEPERS
19528,9667,Elearning-0000-883,g13587,g61012,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""KRONOS Time and Attendance for New Timekeepers"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",g202682,1,FALSE,0,KRONOS TIME AND ATTENDANCE FOR NEW TIMEKEEPERS
19527,9075,Elearning-0000-345,g13585,g61010,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g202677,0,TRUE,1,NSH1287 AMENDMENT 11
19527,9075,Elearning-0000-345,g13585,g61010,1,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",g202678,1,FALSE,0,NSH1287 AMENDMENT 11
19526,9222,Elearning-0000-479,g13584,g60998,0,"You are caring for a nulliparous woman in labor that has been AROM 3 hours ago.  She has remained 4 cm during this time. There is a Cat I FHR tracing.  She has been augmented with Pitocin for 2 1/2 hours.  The provider mentioned at the nurse's station that if she does not have cervical change, that she will need a C/S.   Does the patient meet the criteria for having labor dystocia?",g202645,0,Yes,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g60998,1,"You are caring for a nulliparous woman in labor that has been AROM 3 hours ago.  She has remained 4 cm during this time. There is a Cat I FHR tracing.  She has been augmented with Pitocin for 2 1/2 hours.  The provider mentioned at the nurse's station that if she does not have cervical change, that she will need a C/S.   Does the patient meet the criteria for having labor dystocia?",g202646,1,No,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g60999,0,"Your patient, J.F., G1 P0, has been admitted for elective induction of labor with Pitocin.   Her admitting cervical exam was 3/80/-1, soft and anterior.  Her membranes were ruptured 18 hours ago and she has been on Pitocin for over 24 hours.  There is a CAT I FHR tracing, and the patient remains afebrile. The provider has diagnosed her as a Failed Elective Induction.  Do you agree?",g202647,0,Yes,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g60999,1,"Your patient, J.F., G1 P0, has been admitted for elective induction of labor with Pitocin.   Her admitting cervical exam was 3/80/-1, soft and anterior.  Her membranes were ruptured 18 hours ago and she has been on Pitocin for over 24 hours.  There is a CAT I FHR tracing, and the patient remains afebrile. The provider has diagnosed her as a Failed Elective Induction.  Do you agree?",g202648,1,No,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61000,0,Only mothers with Category III FHR tracings should have a C/S for Fetal Intolerance.,g202649,0,TRUE,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61000,1,Only mothers with Category III FHR tracings should have a C/S for Fetal Intolerance.,g202650,1,FALSE,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61001,0,What category is this FHR tracing?,g202651,0,Category I,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61001,1,What category is this FHR tracing?,g202652,1,Category II,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61001,2,What category is this FHR tracing?,g202653,2,Category III,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61002,0,What is the FHR variability in this tracing?,g202654,0,Absent,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61002,1,What is the FHR variability in this tracing?,g202655,1,Minimal,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61002,2,What is the FHR variability in this tracing?,g202656,2,Moderate,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61002,3,What is the FHR variability in this tracing?,g202657,3,Marked,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61003,0,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",g202658,0,No corrective measures necessary due to moderate FHRV,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61003,1,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",g202659,1,"Maternal position change, 300-500 ml IVF bolus, and push in the lateral position.",0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61003,2,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",g202660,2,Administer terbutaline,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61003,3,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",g202661,3,Call the provider,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61003,4,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",g202662,4,Both B&C,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61003,5,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",g202663,5,Both B&D,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61004,0,"Are there ""Clinically Significant decelerations"" = 50% of contractions?",g202664,0,Yes,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61004,1,"Are there ""Clinically Significant decelerations"" = 50% of contractions?",g202665,1,No,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61005,0,"As long as the patient is progressing normally in the second stage, we can observe and continue to push.",g202666,0,TRUE,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61005,1,"As long as the patient is progressing normally in the second stage, we can observe and continue to push.",g202667,1,FALSE,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61006,0,"The patent is G2P1 admitted for early labor. Her SVE is 2-3/70/-2.  There is no known maternal or fetal risk factors noted upon admission.  Her last delivery was a NSVD. In the tracing below, is there moderate FHRV or accelerations?",g202668,0,Yes,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61006,1,"The patent is G2P1 admitted for early labor. Her SVE is 2-3/70/-2.  There is no known maternal or fetal risk factors noted upon admission.  Her last delivery was a NSVD. In the tracing below, is there moderate FHRV or accelerations?",g202669,1,No,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61007,0,"In the tracing below, are there clinically significant decelerations with = 50% of contractions?",g202670,0,Yes,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61007,1,"In the tracing below, are there clinically significant decelerations with = 50% of contractions?",g202671,1,No,1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61008,0,Would you perform and conservative corrective measures for this tracing?,g202672,0,"Yes, that is an appropriate action at this point.",1,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61008,1,Would you perform and conservative corrective measures for this tracing?,g202673,1,"No, this is a category III tracing and she should be delivered as soon as possible.",0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61009,0,"After performing conservative corrective measures, the pattern below persists for an hour. What should the plan of care be?",g202674,0,Observe for an additional hour since she is a multip,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61009,1,"After performing conservative corrective measures, the pattern below persists for an hour. What should the plan of care be?",g202675,1,Observe for 30 additional minutes since there are no decels,0,LD FY 2021 NTSV INITIATIVE EDUCATION
19526,9222,Elearning-0000-479,g13584,g61009,2,"After performing conservative corrective measures, the pattern below persists for an hour. What should the plan of care be?",g202676,2,Move towards cesarean delivery,1,LD FY 2021 NTSV INITIATIVE EDUCATION
